ss_d,ss_sbclllr_frctn,cnfdnc_scr,dscrptn,ss_rgnsm,ss_strn,vrnt_d,ss_tss,tss_d,cll_d,src_d,ss_tx_d,ss_tp,chmbl_d,td,ss_ctgr,rltnshp_tp,crtd_b,src_ss_d,b_frmt
7524,,1,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL618647,50597,,N,Intermediate,,BAO_0000218
7525,,1,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL618648,50597,,N,Intermediate,,BAO_0000218
7526,,1,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL618649,50597,,N,Intermediate,,BAO_0000218
7527,,1,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL618650,50597,,N,Intermediate,,BAO_0000218
7528,,1,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL618651,50597,,N,Intermediate,,BAO_0000218
7529,,1,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL876497,50597,,N,Intermediate,,BAO_0000218
7530,,1,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL618652,50597,,N,Intermediate,,BAO_0000218
7531,,1,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL618653,50597,,N,Intermediate,,BAO_0000218
7532,,1,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL618654,50597,,N,Intermediate,,BAO_0000218
7533,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618655,50597,,N,Intermediate,,BAO_0000218
7534,,1,Compound was tested for solubility in water,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618656,50597,,N,Intermediate,,BAO_0000218
7535,,0,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,,,,,,1,,P,CHEMBL618657,22229,,U,Intermediate,,BAO_0000100
7536,,1,Solubility was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618658,50597,,N,Intermediate,,BAO_0000218
7537,,1,solubility in water (ug/mL) at 37 degree C.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618659,50597,,N,Intermediate,,BAO_0000218
7538,,1,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618660,50597,,N,Intermediate,,BAO_0000218
7539,,1,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618661,50597,,N,Intermediate,,BAO_0000218
7540,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873807,50597,,N,Intermediate,,BAO_0000218
7541,,1,Half life in Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618662,50597,,N,Intermediate,,BAO_0000218
7542,,1,Half life period after 3 mg/kg iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618663,50597,,N,Intermediate,,BAO_0000218
7543,,1,Half life period after 3 mg/kg iv administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618664,50597,,N,Intermediate,,BAO_0000218
7544,,1,Half life period after 3 mg/kg iv administration in the rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618665,50597,,N,Intermediate,,BAO_0000218
7545,,1,Half life period in female Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876498,50597,,N,Intermediate,,BAO_0000218
7546,,1,Half life period in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618666,50597,,N,Intermediate,,BAO_0000218
7547,,1,Half-life in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620440,50597,,N,Intermediate,,BAO_0000218
7548,,1,Half-life in rats with metabolic oxidation,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620441,50597,,N,Intermediate,,BAO_0000218
7549,,1,Half-life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620442,50597,,N,Intermediate,,BAO_0000218
7550,,1,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620443,50597,,N,Intermediate,,BAO_0000218
7551,,1,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620444,50597,,N,Intermediate,,BAO_0000218
7552,,1,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620445,50597,,N,Intermediate,,BAO_0000218
7553,,1,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620446,50597,,N,Intermediate,,BAO_0000218
7554,,1,Biological half-life measured in plasma of rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620447,50597,,N,Intermediate,,BAO_0000218
7555,,1,Biological half-life measured in plasma of rat; 22-25,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621129,50597,,N,Intermediate,,BAO_0000218
7556,,1,Biological half-life measured in plasma of rat; 9-16,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621130,50597,,N,Intermediate,,BAO_0000218
7557,,1,Compound was evaluated for its half life when administered intravenously in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873808,50597,,N,Intermediate,,BAO_0000218
7558,,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876598,50597,,N,Intermediate,,BAO_0000218
7559,,1,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621131,50597,,N,Intermediate,,BAO_0000218
7560,,1,Half life (T1/2) after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621132,50597,,N,Intermediate,,BAO_0000218
7561,,1,Half life of compound after iv administration of 20 mg/kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621133,50597,,N,Intermediate,,BAO_0000218
7562,,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621312,50597,,N,Expert,,BAO_0000218
7563,,1,Half life of compound was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621313,50597,,N,Intermediate,,BAO_0000218
7564,,1,Half life of compound was determined in rat blood,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621314,50597,,N,Intermediate,,BAO_0000218
7565,,1,Half life at 1 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621315,50597,,N,Intermediate,,BAO_0000218
7566,,1,Half life at 10 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621316,50597,,N,Intermediate,,BAO_0000218
7567,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621317,50597,,N,Intermediate,,BAO_0000218
7568,,1,Half life in rats in hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621318,50597,,N,Intermediate,,BAO_0000218
7569,,1,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621319,50597,,N,Intermediate,,BAO_0000218
7570,,1,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621377,50597,,N,Intermediate,,BAO_0000218
7571,,1,Half life was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621378,50597,,N,Intermediate,,BAO_0000218
7572,,1,Half life after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876599,50597,,N,Intermediate,,BAO_0000218
7573,,1,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621379,50597,,N,Intermediate,,BAO_0000218
7574,,1,Half life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621380,50597,,N,Intermediate,,BAO_0000218
7575,,1,Half life in rat plasma; Not detected,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621381,50597,,N,Intermediate,,BAO_0000218
7576,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618515,50597,,N,Intermediate,,BAO_0000218
7577,,1,Half life period of compound was determined after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618516,50597,,N,Intermediate,,BAO_0000218
7578,,1,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618517,50597,,N,Intermediate,,BAO_0000218
7579,,1,Half life period in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618518,50597,,N,Intermediate,,BAO_0000218
7580,,1,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618519,50597,,N,Intermediate,,BAO_0000218
7581,,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618698,50597,,N,Intermediate,,BAO_0000218
7582,,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618862,50597,,N,Intermediate,,BAO_0000218
7583,,1,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618863,50597,,N,Intermediate,,BAO_0000218
7584,,1,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618864,50597,,N,Intermediate,,BAO_0000218
7585,,1,Half life time in rat the dose of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618865,50597,,N,Intermediate,,BAO_0000218
7586,,1,Half-life 24 hr after 10 mg/kg iv administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618866,50597,,N,Intermediate,,BAO_0000218
7587,,1,Half-life 24 hr after 2 mg/kg iv administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618867,50597,,N,Intermediate,,BAO_0000218
7588,,1,Half-life consistent with the observed metabolic steady state in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875828,50597,,N,Intermediate,,BAO_0000218
7589,,1,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618868,50597,,N,Intermediate,,BAO_0000218
7590,,1,Half-life for oxidative metabolic stability was determined using male human,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618869,50597,,N,Intermediate,,BAO_0000218
7591,,1,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618870,50597,,N,Intermediate,,BAO_0000218
7592,,1,Half-life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618871,50597,,N,Intermediate,,BAO_0000218
7593,,1,Half-life in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618872,50597,,N,Intermediate,,BAO_0000218
7594,,1,Half-life in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873816,50597,,N,Intermediate,,BAO_0000218
7595,,0,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,,,,,,1,,A,CHEMBL618873,22224,,U,Autocuration,,BAO_0000218
7596,,0,Area under curve after oral dose of 0.1 mg//kg,,,,,,,1,,A,CHEMBL621602,22224,,U,Autocuration,,BAO_0000019
7597,,0,Area under curve after oral dose of 0.3 mg/kg,,,,,,,1,,A,CHEMBL621603,22224,,U,Autocuration,,BAO_0000218
7598,,0,Area under curve after oral dose of 1 mg/kg,,,,,,,1,,A,CHEMBL621604,22224,,U,Autocuration,,BAO_0000218
7599,,0,Area under curve after oral dose of 10 mg/kg,,,,,,,1,,A,CHEMBL621605,22224,,U,Autocuration,,BAO_0000218
7600,,0,Area under curve after oral dose of 23.4 mg/kg,,,,,,,1,,A,CHEMBL621606,22224,,U,Autocuration,,BAO_0000218
7601,,0,Area under curve after oral dose of 3 mg/kg,,,,,,,1,,A,CHEMBL621607,22224,,U,Autocuration,,BAO_0000218
7602,,0,Area under curve after oral dose of 3.87 mg/kg,,,,,,,1,,A,CHEMBL621608,22224,,U,Autocuration,,BAO_0000218
7603,,0,Area under curve was determined,,,,,,,1,,A,CHEMBL621609,22224,,U,Autocuration,,BAO_0000019
7604,,0,Area under curve at a dose of 10 mg/kg,,,,,,,1,,A,CHEMBL621610,22224,,U,Autocuration,,BAO_0000218
7605,,1,Area under curve was determined; ND=No data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621611,50597,,N,Intermediate,,BAO_0000218
7606,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621612,50597,,N,Intermediate,,BAO_0000218
7607,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622308,50597,,N,Intermediate,,BAO_0000218
7608,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622309,50597,,N,Intermediate,,BAO_0000218
7609,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622310,50597,,N,Intermediate,,BAO_0000218
7610,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622311,50597,,N,Intermediate,,BAO_0000218
7611,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622312,50597,,N,Intermediate,,BAO_0000218
7612,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622931,50597,,N,Intermediate,,BAO_0000218
7613,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622932,50597,,N,Intermediate,,BAO_0000218
7614,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622736,50597,,N,Intermediate,,BAO_0000218
7615,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622737,50597,,N,Intermediate,,BAO_0000218
7616,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622738,50597,,N,Intermediate,,BAO_0000218
7617,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622739,50597,,N,Intermediate,,BAO_0000218
7618,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622740,50597,,N,Intermediate,,BAO_0000218
7619,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622741,50597,,N,Intermediate,,BAO_0000218
7620,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622742,50597,,N,Intermediate,,BAO_0000218
7621,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622743,50597,,N,Intermediate,,BAO_0000218
7622,,1,AUC in mice,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL622744,50594,,N,Intermediate,,BAO_0000218
7623,,0,Area under curve was measured from the graph obtained from concentration Vs time,,,,,,,1,,A,CHEMBL624134,22224,,U,Autocuration,,BAO_0000019
7624,,0,Area under curve value of compound per hour after oral administration,,,,,,,1,,A,CHEMBL624135,22224,,U,Autocuration,,BAO_0000019
7625,,1,Area under curve was determined after oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624136,50597,,N,Intermediate,,BAO_0000218
7626,,1,Area under curve was determined after oral administration in rats; No data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624137,50597,,N,Intermediate,,BAO_0000218
7627,,1,Area under curve was determined after oral administration in rats;No data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624320,50597,,N,Intermediate,,BAO_0000218
7628,,1,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624321,50588,,N,Intermediate,,BAO_0000218
7629,,1,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624322,50597,,N,Intermediate,,BAO_0000218
7630,,1,Area under curve was determined for the compound after iv dose of 5.06 in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624323,50597,,N,Intermediate,,BAO_0000218
7631,,1,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624324,50597,,N,Intermediate,,BAO_0000218
7632,,1,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624325,50597,,N,Intermediate,,BAO_0000218
7633,,1,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624326,50597,,N,Intermediate,,BAO_0000218
7634,,1,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624327,50597,,N,Intermediate,,BAO_0000218
7635,,1,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624328,50597,,N,Intermediate,,BAO_0000218
7636,,1,Area under curve was determined in Dogs after peroral administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL627848,50588,,N,Intermediate,,BAO_0000218
7637,,1,Area under curve was determined in Rats after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627849,50597,,N,Intermediate,,BAO_0000218
7638,,1,Area under curve was determined in carotid blood of rat when administered intradermally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627850,50597,,N,Intermediate,,BAO_0000218
7639,,1,Area under curve was determined in portal blood of rat when administered intradermally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627851,50597,,N,Intermediate,,BAO_0000218
7640,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627852,50594,,N,Intermediate,,BAO_0000218
7641,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627853,50594,,N,Intermediate,,BAO_0000218
7642,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Mus musculus,,,,,,1,10090.0,A,CHEMBL627854,50594,,N,Intermediate,,BAO_0000218
7643,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627855,50594,,N,Intermediate,,BAO_0000218
7644,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),Mus musculus,,,,,,1,10090.0,A,CHEMBL627856,50594,,N,Intermediate,,BAO_0000218
7645,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL875339,50594,,N,Intermediate,,BAO_0000218
7646,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),Mus musculus,,,,,,1,10090.0,A,CHEMBL627857,50594,,N,Intermediate,,BAO_0000218
7647,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627858,50597,,N,Intermediate,,BAO_0000218
7648,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627859,50597,,N,Intermediate,,BAO_0000218
7649,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627860,50597,,N,Intermediate,,BAO_0000218
7650,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627019,50597,,N,Intermediate,,BAO_0000218
7651,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627020,50597,,N,Intermediate,,BAO_0000218
7652,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627021,50597,,N,Intermediate,,BAO_0000218
7653,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627022,50597,,N,Intermediate,,BAO_0000218
7654,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627023,50597,,N,Intermediate,,BAO_0000218
7655,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627024,50597,,N,Intermediate,,BAO_0000218
7656,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627025,50597,,N,Intermediate,,BAO_0000218
7657,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627026,50597,,N,Intermediate,,BAO_0000218
7658,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627027,50597,,N,Intermediate,,BAO_0000218
7659,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627028,50597,,N,Intermediate,,BAO_0000218
7660,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627029,50597,,N,Intermediate,,BAO_0000218
7661,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627030,50597,,N,Intermediate,,BAO_0000218
7662,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627031,50597,,N,Intermediate,,BAO_0000218
7663,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627032,50597,,N,Intermediate,,BAO_0000218
7664,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627033,50597,,N,Intermediate,,BAO_0000218
7665,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627034,50597,,N,Intermediate,,BAO_0000218
7666,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627035,50597,,N,Intermediate,,BAO_0000218
7667,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627036,50597,,N,Intermediate,,BAO_0000218
7668,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL875340,50597,,N,Intermediate,,BAO_0000218
7669,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627037,50597,,N,Intermediate,,BAO_0000218
7670,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627038,50597,,N,Intermediate,,BAO_0000218
7671,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627039,50597,,N,Intermediate,,BAO_0000218
7672,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627040,50597,,N,Intermediate,,BAO_0000218
7673,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL624663,50597,,N,Intermediate,,BAO_0000218
7674,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL625963,50597,,N,Intermediate,,BAO_0000218
7675,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL876799,50597,,N,Intermediate,,BAO_0000218
7676,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626133,50597,,N,Intermediate,,BAO_0000218
7677,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626134,50597,,N,Intermediate,,BAO_0000218
7678,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626135,50597,,N,Intermediate,,BAO_0000218
7679,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626136,50597,,N,Intermediate,,BAO_0000218
7680,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626137,50597,,N,Intermediate,,BAO_0000218
7681,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626138,50597,,N,Intermediate,,BAO_0000218
7682,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626139,50597,,N,Intermediate,,BAO_0000218
7683,,1,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626140,50597,,N,Intermediate,,BAO_0000218
7684,,1,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626141,50597,,N,Intermediate,,BAO_0000218
7685,,1,C24h in rat p.o. at 20 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626142,50597,,N,Intermediate,,BAO_0000218
7686,,1,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627930,50597,,N,Intermediate,,BAO_0000218
7687,,1,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627931,50597,,N,Intermediate,,BAO_0000218
7688,,1,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627932,50597,,N,Intermediate,,BAO_0000218
7689,,1,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627933,50597,,N,Intermediate,,BAO_0000218
7690,,1,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627934,50597,,N,Intermediate,,BAO_0000218
7691,,1,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627935,50597,,N,Intermediate,,BAO_0000218
7692,,1,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627936,50597,,N,Intermediate,,BAO_0000218
7693,,1,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627937,50597,,N,Intermediate,,BAO_0000218
7694,,1,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627938,50597,,N,Intermediate,,BAO_0000218
7695,,1,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627939,50597,,N,Intermediate,,BAO_0000218
7696,,1,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627940,50597,,N,Intermediate,,BAO_0000218
7697,,1,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627941,50597,,N,Intermediate,,BAO_0000218
7698,,1,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL876800,50597,,N,Intermediate,,BAO_0000218
7699,,1,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627942,50597,,N,Intermediate,,BAO_0000218
7700,,1,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627943,50597,,N,Intermediate,,BAO_0000218
7701,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627944,50597,,N,Intermediate,,BAO_0000218
7702,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627945,50597,,N,Intermediate,,BAO_0000218
7703,,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628584,50597,,N,Intermediate,,BAO_0000218
7704,,1,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628585,50597,,N,Intermediate,,BAO_0000218
7705,,1,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628586,50597,,N,Intermediate,,BAO_0000218
7706,,1,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628587,50597,,N,Intermediate,,BAO_0000218
7707,,1,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628588,50597,,N,Intermediate,,BAO_0000218
7708,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628589,50597,,N,Intermediate,,BAO_0000218
7709,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625304,50597,,N,Intermediate,,BAO_0000218
7710,,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625305,50597,,N,Intermediate,,BAO_0000218
7711,,1,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625306,50597,,N,Intermediate,,BAO_0000218
7712,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625307,50597,,N,Intermediate,,BAO_0000218
7713,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625308,50597,,N,Intermediate,,BAO_0000218
7714,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627740,50597,,N,Intermediate,,BAO_0000218
7715,,1,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627741,50597,,N,Intermediate,,BAO_0000218
7716,,1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627742,50597,,N,Intermediate,,BAO_0000218
7717,,1,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627743,50597,,N,Intermediate,,BAO_0000218
7718,,1,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627744,50597,,N,Intermediate,,BAO_0000218
7719,,1,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627745,50597,,N,Intermediate,,BAO_0000218
7720,,1,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627746,50597,,N,Intermediate,,BAO_0000218
7721,,1,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627747,50597,,N,Intermediate,,BAO_0000218
7722,,1,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL876810,50597,,N,Intermediate,,BAO_0000218
7723,,1,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627748,50597,,N,Intermediate,,BAO_0000218
7724,,1,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627749,50597,,N,Intermediate,,BAO_0000218
7725,,1,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627750,50597,,N,Intermediate,,BAO_0000218
7726,,1,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618728,50597,,N,Intermediate,,BAO_0000218
7727,,1,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618729,50597,,N,Intermediate,,BAO_0000218
7728,,1,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618730,50597,,N,Intermediate,,BAO_0000218
7729,,1,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618731,50597,,N,Intermediate,,BAO_0000218
7730,,1,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618732,50597,,N,Intermediate,,BAO_0000218
7731,,1,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618733,50597,,N,Intermediate,,BAO_0000218
7732,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618734,50597,,N,Intermediate,,BAO_0000218
7733,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618735,50597,,N,Intermediate,,BAO_0000218
7734,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL876602,50597,,N,Intermediate,,BAO_0000218
7735,,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618736,50597,,N,Intermediate,,BAO_0000218
7736,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618737,50597,,N,Intermediate,,BAO_0000218
7737,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618738,50597,,N,Intermediate,,BAO_0000218
7738,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618739,50597,,N,Intermediate,,BAO_0000218
7739,,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618740,50597,,N,Intermediate,,BAO_0000218
7740,,1,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618741,50597,,N,Intermediate,,BAO_0000218
7741,,1,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618742,50597,,N,Intermediate,,BAO_0000218
7742,,1,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL618743,50597,,N,Intermediate,,BAO_0000218
7743,,1,Half-life from rat plasma at a single oral dose of 25 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618744,50597,,N,Intermediate,,BAO_0000218
7744,,1,Half-life in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618745,50597,,N,Intermediate,,BAO_0000218
7745,,1,Half-life in rat after peroral administration at 10 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620479,50597,,N,Intermediate,,BAO_0000218
7746,,1,Half-life in rat after peroral administration at 5 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620480,50597,,N,Intermediate,,BAO_0000218
7747,,1,Half-life in rat at a dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620481,50597,,N,Intermediate,,BAO_0000218
7748,,1,Half-life was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620482,50597,,N,Intermediate,,BAO_0000218
7749,,1,Half-life was measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876603,50597,,N,Intermediate,,BAO_0000218
7750,,1,Half-life period for the compound was determined in rats at 50 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620483,50597,,N,Intermediate,,BAO_0000218
7751,,1,Half-life period in rats after intravenous administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620484,50597,,N,Intermediate,,BAO_0000218
7752,,1,Half-life period in rat at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620485,50597,,N,Intermediate,,BAO_0000218
7753,,1,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620486,50597,,N,Intermediate,,BAO_0000218
7754,,1,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620487,50597,,N,Intermediate,,BAO_0000218
7755,,1,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620488,50597,,N,Intermediate,,BAO_0000218
7756,,1,Half-life time in rat the dose of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620489,50597,,N,Intermediate,,BAO_0000218
7757,,1,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620490,50597,,N,Intermediate,,BAO_0000218
7758,,1,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620491,50597,,N,Intermediate,,BAO_0000218
7759,,1,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876604,50597,,N,Intermediate,,BAO_0000218
7760,,1,Oral half life was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620492,50597,,N,Intermediate,,BAO_0000218
7761,,1,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620493,50597,,N,Intermediate,,BAO_0000218
7762,,1,Pharmacokinetic property (t1/2) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620494,50597,,N,Intermediate,,BAO_0000218
7763,,1,Plasma elimination half-life was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620495,50597,,N,Intermediate,,BAO_0000218
7764,,1,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620496,50597,,N,Intermediate,,BAO_0000218
7765,,1,Plasma half life was observed after intravenous administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620497,50597,,N,Intermediate,,BAO_0000218
7766,,1,Plasma half-life was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620498,50597,,N,Intermediate,,BAO_0000218
7767,,1,Plasma half-life following oral administration in Fisher rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620499,50597,,N,Intermediate,,BAO_0000218
7768,,1,Plasma half-life in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620500,50597,,N,Intermediate,,BAO_0000218
7769,,1,Plasmatic Half-life after intravenous administration to rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873809,50597,,N,Intermediate,,BAO_0000218
7770,,1,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620501,50597,,N,Intermediate,,BAO_0000218
7771,,1,Terminal half life after intravenous administration (1 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620502,50597,,N,Intermediate,,BAO_0000218
7772,,1,Terminal half life in Rat at a oral dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620503,50597,,N,Intermediate,,BAO_0000218
7773,,1,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620504,50597,,N,Intermediate,,BAO_0000218
7774,,1,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876605,50597,,N,Intermediate,,BAO_0000218
7775,,1,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620505,50597,,N,Intermediate,,BAO_0000218
7776,,1,plasma half life was observed after intravenous administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873811,50597,,N,Intermediate,,BAO_0000218
7777,,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624016,50597,,N,Expert,,BAO_0000218
7778,,1,Half life of compound determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624017,50597,,N,Intermediate,,BAO_0000218
7779,,1,Mean residence time determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624018,50597,,N,Intermediate,,BAO_0000218
7780,,1,Plasma half life determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624019,50597,,N,Intermediate,,BAO_0000218
7781,,1,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624020,50597,,N,Intermediate,,BAO_0000218
7782,,1,Compound was evaluated for pharmacokinetic parameter maximum time period,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624201,50597,,N,Intermediate,,BAO_0000218
7783,,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL872528,50597,,N,Intermediate,,BAO_0000218
7784,,1,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624202,50597,,N,Intermediate,,BAO_0000218
7785,,1,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624203,50597,,N,Intermediate,,BAO_0000218
7786,,1,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624350,50597,,N,Intermediate,,BAO_0000218
7787,,1,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621320,50597,,N,Intermediate,,BAO_0000218
7788,,1,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621321,50597,,N,Intermediate,,BAO_0000218
7789,,1,Maximum time (Tmax) required to reach Cmax in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621322,50597,,N,Intermediate,,BAO_0000218
7790,,1,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621323,50597,,N,Intermediate,,BAO_0000218
7791,,1,Maximum time of clearance of compound in rats after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621324,50597,,N,Intermediate,,BAO_0000218
7792,,1,Maximum time at the dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621325,50597,,N,Intermediate,,BAO_0000218
7793,,1,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL875837,50597,,N,Intermediate,,BAO_0000218
7794,,1,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621326,50597,,N,Intermediate,,BAO_0000218
7795,,1,Tmax in Guinea pig (PO dose),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621327,50597,,N,Intermediate,,BAO_0000218
7796,,1,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621328,50597,,N,Intermediate,,BAO_0000218
7797,,1,Pharmacokinetic parameter (Tmax) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621329,50597,,N,Intermediate,,BAO_0000218
7798,,1,Pharmacokinetic parameter (Tmax) was estimated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621330,50597,,N,Intermediate,,BAO_0000218
7799,,1,Pharmacokinetic property (Tmax) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621331,50597,,N,Intermediate,,BAO_0000218
7800,,1,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621332,50597,,N,Intermediate,,BAO_0000218
7801,,1,T max in Rat at a oral dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621333,50597,,N,Intermediate,,BAO_0000218
7802,,1,T max was determined at 10 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621334,50597,,N,Intermediate,,BAO_0000218
7803,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),Mus musculus,,,,,,1,10090.0,A,CHEMBL621335,50594,,N,Intermediate,,BAO_0000218
7804,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621336,50588,,N,Intermediate,,BAO_0000218
7805,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621337,50597,,N,Intermediate,,BAO_0000218
7806,,1,Area under curve was measured after i.v. administration into Beagle dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621338,50588,,N,Intermediate,,BAO_0000218
7807,,1,Area under curve was measured after iv administration into Beagle dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL875838,50588,,N,Intermediate,,BAO_0000218
7808,,1,Area under curve was measured after po administration into Beagle dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621339,50588,,N,Intermediate,,BAO_0000218
7809,,1,Area under curve was measured after po administration into Beagle dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621340,50588,,N,Intermediate,,BAO_0000218
7810,,0,Area under curve was measured at peroral dose of 3 mg/kg,,,,,,,1,,A,CHEMBL621341,22224,,U,Autocuration,,BAO_0000218
7811,,0,Area under curve was measured by using concentration Vs time,,,,,,,1,,A,CHEMBL621342,22224,,U,Autocuration,,BAO_0000019
7812,,0,Area under curve was measured by using concentration Vs time; not tested,,,,,,,1,,A,CHEMBL621343,22224,,U,Autocuration,,BAO_0000019
7813,,1,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),Mus musculus,,,,,,1,10090.0,A,CHEMBL621344,50594,,N,Intermediate,,BAO_0000218
7814,,1,Area under curve(AUC) was measured in mice after oral administration.,Mus musculus,,,,,,1,10090.0,A,CHEMBL621345,50594,,N,Intermediate,,BAO_0000218
7815,,0,Area under curve(AUC) value of the compound,,,,,,,1,,A,CHEMBL621346,22224,,U,Autocuration,,BAO_0000019
7816,,0,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,,,,,,1,,A,CHEMBL621347,22224,,U,Autocuration,,BAO_0000218
7817,,1,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621348,50588,,N,Intermediate,,BAO_0000218
7818,,0,Area under curve(carotid artery) was determined by the availability in blood,,,,Blood,178.0,,1,,A,CHEMBL621349,22224,,U,Autocuration,,BAO_0000019
7819,,0,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,,,Blood,178.0,,1,,A,CHEMBL621350,22224,,U,Autocuration,,BAO_0000019
7820,,0,Area under curve(carotid artery) was determined by the availability in blood; No data,,,,Blood,178.0,,1,,A,CHEMBL875839,22224,,U,Autocuration,,BAO_0000019
7821,,0,Area under curve(portal vein) was determined by the availability in blood,,,,Blood,178.0,,1,,A,CHEMBL620211,22224,,U,Autocuration,,BAO_0000019
7822,,0,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,,,Blood,178.0,,1,,A,CHEMBL620212,22224,,U,Autocuration,,BAO_0000019
7823,,0,Area under curve(portal vein) was determined by the availability in blood; No data,,,,Blood,178.0,,1,,A,CHEMBL620213,22224,,U,Autocuration,,BAO_0000019
7824,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL620214,50797,,N,Intermediate,,BAO_0000218
7825,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL620215,50797,,N,Intermediate,,BAO_0000218
7826,,1,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL620216,50797,,N,Intermediate,,BAO_0000218
7827,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL620888,50588,,N,Intermediate,,BAO_0000218
7828,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL620889,50588,,N,Intermediate,,BAO_0000218
7829,,0,Area under plasma concentration vs time curve observed in rats for 0-3 h,,,,Plasma,1969.0,,1,,A,CHEMBL620890,22224,,U,Autocuration,,BAO_0000019
7830,,1,Area under plasma time curve determined in male rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL620891,50597,,N,Intermediate,,BAO_0000218
7831,,0,Area under the MAP curve measured over 5 min.,,,,,,,1,,A,CHEMBL620892,22224,,U,Autocuration,,BAO_0000019
7832,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL621079,50594,,N,Intermediate,,BAO_0000218
7833,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL621080,50594,,N,Intermediate,,BAO_0000218
7834,,1,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621081,50588,,N,Intermediate,,BAO_0000218
7835,,1,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,Cricetinae,,,,,,1,10026.0,A,CHEMBL621082,100712,,N,Intermediate,,BAO_0000218
7836,,1,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621083,50597,,N,Intermediate,,BAO_0000218
7837,,1,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621084,50588,,N,Intermediate,,BAO_0000218
7838,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621085,50588,,N,Intermediate,,BAO_0000218
7839,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621086,50588,,N,Intermediate,,BAO_0000218
7840,,1,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621087,50588,,N,Intermediate,,BAO_0000218
7841,,1,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622607,50588,,N,Intermediate,,BAO_0000218
7842,,1,Serum AUC in marmosets (IV dose),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622608,50588,,N,Intermediate,,BAO_0000218
7843,,0,Area under the curve after intravenous administration at a dose of 10 umol/kg,,,,,,,1,,A,CHEMBL624481,22224,,U,Autocuration,,BAO_0000019
7844,,0,Area under the curve after intravenous administration at a dose of 2 umol/kg,,,,,,,1,,A,CHEMBL624482,22224,,U,Autocuration,,BAO_0000019
7845,,0,Area under the curve after intravenous administration at a dose of 4 umol/kg,,,,,,,1,,A,CHEMBL624483,22224,,U,Autocuration,,BAO_0000019
7846,,0,Area under the curve after intravenous administration at a dose of 40 umol/kg,,,,,,,1,,A,CHEMBL624484,22224,,U,Autocuration,,BAO_0000019
7847,,0,Area under the curve after intravenous administration at a dose of 5 umol/kg,,,,,,,1,,A,CHEMBL624485,22224,,U,Autocuration,,BAO_0000019
7848,,1,Area under the curve for fumarate salt was evaluated in F344 Rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624486,50597,,N,Intermediate,,BAO_0000218
7849,,0,Area under the curve for the compound was calculated.,,,,,,,1,,A,CHEMBL624487,22224,,U,Autocuration,,BAO_0000019
7850,,0,Area under the curve in concentration/ time,,,,,,,1,,A,CHEMBL624488,22224,,U,Autocuration,,BAO_0000019
7851,,1,Area under the curve administered intraintestinal in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624489,50597,,N,Intermediate,,BAO_0000218
7852,,1,Area under the curve administered intravenously in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625184,50597,,N,Intermediate,,BAO_0000218
7853,,0,Area under the curve during intravenous administration,,,,,,,1,,A,CHEMBL625185,22224,,U,Autocuration,,BAO_0000019
7854,,0,Area under the curve during intravenous administration; Not determined,,,,,,,1,,A,CHEMBL875954,22224,,U,Autocuration,,BAO_0000019
7855,,0,Area under the curve during systemic administration,,,,,,,1,,A,CHEMBL625186,22224,,U,Autocuration,,BAO_0000019
7856,,0,Area under the curve during systemic administration; Not determined,,,,,,,1,,A,CHEMBL625187,22224,,U,Autocuration,,BAO_0000019
7857,,0,Area under the curve was calculated for the compound.,,,,,,,1,,A,CHEMBL625188,22224,,U,Autocuration,,BAO_0000019
7858,,1,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625189,50588,,N,Intermediate,,BAO_0000218
7859,,1,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625190,50588,,N,Intermediate,,BAO_0000218
7860,,1,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621733,50597,,N,Intermediate,,BAO_0000218
7861,,1,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621734,50597,,N,Intermediate,,BAO_0000218
7862,,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621735,50597,,N,Intermediate,,BAO_0000218
7863,,1,Clearance of the drug was measured in the plasma of rat; No data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621736,50597,,N,Intermediate,,BAO_0000218
7864,,1,The pharmacokinetic parameter plasma clearance in vivo in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621737,50597,,N,Intermediate,,BAO_0000218
7865,,1,Plasma clearance at the dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621738,50597,,N,Intermediate,,BAO_0000218
7866,,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622806,50597,,N,Intermediate,,BAO_0000218
7867,,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623519,50597,,N,Intermediate,,BAO_0000218
7868,,1,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623520,50597,,N,Intermediate,,BAO_0000218
7869,,1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623521,50597,,N,Intermediate,,BAO_0000218
7870,,1,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623522,50597,,N,Intermediate,,BAO_0000218
7871,,1,Clearance rate in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623523,50597,,N,Intermediate,,BAO_0000218
7872,,1,Clearance rate in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623690,50597,,N,Intermediate,,BAO_0000218
7873,,1,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623691,50597,,N,Intermediate,,BAO_0000218
7874,,1,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623692,50597,,N,Intermediate,,BAO_0000218
7875,,1,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623693,50597,,N,Intermediate,,BAO_0000218
7876,,1,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623694,50597,,N,Intermediate,,BAO_0000218
7877,,1,Clearance of compound after iv administration of 20 mg/kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623695,50597,,N,Intermediate,,BAO_0000218
7878,,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623696,50597,,N,Intermediate,,BAO_0000218
7879,,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623697,50597,,N,Intermediate,,BAO_0000218
7880,,0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL623698,22224,,U,Intermediate,,BAO_0000218
7881,,0,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623699,22224,,U,Intermediate,,BAO_0000218
7882,,1,Mean (%CV) PK parameters for CL(mL/min/kg).,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623700,50597,,N,Intermediate,,BAO_0000218
7883,,1,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623701,50597,,N,Intermediate,,BAO_0000218
7884,,1,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623702,50597,,N,Intermediate,,BAO_0000218
7885,,1,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623703,50597,,N,Intermediate,,BAO_0000218
7886,,1,Plasma clearance in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623704,50597,,N,Intermediate,,BAO_0000218
7887,,1,Plasma clearance in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623705,50597,,N,Intermediate,,BAO_0000218
7888,,1,Plasma clearance in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623706,50597,,N,Intermediate,,BAO_0000218
7889,,1,Plasma clearance was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623707,50597,,N,Intermediate,,BAO_0000218
7890,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623708,50597,,N,Intermediate,,BAO_0000218
7891,,1,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623709,50597,,N,Intermediate,,BAO_0000218
7892,,1,Plasma clearance in rat by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623710,50597,,N,Intermediate,,BAO_0000218
7893,,1,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623711,50597,,N,Intermediate,,BAO_0000218
7894,,1,Plasma clearance in rat p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623712,50597,,N,Intermediate,,BAO_0000218
7895,,1,Plasma clearance in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623713,50597,,N,Intermediate,,BAO_0000218
7896,,1,Plasma clearance was determined; ND denotes no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623714,50597,,N,Intermediate,,BAO_0000218
7897,,1,Plasma clearance was determined; ND denotes not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623715,50597,,N,Intermediate,,BAO_0000218
7898,,1,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623716,50597,,N,Intermediate,,BAO_0000218
7899,,1,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622980,50597,,N,Intermediate,,BAO_0000218
7900,,1,Plasma administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622981,50597,,N,Intermediate,,BAO_0000218
7901,,1,Plasma clearance of the compound in female Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622982,50597,,N,Intermediate,,BAO_0000218
7902,,1,Plasma clearance was observed after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622983,50597,,N,Intermediate,,BAO_0000218
7903,,1,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622984,50597,,N,Intermediate,,BAO_0000218
7904,,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622985,50597,,N,Intermediate,,BAO_0000218
7905,,1,plasma clearance was observed after intravenous administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623631,50597,,N,Intermediate,,BAO_0000218
7906,,1,In vivo CL/F determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623632,50597,,N,Intermediate,,BAO_0000218
7907,,1,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623633,50597,,N,Intermediate,,BAO_0000218
7908,,1,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623634,50597,,N,Intermediate,,BAO_0000218
7909,,1,Compound was tested for the lower blood clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623635,50597,,N,Intermediate,,BAO_0000218
7910,,1,Evaluated for the low clearance in rat (in vivo),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621195,50597,,N,Intermediate,,BAO_0000218
7911,,1,Pharmacokinetic property (CLb)of the compound was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621196,50597,,N,Intermediate,,BAO_0000218
7912,,1,Rapid clearance after intravenous administration in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875287,50597,,N,Intermediate,,BAO_0000218
7913,,1,Clearance measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621197,50597,,N,Intermediate,,BAO_0000218
7914,,1,Compound was evaluated for plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621198,50597,,N,Intermediate,,BAO_0000218
7915,,1,Low plasma clearance was calculated in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621199,50597,,N,Intermediate,,BAO_0000218
7916,,1,Pharmacokinetic property (Clp) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621200,50597,,N,Intermediate,,BAO_0000218
7917,,1,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621201,50597,,N,Intermediate,,BAO_0000218
7918,,1,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621202,50597,,N,Intermediate,,BAO_0000218
7919,,1,Plasma clearance after IV dosing at 0.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621203,50597,,N,Intermediate,,BAO_0000218
7920,,1,Plasma clearance after IV dosing at 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621204,50597,,N,Intermediate,,BAO_0000218
7921,,1,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621205,50597,,N,Intermediate,,BAO_0000218
7922,,1,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621206,50597,,N,Intermediate,,BAO_0000218
7923,,1,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621207,50597,,N,Intermediate,,BAO_0000218
7924,,1,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621208,50597,,N,Intermediate,,BAO_0000218
7925,,1,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621209,50597,,N,Intermediate,,BAO_0000218
7926,,1,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL876484,50597,,N,Intermediate,,BAO_0000218
7927,,1,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621210,50597,,N,Intermediate,,BAO_0000218
7928,,1,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621211,50597,,N,Intermediate,,BAO_0000218
7929,,1,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621212,50597,,N,Intermediate,,BAO_0000218
7930,,1,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621213,50597,,N,Intermediate,,BAO_0000218
7931,,1,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621214,50597,,N,Intermediate,,BAO_0000218
7932,,1,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621215,50597,,N,Intermediate,,BAO_0000218
7933,,1,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621216,50597,,N,Intermediate,,BAO_0000218
7934,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621217,50597,,N,Intermediate,,BAO_0000218
7935,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621218,50597,,N,Intermediate,,BAO_0000218
7936,,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621219,50597,,N,Intermediate,,BAO_0000218
7937,,1,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621220,50597,,N,Intermediate,,BAO_0000218
7938,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621221,50597,,N,Intermediate,,BAO_0000218
7939,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621222,50597,,N,Intermediate,,BAO_0000218
7940,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621223,50597,,N,Intermediate,,BAO_0000218
7941,,1,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL876485,50597,,N,Intermediate,,BAO_0000218
7942,,1,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621224,50597,,N,Intermediate,,BAO_0000218
7943,,1,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621225,50597,,N,Intermediate,,BAO_0000218
7944,,1,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621226,50597,,N,Intermediate,,BAO_0000218
7945,,1,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621227,50597,,N,Intermediate,,BAO_0000218
7946,,1,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621228,50597,,N,Intermediate,,BAO_0000218
7947,,1,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621229,50597,,N,Intermediate,,BAO_0000218
7948,,1,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621230,50597,,N,Intermediate,,BAO_0000218
7949,,1,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621231,50597,,N,Intermediate,,BAO_0000218
7950,,1,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621232,50597,,N,Intermediate,,BAO_0000218
7951,,1,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621233,50597,,N,Intermediate,,BAO_0000218
7952,,1,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621234,50597,,N,Intermediate,,BAO_0000218
7953,,1,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621235,50597,,N,Intermediate,,BAO_0000218
7954,,1,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621236,50597,,N,Intermediate,,BAO_0000218
7955,,1,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621237,50597,,N,Intermediate,,BAO_0000218
7956,,1,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL876486,50597,,N,Intermediate,,BAO_0000218
7957,,1,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622436,50597,,N,Intermediate,,BAO_0000218
7958,,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622437,50597,,N,Intermediate,,BAO_0000218
7959,,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622438,50597,,N,Intermediate,,BAO_0000218
7960,,1,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622439,50597,,N,Intermediate,,BAO_0000218
7961,,1,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622440,50597,,N,Intermediate,,BAO_0000218
7962,,1,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622441,50597,,N,Intermediate,,BAO_0000218
7963,,1,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622442,50597,,N,Intermediate,,BAO_0000218
7964,,1,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622443,50597,,N,Intermediate,,BAO_0000218
7965,,1,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622444,50597,,N,Intermediate,,BAO_0000218
7966,,1,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622445,50597,,N,Intermediate,,BAO_0000218
7967,,1,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622446,50597,,N,Intermediate,,BAO_0000218
7968,,1,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622447,50597,,N,Intermediate,,BAO_0000218
7969,,1,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622448,50597,,N,Intermediate,,BAO_0000218
7970,,1,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622449,50597,,N,Intermediate,,BAO_0000218
7971,,1,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622450,50597,,N,Intermediate,,BAO_0000218
7972,,1,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622451,50597,,N,Intermediate,,BAO_0000218
7973,,1,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622452,50597,,N,Intermediate,,BAO_0000218
7974,,1,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622453,50597,,N,Intermediate,,BAO_0000218
7975,,1,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622454,50597,,N,Intermediate,,BAO_0000218
7976,,1,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622455,50597,,N,Intermediate,,BAO_0000218
7977,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL876024,50597,,N,Intermediate,,BAO_0000218
7978,,1,T max was determined at 3 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622456,50597,,N,Intermediate,,BAO_0000218
7979,,1,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622457,50597,,N,Intermediate,,BAO_0000218
7980,,1,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622458,50597,,N,Intermediate,,BAO_0000218
7981,,1,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622459,50597,,N,Intermediate,,BAO_0000218
7982,,1,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873343,50597,,N,Intermediate,,BAO_0000218
7983,,1,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622460,50597,,N,Intermediate,,BAO_0000218
7984,,1,Time for maximum plasma concentration determined in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622461,50597,,N,Intermediate,,BAO_0000218
7985,,1,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622462,50597,,N,Intermediate,,BAO_0000218
7986,,1,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622463,50597,,N,Intermediate,,BAO_0000218
7987,,1,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622464,50597,,N,Intermediate,,BAO_0000218
7988,,1,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622465,50597,,N,Intermediate,,BAO_0000218
7989,,1,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622466,50597,,N,Intermediate,,BAO_0000218
7990,,1,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622467,50597,,N,Intermediate,,BAO_0000218
7991,,1,Time of maximum plasma concentration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622468,50597,,N,Intermediate,,BAO_0000218
7992,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876025,50597,,N,Intermediate,,BAO_0000218
7993,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622469,50597,,N,Intermediate,,BAO_0000218
7994,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622470,50597,,N,Intermediate,,BAO_0000218
7995,,1,Time required to reach maximum concentration (Cmax) after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622471,50597,,N,Intermediate,,BAO_0000218
7996,,1,Time required to reach maximum concentration in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622472,50597,,N,Intermediate,,BAO_0000218
7997,,1,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622473,50597,,N,Intermediate,,BAO_0000218
7998,,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624282,50597,,N,Intermediate,,BAO_0000218
7999,,1,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624283,50597,,N,Intermediate,,BAO_0000218
8000,,1,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624284,50597,,N,Intermediate,,BAO_0000218
8001,,1,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624285,50597,,N,Intermediate,,BAO_0000218
8002,,1,Time to reach Cmax after oral administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624286,50597,,N,Intermediate,,BAO_0000218
8003,,1,Time to reach Cmax when a dose of 1 mg/kg is administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624287,50597,,N,Intermediate,,BAO_0000218
8004,,1,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624288,50597,,N,Intermediate,,BAO_0000218
8005,,1,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624289,50597,,N,Intermediate,,BAO_0000218
8006,,1,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873344,50597,,N,Intermediate,,BAO_0000218
8007,,1,Tmax after peroral administration (10 mg/kg) was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619623,50597,,N,Intermediate,,BAO_0000218
8008,,1,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621399,50597,,N,Expert,,BAO_0000218
8009,,1,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621400,50597,,N,Intermediate,,BAO_0000218
8010,,1,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621401,50597,,N,Intermediate,,BAO_0000218
8011,,1,Tmax was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621402,50597,,N,Intermediate,,BAO_0000218
8012,,1,Tmax was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621403,50597,,N,Intermediate,,BAO_0000218
8013,,1,Tmax after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621121,50597,,N,Intermediate,,BAO_0000218
8014,,1,Tmax after peroral administration in rats at 2.4 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL872525,50597,,N,Intermediate,,BAO_0000218
8015,,1,Tmax in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621122,50597,,N,Intermediate,,BAO_0000218
8016,,1,Tmax in rat at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621123,50597,,N,Intermediate,,BAO_0000218
8017,,1,Tmax in rat by po administration at a dose of 40 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621124,50597,,N,Intermediate,,BAO_0000218
8018,,1,Tmax in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621125,50597,,N,Intermediate,,BAO_0000218
8019,,1,Tmax was measured in rats after peroral administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621126,50597,,N,Intermediate,,BAO_0000218
8020,,1,Tmax value after oral dose at a dose of 10 mg/kg in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621127,50597,,N,Intermediate,,BAO_0000218
8021,,1,Tmax value after administration of 20 mg/Kg oral dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621128,50597,,N,Intermediate,,BAO_0000218
8022,,1,Tmax value at a dose of 10 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618263,50597,,N,Intermediate,,BAO_0000218
8023,,1,Tmax value at a dose of 100 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618264,50597,,N,Intermediate,,BAO_0000218
8024,,1,Tmax value at a dose of 50 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618265,50597,,N,Intermediate,,BAO_0000218
8025,,1,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618266,50597,,N,Intermediate,,BAO_0000218
8026,,1,time required to reach maximum concentration (Cmax) after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618267,50597,,N,Intermediate,,BAO_0000218
8027,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL618450,50597,,N,Intermediate,,BAO_0000218
8028,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL618451,50597,,N,Intermediate,,BAO_0000218
8029,,1,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618452,50597,,N,Intermediate,,BAO_0000218
8030,,1,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL618453,50597,,N,Intermediate,,BAO_0000218
8031,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL618454,50597,,N,Intermediate,,BAO_0000218
8032,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL618455,50597,,N,Intermediate,,BAO_0000218
8033,,1,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618456,50597,,N,Intermediate,,BAO_0000218
8034,,1,Compound distribution in rat tissues was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618457,50597,,N,Intermediate,,BAO_0000218
8035,,1,Volume of distribution was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618458,50597,,N,Intermediate,,BAO_0000218
8036,,1,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618459,50597,,N,Intermediate,,BAO_0000218
8037,,1,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876733,50597,,N,Intermediate,,BAO_0000218
8038,,1,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL618460,50588,,N,Intermediate,,BAO_0000218
8039,,1,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618461,50597,,N,Intermediate,,BAO_0000218
8040,,0,Area under the curve was determined after oral administration (300 uM/Kg),,,,,,,1,,A,CHEMBL618462,22224,,U,Autocuration,,BAO_0000019
8041,,1,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618463,50597,,N,Intermediate,,BAO_0000218
8042,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618464,50597,,N,Intermediate,,BAO_0000218
8043,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618465,50597,,N,Intermediate,,BAO_0000218
8044,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618466,50597,,N,Intermediate,,BAO_0000218
8045,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618467,50597,,N,Intermediate,,BAO_0000218
8046,,1,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618468,50597,,N,Intermediate,,BAO_0000218
8047,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL618469,50588,,N,Intermediate,,BAO_0000218
8048,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL618470,50588,,N,Intermediate,,BAO_0000218
8049,,0,Plasma drug AUC in rat (PO dose),,,,,,,1,,A,CHEMBL618471,22224,,U,Autocuration,,BAO_0000218
8050,,1,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,Mus musculus,,,,,,1,10090.0,A,CHEMBL618472,50594,,N,Intermediate,,BAO_0000218
8051,,0,Area under was determined at a dose of 30 mg/kg,,,,,,,1,,A,CHEMBL618473,22224,,U,Autocuration,,BAO_0000218
8052,,1,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL621699,50506,,N,Intermediate,,BAO_0000218
8053,,1,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621700,50597,,N,Intermediate,,BAO_0000218
8054,,1,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621701,50597,,N,Intermediate,,BAO_0000218
8055,,1,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL621702,50506,,N,Intermediate,,BAO_0000218
8056,,1,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621703,50588,,N,Intermediate,,BAO_0000218
8057,,1,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL621704,50588,,N,Intermediate,,BAO_0000218
8058,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624259,50597,,N,Intermediate,,BAO_0000218
8059,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624260,50597,,N,Intermediate,,BAO_0000218
8060,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624430,50597,,N,Intermediate,,BAO_0000218
8061,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624431,50597,,N,Intermediate,,BAO_0000218
8062,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624432,50597,,N,Intermediate,,BAO_0000218
8063,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624433,50597,,N,Intermediate,,BAO_0000218
8064,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624434,50597,,N,Intermediate,,BAO_0000218
8065,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624435,50597,,N,Intermediate,,BAO_0000218
8066,,1,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL618570,50594,,N,Intermediate,,BAO_0000218
8067,,1,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Mus musculus,,,,,,1,10090.0,A,CHEMBL618571,50594,,N,Intermediate,,BAO_0000218
8068,,1,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL618572,50594,,N,Intermediate,,BAO_0000218
8069,,1,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Mus musculus,,,,,,1,10090.0,A,CHEMBL618573,50594,,N,Intermediate,,BAO_0000218
8070,,1,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL619267,50594,,N,Intermediate,,BAO_0000218
8071,,1,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Mus musculus,,,,,,1,10090.0,A,CHEMBL619431,50594,,N,Intermediate,,BAO_0000218
8072,,1,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL619432,50594,,N,Intermediate,,BAO_0000218
8073,,1,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Mus musculus,,,,,,1,10090.0,A,CHEMBL619433,50594,,N,Intermediate,,BAO_0000218
8074,,0,AUC in mice after oral dose (50 mg/kg),,,,Plasma,1969.0,,1,,A,CHEMBL619434,22224,,U,Autocuration,,BAO_0000218
8075,,1,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Mus musculus,,,Serum,1977.0,,1,10090.0,A,CHEMBL619435,50594,,N,Intermediate,,BAO_0000218
8076,,0,AUC (0-4 hr) ug/ml/h,,,,Plasma,1969.0,,1,,A,CHEMBL619436,22224,,U,Autocuration,,BAO_0000019
8077,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619437,50597,,N,Intermediate,,BAO_0000218
8078,,0,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,,,,,,1,,A,CHEMBL619438,22224,,U,Autocuration,,BAO_0000218
8079,,1,Compound was evaluated for Area under curve in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL619439,50594,,N,Intermediate,,BAO_0000218
8080,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619440,50597,,N,Intermediate,,BAO_0000218
8081,,0,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,,,,,,1,,F,CHEMBL619441,22224,,U,Autocuration,,BAO_0000218
8082,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619442,50597,,N,Intermediate,,BAO_0000218
8083,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,,,,,,1,,A,CHEMBL875156,22224,,U,Autocuration,,BAO_0000019
8084,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,,,,,,1,,A,CHEMBL619443,22224,,U,Autocuration,,BAO_0000019
8085,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,,,,,,1,,A,CHEMBL619444,22224,,U,Autocuration,,BAO_0000019
8086,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,,,,,,1,,A,CHEMBL623464,22224,,U,Autocuration,,BAO_0000019
8087,,1,Compound was evaluated for area under curve when administered through oral route in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL623465,50594,,N,Intermediate,,BAO_0000218
8088,,1,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623466,50597,,N,Intermediate,,BAO_0000218
8089,,1,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623467,50597,,N,Intermediate,,BAO_0000218
8090,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623468,50597,,N,Intermediate,,BAO_0000218
8091,,1,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622660,50597,,N,Intermediate,,BAO_0000218
8092,,1,Plasma clearance rate in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622661,50597,,N,Intermediate,,BAO_0000218
8093,,1,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL622662,50597,,N,Intermediate,,BAO_0000218
8094,,1,Pharmacokinetic property (total body clearance) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622663,50597,,N,Intermediate,,BAO_0000218
8095,,1,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622664,50597,,N,Intermediate,,BAO_0000218
8096,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622665,50597,,N,Intermediate,,BAO_0000218
8097,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622666,50597,,N,Intermediate,,BAO_0000218
8098,,1,Cl in rat i.v. at 2 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621615,50597,,N,Intermediate,,BAO_0000218
8099,,1,Clearance of compound after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621616,50597,,N,Intermediate,,BAO_0000218
8100,,1,Clearance was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621617,50597,,N,Intermediate,,BAO_0000218
8101,,1,Clearance by intravenous administration of 3.4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621618,50597,,N,Intermediate,,BAO_0000218
8102,,1,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621619,50597,,N,Intermediate,,BAO_0000218
8103,,1,Clearance rate after i.v. administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621620,50597,,N,Intermediate,,BAO_0000218
8104,,1,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621786,50597,,N,Intermediate,,BAO_0000218
8105,,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621787,50597,,N,Intermediate,,BAO_0000218
8106,,1,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621788,50597,,N,Intermediate,,BAO_0000218
8107,,1,Clearance (Cl) after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621789,50597,,N,Intermediate,,BAO_0000218
8108,,1,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621790,50597,,N,Intermediate,,BAO_0000218
8109,,1,Compound was tested for plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621791,50597,,N,Intermediate,,BAO_0000218
8110,Microsomes,1,In vitro microsome metabolism clearance in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621792,50597,,N,Intermediate,,BAO_0000218
8111,Microsomes,1,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621793,50597,,N,Intermediate,,BAO_0000218
8112,,1,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621794,50597,,N,Intermediate,,BAO_0000218
8113,,1,In vivo plasma clearance was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621795,50597,,N,Intermediate,,BAO_0000218
8114,,1,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621796,50597,,N,Intermediate,,BAO_0000218
8115,,1,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Rattus norvegicus,,,Liver,2107.0,401.0,1,10116.0,A,CHEMBL621797,50597,,N,Intermediate,,BAO_0000218
8116,,1,Pharmacokinetic property (Plasma clearance) was measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621798,50597,,N,Intermediate,,BAO_0000218
8117,,1,Pharmacokinetic property (clearance) in rat i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621799,50597,,N,Intermediate,,BAO_0000218
8118,,1,"Plasma Clearance was evaluated in rats, iv",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621800,50597,,N,Intermediate,,BAO_0000218
8119,,1,Plasma clearance (in vivo) in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621801,50597,,N,Intermediate,,BAO_0000218
8120,,1,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621802,50597,,N,Intermediate,,BAO_0000218
8121,,1,Plasma clearance was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618596,50597,,N,Intermediate,,BAO_0000218
8122,,1,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618597,50597,,N,Intermediate,,BAO_0000218
8123,,1,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618598,50597,,N,Intermediate,,BAO_0000218
8124,,1,Plasma clearance in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618599,50597,,N,Intermediate,,BAO_0000218
8125,,1,Plasma clearance rate determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618600,50597,,N,Intermediate,,BAO_0000218
8126,,1,Plasma clearance was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618601,50597,,N,Intermediate,,BAO_0000218
8127,,1,Plasma clearance was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618602,50597,,N,Intermediate,,BAO_0000218
8128,,1,Plasma clearance value in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618603,50597,,N,Intermediate,,BAO_0000218
8129,,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL618604,50597,,N,Intermediate,,BAO_0000218
8130,,1,Clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618605,50597,,N,Intermediate,,BAO_0000218
8131,,1,Total body clearance in rat i.v. at 2 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618606,50597,,N,Intermediate,,BAO_0000218
8132,,1,Clearance of compound in rats after intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618607,50597,,N,Intermediate,,BAO_0000218
8133,,1,Clearance after iv administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618608,50597,,N,Intermediate,,BAO_0000218
8134,,1,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618609,50597,,N,Intermediate,,BAO_0000218
8135,,1,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618610,50597,,N,Intermediate,,BAO_0000218
8136,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618611,50597,,N,Intermediate,,BAO_0000218
8137,,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618612,50597,,N,Intermediate,,BAO_0000218
8138,,1,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618613,50597,,N,Intermediate,,BAO_0000218
8139,,1,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621076,50597,,N,Intermediate,,BAO_0000218
8140,,1,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621077,50597,,N,Intermediate,,BAO_0000218
8141,,1,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621078,50597,,N,Intermediate,,BAO_0000218
8142,,1,Clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621251,50597,,N,Intermediate,,BAO_0000218
8143,,1,Clearance in rat after oral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621252,50597,,N,Intermediate,,BAO_0000218
8144,,1,Clearance in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621253,50597,,N,Intermediate,,BAO_0000218
8145,,1,Clearance rate following an oral dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621254,50597,,N,Intermediate,,BAO_0000218
8146,,1,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621255,50597,,N,Intermediate,,BAO_0000218
8147,,1,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621256,50597,,N,Intermediate,,BAO_0000218
8148,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621257,50597,,N,Intermediate,,BAO_0000218
8149,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621258,50597,,N,Intermediate,,BAO_0000218
8150,,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621259,50597,,N,Intermediate,,BAO_0000218
8151,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621260,50597,,N,Intermediate,,BAO_0000218
8152,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL876494,50597,,N,Intermediate,,BAO_0000218
8153,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621261,50597,,N,Intermediate,,BAO_0000218
8154,,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621262,50597,,N,Intermediate,,BAO_0000218
8155,,1,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621263,50597,,N,Intermediate,,BAO_0000218
8156,,1,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621264,50597,,N,Intermediate,,BAO_0000218
8157,,1,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621265,50597,,N,Intermediate,,BAO_0000218
8158,,1,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621266,50597,,N,Intermediate,,BAO_0000218
8159,,1,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621267,50597,,N,Intermediate,,BAO_0000218
8160,,1,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621268,50597,,N,Intermediate,,BAO_0000218
8161,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621269,50597,,N,Intermediate,,BAO_0000218
8162,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621270,50597,,N,Intermediate,,BAO_0000218
8163,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621271,50597,,N,Intermediate,,BAO_0000218
8164,,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621272,50597,,N,Intermediate,,BAO_0000218
8165,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621273,50597,,N,Intermediate,,BAO_0000218
8166,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621274,50597,,N,Intermediate,,BAO_0000218
8167,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL876495,50597,,N,Intermediate,,BAO_0000218
8168,,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621275,50597,,N,Intermediate,,BAO_0000218
8169,,1,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621276,50597,,N,Intermediate,,BAO_0000218
8170,,1,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621277,50597,,N,Intermediate,,BAO_0000218
8171,,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621278,50597,,N,Intermediate,,BAO_0000218
8172,,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621279,50597,,N,Intermediate,,BAO_0000218
8173,,1,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621280,50597,,N,Intermediate,,BAO_0000218
8174,,1,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621281,50597,,N,Intermediate,,BAO_0000218
8175,,1,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621282,50597,,N,Intermediate,,BAO_0000218
8176,,1,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621283,50597,,N,Intermediate,,BAO_0000218
8177,,1,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621284,50597,,N,Intermediate,,BAO_0000218
8178,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621285,50597,,N,Intermediate,,BAO_0000218
8179,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621286,50597,,N,Intermediate,,BAO_0000218
8180,,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL623220,50597,,N,Intermediate,,BAO_0000218
8181,,1,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL623221,50597,,N,Intermediate,,BAO_0000218
8182,,1,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL876029,50597,,N,Intermediate,,BAO_0000218
8183,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL623222,50597,,N,Intermediate,,BAO_0000218
8184,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL623223,50597,,N,Intermediate,,BAO_0000218
8185,,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL621445,50597,,N,Intermediate,,BAO_0000218
8186,,1,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621446,50597,,N,Intermediate,,BAO_0000218
8187,,1,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621447,50597,,N,Intermediate,,BAO_0000218
8188,,1,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL619681,50597,,N,Intermediate,,BAO_0000218
8189,,1,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL619682,50597,,N,Intermediate,,BAO_0000218
8190,,1,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL619683,50597,,N,Intermediate,,BAO_0000218
8191,,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619684,50597,,N,Intermediate,,BAO_0000218
8192,,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619685,50597,,N,Intermediate,,BAO_0000218
8193,,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619686,50597,,N,Intermediate,,BAO_0000218
8194,,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619687,50597,,N,Intermediate,,BAO_0000218
8195,,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619688,50597,,N,Intermediate,,BAO_0000218
8196,,1,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL619689,50597,,N,Intermediate,,BAO_0000218
8197,,1,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL619690,50597,,N,Intermediate,,BAO_0000218
8198,,1,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL619691,50597,,N,Intermediate,,BAO_0000218
8199,,1,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619692,50597,,N,Intermediate,,BAO_0000218
8200,,1,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619693,50597,,N,Expert,,BAO_0000218
8201,,1,Vc value after IV dose at a dose of 5 mg/kg in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619694,50597,,N,Intermediate,,BAO_0000218
8202,,1,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619695,50597,,N,Intermediate,,BAO_0000218
8203,,1,Compound was evaluated for pharmacokinetic parameter volume of distribution,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619696,50597,,N,Intermediate,,BAO_0000218
8204,,1,Compound was evaluated for volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619697,50597,,N,Intermediate,,BAO_0000218
8205,,1,Steady state volume distribution was determined; steady state(ss),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619698,50597,,N,Intermediate,,BAO_0000218
8206,,1,Steady state volume of distribution after iv administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619699,50597,,N,Intermediate,,BAO_0000218
8207,,1,Steady state volume of distribution dosing at 3 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619700,50597,,N,Intermediate,,BAO_0000218
8208,,1,The compound was evaluated for volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619701,50597,,N,Intermediate,,BAO_0000218
8209,,1,The compound was tested for volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL619702,50597,,N,Intermediate,,BAO_0000218
8210,,1,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620335,50597,,N,Intermediate,,BAO_0000218
8211,,1,Volume distribution (VD) after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620336,50597,,N,Intermediate,,BAO_0000218
8212,,1,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620337,50597,,N,Intermediate,,BAO_0000218
8213,,1,Volume distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620520,50597,,N,Intermediate,,BAO_0000218
8214,,1,Volume distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620521,50597,,N,Intermediate,,BAO_0000218
8215,,1,Volume distribution in rat after peroral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875825,50597,,N,Intermediate,,BAO_0000218
8216,,1,Volume distribution in rat after peroral administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620522,50597,,N,Intermediate,,BAO_0000218
8217,,1,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620523,50597,,N,Intermediate,,BAO_0000218
8218,,1,Volume of distribution in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620524,50597,,N,Intermediate,,BAO_0000218
8219,,1,Volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620525,50597,,N,Intermediate,,BAO_0000218
8220,,1,Volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620526,50597,,N,Intermediate,,BAO_0000218
8221,,1,Volume of distribution in rat by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620527,50597,,N,Intermediate,,BAO_0000218
8222,,1,Volume of distribution in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620528,50597,,N,Intermediate,,BAO_0000218
8223,,1,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620529,50597,,N,Intermediate,,BAO_0000218
8224,,1,Volume distribution at the dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620530,50597,,N,Intermediate,,BAO_0000218
8225,,1,Steady state volume of distribution was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620531,50597,,N,Intermediate,,BAO_0000218
8226,,0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL620532,22224,,U,Intermediate,,BAO_0000218
8227,,0,Compound was tested for its plasma volume distribution in Sprague Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620533,22224,,U,Intermediate,,BAO_0000218
8228,,0,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620534,22224,,U,Intermediate,,BAO_0000218
8229,,1,Mean (%CV) PK parameters for Vdss(mL/kg).,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620535,50597,,N,Intermediate,,BAO_0000218
8230,,1,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875826,50597,,N,Intermediate,,BAO_0000218
8231,,1,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620536,50597,,N,Intermediate,,BAO_0000218
8232,,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620537,50597,,N,Intermediate,,BAO_0000218
8233,,1,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618526,50597,,N,Intermediate,,BAO_0000218
8234,,1,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618527,50597,,N,Intermediate,,BAO_0000218
8235,,1,Pharmacokinetic property (Vdss) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618528,50597,,N,Intermediate,,BAO_0000218
8236,,1,Pharmacokinetic property (vdss) was measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618529,50597,,N,Intermediate,,BAO_0000218
8237,,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618530,50597,,N,Intermediate,,BAO_0000218
8238,,1,Volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618531,50597,,N,Intermediate,,BAO_0000218
8239,,1,The pharmacokinetic parameter volume of distribution in vivo in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618532,50597,,N,Intermediate,,BAO_0000218
8240,,1,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL618533,50597,,N,Intermediate,,BAO_0000218
8241,,1,Vdss in rat i.v. at 2 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618534,50597,,N,Intermediate,,BAO_0000218
8242,,1,Volume distribution after intravenous administration (1 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618535,50597,,N,Intermediate,,BAO_0000218
8243,,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618536,50597,,N,Intermediate,,BAO_0000218
8244,,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618537,50597,,N,Intermediate,,BAO_0000218
8245,,1,Volume distribution at a dose of 10 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618538,50597,,N,Intermediate,,BAO_0000218
8246,,1,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618539,50597,,N,Intermediate,,BAO_0000218
8247,,1,Volume distribution was calculated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618540,50597,,N,Intermediate,,BAO_0000218
8248,,1,Volume distribution was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618541,50597,,N,Intermediate,,BAO_0000218
8249,,1,Volume of distribution after intravenous administration was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618542,50597,,N,Intermediate,,BAO_0000218
8250,,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622544,50597,,N,Intermediate,,BAO_0000218
8251,,1,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622545,50597,,N,Intermediate,,BAO_0000218
8252,,1,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622546,50597,,N,Intermediate,,BAO_0000218
8253,,1,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622547,50597,,N,Intermediate,,BAO_0000218
8254,,1,Volume of distribution in steady state was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622548,50597,,N,Intermediate,,BAO_0000218
8255,,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622549,50597,,N,Intermediate,,BAO_0000218
8256,,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622550,50597,,N,Intermediate,,BAO_0000218
8257,,1,Compound was evaluated for area under curve when administered through oral route to mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL622551,50594,,N,Intermediate,,BAO_0000218
8258,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622552,50597,,N,Intermediate,,BAO_0000218
8259,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622553,50597,,N,Intermediate,,BAO_0000218
8260,,0,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,,,,,,1,,F,CHEMBL622554,22224,,U,Autocuration,,BAO_0000218
8261,,1,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622555,50588,,N,Intermediate,,BAO_0000218
8262,,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL622556,50594,,N,Intermediate,,BAO_0000218
8263,,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL622557,50594,,N,Intermediate,,BAO_0000218
8264,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL622558,50594,,N,Intermediate,,BAO_0000218
8265,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL622559,50594,,N,Intermediate,,BAO_0000218
8266,,1,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622560,50588,,N,Intermediate,,BAO_0000218
8267,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622561,50597,,N,Intermediate,,BAO_0000218
8268,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622562,50597,,N,Intermediate,,BAO_0000218
8269,,1,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622563,50597,,N,Intermediate,,BAO_0000218
8270,,0,Concentration of compound in Central nervous system,,,,,,,1,,A,CHEMBL622564,22224,,U,Autocuration,,BAO_0000019
8271,,0,Concentration of compound in Central nervous system; Not detectable,,,,,,,1,,A,CHEMBL622565,22224,,U,Autocuration,,BAO_0000019
8272,,1,"Concentration of diester in the blood, following oral administration in mice",Mus musculus,,,,,,1,10090.0,A,CHEMBL622566,50594,,N,Intermediate,,BAO_0000218
8273,,1,"Concentration of monoester in the blood, following oral administration in mice",Mus musculus,,,,,,1,10090.0,A,CHEMBL624515,50594,,N,Intermediate,,BAO_0000218
8274,,1,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL624516,50594,,N,Intermediate,,BAO_0000218
8275,,0,Evaluated for Pharmacokinetic property: Area under the curve,,,,,,,1,,A,CHEMBL624517,22224,,U,Autocuration,,BAO_0000019
8276,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL624518,50594,,N,Intermediate,,BAO_0000218
8277,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624519,100710,,N,Intermediate,,BAO_0000218
8278,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624520,100710,,N,Intermediate,,BAO_0000218
8279,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624521,100710,,N,Intermediate,,BAO_0000218
8280,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624522,100710,,N,Intermediate,,BAO_0000218
8281,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624523,100710,,N,Intermediate,,BAO_0000218
8282,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624409,100710,,N,Intermediate,,BAO_0000218
8283,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624410,100710,,N,Intermediate,,BAO_0000218
8284,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL624411,100710,,N,Intermediate,,BAO_0000218
8285,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623531,100710,,N,Intermediate,,BAO_0000218
8286,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623532,100710,,N,Intermediate,,BAO_0000218
8287,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623533,100710,,N,Intermediate,,BAO_0000218
8288,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623534,100710,,N,Intermediate,,BAO_0000218
8289,,1,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623535,50594,,N,Intermediate,,BAO_0000218
8290,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623536,50594,,N,Intermediate,,BAO_0000218
8291,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623537,50594,,N,Intermediate,,BAO_0000218
8292,,1,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623538,50594,,N,Intermediate,,BAO_0000218
8293,,1,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623539,50594,,N,Intermediate,,BAO_0000218
8294,,1,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,Mus musculus,,,,,,1,10090.0,A,CHEMBL623540,50594,,N,Intermediate,,BAO_0000218
8295,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",Mus musculus,,,,,,1,10090.0,A,CHEMBL623541,50594,,N,Intermediate,,BAO_0000218
8296,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL623542,50594,,N,Intermediate,,BAO_0000218
8297,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL623543,50594,,N,Intermediate,,BAO_0000218
8298,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",Mus musculus,,,,,,1,10090.0,A,CHEMBL623544,50594,,N,Intermediate,,BAO_0000218
8299,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL623545,50594,,N,Intermediate,,BAO_0000218
8300,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL623546,50594,,N,Intermediate,,BAO_0000218
8301,,1,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623547,50597,,N,Intermediate,,BAO_0000218
8302,,1,High i.v. clearance in Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623548,50597,,N,Intermediate,,BAO_0000218
8303,Microsomes,1,In vitro clearance in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623549,50597,,N,Intermediate,,BAO_0000218
8304,Microsomes,1,Intrinsic clearance in rat liver microsomes was determined,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623550,50597,,N,Intermediate,,BAO_0000218
8305,,1,Intrinsic clearance in rat hepatocytes was determined,Rattus norvegicus,,,Liver,2107.0,401.0,1,10116.0,A,CHEMBL875276,50597,,N,Intermediate,,BAO_0000218
8306,,1,Plasma Clearance was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621872,50597,,N,Intermediate,,BAO_0000218
8307,,1,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621873,50597,,N,Intermediate,,BAO_0000218
8308,,1,Plasma clearance in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621874,50597,,N,Intermediate,,BAO_0000218
8309,,1,Plasma clearance in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621875,50597,,N,Intermediate,,BAO_0000218
8310,,1,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621876,50597,,N,Intermediate,,BAO_0000218
8311,,1,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621877,50597,,N,Intermediate,,BAO_0000218
8312,,1,Plasma clearance was measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621878,50597,,N,Intermediate,,BAO_0000218
8313,,1,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621879,50597,,N,Intermediate,,BAO_0000218
8314,,1,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621880,50597,,N,Intermediate,,BAO_0000218
8315,,1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621881,50597,,N,Intermediate,,BAO_0000218
8316,,1,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621882,50597,,N,Intermediate,,BAO_0000218
8317,,1,Total clearance at 1 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875283,50597,,N,Intermediate,,BAO_0000218
8318,,1,Total clearance at 10 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621883,50597,,N,Intermediate,,BAO_0000218
8319,,1,Clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621884,50597,,N,Intermediate,,BAO_0000218
8320,,1,Plasma clearance rate determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621885,50597,,N,Intermediate,,BAO_0000218
8321,,1,Clearance of compound in rat was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621886,50597,,N,Intermediate,,BAO_0000218
8322,,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621887,50597,,N,Intermediate,,BAO_0000218
8323,,1,Pharmacokinetic property (blood clearance) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621888,50597,,N,Intermediate,,BAO_0000218
8324,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621889,50597,,N,Intermediate,,BAO_0000218
8325,,1,Plasma clearance in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621890,50597,,N,Intermediate,,BAO_0000218
8326,Microsomes,1,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621891,50597,,N,Intermediate,,BAO_0000218
8327,,1,Clearance in Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621892,50597,,N,Intermediate,,BAO_0000218
8328,,1,Clearance rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621893,50597,,N,Intermediate,,BAO_0000218
8329,,1,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621894,50597,,N,Intermediate,,BAO_0000218
8330,,1,Clearance rat; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621895,50597,,N,Intermediate,,BAO_0000218
8331,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875284,50597,,N,Intermediate,,BAO_0000218
8332,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618699,50597,,N,Intermediate,,BAO_0000218
8333,,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618700,50597,,N,Intermediate,,BAO_0000218
8334,,1,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618701,50597,,N,Intermediate,,BAO_0000218
8335,,1,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876600,50597,,N,Intermediate,,BAO_0000218
8336,,1,Clearance of compound in rat after 1 mg/kg i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618702,50597,,N,Intermediate,,BAO_0000218
8337,,1,Compound was evaluated for Hepatic clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618703,50597,,N,Intermediate,,BAO_0000218
8338,,1,In vivo clearance after 5 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618704,50597,,N,Intermediate,,BAO_0000218
8339,,1,Compound was tested for plasma clearance in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618705,50597,,N,Intermediate,,BAO_0000218
8340,,1,Hepatic clearance after intravenous administration was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618706,50597,,N,Intermediate,,BAO_0000218
8341,,1,Lower clearance in rat (i.v.) at 0.5 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618707,50597,,N,Intermediate,,BAO_0000218
8342,,1,Pharmacokinetic parameter expressed as plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618708,50597,,N,Intermediate,,BAO_0000218
8343,,1,Pharmacokinetic property (Clp) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618709,50597,,N,Intermediate,,BAO_0000218
8344,,1,Plasma clearance in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618710,50597,,N,Intermediate,,BAO_0000218
8345,,1,Plasma clearance (Clp) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618711,50597,,N,Intermediate,,BAO_0000218
8346,,1,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618712,50597,,N,Intermediate,,BAO_0000218
8347,,1,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618713,50597,,N,Intermediate,,BAO_0000218
8348,,1,Plasma clearance after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618714,50597,,N,Intermediate,,BAO_0000218
8349,,1,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618715,50597,,N,Intermediate,,BAO_0000218
8350,,1,Plasma clearance in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618716,50597,,N,Intermediate,,BAO_0000218
8351,,1,Plasma clearance measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876601,50597,,N,Intermediate,,BAO_0000218
8352,,1,Plasma clearance was calculated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618717,50597,,N,Intermediate,,BAO_0000218
8353,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618718,50597,,N,Intermediate,,BAO_0000218
8354,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618719,50597,,N,Intermediate,,BAO_0000218
8355,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618720,50597,,N,Intermediate,,BAO_0000218
8356,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618721,50597,,N,Intermediate,,BAO_0000218
8357,,1,Plasma clearance in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621477,50597,,N,Intermediate,,BAO_0000218
8358,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621478,50597,,N,Intermediate,,BAO_0000218
8359,,1,Plasma clearance was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621479,50597,,N,Intermediate,,BAO_0000218
8360,,1,Plasma clearance was evaluated in rat; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621480,50597,,N,Intermediate,,BAO_0000218
8361,,1,Plasma clearance rate was determined for the compound in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621481,50597,,N,Intermediate,,BAO_0000218
8362,,1,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621482,50597,,N,Intermediate,,BAO_0000218
8363,,1,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621483,50597,,N,Intermediate,,BAO_0000218
8364,,1,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621484,50597,,N,Intermediate,,BAO_0000218
8365,,1,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621485,50597,,N,Intermediate,,BAO_0000218
8366,,1,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL621486,50597,,N,Intermediate,,BAO_0000218
8367,,1,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621487,50597,,N,Intermediate,,BAO_0000218
8368,,1,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621488,50597,,N,Intermediate,,BAO_0000218
8369,,1,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621489,50597,,N,Intermediate,,BAO_0000218
8370,,1,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621490,50597,,N,Intermediate,,BAO_0000218
8371,,1,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL621491,50597,,N,Intermediate,,BAO_0000218
8372,,1,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621492,50597,,N,Intermediate,,BAO_0000218
8373,,1,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621493,50597,,N,Intermediate,,BAO_0000218
8374,,1,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621494,50597,,N,Intermediate,,BAO_0000218
8375,,1,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621495,50597,,N,Intermediate,,BAO_0000218
8376,,1,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621496,50597,,N,Intermediate,,BAO_0000218
8377,,1,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621497,50597,,N,Intermediate,,BAO_0000218
8378,,1,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621498,50597,,N,Intermediate,,BAO_0000218
8379,,1,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621499,50597,,N,Intermediate,,BAO_0000218
8380,,1,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL618634,50597,,N,Intermediate,,BAO_0000218
8381,,1,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL618635,50597,,N,Intermediate,,BAO_0000218
8382,,1,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL618636,50597,,N,Intermediate,,BAO_0000218
8383,,1,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL619737,50597,,N,Intermediate,,BAO_0000218
8384,,1,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL619738,50597,,N,Intermediate,,BAO_0000218
8385,,1,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624329,50597,,N,Intermediate,,BAO_0000218
8386,,1,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624330,50597,,N,Intermediate,,BAO_0000218
8387,,1,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624331,50597,,N,Intermediate,,BAO_0000218
8388,,1,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624332,50597,,N,Intermediate,,BAO_0000218
8389,,1,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624333,50597,,N,Intermediate,,BAO_0000218
8390,,1,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624334,50597,,N,Intermediate,,BAO_0000218
8391,,1,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624335,50597,,N,Intermediate,,BAO_0000218
8392,,1,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL620016,50597,,N,Intermediate,,BAO_0000218
8393,,1,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL620169,50597,,N,Intermediate,,BAO_0000218
8394,,1,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL620170,50597,,N,Intermediate,,BAO_0000218
8395,,1,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL620171,50597,,N,Intermediate,,BAO_0000218
8396,,1,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL620172,50597,,N,Intermediate,,BAO_0000218
8397,,1,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL620173,50597,,N,Intermediate,,BAO_0000218
8398,,1,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL620174,50597,,N,Intermediate,,BAO_0000218
8399,,1,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL620175,50597,,N,Intermediate,,BAO_0000218
8400,,1,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL620176,50597,,N,Intermediate,,BAO_0000218
8401,,1,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL620177,50597,,N,Intermediate,,BAO_0000218
8402,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL620178,50597,,N,Intermediate,,BAO_0000218
8403,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL620179,50597,,N,Intermediate,,BAO_0000218
8404,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620180,50597,,N,Intermediate,,BAO_0000218
8405,,1,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620181,50597,,N,Intermediate,,BAO_0000218
8406,,1,Volume of distribution of compound in rats after intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620182,50597,,N,Intermediate,,BAO_0000218
8407,,1,Volume of distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620183,50597,,N,Intermediate,,BAO_0000218
8408,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620184,50597,,N,Intermediate,,BAO_0000218
8409,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620185,50597,,N,Intermediate,,BAO_0000218
8410,,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620186,50597,,N,Intermediate,,BAO_0000218
8411,,1,Volume of distribution was determined in Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620187,50597,,N,Intermediate,,BAO_0000218
8412,,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620188,50597,,N,Intermediate,,BAO_0000218
8413,,1,Volume of distribution was reported in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620189,50597,,N,Intermediate,,BAO_0000218
8414,,1,Volumes of distribution in rat after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620190,50597,,N,Intermediate,,BAO_0000218
8415,,1,Volumes of distribution in rat after po administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620191,50597,,N,Intermediate,,BAO_0000218
8416,,1,Volumes of distribution in rat after po administration; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620192,50597,,N,Intermediate,,BAO_0000218
8417,,1,Pharmacokinetic property (Volume) in rat i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620193,50597,,N,Intermediate,,BAO_0000218
8418,,1,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620194,50597,,N,Intermediate,,BAO_0000218
8419,,1,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876730,50597,,N,Intermediate,,BAO_0000218
8420,,1,Volume distribution in rat after oral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620195,50597,,N,Intermediate,,BAO_0000218
8421,,1,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620196,50597,,N,Intermediate,,BAO_0000218
8422,,1,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620197,50597,,N,Intermediate,,BAO_0000218
8423,,1,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620198,50597,,N,Intermediate,,BAO_0000218
8424,,1,Volume of distribution in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620199,50597,,N,Intermediate,,BAO_0000218
8425,,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620200,50597,,N,Intermediate,,BAO_0000218
8426,,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620201,50597,,N,Intermediate,,BAO_0000218
8427,,1,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620202,50597,,N,Intermediate,,BAO_0000218
8428,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620203,50597,,N,Intermediate,,BAO_0000218
8429,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620204,50597,,N,Intermediate,,BAO_0000218
8430,,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620205,50597,,N,Intermediate,,BAO_0000218
8431,,1,Pharmacokinetic parameter (Vss) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624664,50597,,N,Intermediate,,BAO_0000218
8432,,1,Pharmacokinetic property (Volume) in rat i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624665,50597,,N,Intermediate,,BAO_0000218
8433,,1,Pharmacokinetic property (Vss) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624666,50597,,N,Intermediate,,BAO_0000218
8434,,1,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624667,50597,,N,Intermediate,,BAO_0000218
8435,,1,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624668,50597,,N,Intermediate,,BAO_0000218
8436,,1,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624669,50597,,N,Intermediate,,BAO_0000218
8437,,1,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624670,50597,,N,Intermediate,,BAO_0000218
8438,,1,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624671,50597,,N,Intermediate,,BAO_0000218
8439,,1,Steady state volume distribution in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624672,50597,,N,Intermediate,,BAO_0000218
8440,,1,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624673,50597,,N,Intermediate,,BAO_0000218
8441,,1,Steady state volume of distribution determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624674,50597,,N,Intermediate,,BAO_0000218
8442,,1,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624675,50597,,N,Intermediate,,BAO_0000218
8443,,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621728,50597,,N,Intermediate,,BAO_0000218
8444,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621729,50597,,N,Intermediate,,BAO_0000218
8445,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621730,50597,,N,Intermediate,,BAO_0000218
8446,,1,Volume distribution in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621731,50597,,N,Intermediate,,BAO_0000218
8447,,1,Volume distribution in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621732,50597,,N,Intermediate,,BAO_0000218
8448,,1,Volume in steady state distribution value was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621908,50597,,N,Intermediate,,BAO_0000218
8449,,1,Volume in steady state distribution value was determined; ND denotes no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875347,50597,,N,Intermediate,,BAO_0000218
8450,,1,Volume in steady state distribution value was determined; ND denotes not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621909,50597,,N,Intermediate,,BAO_0000218
8451,,1,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621910,50597,,N,Intermediate,,BAO_0000218
8452,,1,Volume of distribution at steady state was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621911,50597,,N,Intermediate,,BAO_0000218
8453,,1,Volume of distribution at steady state was observed after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621912,50597,,N,Intermediate,,BAO_0000218
8454,,1,Volume of distribution in steady state was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621913,50597,,N,Intermediate,,BAO_0000218
8455,,1,Volume of distribution in steady state was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621914,50597,,N,Intermediate,,BAO_0000218
8456,,1,Volume of distribution after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621915,50597,,N,Intermediate,,BAO_0000218
8457,,1,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621916,50597,,N,Intermediate,,BAO_0000218
8458,,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL621917,50594,,N,Intermediate,,BAO_0000218
8459,,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL621918,50594,,N,Intermediate,,BAO_0000218
8460,,1,Biodistribution of compound (oxidized form) in spleen tissue,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL621919,50594,,N,Intermediate,,BAO_0000218
8461,,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL621920,50594,,N,Intermediate,,BAO_0000218
8462,,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL621921,50594,,N,Intermediate,,BAO_0000218
8463,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL622401,50594,,N,Intermediate,,BAO_0000218
8464,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL875348,50594,,N,Intermediate,,BAO_0000218
8465,,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL622402,50594,,N,Intermediate,,BAO_0000218
8466,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL622403,50594,,N,Intermediate,,BAO_0000218
8467,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL622404,50594,,N,Intermediate,,BAO_0000218
8468,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622405,50594,,N,Intermediate,,BAO_0000218
8469,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622406,50594,,N,Intermediate,,BAO_0000218
8470,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622407,50594,,N,Intermediate,,BAO_0000218
8471,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL622408,50594,,N,Intermediate,,BAO_0000218
8472,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL622409,50594,,N,Intermediate,,BAO_0000218
8473,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL622410,50594,,N,Intermediate,,BAO_0000218
8474,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL622411,50594,,N,Intermediate,,BAO_0000218
8475,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL627864,50594,,N,Intermediate,,BAO_0000218
8476,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL627865,50594,,N,Intermediate,,BAO_0000218
8477,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627866,50594,,N,Intermediate,,BAO_0000218
8478,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627751,50594,,N,Intermediate,,BAO_0000218
8479,,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL627752,50594,,N,Intermediate,,BAO_0000218
8480,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL627753,50594,,N,Intermediate,,BAO_0000218
8481,,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL627754,50594,,N,Intermediate,,BAO_0000218
8482,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,Mus musculus,,,,,,1,10090.0,A,CHEMBL627755,50594,,N,Intermediate,,BAO_0000218
8483,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627756,50594,,N,Intermediate,,BAO_0000218
8484,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627757,50594,,N,Intermediate,,BAO_0000218
8485,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627758,50594,,N,Intermediate,,BAO_0000218
8486,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627759,50594,,N,Intermediate,,BAO_0000218
8487,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627760,50594,,N,Intermediate,,BAO_0000218
8488,,1,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627761,50594,,N,Intermediate,,BAO_0000218
8489,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL876811,50594,,N,Intermediate,,BAO_0000218
8490,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL627762,50594,,N,Intermediate,,BAO_0000218
8491,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL627763,50594,,N,Intermediate,,BAO_0000218
8492,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL627764,50594,,N,Intermediate,,BAO_0000218
8493,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL627765,50594,,N,Intermediate,,BAO_0000218
8494,,1,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL627766,50594,,N,Intermediate,,BAO_0000218
8495,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL627767,50594,,N,Intermediate,,BAO_0000218
8496,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL627768,50594,,N,Intermediate,,BAO_0000218
8497,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL628422,50594,,N,Intermediate,,BAO_0000218
8498,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL628423,50594,,N,Intermediate,,BAO_0000218
8499,,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628424,50597,,N,Intermediate,,BAO_0000218
8500,,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628425,50597,,N,Intermediate,,BAO_0000218
8501,,1,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628426,50597,,N,Intermediate,,BAO_0000218
8502,,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628427,50597,,N,Intermediate,,BAO_0000218
8503,,1,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626938,50597,,N,Intermediate,,BAO_0000218
8504,,1,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626939,50597,,N,Intermediate,,BAO_0000218
8505,,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626940,50597,,N,Intermediate,,BAO_0000218
8506,,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626941,50597,,N,Intermediate,,BAO_0000218
8507,,1,Plasma clearance was reported in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626942,50597,,N,Intermediate,,BAO_0000218
8508,,1,Plasma clearance after intravenous administration (1 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876812,50597,,N,Intermediate,,BAO_0000218
8509,,1,Plasma clearance of compound in rats was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626943,50597,,N,Intermediate,,BAO_0000218
8510,,1,Plasma clearance of compound in rats was evaluated; ND indicates not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626944,50597,,N,Intermediate,,BAO_0000218
8511,,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626945,50597,,N,Intermediate,,BAO_0000218
8512,,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626946,50597,,N,Intermediate,,BAO_0000218
8513,,1,Plasma clearance rate in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626856,50597,,N,Intermediate,,BAO_0000218
8514,,1,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626857,50597,,N,Intermediate,,BAO_0000218
8515,,1,The compound was evaluated for plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626858,50597,,N,Intermediate,,BAO_0000218
8516,,1,Total plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627018,50597,,N,Intermediate,,BAO_0000218
8517,,1,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625331,50597,,N,Intermediate,,BAO_0000218
8518,,1,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625332,50597,,N,Intermediate,,BAO_0000218
8519,,1,C max was determined at 10 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877590,50597,,N,Intermediate,,BAO_0000218
8520,,1,C max was determined at 3 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625333,50597,,N,Intermediate,,BAO_0000218
8521,,1,Cmax after repeated oral dose of compound at 1 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625334,50597,,N,Intermediate,,BAO_0000218
8522,,1,Cmax after single intravenous bolus of 1 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625335,50597,,N,Intermediate,,BAO_0000218
8523,,1,Cmax of compound at 5 mg/kg after po administration was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625336,50597,,N,Intermediate,,BAO_0000218
8524,,1,Cmax 24 hr after 10 mg/kg oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625337,50597,,N,Intermediate,,BAO_0000218
8525,,1,Cmax 24 hr after 2 mg/kg oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625338,50597,,N,Intermediate,,BAO_0000218
8526,,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625339,50597,,N,Intermediate,,BAO_0000218
8527,,1,Cmax in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625340,50597,,N,Intermediate,,BAO_0000218
8528,,1,Cmax in rat after administration of 2 mg/kg iv,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625341,50597,,N,Intermediate,,BAO_0000218
8529,,1,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622687,50597,,N,Intermediate,,BAO_0000218
8530,,1,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622688,50597,,N,Intermediate,,BAO_0000218
8531,,1,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622689,50597,,N,Intermediate,,BAO_0000218
8532,,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL620295,50597,,N,Intermediate,,BAO_0000218
8533,,1,Cmax after 10 mg/kg oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620296,50597,,N,Intermediate,,BAO_0000218
8534,,1,Cmax after IV dosing at 0.5 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620297,50597,,N,Intermediate,,BAO_0000218
8535,,1,Cmax after IV dosing at 1 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620298,50597,,N,Intermediate,,BAO_0000218
8536,,1,Cmax after oral administration at 20 mpk in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620299,50597,,N,Intermediate,,BAO_0000218
8537,,1,Cmax after oral administration at 20 mpk in rats; Not performed.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620300,50597,,N,Intermediate,,BAO_0000218
8538,,1,Cmax after oral administration at 20 mpk in rats d; Not performed.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620301,50597,,N,Intermediate,,BAO_0000218
8539,,1,Cmax after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620302,50597,,N,Intermediate,,BAO_0000218
8540,,1,Cmax after oral administration at a dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620303,50597,,N,Intermediate,,BAO_0000218
8541,,1,Cmax after oral administration at a dose of 4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620304,50597,,N,Intermediate,,BAO_0000218
8542,,1,Cmax in rats after 20 mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620305,50597,,N,Intermediate,,BAO_0000218
8543,,1,Cmax after peroral administration in rats at 2.4 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620306,50597,,N,Intermediate,,BAO_0000218
8544,,1,Cmax at the dose of 2 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620307,50597,,N,Intermediate,,BAO_0000218
8545,,1,Cmax at the dose of 5 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620308,50597,,N,Intermediate,,BAO_0000218
8546,,1,Cmax by administering at 20 mg/kg p.o. in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620309,50597,,N,Intermediate,,BAO_0000218
8547,,1,Cmax in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620310,50597,,N,Intermediate,,BAO_0000218
8548,,1,Cmax in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620311,50597,,N,Intermediate,,BAO_0000218
8549,,1,Cmax in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620312,50597,,N,Intermediate,,BAO_0000218
8550,,1,Cmax in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620313,50597,,N,Intermediate,,BAO_0000218
8551,,1,Cmax in rat at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620314,50597,,N,Intermediate,,BAO_0000218
8552,,1,Cmax in rat at the dose of 1 mg/kg i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620315,50597,,N,Intermediate,,BAO_0000218
8553,,1,Cmax in rat by po administration at a dose of 40 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620316,50597,,N,Intermediate,,BAO_0000218
8554,,1,Cmax in rat p.o. at 20 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620317,50597,,N,Intermediate,,BAO_0000218
8555,,1,Cmax in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620318,50597,,N,Intermediate,,BAO_0000218
8556,,1,Cmax in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620319,50597,,N,Intermediate,,BAO_0000218
8557,,1,Cmax was evaluated after 20 uM/kg of peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620320,50597,,N,Intermediate,,BAO_0000218
8558,,1,Cmax was measured in rats after peroral administration at 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620321,50597,,N,Intermediate,,BAO_0000218
8559,,1,Cmax value after oral dose at a dose of 10 mg/kg in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620322,50597,,N,Intermediate,,BAO_0000218
8560,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620323,50597,,N,Intermediate,,BAO_0000218
8561,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Frontal cortex,1870.0,,1,10116.0,A,CHEMBL620324,50597,,N,Intermediate,,BAO_0000218
8562,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Frontal cortex,1870.0,,1,10116.0,A,CHEMBL620325,50597,,N,Intermediate,,BAO_0000218
8563,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL620326,50597,,N,Intermediate,,BAO_0000218
8564,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL620327,50597,,N,Intermediate,,BAO_0000218
8565,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620328,50597,,N,Intermediate,,BAO_0000218
8566,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620329,50597,,N,Intermediate,,BAO_0000218
8567,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Midbrain,1891.0,,1,10116.0,A,CHEMBL620330,50597,,N,Intermediate,,BAO_0000218
8568,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Midbrain,1891.0,,1,10116.0,A,CHEMBL875286,50597,,N,Intermediate,,BAO_0000218
8569,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620331,50597,,N,Intermediate,,BAO_0000218
8570,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620332,50597,,N,Intermediate,,BAO_0000218
8571,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL620333,50597,,N,Intermediate,,BAO_0000218
8572,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL620334,50597,,N,Intermediate,,BAO_0000218
8573,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621015,50597,,N,Intermediate,,BAO_0000218
8574,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621016,50597,,N,Intermediate,,BAO_0000218
8575,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621191,50597,,N,Intermediate,,BAO_0000218
8576,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621192,50597,,N,Intermediate,,BAO_0000218
8577,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621193,50597,,N,Intermediate,,BAO_0000218
8578,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621194,50597,,N,Intermediate,,BAO_0000218
8579,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624204,50597,,N,Intermediate,,BAO_0000218
8580,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624205,50597,,N,Intermediate,,BAO_0000218
8581,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624206,50597,,N,Intermediate,,BAO_0000218
8582,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624207,50597,,N,Intermediate,,BAO_0000218
8583,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624208,50597,,N,Intermediate,,BAO_0000218
8584,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624209,50597,,N,Intermediate,,BAO_0000218
8585,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624210,50597,,N,Intermediate,,BAO_0000218
8586,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624211,50597,,N,Intermediate,,BAO_0000218
8587,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624212,50597,,N,Intermediate,,BAO_0000218
8588,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624213,50597,,N,Intermediate,,BAO_0000218
8589,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL876611,50597,,N,Intermediate,,BAO_0000218
8590,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624214,50597,,N,Intermediate,,BAO_0000218
8591,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624215,50597,,N,Intermediate,,BAO_0000218
8592,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624216,50597,,N,Intermediate,,BAO_0000218
8593,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624217,50597,,N,Intermediate,,BAO_0000218
8594,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624218,50597,,N,Intermediate,,BAO_0000218
8595,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624219,50597,,N,Intermediate,,BAO_0000218
8596,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624220,50597,,N,Intermediate,,BAO_0000218
8597,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624221,50597,,N,Intermediate,,BAO_0000218
8598,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624222,50597,,N,Intermediate,,BAO_0000218
8599,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624223,50597,,N,Intermediate,,BAO_0000218
8600,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624224,50597,,N,Intermediate,,BAO_0000218
8601,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624225,50597,,N,Intermediate,,BAO_0000218
8602,,1,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622420,50597,,N,Intermediate,,BAO_0000218
8603,,1,Volume of steady state distribution after i.v. administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622421,50597,,N,Intermediate,,BAO_0000218
8604,,1,Vss after intravenous administration (5.0 mg/kg) was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622422,50597,,N,Intermediate,,BAO_0000218
8605,,1,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622423,50597,,N,Intermediate,,BAO_0000218
8606,,1,Vss was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622424,50597,,N,Intermediate,,BAO_0000218
8607,,1,Vss in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622425,50597,,N,Intermediate,,BAO_0000218
8608,,1,Vss was evaluated after 10 uM/kg of intra arterial administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876612,50597,,N,Intermediate,,BAO_0000218
8609,,1,volume of distribution at steady state was observed after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622426,50597,,N,Intermediate,,BAO_0000218
8610,,1,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622427,50597,,N,Intermediate,,BAO_0000218
8611,,1,Pharmacokinetic (PK) parameter Vz in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622428,50597,,N,Intermediate,,BAO_0000218
8612,,1,Volume distribution in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622429,50597,,N,Intermediate,,BAO_0000218
8613,,1,Volume of distribution in rat; No data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622430,50597,,N,Intermediate,,BAO_0000218
8614,,1,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622431,50597,,N,Intermediate,,BAO_0000218
8615,,1,% absorption predicted from in vitro rat ileum transport studies,Rattus norvegicus,,,Ileum,2116.0,,1,10116.0,A,CHEMBL622432,50597,,N,Intermediate,,BAO_0000218
8616,,1,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622433,50597,,N,Intermediate,,BAO_0000218
8617,,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622434,50597,,N,Intermediate,,BAO_0000218
8618,,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622435,50597,,N,Intermediate,,BAO_0000218
8619,,1,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618748,50597,,N,Intermediate,,BAO_0000218
8620,,1,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618749,50597,,N,Intermediate,,BAO_0000218
8621,,1,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618750,50597,,N,Intermediate,,BAO_0000218
8622,,1,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618751,50597,,N,Intermediate,,BAO_0000218
8623,,1,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618752,50597,,N,Intermediate,,BAO_0000218
8624,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618753,50597,,N,Intermediate,,BAO_0000218
8625,,1,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL618754,50597,,N,Intermediate,,BAO_0000218
8626,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618755,50597,,N,Intermediate,,BAO_0000218
8627,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618756,50597,,N,Intermediate,,BAO_0000218
8628,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618757,50597,,N,Intermediate,,BAO_0000218
8629,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618758,50597,,N,Intermediate,,BAO_0000218
8630,,1,Oral bioavailability in rat (dose 30 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621088,50597,,N,Intermediate,,BAO_0000218
8631,,1,Pharmacokinetic property (cLogP) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621089,50597,,N,Intermediate,,BAO_0000218
8632,,1,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Rattus norvegicus,,,Blood,178.0,,1,10116.0,F,CHEMBL621090,50597,,N,Intermediate,,BAO_0000218
8633,,1,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Rattus norvegicus,,,Blood,178.0,,1,10116.0,F,CHEMBL621091,50597,,N,Intermediate,,BAO_0000218
8634,,1,Clearance in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876731,50597,,N,Intermediate,,BAO_0000218
8635,,1,Compound was evaluated for its clearance when administered intravenously in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621092,50597,,N,Intermediate,,BAO_0000218
8636,,1,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621093,50597,,N,Intermediate,,BAO_0000218
8637,,1,Blood: Brain distribution ratio is determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621094,50597,,N,Intermediate,,BAO_0000218
8638,,1,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621095,50597,,N,Intermediate,,BAO_0000218
8639,,1,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621096,50597,,N,Intermediate,,BAO_0000218
8640,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621097,50597,,N,Intermediate,,BAO_0000218
8641,,1,Percent dose excreted in 0-48 hours administered ip to male rat,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL621098,50597,,N,Intermediate,,BAO_0000218
8642,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL621099,50597,,N,Intermediate,,BAO_0000218
8643,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL621100,50597,,N,Intermediate,,BAO_0000218
8644,,1,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL621101,50597,,N,Intermediate,,BAO_0000218
8645,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL621102,50597,,N,Intermediate,,BAO_0000218
8646,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL876732,50597,,N,Intermediate,,BAO_0000218
8647,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621103,50597,,N,Intermediate,,BAO_0000218
8648,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621104,50597,,N,Intermediate,,BAO_0000218
8649,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621105,50597,,N,Intermediate,,BAO_0000218
8650,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621106,50597,,N,Intermediate,,BAO_0000218
8651,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621107,50597,,N,Intermediate,,BAO_0000218
8652,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621108,50597,,N,Intermediate,,BAO_0000218
8653,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621109,50597,,N,Intermediate,,BAO_0000218
8654,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL621110,50594,,N,Intermediate,,BAO_0000218
8655,,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL621111,50594,,N,Intermediate,,BAO_0000218
8656,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL622541,50594,,N,Intermediate,,BAO_0000218
8657,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL622542,50594,,N,Intermediate,,BAO_0000218
8658,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL622543,50594,,N,Intermediate,,BAO_0000218
8659,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL624412,50594,,N,Intermediate,,BAO_0000218
8660,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL624413,50594,,N,Intermediate,,BAO_0000218
8661,,1,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL624414,50594,,N,Intermediate,,BAO_0000218
8662,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624415,50594,,N,Intermediate,,BAO_0000218
8663,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624416,50594,,N,Intermediate,,BAO_0000218
8664,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624417,50594,,N,Intermediate,,BAO_0000218
8665,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624418,50594,,N,Intermediate,,BAO_0000218
8666,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624419,50594,,N,Intermediate,,BAO_0000218
8667,,1,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL624420,50594,,N,Intermediate,,BAO_0000218
8668,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL624421,50594,,N,Intermediate,,BAO_0000218
8669,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL624422,50594,,N,Intermediate,,BAO_0000218
8670,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL624423,50594,,N,Intermediate,,BAO_0000218
8671,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL625123,50594,,N,Intermediate,,BAO_0000218
8672,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL625124,50594,,N,Intermediate,,BAO_0000218
8673,,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL625125,50594,,N,Intermediate,,BAO_0000218
8674,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL625126,50594,,N,Intermediate,,BAO_0000218
8675,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL626947,50594,,N,Intermediate,,BAO_0000218
8676,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL626948,50594,,N,Intermediate,,BAO_0000218
8677,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL626949,50594,,N,Intermediate,,BAO_0000218
8678,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL626950,50594,,N,Intermediate,,BAO_0000218
8679,,1,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL626951,50594,,N,Intermediate,,BAO_0000218
8680,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626952,50594,,N,Intermediate,,BAO_0000218
8681,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626953,50594,,N,Intermediate,,BAO_0000218
8682,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626954,50594,,N,Intermediate,,BAO_0000218
8683,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626955,50594,,N,Intermediate,,BAO_0000218
8684,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626956,50594,,N,Intermediate,,BAO_0000218
8685,,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL626957,50594,,N,Intermediate,,BAO_0000218
8686,,1,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626958,50594,,N,Intermediate,,BAO_0000218
8687,,1,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626959,50594,,N,Intermediate,,BAO_0000218
8688,,1,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626960,50594,,N,Intermediate,,BAO_0000218
8689,,1,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626961,50594,,N,Intermediate,,BAO_0000218
8690,,1,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL627589,50594,,N,Intermediate,,BAO_0000218
8691,,1,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL627590,50594,,N,Intermediate,,BAO_0000218
8692,,1,Time taken for EC90 was determined when tested in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL627591,50594,,N,Intermediate,,BAO_0000218
8693,,1,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627592,50594,,N,Intermediate,,BAO_0000218
8694,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Mus musculus,,,,,,1,10090.0,A,CHEMBL627593,50594,,N,Intermediate,,BAO_0000218
8695,,1,Half life in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL627594,50594,,N,Intermediate,,BAO_0000218
8696,,1,Half life period in mouse after 10 mg/Kg dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL876813,50594,,N,Intermediate,,BAO_0000218
8697,,1,Half life period in mouse after 10 mg/kg dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL627595,50594,,N,Intermediate,,BAO_0000218
8698,,1,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL627596,50594,,N,Intermediate,,BAO_0000218
8699,,1,Cmax value at 5 mg/kg po was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627597,50597,,N,Intermediate,,BAO_0000218
8700,,1,Cmax value evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627598,50597,,N,Intermediate,,BAO_0000218
8701,,1,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627599,50597,,N,Intermediate,,BAO_0000218
8702,,1,Cmax value after administration of 20 mg/Kg oral dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627600,50597,,N,Intermediate,,BAO_0000218
8703,,1,Cmax value at 1 mg/kg po in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627601,50597,,N,Intermediate,,BAO_0000218
8704,,1,Cmax value at 5 mg/kg po in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627776,50597,,N,Intermediate,,BAO_0000218
8705,,1,Cmax value at a dose of 10 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627777,50597,,N,Intermediate,,BAO_0000218
8706,,1,Cmax value at a dose of 100 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627778,50597,,N,Intermediate,,BAO_0000218
8707,,1,Cmax value at a dose of 50 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627779,50597,,N,Intermediate,,BAO_0000218
8708,,1,Cmax value in rats at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876814,50597,,N,Intermediate,,BAO_0000218
8709,,1,Cmax value was evaluated in rats at a dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627780,50597,,N,Intermediate,,BAO_0000218
8710,,1,Cmax value was determined after peroral administration of 20 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627781,50597,,N,Intermediate,,BAO_0000218
8711,,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627782,50597,,N,Intermediate,,BAO_0000218
8712,,1,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627783,50597,,N,Intermediate,,BAO_0000218
8713,,1,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627784,50597,,N,Intermediate,,BAO_0000218
8714,,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627785,50597,,N,Intermediate,,BAO_0000218
8715,,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627786,50597,,N,Intermediate,,BAO_0000218
8716,,1,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627787,50597,,N,Intermediate,,BAO_0000218
8717,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627788,50597,,N,Intermediate,,BAO_0000218
8718,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626579,50597,,N,Intermediate,,BAO_0000218
8719,,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626580,50597,,N,Intermediate,,BAO_0000218
8720,,1,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876815,50597,,N,Intermediate,,BAO_0000218
8721,,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626581,50597,,N,Intermediate,,BAO_0000218
8722,,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626582,50597,,N,Intermediate,,BAO_0000218
8723,,1,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626583,50597,,N,Intermediate,,BAO_0000218
8724,,1,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626205,50597,,N,Intermediate,,BAO_0000218
8725,,1,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626206,50597,,N,Intermediate,,BAO_0000218
8726,,1,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626207,50597,,N,Intermediate,,BAO_0000218
8727,,1,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623882,50597,,N,Intermediate,,BAO_0000218
8728,,1,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623883,50597,,N,Intermediate,,BAO_0000218
8729,,1,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623884,50597,,N,Intermediate,,BAO_0000218
8730,,1,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623885,50597,,N,Intermediate,,BAO_0000218
8731,,1,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623886,50597,,N,Intermediate,,BAO_0000218
8732,,1,Maximal concentration in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623887,50597,,N,Intermediate,,BAO_0000218
8733,,1,Maximal concentration after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623888,50597,,N,Intermediate,,BAO_0000218
8734,,1,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623889,50597,,N,Intermediate,,BAO_0000218
8735,,1,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623890,50597,,N,Intermediate,,BAO_0000218
8736,,1,Cmax in rat plasma after oral dose (50 mg/Kg),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623891,50597,,N,Intermediate,,BAO_0000218
8737,,1,Maximal plasma concentration was determined.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623892,50597,,N,Intermediate,,BAO_0000218
8738,,1,Maximal plasma drug concentration was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623893,50597,,N,Intermediate,,BAO_0000218
8739,,1,Maximal concentration in rats after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877616,50597,,N,Intermediate,,BAO_0000218
8740,,1,Maximum concentration in rat after 2 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623894,50597,,N,Intermediate,,BAO_0000218
8741,,1,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623895,50597,,N,Intermediate,,BAO_0000218
8742,,1,Maximum concentration of compound in rat was evaluated.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623896,50597,,N,Intermediate,,BAO_0000218
8743,,1,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623897,50597,,N,Intermediate,,BAO_0000218
8744,,1,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623898,50597,,N,Intermediate,,BAO_0000218
8745,,1,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623899,50597,,N,Intermediate,,BAO_0000218
8746,,1,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623900,50597,,N,Intermediate,,BAO_0000218
8747,,1,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623901,50597,,N,Intermediate,,BAO_0000218
8748,,1,Maximum concentration was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623902,50597,,N,Intermediate,,BAO_0000218
8749,,1,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Rattus norvegicus,,,Cerebrospinal fluid,1359.0,,1,10116.0,A,CHEMBL623903,50597,,N,Intermediate,,BAO_0000218
8750,,1,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623904,50597,,N,Intermediate,,BAO_0000218
8751,,1,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL877617,50597,,N,Intermediate,,BAO_0000218
8752,,1,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623905,50597,,N,Intermediate,,BAO_0000218
8753,,1,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623906,50597,,N,Intermediate,,BAO_0000218
8754,,1,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623907,50597,,N,Intermediate,,BAO_0000218
8755,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623908,50597,,N,Intermediate,,BAO_0000218
8756,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623909,50597,,N,Intermediate,,BAO_0000218
8757,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623910,50597,,N,Intermediate,,BAO_0000218
8758,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623911,50597,,N,Intermediate,,BAO_0000218
8759,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623912,50597,,N,Intermediate,,BAO_0000218
8760,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624616,50597,,N,Intermediate,,BAO_0000218
8761,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624617,50597,,N,Intermediate,,BAO_0000218
8762,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624618,50597,,N,Intermediate,,BAO_0000218
8763,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624619,50597,,N,Intermediate,,BAO_0000218
8764,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624794,50597,,N,Intermediate,,BAO_0000218
8765,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624795,50597,,N,Intermediate,,BAO_0000218
8766,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623921,50597,,N,Intermediate,,BAO_0000218
8767,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623922,50597,,N,Intermediate,,BAO_0000218
8768,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623923,50597,,N,Intermediate,,BAO_0000218
8769,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623924,50597,,N,Intermediate,,BAO_0000218
8770,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623925,50597,,N,Intermediate,,BAO_0000218
8771,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623926,50597,,N,Intermediate,,BAO_0000218
8772,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623927,50597,,N,Intermediate,,BAO_0000218
8773,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623928,50597,,N,Intermediate,,BAO_0000218
8774,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623929,50597,,N,Intermediate,,BAO_0000218
8775,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623930,50597,,N,Intermediate,,BAO_0000218
8776,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623931,50597,,N,Intermediate,,BAO_0000218
8777,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622165,50597,,N,Intermediate,,BAO_0000218
8778,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621249,50597,,N,Intermediate,,BAO_0000218
8779,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621250,50597,,N,Intermediate,,BAO_0000218
8780,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621448,50597,,N,Intermediate,,BAO_0000218
8781,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621449,50597,,N,Intermediate,,BAO_0000218
8782,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621450,50597,,N,Intermediate,,BAO_0000218
8783,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621451,50597,,N,Intermediate,,BAO_0000218
8784,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621452,50597,,N,Intermediate,,BAO_0000218
8785,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621453,50597,,N,Intermediate,,BAO_0000218
8786,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621454,50597,,N,Intermediate,,BAO_0000218
8787,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621455,50597,,N,Intermediate,,BAO_0000218
8788,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621456,50597,,N,Intermediate,,BAO_0000218
8789,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625145,50597,,N,Intermediate,,BAO_0000218
8790,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL875847,50597,,N,Intermediate,,BAO_0000218
8791,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625146,50597,,N,Intermediate,,BAO_0000218
8792,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625147,50597,,N,Intermediate,,BAO_0000218
8793,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625148,50597,,N,Intermediate,,BAO_0000218
8794,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625149,50597,,N,Intermediate,,BAO_0000218
8795,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625150,50597,,N,Intermediate,,BAO_0000218
8796,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625151,50597,,N,Intermediate,,BAO_0000218
8797,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625152,50597,,N,Intermediate,,BAO_0000218
8798,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625153,50597,,N,Intermediate,,BAO_0000218
8799,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625154,50597,,N,Intermediate,,BAO_0000218
8800,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625155,50597,,N,Intermediate,,BAO_0000218
8801,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625156,50597,,N,Intermediate,,BAO_0000218
8802,,1,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624354,50597,,N,Intermediate,,BAO_0000218
8803,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL624355,50597,,N,Intermediate,,BAO_0000218
8804,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL624356,50597,,N,Intermediate,,BAO_0000218
8805,,1,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL624357,50597,,N,Intermediate,,BAO_0000218
8806,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL624358,50597,,N,Intermediate,,BAO_0000218
8807,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL624359,50597,,N,Intermediate,,BAO_0000218
8808,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL624360,50597,,N,Intermediate,,BAO_0000218
8809,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL624361,50597,,N,Intermediate,,BAO_0000218
8810,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL624362,50597,,N,Intermediate,,BAO_0000218
8811,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL624363,50597,,N,Intermediate,,BAO_0000218
8812,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624364,50597,,N,Intermediate,,BAO_0000218
8813,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624365,50597,,N,Intermediate,,BAO_0000218
8814,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624366,50597,,N,Intermediate,,BAO_0000218
8815,,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624367,50597,,N,Intermediate,,BAO_0000218
8816,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624368,50597,,N,Intermediate,,BAO_0000218
8817,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624369,50597,,N,Intermediate,,BAO_0000218
8818,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624370,50597,,N,Intermediate,,BAO_0000218
8819,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625069,50597,,N,Intermediate,,BAO_0000218
8820,,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625070,50597,,N,Intermediate,,BAO_0000218
8821,,1,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626051,50597,,N,Intermediate,,BAO_0000218
8822,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626052,50597,,N,Intermediate,,BAO_0000218
8823,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626053,50597,,N,Intermediate,,BAO_0000218
8824,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626054,50597,,N,Intermediate,,BAO_0000218
8825,,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626055,50597,,N,Intermediate,,BAO_0000218
8826,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626056,50597,,N,Intermediate,,BAO_0000218
8827,,1,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626057,50597,,N,Intermediate,,BAO_0000218
8828,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625193,50597,,N,Intermediate,,BAO_0000218
8829,,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625194,50597,,N,Intermediate,,BAO_0000218
8830,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625195,50597,,N,Intermediate,,BAO_0000218
8831,,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625196,50597,,N,Intermediate,,BAO_0000218
8832,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625197,50597,,N,Intermediate,,BAO_0000218
8833,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625198,50597,,N,Intermediate,,BAO_0000218
8834,,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627929,50597,,N,Intermediate,,BAO_0000218
8835,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627074,50597,,N,Intermediate,,BAO_0000218
8836,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627075,50597,,N,Intermediate,,BAO_0000218
8837,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627076,50597,,N,Intermediate,,BAO_0000218
8838,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627077,50597,,N,Intermediate,,BAO_0000218
8839,,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627078,50597,,N,Intermediate,,BAO_0000218
8840,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627079,50597,,N,Intermediate,,BAO_0000218
8841,,1,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL873824,50594,,N,Intermediate,,BAO_0000218
8842,,1,Half life in mouse plasma was determined at dose 25 mg/kg,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627080,50594,,N,Intermediate,,BAO_0000218
8843,,1,Half life was determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL627081,50594,,N,Intermediate,,BAO_0000218
8844,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL627082,50594,,N,Intermediate,,BAO_0000218
8845,,1,Half-life in male mice after 1 mg/kg intravenous dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL627083,50594,,N,Intermediate,,BAO_0000218
8847,,1,Half life in mice plasma,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627085,50594,,N,Intermediate,,BAO_0000218
8848,,1,Half life in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL627086,50594,,N,Intermediate,,BAO_0000218
8849,,1,Half life in mouse plasma at dose 25 mg/kg,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627087,50594,,N,Intermediate,,BAO_0000218
8850,,1,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL627088,50594,,N,Intermediate,,BAO_0000218
8851,,1,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL627089,50594,,N,Intermediate,,BAO_0000218
8852,,1,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL627090,50594,,N,Intermediate,,BAO_0000218
8853,,1,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Mus musculus,,,,,,1,10090.0,A,CHEMBL627091,50594,,N,Intermediate,,BAO_0000218
8854,,1,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",Mus musculus,,,,,,1,10090.0,A,CHEMBL627092,50594,,N,Intermediate,,BAO_0000218
8855,,1,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",Mus musculus,,,,,,1,10090.0,A,CHEMBL876785,50594,,N,Intermediate,,BAO_0000218
8856,,1,Half-life by iv administration in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL627093,50594,,N,Intermediate,,BAO_0000218
8857,,1,Half-life by oral administration in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL627094,50594,,N,Intermediate,,BAO_0000218
8858,,1,Half-life in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL627095,50594,,N,Intermediate,,BAO_0000218
8859,,1,Half-life using mouse brain homogenate,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627096,50594,,N,Intermediate,,BAO_0000218
8860,,1,Half-life was measured in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL627097,50594,,N,Intermediate,,BAO_0000218
8861,,1,Half-life was measured in mouse after an iv dose of 1 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627098,50594,,N,Intermediate,,BAO_0000218
8862,,1,Half-life period was determined in mouse blood,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL627099,50594,,N,Intermediate,,BAO_0000218
8863,,1,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL627100,50594,,N,Intermediate,,BAO_0000218
8864,,1,Plasma half life in mouse,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627101,50594,,N,Intermediate,,BAO_0000218
8865,,1,Stability of the peptide in the presence of mouse serum,Mus musculus,,,,,,1,10090.0,A,CHEMBL627102,50594,,N,Intermediate,,BAO_0000218
8866,,1,Terminal half life of compound was determined in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL627103,50594,,N,Intermediate,,BAO_0000218
8867,,1,Terminal half life was evaluated in mice after intravenous administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL627104,50594,,N,Intermediate,,BAO_0000218
8868,,1,Terminal half life was evaluated in mice after oral administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL627105,50594,,N,Intermediate,,BAO_0000218
8869,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,Mus musculus,,,,,,1,10090.0,A,CHEMBL876786,50594,,N,Intermediate,,BAO_0000218
8870,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,Mus musculus,,,,,,1,10090.0,A,CHEMBL873825,50594,,N,Intermediate,,BAO_0000218
8871,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,Mus musculus,,,,,,1,10090.0,A,CHEMBL627106,50594,,N,Intermediate,,BAO_0000218
8872,,1,half life period is evaluated by administering intravenously at 25 mg/kg in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL626336,50594,,N,Intermediate,,BAO_0000218
8873,,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",Mus musculus,,,,,,1,10090.0,A,CHEMBL877462,50594,,N,Intermediate,,BAO_0000218
8874,,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",Mus musculus,,,,,,1,10090.0,A,CHEMBL626337,50594,,N,Intermediate,,BAO_0000218
8875,,1,Half life after intraperitoneal administration of 100 mg/kg in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL626338,50594,,N,Intermediate,,BAO_0000218
8876,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL626339,50594,,N,Intermediate,,BAO_0000218
8877,,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL626340,50594,,N,Intermediate,,BAO_0000218
8878,,1,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL625377,50594,,N,Intermediate,,BAO_0000218
8879,,1,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL625378,50594,,N,Intermediate,,BAO_0000218
8880,,1,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,Mus musculus,,,,,,1,10090.0,A,CHEMBL625379,50594,,N,Intermediate,,BAO_0000218
8881,Microsomes,0,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Sus scrofa,,,,,,1,9823.0,A,CHEMBL625380,22224,,U,Autocuration,,BAO_0000251
8882,Microsomes,0,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Sus scrofa,,,,,,1,9823.0,A,CHEMBL625381,22224,,U,Autocuration,,BAO_0000251
8883,,0,Stability to porcine renal DHP-I,Sus scrofa,,,,,,1,9823.0,A,CHEMBL625382,22224,,U,Autocuration,,BAO_0000019
8884,,0,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,Sus scrofa,,,,,,1,9823.0,A,CHEMBL873828,22224,,U,Autocuration,,BAO_0000218
8885,,0,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,Sus scrofa,,,,,,1,9823.0,A,CHEMBL625383,22224,,U,Autocuration,,BAO_0000218
8886,,0,Half-life of the parent prodrug in porcine esterase solution,Sus scrofa,,,,,,1,9823.0,A,CHEMBL625384,22224,,U,Autocuration,,BAO_0000019
8887,,0,"First order rate constant, k was determined in in pig liver Esterase",Sus scrofa,,,,,,1,9823.0,A,CHEMBL625385,22224,,U,Autocuration,,BAO_0000019
8888,,0,Half life of the in pig liver Esterase,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL625386,22224,,U,Autocuration,,BAO_0000221
8889,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623571,22224,,U,Autocuration,,BAO_0000221
8890,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623572,22224,,U,Autocuration,,BAO_0000221
8891,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623573,22224,,U,Autocuration,,BAO_0000221
8892,,0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623574,22224,,U,Autocuration,,BAO_0000221
8893,,0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623575,22224,,U,Autocuration,,BAO_0000221
8894,,0,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623749,22224,,U,Autocuration,,BAO_0000221
8895,,0,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623750,22224,,U,Autocuration,,BAO_0000221
8896,,0,Half-life in vitro in pig liver,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623751,22224,,U,Autocuration,,BAO_0000221
8897,,0,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Sus scrofa,,,Liver,2107.0,,1,9823.0,A,CHEMBL623752,22224,,U,Autocuration,,BAO_0000221
8898,,1,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623753,50597,,N,Intermediate,,BAO_0000218
8899,,1,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623754,50597,,N,Intermediate,,BAO_0000218
8900,,1,Maximum concentration in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623755,50597,,N,Intermediate,,BAO_0000218
8901,,1,Maximum concentration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623756,50597,,N,Intermediate,,BAO_0000218
8902,,1,Maximum concentration in rats at 1-2 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623757,50597,,N,Intermediate,,BAO_0000218
8903,,1,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623758,50597,,N,Intermediate,,BAO_0000218
8904,,1,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623759,50597,,N,Intermediate,,BAO_0000218
8905,,1,Maximum concentration at the dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623760,50597,,N,Intermediate,,BAO_0000218
8906,,1,Maximum concentration was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623761,50597,,N,Intermediate,,BAO_0000218
8907,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623762,50597,,N,Intermediate,,BAO_0000218
8908,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL877594,50597,,N,Intermediate,,BAO_0000218
8909,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623763,50597,,N,Intermediate,,BAO_0000218
8910,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623764,50597,,N,Intermediate,,BAO_0000218
8911,,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623765,50597,,N,Intermediate,,BAO_0000218
8912,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623766,50597,,N,Intermediate,,BAO_0000218
8913,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623767,50597,,N,Intermediate,,BAO_0000218
8914,,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623768,50597,,N,Intermediate,,BAO_0000218
8915,,1,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623769,50597,,N,Intermediate,,BAO_0000218
8916,,1,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623770,50597,,N,Intermediate,,BAO_0000218
8917,,1,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623771,50597,,N,Intermediate,,BAO_0000218
8918,,1,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623772,50597,,N,Intermediate,,BAO_0000218
8919,,1,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623773,50597,,N,Intermediate,,BAO_0000218
8920,,1,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623774,50597,,N,Intermediate,,BAO_0000218
8921,,1,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623775,50597,,N,Intermediate,,BAO_0000218
8922,,1,Cmax in rat (PO dose),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623776,50597,,N,Intermediate,,BAO_0000218
8923,,1,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622191,50597,,N,Intermediate,,BAO_0000218
8924,,1,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622192,50597,,N,Intermediate,,BAO_0000218
8925,,1,Maximum plasma concentration determined in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622193,50597,,N,Intermediate,,BAO_0000218
8926,,1,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622194,50597,,N,Intermediate,,BAO_0000218
8927,,1,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622195,50597,,N,Intermediate,,BAO_0000218
8928,,1,Maximum plasma concentration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622196,50597,,N,Intermediate,,BAO_0000218
8929,,1,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622197,50597,,N,Intermediate,,BAO_0000218
8930,,1,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622198,50597,,N,Intermediate,,BAO_0000218
8931,,1,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622199,50597,,N,Intermediate,,BAO_0000218
8932,,1,Maximum plasma concentration of compound was measured in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622200,50597,,N,Intermediate,,BAO_0000218
8933,,1,Maximum plasma concentration after 20 mg/kg oral administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622201,50597,,N,Intermediate,,BAO_0000218
8934,,1,Maximum plasma concentration after oral administration to rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623990,50597,,N,Intermediate,,BAO_0000218
8935,,1,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623991,50597,,N,Intermediate,,BAO_0000218
8936,,1,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623992,50597,,N,Intermediate,,BAO_0000218
8937,,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623993,50597,,N,Intermediate,,BAO_0000218
8938,,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623994,50597,,N,Intermediate,,BAO_0000218
8939,,1,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,F,CHEMBL623995,50597,,N,Intermediate,,BAO_0000218
8940,,1,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,F,CHEMBL623996,50597,,N,Intermediate,,BAO_0000218
8941,,1,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,F,CHEMBL623997,50597,,N,Intermediate,,BAO_0000218
8942,,1,Maximum plasma concentration dosed orally in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623998,50597,,N,Intermediate,,BAO_0000218
8943,,1,Maximum plasma concentration dosed orally in rats after 6 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623999,50597,,N,Intermediate,,BAO_0000218
8944,,1,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624000,50597,,N,Intermediate,,BAO_0000218
8945,,1,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624001,50597,,N,Intermediate,,BAO_0000218
8946,,1,Maximum plasma concentration in rat after po administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624002,50597,,N,Intermediate,,BAO_0000218
8947,,1,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624003,50597,,N,Intermediate,,BAO_0000218
8948,,1,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624004,50597,,N,Intermediate,,BAO_0000218
8949,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624005,50597,,N,Intermediate,,BAO_0000218
8950,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624006,50597,,N,Intermediate,,BAO_0000218
8951,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624007,50597,,N,Intermediate,,BAO_0000218
8952,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624008,50597,,N,Intermediate,,BAO_0000218
8953,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624009,50597,,N,Intermediate,,BAO_0000218
8954,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL874387,50597,,N,Intermediate,,BAO_0000218
8955,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624010,50597,,N,Intermediate,,BAO_0000218
8956,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624011,50597,,N,Intermediate,,BAO_0000218
8957,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624012,50597,,N,Intermediate,,BAO_0000218
8958,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624013,50597,,N,Intermediate,,BAO_0000218
8959,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624736,50597,,N,Intermediate,,BAO_0000218
8960,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624737,50597,,N,Intermediate,,BAO_0000218
8961,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624738,50597,,N,Intermediate,,BAO_0000218
8962,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624739,50597,,N,Intermediate,,BAO_0000218
8963,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624740,50597,,N,Intermediate,,BAO_0000218
8964,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624896,50597,,N,Intermediate,,BAO_0000218
8965,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624897,50597,,N,Intermediate,,BAO_0000218
8966,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624108,50597,,N,Intermediate,,BAO_0000218
8967,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624109,50597,,N,Intermediate,,BAO_0000218
8968,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624110,50597,,N,Intermediate,,BAO_0000218
8969,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624111,50597,,N,Intermediate,,BAO_0000218
8970,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624112,50597,,N,Intermediate,,BAO_0000218
8971,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624113,50597,,N,Intermediate,,BAO_0000218
8972,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL619709,50597,,N,Intermediate,,BAO_0000218
8973,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL619710,50597,,N,Intermediate,,BAO_0000218
8974,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619711,50597,,N,Intermediate,,BAO_0000218
8975,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619712,50597,,N,Intermediate,,BAO_0000218
8976,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619713,50597,,N,Intermediate,,BAO_0000218
8977,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619714,50597,,N,Intermediate,,BAO_0000218
8978,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619715,50597,,N,Intermediate,,BAO_0000218
8979,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619716,50597,,N,Intermediate,,BAO_0000218
8980,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619717,50597,,N,Intermediate,,BAO_0000218
8981,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619718,50597,,N,Intermediate,,BAO_0000218
8982,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619719,50597,,N,Intermediate,,BAO_0000218
8983,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL875329,50597,,N,Intermediate,,BAO_0000218
8984,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619720,50597,,N,Intermediate,,BAO_0000218
8985,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619721,50597,,N,Intermediate,,BAO_0000218
8986,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619722,50597,,N,Intermediate,,BAO_0000218
8987,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619723,50597,,N,Intermediate,,BAO_0000218
8988,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619724,50597,,N,Intermediate,,BAO_0000218
8989,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619725,50597,,N,Intermediate,,BAO_0000218
8990,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619726,50597,,N,Intermediate,,BAO_0000218
8991,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619727,50597,,N,Intermediate,,BAO_0000218
8992,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619728,50597,,N,Intermediate,,BAO_0000218
8993,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL619729,50597,,N,Intermediate,,BAO_0000218
8994,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL619730,50597,,N,Intermediate,,BAO_0000218
8995,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL619731,50597,,N,Intermediate,,BAO_0000218
8996,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL619732,50597,,N,Intermediate,,BAO_0000218
8997,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL619733,50597,,N,Intermediate,,BAO_0000218
8998,,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL619734,50597,,N,Intermediate,,BAO_0000218
8999,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL619735,50597,,N,Intermediate,,BAO_0000218
9000,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL875330,50597,,N,Intermediate,,BAO_0000218
9001,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL628465,50597,,N,Intermediate,,BAO_0000218
9002,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL628466,50597,,N,Intermediate,,BAO_0000218
9003,,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL628467,50597,,N,Intermediate,,BAO_0000218
9004,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628468,50597,,N,Intermediate,,BAO_0000218
9005,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628469,50597,,N,Intermediate,,BAO_0000218
9006,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628470,50597,,N,Intermediate,,BAO_0000218
9007,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628471,50597,,N,Intermediate,,BAO_0000218
9008,,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628472,50597,,N,Intermediate,,BAO_0000218
9009,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL625191,50597,,N,Intermediate,,BAO_0000218
9010,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL625192,50597,,N,Intermediate,,BAO_0000218
9011,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL875337,50597,,N,Intermediate,,BAO_0000218
9012,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626341,50597,,N,Intermediate,,BAO_0000218
9013,,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626342,50597,,N,Intermediate,,BAO_0000218
9014,,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621943,50597,,N,Intermediate,,BAO_0000218
9015,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621944,50597,,N,Intermediate,,BAO_0000218
9016,,1,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621945,50597,,N,Intermediate,,BAO_0000218
9017,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621946,50597,,N,Intermediate,,BAO_0000218
9018,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621947,50597,,N,Intermediate,,BAO_0000218
9019,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621948,50597,,N,Intermediate,,BAO_0000218
9020,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621949,50597,,N,Intermediate,,BAO_0000218
9021,,1,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621950,50597,,N,Intermediate,,BAO_0000218
9022,,1,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621951,50597,,N,Intermediate,,BAO_0000218
9023,,1,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621952,50597,,N,Intermediate,,BAO_0000218
9024,,1,Stability (%) in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621953,50597,,N,Intermediate,,BAO_0000218
9025,,1,Area under curve was calculated after intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621954,50597,,N,Intermediate,,BAO_0000218
9026,,1,Area under the curve was calculated after iv administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621955,50597,,N,Intermediate,,BAO_0000218
9027,,1,Area under the curve was calculated in rat after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621956,50597,,N,Intermediate,,BAO_0000218
9028,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621957,50597,,N,Intermediate,,BAO_0000218
9029,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621958,50597,,N,Intermediate,,BAO_0000218
9030,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621959,50597,,N,Intermediate,,BAO_0000218
9031,,1,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621960,50597,,N,Intermediate,,BAO_0000218
9032,,1,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621961,50597,,N,Intermediate,,BAO_0000218
9033,,1,p value of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621962,50597,,N,Intermediate,,BAO_0000218
9034,,1,p value of the compound,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL876787,50597,,N,Intermediate,,BAO_0000218
9035,,1,p value of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621963,50597,,N,Intermediate,,BAO_0000218
9036,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622637,50597,,N,Intermediate,,BAO_0000218
9037,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622638,50597,,N,Intermediate,,BAO_0000218
9038,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL626561,50597,,N,Intermediate,,BAO_0000218
9039,,0,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL626562,22224,,U,Autocuration,,BAO_0000019
9040,,0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626563,22224,,U,Autocuration,,BAO_0000218
9041,,0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626564,22224,,U,Autocuration,,BAO_0000218
9042,,0,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626565,22224,,U,Autocuration,,BAO_0000218
9043,,0,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626566,22224,,U,Autocuration,,BAO_0000218
9044,,0,Clearance rate in rabbits,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626567,22224,,U,Autocuration,,BAO_0000218
9045,,0,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626568,22224,,U,Autocuration,,BAO_0000218
9046,,0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626569,22224,,U,Autocuration,,BAO_0000218
9047,,0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626570,22224,,U,Autocuration,,BAO_0000218
9048,,0,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626571,22224,,U,Autocuration,,BAO_0000218
9049,,0,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626572,22224,,U,Autocuration,,BAO_0000218
9050,,0,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL626573,22224,,U,Autocuration,,BAO_0000218
9051,Microsomes,0,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Oryctolagus cuniculus,,,Liver,2107.0,,1,9986.0,A,CHEMBL626574,22224,,U,Autocuration,,BAO_0000251
9052,Microsomes,0,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Oryctolagus cuniculus,,,Liver,2107.0,,1,9986.0,A,CHEMBL626575,22224,,U,Autocuration,,BAO_0000251
9053,,0,Dose at which bioavailability of intravenously administered compound was tested in rabbit,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626576,22224,,U,Autocuration,,BAO_0000218
9054,,0,Dose at which bioavailability of perorally administered compound was tested in rabbit,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626577,22224,,U,Autocuration,,BAO_0000218
9055,,0,The compound was tested for its bioavailability in rabbit (by oral dosage).,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626578,22224,,U,Autocuration,,BAO_0000218
9056,,0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625263,22224,,U,Autocuration,,BAO_0000218
9057,,0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625264,22224,,U,Autocuration,,BAO_0000218
9058,,0,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625265,22224,,U,Autocuration,,BAO_0000218
9059,Microsomes,0,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625266,22224,,U,Autocuration,,BAO_0000251
9060,Microsomes,0,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL876796,22224,,U,Autocuration,,BAO_0000251
9061,,0,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625267,22224,,U,Autocuration,,BAO_0000218
9062,,0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL625268,22224,,U,Autocuration,,BAO_0000218
9063,,0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL625269,22224,,U,Autocuration,,BAO_0000218
9064,,0,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL624689,22224,,U,Autocuration,,BAO_0000218
9065,,0,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624690,22224,,U,Autocuration,,BAO_0000218
9066,,0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL624691,22224,,U,Autocuration,,BAO_0000218
9067,,0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL624692,22224,,U,Autocuration,,BAO_0000218
9068,,0,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624693,22224,,U,Autocuration,,BAO_0000218
9069,,0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624694,22224,,U,Autocuration,,BAO_0000218
9070,,0,In vitro Biological half-life in crude homogenate of rabbit renal cortex,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL877596,22224,,U,Autocuration,,BAO_0000221
9071,,0,Time within which only 10% of the drug was degraded,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624695,22224,,U,Autocuration,,BAO_0000019
9072,,0,Half life period in rabbit liver homogenate,Oryctolagus cuniculus,,,Liver,2107.0,,1,9986.0,A,CHEMBL624696,22224,,U,Autocuration,,BAO_0000221
9073,,0,Half life value in rabbits,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624697,22224,,U,Autocuration,,BAO_0000019
9074,,0,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Oryctolagus cuniculus,,,Blood,178.0,,1,9986.0,A,CHEMBL624698,22224,,U,Autocuration,,BAO_0000218
9075,,0,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Oryctolagus cuniculus,,,Blood,178.0,,1,9986.0,A,CHEMBL624699,22224,,U,Autocuration,,BAO_0000218
9076,,0,Half-life period in rabbits following intravenous administration at 2 mg/kg,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL624700,22224,,U,Autocuration,,BAO_0000218
9077,,1,AUC 0-8 hr value in rats at 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622903,50597,,N,Intermediate,,BAO_0000218
9078,,1,AUC after administration at 2000 mg/kg/day in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622904,50597,,N,Intermediate,,BAO_0000218
9079,,1,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622905,50597,,N,Intermediate,,BAO_0000218
9080,,1,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622906,50597,,N,Intermediate,,BAO_0000218
9081,,1,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622907,50597,,N,Intermediate,,BAO_0000218
9082,,1,AUC in rat after oral administration at 10.5 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622908,50597,,N,Intermediate,,BAO_0000218
9083,,1,AUC in rat after oral administration at 11.2 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622909,50597,,N,Intermediate,,BAO_0000218
9084,,1,AUC in rat after oral administration at 9.7 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622910,50597,,N,Intermediate,,BAO_0000218
9085,,1,AUC in rat brain after oral administration at 10 mg/kg,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622911,50597,,N,Intermediate,,BAO_0000218
9086,,1,AUC in rat p.o.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622912,50597,,N,Intermediate,,BAO_0000218
9087,,1,AUC in rat p.o. at 20 mg/kg concentration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622913,50597,,N,Intermediate,,BAO_0000218
9088,,1,AUC in rat plasma after oral administration at 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622914,50597,,N,Intermediate,,BAO_0000218
9089,,1,AUC in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622915,50597,,N,Intermediate,,BAO_0000218
9090,,1,AUC value after IV dose at a dose of 5 mg/kg in rats.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622916,50597,,N,Intermediate,,BAO_0000218
9091,,1,AUC value after oral dose at a dose of 10 mg/kg in rats.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622917,50597,,N,Intermediate,,BAO_0000218
9092,,1,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622918,50597,,N,Intermediate,,BAO_0000218
9093,,1,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622919,50597,,N,Intermediate,,BAO_0000218
9094,,1,Maximum plasma concentration was evaluated in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622920,50597,,N,Intermediate,,BAO_0000218
9095,,1,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622921,50597,,N,Intermediate,,BAO_0000218
9096,,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622922,50597,,N,Intermediate,,BAO_0000218
9097,,1,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622923,50597,,N,Intermediate,,BAO_0000218
9098,,1,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL877604,50597,,N,Intermediate,,BAO_0000218
9099,,1,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622924,50597,,N,Intermediate,,BAO_0000218
9100,,1,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622925,50597,,N,Intermediate,,BAO_0000218
9101,,1,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622926,50597,,N,Intermediate,,BAO_0000218
9102,,1,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623625,50597,,N,Intermediate,,BAO_0000218
9103,,1,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623626,50597,,N,Expert,,BAO_0000218
9104,,1,Maximum plasma drug concentration was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623627,50597,,N,Intermediate,,BAO_0000218
9105,,1,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623628,50597,,N,Intermediate,,BAO_0000218
9106,,1,Mean peak plasma concentration was observed after intravenous administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623629,50597,,N,Intermediate,,BAO_0000218
9107,,1,Mean peak plasma concentration was observed after oral administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623630,50597,,N,Intermediate,,BAO_0000218
9108,,1,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623804,50597,,N,Intermediate,,BAO_0000218
9109,,1,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623805,50597,,N,Intermediate,,BAO_0000218
9110,,1,Peak oral plasma concentration was determined in rats by oral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623806,50597,,N,Intermediate,,BAO_0000218
9111,,1,Peak plasma concentration (Cmax) was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623807,50597,,N,Intermediate,,BAO_0000218
9112,,1,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623808,50597,,N,Intermediate,,BAO_0000218
9113,,1,Peak plasma concentration (Cmax) in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623809,50597,,N,Intermediate,,BAO_0000218
9114,,1,Peak plasma concentration at 1 mg/kg peroral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623810,50597,,N,Intermediate,,BAO_0000218
9115,,1,Peak plasma concentration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623811,50597,,N,Intermediate,,BAO_0000218
9116,,1,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623812,50597,,N,Intermediate,,BAO_0000218
9117,,1,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877605,50597,,N,Intermediate,,BAO_0000218
9118,,1,Pharmacokinetic property (Cmax) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623813,50597,,N,Intermediate,,BAO_0000218
9119,,1,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623814,50597,,N,Intermediate,,BAO_0000218
9120,,1,Cmax in rat after 3mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623815,50597,,N,Intermediate,,BAO_0000218
9121,,1,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Rattus norvegicus,Sprague-Dawley,,,,,1,10116.0,A,CHEMBL623816,50597,,N,Intermediate,,BAO_0000218
9122,,1,Cmax in rats after 20 mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623145,50597,,N,Intermediate,,BAO_0000218
9123,,1,Cmax in rat plasma after 30mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623146,50597,,N,Intermediate,,BAO_0000218
9124,,1,Plasma concentration after oral administration of 100 mg/kg to rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623147,50597,,N,Intermediate,,BAO_0000218
9125,,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623042,50597,,N,Intermediate,,BAO_0000218
9126,,1,Tested for the Cmax in rat at 10 mg/kg per orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623043,50597,,N,Intermediate,,BAO_0000218
9127,,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623044,50597,,N,Intermediate,,BAO_0000218
9128,,1,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623045,50597,,N,Intermediate,,BAO_0000218
9129,,1,Bioavailability as oral Cmax in rats at 30 mins,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623046,50597,,N,Intermediate,,BAO_0000218
9130,,1,Bioavailability as oral Cmax in rats at 6hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623226,50597,,N,Intermediate,,BAO_0000218
9131,,1,The maximum concentration of compound was measured at the dose of 100 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623227,50597,,N,Intermediate,,BAO_0000218
9132,,1,The maximum concentration of compound was measured at the dose of 300 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623228,50597,,N,Intermediate,,BAO_0000218
9133,,1,The maximum concentration of compound was measured at the dose of 30 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623229,50597,,N,Intermediate,,BAO_0000218
9134,,1,The maximum plasma levels for the compounds were determined by LC-MS.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623230,50597,,N,Intermediate,,BAO_0000218
9135,,1,mean peak plasma concentration was observed after intravenous administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623231,50597,,N,Intermediate,,BAO_0000218
9136,,1,mean peak plasma concentration was observed after oral administration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623232,50597,,N,Intermediate,,BAO_0000218
9137,,1,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623233,50597,,N,Intermediate,,BAO_0000218
9138,,1,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623234,50597,,N,Intermediate,,BAO_0000218
9139,,1,Concentration in plasma (portal) following oral dose in rats at 1 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623235,50597,,N,Intermediate,,BAO_0000218
9140,,1,Concentration in plasma (portal) following oral dose in rats at 2 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623236,50597,,N,Intermediate,,BAO_0000218
9141,,1,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623237,50597,,N,Intermediate,,BAO_0000218
9142,,1,Concentration in plasma (systemic) following oral dose in rats at 1 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623238,50597,,N,Intermediate,,BAO_0000218
9143,,1,Concentration in plasma (systemic) following oral dose in rats at 2 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623239,50597,,N,Intermediate,,BAO_0000218
9144,,0,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623240,22224,,U,Intermediate,,BAO_0000218
9145,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL623241,50597,,N,Intermediate,,BAO_0000218
9146,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL623242,50597,,N,Intermediate,,BAO_0000218
9147,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874394,50597,,N,Intermediate,,BAO_0000218
9148,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623243,50597,,N,Intermediate,,BAO_0000218
9149,,1,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623244,50597,,N,Intermediate,,BAO_0000218
9150,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623245,50597,,N,Intermediate,,BAO_0000218
9151,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623246,50597,,N,Intermediate,,BAO_0000218
9152,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623247,50597,,N,Intermediate,,BAO_0000218
9153,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623248,50597,,N,Intermediate,,BAO_0000218
9154,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623249,50597,,N,Intermediate,,BAO_0000218
9155,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625072,50597,,N,Intermediate,,BAO_0000218
9156,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625073,50597,,N,Intermediate,,BAO_0000218
9157,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625074,50597,,N,Intermediate,,BAO_0000218
9158,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625075,50597,,N,Intermediate,,BAO_0000218
9159,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625076,50597,,N,Intermediate,,BAO_0000218
9160,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625077,50597,,N,Intermediate,,BAO_0000218
9161,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625078,50597,,N,Intermediate,,BAO_0000218
9162,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL874395,50597,,N,Intermediate,,BAO_0000218
9163,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625079,50597,,N,Intermediate,,BAO_0000218
9164,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625080,50597,,N,Intermediate,,BAO_0000218
9165,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625081,50597,,N,Intermediate,,BAO_0000218
9166,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625082,50597,,N,Intermediate,,BAO_0000218
9167,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625083,50597,,N,Intermediate,,BAO_0000218
9168,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625084,50597,,N,Intermediate,,BAO_0000218
9169,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625085,50597,,N,Intermediate,,BAO_0000218
9170,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625086,50597,,N,Intermediate,,BAO_0000218
9171,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625087,50597,,N,Intermediate,,BAO_0000218
9172,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625088,50597,,N,Intermediate,,BAO_0000218
9173,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622205,50597,,N,Intermediate,,BAO_0000218
9174,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622206,50597,,N,Intermediate,,BAO_0000218
9175,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622207,50597,,N,Intermediate,,BAO_0000218
9176,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622366,50597,,N,Intermediate,,BAO_0000218
9177,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622367,50597,,N,Intermediate,,BAO_0000218
9178,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL875331,50597,,N,Intermediate,,BAO_0000218
9179,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622368,50597,,N,Intermediate,,BAO_0000218
9180,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622369,50597,,N,Intermediate,,BAO_0000218
9181,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622370,50597,,N,Intermediate,,BAO_0000218
9182,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622371,50597,,N,Intermediate,,BAO_0000218
9183,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622372,50597,,N,Intermediate,,BAO_0000218
9184,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622373,50597,,N,Intermediate,,BAO_0000218
9185,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622374,50597,,N,Intermediate,,BAO_0000218
9186,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622375,50597,,N,Intermediate,,BAO_0000218
9187,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622376,50597,,N,Intermediate,,BAO_0000218
9188,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622377,50597,,N,Intermediate,,BAO_0000218
9189,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622378,50597,,N,Intermediate,,BAO_0000218
9190,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622379,50597,,N,Intermediate,,BAO_0000218
9191,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622380,50597,,N,Intermediate,,BAO_0000218
9192,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622381,50597,,N,Intermediate,,BAO_0000218
9193,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622382,50597,,N,Intermediate,,BAO_0000218
9194,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622383,50597,,N,Intermediate,,BAO_0000218
9195,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL875332,50597,,N,Intermediate,,BAO_0000218
9196,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622384,50597,,N,Intermediate,,BAO_0000218
9197,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622385,50597,,N,Intermediate,,BAO_0000218
9198,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622386,50597,,N,Intermediate,,BAO_0000218
9199,,1,The compound was tested for the plasma binding in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622387,50597,,N,Intermediate,,BAO_0000218
9200,,1,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622388,50597,,N,Intermediate,,BAO_0000218
9201,,1,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622389,50597,,N,Intermediate,,BAO_0000218
9202,,1,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622390,50597,,N,Intermediate,,BAO_0000218
9203,,1,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622391,50597,,N,Intermediate,,BAO_0000218
9204,,1,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622392,50597,,N,Intermediate,,BAO_0000218
9205,,1,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622393,50597,,N,Intermediate,,BAO_0000218
9206,,1,Plasma level at 2 hr after administration of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622394,50597,,N,Intermediate,,BAO_0000218
9207,,1,plasma level at 2 hr after administration of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622395,50597,,N,Intermediate,,BAO_0000218
9208,,1,Stability in rat serum measured as % recovery at 1 min,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL622396,50597,,N,Intermediate,,BAO_0000218
9209,,1,Stability in rat serum measured as % recovery at 10 min,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624894,50597,,N,Intermediate,,BAO_0000218
9210,,1,Stability in rat serum measured as % recovery at 10 mins,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624895,50597,,N,Intermediate,,BAO_0000218
9211,,1,Stability in rat serum measured as % recovery at 2 hr,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624058,50597,,N,Intermediate,,BAO_0000218
9212,,1,Stability in rat serum measured as % recovery at 3 min,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624059,50597,,N,Intermediate,,BAO_0000218
9213,,1,Stability in rat serum measured as % recovery at 3 mins,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624060,50597,,N,Intermediate,,BAO_0000218
9214,,1,Stability in rat serum measured as % recovery at 5 min,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624061,50597,,N,Intermediate,,BAO_0000218
9215,,1,Stability in rat serum measured as % recovery at 5 mins,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL624062,50597,,N,Intermediate,,BAO_0000218
9216,,1,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624063,50597,,N,Intermediate,,BAO_0000218
9217,,1,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624064,50597,,N,Intermediate,,BAO_0000218
9218,,1,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624065,50597,,N,Intermediate,,BAO_0000218
9219,,1,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624066,50597,,N,Intermediate,,BAO_0000218
9220,,1,Half life tested in mature male rat at a dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877490,50597,,N,Intermediate,,BAO_0000218
9221,,1,Half life after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874442,50597,,N,Intermediate,,BAO_0000218
9222,,1,Half life period after administration (30 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626890,50597,,N,Intermediate,,BAO_0000218
9223,,1,Half life period in rat after 5 mg/Kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626891,50597,,N,Intermediate,,BAO_0000218
9224,,1,Half life period in rat after 5 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626892,50597,,N,Intermediate,,BAO_0000218
9225,,1,Half life period was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626893,50597,,N,Intermediate,,BAO_0000218
9226,,1,Half life period was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626894,50597,,N,Intermediate,,BAO_0000218
9227,,1,Half life period was evaluated in rat; 0.5-1.0,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626895,50597,,N,Intermediate,,BAO_0000218
9228,,1,Half life period was evaluated in rat; 5.9-7.5,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626896,50597,,N,Intermediate,,BAO_0000218
9229,,1,Half-life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626897,50597,,N,Intermediate,,BAO_0000218
9230,,1,Half-life time in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626898,50597,,N,Intermediate,,BAO_0000218
9231,,1,Terminal half-life after iv administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626899,50597,,N,Intermediate,,BAO_0000218
9232,,1,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626900,50597,,N,Intermediate,,BAO_0000218
9233,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626901,50597,,N,Intermediate,,BAO_0000218
9234,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626902,50597,,N,Intermediate,,BAO_0000218
9235,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626903,50597,,N,Intermediate,,BAO_0000218
9236,,1,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874443,50597,,N,Intermediate,,BAO_0000218
9237,,1,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626904,50597,,N,Intermediate,,BAO_0000218
9238,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626905,50597,,N,Intermediate,,BAO_0000218
9239,,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873830,50597,,N,Intermediate,,BAO_0000218
9240,,1,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626906,50597,,N,Intermediate,,BAO_0000218
9241,,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631076,50597,,N,Intermediate,,BAO_0000218
9242,,1,Biological half-life was measured in plasma of rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631077,50597,,N,Intermediate,,BAO_0000218
9243,,1,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631078,50597,,N,Intermediate,,BAO_0000218
9244,,1,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631079,50597,,N,Intermediate,,BAO_0000218
9245,,1,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631080,50597,,N,Intermediate,,BAO_0000218
9246,,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631081,50597,,N,Intermediate,,BAO_0000218
9247,,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631239,50597,,N,Intermediate,,BAO_0000218
9248,,1,Compound was evaluated for plasma half life in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631240,50597,,N,Intermediate,,BAO_0000218
9249,,1,AUC value at a dose of 5 mg/kg (p.o.) in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631241,50597,,N,Intermediate,,BAO_0000218
9250,,1,AUC value after administration of 20 mg/Kg oral dose in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631242,50597,,N,Intermediate,,BAO_0000218
9251,,1,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631243,50597,,N,Intermediate,,BAO_0000218
9252,,1,AUC0-96 after administration at 50 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL874444,50597,,N,Intermediate,,BAO_0000218
9253,,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631244,50597,,N,Intermediate,,BAO_0000218
9254,,1,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631245,50597,,N,Intermediate,,BAO_0000218
9255,,1,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627162,50597,,N,Intermediate,,BAO_0000218
9256,,1,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627163,50597,,N,Intermediate,,BAO_0000218
9257,,1,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627164,50597,,N,Intermediate,,BAO_0000218
9258,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627165,50597,,N,Intermediate,,BAO_0000218
9259,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627166,50597,,N,Intermediate,,BAO_0000218
9260,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627167,50597,,N,Intermediate,,BAO_0000218
9261,,1,Area under curve (AUC) at a dose of 30 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627822,50597,,N,Intermediate,,BAO_0000218
9262,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627823,50597,,N,Intermediate,,BAO_0000218
9263,,1,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627824,50597,,N,Intermediate,,BAO_0000218
9264,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627825,50597,,N,Intermediate,,BAO_0000218
9265,,1,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627826,50597,,N,Intermediate,,BAO_0000218
9266,,1,Area under curve (Pharmacokinetic property) was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627827,50597,,N,Intermediate,,BAO_0000218
9267,,1,Area under curve (Pharmacokinetic property) of the compound; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627828,50597,,N,Intermediate,,BAO_0000218
9268,,1,Area under curve after intravenous administration (1 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627829,50597,,N,Intermediate,,BAO_0000218
9269,,1,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627830,50597,,N,Intermediate,,BAO_0000218
9270,,1,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627831,50597,,N,Intermediate,,BAO_0000218
9271,,1,Area under curve in male SD rats was observed after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627832,50597,,N,Intermediate,,BAO_0000218
9272,,1,Area under curve of compound after iv administration of 20 mg/kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627833,50597,,N,Intermediate,,BAO_0000218
9273,,1,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627834,50597,,N,Expert,,BAO_0000218
9274,,1,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628004,50597,,N,Expert,,BAO_0000218
9275,,1,Area under curve at 5 mg/kg po was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628005,50597,,N,Intermediate,,BAO_0000218
9276,,1,Area under curve in Rat at a oral dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628006,50597,,N,Intermediate,,BAO_0000218
9277,,1,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628007,50597,,N,Intermediate,,BAO_0000218
9278,,1,Area under curve was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625676,50597,,N,Intermediate,,BAO_0000218
9279,,1,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631309,50597,,N,Intermediate,,BAO_0000218
9280,,1,Area under curve after intravenous administration at 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631310,50597,,N,Intermediate,,BAO_0000218
9281,,1,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631311,50597,,N,Intermediate,,BAO_0000218
9282,,1,Area under curve at 4 hr in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631312,50597,,N,Intermediate,,BAO_0000218
9283,,1,Area under curve at a dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631313,50597,,N,Intermediate,,BAO_0000218
9284,,1,Area under curve at the dose of 2 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631314,50597,,N,Intermediate,,BAO_0000218
9285,,1,Area under curve at the dose of 5 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631315,50597,,N,Intermediate,,BAO_0000218
9286,,1,Area under curve for a 2-mpk po dose in SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631316,50597,,N,Intermediate,,BAO_0000218
9287,,1,Area under curve in SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631317,50597,,N,Intermediate,,BAO_0000218
9288,,1,Area under curve in rat after oral administration at 13 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874471,50597,,N,Intermediate,,BAO_0000218
9289,,1,Area under curve in rat by po administration at 0-24 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631318,50597,,N,Intermediate,,BAO_0000218
9290,,1,Area under curve in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631319,50597,,N,Intermediate,,BAO_0000218
9291,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631320,50597,,N,Intermediate,,BAO_0000218
9292,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631321,50597,,N,Intermediate,,BAO_0000218
9293,,1,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631322,50597,,N,Intermediate,,BAO_0000218
9294,,1,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631323,50597,,N,Intermediate,,BAO_0000218
9295,,1,Area under curve value in rat at a dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631324,50597,,N,Intermediate,,BAO_0000218
9296,,1,Area under curve was determined after oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631325,50597,,N,Intermediate,,BAO_0000218
9297,,1,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631326,50597,,N,Intermediate,,BAO_0000218
9298,,1,Area under curve was determined after peroral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631327,50597,,N,Intermediate,,BAO_0000218
9299,,1,Area under curve was determined at a dose 30 mpk administered orally.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631328,50597,,N,Intermediate,,BAO_0000218
9300,,1,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631329,50597,,N,Intermediate,,BAO_0000218
9301,,1,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627217,50597,,N,Intermediate,,BAO_0000218
9302,,1,Area under curve was determined in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626352,50597,,N,Intermediate,,BAO_0000218
9303,,1,Area under curve was determined in rat after PO administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626353,50597,,N,Intermediate,,BAO_0000218
9304,,1,Area under curve was determined in rat after a 3 mg/kg of oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626354,50597,,N,Intermediate,,BAO_0000218
9305,,1,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626355,50597,,N,Intermediate,,BAO_0000218
9306,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626356,50597,,N,Intermediate,,BAO_0000218
9307,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626357,50597,,N,Intermediate,,BAO_0000218
9308,,1,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626358,50597,,N,Intermediate,,BAO_0000218
9309,,1,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626359,50597,,N,Intermediate,,BAO_0000218
9310,,1,Peak plasma concentration in rat at a dose of 3 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626360,50597,,N,Intermediate,,BAO_0000218
9311,,1,Plasma concentration at 2 hr in rats was evaluated.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626361,50597,,N,Intermediate,,BAO_0000218
9312,,1,Plasma concentration at 2 hr in rats was evaluated; Not available,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626362,50597,,N,Intermediate,,BAO_0000218
9313,,1,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626363,50597,,N,Intermediate,,BAO_0000218
9314,,1,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626970,50597,,N,Intermediate,,BAO_0000218
9315,,1,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626971,50597,,N,Intermediate,,BAO_0000218
9316,,1,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626972,50597,,N,Intermediate,,BAO_0000218
9317,,1,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626973,50597,,N,Intermediate,,BAO_0000218
9318,,1,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626974,50597,,N,Intermediate,,BAO_0000218
9319,,1,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL874592,50597,,N,Intermediate,,BAO_0000218
9320,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626975,50597,,N,Intermediate,,BAO_0000218
9321,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626976,50597,,N,Intermediate,,BAO_0000218
9322,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626977,50597,,N,Intermediate,,BAO_0000218
9323,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626978,50597,,N,Intermediate,,BAO_0000218
9324,,1,PK study was carried to determine the relative absorption ranking in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626979,50597,,N,Intermediate,,BAO_0000218
9325,,1,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626980,50597,,N,Intermediate,,BAO_0000218
9326,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626981,50597,,N,Intermediate,,BAO_0000218
9327,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626982,50597,,N,Intermediate,,BAO_0000218
9328,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626983,50597,,N,Intermediate,,BAO_0000218
9329,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622522,50597,,N,Intermediate,,BAO_0000218
9330,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622523,50597,,N,Intermediate,,BAO_0000218
9331,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622524,50597,,N,Intermediate,,BAO_0000218
9332,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622525,50597,,N,Intermediate,,BAO_0000218
9333,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622526,50597,,N,Intermediate,,BAO_0000218
9334,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619849,50597,,N,Intermediate,,BAO_0000218
9335,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL619850,50597,,N,Intermediate,,BAO_0000218
9336,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623864,50597,,N,Intermediate,,BAO_0000218
9337,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623865,50597,,N,Intermediate,,BAO_0000218
9338,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623866,50597,,N,Intermediate,,BAO_0000218
9339,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623867,50597,,N,Intermediate,,BAO_0000218
9340,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL877615,50597,,N,Intermediate,,BAO_0000218
9341,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623868,50597,,N,Intermediate,,BAO_0000218
9342,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623869,50597,,N,Intermediate,,BAO_0000218
9343,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623870,50597,,N,Intermediate,,BAO_0000218
9344,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL623871,50597,,N,Intermediate,,BAO_0000218
9345,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL623872,50597,,N,Intermediate,,BAO_0000218
9346,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622129,50597,,N,Intermediate,,BAO_0000218
9347,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622130,50597,,N,Intermediate,,BAO_0000218
9348,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622131,50597,,N,Intermediate,,BAO_0000218
9349,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622132,50597,,N,Intermediate,,BAO_0000218
9350,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622133,50597,,N,Intermediate,,BAO_0000218
9351,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622134,50597,,N,Intermediate,,BAO_0000218
9352,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622135,50597,,N,Intermediate,,BAO_0000218
9353,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622136,50597,,N,Intermediate,,BAO_0000218
9354,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622137,50597,,N,Intermediate,,BAO_0000218
9355,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622138,50597,,N,Intermediate,,BAO_0000218
9356,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623017,50597,,N,Intermediate,,BAO_0000218
9357,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623018,50597,,N,Intermediate,,BAO_0000218
9358,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623019,50597,,N,Intermediate,,BAO_0000218
9359,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623020,50597,,N,Intermediate,,BAO_0000218
9360,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623021,50597,,N,Intermediate,,BAO_0000218
9361,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623022,50597,,N,Intermediate,,BAO_0000218
9362,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623023,50597,,N,Intermediate,,BAO_0000218
9363,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623024,50597,,N,Intermediate,,BAO_0000218
9364,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623025,50597,,N,Intermediate,,BAO_0000218
9365,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620545,50597,,N,Intermediate,,BAO_0000218
9366,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620546,50597,,N,Intermediate,,BAO_0000218
9367,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620547,50597,,N,Intermediate,,BAO_0000218
9368,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620548,50597,,N,Intermediate,,BAO_0000218
9369,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620549,50597,,N,Intermediate,,BAO_0000218
9370,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620550,50597,,N,Intermediate,,BAO_0000218
9371,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620551,50597,,N,Intermediate,,BAO_0000218
9372,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620552,50597,,N,Intermediate,,BAO_0000218
9373,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620553,50597,,N,Intermediate,,BAO_0000218
9374,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620554,50597,,N,Intermediate,,BAO_0000218
9375,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL875845,50597,,N,Intermediate,,BAO_0000218
9376,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620555,50597,,N,Intermediate,,BAO_0000218
9377,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620556,50597,,N,Intermediate,,BAO_0000218
9378,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620557,50597,,N,Intermediate,,BAO_0000218
9379,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620558,50597,,N,Intermediate,,BAO_0000218
9380,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620559,50597,,N,Intermediate,,BAO_0000218
9381,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622939,50597,,N,Intermediate,,BAO_0000218
9382,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622940,50597,,N,Intermediate,,BAO_0000218
9383,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622941,50597,,N,Intermediate,,BAO_0000218
9384,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622942,50597,,N,Intermediate,,BAO_0000218
9385,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622943,50597,,N,Intermediate,,BAO_0000218
9386,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622944,50597,,N,Intermediate,,BAO_0000218
9387,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622945,50597,,N,Intermediate,,BAO_0000218
9388,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622946,50597,,N,Intermediate,,BAO_0000218
9389,,1,Compound was evaluated for terminal half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622947,50597,,N,Intermediate,,BAO_0000218
9390,,1,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622948,50597,,N,Intermediate,,BAO_0000218
9391,,1,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622949,50597,,N,Intermediate,,BAO_0000218
9392,,1,Compound was tested for its half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622950,50597,,N,Intermediate,,BAO_0000218
9393,,0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL622951,22224,,U,Intermediate,,BAO_0000218
9394,,0,Compound was tested for its plasma half life in Sprague Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622952,22224,,U,Intermediate,,BAO_0000366
9395,,0,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622953,22224,,U,Intermediate,,BAO_0000366
9396,,1,Compound was tested for plasma half-life period in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873818,50597,,N,Intermediate,,BAO_0000218
9397,,1,Elimination half life after i.v. administration of compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622954,50597,,N,Intermediate,,BAO_0000218
9398,,1,Elimination half-life after IV dosing at 0.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622955,50597,,N,Intermediate,,BAO_0000218
9399,,1,Elimination half-life after IV dosing at 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875229,50597,,N,Intermediate,,BAO_0000218
9400,,1,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622956,50597,,N,Intermediate,,BAO_0000218
9401,,1,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622957,50597,,N,Intermediate,,BAO_0000218
9402,,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622958,50597,,N,Intermediate,,BAO_0000218
9403,,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622959,50597,,N,Intermediate,,BAO_0000218
9404,,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622960,50597,,N,Intermediate,,BAO_0000218
9405,,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622961,50597,,N,Intermediate,,BAO_0000218
9406,,1,Evaluated for the half life in rat (in vivo),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622962,50597,,N,Intermediate,,BAO_0000218
9407,,1,Hafl life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622963,50597,,N,Intermediate,,BAO_0000218
9408,,1,Hafl life rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622964,50597,,N,Intermediate,,BAO_0000218
9409,,1,Hafl life rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622965,50597,,N,Intermediate,,BAO_0000218
9410,,1,Hafl life rat; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622966,50597,,N,Intermediate,,BAO_0000218
9411,,1,Hafl life rat; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622967,50597,,N,Intermediate,,BAO_0000218
9412,,1,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622968,50597,,N,Intermediate,,BAO_0000218
9413,,1,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622969,50597,,N,Intermediate,,BAO_0000218
9414,,1,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL875327,50597,,N,Intermediate,,BAO_0000218
9415,,1,Half life in rat after 1 mg/kg i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628638,50597,,N,Intermediate,,BAO_0000218
9416,,1,Half life in rat after 2 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628639,50597,,N,Intermediate,,BAO_0000218
9417,,1,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625840,50597,,N,Intermediate,,BAO_0000218
9418,,1,Half life of 10 mg/kg oral dose determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625841,50597,,N,Intermediate,,BAO_0000218
9419,,1,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625842,50597,,N,Intermediate,,BAO_0000218
9420,,1,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625843,50597,,N,Intermediate,,BAO_0000218
9421,,1,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625844,50597,,N,Intermediate,,BAO_0000218
9422,,1,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873822,50597,,N,Intermediate,,BAO_0000218
9423,,1,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625845,50597,,N,Intermediate,,BAO_0000218
9424,,1,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627059,50597,,N,Intermediate,,BAO_0000218
9425,,1,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627060,50597,,N,Intermediate,,BAO_0000218
9426,,1,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627061,50597,,N,Intermediate,,BAO_0000218
9427,,1,Half life of compound at 5 mg/kg after po administration was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627709,50597,,N,Intermediate,,BAO_0000218
9428,,1,Half life of compound determined after intravenous administration to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627710,50597,,N,Intermediate,,BAO_0000218
9429,,1,Half life of compound was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627711,50597,,N,Intermediate,,BAO_0000218
9430,,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627712,50597,,N,Intermediate,,BAO_0000218
9431,,1,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627713,50597,,N,Intermediate,,BAO_0000218
9432,,1,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627714,50597,,N,Intermediate,,BAO_0000218
9433,,0,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL627889,22224,,U,Intermediate,,BAO_0000218
9434,,0,Half life determined in rat by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627890,22224,,U,Intermediate,,BAO_0000218
9435,,1,Half life determined in rats after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627891,50597,,N,Intermediate,,BAO_0000218
9436,,1,Half life in rat plasma after administration of 2 mg/kg iv,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627892,50597,,N,Intermediate,,BAO_0000218
9437,,1,Half life in rat plasma after administration of 2 mg/kg iv,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627893,50597,,N,Intermediate,,BAO_0000218
9438,,1,Half life in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627894,50597,,N,Intermediate,,BAO_0000218
9439,,1,Half life in rat plasma was determined; NA means not applicable,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627895,50597,,N,Intermediate,,BAO_0000218
9440,,1,Half life in rat was tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627896,50597,,N,Intermediate,,BAO_0000218
9441,,1,Half life measured in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627897,50597,,N,Intermediate,,BAO_0000218
9442,,1,Half life recorded in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627898,50597,,N,Intermediate,,BAO_0000218
9443,,1,Half life was calculated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627899,50597,,N,Intermediate,,BAO_0000218
9444,,1,Half life was calculated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873823,50597,,N,Intermediate,,BAO_0000218
9445,,1,Half life was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627900,50597,,N,Intermediate,,BAO_0000218
9446,,1,Half life after 10 mg/kg oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627901,50597,,N,Intermediate,,BAO_0000218
9447,,1,Half life after administering orally a dose of 10 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627902,50597,,N,Intermediate,,BAO_0000218
9448,,1,Half life after administering orally a dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627903,50597,,N,Intermediate,,BAO_0000218
9449,,1,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627904,50597,,N,Intermediate,,BAO_0000218
9450,,1,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627905,50597,,N,Intermediate,,BAO_0000218
9451,,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627906,50597,,N,Intermediate,,BAO_0000218
9452,,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627907,50597,,N,Intermediate,,BAO_0000218
9453,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876783,50597,,N,Intermediate,,BAO_0000218
9454,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627908,50597,,N,Intermediate,,BAO_0000218
9455,,1,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627909,50597,,N,Intermediate,,BAO_0000218
9456,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627910,50597,,N,Intermediate,,BAO_0000218
9457,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627911,50597,,N,Intermediate,,BAO_0000218
9458,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627912,50597,,N,Intermediate,,BAO_0000218
9459,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627913,50597,,N,Intermediate,,BAO_0000218
9460,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627914,50597,,N,Intermediate,,BAO_0000218
9461,,1,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627915,50597,,N,Intermediate,,BAO_0000218
9462,,1,Area under the curve was evaluated after 20 uM/kg of peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627916,50597,,N,Intermediate,,BAO_0000218
9463,,1,Area under the curve was measured in rat after an iv dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627917,50597,,N,Intermediate,,BAO_0000218
9464,,1,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627918,50597,,N,Intermediate,,BAO_0000218
9465,,1,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627919,50597,,N,Intermediate,,BAO_0000218
9466,,1,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627920,50597,,N,Intermediate,,BAO_0000218
9467,,1,Area under the curve was evaluated at an oral dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627921,50597,,N,Intermediate,,BAO_0000218
9468,,1,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627922,50597,,N,Intermediate,,BAO_0000218
9469,,1,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876784,50597,,N,Intermediate,,BAO_0000218
9470,,1,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627923,50597,,N,Intermediate,,BAO_0000218
9471,,1,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626208,50597,,N,Intermediate,,BAO_0000218
9472,,1,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626209,50597,,N,Intermediate,,BAO_0000218
9473,,1,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626210,50597,,N,Intermediate,,BAO_0000218
9474,,1,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627994,50597,,N,Intermediate,,BAO_0000218
9475,,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627995,50597,,N,Intermediate,,BAO_0000218
9476,,1,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627996,50597,,N,Intermediate,,BAO_0000218
9477,,1,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627997,50597,,N,Intermediate,,BAO_0000218
9478,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627998,50597,,N,Intermediate,,BAO_0000218
9479,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628640,50597,,N,Intermediate,,BAO_0000218
9480,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628641,50597,,N,Intermediate,,BAO_0000218
9481,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628642,50597,,N,Intermediate,,BAO_0000218
9482,,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628643,50597,,N,Intermediate,,BAO_0000218
9483,,1,Compound was tested for area under curve in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628644,50597,,N,Intermediate,,BAO_0000218
9484,,1,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628645,50597,,N,Intermediate,,BAO_0000218
9485,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628646,50597,,N,Intermediate,,BAO_0000218
9486,,1,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628647,50597,,N,Intermediate,,BAO_0000218
9487,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628648,50597,,N,Intermediate,,BAO_0000218
9488,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625358,50597,,N,Intermediate,,BAO_0000218
9489,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625359,50597,,N,Intermediate,,BAO_0000218
9490,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625360,50597,,N,Intermediate,,BAO_0000218
9491,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625361,50597,,N,Intermediate,,BAO_0000218
9492,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625362,50597,,N,Intermediate,,BAO_0000218
9493,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625363,50597,,N,Intermediate,,BAO_0000218
9494,,1,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625364,50597,,N,Intermediate,,BAO_0000218
9495,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625365,50597,,N,Intermediate,,BAO_0000218
9496,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625366,50597,,N,Intermediate,,BAO_0000218
9497,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625367,50597,,N,Intermediate,,BAO_0000218
9498,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625368,50597,,N,Intermediate,,BAO_0000218
9499,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625369,50597,,N,Intermediate,,BAO_0000218
9500,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625370,50597,,N,Intermediate,,BAO_0000218
9501,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625371,50597,,N,Intermediate,,BAO_0000218
9502,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625372,50597,,N,Intermediate,,BAO_0000218
9503,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625373,50597,,N,Intermediate,,BAO_0000218
9504,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625374,50597,,N,Intermediate,,BAO_0000218
9505,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL877593,50597,,N,Intermediate,,BAO_0000218
9506,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625375,50597,,N,Intermediate,,BAO_0000218
9507,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625376,50597,,N,Intermediate,,BAO_0000218
9508,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621973,50597,,N,Intermediate,,BAO_0000218
9509,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621974,50597,,N,Intermediate,,BAO_0000218
9510,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL621975,50597,,N,Intermediate,,BAO_0000218
9511,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622166,50597,,N,Intermediate,,BAO_0000218
9512,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622167,50597,,N,Intermediate,,BAO_0000218
9513,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622168,50597,,N,Intermediate,,BAO_0000218
9514,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622169,50597,,N,Intermediate,,BAO_0000218
9515,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622170,50597,,N,Intermediate,,BAO_0000218
9516,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622171,50597,,N,Intermediate,,BAO_0000218
9517,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622172,50597,,N,Intermediate,,BAO_0000218
9518,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622173,50597,,N,Intermediate,,BAO_0000218
9519,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622174,50597,,N,Intermediate,,BAO_0000218
9520,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622175,50597,,N,Intermediate,,BAO_0000218
9521,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622176,50597,,N,Intermediate,,BAO_0000218
9522,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622177,50597,,N,Intermediate,,BAO_0000218
9523,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622178,50597,,N,Intermediate,,BAO_0000218
9524,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622179,50597,,N,Intermediate,,BAO_0000218
9525,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622180,50597,,N,Intermediate,,BAO_0000218
9526,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622181,50597,,N,Intermediate,,BAO_0000218
9527,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622182,50597,,N,Intermediate,,BAO_0000218
9528,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622183,50597,,N,Intermediate,,BAO_0000218
9529,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622184,50597,,N,Intermediate,,BAO_0000218
9530,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622185,50597,,N,Intermediate,,BAO_0000218
9531,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622186,50597,,N,Intermediate,,BAO_0000218
9532,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622187,50597,,N,Intermediate,,BAO_0000218
9533,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625002,50597,,N,Intermediate,,BAO_0000218
9534,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622090,50597,,N,Intermediate,,BAO_0000218
9535,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622091,50597,,N,Intermediate,,BAO_0000218
9536,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622092,50597,,N,Intermediate,,BAO_0000218
9537,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622093,50597,,N,Intermediate,,BAO_0000218
9538,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622094,50597,,N,Intermediate,,BAO_0000218
9539,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622095,50597,,N,Intermediate,,BAO_0000218
9540,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622264,50597,,N,Intermediate,,BAO_0000218
9541,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622265,50597,,N,Intermediate,,BAO_0000218
9542,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622266,50597,,N,Intermediate,,BAO_0000218
9543,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622267,50597,,N,Intermediate,,BAO_0000218
9544,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622268,50597,,N,Intermediate,,BAO_0000218
9545,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622269,50597,,N,Intermediate,,BAO_0000218
9546,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625071,50597,,N,Intermediate,,BAO_0000218
9547,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621621,50597,,N,Intermediate,,BAO_0000218
9548,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621622,50597,,N,Intermediate,,BAO_0000218
9549,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621623,50597,,N,Intermediate,,BAO_0000218
9550,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621624,50597,,N,Intermediate,,BAO_0000218
9551,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621625,50597,,N,Intermediate,,BAO_0000218
9552,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621626,50597,,N,Intermediate,,BAO_0000218
9553,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621627,50597,,N,Intermediate,,BAO_0000218
9554,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621628,50597,,N,Intermediate,,BAO_0000218
9555,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL875328,50597,,N,Intermediate,,BAO_0000218
9556,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621629,50597,,N,Intermediate,,BAO_0000218
9557,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621630,50597,,N,Intermediate,,BAO_0000218
9558,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621631,50597,,N,Intermediate,,BAO_0000218
9559,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621632,50597,,N,Intermediate,,BAO_0000218
9560,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621633,50597,,N,Intermediate,,BAO_0000218
9561,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621634,50597,,N,Intermediate,,BAO_0000218
9562,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621635,50597,,N,Intermediate,,BAO_0000218
9563,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621636,50597,,N,Intermediate,,BAO_0000218
9564,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621637,50597,,N,Intermediate,,BAO_0000218
9565,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL621638,50597,,N,Intermediate,,BAO_0000218
9566,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618883,50597,,N,Intermediate,,BAO_0000218
9567,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618884,50597,,N,Intermediate,,BAO_0000218
9568,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628627,50597,,N,Intermediate,,BAO_0000218
9569,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628628,50597,,N,Intermediate,,BAO_0000218
9570,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628629,50597,,N,Intermediate,,BAO_0000218
9571,,1,Half life after administering orally a dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628630,50597,,N,Intermediate,,BAO_0000218
9572,,1,Half life after administering orally a dose of 3 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628631,50597,,N,Intermediate,,BAO_0000218
9573,,1,Half life after administering intravenously a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628632,50597,,N,Intermediate,,BAO_0000218
9574,,1,Half life after oral dosing in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628633,50597,,N,Intermediate,,BAO_0000218
9575,,1,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628634,50597,,N,Intermediate,,BAO_0000218
9576,,1,Half life by intravenous administration of 3.4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627789,50597,,N,Intermediate,,BAO_0000218
9577,,1,Half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627790,50597,,N,Intermediate,,BAO_0000218
9578,,1,Half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627791,50597,,N,Intermediate,,BAO_0000218
9579,,1,Half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627792,50597,,N,Intermediate,,BAO_0000218
9580,,1,Half life in rat after intravenous administration of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627793,50597,,N,Intermediate,,BAO_0000218
9581,,1,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627794,50597,,N,Intermediate,,BAO_0000218
9582,,1,Half life in rat after po administration of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627795,50597,,N,Intermediate,,BAO_0000218
9583,,1,Half life in rat after po administration of the compound; ND means Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627796,50597,,N,Intermediate,,BAO_0000218
9584,,1,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL875335,50597,,N,Intermediate,,BAO_0000218
9585,,1,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627797,50597,,N,Intermediate,,BAO_0000218
9586,,1,Half life in rat i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627798,50597,,N,Intermediate,,BAO_0000218
9587,,1,Half life in rat i.v. at 2 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627799,50597,,N,Intermediate,,BAO_0000218
9588,,1,Half life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627800,50597,,N,Intermediate,,BAO_0000218
9589,,1,Half life in rats after intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627801,50597,,N,Intermediate,,BAO_0000218
9590,,1,Half life in rats at the dose of 1.0 mpk by i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627802,50597,,N,Intermediate,,BAO_0000218
9591,,1,Half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627803,50597,,N,Expert,,BAO_0000218
9592,,1,Half life was evaluated after intravenous administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873820,50597,,N,Intermediate,,BAO_0000218
9593,,1,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627804,50597,,N,Intermediate,,BAO_0000218
9594,,1,Half life was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627805,50597,,N,Intermediate,,BAO_0000218
9595,,1,Half life was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627806,50597,,N,Intermediate,,BAO_0000218
9596,,1,Half life was evaluated in rat; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627107,50597,,N,Intermediate,,BAO_0000218
9597,,1,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627108,50597,,N,Intermediate,,BAO_0000218
9598,,1,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627109,50597,,N,Intermediate,,BAO_0000218
9599,,1,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627110,50597,,N,Intermediate,,BAO_0000218
9600,,0,Half life was measured in monkey at dose of 10 mg/kg by po administration,Primates,,,,,,1,9443.0,A,CHEMBL627111,22224,,U,Intermediate,,BAO_0000218
9601,,0,Half life was measured in monkey at dose of 10 mg/kg by po administration,Primates,,,,,,1,9443.0,A,CHEMBL627112,22224,,U,Intermediate,,BAO_0000218
9602,,0,Half life was measured in rat at dose of 30 mg/kg by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627113,22224,,U,Intermediate,,BAO_0000218
9603,,0,Half life was measured in rat at dose of 30 mg/kg by po administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627114,22224,,U,Intermediate,,BAO_0000218
9604,,1,Half life (t1/2) was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627115,50597,,N,Intermediate,,BAO_0000218
9605,,1,Half life period at a dose of 10 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627116,50597,,N,Intermediate,,BAO_0000218
9606,,1,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627117,50597,,N,Intermediate,,BAO_0000218
9607,,1,Half life period was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627118,50597,,N,Intermediate,,BAO_0000218
9608,,1,Half life period after intravenous administration at 20 mpk in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627119,50597,,N,Intermediate,,BAO_0000218
9609,,1,Half life period after intravenous administration at 20 mpk in rats; Not performed.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627120,50597,,N,Intermediate,,BAO_0000218
9610,,1,Half life period after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626922,50597,,N,Intermediate,,BAO_0000218
9611,,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626923,50597,,N,Intermediate,,BAO_0000218
9612,,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626924,50597,,N,Intermediate,,BAO_0000218
9613,,1,Half life period in 80% rat plasma at 37 degree Centigrade,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626925,50597,,N,Intermediate,,BAO_0000218
9614,,1,Half life period in SD rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626926,50597,,N,Intermediate,,BAO_0000218
9615,,1,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626927,50597,,N,Intermediate,,BAO_0000218
9616,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626928,50597,,N,Intermediate,,BAO_0000218
9617,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626929,50597,,N,Intermediate,,BAO_0000218
9618,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626930,50597,,N,Intermediate,,BAO_0000218
9619,,1,Half life period in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626931,50597,,N,Intermediate,,BAO_0000218
9620,,1,Half life period in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626932,50597,,N,Intermediate,,BAO_0000218
9621,,1,Half life period in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626933,50597,,N,Intermediate,,BAO_0000218
9622,,1,Half life period in rat after oral administration at 10.5 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873826,50597,,N,Intermediate,,BAO_0000218
9623,,1,Half life period in rat after oral administration at 11.2 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626934,50597,,N,Intermediate,,BAO_0000218
9624,,1,Half life period in rat after oral administration at 13 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626935,50597,,N,Intermediate,,BAO_0000218
9625,,1,Half life period in rat after oral administration at 9.7 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626936,50597,,N,Intermediate,,BAO_0000218
9626,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626937,50597,,N,Intermediate,,BAO_0000218
9627,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625906,50597,,N,Intermediate,,BAO_0000218
9628,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625907,50597,,N,Intermediate,,BAO_0000218
9629,,1,PK study was carried to determine AUC (area under curve) value in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625908,50597,,N,Intermediate,,BAO_0000218
9630,,1,Pharmacokinetic parameter AUC after intravenous administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625909,50597,,N,Intermediate,,BAO_0000218
9631,,1,Pharmacokinetic parameter AUC after oral administration to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625910,50597,,N,Intermediate,,BAO_0000218
9632,,1,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625911,50597,,N,Intermediate,,BAO_0000218
9633,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625912,50597,,N,Intermediate,,BAO_0000218
9634,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626538,50597,,N,Intermediate,,BAO_0000218
9635,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876794,50597,,N,Intermediate,,BAO_0000218
9636,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626539,50597,,N,Intermediate,,BAO_0000218
9637,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626540,50597,,N,Intermediate,,BAO_0000218
9638,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626541,50597,,N,Intermediate,,BAO_0000218
9639,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626542,50597,,N,Intermediate,,BAO_0000218
9640,,1,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626543,50597,,N,Intermediate,,BAO_0000218
9641,,1,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626544,50597,,N,Intermediate,,BAO_0000218
9642,,1,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626545,50597,,N,Intermediate,,BAO_0000218
9643,,1,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626546,50597,,N,Intermediate,,BAO_0000218
9644,,1,Pharmacokinetic parameter area under curve was reported,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626547,50597,,N,Intermediate,,BAO_0000218
9645,,1,Pharmacokinetic property (AUC) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626548,50597,,N,Intermediate,,BAO_0000218
9646,,1,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626549,50597,,N,Intermediate,,BAO_0000218
9647,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626550,50597,,N,Intermediate,,BAO_0000218
9648,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626551,50597,,N,Intermediate,,BAO_0000218
9649,,1,Pharmacokinetic property was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623777,50597,,N,Intermediate,,BAO_0000218
9650,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623778,50597,,N,Intermediate,,BAO_0000218
9651,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623779,50597,,N,Intermediate,,BAO_0000218
9652,,1,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623780,50597,,N,Intermediate,,BAO_0000218
9653,,1,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622015,50597,,N,Intermediate,,BAO_0000218
9654,,1,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622016,50597,,N,Intermediate,,BAO_0000218
9655,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622017,50597,,N,Intermediate,,BAO_0000218
9656,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622018,50597,,N,Intermediate,,BAO_0000218
9657,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622019,50597,,N,Intermediate,,BAO_0000218
9658,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622020,50597,,N,Intermediate,,BAO_0000218
9659,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622021,50597,,N,Intermediate,,BAO_0000218
9660,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622022,50597,,N,Intermediate,,BAO_0000218
9661,,1,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622023,50597,,N,Intermediate,,BAO_0000218
9662,,1,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622024,50597,,N,Intermediate,,BAO_0000218
9663,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622693,50597,,N,Intermediate,,BAO_0000218
9664,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622694,50597,,N,Intermediate,,BAO_0000218
9665,,1,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622695,50597,,N,Intermediate,,BAO_0000218
9666,,1,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622696,50597,,N,Intermediate,,BAO_0000218
9667,,1,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622697,50597,,N,Intermediate,,BAO_0000218
9668,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622874,50597,,N,Intermediate,,BAO_0000218
9669,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622875,50597,,N,Intermediate,,BAO_0000218
9670,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622876,50597,,N,Intermediate,,BAO_0000218
9671,,1,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622877,50597,,N,Intermediate,,BAO_0000218
9672,,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622878,50597,,N,Intermediate,,BAO_0000218
9673,,1,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622879,50597,,N,Intermediate,,BAO_0000218
9674,,1,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877602,50597,,N,Intermediate,,BAO_0000218
9675,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622880,50597,,N,Intermediate,,BAO_0000218
9676,,1,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622881,50597,,N,Intermediate,,BAO_0000218
9677,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622882,50597,,N,Intermediate,,BAO_0000218
9678,,1,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622883,50597,,N,Intermediate,,BAO_0000218
9679,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622884,50597,,N,Intermediate,,BAO_0000218
9680,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622885,50597,,N,Intermediate,,BAO_0000218
9681,,1,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622886,50597,,N,Intermediate,,BAO_0000218
9682,,1,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622887,50597,,N,Intermediate,,BAO_0000218
9683,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622888,50597,,N,Intermediate,,BAO_0000218
9684,,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622889,50597,,N,Intermediate,,BAO_0000218
9685,,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622890,50597,,N,Intermediate,,BAO_0000218
9686,,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622891,50597,,N,Intermediate,,BAO_0000218
9687,,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL877603,50597,,N,Intermediate,,BAO_0000218
9688,,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622892,50597,,N,Intermediate,,BAO_0000218
9689,,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622893,50597,,N,Intermediate,,BAO_0000218
9690,,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622894,50597,,N,Intermediate,,BAO_0000218
9691,,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622895,50597,,N,Intermediate,,BAO_0000218
9692,,1,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622896,50597,,N,Intermediate,,BAO_0000218
9693,,1,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622897,50597,,N,Intermediate,,BAO_0000218
9694,,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622898,50597,,N,Intermediate,,BAO_0000218
9695,,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622899,50597,,N,Intermediate,,BAO_0000218
9696,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622900,50597,,N,Intermediate,,BAO_0000218
9697,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624114,50597,,N,Intermediate,,BAO_0000218
9698,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624115,50597,,N,Intermediate,,BAO_0000218
9699,,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624116,50597,,N,Intermediate,,BAO_0000218
9700,,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624117,50597,,N,Intermediate,,BAO_0000218
9701,,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624118,50597,,N,Intermediate,,BAO_0000218
9702,,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624119,50597,,N,Intermediate,,BAO_0000218
9703,,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624120,50597,,N,Intermediate,,BAO_0000218
9704,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624121,50597,,N,Intermediate,,BAO_0000218
9705,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624122,50597,,N,Intermediate,,BAO_0000218
9706,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624123,50597,,N,Intermediate,,BAO_0000218
9707,,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624124,50597,,N,Intermediate,,BAO_0000218
9708,,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624125,50597,,N,Intermediate,,BAO_0000218
9709,,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624126,50597,,N,Intermediate,,BAO_0000218
9710,,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624127,50597,,N,Intermediate,,BAO_0000218
9711,,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624128,50597,,N,Intermediate,,BAO_0000218
9712,,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL624129,50597,,N,Intermediate,,BAO_0000218
9713,,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL624130,50597,,N,Intermediate,,BAO_0000218
9714,,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL622340,50597,,N,Intermediate,,BAO_0000218
9715,,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL622341,50597,,N,Intermediate,,BAO_0000218
9716,,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622342,50597,,N,Intermediate,,BAO_0000218
9717,,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622343,50597,,N,Intermediate,,BAO_0000218
9718,,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622344,50597,,N,Intermediate,,BAO_0000218
9719,,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622345,50597,,N,Intermediate,,BAO_0000218
9720,,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622346,50597,,N,Intermediate,,BAO_0000218
9721,,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622347,50597,,N,Intermediate,,BAO_0000218
9722,,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622348,50597,,N,Intermediate,,BAO_0000218
9723,,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622349,50597,,N,Intermediate,,BAO_0000218
9724,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622350,50597,,N,Intermediate,,BAO_0000218
9725,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622351,50597,,N,Intermediate,,BAO_0000218
9726,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622352,50597,,N,Intermediate,,BAO_0000218
9727,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622353,50597,,N,Intermediate,,BAO_0000218
9728,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622354,50597,,N,Intermediate,,BAO_0000218
9729,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622355,50597,,N,Intermediate,,BAO_0000218
9730,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622356,50597,,N,Intermediate,,BAO_0000218
9731,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622357,50597,,N,Intermediate,,BAO_0000218
9732,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622358,50597,,N,Intermediate,,BAO_0000218
9733,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622359,50597,,N,Intermediate,,BAO_0000218
9734,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874393,50597,,N,Intermediate,,BAO_0000218
9735,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622872,50597,,N,Intermediate,,BAO_0000218
9736,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622873,50597,,N,Intermediate,,BAO_0000218
9737,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623047,50597,,N,Intermediate,,BAO_0000218
9738,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623048,50597,,N,Intermediate,,BAO_0000218
9739,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623049,50597,,N,Intermediate,,BAO_0000218
9740,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623050,50597,,N,Intermediate,,BAO_0000218
9741,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623051,50597,,N,Intermediate,,BAO_0000218
9742,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623052,50597,,N,Intermediate,,BAO_0000218
9743,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626343,50597,,N,Intermediate,,BAO_0000218
9744,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626344,50597,,N,Intermediate,,BAO_0000218
9745,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626345,50597,,N,Intermediate,,BAO_0000218
9746,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626346,50597,,N,Intermediate,,BAO_0000218
9747,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626347,50597,,N,Intermediate,,BAO_0000218
9748,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626348,50597,,N,Intermediate,,BAO_0000218
9749,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626349,50597,,N,Intermediate,,BAO_0000218
9750,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626350,50597,,N,Intermediate,,BAO_0000218
9751,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626351,50597,,N,Intermediate,,BAO_0000218
9752,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627650,50597,,N,Intermediate,,BAO_0000218
9753,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL627651,50597,,N,Intermediate,,BAO_0000218
9754,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627652,50597,,N,Intermediate,,BAO_0000218
9755,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627653,50597,,N,Intermediate,,BAO_0000218
9756,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627654,50597,,N,Intermediate,,BAO_0000218
9757,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627835,50597,,N,Intermediate,,BAO_0000218
9758,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627836,50597,,N,Intermediate,,BAO_0000218
9759,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627837,50597,,N,Intermediate,,BAO_0000218
9760,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627838,50597,,N,Intermediate,,BAO_0000218
9761,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875338,50597,,N,Intermediate,,BAO_0000218
9762,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627839,50597,,N,Intermediate,,BAO_0000218
9763,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627840,50597,,N,Intermediate,,BAO_0000218
9764,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627841,50597,,N,Intermediate,,BAO_0000218
9765,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627842,50597,,N,Intermediate,,BAO_0000218
9766,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627843,50597,,N,Intermediate,,BAO_0000218
9767,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627844,50597,,N,Intermediate,,BAO_0000218
9768,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627845,50597,,N,Intermediate,,BAO_0000218
9769,,1,Half life period in rat by iv administration at a dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627846,50597,,N,Intermediate,,BAO_0000218
9770,,1,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627847,50597,,N,Intermediate,,BAO_0000218
9771,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873821,50597,,N,Intermediate,,BAO_0000218
9772,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626079,50597,,N,Intermediate,,BAO_0000218
9773,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626080,50597,,N,Intermediate,,BAO_0000218
9774,,1,Half life period was evaluated in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626081,50597,,N,Intermediate,,BAO_0000218
9775,,1,Half life period was evaluated in rat plasma; Not tested,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL875344,50597,,N,Intermediate,,BAO_0000218
9776,,1,Half life period was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626082,50597,,N,Intermediate,,BAO_0000218
9777,,1,"Half life period was evaluated in rats, iv",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626250,50597,,N,Intermediate,,BAO_0000218
9778,,1,Half life period after intravenous administration at 5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626251,50597,,N,Intermediate,,BAO_0000218
9779,,1,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626252,50597,,N,Intermediate,,BAO_0000218
9780,,1,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626253,50597,,N,Intermediate,,BAO_0000218
9781,,1,Half life stability of compound was evaluated in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626254,50597,,N,Intermediate,,BAO_0000218
9782,,1,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626255,50597,,N,Intermediate,,BAO_0000218
9783,,1,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626256,50597,,N,Intermediate,,BAO_0000218
9784,,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626257,50597,,N,Intermediate,,BAO_0000218
9785,,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626258,50597,,N,Intermediate,,BAO_0000218
9786,,1,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626259,50597,,N,Intermediate,,BAO_0000218
9787,,1,Half in rat i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626260,50597,,N,Intermediate,,BAO_0000218
9788,,1,Half period in rat after intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875345,50597,,N,Intermediate,,BAO_0000218
9789,,1,Half-life after repeated oral dose of compound at 1 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626261,50597,,N,Intermediate,,BAO_0000218
9790,,1,Half-life measured in in vitro Cathepsin B assay in rat liver,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626262,50597,,N,Intermediate,,BAO_0000218
9791,,1,Half-life of compound was determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626263,50597,,N,Intermediate,,BAO_0000218
9792,,1,Half-life at 10 mg/kg in rat upon intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625270,50597,,N,Intermediate,,BAO_0000218
9793,,1,Half-life determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625271,50597,,N,Intermediate,,BAO_0000218
9794,,1,Half-life determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625272,50597,,N,Intermediate,,BAO_0000218
9795,,1,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625273,50597,,N,Intermediate,,BAO_0000218
9796,,1,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625274,50597,,N,Intermediate,,BAO_0000218
9797,,1,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625275,50597,,N,Intermediate,,BAO_0000218
9798,,1,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625276,50597,,N,Intermediate,,BAO_0000218
9799,,1,Half-life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625277,50597,,N,Intermediate,,BAO_0000218
9800,,1,Half-life in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625278,50597,,N,Intermediate,,BAO_0000218
9801,,1,Half-life in rat plasma; Not tested,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625279,50597,,N,Intermediate,,BAO_0000218
9802,,1,Half-life in rat serum,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL625280,50597,,N,Intermediate,,BAO_0000218
9803,,1,Half-life in rat serum; na is not available,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL876797,50597,,N,Intermediate,,BAO_0000218
9804,,1,Half-life was calculated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625281,50597,,N,Intermediate,,BAO_0000218
9805,,1,Half-life was calculated in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL873827,50597,,N,Intermediate,,BAO_0000218
9806,,1,Half-life was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625282,50597,,N,Intermediate,,BAO_0000218
9807,,1,Half-life was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625283,50597,,N,Intermediate,,BAO_0000218
9808,,1,Half-life after administration of 20 mg/Kg oral dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625284,50597,,N,Intermediate,,BAO_0000218
9809,,1,Half-life after administration of 3.2 mg/kg intravenously in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625285,50597,,N,Intermediate,,BAO_0000218
9810,,1,Half-life after intravenous administration in female rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625286,50597,,N,Intermediate,,BAO_0000218
9811,,1,Half-life after intravenous administration in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625287,50597,,N,Intermediate,,BAO_0000218
9812,,1,Half-life after intravenous dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625288,50597,,N,Intermediate,,BAO_0000218
9813,,1,Half-life in a rat liver homogenate preparation,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625289,50597,,N,Intermediate,,BAO_0000218
9814,,1,Half-life in plasma of rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625290,50597,,N,Intermediate,,BAO_0000218
9815,,1,Half-life in plasma of rat at dose of 3-10 mgkg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876798,50597,,N,Intermediate,,BAO_0000218
9816,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625291,50597,,N,Intermediate,,BAO_0000218
9817,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625292,50597,,N,Intermediate,,BAO_0000218
9818,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625293,50597,,N,Intermediate,,BAO_0000218
9819,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622832,50597,,N,Intermediate,,BAO_0000218
9820,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622833,50597,,N,Intermediate,,BAO_0000218
9821,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622834,50597,,N,Intermediate,,BAO_0000218
9822,,1,Half-life in rat after oral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622835,50597,,N,Intermediate,,BAO_0000218
9823,,1,Half-life in rat after po administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622836,50597,,N,Intermediate,,BAO_0000218
9824,,1,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622837,50597,,N,Intermediate,,BAO_0000218
9825,,1,Half-life in rat at 3 mg/kg dose administered intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622838,50597,,N,Intermediate,,BAO_0000218
9826,,1,Half-life in rat brain homogenate,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622839,50597,,N,Intermediate,,BAO_0000218
9827,,1,Half-life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622840,50597,,N,Intermediate,,BAO_0000218
9828,,1,Half-life in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622841,50597,,N,Intermediate,,BAO_0000218
9829,,1,Half-life in Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622842,50597,,N,Intermediate,,BAO_0000218
9830,,1,Half-life in vitro in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622843,50597,,N,Intermediate,,BAO_0000218
9831,,1,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622844,50597,,N,Intermediate,,BAO_0000218
9832,,1,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622845,50597,,N,Intermediate,,BAO_0000218
9833,,1,The area under the curve of compound was measured at the dose of 100 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622846,50597,,N,Intermediate,,BAO_0000218
9834,,1,The area under the curve of compound was measured at the dose of 300 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622847,50597,,N,Intermediate,,BAO_0000218
9835,,1,The area under the curve of compound was measured at the dose of 30 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622848,50597,,N,Intermediate,,BAO_0000218
9836,,1,Bioavailability as oral AUC in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622849,50597,,N,Intermediate,,BAO_0000218
9837,,1,The plasma concentration versus time curve (AUC) was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622850,50597,,N,Intermediate,,BAO_0000218
9838,,1,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876807,50597,,N,Intermediate,,BAO_0000218
9839,,1,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622851,50597,,N,Intermediate,,BAO_0000218
9840,,1,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622852,50597,,N,Intermediate,,BAO_0000218
9841,,1,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622853,50597,,N,Intermediate,,BAO_0000218
9842,,1,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622854,50597,,N,Intermediate,,BAO_0000218
9843,,1,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622855,50597,,N,Intermediate,,BAO_0000218
9844,,1,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622856,50597,,N,Intermediate,,BAO_0000218
9845,,1,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622857,50597,,N,Intermediate,,BAO_0000218
9846,,1,AUC in rat after po administration at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622858,50597,,N,Intermediate,,BAO_0000218
9847,,1,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622859,50597,,N,Intermediate,,BAO_0000218
9848,,1,Area under curve value 24 hr after 10 mg/kg iv administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622860,50597,,N,Intermediate,,BAO_0000218
9849,,1,Area under curve value 24 hr after 10 mg/kg oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622861,50597,,N,Intermediate,,BAO_0000218
9850,,1,Area under curve value 24 hr after 2 mg/kg iv administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622862,50597,,N,Intermediate,,BAO_0000218
9851,,1,Area under curve value 24 hr after 2 mg/kg oral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622863,50597,,N,Intermediate,,BAO_0000218
9852,,1,Area under curve value 6 hr after po administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623817,50597,,N,Intermediate,,BAO_0000218
9853,,1,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623818,50597,,N,Intermediate,,BAO_0000218
9854,,1,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623819,50597,,N,Intermediate,,BAO_0000218
9855,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623820,50597,,N,Intermediate,,BAO_0000218
9856,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623821,50597,,N,Intermediate,,BAO_0000218
9857,,1,AUC normalized for dose (AUCN) in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623822,50597,,N,Intermediate,,BAO_0000218
9858,,1,Area under curve in rat after p.o. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623823,50597,,N,Intermediate,,BAO_0000218
9859,,1,Area under curve in rat after p.o. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623824,50597,,N,Intermediate,,BAO_0000218
9860,,1,Area under curve in rat after p.o. administration; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623825,50597,,N,Intermediate,,BAO_0000218
9861,,1,Area under curve in rat after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622070,50597,,N,Intermediate,,BAO_0000218
9862,,1,Area under curve (carotid artery) value of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622071,50597,,N,Intermediate,,BAO_0000218
9863,,1,Bioavailability expressed as the area under curve of rat carotid artery,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622072,50597,,N,Intermediate,,BAO_0000218
9864,,1,Area under curve in male SD rats was observed after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622073,50597,,N,Intermediate,,BAO_0000218
9865,,1,Area under curve of the compound was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622074,50597,,N,Intermediate,,BAO_0000218
9866,,1,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622075,50597,,N,Intermediate,,BAO_0000218
9867,,1,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622076,50597,,N,Intermediate,,BAO_0000218
9868,,1,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622077,50597,,N,Intermediate,,BAO_0000218
9869,,1,Area under curve (portal vein) value of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622078,50597,,N,Intermediate,,BAO_0000218
9870,,1,Bioavailability expressed as the area under curve of rat portal vein,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622079,50597,,N,Intermediate,,BAO_0000218
9871,,1,Area Under plasma concentration time curve in rat upon peroral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622080,50597,,N,Intermediate,,BAO_0000218
9872,,1,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877612,50597,,N,Intermediate,,BAO_0000218
9873,,1,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622081,50597,,N,Intermediate,,BAO_0000218
9874,,1,Compound was evaluated for oral bioavailability in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622082,50597,,N,Intermediate,,BAO_0000218
9875,,1,Compound was evaluated for oral bioavailability in rats after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622083,50597,,N,Intermediate,,BAO_0000218
9876,,1,Compound was evaluated for oral bioavailability in rats; 30-80,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622084,50597,,N,Intermediate,,BAO_0000218
9877,,1,Compound was evaluated for oral bioavailability in rats; 50-60,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622085,50597,,N,Intermediate,,BAO_0000218
9878,,1,Compound was evaluated for oral bioavailability in rats; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622086,50597,,N,Intermediate,,BAO_0000218
9879,,1,Compound was evaluated for oral bioavailability in rats; peptide,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622087,50597,,N,Intermediate,,BAO_0000218
9880,,1,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622088,50597,,N,Intermediate,,BAO_0000218
9881,,1,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622089,50597,,N,Intermediate,,BAO_0000218
9882,,1,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623685,50597,,N,Intermediate,,BAO_0000218
9883,,1,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623686,50597,,N,Intermediate,,BAO_0000218
9884,,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL623687,50597,,N,Intermediate,,BAO_0000218
9885,,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL623688,50597,,N,Intermediate,,BAO_0000218
9886,,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL623689,50597,,N,Intermediate,,BAO_0000218
9887,,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Stomach,945.0,,1,10116.0,A,CHEMBL622485,50597,,N,Intermediate,,BAO_0000218
9888,,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622486,50597,,N,Intermediate,,BAO_0000218
9889,,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL877613,50597,,N,Intermediate,,BAO_0000218
9890,,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622487,50597,,N,Intermediate,,BAO_0000218
9891,,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622488,50597,,N,Intermediate,,BAO_0000218
9892,,1,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622489,50597,,N,Intermediate,,BAO_0000218
9893,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622490,50597,,N,Intermediate,,BAO_0000218
9894,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622491,50597,,N,Intermediate,,BAO_0000218
9895,,1,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622492,50597,,N,Intermediate,,BAO_0000218
9896,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622493,50597,,N,Intermediate,,BAO_0000218
9897,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622494,50597,,N,Intermediate,,BAO_0000218
9898,,1,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622495,50597,,N,Intermediate,,BAO_0000218
9899,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622496,50597,,N,Intermediate,,BAO_0000218
9900,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622497,50597,,N,Intermediate,,BAO_0000218
9901,,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622498,50597,,N,Intermediate,,BAO_0000218
9902,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624918,50597,,N,Intermediate,,BAO_0000218
9903,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624919,50597,,N,Intermediate,,BAO_0000218
9904,,1,Biodistribution of compound in rat blood after 5 min of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624920,50597,,N,Intermediate,,BAO_0000218
9905,,1,Biodistribution of compound in rat blood after 5 min of administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624921,50597,,N,Intermediate,,BAO_0000218
9906,,1,Biodistribution of compound in rat brain after 5 min of administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624922,50597,,N,Intermediate,,BAO_0000218
9907,,1,Biodistribution of compound in rat heart after 5 min of administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624923,50597,,N,Intermediate,,BAO_0000218
9908,,1,Biodistribution of compound in rat heart after 5 min of administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624924,50597,,N,Intermediate,,BAO_0000218
9909,,1,Biodistribution of compound in rat kidney after 5 min of administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624925,50597,,N,Intermediate,,BAO_0000218
9910,,1,Biodistribution of compound in rat kidney after 5 min of administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624926,50597,,N,Intermediate,,BAO_0000218
9911,,1,Biodistribution of compound in rat liver after 5 min of administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624927,50597,,N,Intermediate,,BAO_0000218
9912,,1,Biodistribution of compound in rat liver after 5 min of administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL874402,50597,,N,Intermediate,,BAO_0000218
9913,,1,Biodistribution of compound in rat lung after 5 min of administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624928,50597,,N,Intermediate,,BAO_0000218
9914,,1,Biodistribution of compound in rat lung after 5 min of administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624929,50597,,N,Intermediate,,BAO_0000218
9915,,1,Biodistribution of compound in rat muscle after 5 min of administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624930,50597,,N,Intermediate,,BAO_0000218
9916,,1,Biodistribution of compound in rat muscle after 5 min of administration.,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624931,50597,,N,Intermediate,,BAO_0000218
9917,,1,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624932,50597,,N,Intermediate,,BAO_0000218
9918,,1,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624933,50597,,N,Intermediate,,BAO_0000218
9919,,1,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624934,50597,,N,Intermediate,,BAO_0000218
9920,,1,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624935,50597,,N,Intermediate,,BAO_0000218
9921,,1,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624936,50597,,N,Intermediate,,BAO_0000218
9922,,1,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624937,50597,,N,Intermediate,,BAO_0000218
9923,,1,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL624938,50597,,N,Intermediate,,BAO_0000218
9924,,1,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL624939,50597,,N,Intermediate,,BAO_0000218
9925,,1,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624940,50597,,N,Intermediate,,BAO_0000218
9926,,1,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874403,50597,,N,Intermediate,,BAO_0000218
9927,,1,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624941,50597,,N,Intermediate,,BAO_0000218
9928,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624942,50597,,N,Intermediate,,BAO_0000218
9929,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624943,50597,,N,Intermediate,,BAO_0000218
9930,,1,% Bioavailability after 1 day of the drug administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624944,50597,,N,Intermediate,,BAO_0000218
9931,,1,% Bioavailability after 4 day of the drug administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624945,50597,,N,Intermediate,,BAO_0000218
9932,,1,Absolute bioavailability was evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624946,50597,,N,Intermediate,,BAO_0000218
9933,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624947,50597,,N,Intermediate,,BAO_0000218
9934,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624948,50597,,N,Intermediate,,BAO_0000218
9935,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624949,50597,,N,Intermediate,,BAO_0000218
9936,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622025,50597,,N,Intermediate,,BAO_0000218
9937,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622026,50597,,N,Intermediate,,BAO_0000218
9938,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622027,50597,,N,Intermediate,,BAO_0000218
9939,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622028,50597,,N,Intermediate,,BAO_0000218
9940,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622029,50597,,N,Intermediate,,BAO_0000218
9941,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622208,50597,,N,Intermediate,,BAO_0000218
9942,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622209,50597,,N,Intermediate,,BAO_0000218
9943,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622210,50597,,N,Intermediate,,BAO_0000218
9944,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622211,50597,,N,Intermediate,,BAO_0000218
9945,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622212,50597,,N,Intermediate,,BAO_0000218
9946,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622213,50597,,N,Intermediate,,BAO_0000218
9947,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874404,50597,,N,Intermediate,,BAO_0000218
9948,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620452,50597,,N,Intermediate,,BAO_0000218
9949,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620453,50597,,N,Intermediate,,BAO_0000218
9950,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL620454,50597,,N,Intermediate,,BAO_0000218
9951,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624067,50597,,N,Intermediate,,BAO_0000218
9952,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624068,50597,,N,Intermediate,,BAO_0000218
9953,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL624069,50597,,N,Intermediate,,BAO_0000218
9954,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL624070,50597,,N,Intermediate,,BAO_0000218
9955,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL624071,50597,,N,Intermediate,,BAO_0000218
9956,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL624072,50597,,N,Intermediate,,BAO_0000218
9957,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL624073,50597,,N,Intermediate,,BAO_0000218
9958,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL624788,50597,,N,Intermediate,,BAO_0000218
9959,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL624789,50597,,N,Intermediate,,BAO_0000218
9960,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624790,50597,,N,Intermediate,,BAO_0000218
9961,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624791,50597,,N,Intermediate,,BAO_0000218
9962,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624792,50597,,N,Intermediate,,BAO_0000218
9963,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624793,50597,,N,Intermediate,,BAO_0000218
9964,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL877491,50597,,N,Intermediate,,BAO_0000218
9965,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624957,50597,,N,Intermediate,,BAO_0000218
9966,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624958,50597,,N,Intermediate,,BAO_0000218
9967,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624959,50597,,N,Intermediate,,BAO_0000218
9968,,1,Dissociation constant was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624960,50597,,N,Intermediate,,BAO_0000218
9969,,1,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624961,50597,,N,Intermediate,,BAO_0000218
9970,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624962,50597,,N,Intermediate,,BAO_0000218
9971,,1,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624963,50597,,N,Intermediate,,BAO_0000218
9972,,1,Observed rate constant in 80% rat plasma at 37 degree Centigrade,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624964,50597,,N,Intermediate,,BAO_0000218
9973,,1,LogP value was evaluated in the in situ rat gut perfusion assay,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624965,50597,,N,Intermediate,,BAO_0000218
9974,,1,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624966,50597,,N,Intermediate,,BAO_0000218
9975,,1,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624967,50597,,N,Intermediate,,BAO_0000218
9976,,1,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624968,50597,,N,Intermediate,,BAO_0000218
9977,,1,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624969,50597,,N,Intermediate,,BAO_0000218
9978,,1,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL624970,50597,,N,Expert,,BAO_0000218
9979,,1,Half-life was evaluated after 10 uM/kg of intra arterial administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624971,50597,,N,Intermediate,,BAO_0000218
9980,,1,Half-life was evaluated after 20 uM/kg of peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624972,50597,,N,Intermediate,,BAO_0000218
9981,,1,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624973,50597,,N,Intermediate,,BAO_0000218
9982,,1,Half-life was evaluated in plasma of rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL624974,50597,,N,Intermediate,,BAO_0000218
9983,,1,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624975,50597,,N,Intermediate,,BAO_0000218
9984,,1,Half-life was evaluated in rats at an oral dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877492,50597,,N,Intermediate,,BAO_0000218
9985,,1,Half-life was measured in rat after an iv dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624976,50597,,N,Intermediate,,BAO_0000218
9986,,1,Half-life period of compound in rats after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624977,50597,,N,Intermediate,,BAO_0000218
9987,,1,Half-life period of compound was measured in rat plasma.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626848,50597,,N,Intermediate,,BAO_0000218
9988,,1,Half-life period of compound was measured in rat plasma; ND is not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626849,50597,,N,Intermediate,,BAO_0000218
9989,,1,Half-life period of compound was measured in rat plasma; not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626850,50597,,N,Intermediate,,BAO_0000218
9990,,1,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626851,50597,,N,Intermediate,,BAO_0000218
9991,,1,Half-life period in rat by iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626852,50597,,N,Intermediate,,BAO_0000218
9992,,1,Half-life period in rats following intravenous administration at 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626853,50597,,N,Intermediate,,BAO_0000218
9993,,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626854,50597,,N,Intermediate,,BAO_0000218
9994,,1,Half-life period was determined for the compound in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627486,50597,,N,Intermediate,,BAO_0000218
9995,,1,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627487,50597,,N,Intermediate,,BAO_0000218
9996,,1,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627488,50597,,N,Intermediate,,BAO_0000218
9997,,1,Half-life value after IV dose at a dose of 5 mg/kg in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627489,50597,,N,Intermediate,,BAO_0000218
9998,,1,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627490,50597,,N,Intermediate,,BAO_0000218
9999,,1,Half-life was determined in rat after intravenous administration (0.5 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873829,50597,,N,Intermediate,,BAO_0000218
10000,,1,Half-life was determined in rat at a dose of 1 mpk i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627655,50597,,N,Intermediate,,BAO_0000218
10001,,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625994,50597,,N,Intermediate,,BAO_0000218
10002,,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625995,50597,,N,Intermediate,,BAO_0000218
10003,,1,Half-life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625996,50597,,N,Intermediate,,BAO_0000218
10004,,1,In vitro half life in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625850,50597,,N,Intermediate,,BAO_0000218
10005,,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625851,50597,,N,Intermediate,,BAO_0000218
10006,,1,In vitro half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625852,50597,,N,Intermediate,,BAO_0000218
10007,,1,In vivo half life period after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625853,50597,,N,Intermediate,,BAO_0000218
10008,,1,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625854,50597,,N,Intermediate,,BAO_0000218
10009,,1,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874450,50597,,N,Intermediate,,BAO_0000218
10010,,1,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625855,50597,,N,Intermediate,,BAO_0000218
10011,,1,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625856,50597,,N,Intermediate,,BAO_0000218
10012,,1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625857,50597,,N,Intermediate,,BAO_0000218
10013,,1,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873831,50597,,N,Intermediate,,BAO_0000218
10014,,1,Longer half-life in rat (i.v.) at 0.5 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625858,50597,,N,Intermediate,,BAO_0000218
10015,,1,Longer half-life in rat (p.o.) at 2.0 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625859,50597,,N,Intermediate,,BAO_0000218
10016,,1,Pharmacokinetic property (half life) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625860,50597,,N,Intermediate,,BAO_0000218
10017,,1,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625861,50597,,N,Intermediate,,BAO_0000218
10018,,1,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625862,50597,,N,Intermediate,,BAO_0000218
10019,,1,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625863,50597,,N,Intermediate,,BAO_0000218
10020,,1,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625864,50597,,N,Intermediate,,BAO_0000218
10021,,1,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625865,50597,,N,Intermediate,,BAO_0000218
10022,,1,Pharmacokinetic half time was determined intravenously in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625866,50597,,N,Intermediate,,BAO_0000218
10023,,1,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625867,50597,,N,Intermediate,,BAO_0000218
10024,,1,Plasma half life of hydrolysis of the compound,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625868,50597,,N,Intermediate,,BAO_0000218
10025,,1,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625869,50597,,N,Intermediate,,BAO_0000218
10026,,1,Plasma half life period was calculated in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL874451,50597,,N,Intermediate,,BAO_0000218
10027,,1,Plasma half-life in Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625870,50597,,N,Intermediate,,BAO_0000218
10028,,1,Plasma half-life in Sprague-Dawley rats; Not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625871,50597,,N,Intermediate,,BAO_0000218
10029,,1,Plasma half-life in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625872,50597,,N,Intermediate,,BAO_0000218
10030,,1,Plasma half-life in rats; <MQL,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625873,50597,,N,Intermediate,,BAO_0000218
10031,,1,Plasma half-life period (0-8 h) was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625874,50597,,N,Intermediate,,BAO_0000218
10032,,1,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625875,50597,,N,Intermediate,,BAO_0000218
10033,,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625876,50597,,N,Intermediate,,BAO_0000218
10034,,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631258,50597,,N,Intermediate,,BAO_0000218
10035,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631259,50597,,N,Intermediate,,BAO_0000218
10036,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631260,50597,,N,Intermediate,,BAO_0000218
10037,,1,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631261,50597,,N,Intermediate,,BAO_0000218
10038,,1,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631262,50597,,N,Intermediate,,BAO_0000218
10039,,1,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631263,50597,,N,Intermediate,,BAO_0000218
10040,,1,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631264,50597,,N,Intermediate,,BAO_0000218
10041,,1,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631265,50597,,N,Intermediate,,BAO_0000218
10042,,1,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631266,50597,,N,Intermediate,,BAO_0000218
10043,,1,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631267,50597,,N,Intermediate,,BAO_0000218
10044,,1,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631268,50597,,N,Intermediate,,BAO_0000218
10045,,1,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631269,50597,,N,Intermediate,,BAO_0000218
10046,,1,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631270,50597,,N,Intermediate,,BAO_0000218
10047,,1,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631271,50597,,N,Intermediate,,BAO_0000218
10048,,1,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631272,50597,,N,Intermediate,,BAO_0000218
10049,,1,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631273,50597,,N,Intermediate,,BAO_0000218
10050,,1,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631274,50597,,N,Intermediate,,BAO_0000218
10051,,1,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631275,50597,,N,Intermediate,,BAO_0000218
10052,,1,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626984,50597,,N,Intermediate,,BAO_0000218
10053,,1,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626985,50597,,N,Intermediate,,BAO_0000218
10054,,1,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626986,50597,,N,Intermediate,,BAO_0000218
10055,,1,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626987,50597,,N,Intermediate,,BAO_0000218
10056,,1,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626988,50597,,N,Intermediate,,BAO_0000218
10057,,1,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626989,50597,,N,Intermediate,,BAO_0000218
10058,,1,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626990,50597,,N,Intermediate,,BAO_0000218
10059,,1,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626991,50597,,N,Intermediate,,BAO_0000218
10060,,1,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626992,50597,,N,Intermediate,,BAO_0000218
10061,,1,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626993,50597,,N,Intermediate,,BAO_0000218
10062,,1,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL874593,50597,,N,Intermediate,,BAO_0000218
10063,,1,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626994,50597,,N,Intermediate,,BAO_0000218
10064,,1,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626995,50597,,N,Intermediate,,BAO_0000218
10065,,1,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626190,50597,,N,Intermediate,,BAO_0000218
10066,,1,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626191,50597,,N,Intermediate,,BAO_0000218
10067,,1,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626364,50597,,N,Intermediate,,BAO_0000218
10068,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626365,50597,,N,Intermediate,,BAO_0000218
10069,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626366,50597,,N,Intermediate,,BAO_0000218
10070,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626367,50597,,N,Intermediate,,BAO_0000218
10071,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626368,50597,,N,Intermediate,,BAO_0000218
10072,,1,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626369,50597,,N,Intermediate,,BAO_0000218
10073,,1,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626370,50597,,N,Intermediate,,BAO_0000218
10074,,1,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626371,50597,,N,Intermediate,,BAO_0000218
10075,,1,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626372,50597,,N,Intermediate,,BAO_0000218
10076,,1,Bioavailability after a dose of 10 mg/kg p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626373,50597,,N,Intermediate,,BAO_0000218
10077,,1,Bioavailability after peroral administration (10 mg/kg) was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626374,50597,,N,Intermediate,,BAO_0000218
10078,,1,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626375,50597,,N,Intermediate,,BAO_0000218
10079,,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626376,50597,,N,Intermediate,,BAO_0000218
10080,,1,Bioavailability in rat po was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626377,50597,,N,Intermediate,,BAO_0000218
10081,,1,Bioavailability of compound at 10 mg/kg in rat after oral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626378,50597,,N,Intermediate,,BAO_0000218
10082,,1,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626379,50597,,N,Intermediate,,BAO_0000218
10083,,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626380,50597,,N,Intermediate,,BAO_0000218
10084,,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626381,50597,,N,Intermediate,,BAO_0000218
10085,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626382,50597,,N,Intermediate,,BAO_0000218
10086,,1,Bioavailability in rat (Sprague-Dawley) (female),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626383,50597,,N,Intermediate,,BAO_0000218
10087,,1,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874652,50597,,N,Intermediate,,BAO_0000218
10088,,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626384,50597,,N,Intermediate,,BAO_0000218
10089,,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626385,50597,,N,Intermediate,,BAO_0000218
10090,,1,Bioavailability in rat at an oral dose of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626386,50597,,N,Intermediate,,BAO_0000218
10091,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626387,50597,,N,Intermediate,,BAO_0000218
10092,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626388,50597,,N,Intermediate,,BAO_0000218
10093,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626389,50597,,N,Intermediate,,BAO_0000218
10094,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626390,50597,,N,Intermediate,,BAO_0000218
10095,,1,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626391,50597,,N,Intermediate,,BAO_0000218
10096,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626392,50597,,N,Intermediate,,BAO_0000218
10097,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626393,50597,,N,Intermediate,,BAO_0000218
10098,,1,Bioavailability was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623026,50597,,N,Intermediate,,BAO_0000218
10099,,1,Bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623027,50597,,N,Intermediate,,BAO_0000218
10100,,1,Bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623028,50597,,N,Intermediate,,BAO_0000218
10101,,1,Bioavailability in rat after 1 day dosing,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623029,50597,,N,Intermediate,,BAO_0000218
10102,,1,Bioavailability in rat after 4 day dosing,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623030,50597,,N,Intermediate,,BAO_0000218
10103,,1,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623031,50597,,N,Intermediate,,BAO_0000218
10104,,1,Bioavailability after IV dosing at 1 mg/kg in rat; no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623032,50597,,N,Intermediate,,BAO_0000218
10105,,1,Bioavailability after oral administration at a dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623033,50597,,N,Intermediate,,BAO_0000218
10106,,1,Bioavailability after oral administration at a dose of 4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623034,50597,,N,Intermediate,,BAO_0000218
10107,,1,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623035,50597,,N,Intermediate,,BAO_0000218
10108,,1,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623036,50597,,N,Intermediate,,BAO_0000218
10109,,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623037,50597,,N,Intermediate,,BAO_0000218
10110,,1,Bioavailability by intravenous administration of 3.4 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623038,50597,,N,Intermediate,,BAO_0000218
10111,,1,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL874385,50597,,N,Intermediate,,BAO_0000218
10112,,1,Bioavailability in rat (Fisher) (fasted),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623039,50597,,N,Intermediate,,BAO_0000218
10113,,0,Bioavailability in monkey after po administration of 10 mg/kg dose,Primates,,,,,,1,9443.0,A,CHEMBL623040,22224,,U,Intermediate,,BAO_0000218
10114,,0,Oral bioavailability in monkey (dose 10 mg/kg),Primates,,,,,,1,9443.0,A,CHEMBL623041,22224,,U,Intermediate,,BAO_0000218
10115,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623741,50597,,N,Intermediate,,BAO_0000218
10116,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623742,50597,,N,Intermediate,,BAO_0000218
10117,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623743,50597,,N,Intermediate,,BAO_0000218
10118,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623744,50597,,N,Intermediate,,BAO_0000218
10119,,1,Bioavailability in rat (dose 2.0 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623745,50597,,N,Intermediate,,BAO_0000218
10120,,1,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623746,50597,,N,Intermediate,,BAO_0000218
10121,,1,Oral bioavailability in rat (dose 5 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623747,50597,,N,Intermediate,,BAO_0000218
10122,,0,Bioavailability in rat after po administration of 30 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623748,22224,,U,Intermediate,,BAO_0000218
10123,,0,Bioavailability in rat after po administration of 30 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623916,22224,,U,Intermediate,,BAO_0000218
10124,,1,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623917,50597,,N,Intermediate,,BAO_0000218
10125,,1,Bioavailability in rat (dose 2 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623918,50597,,N,Intermediate,,BAO_0000218
10126,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874386,50597,,N,Intermediate,,BAO_0000218
10127,,1,Bioavailability in rat; Only traces detected in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623919,50597,,N,Intermediate,,BAO_0000218
10128,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623920,50597,,N,Intermediate,,BAO_0000218
10129,,1,Bioavailability upon oral administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623148,50597,,N,Intermediate,,BAO_0000218
10130,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623149,50597,,N,Intermediate,,BAO_0000218
10131,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623150,50597,,N,Intermediate,,BAO_0000218
10132,,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623151,50597,,N,Intermediate,,BAO_0000218
10133,,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623152,50597,,N,Intermediate,,BAO_0000218
10134,,1,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL623153,50597,,N,Expert,,BAO_0000218
10135,,1,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL623154,50597,,N,Expert,,BAO_0000218
10136,,1,In vitro and metabolic stability was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623155,50597,,N,Intermediate,,BAO_0000218
10137,,1,In vitro metabolic stability in rat hepatocytes,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623156,50597,,N,Intermediate,,BAO_0000218
10138,,1,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623157,50597,,N,Intermediate,,BAO_0000218
10139,,1,Metabolic rate for compound was observed in rat hepatocytes,Rattus norvegicus,,,Liver,2107.0,401.0,1,10116.0,A,CHEMBL623158,50597,,N,Intermediate,,BAO_0000218
10140,,1,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623159,50597,,N,Intermediate,,BAO_0000218
10141,,1,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874390,50597,,N,Intermediate,,BAO_0000218
10142,,1,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623160,50597,,N,Intermediate,,BAO_0000218
10143,,1,Metabolism of compound in rat S9 microsomes; Trace,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623161,50597,,N,Intermediate,,BAO_0000218
10144,,1,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623162,50597,,N,Intermediate,,BAO_0000218
10145,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623163,50597,,N,Intermediate,,BAO_0000218
10146,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623164,50597,,N,Intermediate,,BAO_0000218
10147,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623165,50597,,N,Intermediate,,BAO_0000218
10148,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623166,50597,,N,Intermediate,,BAO_0000218
10149,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624983,50597,,N,Intermediate,,BAO_0000218
10150,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624984,50597,,N,Intermediate,,BAO_0000218
10151,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624985,50597,,N,Intermediate,,BAO_0000218
10152,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622970,50597,,N,Intermediate,,BAO_0000218
10153,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622971,50597,,N,Intermediate,,BAO_0000218
10154,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622972,50597,,N,Intermediate,,BAO_0000218
10155,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622973,50597,,N,Intermediate,,BAO_0000218
10156,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622974,50597,,N,Intermediate,,BAO_0000218
10157,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622975,50597,,N,Intermediate,,BAO_0000218
10158,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622976,50597,,N,Intermediate,,BAO_0000218
10159,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622977,50597,,N,Intermediate,,BAO_0000218
10160,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624351,50597,,N,Intermediate,,BAO_0000218
10161,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624352,50597,,N,Intermediate,,BAO_0000218
10162,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624353,50597,,N,Intermediate,,BAO_0000218
10163,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622397,50597,,N,Intermediate,,BAO_0000218
10164,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622398,50597,,N,Intermediate,,BAO_0000218
10165,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622399,50597,,N,Intermediate,,BAO_0000218
10166,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622400,50597,,N,Intermediate,,BAO_0000218
10167,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628428,50597,,N,Intermediate,,BAO_0000218
10168,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628590,50597,,N,Intermediate,,BAO_0000218
10169,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628591,50597,,N,Intermediate,,BAO_0000218
10170,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628592,50597,,N,Intermediate,,BAO_0000218
10171,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628593,50597,,N,Intermediate,,BAO_0000218
10172,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875333,50597,,N,Intermediate,,BAO_0000218
10173,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628594,50597,,N,Intermediate,,BAO_0000218
10174,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628595,50597,,N,Intermediate,,BAO_0000218
10175,,1,Stability in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628596,50597,,N,Intermediate,,BAO_0000218
10176,,1,Stability in rat plasma was determined; ND= no data,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628597,50597,,N,Intermediate,,BAO_0000218
10177,,1,Tested for plasma half life period in rat (0-8 hr),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628598,50597,,N,Intermediate,,BAO_0000218
10178,,1,Tested for plasma half life period in rat (0-8 hr); Not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628599,50597,,N,Intermediate,,BAO_0000218
10179,,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628600,50597,,N,Intermediate,,BAO_0000218
10180,,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628601,50597,,N,Intermediate,,BAO_0000218
10181,,1,Tested for the half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628602,50597,,N,Intermediate,,BAO_0000218
10182,,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628603,50597,,N,Intermediate,,BAO_0000218
10183,,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628604,50597,,N,Intermediate,,BAO_0000218
10184,,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628605,50597,,N,Intermediate,,BAO_0000218
10185,,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628606,50597,,N,Intermediate,,BAO_0000218
10186,,1,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628607,50597,,N,Intermediate,,BAO_0000218
10187,,1,The biological half life the compound was measured at the dose of 100 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628608,50597,,N,Intermediate,,BAO_0000218
10188,,1,The biological half life the compound was measured at the dose of 30 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628609,50597,,N,Intermediate,,BAO_0000218
10189,,1,The compound was evaluated for plasma half life period in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628610,50597,,N,Intermediate,,BAO_0000218
10190,,1,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL873819,50597,,N,Intermediate,,BAO_0000218
10191,,1,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628611,50597,,N,Intermediate,,BAO_0000218
10192,,1,The pharmacokinetic parameter half-life period in vivo in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628612,50597,,N,Intermediate,,BAO_0000218
10193,,1,"The pharmacokinetic property, Half-life was determined",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628613,50597,,N,Intermediate,,BAO_0000218
10194,,1,"The pharmacokinetic property, Half-life in rat in vivo",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628614,50597,,N,Intermediate,,BAO_0000218
10195,,1,"The pharmacokinetic property, Half-life was determined; ND denotes no data",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628615,50597,,N,Intermediate,,BAO_0000218
10196,,1,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628616,50597,,N,Intermediate,,BAO_0000218
10197,,1,The plasma half life period in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627924,50597,,N,Intermediate,,BAO_0000218
10198,,1,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627925,50597,,N,Intermediate,,BAO_0000218
10199,,1,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627926,50597,,N,Intermediate,,BAO_0000218
10200,,1,t1/2 (apparent elimination)of the compound was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627927,50597,,N,Intermediate,,BAO_0000218
10201,,1,t1/2 value in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627928,50597,,N,Intermediate,,BAO_0000218
10202,,1,Half life in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627539,50597,,N,Intermediate,,BAO_0000218
10203,,1,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876790,50597,,N,Intermediate,,BAO_0000218
10204,,1,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL858186,50597,,N,Intermediate,,BAO_0000218
10205,,1,Half-life period in fasted rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627540,50597,,N,Intermediate,,BAO_0000218
10206,,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627541,50597,,N,Intermediate,,BAO_0000218
10207,,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627715,50597,,N,Intermediate,,BAO_0000218
10208,,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627716,50597,,N,Intermediate,,BAO_0000218
10209,,1,Maximum time required to achieve Cmax was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627717,50597,,N,Intermediate,,BAO_0000218
10210,,1,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627718,50597,,N,Intermediate,,BAO_0000218
10211,,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627719,50597,,N,Intermediate,,BAO_0000218
10212,,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627720,50597,,N,Intermediate,,BAO_0000218
10213,,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627721,50597,,N,Intermediate,,BAO_0000218
10214,,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627722,50597,,N,Intermediate,,BAO_0000218
10215,,1,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627723,50597,,N,Intermediate,,BAO_0000218
10216,,1,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626058,50597,,N,Intermediate,,BAO_0000218
10217,,1,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626059,50597,,N,Intermediate,,BAO_0000218
10218,,1,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626060,50597,,N,Intermediate,,BAO_0000218
10219,,1,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626061,50597,,N,Intermediate,,BAO_0000218
10220,,1,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876791,50597,,N,Intermediate,,BAO_0000218
10221,,1,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626062,50597,,N,Intermediate,,BAO_0000218
10222,,1,Tmax at the dose of 2 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626063,50597,,N,Intermediate,,BAO_0000218
10223,,1,Tmax at the dose of 5 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626064,50597,,N,Intermediate,,BAO_0000218
10224,,1,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626065,50597,,N,Intermediate,,BAO_0000218
10225,,1,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626066,50597,,N,Intermediate,,BAO_0000218
10226,,1,tmax upon peroral administration of 10.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626067,50597,,N,Intermediate,,BAO_0000218
10227,,1,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626068,50597,,N,Intermediate,,BAO_0000218
10228,,1,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626069,50597,,N,Intermediate,,BAO_0000218
10229,,1,Percent total excretion of 3-methoxyacetaminophen glucuronide,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626070,50597,,N,Intermediate,,BAO_0000218
10230,,1,Percent total excretion of N-methoxyacetaminophen glucuronide,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626071,50597,,N,Intermediate,,BAO_0000218
10231,,1,Percent total excretion of N-methoxyacetaminophen sulfate,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626072,50597,,N,Intermediate,,BAO_0000218
10232,,1,Percent total excretion of acetaminophen,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626073,50597,,N,Intermediate,,BAO_0000218
10233,,1,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626741,50597,,N,Intermediate,,BAO_0000218
10234,,1,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626742,50597,,N,Intermediate,,BAO_0000218
10235,,1,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626743,50597,,N,Intermediate,,BAO_0000218
10236,,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876792,50597,,N,Intermediate,,BAO_0000218
10237,,1,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626744,50597,,N,Intermediate,,BAO_0000218
10238,,1,Compound was tested for antidiuretic activity in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626745,50597,,N,Intermediate,,BAO_0000218
10239,,1,AUC in rat after 3mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626746,50597,,N,Intermediate,,BAO_0000218
10240,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626747,50597,,N,Intermediate,,BAO_0000218
10241,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626748,50597,,N,Intermediate,,BAO_0000218
10242,,1,Bioavailability administered orally at a dose of 10 mg/kg to rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626749,50597,,N,Intermediate,,BAO_0000218
10243,,1,Oral Bioavailability was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626750,50597,,N,Intermediate,,BAO_0000218
10244,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626751,50597,,N,Intermediate,,BAO_0000218
10245,,1,Oral bioavailability in rat; Not performed.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626913,50597,,N,Intermediate,,BAO_0000218
10246,,1,Bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626914,50597,,N,Intermediate,,BAO_0000218
10247,,1,Bioavailability was determined; ND denotes no data,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626915,50597,,N,Intermediate,,BAO_0000218
10248,,1,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626916,50597,,N,Intermediate,,BAO_0000218
10249,,1,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626917,50597,,N,Intermediate,,BAO_0000218
10250,,1,Binding towards rat plasma protein at 10 uM,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626918,50597,,N,Intermediate,,BAO_0000218
10251,,1,Binding towards rat plasma protein at 100 uM,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626919,50597,,N,Intermediate,,BAO_0000218
10252,,1,Bioavailability in rat (dose 20 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626920,50597,,N,Intermediate,,BAO_0000218
10253,,1,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621976,50597,,N,Intermediate,,BAO_0000218
10254,,1,Bioavailability in rat after 5 mg/kg oral gavage,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877599,50597,,N,Intermediate,,BAO_0000218
10255,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621977,50597,,N,Intermediate,,BAO_0000218
10256,,1,Bioavailability in rat (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621978,50597,,N,Intermediate,,BAO_0000218
10257,,1,Bioavailability in rat (dose 3 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621979,50597,,N,Intermediate,,BAO_0000218
10258,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621980,50597,,N,Intermediate,,BAO_0000218
10259,,1,Bioavailability of the compound in rats after administration of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621981,50597,,N,Intermediate,,BAO_0000218
10260,,1,Bioavailability after administration of 10 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621982,50597,,N,Intermediate,,BAO_0000218
10261,,1,Bioavailability after administration of 2 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL882953,50597,,N,Intermediate,,BAO_0000218
10262,,1,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621983,50597,,N,Intermediate,,BAO_0000218
10263,,1,Bioavailability in dogs was determined; high,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621984,50597,,N,Intermediate,,BAO_0000218
10264,,1,Bioavailability in monkey after intravenous administration at 1 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621985,50597,,N,Intermediate,,BAO_0000218
10265,,1,Bioavailability in monkey after peroral administration at 10 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621986,50597,,N,Intermediate,,BAO_0000218
10266,,1,Bioavailability in rat after intravenous administration at 1 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621987,50597,,N,Intermediate,,BAO_0000218
10267,,1,Bioavailability in rat after intravenous administration at 2 mpk,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL877600,50597,,N,Intermediate,,BAO_0000218
10268,,1,Bioavailability in rat after peroral administration at 30 mpk,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621988,50597,,N,Intermediate,,BAO_0000218
10269,,1,Bioavailability in rat after peroral administration at at 100 mpk,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL621989,50597,,N,Intermediate,,BAO_0000218
10270,,1,Bioavailability in rats was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621990,50597,,N,Intermediate,,BAO_0000218
10271,,1,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621991,50597,,N,Intermediate,,BAO_0000218
10272,,1,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621992,50597,,N,Intermediate,,BAO_0000218
10273,,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621993,50597,,N,Intermediate,,BAO_0000218
10274,,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621994,50597,,N,Intermediate,,BAO_0000218
10275,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621995,50597,,N,Intermediate,,BAO_0000218
10276,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621996,50597,,N,Intermediate,,BAO_0000218
10277,,1,Oral bioavailability in rat (dose 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621997,50597,,N,Intermediate,,BAO_0000218
10278,,1,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621998,50597,,N,Intermediate,,BAO_0000218
10279,,1,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621999,50597,,N,Intermediate,,BAO_0000218
10280,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622000,50597,,N,Intermediate,,BAO_0000218
10281,,1,Bioavailability was measured in rat after oral administration; 2-4,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622001,50597,,N,Intermediate,,BAO_0000218
10282,,1,Bioavailability was measured in rat after oral administration; 3-7,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622002,50597,,N,Intermediate,,BAO_0000218
10283,,1,Bioavailability in rat (intraduodenal administration),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622003,50597,,N,Intermediate,,BAO_0000218
10284,,1,Bioavailability in rat (intraduodenal administration),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877601,50597,,N,Intermediate,,BAO_0000218
10285,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624871,50597,,N,Intermediate,,BAO_0000218
10286,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622004,50597,,N,Intermediate,,BAO_0000218
10287,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL882954,50597,,N,Intermediate,,BAO_0000218
10288,,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622005,50597,,N,Intermediate,,BAO_0000218
10289,,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622006,50597,,N,Intermediate,,BAO_0000218
10290,,1,Bioavailability was measured in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622007,50597,,N,Intermediate,,BAO_0000218
10291,,1,Bioavailability was reported,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622008,50597,,N,Intermediate,,BAO_0000218
10292,,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622009,50597,,N,Intermediate,,BAO_0000218
10293,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622010,50597,,N,Intermediate,,BAO_0000218
10294,,1,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622011,50597,,N,Intermediate,,BAO_0000218
10295,,1,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622012,50597,,N,Intermediate,,BAO_0000218
10296,,1,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622013,50597,,N,Intermediate,,BAO_0000218
10297,,1,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622014,50597,,N,Intermediate,,BAO_0000218
10298,,1,Bioavailability was determined at 3 mg/kg po dose in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624749,50597,,N,Intermediate,,BAO_0000218
10299,,1,Oral bioavailability in rat (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624750,50597,,N,Intermediate,,BAO_0000218
10300,,1,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624751,50597,,N,Intermediate,,BAO_0000218
10301,,1,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624752,50597,,N,Intermediate,,BAO_0000218
10302,,1,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624753,50597,,N,Intermediate,,BAO_0000218
10303,,1,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624754,50597,,N,Intermediate,,BAO_0000218
10304,,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624755,50597,,N,Intermediate,,BAO_0000218
10305,,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624756,50597,,N,Intermediate,,BAO_0000218
10306,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624757,50597,,N,Intermediate,,BAO_0000218
10307,,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624758,50597,,N,Intermediate,,BAO_0000218
10308,,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622270,50597,,N,Intermediate,,BAO_0000218
10309,,1,Bioavailability in rat (Sprague-Dawley),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622271,50597,,N,Intermediate,,BAO_0000218
10310,,1,Bioavailability in rat at the dose of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622272,50597,,N,Intermediate,,BAO_0000218
10311,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622273,50597,,N,Intermediate,,BAO_0000218
10312,,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622274,50597,,N,Intermediate,,BAO_0000218
10313,,1,Bioavailability value of compound in rats was determined after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622275,50597,,N,Intermediate,,BAO_0000218
10314,,1,Oral bioavailability in rat (dose 20 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622276,50597,,N,Intermediate,,BAO_0000218
10315,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622277,50597,,N,Intermediate,,BAO_0000218
10316,,1,Oral bioavailability in rat (dose 5 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622278,50597,,N,Intermediate,,BAO_0000218
10317,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622279,50597,,N,Intermediate,,BAO_0000218
10318,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622280,50597,,N,Intermediate,,BAO_0000218
10319,,1,Compound was evaluated for oral bioavailability in rats; 15-27 %,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624083,50597,,N,Intermediate,,BAO_0000218
10320,,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624084,50597,,N,Intermediate,,BAO_0000218
10321,,1,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624085,50597,,N,Intermediate,,BAO_0000218
10322,,1,Compound was tested for bioavailability in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624086,50597,,N,Intermediate,,BAO_0000218
10323,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624087,50597,,N,Intermediate,,BAO_0000218
10324,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624088,50597,,N,Intermediate,,BAO_0000218
10325,,0,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL624089,22224,,U,Intermediate,,BAO_0000218
10326,,0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624090,22224,,U,Intermediate,,BAO_0000218
10327,,1,Evaluated for the bioavailability in rat (in vivo),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624091,50597,,N,Intermediate,,BAO_0000218
10328,,1,F value of compound in rats was determined after peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624092,50597,,N,Intermediate,,BAO_0000218
10329,,1,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624093,50597,,N,Intermediate,,BAO_0000218
10330,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624094,50597,,N,Intermediate,,BAO_0000218
10331,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624095,50597,,N,Intermediate,,BAO_0000218
10332,,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624096,50597,,N,Intermediate,,BAO_0000218
10333,,1,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624097,50597,,N,Intermediate,,BAO_0000218
10334,,1,Maximum fall in carotid flow in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624098,50597,,N,Intermediate,,BAO_0000218
10335,,1,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874392,50597,,N,Intermediate,,BAO_0000218
10336,,1,Oral bioavailability in rat (dose 5 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624099,50597,,N,Intermediate,,BAO_0000218
10337,,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624100,50597,,N,Intermediate,,BAO_0000218
10338,,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624101,50597,,N,Intermediate,,BAO_0000218
10339,,1,Oral bioavailability in rat (male Wistar),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624102,50597,,N,Intermediate,,BAO_0000218
10340,,1,Oral bioavailability after administration (30 mg/kg) in rat; good,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624103,50597,,N,Intermediate,,BAO_0000218
10341,,1,Oral bioavailability at the dose of 2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624104,50597,,N,Intermediate,,BAO_0000218
10342,,1,Oral bioavailability determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624105,50597,,N,Intermediate,,BAO_0000218
10343,,1,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624106,50597,,N,Intermediate,,BAO_0000218
10344,,1,Oral bioavailability in rat (dose single 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624107,50597,,N,Intermediate,,BAO_0000218
10345,,1,Oral bioavailability in rat (dose single 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623943,50597,,N,Intermediate,,BAO_0000218
10346,,1,Oral bioavailability in rat (dose 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623944,50597,,N,Intermediate,,BAO_0000218
10347,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623945,50597,,N,Intermediate,,BAO_0000218
10348,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623946,50597,,N,Intermediate,,BAO_0000218
10349,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623947,50597,,N,Intermediate,,BAO_0000218
10350,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623948,50597,,N,Intermediate,,BAO_0000218
10351,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623949,50597,,N,Intermediate,,BAO_0000218
10352,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623950,50597,,N,Intermediate,,BAO_0000218
10353,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874398,50597,,N,Intermediate,,BAO_0000218
10354,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623951,50597,,N,Intermediate,,BAO_0000218
10355,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623952,50597,,N,Intermediate,,BAO_0000218
10356,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623953,50597,,N,Intermediate,,BAO_0000218
10357,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623954,50597,,N,Intermediate,,BAO_0000218
10358,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623955,50597,,N,Intermediate,,BAO_0000218
10359,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623956,50597,,N,Intermediate,,BAO_0000218
10360,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627807,50597,,N,Intermediate,,BAO_0000218
10361,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627808,50597,,N,Intermediate,,BAO_0000218
10362,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627809,50597,,N,Intermediate,,BAO_0000218
10363,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627810,50597,,N,Intermediate,,BAO_0000218
10364,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627811,50597,,N,Intermediate,,BAO_0000218
10365,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627812,50597,,N,Intermediate,,BAO_0000218
10366,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627813,50597,,N,Intermediate,,BAO_0000218
10367,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627814,50597,,N,Intermediate,,BAO_0000218
10368,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875336,50597,,N,Intermediate,,BAO_0000218
10369,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627815,50597,,N,Intermediate,,BAO_0000218
10370,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627816,50597,,N,Intermediate,,BAO_0000218
10371,,1,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627817,50597,,N,Intermediate,,BAO_0000218
10372,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627818,50597,,N,Intermediate,,BAO_0000218
10373,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627819,50597,,N,Intermediate,,BAO_0000218
10374,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627820,50597,,N,Intermediate,,BAO_0000218
10375,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627821,50597,,N,Intermediate,,BAO_0000218
10376,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628464,50597,,N,Intermediate,,BAO_0000218
10377,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626239,50597,,N,Intermediate,,BAO_0000218
10378,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626240,50597,,N,Intermediate,,BAO_0000218
10379,,1,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626241,50597,,N,Intermediate,,BAO_0000218
10380,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626242,50597,,N,Intermediate,,BAO_0000218
10381,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626243,50597,,N,Intermediate,,BAO_0000218
10382,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626244,50597,,N,Intermediate,,BAO_0000218
10383,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626907,50597,,N,Intermediate,,BAO_0000218
10384,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626908,50597,,N,Intermediate,,BAO_0000218
10385,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626909,50597,,N,Intermediate,,BAO_0000218
10386,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626910,50597,,N,Intermediate,,BAO_0000218
10387,,1,Percent total excretion of acetaminophen cysteine conjugate,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL875342,50597,,N,Intermediate,,BAO_0000218
10388,,1,Percent total excretion of acetaminophen glucuronide,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626911,50597,,N,Intermediate,,BAO_0000218
10389,,1,Percent total excretion of acetaminophen sulfate,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL626912,50597,,N,Intermediate,,BAO_0000218
10390,,1,Percent total excretion of acetaminophen-mercapturic acid,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL627065,50597,,N,Intermediate,,BAO_0000218
10391,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627066,50597,,N,Intermediate,,BAO_0000218
10392,,1,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627067,50597,,N,Intermediate,,BAO_0000218
10393,,0,Biodistribution of compound in rat muscle after 5 min of administration,ratrat,,,Muscle tissue,2385.0,,1,8656.0,A,CHEMBL627068,22224,,U,Autocuration,,BAO_0000218
10394,,0,Biodistribution of compound in rat muscle after 5 min of administration.,ratrat,,,Muscle tissue,2385.0,,1,8656.0,A,CHEMBL627069,22224,,U,Autocuration,,BAO_0000218
10395,,0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL627070,22224,,U,Autocuration,,BAO_0000218
10396,,0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL627071,22224,,U,Autocuration,,BAO_0000218
10397,,0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL627072,22224,,U,Autocuration,,BAO_0000218
10398,,0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL627073,22224,,U,Autocuration,,BAO_0000218
10399,,0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL625387,22224,,U,Autocuration,,BAO_0000218
10400,,0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Ovis aries,,,,,,1,9940.0,A,CHEMBL625388,22224,,U,Autocuration,,BAO_0000218
10401,,0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Ovis aries,,,Plasma,1969.0,,1,9940.0,A,CHEMBL625389,22224,,U,Autocuration,,BAO_0000218
10402,,0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Ovis aries,,,Plasma,1969.0,,1,9940.0,A,CHEMBL875343,22224,,U,Autocuration,,BAO_0000218
10403,,1,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),Serpentes,,,,,,1,8570.0,A,CHEMBL876795,50497,,N,Intermediate,,BAO_0000218
10404,,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,Serpentes,,,,,,1,8570.0,A,CHEMBL626552,50497,,N,Intermediate,,BAO_0000218
10405,,1,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,Serpentes,,,,,,1,8570.0,A,CHEMBL626553,50497,,N,Intermediate,,BAO_0000218
10406,,0,The human biological plasma half life of the compound,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL626554,22224,,U,Autocuration,,BAO_0000366
10407,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626555,50597,,N,Intermediate,,BAO_0000218
10408,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626556,50597,,N,Intermediate,,BAO_0000218
10409,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626557,50597,,N,Intermediate,,BAO_0000218
10410,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626558,50597,,N,Intermediate,,BAO_0000218
10411,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626559,50597,,N,Intermediate,,BAO_0000218
10412,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626560,50597,,N,Intermediate,,BAO_0000218
10413,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876803,50597,,N,Intermediate,,BAO_0000218
10414,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627964,50597,,N,Intermediate,,BAO_0000218
10415,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627965,50597,,N,Intermediate,,BAO_0000218
10416,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627966,50597,,N,Intermediate,,BAO_0000218
10417,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627967,50597,,N,Intermediate,,BAO_0000218
10418,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627968,50597,,N,Intermediate,,BAO_0000218
10419,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627969,50597,,N,Intermediate,,BAO_0000218
10420,,1,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627970,50597,,N,Intermediate,,BAO_0000218
10421,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627971,50597,,N,Intermediate,,BAO_0000218
10422,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627972,50597,,N,Intermediate,,BAO_0000218
10423,,9,Dissociation constant against binding to human cyclophilin A,Homo sapiens,,,,,,1,9606.0,B,CHEMBL856029,180,,D,Expert,,BAO_0000357
10424,,8,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,Bos taurus,,,,,,1,9913.0,B,CHEMBL627973,11591,,H,Expert,,BAO_0000019
10425,,0,-Log C was determined by performing the electroshock minimum test,,,,,,,1,,A,CHEMBL627974,22224,,U,Autocuration,,BAO_0000019
10426,,0,-Log C was determined by performing the foot shock test,,,,,,,1,,A,CHEMBL627975,22224,,U,Autocuration,,BAO_0000019
10427,,0,-Log C was determined by performing the incl screen test,,,,,,,1,,A,CHEMBL627976,22224,,U,Autocuration,,BAO_0000019
10428,,0,-Log C was determined by performing the maximum electroshock test,,,,,,,1,,A,CHEMBL627977,22224,,U,Autocuration,,BAO_0000019
10429,,0,-Log C was determined by performing the pentylenetetrazole test,,,,,,,1,,A,CHEMBL627978,22224,,U,Autocuration,,BAO_0000019
10430,,0,Tested for experimental arotinoid inhibitory dose,,,,,,,1,,A,CHEMBL627979,22224,,U,Autocuration,,BAO_0000019
10431,,0,Negative log transformed activity,,,,,,,1,,A,CHEMBL876804,22224,,U,Autocuration,,BAO_0000019
10432,,0,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,,,,,,1,,A,CHEMBL627980,22224,,U,Autocuration,,BAO_0000019
10433,,1,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL627981,50512,,N,Intermediate,,BAO_0000218
10434,,1,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL627982,50512,,N,Intermediate,,BAO_0000218
10435,,1,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL627983,50512,,N,Intermediate,,BAO_0000218
10436,,1,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,A,CHEMBL627984,50512,,N,Intermediate,,BAO_0000218
10437,,0,Solubility in water was determined; values expressed as -log,,,,,,,1,,P,CHEMBL627985,22229,,U,Autocuration,,BAO_0000100
10438,,0,Ratio of Kcat to that of Km was determined,,,,,,,1,,A,CHEMBL627986,22224,,U,Autocuration,,BAO_0000019
10439,,0,Observed first order rate constant,,,,,,,1,,A,CHEMBL627987,22224,,U,Autocuration,,BAO_0000019
10440,,0,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,,,,,,1,,A,CHEMBL627988,22224,,U,Autocuration,,BAO_0000019
10441,,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627989,50597,,N,Intermediate,,BAO_0000218
10442,,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627990,50597,,N,Intermediate,,BAO_0000218
10443,,1,Oral Bioavailability after administration of 10 mg/kg in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876805,50597,,N,Intermediate,,BAO_0000218
10444,,1,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627991,50597,,N,Intermediate,,BAO_0000218
10445,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627992,50597,,N,Intermediate,,BAO_0000218
10446,,1,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627993,50597,,N,Intermediate,,BAO_0000218
10447,,1,Oral bioavailability at 1 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622817,50597,,N,Intermediate,,BAO_0000218
10448,,1,Oral bioavailability at 10 mg/kg was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622818,50597,,N,Intermediate,,BAO_0000218
10449,,1,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622819,50597,,N,Intermediate,,BAO_0000218
10450,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL872267,50597,,N,Intermediate,,BAO_0000218
10451,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622820,50597,,N,Intermediate,,BAO_0000218
10452,,1,Oral bioavailability after intravenous administration in rats at 24 uM/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622821,50597,,N,Intermediate,,BAO_0000218
10453,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622822,50597,,N,Intermediate,,BAO_0000218
10454,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622823,50597,,N,Intermediate,,BAO_0000218
10455,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622824,50597,,N,Intermediate,,BAO_0000218
10456,,1,Oral bioavailability in rat at a dose of 3 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622825,50597,,N,Intermediate,,BAO_0000218
10457,,1,Oral bioavailability in rat after oral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622901,50597,,N,Intermediate,,BAO_0000218
10458,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622902,50597,,N,Intermediate,,BAO_0000218
10459,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621844,50597,,N,Intermediate,,BAO_0000218
10460,,1,Oral bioavailability in Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621845,50597,,N,Intermediate,,BAO_0000218
10461,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621846,50597,,N,Intermediate,,BAO_0000218
10462,,1,Oral bioavailability in rat (dose 30 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621847,50597,,N,Intermediate,,BAO_0000218
10463,,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877609,50597,,N,Intermediate,,BAO_0000218
10464,,1,Bioavailability in rat (dose 3 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621848,50597,,N,Intermediate,,BAO_0000218
10465,,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621849,50597,,N,Intermediate,,BAO_0000218
10466,,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622030,50597,,N,Intermediate,,BAO_0000218
10467,,1,Percent oral bioavailability determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622031,50597,,N,Intermediate,,BAO_0000218
10468,,1,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622032,50597,,N,Intermediate,,BAO_0000218
10469,,1,The compound was evaluated for bioavailability in rats; 32-51,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622033,50597,,N,Intermediate,,BAO_0000218
10470,,1,Bioavailability in rat (dose 20 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622034,50597,,N,Intermediate,,BAO_0000218
10471,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622035,50597,,N,Intermediate,,BAO_0000218
10472,,1,Bioavailability percent in rat at the dose of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL882966,50597,,N,Intermediate,,BAO_0000218
10473,,1,Bioavailability was evaluated after 20 uM/kg of peroral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622036,50597,,N,Intermediate,,BAO_0000218
10474,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622037,50597,,N,Intermediate,,BAO_0000218
10475,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622038,50597,,N,Intermediate,,BAO_0000218
10476,,1,Bioavailability in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622039,50597,,N,Intermediate,,BAO_0000218
10477,,1,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622040,50597,,N,Intermediate,,BAO_0000218
10478,,1,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622041,50597,,N,Intermediate,,BAO_0000218
10479,,1,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622042,50597,,N,Intermediate,,BAO_0000218
10480,,1,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622043,50597,,N,Intermediate,,BAO_0000218
10481,,1,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622044,50597,,N,Intermediate,,BAO_0000218
10482,,1,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL622045,50597,,N,Intermediate,,BAO_0000218
10483,,1,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL622046,50597,,N,Intermediate,,BAO_0000218
10484,,1,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL622047,50597,,N,Intermediate,,BAO_0000218
10485,,1,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL877610,50597,,N,Intermediate,,BAO_0000218
10486,,1,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622048,50597,,N,Intermediate,,BAO_0000218
10487,,1,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622049,50597,,N,Intermediate,,BAO_0000218
10488,,1,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622050,50597,,N,Intermediate,,BAO_0000218
10489,,1,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622051,50597,,N,Intermediate,,BAO_0000218
10490,,1,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622052,50597,,N,Intermediate,,BAO_0000218
10491,,1,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622053,50597,,N,Intermediate,,BAO_0000218
10492,,1,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622054,50597,,N,Intermediate,,BAO_0000218
10493,,1,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622055,50597,,N,Intermediate,,BAO_0000218
10494,,1,Oral bioavailability in rats was determined; High,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622056,50597,,N,Intermediate,,BAO_0000218
10495,,1,Oral bioavailability in the rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622057,50597,,N,Intermediate,,BAO_0000218
10496,,1,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628008,50597,,N,Intermediate,,BAO_0000218
10497,,1,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622058,50597,,N,Intermediate,,BAO_0000218
10498,,1,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622059,50597,,N,Intermediate,,BAO_0000218
10499,,1,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622060,50597,,N,Intermediate,,BAO_0000218
10500,,1,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622061,50597,,N,Intermediate,,BAO_0000218
10501,,1,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622062,50597,,N,Intermediate,,BAO_0000218
10502,,1,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622063,50597,,N,Intermediate,,BAO_0000218
10503,,1,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877611,50597,,N,Expert,,BAO_0000218
10504,,1,Oral bioavailability of compound in Sprague Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622064,50597,,N,Intermediate,,BAO_0000218
10505,,1,Oral bioavailability of compound in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622065,50597,,N,Intermediate,,BAO_0000218
10506,,1,Oral bioavailability in rat (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622066,50597,,N,Intermediate,,BAO_0000218
10507,,1,Oral bioavailability of compound in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622067,50597,,N,Intermediate,,BAO_0000218
10508,,1,Oral bioavailability of compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622068,50597,,N,Intermediate,,BAO_0000218
10509,,1,Oral bioavailability of compound was determined in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622069,50597,,N,Intermediate,,BAO_0000218
10510,,1,Oral bioavailability at a dose of 30 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624796,50597,,N,Intermediate,,BAO_0000218
10511,,1,Oral bioavailability in rat (dose 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624797,50597,,N,Intermediate,,BAO_0000218
10512,,1,Oral bioavailability in rat (dose 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623053,50597,,N,Intermediate,,BAO_0000218
10513,,1,Oral bioavailability evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623054,50597,,N,Intermediate,,BAO_0000218
10514,,1,Oral bioavailability in fasted rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623055,50597,,N,Intermediate,,BAO_0000218
10515,,1,Oral bioavailability in fed rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623056,50597,,N,Intermediate,,BAO_0000218
10516,,1,Oral bioavailability in rat (mature male) (dose 30 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623057,50597,,N,Intermediate,,BAO_0000218
10517,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623058,50597,,N,Intermediate,,BAO_0000218
10518,,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623059,50597,,N,Intermediate,,BAO_0000218
10519,,1,Oral bioavailability in rat after administration of 10 mg/kg po,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623060,50597,,N,Intermediate,,BAO_0000218
10520,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623061,50597,,N,Intermediate,,BAO_0000218
10521,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623062,50597,,N,Intermediate,,BAO_0000218
10522,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623063,50597,,N,Intermediate,,BAO_0000218
10523,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623064,50597,,N,Intermediate,,BAO_0000218
10524,,1,Oral bioavailability in ratrs,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623065,50597,,N,Intermediate,,BAO_0000218
10525,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623066,50597,,N,Intermediate,,BAO_0000218
10526,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623067,50597,,N,Intermediate,,BAO_0000218
10527,,1,Oral bioavailability in rats was determined; High,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623068,50597,,N,Intermediate,,BAO_0000218
10528,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623069,50597,,N,Intermediate,,BAO_0000218
10529,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623070,50597,,N,Intermediate,,BAO_0000218
10530,,1,Oral bioavailability was calculated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623071,50597,,N,Intermediate,,BAO_0000218
10531,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623072,50597,,N,Intermediate,,BAO_0000218
10532,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623073,50597,,N,Intermediate,,BAO_0000218
10533,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623074,50597,,N,Intermediate,,BAO_0000218
10534,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623075,50597,,N,Intermediate,,BAO_0000218
10535,,1,Oral bioavailability after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623076,50597,,N,Intermediate,,BAO_0000218
10536,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623077,50597,,N,Intermediate,,BAO_0000218
10537,,1,Oral bioavailability in rat (Sprague-Dawley),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623078,50597,,N,Intermediate,,BAO_0000218
10538,,1,Oral bioavailability in Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623079,50597,,N,Intermediate,,BAO_0000218
10539,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623080,50597,,N,Intermediate,,BAO_0000218
10540,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623081,50597,,N,Intermediate,,BAO_0000218
10541,,1,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623082,50597,,N,Intermediate,,BAO_0000218
10542,,1,Oral bioavailability in fasted rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874400,50597,,N,Intermediate,,BAO_0000218
10543,,1,Oral bioavailability in fed rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623083,50597,,N,Intermediate,,BAO_0000218
10544,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623084,50597,,N,Intermediate,,BAO_0000218
10545,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623085,50597,,N,Intermediate,,BAO_0000218
10546,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623086,50597,,N,Intermediate,,BAO_0000218
10547,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623087,50597,,N,Intermediate,,BAO_0000218
10548,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623088,50597,,N,Intermediate,,BAO_0000218
10549,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623089,50597,,N,Intermediate,,BAO_0000218
10550,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623090,50597,,N,Intermediate,,BAO_0000218
10551,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623091,50597,,N,Intermediate,,BAO_0000218
10552,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623092,50597,,N,Intermediate,,BAO_0000218
10553,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623093,50597,,N,Intermediate,,BAO_0000218
10554,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874401,50597,,N,Intermediate,,BAO_0000218
10555,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623094,50597,,N,Intermediate,,BAO_0000218
10556,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623095,50597,,N,Intermediate,,BAO_0000218
10557,,1,Oral bioavailability in rat after peroral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623096,50597,,N,Intermediate,,BAO_0000218
10558,,1,Oral bioavailability in rat after peroral administration at 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624913,50597,,N,Intermediate,,BAO_0000218
10559,,1,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624914,50597,,N,Intermediate,,BAO_0000218
10560,,1,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624915,50597,,N,Intermediate,,BAO_0000218
10561,,1,Oral bioavailability in rat; Not measured,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624916,50597,,N,Intermediate,,BAO_0000218
10562,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624917,50597,,N,Intermediate,,BAO_0000218
10563,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625157,50597,,N,Intermediate,,BAO_0000218
10564,,1,In vitro metabolic potential in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625158,50597,,N,Intermediate,,BAO_0000218
10565,,1,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625159,50597,,N,Intermediate,,BAO_0000218
10566,,1,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625160,50597,,N,Intermediate,,BAO_0000218
10567,,1,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625161,50597,,N,Intermediate,,BAO_0000218
10568,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625162,50597,,N,Intermediate,,BAO_0000218
10569,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625163,50597,,N,Intermediate,,BAO_0000218
10570,,1,Oral bioavailability in rats at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625164,50597,,N,Intermediate,,BAO_0000218
10571,,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625165,50597,,N,Intermediate,,BAO_0000218
10572,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625166,50597,,N,Intermediate,,BAO_0000218
10573,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625167,50597,,N,Intermediate,,BAO_0000218
10574,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625168,50597,,N,Intermediate,,BAO_0000218
10575,,1,Plasma clearance of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625169,50597,,N,Intermediate,,BAO_0000218
10576,,1,Plasma clearance at 10 mg/kg in rat upon intravenous administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626264,50597,,N,Intermediate,,BAO_0000218
10577,,1,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626265,50597,,N,Intermediate,,BAO_0000218
10578,,1,The compound was tested for plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626266,50597,,N,Intermediate,,BAO_0000218
10579,,1,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626267,50597,,N,Intermediate,,BAO_0000218
10580,,1,Plasma concentration upon oral administration of 1 mg/Kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626268,50597,,N,Intermediate,,BAO_0000218
10581,,1,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626269,50597,,N,Intermediate,,BAO_0000218
10582,,1,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626270,50597,,N,Intermediate,,BAO_0000218
10583,,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626271,50597,,N,Intermediate,,BAO_0000218
10584,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626272,50597,,N,Intermediate,,BAO_0000218
10585,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626273,50597,,N,Intermediate,,BAO_0000218
10586,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875346,50597,,N,Intermediate,,BAO_0000218
10587,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626274,50597,,N,Intermediate,,BAO_0000218
10588,,1,Compound was tested for protein binding in rat plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626275,50597,,N,Intermediate,,BAO_0000218
10589,,1,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624646,50597,,N,Intermediate,,BAO_0000218
10590,,1,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624647,50597,,N,Intermediate,,BAO_0000218
10591,,1,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624648,50597,,N,Intermediate,,BAO_0000218
10592,,1,Area under curve ratio was determined (po/iv) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624649,50597,,N,Intermediate,,BAO_0000218
10593,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624650,50597,,N,Intermediate,,BAO_0000218
10594,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624651,50597,,N,Intermediate,,BAO_0000218
10595,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624652,50597,,N,Intermediate,,BAO_0000218
10596,,1,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624653,50597,,N,Intermediate,,BAO_0000218
10597,,1,Ratio of AUCbrain to AUCplasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624654,50597,,N,Intermediate,,BAO_0000218
10598,,1,Ratio of brain to plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624655,50597,,N,Intermediate,,BAO_0000218
10599,,1,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624656,50597,,N,Intermediate,,BAO_0000218
10600,,1,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624657,50597,,N,Intermediate,,BAO_0000218
10601,,1,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624658,50597,,N,Intermediate,,BAO_0000218
10602,,1,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624659,50597,,N,Intermediate,,BAO_0000218
10603,,1,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624660,50597,,N,Intermediate,,BAO_0000218
10604,,1,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624661,50597,,N,Intermediate,,BAO_0000218
10605,,1,Steady state brain :blood ratio was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624662,50597,,N,Intermediate,,BAO_0000218
10606,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625199,50597,,N,Intermediate,,BAO_0000218
10607,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625200,50597,,N,Intermediate,,BAO_0000218
10608,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625201,50597,,N,Intermediate,,BAO_0000218
10609,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625202,50597,,N,Intermediate,,BAO_0000218
10610,,1,Percentage recovery after 3h incubation with rat hapatocytes was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625203,50597,,N,Intermediate,,BAO_0000218
10611,,1,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625204,50597,,N,Intermediate,,BAO_0000218
10612,,1,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625205,50597,,N,Intermediate,,BAO_0000218
10613,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625206,50597,,N,Intermediate,,BAO_0000218
10614,,0,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,,,,,,1,,A,CHEMBL625207,22224,,U,Autocuration,,BAO_0000019
10615,,0,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,,,,,,1,,A,CHEMBL625208,22224,,U,Autocuration,,BAO_0000019
10616,,1,In vivo absorption in Caco-2 cell line monolayers was determined,Homo sapiens,,,,,495.0,1,9606.0,A,CHEMBL625209,50587,,N,Intermediate,,BAO_0000218
10617,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625210,22229,,U,Autocuration,,BAO_0000100
10618,,1,Area under curve was determine after peroral administration at 10 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625211,50597,,N,Intermediate,,BAO_0000218
10619,,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL625212,50797,,N,Intermediate,,BAO_0000218
10620,,1,Area under curve was determine after peroral administration at 160 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625213,50597,,N,Intermediate,,BAO_0000218
10621,,1,Area under curve was determine after peroral administration at 20 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625214,50597,,N,Intermediate,,BAO_0000218
10622,,1,Area under curve was determine after peroral administration at 50 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874542,50597,,N,Intermediate,,BAO_0000218
10623,,0,Calculated partition coefficient (clogP) (AlogP),,,,,,,1,,P,CHEMBL625215,22229,,U,Autocuration,,BAO_0000100
10624,,0,Activated partial thromboplastin time measured,,,,,,,1,,A,CHEMBL625216,22224,,U,Autocuration,,BAO_0000019
10625,,0,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,,,,,,1,,P,CHEMBL625217,22224,,U,Autocuration,,BAO_0000100
10626,,0,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,,,,,,1,,P,CHEMBL625218,22224,,U,Autocuration,,BAO_0000100
10627,,1,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL622864,50588,,N,Intermediate,,BAO_0000218
10628,,1,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622865,50597,,N,Intermediate,,BAO_0000218
10629,,1,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622866,50597,,N,Intermediate,,BAO_0000218
10630,,1,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL622867,50588,,N,Intermediate,,BAO_0000218
10631,,1,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Cavia porcellus,,,Plasma,1969.0,,1,10141.0,A,CHEMBL876808,50512,,N,Intermediate,,BAO_0000218
10632,,0,AUC in brain,,,,Brain,955.0,,1,,A,CHEMBL627725,22224,,U,Autocuration,,BAO_0000019
10633,,0,AUC in serum,,,,Serum,1977.0,,1,,A,CHEMBL627726,22224,,U,Autocuration,,BAO_0000019
10634,,0,AUC was determined,,,,Plasma,1969.0,,1,,A,CHEMBL627727,22224,,U,Autocuration,,BAO_0000019
10635,,0,AUC of the compound.,,,,Plasma,1969.0,,1,,A,CHEMBL627728,22224,,U,Autocuration,,BAO_0000019
10636,,0,AUC value (0-4 hr),,,,Plasma,1969.0,,1,,A,CHEMBL627729,22224,,U,Autocuration,,BAO_0000019
10637,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,,,Plasma,1969.0,,1,,A,CHEMBL627730,22224,,U,Autocuration,,BAO_0000019
10638,,0,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,,,Plasma,1969.0,,1,,A,CHEMBL627731,22224,,U,Autocuration,,BAO_0000019
10639,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,,,Plasma,1969.0,,1,,A,CHEMBL627732,22224,,U,Autocuration,,BAO_0000019
10640,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,,,Plasma,1969.0,,1,,A,CHEMBL627733,22224,,U,Autocuration,,BAO_0000019
10641,,1,AUC(area under curve) was determined after intravenous administration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627734,50597,,N,Intermediate,,BAO_0000218
10642,,1,AUC(area under curve) was determined after oral administration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627735,50597,,N,Intermediate,,BAO_0000218
10643,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Cavia porcellus,,,Plasma,1969.0,,1,10141.0,A,CHEMBL627736,50512,,N,Intermediate,,BAO_0000218
10644,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876809,50597,,N,Intermediate,,BAO_0000218
10645,,0,Area Under Curve after oral dosing of 100 uM/Kg,,,,,,,1,,A,CHEMBL627737,22224,,U,Autocuration,,BAO_0000019
10646,,0,Area Under Curve after oral dosing of 30 uM/Kg,,,,,,,1,,A,CHEMBL627738,22224,,U,Autocuration,,BAO_0000019
10647,,0,Area Under Curve was measured by ploting the graph between concentration verses time,,,,,,,1,,A,CHEMBL627739,22224,,U,Autocuration,,BAO_0000019
10648,,1,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626143,50588,,N,Intermediate,,BAO_0000218
10649,,0,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,Simiiformes,,,,,,1,314293.0,A,CHEMBL626144,22224,,U,Autocuration,,BAO_0000218
10650,,1,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626145,50592,,N,Intermediate,,BAO_0000218
10651,,1,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626146,50597,,N,Intermediate,,BAO_0000218
10652,,1,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626147,50597,,N,Intermediate,,BAO_0000218
10653,,0,Area under curve (AUC) was determined,,,,,,,1,,A,CHEMBL626148,22224,,U,Autocuration,,BAO_0000019
10654,,0,Area under curve (AUC) following ip administration at 1 mg/kg,,,,,,,1,,A,CHEMBL626149,22224,,U,Autocuration,,BAO_0000218
10655,,0,Area under curve (AUC) was determined; ND is Not determined,,,,,,,1,,A,CHEMBL626150,22224,,U,Autocuration,,BAO_0000019
10656,,1,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626151,50588,,N,Intermediate,,BAO_0000218
10657,,1,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626152,50588,,N,Intermediate,,BAO_0000218
10658,,1,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626153,50588,,N,Intermediate,,BAO_0000218
10659,,0,Area under curve (AUR) was determined,,,,,,,1,,A,CHEMBL626154,22224,,U,Autocuration,,BAO_0000019
10660,,0,Area under curve at 1 uM/dg administered intravenously,,,,,,,1,,A,CHEMBL626155,22224,,U,Autocuration,,BAO_0000019
10661,,0,Area under curve at 10 uM/dg administered perorally,,,,,,,1,,A,CHEMBL626156,22224,,U,Autocuration,,BAO_0000019
10662,,0,Area under curve at 2 uM/dg administered intravenously,,,,,,,1,,A,CHEMBL626157,22224,,U,Autocuration,,BAO_0000019
10663,,0,Area under curve at 20 uM/dg administered perorally,,,,,,,1,,A,CHEMBL626158,22224,,U,Autocuration,,BAO_0000019
10664,,1,Area under curve at a peroral dose of 3 mg/kg in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626159,50588,,N,Intermediate,,BAO_0000218
10665,,1,Area under curve at a peroral dose of 3 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626160,50597,,N,Intermediate,,BAO_0000218
10666,,1,Area under curve at an iv dose of 1 mg/kg in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626161,50588,,N,Intermediate,,BAO_0000218
10667,,1,Area under curve at an iv dose of 1 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626162,50597,,N,Intermediate,,BAO_0000218
10668,,0,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,,,,,,1,,A,CHEMBL626163,22224,,U,Autocuration,,BAO_0000019
10669,,0,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,,,,,,1,,A,CHEMBL626164,22224,,U,Autocuration,,BAO_0000019
10670,,1,Area under curve measured as conc vs time after intravenous administration to mice.,Mus musculus,,,,,,1,10090.0,A,CHEMBL626165,50594,,N,Intermediate,,BAO_0000218
10671,,1,Area under curve measured as conc vs time after peroral administration to mice.,Mus musculus,,,,,,1,10090.0,A,CHEMBL626166,50594,,N,Intermediate,,BAO_0000218
10672,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626167,50588,,N,Intermediate,,BAO_0000218
10673,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626168,50588,,N,Intermediate,,BAO_0000218
10674,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL877463,50588,,N,Intermediate,,BAO_0000218
10675,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626169,50588,,N,Intermediate,,BAO_0000218
10676,,1,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626170,50597,,N,Intermediate,,BAO_0000218
10677,,1,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626171,50597,,N,Intermediate,,BAO_0000218
10678,,1,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626172,50597,,N,Intermediate,,BAO_0000218
10679,,1,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626173,50597,,N,Intermediate,,BAO_0000218
10680,,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626174,50597,,N,Intermediate,,BAO_0000218
10681,,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626175,50597,,N,Intermediate,,BAO_0000218
10682,,1,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626176,50597,,N,Intermediate,,BAO_0000218
10683,,1,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626177,50597,,N,Intermediate,,BAO_0000218
10684,,1,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622499,50597,,N,Intermediate,,BAO_0000218
10685,,1,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622500,50597,,N,Intermediate,,BAO_0000218
10686,,1,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622501,50597,,N,Intermediate,,BAO_0000218
10687,,1,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622502,50597,,N,Intermediate,,BAO_0000218
10688,,1,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622503,50597,,N,Intermediate,,BAO_0000218
10689,,1,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL877614,50597,,N,Intermediate,,BAO_0000218
10690,,1,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624839,50597,,N,Intermediate,,BAO_0000218
10691,,1,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624840,50597,,N,Intermediate,,BAO_0000218
10692,,1,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624841,50597,,N,Intermediate,,BAO_0000218
10693,,1,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624842,50597,,N,Intermediate,,BAO_0000218
10694,,1,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624843,50597,,N,Intermediate,,BAO_0000218
10695,,1,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624844,50597,,N,Intermediate,,BAO_0000218
10696,,1,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624845,50597,,N,Intermediate,,BAO_0000218
10697,,1,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL621904,50597,,N,Intermediate,,BAO_0000218
10698,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621905,50597,,N,Intermediate,,BAO_0000218
10699,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL874382,50597,,N,Intermediate,,BAO_0000218
10700,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL621906,50597,,N,Intermediate,,BAO_0000218
10701,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL621907,50597,,N,Intermediate,,BAO_0000218
10702,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622096,50597,,N,Intermediate,,BAO_0000218
10703,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622097,50597,,N,Intermediate,,BAO_0000218
10704,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622098,50597,,N,Intermediate,,BAO_0000218
10705,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622099,50597,,N,Intermediate,,BAO_0000218
10706,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622100,50597,,N,Intermediate,,BAO_0000218
10707,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622101,50597,,N,Intermediate,,BAO_0000218
10708,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622102,50597,,N,Intermediate,,BAO_0000218
10709,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622103,50597,,N,Intermediate,,BAO_0000218
10710,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622104,50597,,N,Intermediate,,BAO_0000218
10711,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622105,50597,,N,Intermediate,,BAO_0000218
10712,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622106,50597,,N,Intermediate,,BAO_0000218
10713,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622107,50597,,N,Intermediate,,BAO_0000218
10714,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622108,50597,,N,Intermediate,,BAO_0000218
10715,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622109,50597,,N,Intermediate,,BAO_0000218
10716,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622110,50597,,N,Intermediate,,BAO_0000218
10717,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622111,50597,,N,Intermediate,,BAO_0000218
10718,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL874383,50597,,N,Intermediate,,BAO_0000218
10719,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL622112,50597,,N,Intermediate,,BAO_0000218
10720,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL622113,50597,,N,Intermediate,,BAO_0000218
10721,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL622114,50597,,N,Intermediate,,BAO_0000218
10722,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622115,50597,,N,Intermediate,,BAO_0000218
10723,,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622116,50597,,N,Intermediate,,BAO_0000218
10724,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622117,50597,,N,Intermediate,,BAO_0000218
10725,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622118,50597,,N,Intermediate,,BAO_0000218
10726,,1,Oral bioavailability in rats at 6 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622119,50597,,N,Intermediate,,BAO_0000218
10727,,1,Oral bioavailability in rat (dose 6 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622120,50597,,N,Intermediate,,BAO_0000218
10728,,1,Oral bioavailability in rats at 6 mg/kg dose; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622121,50597,,N,Intermediate,,BAO_0000218
10729,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622122,50597,,N,Intermediate,,BAO_0000218
10730,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622123,50597,,N,Intermediate,,BAO_0000218
10731,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622124,50597,,N,Intermediate,,BAO_0000218
10732,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622125,50597,,N,Intermediate,,BAO_0000218
10733,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622126,50597,,N,Intermediate,,BAO_0000218
10734,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620455,50597,,N,Intermediate,,BAO_0000218
10735,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620456,50597,,N,Intermediate,,BAO_0000218
10736,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620457,50597,,N,Intermediate,,BAO_0000218
10737,,1,Oral bioavailability was evaluated; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620458,50597,,N,Intermediate,,BAO_0000218
10738,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620459,50597,,N,Intermediate,,BAO_0000218
10739,,1,Oral bioavailability in rat by oral dosing,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620460,50597,,N,Intermediate,,BAO_0000218
10740,,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620461,50597,,N,Intermediate,,BAO_0000218
10741,,1,Oral bioavailability in rat (Sprague-Dawley),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620462,50597,,N,Intermediate,,BAO_0000218
10742,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620463,50597,,N,Intermediate,,BAO_0000218
10743,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620464,50597,,N,Intermediate,,BAO_0000218
10744,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620465,50597,,N,Intermediate,,BAO_0000218
10745,,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620466,50597,,N,Intermediate,,BAO_0000218
10746,,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620467,50597,,N,Intermediate,,BAO_0000218
10747,,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620468,50597,,N,Intermediate,,BAO_0000218
10748,,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620469,50597,,N,Intermediate,,BAO_0000218
10749,,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620470,50597,,N,Intermediate,,BAO_0000218
10750,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620471,50597,,N,Intermediate,,BAO_0000218
10751,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620472,50597,,N,Intermediate,,BAO_0000218
10752,,1,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620473,50597,,N,Intermediate,,BAO_0000218
10753,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620474,50597,,N,Intermediate,,BAO_0000218
10754,,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620475,50597,,N,Intermediate,,BAO_0000218
10755,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620476,50597,,N,Intermediate,,BAO_0000218
10756,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620477,50597,,N,Intermediate,,BAO_0000218
10757,,1,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620478,50597,,N,Intermediate,,BAO_0000218
10758,,1,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618768,50597,,N,Intermediate,,BAO_0000218
10759,,1,Oral bioavailability in rat after oral administration at 13 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618769,50597,,N,Intermediate,,BAO_0000218
10760,,1,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618770,50597,,N,Intermediate,,BAO_0000218
10761,,1,Oral bioavailability (dose 20 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618771,50597,,N,Intermediate,,BAO_0000218
10762,,1,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618772,50597,,N,Intermediate,,BAO_0000218
10763,,1,Oral bioavailability in rat at 10 mg/kg of the compound,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618773,50597,,N,Intermediate,,BAO_0000218
10764,,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875842,50597,,N,Intermediate,,BAO_0000218
10765,,1,Bioavailability in rat (dose 3 mg/kg i.v.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618774,50597,,N,Intermediate,,BAO_0000218
10766,,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618775,50597,,N,Intermediate,,BAO_0000218
10767,,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618776,50597,,N,Intermediate,,BAO_0000218
10768,,1,Percent bioavailability (F) in rats after iv administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618777,50597,,N,Intermediate,,BAO_0000218
10769,,1,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618778,50597,,N,Intermediate,,BAO_0000218
10770,,1,Bioavailability in rat (dose 5 uM/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618779,50597,,N,Intermediate,,BAO_0000218
10771,,1,Oral bioavailability,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618780,50597,,N,Intermediate,,BAO_0000218
10772,,1,Bioavailability in rat (dose 2 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618781,50597,,N,Intermediate,,BAO_0000218
10773,,1,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618782,50597,,N,Intermediate,,BAO_0000218
10774,,1,Oral bioavailability in rat (dose 20 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618783,50597,,N,Intermediate,,BAO_0000218
10775,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618784,50597,,N,Intermediate,,BAO_0000218
10776,,1,Percent oral bioavailability evaluated in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618785,50597,,N,Intermediate,,BAO_0000218
10777,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618786,50597,,N,Intermediate,,BAO_0000218
10778,,1,Percent oral bioavailability in rat; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618787,50597,,N,Intermediate,,BAO_0000218
10779,,1,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618788,50597,,N,Intermediate,,BAO_0000218
10780,,1,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618789,50597,,N,Intermediate,,BAO_0000218
10781,,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618790,50597,,N,Intermediate,,BAO_0000218
10782,,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618791,50597,,N,Intermediate,,BAO_0000218
10783,,1,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875843,50597,,N,Intermediate,,BAO_0000218
10784,,1,Oral bioavailability in rat (dose 20 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL618792,50597,,N,Intermediate,,BAO_0000218
10785,,1,Cmax at a dose of 30 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623395,50597,,N,Intermediate,,BAO_0000218
10786,,0,Cmax in monkeys at a dose of 1 mg/kg,Simiiformes,,,,,,1,314293.0,A,CHEMBL623396,22224,,U,Autocuration,,BAO_0000218
10787,,1,Cmax in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623397,50597,,N,Intermediate,,BAO_0000218
10788,,1,Cmax in rats at a dose of 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623398,50597,,N,Intermediate,,BAO_0000218
10789,,1,Cmax was measured in mice after an oral dose of 50 mg/kg.,Mus musculus,,,,,,1,10090.0,A,CHEMBL623399,50594,,N,Intermediate,,BAO_0000218
10790,,0,"Cmax value at a dose of 12.7 uM/kg, po",,,,,,,1,,A,CHEMBL623400,22224,,U,Autocuration,,BAO_0000218
10791,,0,"Cmax value at a dose of 6.3 uM/kg, iv",,,,,,,1,,A,CHEMBL623401,22224,,U,Autocuration,,BAO_0000218
10792,,0,"Cmax value at a dose of 7.1 uM/kg, iv",,,,,,,1,,A,CHEMBL623402,22224,,U,Autocuration,,BAO_0000218
10793,,0,Cmax value of compound was determined after 1 hr,,,,,,,1,,A,CHEMBL623403,22224,,U,Autocuration,,BAO_0000218
10794,,0,Cmax value of the compound,,,,,,,1,,A,CHEMBL623404,22224,,U,Autocuration,,BAO_0000218
10795,,1,Cmax value administered intraintestinal in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625997,50597,,N,Intermediate,,BAO_0000218
10796,,1,Cmax value administered perorally was determined in rat; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625998,50597,,N,Intermediate,,BAO_0000218
10797,,0,Cmax value at the dose of 2.3 mg/kg,,,,,,,1,,A,CHEMBL625999,22224,,U,Autocuration,,BAO_0000218
10798,,0,Cmax value at the dose of 5 mg/kg,,,,,,,1,,A,CHEMBL626000,22224,,U,Autocuration,,BAO_0000218
10799,,0,Cmax value in the period of 8 hr after dosing. ,,,,,,,1,,A,CHEMBL626001,22224,,U,Autocuration,,BAO_0000218
10800,,0,Cmax value at a oral dose of 20 mg/kg; Not tested,,,,,,,1,,A,CHEMBL626002,22224,,U,Autocuration,,BAO_0000218
10801,,0,Cmax value at a oral dose of 20 mg/kg,,,,,,,1,,A,CHEMBL626003,22224,,U,Autocuration,,BAO_0000218
10802,,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626004,50597,,N,Intermediate,,BAO_0000218
10803,,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL626005,50512,,N,Intermediate,,BAO_0000218
10804,,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626006,50597,,N,Intermediate,,BAO_0000218
10805,,1,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626007,50597,,N,Intermediate,,BAO_0000218
10806,,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL626008,50594,,N,Intermediate,,BAO_0000218
10807,,1,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Canis lupus familiaris,,,Liver,2107.0,,1,9615.0,A,CHEMBL626009,50588,,N,Intermediate,,BAO_0000218
10808,,1,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626010,50588,,N,Intermediate,,BAO_0000218
10809,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626011,50594,,N,Intermediate,,BAO_0000218
10810,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626012,50594,,N,Intermediate,,BAO_0000218
10811,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626013,50594,,N,Intermediate,,BAO_0000218
10812,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL626014,50594,,N,Intermediate,,BAO_0000218
10813,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL877496,50594,,N,Intermediate,,BAO_0000218
10814,,1,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,F,CHEMBL626015,50588,,N,Intermediate,,BAO_0000218
10815,,1,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,F,CHEMBL626016,50588,,N,Intermediate,,BAO_0000218
10816,,1,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,F,CHEMBL626017,50588,,N,Intermediate,,BAO_0000218
10817,,1,Bioavailability as maximal plasma concentration in dogs,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626018,50588,,N,Intermediate,,BAO_0000218
10818,,1,Bioavailability as maximal plasma concentration in dogs,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626692,50588,,N,Intermediate,,BAO_0000218
10819,,1,Bioavailability as maximal plasma concentration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626693,50597,,N,Intermediate,,BAO_0000218
10820,,0,Bioavailability as maximal plasma concentration in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626694,22224,,U,Autocuration,,BAO_0000218
10821,,1,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626695,50588,,N,Intermediate,,BAO_0000218
10822,,1,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626696,50588,,N,Intermediate,,BAO_0000218
10823,,1,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626697,50588,,N,Intermediate,,BAO_0000218
10824,,1,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626859,50588,,N,Intermediate,,BAO_0000218
10825,,1,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626860,50588,,N,Intermediate,,BAO_0000218
10826,,1,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL626861,50588,,N,Intermediate,,BAO_0000218
10827,,1,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626296,50597,,N,Intermediate,,BAO_0000218
10828,,0,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,,,,,,1,,A,CHEMBL626297,22224,,U,Autocuration,,BAO_0000218
10829,,0,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,,,Plasma,1969.0,,1,,A,CHEMBL626298,22224,,U,Autocuration,,BAO_0000218
10830,,1,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626299,50597,,N,Intermediate,,BAO_0000218
10831,,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626300,50597,,N,Intermediate,,BAO_0000218
10832,,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626301,50597,,N,Intermediate,,BAO_0000218
10833,,1,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626962,50597,,N,Intermediate,,BAO_0000218
10834,,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626963,50597,,N,Intermediate,,BAO_0000218
10835,,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626964,50597,,N,Intermediate,,BAO_0000218
10836,,1,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL626965,100710,,N,Intermediate,,BAO_0000218
10837,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL626966,50594,,N,Intermediate,,BAO_0000218
10838,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL626967,50594,,N,Intermediate,,BAO_0000218
10839,,1,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL626968,100710,,N,Intermediate,,BAO_0000218
10840,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626969,50597,,N,Intermediate,,BAO_0000218
10841,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627126,50597,,N,Intermediate,,BAO_0000218
10842,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631276,50597,,N,Intermediate,,BAO_0000218
10843,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631277,50597,,N,Intermediate,,BAO_0000218
10844,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631278,50597,,N,Intermediate,,BAO_0000218
10845,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL874457,50597,,N,Intermediate,,BAO_0000218
10846,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631279,50597,,N,Intermediate,,BAO_0000218
10847,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631280,50597,,N,Intermediate,,BAO_0000218
10848,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631281,50597,,N,Intermediate,,BAO_0000218
10849,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631968,50597,,N,Intermediate,,BAO_0000218
10850,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631969,50597,,N,Intermediate,,BAO_0000218
10851,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631970,50597,,N,Intermediate,,BAO_0000218
10852,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631971,50597,,N,Intermediate,,BAO_0000218
10853,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL631972,50597,,N,Intermediate,,BAO_0000218
10854,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630435,50597,,N,Intermediate,,BAO_0000218
10855,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630436,50597,,N,Intermediate,,BAO_0000218
10856,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630437,50597,,N,Intermediate,,BAO_0000218
10857,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630438,50597,,N,Intermediate,,BAO_0000218
10858,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630439,50597,,N,Intermediate,,BAO_0000218
10859,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630440,50597,,N,Intermediate,,BAO_0000218
10860,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630441,50597,,N,Intermediate,,BAO_0000218
10861,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630442,50597,,N,Intermediate,,BAO_0000218
10862,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625234,50597,,N,Intermediate,,BAO_0000218
10863,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625235,50597,,N,Intermediate,,BAO_0000218
10864,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625236,50597,,N,Intermediate,,BAO_0000218
10865,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625237,50597,,N,Intermediate,,BAO_0000218
10866,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626125,50597,,N,Intermediate,,BAO_0000218
10867,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626126,50597,,N,Intermediate,,BAO_0000218
10868,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626127,50597,,N,Intermediate,,BAO_0000218
10869,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626128,50597,,N,Intermediate,,BAO_0000218
10870,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626129,50597,,N,Intermediate,,BAO_0000218
10871,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626130,50597,,N,Intermediate,,BAO_0000218
10872,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626131,50597,,N,Intermediate,,BAO_0000218
10873,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626132,50597,,N,Intermediate,,BAO_0000218
10874,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626752,50597,,N,Intermediate,,BAO_0000218
10875,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626753,50597,,N,Intermediate,,BAO_0000218
10876,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626754,50597,,N,Intermediate,,BAO_0000218
10877,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626755,50597,,N,Intermediate,,BAO_0000218
10878,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626756,50597,,N,Intermediate,,BAO_0000218
10879,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626757,50597,,N,Intermediate,,BAO_0000218
10880,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626758,50597,,N,Intermediate,,BAO_0000218
10881,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626759,50597,,N,Intermediate,,BAO_0000218
10882,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626760,50597,,N,Intermediate,,BAO_0000218
10883,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626394,50588,,N,Intermediate,,BAO_0000218
10884,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626395,50588,,N,Intermediate,,BAO_0000218
10885,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626396,50588,,N,Intermediate,,BAO_0000218
10886,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626397,50588,,N,Intermediate,,BAO_0000218
10887,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626398,50588,,N,Intermediate,,BAO_0000218
10888,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626399,50588,,N,Intermediate,,BAO_0000218
10889,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874653,50597,,N,Intermediate,,BAO_0000218
10890,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626400,50597,,N,Intermediate,,BAO_0000218
10891,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626401,50597,,N,Intermediate,,BAO_0000218
10892,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626402,50597,,N,Intermediate,,BAO_0000218
10893,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626403,50597,,N,Intermediate,,BAO_0000218
10894,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626404,50597,,N,Intermediate,,BAO_0000218
10895,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626405,50597,,N,Intermediate,,BAO_0000218
10896,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625529,50597,,N,Intermediate,,BAO_0000218
10897,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625530,50597,,N,Intermediate,,BAO_0000218
10898,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625531,50597,,N,Intermediate,,BAO_0000218
10899,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625532,50597,,N,Intermediate,,BAO_0000218
10900,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625533,50597,,N,Intermediate,,BAO_0000218
10901,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875474,50597,,N,Intermediate,,BAO_0000218
10902,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625534,50597,,N,Intermediate,,BAO_0000218
10903,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625535,50597,,N,Intermediate,,BAO_0000218
10904,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625536,50597,,N,Intermediate,,BAO_0000218
10905,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625537,50597,,N,Intermediate,,BAO_0000218
10906,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625538,50597,,N,Intermediate,,BAO_0000218
10907,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625539,50597,,N,Intermediate,,BAO_0000218
10908,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625540,50597,,N,Intermediate,,BAO_0000218
10909,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625541,50597,,N,Intermediate,,BAO_0000218
10910,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625542,50597,,N,Intermediate,,BAO_0000218
10911,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625543,50597,,N,Intermediate,,BAO_0000218
10912,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625544,50597,,N,Intermediate,,BAO_0000218
10913,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625545,50588,,N,Intermediate,,BAO_0000218
10914,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625546,50588,,N,Intermediate,,BAO_0000218
10915,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625547,50588,,N,Intermediate,,BAO_0000218
10916,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625548,50588,,N,Intermediate,,BAO_0000218
10917,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625549,50588,,N,Intermediate,,BAO_0000218
10918,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625550,50588,,N,Intermediate,,BAO_0000218
10919,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625551,50588,,N,Intermediate,,BAO_0000218
10920,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL875475,50588,,N,Intermediate,,BAO_0000218
10921,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625552,50588,,N,Intermediate,,BAO_0000218
10922,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625553,50588,,N,Intermediate,,BAO_0000218
10923,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625554,50588,,N,Intermediate,,BAO_0000218
10924,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625555,50588,,N,Intermediate,,BAO_0000218
10925,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625556,50588,,N,Intermediate,,BAO_0000218
10926,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624986,50588,,N,Intermediate,,BAO_0000218
10927,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624987,50588,,N,Intermediate,,BAO_0000218
10928,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624988,50588,,N,Intermediate,,BAO_0000218
10929,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624989,50588,,N,Intermediate,,BAO_0000218
10930,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624990,50588,,N,Intermediate,,BAO_0000218
10931,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL874391,50588,,N,Intermediate,,BAO_0000218
10932,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624991,50588,,N,Intermediate,,BAO_0000218
10933,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624992,50588,,N,Intermediate,,BAO_0000218
10934,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624993,50588,,N,Intermediate,,BAO_0000218
10935,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624994,50588,,N,Intermediate,,BAO_0000218
10936,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624995,50588,,N,Intermediate,,BAO_0000218
10937,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624996,50588,,N,Intermediate,,BAO_0000218
10938,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624997,50588,,N,Intermediate,,BAO_0000218
10939,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624998,50588,,N,Intermediate,,BAO_0000218
10940,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624999,50588,,N,Intermediate,,BAO_0000218
10941,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL882955,50588,,N,Intermediate,,BAO_0000218
10942,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625000,50588,,N,Intermediate,,BAO_0000218
10943,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625001,50588,,N,Intermediate,,BAO_0000218
10944,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625089,50588,,N,Intermediate,,BAO_0000218
10945,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625090,50588,,N,Intermediate,,BAO_0000218
10946,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625091,50588,,N,Intermediate,,BAO_0000218
10947,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625092,50588,,N,Intermediate,,BAO_0000218
10948,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625093,50588,,N,Intermediate,,BAO_0000218
10949,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625094,50588,,N,Intermediate,,BAO_0000218
10950,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL625095,50588,,N,Intermediate,,BAO_0000218
10951,,1,Compound was evaluated for its bioavailability in the dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625096,50588,,N,Intermediate,,BAO_0000218
10952,,1,Compound was evaluated for its bioavailability in the rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625097,50597,,N,Intermediate,,BAO_0000218
10953,,0,Compound was evaluated for oral bioavailability,,,,,,,1,,A,CHEMBL882956,22224,,U,Autocuration,,BAO_0000218
10954,,1,Compound was evaluated for percentage of Oral bioavailability in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625098,50597,,N,Intermediate,,BAO_0000218
10955,,0,Bioavailability in guinea pig,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL625099,22224,,U,Autocuration,,BAO_0000218
10956,,1,Compound was evaluated for the oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625100,50597,,N,Intermediate,,BAO_0000218
10957,,1,Compound was evaluated for the oral bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625101,50588,,N,Intermediate,,BAO_0000218
10958,,1,Compound was evaluated for the oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874396,50597,,N,Intermediate,,BAO_0000218
10959,,0,Bioavailability in dog (dosed i.v.),Canis lupus familiaris,,,,,,1,9615.0,F,CHEMBL625102,22224,,U,Autocuration,,BAO_0000218
10960,,1,Compound was tested for in vivo bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625103,50588,,N,Intermediate,,BAO_0000218
10961,,1,Compound was tested for in vivo bioavailability in hamsters,Cricetinae,,,,,,1,10026.0,A,CHEMBL625104,100712,,N,Intermediate,,BAO_0000218
10962,,0,Compound was tested for in vivo bioavailability in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL625105,22224,,U,Autocuration,,BAO_0000218
10963,,1,Compound was tested for in vivo bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625106,50597,,N,Intermediate,,BAO_0000218
10964,,0,Oral bioavailability in mouse,Mus musculus,,,,,,1,10090.0,A,CHEMBL625107,22224,,U,Autocuration,,BAO_0000218
10965,,1,Compound was tested for percent of oral bioavailability in mice; 56-74,Mus musculus,,,,,,1,10090.0,A,CHEMBL625108,50594,,N,Intermediate,,BAO_0000218
10966,,0,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),Mus musculus,,,,,,1,10090.0,A,CHEMBL625109,22224,,U,Autocuration,,BAO_0000218
10967,,0,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL625110,22224,,U,Autocuration,,BAO_0000218
10968,,0,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL625111,22224,,U,Autocuration,,BAO_0000218
10969,,1,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),Mus musculus,,,,,,1,10090.0,A,CHEMBL625112,50594,,N,Intermediate,,BAO_0000218
10970,,1,Oral bioavailability in nude mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL875334,50594,,N,Intermediate,,BAO_0000218
10971,,0,Bioavailability in monkey (i.d. dosing),Primates,,,,,,1,9443.0,A,CHEMBL628617,22224,,U,Autocuration,,BAO_0000218
10972,,0,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628618,22224,,U,Autocuration,,BAO_0000218
10973,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,,,,,,1,,A,CHEMBL628619,22224,,U,Autocuration,,BAO_0000218
10974,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,,,,,,1,,A,CHEMBL628620,22224,,U,Autocuration,,BAO_0000218
10975,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL628621,100710,,N,Intermediate,,BAO_0000218
10976,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL628622,100710,,N,Intermediate,,BAO_0000218
10977,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL628623,100710,,N,Intermediate,,BAO_0000218
10978,,1,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL628624,100710,,N,Intermediate,,BAO_0000218
10979,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL628625,50594,,N,Intermediate,,BAO_0000218
10980,,1,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL628626,100710,,N,Intermediate,,BAO_0000218
10981,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627041,50594,,N,Intermediate,,BAO_0000218
10982,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627042,50594,,N,Intermediate,,BAO_0000218
10983,,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627043,50594,,N,Intermediate,,BAO_0000218
10984,,0,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,,,Plasma,1969.0,,1,,A,CHEMBL627044,22224,,U,Autocuration,,BAO_0000218
10985,,1,Cmax in mouse plasma,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL627045,50594,,N,Intermediate,,BAO_0000218
10986,,0,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,,,Plasma,1969.0,,1,,A,CHEMBL627046,22224,,U,Autocuration,,BAO_0000218
10987,,1,Maximal plasma concentration in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627047,50597,,N,Intermediate,,BAO_0000218
10988,,1,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627048,50597,,N,Intermediate,,BAO_0000218
10989,,1,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627049,50597,,N,Intermediate,,BAO_0000218
10990,,1,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627050,50597,,N,Intermediate,,BAO_0000218
10991,,1,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627051,50597,,N,Intermediate,,BAO_0000218
10992,,1,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627052,50597,,N,Intermediate,,BAO_0000218
10993,,1,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627053,50597,,N,Intermediate,,BAO_0000218
10994,,1,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627054,50597,,N,Intermediate,,BAO_0000218
10995,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627055,50594,,N,Intermediate,,BAO_0000218
10996,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627056,50594,,N,Intermediate,,BAO_0000218
10997,,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Mus musculus,,,,,,1,10090.0,A,CHEMBL627057,50594,,N,Intermediate,,BAO_0000218
10998,,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL627058,50594,,N,Intermediate,,BAO_0000218
10999,,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL626211,50594,,N,Intermediate,,BAO_0000218
11000,,0,Maximum Concentration of the compound.,,,,,,,1,,A,CHEMBL626212,22224,,U,Autocuration,,BAO_0000218
11001,,1,Maximum Concentration was measured after iv administration into Beagle dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626213,50588,,N,Intermediate,,BAO_0000218
11002,,1,Maximum Concentration was measured after iv administration into Beagle dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626214,50588,,N,Intermediate,,BAO_0000218
11003,,1,Maximum Concentration was measured after po administration into Beagle dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626215,50588,,N,Intermediate,,BAO_0000218
11004,,1,Maximum Concentration was measured after po administration into Beagle dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626216,50588,,N,Intermediate,,BAO_0000218
11005,,0,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,,,Blood,178.0,,1,,A,CHEMBL626217,22224,,U,Autocuration,,BAO_0000218
11006,,0,Maximum blood level reached after an iv dose of 12.2 uM/kg,,,,Blood,178.0,,1,,A,CHEMBL626218,22224,,U,Autocuration,,BAO_0000218
11007,,0,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,,,Blood,178.0,,1,,A,CHEMBL626219,22224,,U,Autocuration,,BAO_0000218
11008,,0,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,,,Blood,178.0,,1,,A,CHEMBL626220,22224,,U,Autocuration,,BAO_0000218
11009,,0,Maximum blood level reached after an oral dose of 5.0 mg/kg,,,,Blood,178.0,,1,,A,CHEMBL626221,22224,,U,Autocuration,,BAO_0000218
11010,,0,Maximum blood level reached at dose of 10.6 uM/kg orally,,,,Blood,178.0,,1,,A,CHEMBL626222,22224,,U,Autocuration,,BAO_0000218
11011,,1,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL626223,50512,,N,Intermediate,,BAO_0000218
11012,,1,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL626224,50512,,N,Intermediate,,BAO_0000218
11013,,1,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL626225,50597,,N,Intermediate,,BAO_0000218
11014,,1,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL626226,50597,,N,Intermediate,,BAO_0000218
11015,,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL626227,50597,,N,Intermediate,,BAO_0000218
11016,,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL626228,50597,,N,Intermediate,,BAO_0000218
11017,,1,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626229,50597,,N,Intermediate,,BAO_0000218
11018,,1,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626921,50597,,N,Intermediate,,BAO_0000218
11019,,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876793,50597,,N,Intermediate,,BAO_0000218
11020,,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625309,50597,,N,Intermediate,,BAO_0000218
11021,,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Bacillus subtilis,,,,,,1,1423.0,A,CHEMBL625310,50278,,N,Intermediate,,BAO_0000218
11022,,0,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,Simiiformes,,,,,,1,314293.0,A,CHEMBL625311,22224,,U,Autocuration,,BAO_0000218
11023,,1,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625312,50597,,N,Intermediate,,BAO_0000218
11024,,0,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,,,,,,1,,A,CHEMBL625313,22224,,U,Autocuration,,BAO_0000218
11025,,1,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL625314,50594,,N,Intermediate,,BAO_0000218
11026,,1,Maximum concentration in male rats after iv administration of 20 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625315,50597,,N,Intermediate,,BAO_0000218
11027,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625316,50597,,N,Intermediate,,BAO_0000218
11028,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625317,50597,,N,Intermediate,,BAO_0000218
11029,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625318,50597,,N,Intermediate,,BAO_0000218
11030,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625319,50597,,N,Intermediate,,BAO_0000218
11031,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625320,50597,,N,Intermediate,,BAO_0000218
11032,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625321,50597,,N,Intermediate,,BAO_0000218
11033,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625322,50597,,N,Intermediate,,BAO_0000218
11034,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL876801,50597,,N,Intermediate,,BAO_0000218
11035,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625323,50597,,N,Intermediate,,BAO_0000218
11036,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625324,50597,,N,Intermediate,,BAO_0000218
11037,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625325,50597,,N,Intermediate,,BAO_0000218
11038,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625326,50597,,N,Intermediate,,BAO_0000218
11039,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625327,50597,,N,Intermediate,,BAO_0000218
11040,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625328,50597,,N,Intermediate,,BAO_0000218
11041,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625329,50597,,N,Intermediate,,BAO_0000218
11042,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625330,50597,,N,Intermediate,,BAO_0000218
11043,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627774,50597,,N,Intermediate,,BAO_0000218
11044,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627775,50597,,N,Intermediate,,BAO_0000218
11045,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627949,50597,,N,Intermediate,,BAO_0000218
11046,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627950,50597,,N,Intermediate,,BAO_0000218
11047,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627951,50597,,N,Intermediate,,BAO_0000218
11048,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627952,50597,,N,Intermediate,,BAO_0000218
11049,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627953,50597,,N,Intermediate,,BAO_0000218
11050,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627954,50597,,N,Intermediate,,BAO_0000218
11051,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627955,50597,,N,Intermediate,,BAO_0000218
11052,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627956,50597,,N,Intermediate,,BAO_0000218
11053,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL876802,50597,,N,Intermediate,,BAO_0000218
11054,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627957,50597,,N,Intermediate,,BAO_0000218
11055,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627958,50597,,N,Intermediate,,BAO_0000218
11056,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627959,50597,,N,Intermediate,,BAO_0000218
11057,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627960,50597,,N,Intermediate,,BAO_0000218
11058,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627961,50597,,N,Intermediate,,BAO_0000218
11059,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627962,50597,,N,Intermediate,,BAO_0000218
11060,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627963,50597,,N,Intermediate,,BAO_0000218
11061,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624759,50597,,N,Intermediate,,BAO_0000218
11062,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624760,50597,,N,Intermediate,,BAO_0000218
11063,,1,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624761,50597,,N,Intermediate,,BAO_0000218
11064,,1,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877607,50597,,N,Intermediate,,BAO_0000218
11065,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624762,50597,,N,Intermediate,,BAO_0000218
11066,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624763,50597,,N,Intermediate,,BAO_0000218
11067,,1,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624764,50597,,N,Intermediate,,BAO_0000218
11068,,1,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624765,50597,,N,Intermediate,,BAO_0000218
11069,,1,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624766,50597,,N,Intermediate,,BAO_0000218
11070,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624767,50588,,N,Intermediate,,BAO_0000218
11071,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624768,50588,,N,Intermediate,,BAO_0000218
11072,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624769,50588,,N,Intermediate,,BAO_0000218
11073,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624770,50588,,N,Intermediate,,BAO_0000218
11074,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624771,50588,,N,Intermediate,,BAO_0000218
11075,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624772,50588,,N,Intermediate,,BAO_0000218
11076,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624773,50597,,N,Intermediate,,BAO_0000218
11077,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624774,50597,,N,Intermediate,,BAO_0000218
11078,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624775,50597,,N,Intermediate,,BAO_0000218
11079,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624776,50597,,N,Intermediate,,BAO_0000218
11080,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624777,50597,,N,Intermediate,,BAO_0000218
11081,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624778,50597,,N,Intermediate,,BAO_0000218
11082,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624779,50597,,N,Intermediate,,BAO_0000218
11083,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624780,50597,,N,Intermediate,,BAO_0000218
11084,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624781,50597,,N,Intermediate,,BAO_0000218
11085,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877608,50597,,N,Intermediate,,BAO_0000218
11086,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624782,50597,,N,Intermediate,,BAO_0000218
11087,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624783,50597,,N,Intermediate,,BAO_0000218
11088,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624784,50597,,N,Intermediate,,BAO_0000218
11089,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624785,50597,,N,Intermediate,,BAO_0000218
11090,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624786,50597,,N,Intermediate,,BAO_0000218
11091,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624787,50597,,N,Intermediate,,BAO_0000218
11092,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628676,50597,,N,Intermediate,,BAO_0000218
11093,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621842,50597,,N,Intermediate,,BAO_0000218
11094,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL621843,50597,,N,Intermediate,,BAO_0000218
11095,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623873,50597,,N,Intermediate,,BAO_0000218
11096,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623874,50597,,N,Intermediate,,BAO_0000218
11097,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623875,50597,,N,Intermediate,,BAO_0000218
11098,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623876,50597,,N,Intermediate,,BAO_0000218
11099,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623877,50588,,N,Intermediate,,BAO_0000218
11100,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623878,50588,,N,Intermediate,,BAO_0000218
11101,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623879,50588,,N,Intermediate,,BAO_0000218
11102,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623880,50588,,N,Intermediate,,BAO_0000218
11103,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623881,50588,,N,Intermediate,,BAO_0000218
11104,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623957,50588,,N,Intermediate,,BAO_0000218
11105,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623958,50588,,N,Intermediate,,BAO_0000218
11106,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623959,50588,,N,Intermediate,,BAO_0000218
11107,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623960,50588,,N,Intermediate,,BAO_0000218
11108,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623961,50588,,N,Intermediate,,BAO_0000218
11109,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623962,50588,,N,Intermediate,,BAO_0000218
11110,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624676,50588,,N,Intermediate,,BAO_0000218
11111,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624677,50588,,N,Intermediate,,BAO_0000218
11112,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624678,50588,,N,Intermediate,,BAO_0000218
11113,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624679,50588,,N,Intermediate,,BAO_0000218
11114,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624680,50588,,N,Intermediate,,BAO_0000218
11115,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,,,,,,1,,A,CHEMBL624849,22224,,U,Autocuration,,BAO_0000218
11116,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,,,,,,1,,A,CHEMBL624850,22224,,U,Autocuration,,BAO_0000218
11117,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,,,,,,1,,A,CHEMBL874399,22224,,U,Autocuration,,BAO_0000218
11118,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,,,,,,1,,A,CHEMBL624851,22224,,U,Autocuration,,BAO_0000218
11119,,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,,,,,,1,,A,CHEMBL624852,22224,,U,Autocuration,,BAO_0000218
11120,,0,Oral bioavailability in rat (dose 10 mg/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624853,22224,,U,Autocuration,,BAO_0000218
11121,,0,Oral bioavailability in rat (Sprague-Dawley),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624854,22224,,U,Autocuration,,BAO_0000218
11122,,0,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624855,22224,,U,Autocuration,,BAO_0000218
11123,,0,Oral bioavailability in rats was determined in vivo,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624856,22224,,U,Autocuration,,BAO_0000218
11124,,0,Oral bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL882957,22224,,U,Autocuration,,BAO_0000218
11125,,0,Oral bioavailability of compound in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL624857,22224,,U,Autocuration,,BAO_0000218
11126,,1,Oral bioavailability of compound in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622202,50597,,N,Intermediate,,BAO_0000218
11127,,0,Bioavailability in rat of PMEA prodrug,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622203,22224,,U,Autocuration,,BAO_0000218
11128,,1,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625522,50597,,N,Intermediate,,BAO_0000218
11129,,0,Serum conc at 3 hours following 25 mg/kg dose,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL622868,22224,,U,Autocuration,,BAO_0000218
11130,,0,Urine conc 0-5 hours following 25 mg/kg dose,Macaca mulatta,,,Urine,1088.0,,1,9544.0,A,CHEMBL622869,22224,,U,Autocuration,,BAO_0000218
11131,,0,Urine conc 0-24 hours following 25 mg/kg dose,Macaca mulatta,,,Urine,1088.0,,1,9544.0,A,CHEMBL622870,22224,,U,Autocuration,,BAO_0000218
11132,,0,Oral bioavailability in African green monkeys; 20-25,Chlorocebus aethiops,,,,,,1,9534.0,A,CHEMBL622871,22224,,U,Autocuration,,BAO_0000218
11133,,1,Oral bioavailability in cynomolgus monkey.,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL620560,100710,,N,Intermediate,,BAO_0000218
11134,,0,Oral bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL620561,22224,,U,Autocuration,,BAO_0000218
11135,,1,Oral bioavailability in dog at 10 mg/kg oral dose,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL620562,50588,,N,Intermediate,,BAO_0000218
11136,,1,Oral bioavailability in hamster at 10 mg/kg oral dose,Cricetinae,,,,,,1,10026.0,A,CHEMBL620563,100712,,N,Intermediate,,BAO_0000218
11137,,1,Oral bioavailability in rat at 10 mg/kg oral dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620564,50597,,N,Intermediate,,BAO_0000218
11138,,0,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL872265,22224,,U,Autocuration,,BAO_0000218
11139,,0,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620565,22224,,U,Autocuration,,BAO_0000218
11140,,0,Oral bioavailability,Eutheria,,,,,,1,9347.0,A,CHEMBL620566,22224,,U,Autocuration,,BAO_0000218
11141,,0,Oral bioavailability was determined; range 49-102%,,,,,,,1,,A,CHEMBL620567,22224,,U,Autocuration,,BAO_0000218
11142,,1,Oral bioavailability was determined in dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL620568,50588,,N,Intermediate,,BAO_0000218
11143,,0,Oral bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620569,22224,,U,Autocuration,,BAO_0000218
11144,,0,Oral bioavailability,Eutheria,,,,,,1,9347.0,A,CHEMBL620570,22224,,U,Autocuration,,BAO_0000218
11145,,0,Oral bioavailability was determined; Not orally available,,,,,,,1,,A,CHEMBL620571,22224,,U,Autocuration,,BAO_0000218
11146,,1,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),Mus musculus,,,,,,1,10090.0,A,CHEMBL620572,50594,,N,Intermediate,,BAO_0000218
11147,,0,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),Mus musculus,,,,,,1,10090.0,A,CHEMBL620573,22224,,U,Autocuration,,BAO_0000218
11148,,0,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,Mus musculus,,,,,,1,10090.0,A,CHEMBL620574,22224,,U,Autocuration,,BAO_0000218
11149,,0,Oral bioavailability in Rhesus monkey,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL620575,22224,,U,Autocuration,,BAO_0000218
11150,,0,Oral bioavailability in dog (female mongrel),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL620576,22224,,U,Autocuration,,BAO_0000218
11151,,0,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,,,,,,1,,A,CHEMBL875846,22224,,U,Autocuration,,BAO_0000218
11152,,0,Oral bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL620577,22224,,U,Autocuration,,BAO_0000218
11153,,0,Percentage Bioavailability was evaluated.,,,,,,,1,,A,CHEMBL620578,22224,,U,Autocuration,,BAO_0000218
11154,,0,Bioavailability in rat administered i.d.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL620579,22224,,U,Autocuration,,BAO_0000218
11155,,0,Bioavailability,Eutheria,,,,,,1,9347.0,A,CHEMBL621248,22224,,U,Autocuration,,BAO_0000218
11156,,0,Bioavailability in dog (male Beagle) i.v. administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625390,22224,,U,Autocuration,,BAO_0000218
11157,,0,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625391,22224,,U,Autocuration,,BAO_0000218
11158,,0,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),Primates,,,,,,1,9443.0,A,CHEMBL872266,22224,,U,Autocuration,,BAO_0000218
11159,,0,Oral bioavailability in rat (Sprague-Dawley) (male),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625392,22224,,U,Autocuration,,BAO_0000218
11160,,1,The oral bioavailability was measured on rats after oral administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625393,50597,,N,Intermediate,,BAO_0000218
11161,,1,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625394,50597,,N,Intermediate,,BAO_0000218
11162,,1,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL625395,50797,,N,Intermediate,,BAO_0000218
11163,,0,Bioavailability in rat (dose 10 mg/kg i.d.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625396,22224,,U,Autocuration,,BAO_0000218
11164,,0,Bioavailability in dog (male Beagle) i.v. administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625397,22224,,U,Autocuration,,BAO_0000218
11165,,1,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL625398,50594,,N,Intermediate,,BAO_0000218
11166,,1,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL625399,50594,,N,Intermediate,,BAO_0000218
11167,,1,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Cerebellum,2037.0,,1,10090.0,A,CHEMBL626074,50594,,N,Intermediate,,BAO_0000218
11168,,1,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL626075,50594,,N,Intermediate,,BAO_0000218
11169,,1,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626076,50597,,N,Intermediate,,BAO_0000218
11170,,1,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL626077,50797,,N,Intermediate,,BAO_0000218
11171,,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626078,50597,,N,Intermediate,,BAO_0000218
11172,,0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,,,Blood,178.0,,1,,A,CHEMBL625846,22224,,U,Autocuration,,BAO_0000218
11173,,0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,,,Blood,178.0,,1,,A,CHEMBL625847,22224,,U,Autocuration,,BAO_0000218
11174,,1,Maximum concentration observed in rats at an oral dose of 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625848,50597,,N,Expert,,BAO_0000218
11175,,1,Maximum concentration of compound in plasma administered orally to rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625849,50597,,N,Intermediate,,BAO_0000218
11176,,1,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626023,50588,,N,Intermediate,,BAO_0000218
11177,,1,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626024,50588,,N,Intermediate,,BAO_0000218
11178,,1,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626025,50588,,N,Intermediate,,BAO_0000218
11179,,0,Maximum concentration after 10 mg/kg by oral administration,,,,,,,1,,A,CHEMBL626026,22224,,U,Autocuration,,BAO_0000218
11180,,0,Maximum concentration at a dose of 1.5 mg/kg,,,,,,,1,,A,CHEMBL626027,22224,,U,Autocuration,,BAO_0000218
11181,,0,Maximum concentration at a dose of 2.0 mg/kg,,,,,,,1,,A,CHEMBL626028,22224,,U,Autocuration,,BAO_0000218
11182,,1,Maximum concentration in dog plasma,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626029,50588,,N,Intermediate,,BAO_0000218
11183,,0,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,,,Plasma,1969.0,,1,,A,CHEMBL626030,22224,,U,Autocuration,,BAO_0000218
11184,,0,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,,,Plasma,1969.0,,1,,A,CHEMBL626031,22224,,U,Autocuration,,BAO_0000218
11185,,0,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,,,Plasma,1969.0,,1,,A,CHEMBL626032,22224,,U,Autocuration,,BAO_0000218
11186,,0,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,,,Plasma,1969.0,,1,,A,CHEMBL626033,22224,,U,Autocuration,,BAO_0000218
11187,,0,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,,,Plasma,1969.0,,1,,A,CHEMBL626034,22224,,U,Autocuration,,BAO_0000218
11188,,1,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626035,50588,,N,Intermediate,,BAO_0000218
11189,,0,Maximum concentration in plasma at Tmax,,,,Plasma,1969.0,,1,,A,CHEMBL626036,22224,,U,Autocuration,,BAO_0000218
11190,,1,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626037,50588,,N,Expert,,BAO_0000218
11191,,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Cricetinae,,,Plasma,1969.0,,1,10026.0,A,CHEMBL626038,100712,,N,Intermediate,,BAO_0000218
11192,,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626039,50597,,N,Intermediate,,BAO_0000218
11193,,1,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626040,50597,,N,Intermediate,,BAO_0000218
11194,,1,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL626041,50592,,N,Intermediate,,BAO_0000218
11195,,0,Maximum concentration was calculated,,,,,,,1,,A,CHEMBL626042,22224,,U,Autocuration,,BAO_0000218
11196,,0,Maximum concentration was calculated.,,,,,,,1,,A,CHEMBL626043,22224,,U,Autocuration,,BAO_0000218
11197,,0,Maximum concentration at a peroral dose of 10 mg/kg,,,,,,,1,,A,CHEMBL626044,22224,,U,Autocuration,,BAO_0000218
11198,,0,Maximum concentration of the drug at 10 uM/dg administered perorally,,,,,,,1,,A,CHEMBL626045,22224,,U,Autocuration,,BAO_0000218
11199,,0,Maximum concentration of the drug at 2 uM/dg administered intravenously,,,,,,,1,,A,CHEMBL626046,22224,,U,Autocuration,,BAO_0000218
11200,,1,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626047,50588,,N,Intermediate,,BAO_0000218
11201,,1,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Cricetinae,,,Plasma,1969.0,,1,10026.0,A,CHEMBL626048,100712,,N,Intermediate,,BAO_0000218
11202,,1,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626049,50597,,N,Intermediate,,BAO_0000218
11203,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626050,50597,,N,Intermediate,,BAO_0000218
11204,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL874541,50588,,N,Intermediate,,BAO_0000218
11205,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Cricetinae,,,Plasma,1969.0,,1,10026.0,A,CHEMBL622826,100712,,N,Intermediate,,BAO_0000218
11206,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Cricetinae,,,Plasma,1969.0,,1,10026.0,A,CHEMBL622827,100712,,N,Intermediate,,BAO_0000218
11207,,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622828,50597,,N,Intermediate,,BAO_0000218
11208,,1,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622829,50597,,N,Intermediate,,BAO_0000218
11209,,1,Maximum concentration reached following intravenous administration in male rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876806,50597,,N,Intermediate,,BAO_0000218
11210,,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622830,50588,,N,Intermediate,,BAO_0000218
11211,,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622831,50597,,N,Intermediate,,BAO_0000218
11212,,1,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626794,50588,,N,Intermediate,,BAO_0000218
11213,,1,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626795,50597,,N,Intermediate,,BAO_0000218
11214,,1,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626796,50597,,N,Intermediate,,BAO_0000218
11215,,1,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626797,50597,,N,Intermediate,,BAO_0000218
11216,,1,Maximum drug concentration is determined after oral dosing in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626798,50597,,N,Intermediate,,BAO_0000218
11217,,1,Maximum observed concentration in oral (5 mg/kg) fasted dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626799,50588,,N,Intermediate,,BAO_0000218
11218,,1,Maximum observed concentration in oral (5 mg/kg) fed dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626800,50588,,N,Intermediate,,BAO_0000218
11219,,0,Maximum plasma concentration,,,,Plasma,1969.0,,1,,A,CHEMBL626801,22224,,U,Autocuration,,BAO_0000218
11220,,1,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876816,50597,,N,Intermediate,,BAO_0000218
11221,,1,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626802,50597,,N,Intermediate,,BAO_0000218
11222,,1,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626803,50588,,N,Intermediate,,BAO_0000218
11223,,0,Maximum plasma concentration following oral administration of 30 umol/kg,,,,Plasma,1969.0,,1,,A,CHEMBL626804,22224,,U,Autocuration,,BAO_0000218
11224,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626805,50597,,N,Intermediate,,BAO_0000218
11225,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626309,50597,,N,Intermediate,,BAO_0000218
11226,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626310,50597,,N,Intermediate,,BAO_0000218
11227,,1,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626311,50597,,N,Intermediate,,BAO_0000218
11228,,1,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626312,50597,,N,Intermediate,,BAO_0000218
11229,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626313,50597,,N,Intermediate,,BAO_0000218
11230,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626314,50597,,N,Intermediate,,BAO_0000218
11231,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626315,50597,,N,Intermediate,,BAO_0000218
11232,,1,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626316,50597,,N,Intermediate,,BAO_0000218
11233,,1,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626317,50597,,N,Intermediate,,BAO_0000218
11234,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626318,50597,,N,Intermediate,,BAO_0000218
11235,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626319,50597,,N,Intermediate,,BAO_0000218
11236,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626320,50597,,N,Intermediate,,BAO_0000218
11237,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875053,50597,,N,Intermediate,,BAO_0000218
11238,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626321,50597,,N,Intermediate,,BAO_0000218
11239,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626322,50597,,N,Intermediate,,BAO_0000218
11240,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626323,50597,,N,Intermediate,,BAO_0000218
11241,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626324,50597,,N,Intermediate,,BAO_0000218
11242,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626325,50597,,N,Intermediate,,BAO_0000218
11243,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626326,50597,,N,Intermediate,,BAO_0000218
11244,,1,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626327,50597,,N,Intermediate,,BAO_0000218
11245,,1,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626328,50597,,N,Intermediate,,BAO_0000218
11246,,1,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626329,50597,,N,Intermediate,,BAO_0000218
11247,,1,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626330,50597,,N,Intermediate,,BAO_0000218
11248,,1,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626331,50597,,N,Intermediate,,BAO_0000218
11249,,1,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626332,50597,,N,Intermediate,,BAO_0000218
11250,,1,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626333,50597,,N,Intermediate,,BAO_0000218
11251,,1,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626334,50597,,N,Intermediate,,BAO_0000218
11252,,1,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626335,50597,,N,Intermediate,,BAO_0000218
11253,,1,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624798,50597,,N,Intermediate,,BAO_0000218
11254,,1,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624799,50597,,N,Intermediate,,BAO_0000218
11255,,1,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624800,50597,,N,Intermediate,,BAO_0000218
11256,,1,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624801,50597,,N,Intermediate,,BAO_0000218
11257,,1,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624802,50597,,N,Intermediate,,BAO_0000218
11258,,1,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624803,50597,,N,Intermediate,,BAO_0000218
11259,,1,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624804,50597,,N,Intermediate,,BAO_0000218
11260,,1,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624805,50597,,N,Intermediate,,BAO_0000218
11261,,1,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL624806,50597,,N,Intermediate,,BAO_0000218
11262,,1,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624807,50597,,N,Intermediate,,BAO_0000218
11263,,1,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624808,50597,,N,Intermediate,,BAO_0000218
11264,,1,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624809,50597,,N,Intermediate,,BAO_0000218
11265,,1,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624810,50597,,N,Intermediate,,BAO_0000218
11266,,1,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877618,50597,,N,Intermediate,,BAO_0000218
11267,,1,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624811,50597,,N,Intermediate,,BAO_0000218
11268,,1,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624812,50597,,N,Intermediate,,BAO_0000218
11269,,1,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624813,50597,,N,Intermediate,,BAO_0000218
11270,,1,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624814,50597,,N,Intermediate,,BAO_0000218
11271,,1,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624815,50597,,N,Intermediate,,BAO_0000218
11272,,1,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624816,50597,,N,Intermediate,,BAO_0000218
11273,,1,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624817,50597,,N,Intermediate,,BAO_0000218
11274,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624818,50588,,N,Intermediate,,BAO_0000218
11275,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624819,50588,,N,Intermediate,,BAO_0000218
11276,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624820,50588,,N,Intermediate,,BAO_0000218
11277,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624821,50588,,N,Intermediate,,BAO_0000218
11278,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624822,50588,,N,Intermediate,,BAO_0000218
11279,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624823,50588,,N,Intermediate,,BAO_0000218
11280,,1,Observed diffusion coefficient in organic solvent for Escherichia coli,Escherichia coli,,,,,,1,562.0,A,CHEMBL624824,50212,,N,Intermediate,,BAO_0000218
11281,,1,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624825,50597,,N,Intermediate,,BAO_0000218
11282,,1,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624826,50597,,N,Intermediate,,BAO_0000218
11283,,1,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,Cardiac atrium,2081.0,,1,10116.0,A,CHEMBL876817,50597,,N,Intermediate,,BAO_0000218
11284,,1,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,Cardiac atrium,2081.0,,1,10116.0,A,CHEMBL624827,50597,,N,Intermediate,,BAO_0000218
11285,,1,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624828,50597,,N,Intermediate,,BAO_0000218
11286,,1,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624829,50597,,N,Intermediate,,BAO_0000218
11287,,1,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624830,50597,,N,Intermediate,,BAO_0000218
11288,,1,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624831,50597,,N,Intermediate,,BAO_0000218
11289,,1,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,Cardiac atrium,2081.0,,1,10116.0,A,CHEMBL624832,50597,,N,Intermediate,,BAO_0000218
11290,,1,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,Cardiac atrium,2081.0,,1,10116.0,A,CHEMBL624833,50597,,N,Intermediate,,BAO_0000218
11291,,1,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624834,50597,,N,Intermediate,,BAO_0000218
11292,,1,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624835,50597,,N,Intermediate,,BAO_0000218
11293,,1,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL624836,50597,,N,Intermediate,,BAO_0000218
11294,,1,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL624837,50597,,N,Intermediate,,BAO_0000218
11295,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624838,50597,,N,Intermediate,,BAO_0000218
11296,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622188,50597,,N,Intermediate,,BAO_0000218
11297,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622189,50597,,N,Intermediate,,BAO_0000218
11298,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622190,50597,,N,Intermediate,,BAO_0000218
11299,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625170,50597,,N,Intermediate,,BAO_0000218
11300,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625171,50597,,N,Intermediate,,BAO_0000218
11301,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625172,50597,,N,Intermediate,,BAO_0000218
11302,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625173,50597,,N,Intermediate,,BAO_0000218
11303,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625174,50597,,N,Intermediate,,BAO_0000218
11304,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625175,50597,,N,Intermediate,,BAO_0000218
11305,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625176,50597,,N,Intermediate,,BAO_0000218
11306,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625177,50597,,N,Intermediate,,BAO_0000218
11307,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625178,50597,,N,Intermediate,,BAO_0000218
11308,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625179,50597,,N,Intermediate,,BAO_0000218
11309,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625180,50597,,N,Intermediate,,BAO_0000218
11310,,0,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,,,,,,1,,A,CHEMBL625181,22224,,U,Autocuration,,BAO_0000218
11311,,1,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL625182,50594,,N,Intermediate,,BAO_0000218
11312,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625183,50597,,N,Intermediate,,BAO_0000218
11313,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875848,50597,,N,Intermediate,,BAO_0000218
11314,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622260,50597,,N,Intermediate,,BAO_0000218
11315,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622261,50597,,N,Intermediate,,BAO_0000218
11316,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622262,50597,,N,Intermediate,,BAO_0000218
11317,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622263,50597,,N,Intermediate,,BAO_0000218
11318,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622418,50597,,N,Intermediate,,BAO_0000218
11319,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622419,50597,,N,Intermediate,,BAO_0000218
11320,,1,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL623388,50594,,N,Intermediate,,BAO_0000218
11321,,1,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL623389,50594,,N,Intermediate,,BAO_0000218
11322,,1,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL623390,50594,,N,Intermediate,,BAO_0000218
11323,,1,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL623391,50594,,N,Intermediate,,BAO_0000218
11324,,1,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL623392,50594,,N,Intermediate,,BAO_0000218
11325,,1,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Cerebellum,2037.0,,1,10090.0,A,CHEMBL623393,50594,,N,Intermediate,,BAO_0000218
11326,,1,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL623394,50594,,N,Intermediate,,BAO_0000218
11327,,1,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL618885,50594,,N,Intermediate,,BAO_0000218
11328,,1,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618886,50594,,N,Intermediate,,BAO_0000218
11329,,1,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL618887,50594,,N,Intermediate,,BAO_0000218
11330,,1,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL619535,50594,,N,Intermediate,,BAO_0000218
11331,,1,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL619536,50594,,N,Intermediate,,BAO_0000218
11332,,1,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Cerebellum,2037.0,,1,10090.0,A,CHEMBL619537,50594,,N,Intermediate,,BAO_0000218
11333,,1,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL619705,50594,,N,Intermediate,,BAO_0000218
11334,,1,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL619706,50594,,N,Intermediate,,BAO_0000218
11335,,1,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL619707,50594,,N,Intermediate,,BAO_0000218
11336,,1,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL619708,50594,,N,Intermediate,,BAO_0000218
11337,,1,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL625219,50594,,N,Intermediate,,BAO_0000218
11338,,1,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL625220,50594,,N,Intermediate,,BAO_0000218
11339,,1,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Cerebellum,2037.0,,1,10090.0,A,CHEMBL625221,50594,,N,Intermediate,,BAO_0000218
11340,,1,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL625222,50594,,N,Intermediate,,BAO_0000218
11341,,1,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL625223,50594,,N,Intermediate,,BAO_0000218
11342,,1,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL625224,50594,,N,Intermediate,,BAO_0000218
11343,,1,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),Mus musculus,,,,,,1,10090.0,A,CHEMBL625225,50594,,N,Intermediate,,BAO_0000218
11344,,1,Biodistribution in Rat blood after 24 hours of iv administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625226,50597,,N,Intermediate,,BAO_0000218
11345,,1,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625227,50597,,N,Intermediate,,BAO_0000218
11346,,1,Biodistribution in Rat blood after 30 minutes of iv administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625228,50597,,N,Intermediate,,BAO_0000218
11347,,1,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL875354,50597,,N,Intermediate,,BAO_0000218
11348,,1,Biodistribution in Rat blood after 5 minutes of iv administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625229,50597,,N,Intermediate,,BAO_0000218
11349,,1,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625230,50597,,N,Intermediate,,BAO_0000218
11350,,1,Biodistribution in Rat heart after 24 hours of iv administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625231,50597,,N,Intermediate,,BAO_0000218
11351,,1,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625900,50597,,N,Intermediate,,BAO_0000218
11352,,1,Biodistribution in Rat heart after 30 minutes of iv administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625901,50597,,N,Intermediate,,BAO_0000218
11353,,1,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625902,50597,,N,Intermediate,,BAO_0000218
11354,,1,Biodistribution in Rat heart after 5 minutes of iv administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625903,50597,,N,Intermediate,,BAO_0000218
11355,,1,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625904,50597,,N,Intermediate,,BAO_0000218
11356,,1,Biodistribution in Rat liver after 24 hours of iv administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625905,50597,,N,Intermediate,,BAO_0000218
11357,,1,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627861,50597,,N,Intermediate,,BAO_0000218
11358,,1,Biodistribution in Rat liver after 30 minutes of iv administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627862,50597,,N,Intermediate,,BAO_0000218
11359,,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627863,50597,,N,Intermediate,,BAO_0000218
11360,,1,Biodistribution in Rat liver after 30 minutes of iv administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627769,50597,,N,Intermediate,,BAO_0000218
11361,,1,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL627770,50588,,N,Intermediate,,BAO_0000218
11362,,1,Cmax in cynomolgus monkey (PO dose),Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL627771,100710,,N,Intermediate,,BAO_0000218
11363,,1,Cmax in rat (PO dose),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627772,50597,,N,Intermediate,,BAO_0000218
11364,,1,Cmax in rat (PO dose),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627773,50597,,N,Intermediate,,BAO_0000218
11365,,1,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621922,50597,,N,Intermediate,,BAO_0000218
11366,,1,Cmax in rat plasma after oral dose (10 mg/kg),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621923,50597,,N,Intermediate,,BAO_0000218
11367,,0,Cmax in plasma after oral dose (10 mg/kg),,,,Plasma,1969.0,,1,,A,CHEMBL621924,22224,,U,Autocuration,,BAO_0000218
11368,,1,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL621925,50588,,N,Intermediate,,BAO_0000218
11369,,0,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL621926,22224,,U,Autocuration,,BAO_0000218
11370,,1,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL621927,50592,,N,Intermediate,,BAO_0000218
11371,,1,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621928,50597,,N,Intermediate,,BAO_0000218
11372,,1,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621929,50597,,N,Intermediate,,BAO_0000218
11373,,1,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL621930,50594,,N,Intermediate,,BAO_0000218
11374,,1,Maximum plasma concentration after oral dosing in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621931,50597,,N,Intermediate,,BAO_0000218
11375,,0,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621932,22224,,U,Autocuration,,BAO_0000218
11376,,0,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621933,22224,,U,Autocuration,,BAO_0000218
11377,,1,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL621934,50588,,N,Intermediate,,BAO_0000218
11378,,1,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL621935,50588,,N,Intermediate,,BAO_0000218
11379,,1,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL621936,50597,,N,Intermediate,,BAO_0000218
11380,,0,Maximum plasma concentration was determined,,,,Plasma,1969.0,,1,,A,CHEMBL621937,22224,,U,Autocuration,,BAO_0000218
11381,,0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621938,22224,,U,Autocuration,,BAO_0000218
11382,,0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621939,22224,,U,Autocuration,,BAO_0000218
11383,,0,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621940,22224,,U,Autocuration,,BAO_0000218
11384,,0,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621941,22224,,U,Autocuration,,BAO_0000218
11385,,0,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL621942,22224,,U,Autocuration,,BAO_0000218
11386,,0,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL626178,22224,,U,Autocuration,,BAO_0000218
11387,,0,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL626179,22224,,U,Autocuration,,BAO_0000218
11388,,0,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,,,Plasma,1969.0,,1,,A,CHEMBL626180,22224,,U,Autocuration,,BAO_0000218
11389,,1,Plasma Cmax in rat (PO dose),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626181,50597,,N,Intermediate,,BAO_0000218
11390,,1,Maximum serum concentration after po dose of 5.22 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626182,50597,,N,Intermediate,,BAO_0000218
11391,,1,Maximum serum concentration after po dose of 5.46 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626183,50597,,N,Intermediate,,BAO_0000218
11392,,1,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626184,50597,,N,Intermediate,,BAO_0000218
11393,,1,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626185,50597,,N,Intermediate,,BAO_0000218
11394,,1,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626186,50588,,N,Intermediate,,BAO_0000218
11395,,1,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL877589,50588,,N,Intermediate,,BAO_0000218
11396,,0,Maximum concentration of the drug at 1 uM/dg administered intravenously,,,,,,,1,,A,CHEMBL626187,22224,,U,Autocuration,,BAO_0000218
11397,,0,Maximum concentration of the drug at 20 uM/dg administered perorally,,,,,,,1,,A,CHEMBL626188,22224,,U,Autocuration,,BAO_0000218
11398,,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,,,,,,1,,A,CHEMBL626189,22224,,U,Autocuration,,BAO_0000218
11399,,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL626855,22224,,U,Autocuration,,BAO_0000218
11400,,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL623781,22224,,U,Autocuration,,BAO_0000218
11401,,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL623782,22224,,U,Autocuration,,BAO_0000218
11402,,1,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623783,50597,,N,Intermediate,,BAO_0000218
11403,,1,Cmax in dog plasma after 1mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL623784,50588,,N,Intermediate,,BAO_0000218
11404,,1,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL623785,50588,,N,Intermediate,,BAO_0000218
11405,,1,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623786,50597,,N,Intermediate,,BAO_0000218
11406,,1,Oral maximum concentration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623787,50597,,N,Intermediate,,BAO_0000218
11407,,1,Oral maximum concentration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623788,50597,,N,Intermediate,,BAO_0000218
11408,,1,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL623789,50594,,N,Intermediate,,BAO_0000218
11409,,1,Peak concentration in blood after intravenous administration to mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL623790,50594,,N,Intermediate,,BAO_0000218
11410,,1,Peak concentration in blood after peroral administration to mice,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL623791,50594,,N,Intermediate,,BAO_0000218
11411,,1,Peak concentration in rat plasma was determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623792,50597,,N,Intermediate,,BAO_0000218
11412,,0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL623793,22224,,U,Autocuration,,BAO_0000218
11413,,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL623794,50594,,N,Intermediate,,BAO_0000218
11414,,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623795,50597,,N,Intermediate,,BAO_0000218
11415,,1,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623796,50597,,N,Intermediate,,BAO_0000218
11416,,1,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623797,50597,,N,Intermediate,,BAO_0000218
11417,,1,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623798,50597,,N,Intermediate,,BAO_0000218
11418,,1,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623799,50597,,N,Intermediate,,BAO_0000218
11419,,1,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624490,50597,,N,Intermediate,,BAO_0000218
11420,,1,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624491,50597,,N,Intermediate,,BAO_0000218
11421,,1,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624492,50597,,N,Intermediate,,BAO_0000218
11422,,1,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624493,50597,,N,Intermediate,,BAO_0000218
11423,,1,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL877595,50597,,N,Intermediate,,BAO_0000218
11424,,1,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624494,50597,,N,Intermediate,,BAO_0000218
11425,,1,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624495,50597,,N,Intermediate,,BAO_0000218
11426,,1,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL624681,50597,,N,Intermediate,,BAO_0000218
11427,,1,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624682,50597,,N,Intermediate,,BAO_0000218
11428,,1,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624683,50597,,N,Intermediate,,BAO_0000218
11429,,1,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624684,50597,,N,Intermediate,,BAO_0000218
11430,,1,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624685,50597,,N,Intermediate,,BAO_0000218
11431,,1,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624686,50597,,N,Intermediate,,BAO_0000218
11432,,1,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624687,50597,,N,Intermediate,,BAO_0000218
11433,,1,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624688,50597,,N,Intermediate,,BAO_0000218
11434,,1,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627161,50597,,N,Intermediate,,BAO_0000218
11435,,1,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622127,50597,,N,Intermediate,,BAO_0000218
11436,,1,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622128,50597,,N,Intermediate,,BAO_0000218
11437,,1,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874384,50597,,N,Intermediate,,BAO_0000218
11438,,1,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624898,50597,,N,Intermediate,,BAO_0000218
11439,,1,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624899,50597,,N,Intermediate,,BAO_0000218
11440,,1,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624900,50597,,N,Intermediate,,BAO_0000218
11441,,1,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624901,50597,,N,Intermediate,,BAO_0000218
11442,,1,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624902,50597,,N,Intermediate,,BAO_0000218
11443,,1,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624903,50597,,N,Intermediate,,BAO_0000218
11444,,1,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624904,50597,,N,Intermediate,,BAO_0000218
11445,,1,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624905,50597,,N,Intermediate,,BAO_0000218
11446,,1,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624906,50597,,N,Intermediate,,BAO_0000218
11447,,1,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624907,50597,,N,Intermediate,,BAO_0000218
11448,,1,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624908,50597,,N,Intermediate,,BAO_0000218
11449,,1,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624909,50597,,N,Intermediate,,BAO_0000218
11450,,1,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624910,50597,,N,Intermediate,,BAO_0000218
11451,,1,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624911,50597,,N,Intermediate,,BAO_0000218
11452,,1,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL874388,50597,,N,Intermediate,,BAO_0000218
11453,,1,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL624912,50597,,N,Intermediate,,BAO_0000218
11454,,1,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622930,50597,,N,Intermediate,,BAO_0000218
11455,,1,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623121,50597,,N,Intermediate,,BAO_0000218
11456,,1,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623122,50597,,N,Intermediate,,BAO_0000218
11457,,1,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623123,50597,,N,Intermediate,,BAO_0000218
11458,,1,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623124,50597,,N,Intermediate,,BAO_0000218
11459,,1,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623125,50597,,N,Intermediate,,BAO_0000218
11460,,1,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623126,50597,,N,Intermediate,,BAO_0000218
11461,,1,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623127,50597,,N,Intermediate,,BAO_0000218
11462,,1,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623128,50597,,N,Intermediate,,BAO_0000218
11463,,1,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623129,50597,,N,Intermediate,,BAO_0000218
11464,,1,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623130,50597,,N,Intermediate,,BAO_0000218
11465,,1,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623131,50597,,N,Intermediate,,BAO_0000218
11466,,1,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623132,50597,,N,Intermediate,,BAO_0000218
11467,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623133,50597,,N,Intermediate,,BAO_0000218
11468,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623134,50597,,N,Intermediate,,BAO_0000218
11469,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874389,50597,,N,Intermediate,,BAO_0000218
11470,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623135,50597,,N,Intermediate,,BAO_0000218
11471,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623136,50597,,N,Intermediate,,BAO_0000218
11472,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623137,50597,,N,Intermediate,,BAO_0000218
11473,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623138,50597,,N,Intermediate,,BAO_0000218
11474,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623139,50597,,N,Intermediate,,BAO_0000218
11475,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623140,50597,,N,Intermediate,,BAO_0000218
11476,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623141,50597,,N,Intermediate,,BAO_0000218
11477,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623142,50597,,N,Intermediate,,BAO_0000218
11478,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623143,50597,,N,Intermediate,,BAO_0000218
11479,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL623144,50594,,N,Intermediate,,BAO_0000218
11480,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623405,50597,,N,Intermediate,,BAO_0000218
11481,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624074,50597,,N,Intermediate,,BAO_0000218
11482,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624075,50597,,N,Intermediate,,BAO_0000218
11483,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624076,50597,,N,Intermediate,,BAO_0000218
11484,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624077,50597,,N,Intermediate,,BAO_0000218
11485,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624078,50597,,N,Intermediate,,BAO_0000218
11486,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624079,50597,,N,Intermediate,,BAO_0000218
11487,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624261,50597,,N,Intermediate,,BAO_0000218
11488,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624262,50597,,N,Intermediate,,BAO_0000218
11489,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624263,50597,,N,Intermediate,,BAO_0000218
11490,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624264,50597,,N,Intermediate,,BAO_0000218
11491,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624265,50597,,N,Intermediate,,BAO_0000218
11492,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624266,50597,,N,Intermediate,,BAO_0000218
11493,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624267,50597,,N,Intermediate,,BAO_0000218
11494,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624268,50597,,N,Intermediate,,BAO_0000218
11495,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875227,50597,,N,Intermediate,,BAO_0000218
11496,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624269,50597,,N,Intermediate,,BAO_0000218
11497,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624270,50597,,N,Intermediate,,BAO_0000218
11498,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624271,50597,,N,Intermediate,,BAO_0000218
11499,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624272,50597,,N,Intermediate,,BAO_0000218
11500,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624273,50597,,N,Intermediate,,BAO_0000218
11501,,1,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624274,50597,,N,Intermediate,,BAO_0000218
11502,,1,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624275,50597,,N,Intermediate,,BAO_0000218
11503,,1,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624276,50597,,N,Intermediate,,BAO_0000218
11504,,1,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624277,50597,,N,Intermediate,,BAO_0000218
11505,,0,% dose converted to 2-amino-5-chlorophenyl sulfate,,,,,,,1,,A,CHEMBL624278,22224,,U,Autocuration,,BAO_0000019
11506,,0,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,,,,,,1,,A,CHEMBL624279,22224,,U,Autocuration,,BAO_0000019
11507,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL624280,50597,,N,Intermediate,,BAO_0000218
11508,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL624281,50597,,N,Intermediate,,BAO_0000218
11509,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL622933,50597,,N,Intermediate,,BAO_0000218
11510,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL622934,50597,,N,Intermediate,,BAO_0000218
11511,,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622935,50597,,N,Intermediate,,BAO_0000218
11512,,1,Biodistribution in Rat liver after 5 minutes of iv administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622936,50597,,N,Intermediate,,BAO_0000218
11513,,1,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL875228,50597,,N,Intermediate,,BAO_0000218
11514,,1,Biodistribution in Rat lung after 24 hours of iv administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622937,50597,,N,Intermediate,,BAO_0000218
11515,,1,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622938,50597,,N,Intermediate,,BAO_0000218
11516,,1,Biodistribution in Rat lung after 30 minutes of iv administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL619736,50597,,N,Intermediate,,BAO_0000218
11517,,1,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625117,50597,,N,Intermediate,,BAO_0000218
11518,,1,Biodistribution in Rat lung after 5 minutes of iv administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625118,50597,,N,Intermediate,,BAO_0000218
11519,,1,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625119,50597,,N,Intermediate,,BAO_0000218
11520,,1,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL625120,50597,,N,Intermediate,,BAO_0000218
11521,,1,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625121,50597,,N,Intermediate,,BAO_0000218
11522,,1,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Rattus norvegicus,,,Thalamus,10000006.0,,1,10116.0,A,CHEMBL625122,50597,,N,Intermediate,,BAO_0000218
11523,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL622204,50597,,N,Intermediate,,BAO_0000218
11524,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL877503,50597,,N,Intermediate,,BAO_0000218
11525,,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627127,50597,,N,Intermediate,,BAO_0000218
11526,,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,,,Hippocampus,10000000.0,,1,,A,CHEMBL627128,22224,,U,Autocuration,,BAO_0000218
11527,,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,,,Hippocampus,10000000.0,,1,,A,CHEMBL627129,22224,,U,Autocuration,,BAO_0000218
11528,,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,,,Hippocampus,10000000.0,,1,,A,CHEMBL627130,22224,,U,Autocuration,,BAO_0000218
11529,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627131,50597,,N,Intermediate,,BAO_0000218
11530,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627132,50597,,N,Intermediate,,BAO_0000218
11531,,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL627133,50597,,N,Intermediate,,BAO_0000218
11532,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL627134,50597,,N,Intermediate,,BAO_0000218
11533,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL627135,50597,,N,Intermediate,,BAO_0000218
11534,,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL627136,50597,,N,Intermediate,,BAO_0000218
11535,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628435,50597,,N,Intermediate,,BAO_0000218
11536,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628436,50597,,N,Intermediate,,BAO_0000218
11537,,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628437,50597,,N,Intermediate,,BAO_0000218
11538,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL628438,50597,,N,Intermediate,,BAO_0000218
11539,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL628439,50597,,N,Intermediate,,BAO_0000218
11540,,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL628440,50597,,N,Intermediate,,BAO_0000218
11541,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628441,50597,,N,Intermediate,,BAO_0000218
11542,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628442,50597,,N,Intermediate,,BAO_0000218
11543,,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628443,50597,,N,Intermediate,,BAO_0000218
11544,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628444,50597,,N,Intermediate,,BAO_0000218
11545,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628445,50597,,N,Intermediate,,BAO_0000218
11546,,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL877504,50597,,N,Intermediate,,BAO_0000218
11547,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628446,50597,,N,Intermediate,,BAO_0000218
11548,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626874,50597,,N,Intermediate,,BAO_0000218
11549,,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626875,50597,,N,Intermediate,,BAO_0000218
11550,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626876,50597,,N,Intermediate,,BAO_0000218
11551,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626877,50597,,N,Intermediate,,BAO_0000218
11552,,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626878,50597,,N,Intermediate,,BAO_0000218
11553,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL626879,50597,,N,Intermediate,,BAO_0000218
11554,,0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL626880,22224,,U,Autocuration,,BAO_0000218
11555,,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL626881,50594,,N,Intermediate,,BAO_0000218
11556,,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626882,50597,,N,Intermediate,,BAO_0000218
11557,,1,Peak plasma concentration was measured in dogs,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626883,50588,,N,Intermediate,,BAO_0000218
11558,,1,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626884,50597,,N,Intermediate,,BAO_0000218
11559,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626885,50597,,N,Intermediate,,BAO_0000218
11560,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626886,50597,,N,Intermediate,,BAO_0000218
11561,,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626887,50597,,N,Intermediate,,BAO_0000218
11562,,1,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626888,50597,,N,Intermediate,,BAO_0000218
11563,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626889,50588,,N,Intermediate,,BAO_0000218
11564,,0,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL626761,22224,,U,Autocuration,,BAO_0000218
11565,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626762,50588,,N,Intermediate,,BAO_0000218
11566,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626763,50588,,N,Intermediate,,BAO_0000218
11567,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626764,50597,,N,Intermediate,,BAO_0000218
11568,,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626765,50597,,N,Intermediate,,BAO_0000218
11569,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626766,50588,,N,Intermediate,,BAO_0000218
11570,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626767,50597,,N,Intermediate,,BAO_0000218
11571,,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626768,50597,,N,Intermediate,,BAO_0000218
11572,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626769,50588,,N,Intermediate,,BAO_0000218
11573,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL874463,50588,,N,Intermediate,,BAO_0000218
11574,,0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL626770,22224,,U,Autocuration,,BAO_0000218
11575,,0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,Simiiformes,,,,,,1,314293.0,A,CHEMBL626771,22224,,U,Autocuration,,BAO_0000218
11576,,1,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626772,50597,,N,Intermediate,,BAO_0000218
11577,,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL626773,100710,,N,Intermediate,,BAO_0000218
11578,,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,Mus musculus,,,,,,1,10090.0,A,CHEMBL626774,50594,,N,Intermediate,,BAO_0000218
11579,,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626775,50588,,N,Intermediate,,BAO_0000218
11580,,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626776,50588,,N,Intermediate,,BAO_0000218
11581,,1,Maximum concentration (Cmax) in rat when administered orally,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626777,50597,,N,Intermediate,,BAO_0000218
11582,,0,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL626778,22224,,U,Autocuration,,BAO_0000218
11583,,0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626779,22224,,U,Autocuration,,BAO_0000218
11584,,0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626780,22224,,U,Autocuration,,BAO_0000218
11585,,0,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,,,Plasma,1969.0,,1,,A,CHEMBL626781,22224,,U,Autocuration,,BAO_0000218
11586,,1,Pharmacokinetic profile Cmax was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632164,50597,,N,Intermediate,,BAO_0000218
11587,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL632165,50588,,N,Intermediate,,BAO_0000218
11588,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),Mus musculus,,,,,,1,10090.0,A,CHEMBL632166,50594,,N,Intermediate,,BAO_0000218
11589,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL632167,50588,,N,Intermediate,,BAO_0000218
11590,,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),Mus musculus,,,,,,1,10090.0,A,CHEMBL632168,50594,,N,Intermediate,,BAO_0000218
11591,,0,Cmax in rat plasma,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632169,22224,,U,Autocuration,,BAO_0000218
11592,,1,Cmax in dog plasma after 30mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL632170,50588,,N,Intermediate,,BAO_0000218
11593,,1,Cmax in rat plasma after 30mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632171,50597,,N,Intermediate,,BAO_0000218
11594,,1,Plasma level in rats at 30 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632172,50597,,N,Intermediate,,BAO_0000218
11595,,1,Tested for maximum plasma concentration in mice,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL632173,50594,,N,Intermediate,,BAO_0000218
11596,,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632174,50597,,N,Intermediate,,BAO_0000218
11597,,1,The Cmax values in female wistar rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632175,50597,,N,Intermediate,,BAO_0000218
11598,,1,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL632176,50588,,N,Intermediate,,BAO_0000218
11599,,1,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632177,50597,,N,Intermediate,,BAO_0000218
11600,,1,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632178,50597,,N,Intermediate,,BAO_0000218
11601,,1,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632179,50597,,N,Intermediate,,BAO_0000218
11602,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632180,50597,,N,Intermediate,,BAO_0000218
11603,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632181,50597,,N,Intermediate,,BAO_0000218
11604,,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632182,50597,,N,Intermediate,,BAO_0000218
11605,,0,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL632183,22224,,U,Autocuration,,BAO_0000218
11606,,1,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL632184,50588,,N,Intermediate,,BAO_0000218
11607,,1,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874470,50597,,N,Intermediate,,BAO_0000218
11608,,1,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631302,50597,,N,Intermediate,,BAO_0000218
11609,,1,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631303,50597,,N,Intermediate,,BAO_0000218
11610,,1,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631304,50597,,N,Intermediate,,BAO_0000218
11611,,1,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631305,50597,,N,Intermediate,,BAO_0000218
11612,,1,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631306,50597,,N,Intermediate,,BAO_0000218
11613,,1,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631307,50597,,N,Intermediate,,BAO_0000218
11614,,1,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631308,50597,,N,Intermediate,,BAO_0000218
11615,,1,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625557,50597,,N,Intermediate,,BAO_0000218
11616,,1,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625558,50597,,N,Intermediate,,BAO_0000218
11617,,1,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625559,50597,,N,Intermediate,,BAO_0000218
11618,,1,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625560,50597,,N,Intermediate,,BAO_0000218
11619,,1,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625561,50597,,N,Intermediate,,BAO_0000218
11620,,1,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625562,50597,,N,Intermediate,,BAO_0000218
11621,,1,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL875320,50597,,N,Intermediate,,BAO_0000218
11622,,1,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625563,50597,,N,Intermediate,,BAO_0000218
11623,,1,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625564,50597,,N,Intermediate,,BAO_0000218
11624,,1,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL625565,50597,,N,Intermediate,,BAO_0000218
11625,,1,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL625566,50597,,N,Intermediate,,BAO_0000218
11626,,1,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL625567,50597,,N,Intermediate,,BAO_0000218
11627,,1,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL625568,50597,,N,Intermediate,,BAO_0000218
11628,,1,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL628217,50597,,N,Intermediate,,BAO_0000218
11629,,1,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL628218,50597,,N,Intermediate,,BAO_0000218
11630,,1,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL628219,50597,,N,Intermediate,,BAO_0000218
11631,,1,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL628220,50597,,N,Intermediate,,BAO_0000218
11632,,0,Distribution in the blood after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628221,22224,,U,Autocuration,,BAO_0000019
11633,,0,Distribution in the blood after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL628222,22224,,U,Autocuration,,BAO_0000019
11634,,0,Distribution in the blood after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628223,22224,,U,Autocuration,,BAO_0000019
11635,,0,Distribution in the blood after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628224,22224,,U,Autocuration,,BAO_0000019
11636,,0,Distribution in the blood after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628225,22224,,U,Autocuration,,BAO_0000019
11637,,0,Distribution in the blood after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL628226,22224,,U,Autocuration,,BAO_0000019
11638,,0,Distribution in the bone after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628227,22224,,U,Autocuration,,BAO_0000019
11639,,0,Distribution in the bone after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL875481,22224,,U,Autocuration,,BAO_0000019
11640,,0,Distribution in the bone after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628228,22224,,U,Autocuration,,BAO_0000019
11641,,0,Distribution in the bone after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628229,22224,,U,Autocuration,,BAO_0000019
11642,,0,Distribution in the bone after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628230,22224,,U,Autocuration,,BAO_0000019
11643,,0,Distribution in the bone after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL628231,22224,,U,Autocuration,,BAO_0000019
11644,,0,Distribution in the heart after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628232,22224,,U,Autocuration,,BAO_0000019
11645,,0,Distribution in the heart after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL628233,22224,,U,Autocuration,,BAO_0000019
11646,,0,Distribution in the heart after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628234,22224,,U,Autocuration,,BAO_0000019
11647,,0,Distribution in the heart after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628235,22224,,U,Autocuration,,BAO_0000019
11648,,0,Distribution in the heart after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628236,22224,,U,Autocuration,,BAO_0000019
11649,,0,Distribution in the heart after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL628237,22224,,U,Autocuration,,BAO_0000019
11650,,0,Distribution in the kidneys after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628238,22224,,U,Autocuration,,BAO_0000019
11651,,0,Distribution in the kidneys after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL628239,22224,,U,Autocuration,,BAO_0000019
11652,,0,Distribution in the kidneys after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628240,22224,,U,Autocuration,,BAO_0000019
11653,,0,Distribution in the kidneys after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628241,22224,,U,Autocuration,,BAO_0000019
11654,,0,Distribution in the kidneys after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628242,22224,,U,Autocuration,,BAO_0000019
11655,,0,Distribution in the kidneys after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL875482,22224,,U,Autocuration,,BAO_0000019
11656,,0,Distribution in the liver after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628243,22224,,U,Autocuration,,BAO_0000019
11657,,0,Distribution in the liver after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL628244,22224,,U,Autocuration,,BAO_0000019
11658,,0,Distribution in the liver after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628245,22224,,U,Autocuration,,BAO_0000019
11659,,0,Distribution in the liver after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628246,22224,,U,Autocuration,,BAO_0000019
11660,,0,Distribution in the liver after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628247,22224,,U,Autocuration,,BAO_0000019
11661,,0,Distribution in the liver after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL628248,22224,,U,Autocuration,,BAO_0000019
11662,,0,Distribution in the lung after 120 min of intravenous administration,,,,,,,1,,A,CHEMBL628249,22224,,U,Autocuration,,BAO_0000019
11663,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL625452,50594,,N,Intermediate,,BAO_0000218
11664,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL625453,50594,,N,Intermediate,,BAO_0000218
11665,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL625454,50594,,N,Intermediate,,BAO_0000218
11666,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",Mus musculus,,,,,,1,10090.0,A,CHEMBL623844,50594,,N,Intermediate,,BAO_0000218
11667,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623845,50597,,N,Intermediate,,BAO_0000218
11668,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623846,50597,,N,Intermediate,,BAO_0000218
11669,,0,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,,,,,,1,,A,CHEMBL623847,22224,,U,Autocuration,,BAO_0000218
11670,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623848,100710,,N,Intermediate,,BAO_0000218
11671,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623849,100710,,N,Intermediate,,BAO_0000218
11672,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623850,100710,,N,Intermediate,,BAO_0000218
11673,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623851,100710,,N,Intermediate,,BAO_0000218
11674,,0,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL623852,22224,,U,Autocuration,,BAO_0000218
11675,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL624551,50506,,N,Intermediate,,BAO_0000218
11676,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL624552,50506,,N,Intermediate,,BAO_0000218
11677,,0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL624553,22224,,U,Autocuration,,BAO_0000218
11678,,0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,Simiiformes,,,,,,1,314293.0,A,CHEMBL624554,22224,,U,Autocuration,,BAO_0000218
11679,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624555,50597,,N,Intermediate,,BAO_0000218
11680,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624741,50597,,N,Intermediate,,BAO_0000218
11681,,1,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624742,50588,,N,Intermediate,,BAO_0000218
11682,,1,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",Cricetinae,,,,,,1,10026.0,A,CHEMBL624743,100712,,N,Intermediate,,BAO_0000218
11683,,1,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877606,50597,,N,Intermediate,,BAO_0000218
11684,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,,,,,,1,,A,CHEMBL624744,22224,,U,Autocuration,,BAO_0000218
11685,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL624745,22224,,U,Autocuration,,BAO_0000218
11686,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL624746,22224,,U,Autocuration,,BAO_0000218
11687,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,,,Blood,178.0,,1,,A,CHEMBL624747,22224,,U,Autocuration,,BAO_0000218
11688,,0,Oral absorption expressed as Area under curve was determined,,,,,,,1,,A,CHEMBL624748,22224,,U,Autocuration,,BAO_0000019
11689,,1,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622504,50588,,N,Intermediate,,BAO_0000218
11690,,1,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622505,50588,,N,Intermediate,,BAO_0000218
11691,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Cricetinae,,,,,,1,10026.0,A,CHEMBL622506,100712,,N,Intermediate,,BAO_0000218
11692,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",Cricetinae,,,,,,1,10026.0,A,CHEMBL622507,100712,,N,Intermediate,,BAO_0000218
11693,,1,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622508,50597,,N,Intermediate,,BAO_0000218
11694,,0,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,,,,,,1,,A,CHEMBL622509,22224,,U,Autocuration,,BAO_0000019
11695,,1,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622510,50597,,N,Intermediate,,BAO_0000218
11696,,1,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622511,50597,,N,Intermediate,,BAO_0000218
11697,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL622512,100710,,N,Intermediate,,BAO_0000218
11698,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL622513,100710,,N,Intermediate,,BAO_0000218
11699,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL622514,100710,,N,Intermediate,,BAO_0000218
11700,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622515,50588,,N,Intermediate,,BAO_0000218
11701,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622516,50588,,N,Intermediate,,BAO_0000218
11702,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622517,50597,,N,Intermediate,,BAO_0000218
11703,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622518,50597,,N,Intermediate,,BAO_0000218
11704,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622519,50597,,N,Intermediate,,BAO_0000218
11705,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622520,50597,,N,Intermediate,,BAO_0000218
11706,,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622521,50597,,N,Intermediate,,BAO_0000218
11707,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL625113,50594,,N,Intermediate,,BAO_0000218
11708,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL625114,50597,,N,Intermediate,,BAO_0000218
11709,,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL874397,50597,,N,Intermediate,,BAO_0000218
11710,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625115,50597,,N,Intermediate,,BAO_0000218
11711,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625116,50597,,N,Intermediate,,BAO_0000218
11712,,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL623932,50597,,N,Intermediate,,BAO_0000218
11713,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL623933,50597,,N,Intermediate,,BAO_0000218
11714,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL623934,50597,,N,Intermediate,,BAO_0000218
11715,,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL623935,50597,,N,Intermediate,,BAO_0000218
11716,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL623936,50597,,N,Intermediate,,BAO_0000218
11717,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL623937,50597,,N,Intermediate,,BAO_0000218
11718,,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL623938,50597,,N,Intermediate,,BAO_0000218
11719,,1,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,,,,1,10090.0,A,CHEMBL623939,50594,,N,Intermediate,,BAO_0000218
11720,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL623940,50594,,N,Intermediate,,BAO_0000218
11721,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL623941,50594,,N,Intermediate,,BAO_0000218
11722,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL627216,50594,,N,Intermediate,,BAO_0000218
11723,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL623942,50594,,N,Intermediate,,BAO_0000218
11724,,1,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL618793,50594,,N,Intermediate,,BAO_0000218
11725,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL618794,50594,,N,Intermediate,,BAO_0000218
11726,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL618795,50594,,N,Intermediate,,BAO_0000218
11727,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL618796,50594,,N,Intermediate,,BAO_0000218
11728,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL618797,50594,,N,Intermediate,,BAO_0000218
11729,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618798,50594,,N,Intermediate,,BAO_0000218
11730,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618799,50594,,N,Intermediate,,BAO_0000218
11731,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618800,50594,,N,Intermediate,,BAO_0000218
11732,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618801,50594,,N,Intermediate,,BAO_0000218
11733,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618802,50594,,N,Intermediate,,BAO_0000218
11734,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL618803,50594,,N,Intermediate,,BAO_0000218
11735,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618804,50594,,N,Intermediate,,BAO_0000218
11736,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618805,50594,,N,Intermediate,,BAO_0000218
11737,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618806,50594,,N,Intermediate,,BAO_0000218
11738,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618807,50594,,N,Intermediate,,BAO_0000218
11739,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618808,50594,,N,Intermediate,,BAO_0000218
11740,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL618809,50594,,N,Intermediate,,BAO_0000218
11741,,1,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL618810,50594,,N,Intermediate,,BAO_0000218
11742,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL618811,50594,,N,Intermediate,,BAO_0000218
11743,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL875844,50594,,N,Intermediate,,BAO_0000218
11744,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL618812,50594,,N,Intermediate,,BAO_0000218
11745,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL618813,50594,,N,Intermediate,,BAO_0000218
11746,,1,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,,,,1,10090.0,A,CHEMBL618814,50594,,N,Intermediate,,BAO_0000218
11747,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL618815,50594,,N,Intermediate,,BAO_0000218
11748,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL618816,50594,,N,Intermediate,,BAO_0000218
11749,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL618817,50594,,N,Intermediate,,BAO_0000218
11750,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL620544,50594,,N,Intermediate,,BAO_0000218
11751,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626230,50597,,N,Intermediate,,BAO_0000218
11752,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626231,50597,,N,Intermediate,,BAO_0000218
11753,,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626232,50597,,N,Intermediate,,BAO_0000218
11754,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626233,50588,,N,Intermediate,,BAO_0000218
11755,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626234,50597,,N,Intermediate,,BAO_0000218
11756,,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL875341,50597,,N,Intermediate,,BAO_0000218
11757,,1,The maximum plasma concentration (100 mg/kg) administered orally in human,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL626235,50587,,N,Intermediate,,BAO_0000218
11758,,0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Callithrix,,,Plasma,1969.0,,1,9481.0,A,CHEMBL626236,22224,,U,Autocuration,,BAO_0000218
11759,,0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL626237,22224,,U,Autocuration,,BAO_0000218
11760,,1,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626238,50588,,N,Intermediate,,BAO_0000218
11761,,1,The maximum plasma concentration (200 mg/kg) administered orally in human,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL622412,50587,,N,Intermediate,,BAO_0000218
11762,,1,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623114,50597,,N,Intermediate,,BAO_0000218
11763,,0,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Callithrix,,,Plasma,1969.0,,1,9481.0,A,CHEMBL623115,22224,,U,Autocuration,,BAO_0000218
11764,,0,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL623116,22224,,U,Autocuration,,BAO_0000218
11765,,0,The maximum plasma concentration (30 mg/kg) administered orally in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL623117,22224,,U,Autocuration,,BAO_0000218
11766,,1,The maximum plasma concentration (400 mg/kg) administered orally in human,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL623118,50587,,N,Intermediate,,BAO_0000218
11767,,1,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623119,50597,,N,Intermediate,,BAO_0000218
11768,,1,The maximum plasma concentration (50 mg/kg) administered orally in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623120,50597,,N,Intermediate,,BAO_0000218
11769,,1,The maximum plasma concentration (800 mg/kg) administered orally in human,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL623286,50587,,N,Intermediate,,BAO_0000218
11770,,1,The maximum plasma concentration was measured on rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623287,50597,,N,Intermediate,,BAO_0000218
11771,,1,The maximum plasma concentration was measured on rats after oral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623288,50597,,N,Intermediate,,BAO_0000218
11772,,1,Plasma drug Cmax in rat (PO dose),Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623289,50597,,N,Intermediate,,BAO_0000218
11773,,0,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,,,,,,1,,A,CHEMBL623290,22224,,U,Autocuration,,BAO_0000218
11774,,1,maximum Plasma concentration in Dog was determined after Peroral administration,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL623291,50588,,N,Intermediate,,BAO_0000218
11775,,1,maximum Plasma concentration in Rats was determined after Peroral administration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623292,50597,,N,Intermediate,,BAO_0000218
11776,,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL623293,50588,,N,Intermediate,,BAO_0000218
11777,,0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL623294,22224,,U,Autocuration,,BAO_0000218
11778,,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623295,50597,,N,Intermediate,,BAO_0000218
11779,,1,maximum concentration was measured when administered through oral route in mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL623296,50594,,N,Intermediate,,BAO_0000218
11780,,1,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,Mus musculus,,,,,,1,10090.0,A,CHEMBL875349,50594,,N,Intermediate,,BAO_0000218
11781,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,Simiiformes,,,,,,1,314293.0,A,CHEMBL623297,22224,,U,Autocuration,,BAO_0000019
11782,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,Simiiformes,,,,,,1,314293.0,A,CHEMBL623298,22224,,U,Autocuration,,BAO_0000019
11783,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,Simiiformes,,,,,,1,314293.0,A,CHEMBL623299,22224,,U,Autocuration,,BAO_0000019
11784,,1,Pharmacokinetic parameter was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623300,50597,,N,Intermediate,,BAO_0000218
11785,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Mus musculus,,,,,,1,10090.0,A,CHEMBL623301,50594,,N,Intermediate,,BAO_0000218
11786,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,Mus musculus,,,,,,1,10090.0,A,CHEMBL623302,50594,,N,Intermediate,,BAO_0000218
11787,,1,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,Mus musculus,,,,,,1,10090.0,A,CHEMBL623303,50594,,N,Intermediate,,BAO_0000218
11788,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,Mus musculus,,,,,,1,10090.0,A,CHEMBL623304,50594,,N,Intermediate,,BAO_0000218
11789,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,Mus musculus,,,,,,1,10090.0,A,CHEMBL623305,50594,,N,Intermediate,,BAO_0000218
11790,,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623306,50597,,N,Intermediate,,BAO_0000218
11791,,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623307,50597,,N,Intermediate,,BAO_0000218
11792,,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL623308,50597,,N,Intermediate,,BAO_0000218
11793,,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL623309,50594,,N,Intermediate,,BAO_0000218
11794,,1,Plasma Concentration after 120 min of oral administration to mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL623310,50594,,N,Intermediate,,BAO_0000218
11795,,1,Plasma Concentration after 30 min of oral administration to mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL623311,50594,,N,Intermediate,,BAO_0000218
11796,,1,Plasma Concentration after 60 min of oral administration to mice,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL623312,100710,,N,Intermediate,,BAO_0000218
11797,,1,Plasma Concentration after 60 min of oral administration to mice; Not determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL875350,50594,,N,Intermediate,,BAO_0000218
11798,,1,Plasma Concentration after 90 min of oral administration to mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL628635,50594,,N,Intermediate,,BAO_0000218
11799,,1,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628636,50597,,N,Intermediate,,BAO_0000218
11800,,1,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628637,50597,,N,Intermediate,,BAO_0000218
11801,,1,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628058,50597,,N,Intermediate,,BAO_0000218
11802,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628059,50597,,N,Intermediate,,BAO_0000218
11803,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628060,50597,,N,Intermediate,,BAO_0000218
11804,,0,Distribution in the lung after 15 min of intravenous administration,,,,,,,1,,A,CHEMBL628061,22224,,U,Autocuration,,BAO_0000019
11805,,0,Distribution in the lung after 30 min of intravenous administration,,,,,,,1,,A,CHEMBL628062,22224,,U,Autocuration,,BAO_0000019
11806,,0,Distribution in the lung after 5 min of intravenous administration,,,,,,,1,,A,CHEMBL628063,22224,,U,Autocuration,,BAO_0000019
11807,,0,Distribution in the lung after 60 min of intravenous administration,,,,,,,1,,A,CHEMBL628064,22224,,U,Autocuration,,BAO_0000019
11808,,0,Distribution in the lung after 90 min of intravenous administration,,,,,,,1,,A,CHEMBL628065,22224,,U,Autocuration,,BAO_0000019
11809,,0,Distribution in the muscle after 120 min of intravenous administration,,,,Muscle tissue,2385.0,,1,,A,CHEMBL628066,22224,,U,Autocuration,,BAO_0000019
11810,,0,Distribution in the muscle after 15 min of intravenous administration,,,,Muscle tissue,2385.0,,1,,A,CHEMBL628067,22224,,U,Autocuration,,BAO_0000019
11811,,1,Distribution in the muscle after 30 min of intravenous administration,Mus musculus,,,Muscle tissue,2385.0,,1,10090.0,A,CHEMBL874646,50594,,N,Intermediate,,BAO_0000218
11812,,0,Distribution in the muscle after 5 min of intravenous administration,,,,Muscle tissue,2385.0,,1,,A,CHEMBL628068,22224,,U,Autocuration,,BAO_0000019
11813,,0,Distribution in the muscle after 60 min of intravenous administration,,,,Muscle tissue,2385.0,,1,,A,CHEMBL628069,22224,,U,Autocuration,,BAO_0000019
11814,,0,Distribution in the muscle after 90 min of intravenous administration,,,,Muscle tissue,2385.0,,1,,A,CHEMBL628070,22224,,U,Autocuration,,BAO_0000019
11815,,0,Distribution in the spleen after 120 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628071,22224,,U,Autocuration,,BAO_0000019
11816,,0,Distribution in the spleen after 15 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628072,22224,,U,Autocuration,,BAO_0000019
11817,,0,Distribution in the spleen after 30 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628073,22224,,U,Autocuration,,BAO_0000019
11818,,0,Distribution in the spleen after 5 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628074,22224,,U,Autocuration,,BAO_0000019
11819,,0,Distribution in the spleen after 60 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628075,22224,,U,Autocuration,,BAO_0000019
11820,,0,Distribution in the spleen after 90 min of intravenous administration,,,,Spleen,2106.0,,1,,A,CHEMBL628076,22224,,U,Autocuration,,BAO_0000019
11821,,1,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Rattus norvegicus,,,Adrenal cortex,1235.0,,1,10116.0,A,CHEMBL628077,50597,,N,Intermediate,,BAO_0000218
11822,,1,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628078,50597,,N,Intermediate,,BAO_0000218
11823,,1,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628079,50597,,N,Intermediate,,BAO_0000218
11824,,1,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL628080,50597,,N,Intermediate,,BAO_0000218
11825,,1,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628081,50597,,N,Intermediate,,BAO_0000218
11826,,1,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Rattus norvegicus,,,Adrenal cortex,1235.0,,1,10116.0,A,CHEMBL628082,50597,,N,Intermediate,,BAO_0000218
11827,,1,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL874647,50597,,N,Intermediate,,BAO_0000218
11828,,1,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626406,50597,,N,Intermediate,,BAO_0000218
11829,,1,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL626407,50597,,N,Intermediate,,BAO_0000218
11830,,1,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626408,50597,,N,Intermediate,,BAO_0000218
11831,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626409,50597,,N,Intermediate,,BAO_0000218
11832,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626410,50597,,N,Intermediate,,BAO_0000218
11833,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626411,50597,,N,Intermediate,,BAO_0000218
11834,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626412,50597,,N,Intermediate,,BAO_0000218
11835,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626413,50597,,N,Intermediate,,BAO_0000218
11836,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626414,50597,,N,Intermediate,,BAO_0000218
11837,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626415,50597,,N,Intermediate,,BAO_0000218
11838,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626416,50597,,N,Intermediate,,BAO_0000218
11839,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627062,50597,,N,Intermediate,,BAO_0000218
11840,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627063,50597,,N,Intermediate,,BAO_0000218
11841,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627064,50597,,N,Intermediate,,BAO_0000218
11842,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627227,50597,,N,Intermediate,,BAO_0000218
11843,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627228,50597,,N,Intermediate,,BAO_0000218
11844,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627229,50597,,N,Intermediate,,BAO_0000218
11845,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625792,50597,,N,Intermediate,,BAO_0000218
11846,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625793,50597,,N,Intermediate,,BAO_0000218
11847,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625794,50597,,N,Intermediate,,BAO_0000218
11848,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625795,50597,,N,Intermediate,,BAO_0000218
11849,,1,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,Mus musculus,,,,,,1,10090.0,A,CHEMBL625796,50594,,N,Intermediate,,BAO_0000218
11850,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625797,50588,,N,Intermediate,,BAO_0000218
11851,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625798,50588,,N,Intermediate,,BAO_0000218
11852,,0,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL875613,22224,,U,Autocuration,,BAO_0000218
11853,,0,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL625799,22224,,U,Autocuration,,BAO_0000218
11854,,0,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL625800,22224,,U,Autocuration,,BAO_0000218
11855,,0,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL625801,22224,,U,Autocuration,,BAO_0000218
11856,,0,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL625802,22224,,U,Autocuration,,BAO_0000218
11857,,0,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL625803,22224,,U,Autocuration,,BAO_0000218
11858,,0,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,,,,,,1,,A,CHEMBL625804,22224,,U,Autocuration,,BAO_0000019
11859,,0,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,,,,,,1,,A,CHEMBL622530,22224,,U,Autocuration,,BAO_0000218
11860,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,Mus musculus,,,,,,1,10090.0,A,CHEMBL622531,50594,,N,Intermediate,,BAO_0000218
11861,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL622532,50594,,N,Intermediate,,BAO_0000218
11862,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL623176,50594,,N,Intermediate,,BAO_0000218
11863,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL623177,50594,,N,Intermediate,,BAO_0000218
11864,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL623178,50594,,N,Intermediate,,BAO_0000218
11865,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,Mus musculus,,,,,,1,10090.0,A,CHEMBL623179,50594,,N,Intermediate,,BAO_0000218
11866,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL623180,50594,,N,Intermediate,,BAO_0000218
11867,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL623181,50594,,N,Intermediate,,BAO_0000218
11868,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL624131,50594,,N,Intermediate,,BAO_0000218
11869,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL624132,50594,,N,Intermediate,,BAO_0000218
11870,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL624133,50594,,N,Intermediate,,BAO_0000218
11871,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,Mus musculus,,,,,,1,10090.0,A,CHEMBL624846,50594,,N,Intermediate,,BAO_0000218
11872,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL624847,50594,,N,Intermediate,,BAO_0000218
11873,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL624848,50594,,N,Intermediate,,BAO_0000218
11874,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625012,50594,,N,Intermediate,,BAO_0000218
11875,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625013,50594,,N,Intermediate,,BAO_0000218
11876,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,Mus musculus,,,,,,1,10090.0,A,CHEMBL625014,50594,,N,Intermediate,,BAO_0000218
11877,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625015,50594,,N,Intermediate,,BAO_0000218
11878,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625016,50594,,N,Intermediate,,BAO_0000218
11879,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,Mus musculus,,,,,,1,10090.0,A,CHEMBL625017,50594,,N,Intermediate,,BAO_0000218
11880,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625018,50594,,N,Intermediate,,BAO_0000218
11881,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625019,50594,,N,Intermediate,,BAO_0000218
11882,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL625020,50594,,N,Intermediate,,BAO_0000218
11883,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,Mus musculus,,,,,,1,10090.0,A,CHEMBL625021,50594,,N,Intermediate,,BAO_0000218
11884,,1,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625022,50597,,N,Intermediate,,BAO_0000218
11885,,1,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,Mus musculus,,,,,,1,10090.0,A,CHEMBL625023,50594,,N,Intermediate,,BAO_0000218
11886,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL625024,100710,,N,Intermediate,,BAO_0000218
11887,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL627626,100710,,N,Intermediate,,BAO_0000218
11888,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,,Brain,955.0,,1,,A,CHEMBL627627,22224,,U,Autocuration,,BAO_0000218
11889,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,,,Serum,1977.0,,1,,A,CHEMBL627628,22224,,U,Autocuration,,BAO_0000218
11890,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,,Brain,955.0,,1,,A,CHEMBL627629,22224,,U,Autocuration,,BAO_0000218
11891,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,,,Serum,1977.0,,1,,A,CHEMBL627630,22224,,U,Autocuration,,BAO_0000218
11892,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,,,,,,1,,A,CHEMBL627631,22224,,U,Autocuration,,BAO_0000019
11893,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,,,,,,1,,A,CHEMBL629515,22224,,U,Autocuration,,BAO_0000218
11894,,1,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL629516,50594,,N,Intermediate,,BAO_0000218
11895,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL629517,50594,,N,Intermediate,,BAO_0000218
11896,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL629518,50594,,N,Intermediate,,BAO_0000218
11897,,1,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Mus musculus,,,,,,1,10090.0,A,CHEMBL877499,50594,,N,Intermediate,,BAO_0000218
11898,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL629519,50594,,N,Intermediate,,BAO_0000218
11899,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL629520,50594,,N,Intermediate,,BAO_0000218
11900,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Mus musculus,,,,,,1,10090.0,A,CHEMBL629521,50594,,N,Intermediate,,BAO_0000218
11901,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL629522,50594,,N,Intermediate,,BAO_0000218
11902,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL629523,50594,,N,Intermediate,,BAO_0000218
11903,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL629524,50594,,N,Intermediate,,BAO_0000218
11904,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL629525,50594,,N,Intermediate,,BAO_0000218
11905,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL629526,50594,,N,Intermediate,,BAO_0000218
11906,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL629527,50594,,N,Intermediate,,BAO_0000218
11907,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL629528,50594,,N,Intermediate,,BAO_0000218
11908,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL629529,50594,,N,Intermediate,,BAO_0000218
11909,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL629530,50594,,N,Intermediate,,BAO_0000218
11910,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL629531,50594,,N,Intermediate,,BAO_0000218
11911,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL628656,50594,,N,Intermediate,,BAO_0000218
11912,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL628657,50594,,N,Intermediate,,BAO_0000218
11913,,1,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628658,50597,,N,Intermediate,,BAO_0000218
11914,,1,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628659,50597,,N,Intermediate,,BAO_0000218
11915,,1,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877500,50597,,N,Intermediate,,BAO_0000218
11916,,1,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628660,50597,,N,Intermediate,,BAO_0000218
11917,,1,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628661,50597,,N,Intermediate,,BAO_0000218
11918,,1,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628662,50597,,N,Intermediate,,BAO_0000218
11919,,1,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628663,50597,,N,Intermediate,,BAO_0000218
11920,,1,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628664,50597,,N,Intermediate,,BAO_0000218
11921,,1,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628665,50597,,N,Intermediate,,BAO_0000218
11922,,1,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628666,50597,,N,Intermediate,,BAO_0000218
11923,,1,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628667,50597,,N,Intermediate,,BAO_0000218
11924,,1,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628668,50597,,N,Intermediate,,BAO_0000218
11925,,1,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628669,50597,,N,Intermediate,,BAO_0000218
11926,,1,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628670,50597,,N,Intermediate,,BAO_0000218
11927,,1,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628671,50597,,N,Intermediate,,BAO_0000218
11928,,1,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL628672,50597,,N,Intermediate,,BAO_0000218
11929,,1,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL630300,50597,,N,Intermediate,,BAO_0000218
11930,,1,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL629787,50597,,N,Intermediate,,BAO_0000218
11931,,1,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL629788,50597,,N,Intermediate,,BAO_0000218
11932,,1,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629789,50597,,N,Intermediate,,BAO_0000218
11933,,1,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629790,50597,,N,Intermediate,,BAO_0000218
11934,,1,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629791,50597,,N,Intermediate,,BAO_0000218
11935,,1,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629792,50597,,N,Intermediate,,BAO_0000218
11936,,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629793,50597,,N,Intermediate,,BAO_0000218
11937,,1,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629794,50597,,N,Intermediate,,BAO_0000218
11938,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874459,50597,,N,Intermediate,,BAO_0000218
11939,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629795,50597,,N,Intermediate,,BAO_0000218
11940,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629796,50597,,N,Intermediate,,BAO_0000218
11941,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629797,50597,,N,Intermediate,,BAO_0000218
11942,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629798,50597,,N,Intermediate,,BAO_0000218
11943,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,A,CHEMBL629799,50597,,N,Intermediate,,BAO_0000218
11944,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,A,CHEMBL629800,50597,,N,Intermediate,,BAO_0000218
11945,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,A,CHEMBL629801,50597,,N,Intermediate,,BAO_0000218
11946,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,A,CHEMBL629802,50597,,N,Intermediate,,BAO_0000218
11947,,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,A,CHEMBL629803,50597,,N,Intermediate,,BAO_0000218
11948,,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629804,50597,,N,Intermediate,,BAO_0000218
11949,,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629805,50597,,N,Intermediate,,BAO_0000218
11950,,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629806,50597,,N,Intermediate,,BAO_0000218
11951,,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629807,50597,,N,Intermediate,,BAO_0000218
11952,,1,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629808,50597,,N,Intermediate,,BAO_0000218
11953,,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629809,50597,,N,Intermediate,,BAO_0000218
11954,,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629810,50597,,N,Intermediate,,BAO_0000218
11955,,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629811,50597,,N,Intermediate,,BAO_0000218
11956,,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629812,50597,,N,Intermediate,,BAO_0000218
11957,,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629813,50597,,N,Intermediate,,BAO_0000218
11958,,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL874460,50597,,N,Intermediate,,BAO_0000218
11959,,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629814,50597,,N,Intermediate,,BAO_0000218
11960,,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629815,50597,,N,Intermediate,,BAO_0000218
11961,,1,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629816,50597,,N,Intermediate,,BAO_0000218
11962,,1,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629817,50597,,N,Intermediate,,BAO_0000218
11963,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626643,50597,,N,Intermediate,,BAO_0000218
11964,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626644,50597,,N,Intermediate,,BAO_0000218
11965,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626806,50597,,N,Intermediate,,BAO_0000218
11966,,1,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626807,50597,,N,Intermediate,,BAO_0000218
11967,,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627261,50597,,N,Intermediate,,BAO_0000218
11968,,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627262,50597,,N,Intermediate,,BAO_0000218
11969,,1,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627263,50597,,N,Intermediate,,BAO_0000218
11970,,1,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627264,50597,,N,Intermediate,,BAO_0000218
11971,,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627265,50597,,N,Intermediate,,BAO_0000218
11972,,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627266,50597,,N,Intermediate,,BAO_0000218
11973,,1,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627267,50597,,N,Intermediate,,BAO_0000218
11974,,1,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627268,50597,,N,Intermediate,,BAO_0000218
11975,,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627269,50597,,N,Intermediate,,BAO_0000218
11976,,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627270,50597,,N,Intermediate,,BAO_0000218
11977,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627271,50597,,N,Intermediate,,BAO_0000218
11978,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627946,50597,,N,Intermediate,,BAO_0000218
11979,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875472,50597,,N,Intermediate,,BAO_0000218
11980,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627947,50597,,N,Intermediate,,BAO_0000218
11981,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627948,50597,,N,Intermediate,,BAO_0000218
11982,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628113,50597,,N,Intermediate,,BAO_0000218
11983,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628114,50597,,N,Intermediate,,BAO_0000218
11984,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628115,50597,,N,Intermediate,,BAO_0000218
11985,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628116,50597,,N,Intermediate,,BAO_0000218
11986,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628117,50597,,N,Intermediate,,BAO_0000218
11987,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628118,50597,,N,Intermediate,,BAO_0000218
11988,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628119,50597,,N,Intermediate,,BAO_0000218
11989,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628120,50597,,N,Intermediate,,BAO_0000218
11990,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628121,50597,,N,Intermediate,,BAO_0000218
11991,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628122,50597,,N,Intermediate,,BAO_0000218
11992,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627297,50597,,N,Intermediate,,BAO_0000218
11993,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627298,50597,,N,Intermediate,,BAO_0000218
11994,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627299,50597,,N,Intermediate,,BAO_0000218
11995,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627300,50597,,N,Intermediate,,BAO_0000218
11996,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627301,50597,,N,Intermediate,,BAO_0000218
11997,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627302,50597,,N,Intermediate,,BAO_0000218
11998,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627303,50597,,N,Intermediate,,BAO_0000218
11999,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627304,50597,,N,Intermediate,,BAO_0000218
12000,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627305,50597,,N,Intermediate,,BAO_0000218
12001,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627306,50597,,N,Intermediate,,BAO_0000218
12002,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623982,50597,,N,Intermediate,,BAO_0000218
12003,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623983,50597,,N,Intermediate,,BAO_0000218
12004,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623984,50597,,N,Intermediate,,BAO_0000218
12005,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623985,50597,,N,Intermediate,,BAO_0000218
12006,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623986,50597,,N,Intermediate,,BAO_0000218
12007,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623987,50597,,N,Intermediate,,BAO_0000218
12008,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623988,50597,,N,Intermediate,,BAO_0000218
12009,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623989,50597,,N,Intermediate,,BAO_0000218
12010,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622215,50597,,N,Intermediate,,BAO_0000218
12011,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622216,50597,,N,Intermediate,,BAO_0000218
12012,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877481,50597,,N,Intermediate,,BAO_0000218
12013,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,,,,,,1,,A,CHEMBL622217,22224,,U,Autocuration,,BAO_0000218
12014,,1,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),Mus musculus,,,,,,1,10090.0,A,CHEMBL622218,50594,,N,Intermediate,,BAO_0000218
12015,,1,Pharmacokinetic profile AUC was evaluated in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622219,50597,,N,Intermediate,,BAO_0000218
12016,,0,Pharmacokinetic property (Area under curve),,,,,,,1,,A,CHEMBL622220,22224,,U,Autocuration,,BAO_0000019
12017,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622221,50588,,N,Intermediate,,BAO_0000218
12018,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",Mus musculus,,,,,,1,10090.0,A,CHEMBL622222,50594,,N,Intermediate,,BAO_0000218
12019,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL622223,50588,,N,Intermediate,,BAO_0000218
12020,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",Mus musculus,,,,,,1,10090.0,A,CHEMBL622224,50594,,N,Intermediate,,BAO_0000218
12021,,0,Plasma concentration (AUC) was determined,,,,,,,1,,A,CHEMBL622225,22224,,U,Autocuration,,BAO_0000019
12022,,0,Plasma concentration (AUC) was determined; Not detectable,,,,,,,1,,A,CHEMBL622226,22224,,U,Autocuration,,BAO_0000019
12023,,1,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),Cavia porcellus,,,,,,1,10141.0,A,CHEMBL624154,50512,,N,Intermediate,,BAO_0000218
12024,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624155,50597,,N,Intermediate,,BAO_0000218
12025,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624156,50597,,N,Intermediate,,BAO_0000218
12026,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624157,50597,,N,Intermediate,,BAO_0000218
12027,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624158,50597,,N,Intermediate,,BAO_0000218
12028,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624159,50597,,N,Intermediate,,BAO_0000218
12029,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624160,50597,,N,Intermediate,,BAO_0000218
12030,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624161,50597,,N,Intermediate,,BAO_0000218
12031,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624162,50597,,N,Intermediate,,BAO_0000218
12032,,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624163,50588,,N,Intermediate,,BAO_0000218
12033,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624164,50597,,N,Intermediate,,BAO_0000218
12034,,1,The AUC(0-infinity) values in female wistar rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624165,50597,,N,Intermediate,,BAO_0000218
12035,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624166,50597,,N,Intermediate,,BAO_0000218
12036,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624167,50597,,N,Intermediate,,BAO_0000218
12037,,1,The AUC(0-t)values in female wistar rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624168,50597,,N,Intermediate,,BAO_0000218
12038,,1,The Area under the concentration time curve of compound was measured on rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624169,50597,,N,Intermediate,,BAO_0000218
12039,,1,The area under curve (100 mg/kg) administered orally in humans,Homo sapiens,,,,,,1,9606.0,A,CHEMBL624170,50587,,N,Intermediate,,BAO_0000218
12040,,0,The area under curve (12.5 mg/kg) administered intravenously in marmoset,Callithrix,,,,,,1,9481.0,A,CHEMBL624171,22224,,U,Autocuration,,BAO_0000218
12041,,0,The area under curve (12.5 mg/kg) administered intravenously in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL624172,22224,,U,Autocuration,,BAO_0000218
12042,,1,The area under curve (15 mg/kg) administered intravenously in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624173,50588,,N,Intermediate,,BAO_0000218
12043,,1,The area under curve (200 mg/kg) administered orally in humans,Homo sapiens,,,,,,1,9606.0,A,CHEMBL877488,50587,,N,Intermediate,,BAO_0000218
12044,,1,The area under curve (25 mg/kg) administered intravenously in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624174,50597,,N,Intermediate,,BAO_0000218
12045,,0,The area under curve (25 mg/kg) administered orally in marmoset,Callithrix,,,,,,1,9481.0,A,CHEMBL624175,22224,,U,Autocuration,,BAO_0000218
12046,,0,The area under curve (25 mg/kg) administered orally in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL624176,22224,,U,Autocuration,,BAO_0000218
12047,,1,The area under curve (30 mg/kg) administered orally in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624177,50588,,N,Intermediate,,BAO_0000218
12048,,1,The area under curve (400 mg/kg) administered orally in humans,Homo sapiens,,,,,,1,9606.0,A,CHEMBL624178,50587,,N,Intermediate,,BAO_0000218
12049,,1,The area under curve (50 mg/kg) administered orally in fasted rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624179,50597,,N,Intermediate,,BAO_0000218
12050,,1,The area under curve (50 mg/kg) administered orally in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627689,50597,,N,Intermediate,,BAO_0000218
12051,,1,The area under curve (800 mg/kg) administered orally in humans,Homo sapiens,,,,,,1,9606.0,A,CHEMBL627690,50587,,N,Intermediate,,BAO_0000218
12052,,0,The compound was evaluated for area under the curve,,,,,,,1,,A,CHEMBL627691,22224,,U,Autocuration,,BAO_0000019
12053,,0,The compound was evaluated for area under the curve in marmosets,Callithrix,,,,,,1,9481.0,A,CHEMBL627692,22224,,U,Autocuration,,BAO_0000019
12054,,0,The compound was evaluated for area under the curve in marmosets,Callithrix,,,,,,1,9481.0,A,CHEMBL627693,22224,,U,Autocuration,,BAO_0000019
12055,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627694,50597,,N,Intermediate,,BAO_0000218
12056,,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627695,50597,,N,Intermediate,,BAO_0000218
12057,,0,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,,,,,,1,,A,CHEMBL627696,22224,,U,Autocuration,,BAO_0000218
12058,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627697,50597,,N,Intermediate,,BAO_0000218
12059,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627698,50597,,N,Intermediate,,BAO_0000218
12060,,1,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627699,50597,,N,Intermediate,,BAO_0000218
12061,,1,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627700,50597,,N,Intermediate,,BAO_0000218
12062,,1,Total drug exposure is determined after oral dosing in rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627701,50597,,N,Intermediate,,BAO_0000218
12063,,0,Total drug exposure (5 mg/kg) when administered intravenously,,,,,,,1,,A,CHEMBL627702,22224,,U,Autocuration,,BAO_0000218
12064,,0,Total drug exposure (5 mg/kg) when administered orally,,,,,,,1,,A,CHEMBL627703,22224,,U,Autocuration,,BAO_0000218
12065,,0,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL626873,22224,,U,Autocuration,,BAO_0000218
12066,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629583,50597,,N,Intermediate,,BAO_0000218
12067,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629584,50588,,N,Intermediate,,BAO_0000218
12068,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629585,50588,,N,Intermediate,,BAO_0000218
12069,,1,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629586,50597,,N,Intermediate,,BAO_0000218
12070,,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL629587,50597,,N,Intermediate,,BAO_0000218
12071,,1,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629588,50597,,N,Intermediate,,BAO_0000218
12072,,1,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629589,50597,,N,Intermediate,,BAO_0000218
12073,,1,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629590,50597,,N,Intermediate,,BAO_0000218
12074,,1,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629591,50597,,N,Intermediate,,BAO_0000218
12075,,1,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629592,50597,,N,Intermediate,,BAO_0000218
12076,,1,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629593,50597,,N,Intermediate,,BAO_0000218
12077,,1,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629594,50597,,N,Intermediate,,BAO_0000218
12078,,1,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL629595,50597,,N,Intermediate,,BAO_0000218
12079,,1,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630290,50597,,N,Intermediate,,BAO_0000218
12080,,1,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627137,50597,,N,Intermediate,,BAO_0000218
12081,,1,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627138,50597,,N,Intermediate,,BAO_0000218
12082,,1,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627139,50597,,N,Intermediate,,BAO_0000218
12083,,1,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627140,50597,,N,Intermediate,,BAO_0000218
12084,,1,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627141,50597,,N,Intermediate,,BAO_0000218
12085,,1,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627142,50597,,N,Intermediate,,BAO_0000218
12086,,1,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627143,50597,,N,Intermediate,,BAO_0000218
12087,,1,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL874449,50597,,N,Intermediate,,BAO_0000218
12088,,1,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627144,50597,,N,Intermediate,,BAO_0000218
12089,,1,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627145,50597,,N,Intermediate,,BAO_0000218
12090,,1,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627146,50597,,N,Intermediate,,BAO_0000218
12091,,1,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627147,50597,,N,Intermediate,,BAO_0000218
12092,,1,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627148,50597,,N,Intermediate,,BAO_0000218
12093,,1,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627149,50597,,N,Intermediate,,BAO_0000218
12094,,1,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL632160,50597,,N,Intermediate,,BAO_0000218
12095,,1,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL632161,50597,,N,Intermediate,,BAO_0000218
12096,,1,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL632162,50597,,N,Intermediate,,BAO_0000218
12097,,1,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL632163,50597,,N,Intermediate,,BAO_0000218
12098,,1,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL874469,50597,,N,Intermediate,,BAO_0000218
12099,,1,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627182,50597,,N,Intermediate,,BAO_0000218
12100,,1,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627183,50597,,N,Intermediate,,BAO_0000218
12101,,1,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627184,50597,,N,Intermediate,,BAO_0000218
12102,,1,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627185,50597,,N,Intermediate,,BAO_0000218
12103,,1,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627186,50597,,N,Intermediate,,BAO_0000218
12104,,1,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627187,50597,,N,Intermediate,,BAO_0000218
12105,,1,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627188,50597,,N,Intermediate,,BAO_0000218
12106,,1,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627189,50597,,N,Intermediate,,BAO_0000218
12107,,1,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627190,50597,,N,Intermediate,,BAO_0000218
12108,,1,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627191,50597,,N,Intermediate,,BAO_0000218
12109,,1,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627192,50597,,N,Intermediate,,BAO_0000218
12110,,1,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627193,50597,,N,Intermediate,,BAO_0000218
12111,,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL874590,50597,,N,Intermediate,,BAO_0000218
12112,,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627194,50597,,N,Intermediate,,BAO_0000218
12113,,1,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627195,50597,,N,Intermediate,,BAO_0000218
12114,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL627196,50597,,N,Intermediate,,BAO_0000218
12115,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL627197,50597,,N,Intermediate,,BAO_0000218
12116,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL627198,50597,,N,Intermediate,,BAO_0000218
12117,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL627199,50597,,N,Intermediate,,BAO_0000218
12118,,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Female gonad,992.0,,1,10116.0,A,CHEMBL627200,50597,,N,Intermediate,,BAO_0000218
12119,,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627201,50597,,N,Intermediate,,BAO_0000218
12120,,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627202,50597,,N,Intermediate,,BAO_0000218
12121,,1,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627203,50597,,N,Intermediate,,BAO_0000218
12122,,1,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627204,50597,,N,Intermediate,,BAO_0000218
12123,,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627205,50597,,N,Intermediate,,BAO_0000218
12124,,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627206,50597,,N,Intermediate,,BAO_0000218
12125,,1,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627207,50597,,N,Intermediate,,BAO_0000218
12126,,1,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627208,50597,,N,Intermediate,,BAO_0000218
12127,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627209,50597,,N,Intermediate,,BAO_0000218
12128,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627210,50597,,N,Intermediate,,BAO_0000218
12129,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627211,50597,,N,Intermediate,,BAO_0000218
12130,,1,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627212,50597,,N,Intermediate,,BAO_0000218
12131,,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL627213,50597,,N,Intermediate,,BAO_0000218
12132,,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626599,50597,,N,Intermediate,,BAO_0000218
12133,,1,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626600,50597,,N,Intermediate,,BAO_0000218
12134,,1,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL626601,50597,,N,Intermediate,,BAO_0000218
12135,,0,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,,,,,,1,,A,CHEMBL627484,22224,,U,Autocuration,,BAO_0000019
12136,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL627485,100710,,N,Intermediate,,BAO_0000218
12137,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL628147,100710,,N,Intermediate,,BAO_0000218
12138,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL628148,100710,,N,Intermediate,,BAO_0000218
12139,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628149,50588,,N,Intermediate,,BAO_0000218
12140,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628150,50588,,N,Intermediate,,BAO_0000218
12141,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628318,50588,,N,Intermediate,,BAO_0000218
12142,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628319,50588,,N,Intermediate,,BAO_0000218
12143,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL875609,50588,,N,Intermediate,,BAO_0000218
12144,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,,,,,,1,,A,CHEMBL628320,22224,,U,Autocuration,,BAO_0000019
12145,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,,,,,,1,,A,CHEMBL628321,22224,,U,Autocuration,,BAO_0000019
12146,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,,,,,,1,,A,CHEMBL628322,22224,,U,Autocuration,,BAO_0000019
12147,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,,,,,,1,,A,CHEMBL628323,22224,,U,Autocuration,,BAO_0000019
12148,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,,,,,,1,,A,CHEMBL628324,22224,,U,Autocuration,,BAO_0000019
12149,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,,,,,,1,,A,CHEMBL628325,22224,,U,Autocuration,,BAO_0000019
12150,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,,,,,,1,,A,CHEMBL628326,22224,,U,Autocuration,,BAO_0000019
12151,,1,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL628327,50588,,N,Intermediate,,BAO_0000218
12152,,1,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL628328,50588,,N,Intermediate,,BAO_0000218
12153,,1,"Concentration of compound in blood of dog 1, after administering intravenously",Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL628329,50588,,N,Intermediate,,BAO_0000218
12154,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628330,50597,,N,Intermediate,,BAO_0000218
12155,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628331,50597,,N,Intermediate,,BAO_0000218
12156,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628332,50597,,N,Intermediate,,BAO_0000218
12157,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628333,50597,,N,Intermediate,,BAO_0000218
12158,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628334,50597,,N,Intermediate,,BAO_0000218
12159,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628335,50597,,N,Intermediate,,BAO_0000218
12160,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628336,50597,,N,Intermediate,,BAO_0000218
12161,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628337,50597,,N,Intermediate,,BAO_0000218
12162,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628338,50597,,N,Intermediate,,BAO_0000218
12163,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL875610,50597,,N,Intermediate,,BAO_0000218
12164,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628339,50597,,N,Intermediate,,BAO_0000218
12165,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628340,50597,,N,Intermediate,,BAO_0000218
12166,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628341,50597,,N,Intermediate,,BAO_0000218
12167,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622214,50597,,N,Intermediate,,BAO_0000218
12168,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623167,50597,,N,Intermediate,,BAO_0000218
12169,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623168,50597,,N,Intermediate,,BAO_0000218
12170,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623169,50597,,N,Intermediate,,BAO_0000218
12171,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623170,50597,,N,Intermediate,,BAO_0000218
12172,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627224,50597,,N,Intermediate,,BAO_0000218
12173,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL875634,50597,,N,Intermediate,,BAO_0000218
12174,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627225,50597,,N,Intermediate,,BAO_0000218
12175,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627226,50597,,N,Intermediate,,BAO_0000218
12176,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626083,50597,,N,Intermediate,,BAO_0000218
12177,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626084,50597,,N,Intermediate,,BAO_0000218
12178,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626085,50597,,N,Intermediate,,BAO_0000218
12179,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626086,50597,,N,Intermediate,,BAO_0000218
12180,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626087,50597,,N,Intermediate,,BAO_0000218
12181,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626088,50597,,N,Intermediate,,BAO_0000218
12182,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626089,50597,,N,Intermediate,,BAO_0000218
12183,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626090,50597,,N,Intermediate,,BAO_0000218
12184,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626091,50597,,N,Intermediate,,BAO_0000218
12185,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626092,50597,,N,Intermediate,,BAO_0000218
12186,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626093,50597,,N,Intermediate,,BAO_0000218
12187,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626094,50597,,N,Intermediate,,BAO_0000218
12188,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626095,50597,,N,Intermediate,,BAO_0000218
12189,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL626096,50597,,N,Intermediate,,BAO_0000218
12190,,0,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL626097,22224,,U,Autocuration,,BAO_0000218
12191,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626098,50597,,N,Intermediate,,BAO_0000218
12192,,0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,,,Plasma,1969.0,,1,,A,CHEMBL626099,22224,,U,Autocuration,,BAO_0000218
12193,,0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,,,Plasma,1969.0,,1,,A,CHEMBL626100,22224,,U,Autocuration,,BAO_0000218
12194,,1,AUC 0-inf in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626101,50588,,N,Intermediate,,BAO_0000218
12195,,1,AUC 0-inf in guinea pig,Cavia porcellus,,,Plasma,1969.0,,1,10141.0,A,CHEMBL626102,50512,,N,Intermediate,,BAO_0000218
12196,,1,AUC 0-t in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626103,50588,,N,Intermediate,,BAO_0000218
12197,,1,AUC 0-t in guinea pig,Cavia porcellus,,,Plasma,1969.0,,1,10141.0,A,CHEMBL628391,50512,,N,Intermediate,,BAO_0000218
12198,,1,The compound was tested for brain to plasma partition in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628392,50597,,N,Intermediate,,BAO_0000218
12199,,1,The compound was tested for brain to plasma partition in rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628393,50597,,N,Intermediate,,BAO_0000218
12200,,0,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,,,Blood,178.0,,1,,A,CHEMBL628394,22224,,U,Autocuration,,BAO_0000019
12201,,1,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628395,50588,,N,Intermediate,,BAO_0000218
12202,,0,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,Simiiformes,,,,,,1,314293.0,A,CHEMBL628396,22224,,U,Autocuration,,BAO_0000218
12203,,1,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL628397,50592,,N,Intermediate,,BAO_0000218
12204,,1,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628398,50597,,N,Intermediate,,BAO_0000218
12205,,1,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL628399,50797,,N,Intermediate,,BAO_0000218
12206,,1,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628400,50588,,N,Intermediate,,BAO_0000218
12207,,1,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874907,50597,,N,Intermediate,,BAO_0000218
12208,,0,Area under curve of the compound was determined,,,,,,,1,,A,CHEMBL628401,22224,,U,Autocuration,,BAO_0000019
12209,,0,AUC in monkeys at a dose of 1 mg/kg,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL628402,22224,,U,Autocuration,,BAO_0000218
12210,,1,AUC in rats at a dose of 1 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628403,50597,,N,Intermediate,,BAO_0000218
12211,,0,Compound was evaluated for the overall absorbance loss at pH of 2,,,,,,,1,,A,CHEMBL628404,22224,,U,Autocuration,,BAO_0000019
12212,,0,Compound was evaluated for the overall absorbance loss at pH of 4,,,,,,,1,,A,CHEMBL628405,22224,,U,Autocuration,,BAO_0000019
12213,,0,Compound was evaluated for the overall absorbance loss at pH of 7,,,,,,,1,,A,CHEMBL628406,22224,,U,Autocuration,,BAO_0000019
12214,,1,Compound was evaluated for its absorption in the rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628407,50597,,N,Intermediate,,BAO_0000218
12215,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628408,50597,,N,Intermediate,,BAO_0000218
12216,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629171,50597,,N,Intermediate,,BAO_0000218
12217,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629172,50597,,N,Intermediate,,BAO_0000218
12218,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629173,50597,,N,Intermediate,,BAO_0000218
12219,,1,In vitro percent permeability into rat ileum,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629174,50597,,N,Intermediate,,BAO_0000218
12220,,1,In vitro percent permeability into rat ileum; Range is 10-17,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629175,50597,,N,Intermediate,,BAO_0000218
12221,,1,In vitro percent permeability into rat ileum; Range is 10-18,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629176,50597,,N,Intermediate,,BAO_0000218
12222,,1,In vitro percent permeability into rat ileum; Range is 10-19,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629177,50597,,N,Intermediate,,BAO_0000218
12223,,1,In vitro percent permeability into rat ileum; Range is 12-15,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629178,50597,,N,Intermediate,,BAO_0000218
12224,,1,In vitro percent permeability into rat ileum; Range is 13-19,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631869,50597,,N,Intermediate,,BAO_0000218
12225,,1,In vitro percent permeability into rat ileum; Range is 14-17,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631870,50597,,N,Intermediate,,BAO_0000218
12226,,1,In vitro percent permeability into rat ileum; Range is 15-18,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631871,50597,,N,Intermediate,,BAO_0000218
12227,,1,In vitro percent permeability into rat ileum; Range is 2-5,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631872,50597,,N,Intermediate,,BAO_0000218
12228,,0,In vitro percent permeability into rat ileum; Range is 23-42,,,,Ileum,2116.0,,1,,A,CHEMBL875775,22224,,U,Autocuration,,BAO_0000221
12229,,1,In vitro percent permeability into rat ileum; Range is 28-36,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631873,50597,,N,Intermediate,,BAO_0000218
12230,,1,In vitro percent permeability into rat ileum; Range is 29-35,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631874,50597,,N,Intermediate,,BAO_0000218
12231,,1,In vitro percent permeability into rat ileum; Range is 46-66,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631875,50597,,N,Intermediate,,BAO_0000218
12232,,1,In vitro percent permeability into rat ileum; Range is 50-68,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631876,50597,,N,Intermediate,,BAO_0000218
12233,,1,In vitro percent permeability into rat ileum; Range is 78-81,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631877,50597,,N,Intermediate,,BAO_0000218
12234,,1,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631878,50597,,N,Intermediate,,BAO_0000218
12235,,1,In vitro percent permeability into rat ileum; nd indicates not detected,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631879,50597,,N,Intermediate,,BAO_0000218
12236,,1,In vitro percent permeability into rat ileum; nt indicates not detected,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631880,50597,,N,Intermediate,,BAO_0000218
12237,,1,In vitro percent permeability into rat ileum; nt indicates not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631881,50597,,N,Intermediate,,BAO_0000218
12238,,1,Compound was tested for oral absorption in bile-duct cannulated rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631882,50597,,N,Intermediate,,BAO_0000218
12239,,1,Compound was tested for oral absorption in bile-duct cannulated rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630749,50597,,N,Intermediate,,BAO_0000218
12240,,1,Oral absorption using Caco-2 cell monolayers.,Homo sapiens,,,,,,1,9606.0,A,CHEMBL630750,50587,,N,Intermediate,,BAO_0000218
12241,,1,Percent of the drug absorbed after administration to humans was determined,Homo sapiens,,,,,,1,9606.0,A,CHEMBL630253,50587,,N,Intermediate,,BAO_0000218
12242,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL630254,50597,,N,Intermediate,,BAO_0000218
12243,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL630255,50597,,N,Intermediate,,BAO_0000218
12244,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL630256,50597,,N,Intermediate,,BAO_0000218
12245,,1,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL875781,50597,,N,Intermediate,,BAO_0000218
12246,,1,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL630257,50597,,N,Intermediate,,BAO_0000218
12247,,1,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL630258,50597,,N,Intermediate,,BAO_0000218
12248,,1,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630259,50597,,N,Intermediate,,BAO_0000218
12249,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL630260,50597,,N,Intermediate,,BAO_0000218
12250,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL630261,50597,,N,Intermediate,,BAO_0000218
12251,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630262,50597,,N,Intermediate,,BAO_0000218
12252,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630263,50597,,N,Intermediate,,BAO_0000218
12253,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630264,50597,,N,Intermediate,,BAO_0000218
12254,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630265,50597,,N,Intermediate,,BAO_0000218
12255,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630266,50597,,N,Intermediate,,BAO_0000218
12256,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630267,50597,,N,Intermediate,,BAO_0000218
12257,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630268,50597,,N,Intermediate,,BAO_0000218
12258,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630269,50597,,N,Intermediate,,BAO_0000218
12259,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630270,50597,,N,Intermediate,,BAO_0000218
12260,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630141,50597,,N,Intermediate,,BAO_0000218
12261,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630142,50597,,N,Intermediate,,BAO_0000218
12262,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630143,50597,,N,Intermediate,,BAO_0000218
12263,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630144,50597,,N,Intermediate,,BAO_0000218
12264,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Rattus norvegicus,,,Prostate gland,2367.0,,1,10116.0,A,CHEMBL630145,50597,,N,Intermediate,,BAO_0000218
12265,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Rattus norvegicus,,,Prostate gland,2367.0,,1,10116.0,A,CHEMBL630146,50597,,N,Intermediate,,BAO_0000218
12266,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630147,50597,,N,Intermediate,,BAO_0000218
12267,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630148,50597,,N,Intermediate,,BAO_0000218
12268,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630149,50597,,N,Intermediate,,BAO_0000218
12269,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630150,50597,,N,Intermediate,,BAO_0000218
12270,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630151,50597,,N,Intermediate,,BAO_0000218
12271,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL632031,50597,,N,Intermediate,,BAO_0000218
12272,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL632032,50597,,N,Intermediate,,BAO_0000218
12273,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632033,50597,,N,Intermediate,,BAO_0000218
12274,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632034,50597,,N,Intermediate,,BAO_0000218
12275,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL632035,50597,,N,Intermediate,,BAO_0000218
12276,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632036,50597,,N,Intermediate,,BAO_0000218
12277,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL632037,50597,,N,Intermediate,,BAO_0000218
12278,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632038,50597,,N,Intermediate,,BAO_0000218
12279,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632039,50597,,N,Intermediate,,BAO_0000218
12280,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632040,50597,,N,Intermediate,,BAO_0000218
12281,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL632041,50597,,N,Intermediate,,BAO_0000218
12282,,1,"Concentration of compound in blood of dog 2, after administering intravenously",Canis lupus familiaris,,,Blood,178.0,,1,9615.0,A,CHEMBL632042,50588,,N,Intermediate,,BAO_0000218
12283,,1,"Concentration of compound in left ventricle of dog 1, after administering intravenously",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL632043,50588,,N,Intermediate,,BAO_0000218
12284,,1,"Concentration of compound in left ventricle of dog 2, after administering intravenously",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL632044,50588,,N,Intermediate,,BAO_0000218
12285,,1,"Concentration of compound in liver of dog 1, after administering intravenously",Canis lupus familiaris,,,Liver,2107.0,,1,9615.0,A,CHEMBL632045,50588,,N,Intermediate,,BAO_0000218
12286,,1,"Concentration of compound in liver of dog 2, after administering intravenously",Canis lupus familiaris,,,Liver,2107.0,,1,9615.0,A,CHEMBL632046,50588,,N,Intermediate,,BAO_0000218
12287,,1,"Concentration of compound in lung of dog 1, after administering intravenously",Canis lupus familiaris,,,Lung,2048.0,,1,9615.0,A,CHEMBL632047,50588,,N,Intermediate,,BAO_0000218
12288,,1,"Concentration of compound in lung of dog 2, after administering intravenously",Canis lupus familiaris,,,Lung,2048.0,,1,9615.0,A,CHEMBL632048,50588,,N,Intermediate,,BAO_0000218
12289,,1,"Concentration of compound in muscle of dog 1, after administering intravenously",Canis lupus familiaris,,,Muscle tissue,2385.0,,1,9615.0,A,CHEMBL632049,50588,,N,Intermediate,,BAO_0000218
12290,,1,"Concentration of compound in muscle of dog 2, after administering intravenously",Canis lupus familiaris,,,Muscle tissue,2385.0,,1,9615.0,A,CHEMBL876418,50588,,N,Intermediate,,BAO_0000218
12291,,1,"Concentration of compound in spleen of dog 1,after administering intravenously",Canis lupus familiaris,,,Spleen,2106.0,,1,9615.0,A,CHEMBL632050,50588,,N,Intermediate,,BAO_0000218
12292,,1,"Concentration of compound in spleen of dog 2, after administering intravenously",Canis lupus familiaris,,,Spleen,2106.0,,1,9615.0,A,CHEMBL632051,50588,,N,Intermediate,,BAO_0000218
12293,,0,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,,,,,,1,,F,CHEMBL632052,22224,,U,Autocuration,,BAO_0000218
12294,,0,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,,,,,,1,,F,CHEMBL632053,22224,,U,Autocuration,,BAO_0000218
12295,,0,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,1,,A,CHEMBL632054,22224,,U,Autocuration,,BAO_0000218
12296,,0,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,,,,,,1,,F,CHEMBL632055,22224,,U,Autocuration,,BAO_0000218
12297,,0,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,,,,,,1,,F,CHEMBL631181,22224,,U,Autocuration,,BAO_0000218
12298,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,,,,,,1,,A,CHEMBL631182,22224,,U,Autocuration,,BAO_0000218
12299,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,1,,A,CHEMBL631183,22224,,U,Autocuration,,BAO_0000218
12300,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL631184,22224,,U,Autocuration,,BAO_0000218
12301,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL629774,22224,,U,Autocuration,,BAO_0000218
12302,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL629775,22224,,U,Autocuration,,BAO_0000218
12303,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL876549,22224,,U,Autocuration,,BAO_0000218
12304,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL628172,22224,,U,Autocuration,,BAO_0000218
12305,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL628173,22224,,U,Autocuration,,BAO_0000218
12306,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,,,,,,1,,A,CHEMBL628174,22224,,U,Autocuration,,BAO_0000218
12307,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,,,,,,1,,A,CHEMBL628175,22224,,U,Autocuration,,BAO_0000218
12308,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL628176,22224,,U,Autocuration,,BAO_0000218
12309,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL628177,22224,,U,Autocuration,,BAO_0000218
12310,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL628178,22224,,U,Autocuration,,BAO_0000218
12311,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL628179,22224,,U,Autocuration,,BAO_0000218
12312,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,1,,A,CHEMBL628180,22224,,U,Autocuration,,BAO_0000218
12313,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,,,,,,1,,A,CHEMBL628181,22224,,U,Autocuration,,BAO_0000218
12314,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL628182,22224,,U,Autocuration,,BAO_0000218
12315,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL628183,22224,,U,Autocuration,,BAO_0000218
12316,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,,,,,,1,,A,CHEMBL628184,22224,,U,Autocuration,,BAO_0000218
12317,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL628185,22224,,U,Autocuration,,BAO_0000218
12318,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL875617,22224,,U,Autocuration,,BAO_0000218
12319,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,1,,A,CHEMBL628186,22224,,U,Autocuration,,BAO_0000218
12320,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL628187,22224,,U,Autocuration,,BAO_0000218
12321,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL628188,22224,,U,Autocuration,,BAO_0000218
12322,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL628189,22224,,U,Autocuration,,BAO_0000218
12323,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,,,,,,1,,A,CHEMBL628190,22224,,U,Autocuration,,BAO_0000218
12324,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL628191,22224,,U,Autocuration,,BAO_0000218
12325,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,,,,,,1,,A,CHEMBL626513,22224,,U,Autocuration,,BAO_0000218
12326,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626514,50597,,N,Intermediate,,BAO_0000218
12327,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626515,50597,,N,Intermediate,,BAO_0000218
12328,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626516,50597,,N,Intermediate,,BAO_0000218
12329,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626517,50597,,N,Intermediate,,BAO_0000218
12330,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626518,50597,,N,Intermediate,,BAO_0000218
12331,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626519,50597,,N,Intermediate,,BAO_0000218
12332,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626520,50597,,N,Intermediate,,BAO_0000218
12333,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626521,50597,,N,Intermediate,,BAO_0000218
12334,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626522,50597,,N,Intermediate,,BAO_0000218
12335,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626523,50597,,N,Intermediate,,BAO_0000218
12336,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626524,50597,,N,Intermediate,,BAO_0000218
12337,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626688,50597,,N,Intermediate,,BAO_0000218
12338,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626689,50597,,N,Intermediate,,BAO_0000218
12339,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626690,50597,,N,Intermediate,,BAO_0000218
12340,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626691,50597,,N,Intermediate,,BAO_0000218
12341,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL627319,50597,,N,Intermediate,,BAO_0000218
12342,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL624052,50597,,N,Intermediate,,BAO_0000218
12343,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL624053,50597,,N,Intermediate,,BAO_0000218
12344,,1,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624054,50597,,N,Intermediate,,BAO_0000218
12345,,1,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624055,50597,,N,Intermediate,,BAO_0000218
12346,,1,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624056,50597,,N,Intermediate,,BAO_0000218
12347,,1,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL624057,50597,,N,Intermediate,,BAO_0000218
12348,,1,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622281,50597,,N,Intermediate,,BAO_0000218
12349,,1,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622282,50597,,N,Intermediate,,BAO_0000218
12350,,1,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622283,50597,,N,Intermediate,,BAO_0000218
12351,,1,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622284,50597,,N,Intermediate,,BAO_0000218
12352,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622285,50597,,N,Intermediate,,BAO_0000218
12353,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL622286,50597,,N,Intermediate,,BAO_0000218
12354,,0,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,,,,,,1,,P,CHEMBL622287,22224,,U,Autocuration,,BAO_0000100
12355,,1,Partition coefficient (logD7.4),Mus musculus,,,,,,1,10090.0,A,CHEMBL622288,50594,,N,Intermediate,,BAO_0000218
12356,,1,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL622289,50594,,N,Intermediate,,BAO_0000218
12357,,1,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622290,50594,,N,Intermediate,,BAO_0000218
12358,,1,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Mus musculus,,,,,,1,10090.0,A,CHEMBL622291,50594,,N,Intermediate,,BAO_0000218
12359,,1,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622292,50594,,N,Intermediate,,BAO_0000218
12360,,1,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL622293,50594,,N,Intermediate,,BAO_0000218
12361,,1,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL622294,50594,,N,Intermediate,,BAO_0000218
12362,,1,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,Mus musculus,,,,,,1,10090.0,A,CHEMBL622295,50594,,N,Intermediate,,BAO_0000218
12363,,1,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL622296,50597,,N,Intermediate,,BAO_0000218
12364,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL874409,50597,,N,Intermediate,,BAO_0000218
12365,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622297,50597,,N,Intermediate,,BAO_0000218
12366,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622298,50597,,N,Intermediate,,BAO_0000218
12367,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622299,50597,,N,Intermediate,,BAO_0000218
12368,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622300,50597,,N,Intermediate,,BAO_0000218
12369,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622301,50597,,N,Intermediate,,BAO_0000218
12370,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622302,50597,,N,Intermediate,,BAO_0000218
12371,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622303,50597,,N,Intermediate,,BAO_0000218
12372,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622304,50597,,N,Intermediate,,BAO_0000218
12373,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622305,50597,,N,Intermediate,,BAO_0000218
12374,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622306,50597,,N,Intermediate,,BAO_0000218
12375,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626864,50597,,N,Intermediate,,BAO_0000218
12376,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626865,50597,,N,Intermediate,,BAO_0000218
12377,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626866,50597,,N,Intermediate,,BAO_0000218
12378,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626867,50597,,N,Intermediate,,BAO_0000218
12379,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626868,50597,,N,Intermediate,,BAO_0000218
12380,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626869,50597,,N,Intermediate,,BAO_0000218
12381,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626870,50597,,N,Intermediate,,BAO_0000218
12382,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626871,50597,,N,Intermediate,,BAO_0000218
12383,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626872,50597,,N,Intermediate,,BAO_0000218
12384,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632185,50597,,N,Intermediate,,BAO_0000218
12385,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL632186,50597,,N,Intermediate,,BAO_0000218
12386,,0,Amount of acetic acid produced by the compound,,,,,,,1,,A,CHEMBL629310,22224,,U,Autocuration,,BAO_0000019
12387,,0,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,,,,,,1,,A,CHEMBL629311,22224,,U,Autocuration,,BAO_0000019
12388,,1,Log of (Cbrain/Cblood) in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629312,50597,,N,Intermediate,,BAO_0000218
12389,,0,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629313,22224,,U,Autocuration,,BAO_0000221
12390,,0,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629314,22224,,U,Autocuration,,BAO_0000221
12391,,0,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629315,22224,,U,Autocuration,,BAO_0000221
12392,,0,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,,,,,,1,,B,CHEMBL629316,22224,,U,Autocuration,,BAO_0000219
12393,,0,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629317,22224,,U,Autocuration,,BAO_0000221
12394,,0,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629318,22224,,U,Autocuration,,BAO_0000019
12395,,0,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL877497,22224,,U,Autocuration,,BAO_0000019
12396,,0,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629319,22224,,U,Autocuration,,BAO_0000019
12397,,0,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629320,22224,,U,Autocuration,,BAO_0000019
12398,,0,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629496,22224,,U,Autocuration,,BAO_0000019
12399,,0,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629497,22224,,U,Autocuration,,BAO_0000019
12400,,0,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629498,22224,,U,Autocuration,,BAO_0000019
12401,,0,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629499,22224,,U,Autocuration,,BAO_0000019
12402,,0,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629500,22224,,U,Autocuration,,BAO_0000019
12403,,0,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629501,22224,,U,Autocuration,,BAO_0000019
12404,,0,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,,,,,,1,,A,CHEMBL629502,22224,,U,Autocuration,,BAO_0000019
12405,,0,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,,,,,,1,,F,CHEMBL629503,22224,,U,Autocuration,,BAO_0000218
12406,,1,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629504,50588,,N,Intermediate,,BAO_0000218
12407,,0,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,,,,,,1,,A,CHEMBL629505,22224,,U,Autocuration,,BAO_0000019
12408,,0,Compound was evaluated for total body clearance,,,,,,,1,,A,CHEMBL629506,22224,,U,Autocuration,,BAO_0000019
12409,,0,Compound was evaluated for volume of distribution at steady state,,,,,,,1,,A,CHEMBL629507,22224,,U,Autocuration,,BAO_0000019
12410,,0,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,,,,,,1,,A,CHEMBL877498,22224,,U,Autocuration,,BAO_0000019
12411,,0,Percentage of the diamine which is monoprotonated at pH 7.4,,,,,,,1,,A,CHEMBL629508,22224,,U,Autocuration,,BAO_0000019
12412,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,,,,,,1,,A,CHEMBL629509,22224,,U,Autocuration,,BAO_0000019
12413,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629510,50597,,N,Intermediate,,BAO_0000218
12414,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629511,50597,,N,Intermediate,,BAO_0000218
12415,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629512,50597,,N,Intermediate,,BAO_0000218
12416,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629513,50597,,N,Intermediate,,BAO_0000218
12417,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629514,50597,,N,Intermediate,,BAO_0000218
12418,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628447,50597,,N,Intermediate,,BAO_0000218
12419,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628448,50597,,N,Intermediate,,BAO_0000218
12420,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628449,50597,,N,Intermediate,,BAO_0000218
12421,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631119,50597,,N,Intermediate,,BAO_0000218
12422,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631120,50597,,N,Intermediate,,BAO_0000218
12423,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631121,50597,,N,Intermediate,,BAO_0000218
12424,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL874458,50597,,N,Intermediate,,BAO_0000218
12425,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631122,50597,,N,Intermediate,,BAO_0000218
12426,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631123,50597,,N,Intermediate,,BAO_0000218
12427,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631124,50597,,N,Intermediate,,BAO_0000218
12428,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631125,50597,,N,Intermediate,,BAO_0000218
12429,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631290,50597,,N,Intermediate,,BAO_0000218
12430,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631291,50597,,N,Intermediate,,BAO_0000218
12431,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631292,50597,,N,Intermediate,,BAO_0000218
12432,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631293,50597,,N,Intermediate,,BAO_0000218
12433,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631294,50597,,N,Intermediate,,BAO_0000218
12434,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631295,50597,,N,Intermediate,,BAO_0000218
12435,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631296,50597,,N,Intermediate,,BAO_0000218
12436,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631297,50597,,N,Intermediate,,BAO_0000218
12437,,0,Maximum biodistribution (Bmax) was determined.,,,,,,,1,,A,CHEMBL631298,22224,,U,Autocuration,,BAO_0000218
12438,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL631299,50594,,N,Intermediate,,BAO_0000218
12439,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL631300,50594,,N,Intermediate,,BAO_0000218
12440,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL631301,50594,,N,Intermediate,,BAO_0000218
12441,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,Mus musculus,,,,,,1,10090.0,A,CHEMBL630291,50594,,N,Intermediate,,BAO_0000218
12442,,0,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,1,,A,CHEMBL630292,22224,,U,Autocuration,,BAO_0000218
12443,,0,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,,,,,,1,,A,CHEMBL630293,22224,,U,Autocuration,,BAO_0000218
12444,,0,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL630294,22224,,U,Autocuration,,BAO_0000218
12445,,0,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,1,,A,CHEMBL630295,22224,,U,Autocuration,,BAO_0000218
12446,,0,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,1,,A,CHEMBL630296,22224,,U,Autocuration,,BAO_0000218
12447,,0,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626782,22224,,U,Autocuration,,BAO_0000218
12448,,0,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626783,22224,,U,Autocuration,,BAO_0000218
12449,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,1,,A,CHEMBL626784,22224,,U,Autocuration,,BAO_0000218
12450,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,1,,A,CHEMBL626785,22224,,U,Autocuration,,BAO_0000218
12451,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626786,22224,,U,Autocuration,,BAO_0000218
12452,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL626787,22224,,U,Autocuration,,BAO_0000218
12453,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,,,,,,1,,A,CHEMBL626788,22224,,U,Autocuration,,BAO_0000218
12454,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL625927,22224,,U,Autocuration,,BAO_0000218
12455,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625928,50597,,N,Intermediate,,BAO_0000218
12456,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625929,50597,,N,Intermediate,,BAO_0000218
12457,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625930,50597,,N,Intermediate,,BAO_0000218
12458,,1,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625931,50597,,N,Intermediate,,BAO_0000218
12459,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627230,50597,,N,Intermediate,,BAO_0000218
12460,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627231,50597,,N,Intermediate,,BAO_0000218
12461,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627232,50597,,N,Intermediate,,BAO_0000218
12462,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627233,50597,,N,Intermediate,,BAO_0000218
12463,,1,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL875470,50597,,N,Intermediate,,BAO_0000218
12464,,1,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627234,50597,,N,Intermediate,,BAO_0000218
12465,,1,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627235,50597,,N,Intermediate,,BAO_0000218
12466,,1,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627236,50597,,N,Intermediate,,BAO_0000218
12467,,1,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627237,50597,,N,Intermediate,,BAO_0000218
12468,,1,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627238,50597,,N,Intermediate,,BAO_0000218
12469,,1,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627239,50597,,N,Intermediate,,BAO_0000218
12470,,1,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627240,50597,,N,Intermediate,,BAO_0000218
12471,,1,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627241,50597,,N,Intermediate,,BAO_0000218
12472,,1,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627242,50597,,N,Intermediate,,BAO_0000218
12473,,1,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627243,50597,,N,Intermediate,,BAO_0000218
12474,,1,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627244,50597,,N,Intermediate,,BAO_0000218
12475,,1,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627245,50597,,N,Intermediate,,BAO_0000218
12476,,1,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627246,50597,,N,Intermediate,,BAO_0000218
12477,,1,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627247,50597,,N,Intermediate,,BAO_0000218
12478,,1,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627248,50597,,N,Intermediate,,BAO_0000218
12479,,1,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627249,50597,,N,Intermediate,,BAO_0000218
12480,,1,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625569,50597,,N,Intermediate,,BAO_0000218
12481,,1,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625570,50597,,N,Intermediate,,BAO_0000218
12482,,1,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625571,50597,,N,Intermediate,,BAO_0000218
12483,,1,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625572,50597,,N,Intermediate,,BAO_0000218
12484,,1,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625573,50597,,N,Intermediate,,BAO_0000218
12485,,1,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625574,50597,,N,Intermediate,,BAO_0000218
12486,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626245,50597,,N,Intermediate,,BAO_0000218
12487,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626246,50597,,N,Intermediate,,BAO_0000218
12488,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL626247,22224,,U,Autocuration,,BAO_0000218
12489,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL626248,22224,,U,Autocuration,,BAO_0000218
12490,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,1,,A,CHEMBL626249,22224,,U,Autocuration,,BAO_0000218
12491,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL626420,22224,,U,Autocuration,,BAO_0000218
12492,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,1,,A,CHEMBL626421,22224,,U,Autocuration,,BAO_0000218
12493,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL626422,22224,,U,Autocuration,,BAO_0000218
12494,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL626423,22224,,U,Autocuration,,BAO_0000218
12495,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL626424,22224,,U,Autocuration,,BAO_0000218
12496,,1,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626425,50588,,N,Intermediate,,BAO_0000218
12497,,1,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875476,50597,,N,Intermediate,,BAO_0000218
12498,,1,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL626426,100710,,N,Intermediate,,BAO_0000218
12499,,0,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,1,,P,CHEMBL626427,22224,,U,Autocuration,,BAO_0000100
12500,,0,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,,,,,,1,,P,CHEMBL626428,22224,,U,Autocuration,,BAO_0000100
12501,,0,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,,,,,,1,,A,CHEMBL626429,22224,,U,Autocuration,,BAO_0000019
12502,,0,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,,,Urine,1088.0,,1,,A,CHEMBL625025,22224,,U,Autocuration,,BAO_0000019
12503,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625026,50597,,N,Intermediate,,BAO_0000218
12504,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625027,50597,,N,Intermediate,,BAO_0000218
12505,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL874410,50597,,N,Intermediate,,BAO_0000218
12506,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625028,50597,,N,Intermediate,,BAO_0000218
12507,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625029,50597,,N,Intermediate,,BAO_0000218
12508,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625030,50597,,N,Intermediate,,BAO_0000218
12509,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625031,50597,,N,Intermediate,,BAO_0000218
12510,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625032,50597,,N,Intermediate,,BAO_0000218
12511,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625033,50597,,N,Intermediate,,BAO_0000218
12512,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625034,50597,,N,Intermediate,,BAO_0000218
12513,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624872,50597,,N,Intermediate,,BAO_0000218
12514,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624873,50597,,N,Intermediate,,BAO_0000218
12515,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624874,50597,,N,Intermediate,,BAO_0000218
12516,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624875,50597,,N,Intermediate,,BAO_0000218
12517,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624876,50597,,N,Intermediate,,BAO_0000218
12518,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624877,50597,,N,Intermediate,,BAO_0000218
12519,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624878,50597,,N,Intermediate,,BAO_0000218
12520,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624879,50597,,N,Intermediate,,BAO_0000218
12521,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624880,50597,,N,Intermediate,,BAO_0000218
12522,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624881,50597,,N,Intermediate,,BAO_0000218
12523,,1,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL624882,50597,,N,Intermediate,,BAO_0000218
12524,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624883,50597,,N,Intermediate,,BAO_0000218
12525,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624884,50597,,N,Intermediate,,BAO_0000218
12526,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624885,50597,,N,Intermediate,,BAO_0000218
12527,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624886,50597,,N,Intermediate,,BAO_0000218
12528,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624887,50597,,N,Intermediate,,BAO_0000218
12529,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624888,50597,,N,Intermediate,,BAO_0000218
12530,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624889,50597,,N,Intermediate,,BAO_0000218
12531,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL624890,50597,,N,Intermediate,,BAO_0000218
12532,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621964,50597,,N,Intermediate,,BAO_0000218
12533,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL621965,50597,,N,Intermediate,,BAO_0000218
12534,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621966,50597,,N,Intermediate,,BAO_0000218
12535,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL621967,50597,,N,Intermediate,,BAO_0000218
12536,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL622164,50597,,N,Intermediate,,BAO_0000218
12537,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,,,,,,1,,A,CHEMBL623097,22224,,U,Autocuration,,BAO_0000019
12538,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,,,,,,1,,A,CHEMBL623098,22224,,U,Autocuration,,BAO_0000019
12539,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,,,,,,1,,A,CHEMBL623099,22224,,U,Autocuration,,BAO_0000019
12540,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,,,,,,1,,A,CHEMBL623100,22224,,U,Autocuration,,BAO_0000019
12541,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628673,50597,,N,Intermediate,,BAO_0000218
12542,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628674,50597,,N,Intermediate,,BAO_0000218
12543,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628675,50597,,N,Intermediate,,BAO_0000218
12544,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627644,50597,,N,Intermediate,,BAO_0000218
12545,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627645,50597,,N,Intermediate,,BAO_0000218
12546,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627646,50597,,N,Intermediate,,BAO_0000218
12547,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627647,50597,,N,Intermediate,,BAO_0000218
12548,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627648,50597,,N,Intermediate,,BAO_0000218
12549,,1,Free level in rat plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627649,50597,,N,Intermediate,,BAO_0000218
12550,,0,Level reaching in blood plasma of rat or human was determined,,,,,,,1,,A,CHEMBL628313,22224,,U,Autocuration,,BAO_0000019
12551,,1,Log (Cbrain/Cblood) in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628314,50597,,N,Intermediate,,BAO_0000218
12552,,0,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,,,,,,1,,A,CHEMBL628315,22224,,U,Autocuration,,BAO_0000019
12553,,0,Mean percentage of compound transport through membrane; expressed as membrane transport,,,,,,,1,,A,CHEMBL628316,22224,,U,Autocuration,,BAO_0000019
12554,,0,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,,,,,,1,,A,CHEMBL628317,22224,,U,Autocuration,,BAO_0000218
12555,,0,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,,,,,,1,,A,CHEMBL628473,22224,,U,Autocuration,,BAO_0000019
12556,,0,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,,,,,,1,,A,CHEMBL628474,22224,,U,Autocuration,,BAO_0000019
12557,,0,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,,,,,,1,,A,CHEMBL628475,22224,,U,Autocuration,,BAO_0000019
12558,,0,Net water uptake by a carrier mediated transport (%cm) mechanism,,,,,,,1,,A,CHEMBL628476,22224,,U,Autocuration,,BAO_0000019
12559,,0,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL628477,22224,,U,Autocuration,,BAO_0000218
12560,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL628478,50506,,N,Intermediate,,BAO_0000218
12561,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL628479,50506,,N,Intermediate,,BAO_0000218
12562,,0,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL628480,22224,,U,Autocuration,,BAO_0000218
12563,,0,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",Simiiformes,,,,,,1,314293.0,A,CHEMBL628481,22224,,U,Autocuration,,BAO_0000218
12564,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628482,50597,,N,Intermediate,,BAO_0000218
12565,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628483,50597,,N,Intermediate,,BAO_0000218
12566,,1,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628484,50597,,N,Intermediate,,BAO_0000218
12567,,1,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628485,50597,,N,Intermediate,,BAO_0000218
12568,,1,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL628486,100710,,N,Intermediate,,BAO_0000218
12569,,1,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL628487,50587,,N,Intermediate,,BAO_0000218
12570,,1,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628488,50597,,N,Intermediate,,BAO_0000218
12571,,1,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628489,50597,,N,Intermediate,,BAO_0000218
12572,,1,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628490,50597,,N,Intermediate,,BAO_0000218
12573,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL628491,100710,,N,Intermediate,,BAO_0000218
12574,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL877507,100710,,N,Intermediate,,BAO_0000218
12575,,0,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,,,,,,1,,A,CHEMBL628492,22224,,U,Autocuration,,BAO_0000218
12576,,0,% metabolized in monkey S-9 after 2 hours (10 ug/mL),Simiiformes,,,,,,1,314293.0,A,CHEMBL628493,22224,,U,Autocuration,,BAO_0000019
12577,,0,% metabolized in monkey S-9 after 2 hours (1 ug/ml),Simiiformes,,,,,,1,314293.0,A,CHEMBL628494,22224,,U,Autocuration,,BAO_0000019
12578,,0,% metabolized in monkey S-9 after 2 hours (10 ug/ml),Simiiformes,,,,,,1,314293.0,A,CHEMBL628495,22224,,U,Autocuration,,BAO_0000019
12579,,1,Permeability in Caco-2 assay at 10E-6,Homo sapiens,,,,,,1,9606.0,A,CHEMBL628496,50587,,N,Intermediate,,BAO_0000218
12580,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,,,Brain,955.0,,1,,A,CHEMBL628497,22224,,U,Autocuration,,BAO_0000218
12581,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,,,Brain,955.0,,1,,A,CHEMBL628498,22224,,U,Autocuration,,BAO_0000218
12582,,0,Plasma protein binding was determined,,,,,,,1,,A,CHEMBL628499,22224,,U,Autocuration,,BAO_0000019
12583,,0,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL627656,22224,,U,Autocuration,,BAO_0000218
12584,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,1,,A,CHEMBL627657,22224,,U,Autocuration,,BAO_0000218
12585,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,1,,A,CHEMBL626808,22224,,U,Autocuration,,BAO_0000218
12586,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626809,22224,,U,Autocuration,,BAO_0000218
12587,,0,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626810,22224,,U,Autocuration,,BAO_0000218
12588,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,,,,,,1,,A,CHEMBL626811,22224,,U,Autocuration,,BAO_0000218
12589,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,,,,,,1,,A,CHEMBL874465,22224,,U,Autocuration,,BAO_0000218
12590,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626812,22224,,U,Autocuration,,BAO_0000218
12591,,0,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626813,22224,,U,Autocuration,,BAO_0000218
12592,,0,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,,,,,,1,,A,CHEMBL626814,22224,,U,Autocuration,,BAO_0000218
12593,,0,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,,,,,,1,,A,CHEMBL626815,22224,,U,Autocuration,,BAO_0000019
12594,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL628566,22224,,U,Autocuration,,BAO_0000019
12595,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,1,,P,CHEMBL628567,22229,,U,Autocuration,,BAO_0000100
12596,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL628568,22229,,U,Autocuration,,BAO_0000100
12597,,1,C max in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628569,50588,,N,Intermediate,,BAO_0000218
12598,,1,C max in guinea pig,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL628570,50512,,N,Intermediate,,BAO_0000218
12599,,0,C max value was evaluated,,,,,,,1,,A,CHEMBL628571,22224,,U,Autocuration,,BAO_0000218
12600,,0,Cmax value after oral dose of 0.1 mg//kg,,,,,,,1,,A,CHEMBL628572,22224,,U,Autocuration,,BAO_0000218
12601,,0,Cmax value after oral dose of 0.3 mg/kg,,,,,,,1,,A,CHEMBL628573,22224,,U,Autocuration,,BAO_0000218
12602,,0,Cmax value after oral dose of 1 mg/kg,,,,,,,1,,A,CHEMBL628574,22224,,U,Autocuration,,BAO_0000218
12603,,0,Cmax value after oral dose of 10 mg/kg,,,,,,,1,,A,CHEMBL628575,22224,,U,Autocuration,,BAO_0000218
12604,,0,Cmax value after oral dose of 23.4 mg/kg,,,,,,,1,,A,CHEMBL628576,22224,,U,Autocuration,,BAO_0000218
12605,,0,Cmax value after oral dose of 3 mg/kg,,,,,,,1,,A,CHEMBL628577,22224,,U,Autocuration,,BAO_0000218
12606,,0,Cmax value after oral dose of 3.87 mg/kg,,,,,,,1,,A,CHEMBL628578,22224,,U,Autocuration,,BAO_0000218
12607,,1,Cmax value in female Beagle dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL874466,50588,,N,Intermediate,,BAO_0000218
12608,,1,Cmax value in male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628579,50597,,N,Intermediate,,BAO_0000218
12609,,1,Cmax value in rat plasma when administered 20 mg/kg perorally,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628580,50597,,N,Intermediate,,BAO_0000218
12610,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628581,50588,,N,Intermediate,,BAO_0000218
12611,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL628582,50588,,N,Intermediate,,BAO_0000218
12612,,1,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628583,50588,,N,Intermediate,,BAO_0000218
12613,,0,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,Simiiformes,,,,,,1,314293.0,A,CHEMBL625782,22224,,U,Autocuration,,BAO_0000218
12614,,1,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625783,50592,,N,Intermediate,,BAO_0000218
12615,,1,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625784,50597,,N,Intermediate,,BAO_0000218
12616,,1,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL625785,50797,,N,Intermediate,,BAO_0000218
12617,,1,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625786,50597,,N,Intermediate,,BAO_0000218
12618,,0,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,,,,,,1,,A,CHEMBL874467,22224,,U,Autocuration,,BAO_0000019
12619,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625787,50588,,N,Intermediate,,BAO_0000218
12620,,1,cytotoxicity against HIV protease enzyme.,Human immunodeficiency virus,,,,,,1,12721.0,A,CHEMBL625964,50677,,N,Intermediate,,BAO_0000218
12621,,1,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL625965,50594,,N,Intermediate,,BAO_0000218
12622,,1,Apparent clearance in mice after oral administration of 100 mg/kg of dose,Mus musculus,,,,,,1,10090.0,A,CHEMBL625966,50594,,N,Intermediate,,BAO_0000218
12623,,1,The plasma clearance in dog.,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625967,50588,,N,Intermediate,,BAO_0000218
12624,,1,The plasma clearance in rat.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625968,50597,,N,Intermediate,,BAO_0000218
12625,,1,Clearance from plasma in male Sprague-Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625969,50597,,N,Intermediate,,BAO_0000218
12626,,1,Clearance from plasma in male cynomolgus monkeys,Macaca fascicularis,,,Plasma,1969.0,,1,9541.0,A,CHEMBL625970,100710,,N,Intermediate,,BAO_0000218
12627,,1,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625971,50588,,N,Intermediate,,BAO_0000218
12628,,1,Clearance of compound in dog plasma,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625972,50588,,N,Intermediate,,BAO_0000218
12629,,1,Clearance of compound in human plasma,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL625973,50587,,N,Intermediate,,BAO_0000218
12630,,1,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625974,50588,,N,Intermediate,,BAO_0000218
12631,,1,Clearance of compound when administered intravenously as an individual dose to a single dog.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625975,50588,,N,Intermediate,,BAO_0000218
12632,,1,"Clearance (10 mg/kg, intravenously) in dog plasma",Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625976,50588,,N,Intermediate,,BAO_0000218
12633,,1,Clearance value in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625977,50588,,N,Intermediate,,BAO_0000218
12634,,1,Clearance value in guinea pig,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL625978,50512,,N,Intermediate,,BAO_0000218
12635,,1,Clearance values in rats after iv administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874468,50597,,N,Intermediate,,BAO_0000218
12636,,0,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,,,Plasma,1969.0,,1,,A,CHEMBL625421,22224,,U,Autocuration,,BAO_0000218
12637,,1,In vivo clearance (5 mg/kg) was determined in rabbits,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625422,50592,,N,Intermediate,,BAO_0000218
12638,,1,Plasma Clearance rate was determined for the compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625423,50597,,N,Intermediate,,BAO_0000218
12639,,0,Plasma Clearance rate was determined for the compound in squirrel monkeys,Saimiri,,,,,,1,9520.0,A,CHEMBL625424,22224,,U,Autocuration,,BAO_0000218
12640,,1,Plasma clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625425,50597,,N,Intermediate,,BAO_0000218
12641,,0,Plasma clearance of the compound,,,,,,,1,,A,CHEMBL625426,22224,,U,Autocuration,,BAO_0000218
12642,,1,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL625427,50512,,N,Intermediate,,BAO_0000218
12643,,1,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL625428,50512,,N,Intermediate,,BAO_0000218
12644,,0,Plasma clearance was determined,,,,,,,1,,A,CHEMBL625429,22224,,U,Autocuration,,BAO_0000218
12645,,1,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625430,50588,,N,Intermediate,,BAO_0000218
12646,,1,Plasma clearance rate was determined for the compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625431,50597,,N,Intermediate,,BAO_0000218
12647,,0,Plasma clearance rate was determined for the compound in squirrel monkeys,Saimiri,,,,,,1,9520.0,A,CHEMBL627307,22224,,U,Autocuration,,BAO_0000218
12648,,0,Slow clearance (CL) was determined,,,,,,,1,,A,CHEMBL627308,22224,,U,Autocuration,,BAO_0000218
12649,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL627309,22224,,U,Autocuration,,BAO_0000218
12650,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,,,,,,1,,A,CHEMBL627310,22224,,U,Autocuration,,BAO_0000218
12651,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,1,,A,CHEMBL627311,22224,,U,Autocuration,,BAO_0000218
12652,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL627312,22224,,U,Autocuration,,BAO_0000218
12653,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,1,,A,CHEMBL627313,22224,,U,Autocuration,,BAO_0000218
12654,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL627314,22224,,U,Autocuration,,BAO_0000218
12655,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL627315,22224,,U,Autocuration,,BAO_0000218
12656,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL627316,22224,,U,Autocuration,,BAO_0000218
12657,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,,,,,,1,,A,CHEMBL627317,22224,,U,Autocuration,,BAO_0000218
12658,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL627318,22224,,U,Autocuration,,BAO_0000218
12659,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,,,,,,1,,A,CHEMBL627999,22224,,U,Autocuration,,BAO_0000218
12660,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,,,,,,1,,A,CHEMBL628000,22224,,U,Autocuration,,BAO_0000218
12661,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,,,,,,1,,A,CHEMBL628001,22224,,U,Autocuration,,BAO_0000218
12662,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL628002,22224,,U,Autocuration,,BAO_0000218
12663,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL625610,22224,,U,Autocuration,,BAO_0000218
12664,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL625611,22224,,U,Autocuration,,BAO_0000218
12665,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,,,,,,1,,A,CHEMBL625612,22224,,U,Autocuration,,BAO_0000218
12666,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,,,,,,1,,A,CHEMBL625613,22224,,U,Autocuration,,BAO_0000218
12667,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,,,,,,1,,A,CHEMBL875479,22224,,U,Autocuration,,BAO_0000218
12668,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,,,,,,1,,A,CHEMBL625614,22224,,U,Autocuration,,BAO_0000218
12669,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,,,,,,1,,A,CHEMBL625615,22224,,U,Autocuration,,BAO_0000218
12670,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,,,,,,1,,A,CHEMBL626302,22224,,U,Autocuration,,BAO_0000218
12671,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626303,50597,,N,Intermediate,,BAO_0000218
12672,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627420,50597,,N,Intermediate,,BAO_0000218
12673,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627421,50597,,N,Intermediate,,BAO_0000218
12674,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625695,50597,,N,Intermediate,,BAO_0000218
12675,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625696,50597,,N,Intermediate,,BAO_0000218
12676,,1,Distribution of compound in mice brain was measured after 1 hr,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL875606,50594,,N,Intermediate,,BAO_0000218
12677,,1,Distribution of compound in mice brain was measured after 24 hr r,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL625697,50594,,N,Intermediate,,BAO_0000218
12678,,1,Distribution of compound in mice brain was measured after 2 hr,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL625698,50594,,N,Intermediate,,BAO_0000218
12679,,1,Distribution of compound in mice brain was measured after 3 hr,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL625699,50594,,N,Intermediate,,BAO_0000218
12680,,1,Distribution of compound in mice brain was measured after 6 hr,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL625700,50594,,N,Intermediate,,BAO_0000218
12681,,1,Distribution of compound in mice liver was measured after 1 hr,Mus musculus,,,,,,1,10090.0,A,CHEMBL625701,50594,,N,Intermediate,,BAO_0000218
12682,,1,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,Mus musculus,,,,,,1,10090.0,A,CHEMBL625702,50594,,N,Intermediate,,BAO_0000218
12683,,1,Distribution of compound in mice liver was measured after 2 hr,Mus musculus,,,,,,1,10090.0,A,CHEMBL625703,50594,,N,Intermediate,,BAO_0000218
12684,,1,Distribution of compound in mice liver was measured after 3 hr,Mus musculus,,,,,,1,10090.0,A,CHEMBL625704,50594,,N,Intermediate,,BAO_0000218
12685,,1,Distribution of compound in mice liver was measured after 6 hr,Mus musculus,,,,,,1,10090.0,A,CHEMBL625705,50594,,N,Intermediate,,BAO_0000218
12686,,1,Distribution in dog adrenal medulla 30 min after administration.,Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL625706,50588,,N,Intermediate,,BAO_0000218
12687,,1,Distribution in dog adrenal medulla 72 hours after administration.,Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL625707,50588,,N,Intermediate,,BAO_0000218
12688,,1,Distribution in female dog Ovary 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625708,50588,,N,Intermediate,,BAO_0000218
12689,,1,Distribution in female dog Ovary 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625709,50588,,N,Intermediate,,BAO_0000218
12690,,1,Distribution in female dog adipose 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624180,50588,,N,Intermediate,,BAO_0000218
12691,,1,Distribution in female dog adipose 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624181,50588,,N,Intermediate,,BAO_0000218
12692,,1,Distribution in female dog adrenal cortex 72 hours after administration.,Canis lupus familiaris,,,Adrenal cortex,1235.0,,1,9615.0,A,CHEMBL624182,50588,,N,Intermediate,,BAO_0000218
12693,,1,Distribution in female dog adrenal cortex 72 hours after administration.,Canis lupus familiaris,,,Adrenal cortex,1235.0,,1,9615.0,A,CHEMBL624183,50588,,N,Intermediate,,BAO_0000218
12694,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624184,50597,,N,Intermediate,,BAO_0000218
12695,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL877489,50597,,N,Intermediate,,BAO_0000218
12696,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624185,50597,,N,Intermediate,,BAO_0000218
12697,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624186,50597,,N,Intermediate,,BAO_0000218
12698,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624187,50597,,N,Intermediate,,BAO_0000218
12699,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL624188,50597,,N,Intermediate,,BAO_0000218
12700,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624189,50597,,N,Intermediate,,BAO_0000218
12701,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624190,50597,,N,Intermediate,,BAO_0000218
12702,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624191,50597,,N,Intermediate,,BAO_0000218
12703,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624192,50597,,N,Intermediate,,BAO_0000218
12704,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624193,50597,,N,Intermediate,,BAO_0000218
12705,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624194,50597,,N,Intermediate,,BAO_0000218
12706,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624891,50597,,N,Intermediate,,BAO_0000218
12707,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624892,50597,,N,Intermediate,,BAO_0000218
12708,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL624893,50597,,N,Intermediate,,BAO_0000218
12709,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627632,50597,,N,Intermediate,,BAO_0000218
12710,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627633,50597,,N,Intermediate,,BAO_0000218
12711,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627634,50597,,N,Intermediate,,BAO_0000218
12712,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627635,50597,,N,Intermediate,,BAO_0000218
12713,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627636,50597,,N,Intermediate,,BAO_0000218
12714,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626816,50597,,N,Intermediate,,BAO_0000218
12715,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626817,50597,,N,Intermediate,,BAO_0000218
12716,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626818,50597,,N,Intermediate,,BAO_0000218
12717,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626819,50597,,N,Intermediate,,BAO_0000218
12718,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626820,50597,,N,Intermediate,,BAO_0000218
12719,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626821,50597,,N,Intermediate,,BAO_0000218
12720,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626822,50597,,N,Intermediate,,BAO_0000218
12721,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626823,50597,,N,Intermediate,,BAO_0000218
12722,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626824,50597,,N,Intermediate,,BAO_0000218
12723,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626825,50597,,N,Intermediate,,BAO_0000218
12724,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626826,50597,,N,Intermediate,,BAO_0000218
12725,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626827,50597,,N,Intermediate,,BAO_0000218
12726,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626828,50597,,N,Intermediate,,BAO_0000218
12727,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626829,50597,,N,Intermediate,,BAO_0000218
12728,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL626830,50597,,N,Intermediate,,BAO_0000218
12729,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627150,50597,,N,Intermediate,,BAO_0000218
12730,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627151,50597,,N,Intermediate,,BAO_0000218
12731,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627152,50597,,N,Intermediate,,BAO_0000218
12732,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627153,50597,,N,Intermediate,,BAO_0000218
12733,,0,Rate of acetate production by the compound was determined,,,,,,,1,,A,CHEMBL627154,22224,,U,Autocuration,,BAO_0000019
12734,,0,Rate of acetate production by the compound was determined; Not determined,,,,,,,1,,A,CHEMBL627155,22224,,U,Autocuration,,BAO_0000019
12735,,0,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,,,,,,1,,A,CHEMBL627156,22224,,U,Autocuration,,BAO_0000019
12736,,0,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,,,,,,1,,A,CHEMBL627157,22224,,U,Autocuration,,BAO_0000019
12737,,1,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL627158,50592,,N,Intermediate,,BAO_0000218
12738,,1,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Oryctolagus cuniculus,,,Plasma,1969.0,,1,9986.0,A,CHEMBL627159,50592,,N,Intermediate,,BAO_0000218
12739,,1,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Mus musculus,,,,,,1,10090.0,A,CHEMBL627160,50594,,N,Intermediate,,BAO_0000218
12740,,1,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628540,50597,,N,Intermediate,,BAO_0000218
12741,,1,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628541,50597,,N,Intermediate,,BAO_0000218
12742,,1,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628542,50597,,N,Intermediate,,BAO_0000218
12743,,0,Solubility after at a pH 1.2,,,,,,,1,,P,CHEMBL628543,22229,,U,Autocuration,,BAO_0000100
12744,,0,Solubility after at pH 1.2,,,,,,,1,,P,CHEMBL628544,22229,,U,Autocuration,,BAO_0000100
12745,,0,Solubility after injection of water,,,,,,,1,,P,CHEMBL628545,22229,,U,Autocuration,,BAO_0000100
12746,,0,Statistical significance of IC 50 values; Expressed as R value,,,,,,,1,,A,CHEMBL628546,22224,,U,Autocuration,,BAO_0000019
12747,,0,Systemic availability with respect to methyldopa was determined,,,,,,,1,,A,CHEMBL874455,22224,,U,Autocuration,,BAO_0000019
12748,,1,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628547,50597,,N,Intermediate,,BAO_0000218
12749,,1,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL628548,50597,,N,Intermediate,,BAO_0000218
12750,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628549,50592,,N,Intermediate,,BAO_0000218
12751,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628550,50592,,N,Intermediate,,BAO_0000218
12752,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628551,50592,,N,Intermediate,,BAO_0000218
12753,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628552,50592,,N,Intermediate,,BAO_0000218
12754,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628553,50592,,N,Intermediate,,BAO_0000218
12755,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628554,50592,,N,Intermediate,,BAO_0000218
12756,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628555,50592,,N,Intermediate,,BAO_0000218
12757,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628556,50592,,N,Intermediate,,BAO_0000218
12758,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Kidney,2113.0,,1,9986.0,A,CHEMBL628557,50592,,N,Intermediate,,BAO_0000218
12759,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628558,50592,,N,Intermediate,,BAO_0000218
12760,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628559,50592,,N,Intermediate,,BAO_0000218
12761,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628560,50592,,N,Intermediate,,BAO_0000218
12762,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL874456,50592,,N,Intermediate,,BAO_0000218
12763,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628561,50592,,N,Intermediate,,BAO_0000218
12764,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL628562,50592,,N,Intermediate,,BAO_0000218
12765,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628563,50592,,N,Intermediate,,BAO_0000218
12766,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628564,50592,,N,Intermediate,,BAO_0000218
12767,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL628565,50592,,N,Intermediate,,BAO_0000218
12768,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL631248,50592,,N,Intermediate,,BAO_0000218
12769,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL631249,50592,,N,Intermediate,,BAO_0000218
12770,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Kidney,2113.0,,1,9986.0,A,CHEMBL627214,50592,,N,Intermediate,,BAO_0000218
12771,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL874591,50592,,N,Intermediate,,BAO_0000218
12772,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL627215,50592,,N,Intermediate,,BAO_0000218
12773,,1,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL625471,50592,,N,Intermediate,,BAO_0000218
12774,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625472,50592,,N,Intermediate,,BAO_0000218
12775,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL625473,50592,,N,Intermediate,,BAO_0000218
12776,,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625474,50588,,N,Intermediate,,BAO_0000218
12777,,1,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625475,50588,,N,Intermediate,,BAO_0000218
12778,,1,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625476,50597,,N,Intermediate,,BAO_0000218
12779,,1,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625477,50597,,N,Intermediate,,BAO_0000218
12780,,1,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625478,50597,,N,Intermediate,,BAO_0000218
12781,,1,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,Rattus norvegicus,,,esophageal tunica muscularis mucosae,,,1,10116.0,A,CHEMBL625479,50597,,N,Intermediate,,BAO_0000218
12782,,1,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,Rattus norvegicus,,,esophageal tunica muscularis mucosae,,,1,10116.0,A,CHEMBL625480,50597,,N,Intermediate,,BAO_0000218
12783,,1,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625481,50597,,N,Intermediate,,BAO_0000218
12784,,1,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625482,50597,,N,Intermediate,,BAO_0000218
12785,,1,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625483,50597,,N,Intermediate,,BAO_0000218
12786,,1,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625484,50597,,N,Intermediate,,BAO_0000218
12787,,1,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625485,50597,,N,Intermediate,,BAO_0000218
12788,,1,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625486,50588,,N,Intermediate,,BAO_0000218
12789,,1,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625487,50597,,N,Intermediate,,BAO_0000218
12790,,1,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625488,50597,,N,Intermediate,,BAO_0000218
12791,,1,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625489,50597,,N,Intermediate,,BAO_0000218
12792,,1,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625490,50597,,N,Intermediate,,BAO_0000218
12793,,1,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL625491,50588,,N,Intermediate,,BAO_0000218
12794,,1,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625492,50597,,N,Intermediate,,BAO_0000218
12795,,1,plasma clearance in human,Homo sapiens,,,Plasma,1969.0,,1,9606.0,A,CHEMBL625493,50587,,N,Intermediate,,BAO_0000218
12796,,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625494,50597,,N,Intermediate,,BAO_0000218
12797,,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625495,50597,,N,Intermediate,,BAO_0000218
12798,,1,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625496,50597,,N,Intermediate,,BAO_0000218
12799,,0,1-Octanol/water partition coefficient measured at 7.4,,,,,,,1,,P,CHEMBL625497,22229,,U,Autocuration,,BAO_0000100
12800,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625498,22229,,U,Autocuration,,BAO_0000100
12801,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL625499,22224,,U,Autocuration,,BAO_0000019
12802,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625500,22229,,U,Autocuration,,BAO_0000100
12803,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625501,22229,,U,Autocuration,,BAO_0000100
12804,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625502,22229,,U,Autocuration,,BAO_0000100
12805,,0,Calculated partition coefficient (clogP) (relative to BAY K 8644),,,,,,,1,,P,CHEMBL625503,22229,,U,Autocuration,,BAO_0000100
12806,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625504,22229,,U,Autocuration,,BAO_0000100
12807,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625505,22229,,U,Autocuration,,BAO_0000100
12808,,0,Calculated partition coefficient of the compound,,,,,,,1,,P,CHEMBL625506,22229,,U,Autocuration,,BAO_0000100
12809,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL625507,22224,,U,Autocuration,,BAO_0000019
12810,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625508,22229,,U,Autocuration,,BAO_0000100
12811,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625509,22229,,U,Autocuration,,BAO_0000100
12812,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625510,22229,,U,Autocuration,,BAO_0000100
12813,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL883125,22229,,U,Autocuration,,BAO_0000100
12814,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625511,22229,,U,Autocuration,,BAO_0000100
12815,,0,Partition coefficient of the compound,,,,,,,1,,A,CHEMBL874650,22224,,U,Autocuration,,BAO_0000019
12816,,0,Partition coefficient of the compound,,,,,,,1,,A,CHEMBL625512,22224,,U,Autocuration,,BAO_0000019
12817,,0,Partition coefficient of compound was determined,,,,,,,1,,A,CHEMBL625513,22224,,U,Autocuration,,BAO_0000019
12818,,0,Partition coefficient was determined,,,,,,,1,,A,CHEMBL625514,22224,,U,Autocuration,,BAO_0000019
12819,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625515,22229,,U,Autocuration,,BAO_0000100
12820,,0,partition coefficient of compound was determined,,,,,,,1,,P,CHEMBL625516,22229,,U,Autocuration,,BAO_0000100
12821,,1,The total body administered intravenously in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625517,50588,,N,Intermediate,,BAO_0000218
12822,,1,The total body administered intravenously in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625518,50597,,N,Intermediate,,BAO_0000218
12823,,1,Time taken for the administration to female NIH mice weighing 25-30 g.,Mus musculus,,,,,,1,10090.0,A,CHEMBL625519,50594,,N,Intermediate,,BAO_0000218
12824,,0,Time taken for the administration,,,,,,,1,,A,CHEMBL625520,22224,,U,Autocuration,,BAO_0000019
12825,,1,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL874651,50588,,N,Intermediate,,BAO_0000218
12826,,0,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,Simiiformes,,,,,,1,314293.0,A,CHEMBL625521,22224,,U,Autocuration,,BAO_0000218
12827,,1,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL623171,50592,,N,Intermediate,,BAO_0000218
12828,,1,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623853,50597,,N,Intermediate,,BAO_0000218
12829,,0,Plasma clearance for the compound was determined.,,,,,,,1,,A,CHEMBL623854,22224,,U,Autocuration,,BAO_0000019
12830,,0,CLog P value of the compound,,,,,,,1,,P,CHEMBL874405,22224,,U,Autocuration,,BAO_0000100
12831,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL623855,22229,,U,Autocuration,,BAO_0000100
12832,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL623856,22229,,U,Autocuration,,BAO_0000100
12833,,0,ClogP value of the compound; nd ='no data',,,,,,,1,,P,CHEMBL623857,22224,,U,Autocuration,,BAO_0000100
12834,,0,ClogP value of the compound; nd ='not determined',,,,,,,1,,P,CHEMBL623858,22224,,U,Autocuration,,BAO_0000100
12835,,0,CLog P was determined,,,,,,,1,,P,CHEMBL623859,22224,,U,Autocuration,,BAO_0000100
12836,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL839829,22229,,U,Autocuration,,BAO_0000100
12837,,0,CLogP was calculated,,,,,,,1,,A,CHEMBL623860,22224,,U,Autocuration,,BAO_0000019
12838,,0,CLogP value was determined,,,,,,,1,,A,CHEMBL623861,22224,,U,Autocuration,,BAO_0000019
12839,,0,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,,,,,,1,,A,CHEMBL623862,22224,,U,Autocuration,,BAO_0000019
12840,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL874406,22229,,U,Autocuration,,BAO_0000100
12841,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL623863,22229,,U,Autocuration,,BAO_0000100
12842,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624021,22229,,U,Autocuration,,BAO_0000100
12843,,1,Distribution in female dog adrenal medulla 24 hours after administration.,Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL624022,50588,,N,Intermediate,,BAO_0000218
12844,,1,Distribution in female dog adrenal medulla 72 hours after administration.,Canis lupus familiaris,,,Adrenal medulla,1236.0,,1,9615.0,A,CHEMBL624023,50588,,N,Intermediate,,BAO_0000218
12845,,1,Distribution in female dog bile 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624024,50588,,N,Intermediate,,BAO_0000218
12846,,1,Distribution in female dog bile 72 hr after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624025,50588,,N,Intermediate,,BAO_0000218
12847,,1,Distribution in female dog blood 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624026,50588,,N,Intermediate,,BAO_0000218
12848,,1,Distribution in female dog blood 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624027,50588,,N,Intermediate,,BAO_0000218
12849,,1,Distribution in female dog heart 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624028,50588,,N,Intermediate,,BAO_0000218
12850,,1,Distribution in female dog heart 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624029,50588,,N,Intermediate,,BAO_0000218
12851,,1,Distribution in female dog kidney 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624030,50588,,N,Intermediate,,BAO_0000218
12852,,1,Distribution in female dog kidney 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624031,50588,,N,Intermediate,,BAO_0000218
12853,,1,Distribution in female dog large intestine 24 hours after administration.,Canis lupus familiaris,,,Intestine,160.0,,1,9615.0,A,CHEMBL624032,50588,,N,Intermediate,,BAO_0000218
12854,,1,Distribution in female dog large intestine 72 hours after administration.,Canis lupus familiaris,,,Intestine,160.0,,1,9615.0,A,CHEMBL874407,50588,,N,Intermediate,,BAO_0000218
12855,,1,Distribution in female dog liver 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624033,50588,,N,Intermediate,,BAO_0000218
12856,,1,Distribution in female dog liver 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624034,50588,,N,Intermediate,,BAO_0000218
12857,,1,Distribution in female dog lung 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624035,50588,,N,Intermediate,,BAO_0000218
12858,,1,Distribution in female dog lung 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624036,50588,,N,Intermediate,,BAO_0000218
12859,,1,Distribution in female dog muscle 24 hours after administration.,Canis lupus familiaris,,,Muscle tissue,2385.0,,1,9615.0,A,CHEMBL624037,50588,,N,Intermediate,,BAO_0000218
12860,,1,Distribution in female dog muscle 72 hours after administration.,Canis lupus familiaris,,,Muscle tissue,2385.0,,1,9615.0,A,CHEMBL624038,50588,,N,Intermediate,,BAO_0000218
12861,,1,Distribution in female dog pancreas 24 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624039,50588,,N,Intermediate,,BAO_0000218
12862,,1,Distribution in female dog pancreas 72 hours after administration.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624040,50588,,N,Intermediate,,BAO_0000218
12863,,1,Distribution in female dog small intestine 24 hours after administration.,Canis lupus familiaris,,,Intestine,160.0,,1,9615.0,A,CHEMBL624041,50588,,N,Intermediate,,BAO_0000218
12864,,1,Distribution in female dog small intestine 72 hours after administration.,Canis lupus familiaris,,,Intestine,160.0,,1,9615.0,A,CHEMBL624042,50588,,N,Intermediate,,BAO_0000218
12865,,1,Distribution in female dog spleen 24 hours after administration.,Canis lupus familiaris,,,Spleen,2106.0,,1,9615.0,A,CHEMBL624043,50588,,N,Intermediate,,BAO_0000218
12866,,1,Distribution in female dog spleen 72 hours after administration.,Canis lupus familiaris,,,Spleen,2106.0,,1,9615.0,A,CHEMBL624044,50588,,N,Intermediate,,BAO_0000218
12867,,1,Distribution in female dog stomach 24 hours after administration.,Canis lupus familiaris,,,Stomach,945.0,,1,9615.0,A,CHEMBL624045,50588,,N,Intermediate,,BAO_0000218
12868,,1,Distribution in female dog stomach 72 hours after administration.,Canis lupus familiaris,,,Stomach,945.0,,1,9615.0,A,CHEMBL624046,50588,,N,Intermediate,,BAO_0000218
12869,,1,Distribution in female dog thyroid 24 hours after administration.,Canis lupus familiaris,,,Thyroid gland,2046.0,,1,9615.0,A,CHEMBL624047,50588,,N,Intermediate,,BAO_0000218
12870,,1,Distribution in female dog thyroid 72 hours after administration.,Canis lupus familiaris,,,Thyroid gland,2046.0,,1,9615.0,A,CHEMBL624048,50588,,N,Intermediate,,BAO_0000218
12871,,1,Distribution in female dog urine 24 hours after administration.,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL874408,50588,,N,Intermediate,,BAO_0000218
12872,,1,Distribution in female dog urine 72 hr after administration.,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL624049,50588,,N,Intermediate,,BAO_0000218
12873,,0,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,,,Plasma,1969.0,,1,,A,CHEMBL624050,22224,,U,Autocuration,,BAO_0000218
12874,,0,Plasma concentration at 7 hr after intravenous dosing,,,,,,,1,,A,CHEMBL624051,22224,,U,Autocuration,,BAO_0000019
12875,,1,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623278,50597,,N,Intermediate,,BAO_0000218
12876,,1,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623279,50597,,N,Intermediate,,BAO_0000218
12877,,1,Plasma concentration of 3 mg/kg iv after 1 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623280,50597,,N,Intermediate,,BAO_0000218
12878,,1,Plasma concentration of 3 mg/kg iv after 2 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623963,50597,,N,Intermediate,,BAO_0000218
12879,,1,Plasma concentration of 3 mg/kg iv after 4 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623964,50597,,N,Intermediate,,BAO_0000218
12880,,1,Plasma concentration of 3 mg/kg iv after 6 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623965,50597,,N,Intermediate,,BAO_0000218
12881,,1,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623966,50597,,N,Intermediate,,BAO_0000218
12882,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874415,50597,,N,Intermediate,,BAO_0000218
12883,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623967,50597,,N,Intermediate,,BAO_0000218
12884,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623968,50597,,N,Intermediate,,BAO_0000218
12885,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623969,50597,,N,Intermediate,,BAO_0000218
12886,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628409,50597,,N,Intermediate,,BAO_0000218
12887,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628410,50597,,N,Intermediate,,BAO_0000218
12888,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628411,50597,,N,Intermediate,,BAO_0000218
12889,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628412,50597,,N,Intermediate,,BAO_0000218
12890,,0,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,,,,,,1,,A,CHEMBL628413,22224,,U,Autocuration,,BAO_0000019
12891,,0,The concentration in plasmat; Not determined,,,,Plasma,1969.0,,1,,A,CHEMBL628414,22224,,U,Autocuration,,BAO_0000019
12892,,1,Tissue level at 10 mg/kg/po in wistar rats in blood,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628415,50597,,N,Intermediate,,BAO_0000218
12893,,1,Tissue level at 10 mg/kg/po in wistar rats in brown fat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628416,50597,,N,Intermediate,,BAO_0000218
12894,,1,Tissue level at 10 mg/kg/po in wistar rats in heart,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628417,50597,,N,Intermediate,,BAO_0000218
12895,,1,Tissue level at 10 mg/kg/po in wistar rats in liver,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL874908,50597,,N,Intermediate,,BAO_0000218
12896,,1,Tissue level at 10 mg/kg/po in wistar rats in plasma,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628418,50597,,N,Intermediate,,BAO_0000218
12897,,1,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL628419,50597,,N,Intermediate,,BAO_0000218
12898,,1,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628420,50597,,N,Intermediate,,BAO_0000218
12899,,0,Water solubility at 37 degree C.,,,,,,,1,,A,CHEMBL628421,22224,,U,Autocuration,,BAO_0000019
12900,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,1,,P,CHEMBL626726,22229,,U,Autocuration,,BAO_0000100
12901,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,1,,P,CHEMBL626727,22229,,U,Autocuration,,BAO_0000100
12902,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626728,50597,,N,Intermediate,,BAO_0000218
12903,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626729,50597,,N,Intermediate,,BAO_0000218
12904,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626730,50597,,N,Intermediate,,BAO_0000218
12905,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626731,50597,,N,Intermediate,,BAO_0000218
12906,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL626732,50597,,N,Intermediate,,BAO_0000218
12907,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626733,50597,,N,Intermediate,,BAO_0000218
12908,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626734,50597,,N,Intermediate,,BAO_0000218
12909,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626735,50597,,N,Intermediate,,BAO_0000218
12910,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL874909,50597,,N,Intermediate,,BAO_0000218
12911,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL626736,50597,,N,Intermediate,,BAO_0000218
12912,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL626737,50597,,N,Intermediate,,BAO_0000218
12913,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630999,50597,,N,Intermediate,,BAO_0000218
12914,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631000,50597,,N,Intermediate,,BAO_0000218
12915,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631001,50597,,N,Intermediate,,BAO_0000218
12916,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631002,50597,,N,Intermediate,,BAO_0000218
12917,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631003,50597,,N,Intermediate,,BAO_0000218
12918,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631004,50597,,N,Intermediate,,BAO_0000218
12919,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631005,50597,,N,Intermediate,,BAO_0000218
12920,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631006,50597,,N,Intermediate,,BAO_0000218
12921,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631007,50597,,N,Intermediate,,BAO_0000218
12922,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL631008,50597,,N,Intermediate,,BAO_0000218
12923,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL631009,50597,,N,Intermediate,,BAO_0000218
12924,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL631010,50597,,N,Intermediate,,BAO_0000218
12925,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL631011,50597,,N,Intermediate,,BAO_0000218
12926,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL631012,50597,,N,Intermediate,,BAO_0000218
12927,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630271,50597,,N,Intermediate,,BAO_0000218
12928,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630272,50597,,N,Intermediate,,BAO_0000218
12929,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630273,50597,,N,Intermediate,,BAO_0000218
12930,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630274,50597,,N,Intermediate,,BAO_0000218
12931,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630275,50597,,N,Intermediate,,BAO_0000218
12932,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875782,50597,,N,Intermediate,,BAO_0000218
12933,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630276,50597,,N,Intermediate,,BAO_0000218
12934,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630277,50597,,N,Intermediate,,BAO_0000218
12935,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630278,50597,,N,Intermediate,,BAO_0000218
12936,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630279,50597,,N,Intermediate,,BAO_0000218
12937,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,,,,,,1,,A,CHEMBL630280,22224,,U,Autocuration,,BAO_0000019
12938,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,1,,A,CHEMBL630281,22224,,U,Autocuration,,BAO_0000019
12939,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630282,50592,,N,Intermediate,,BAO_0000218
12940,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630283,50592,,N,Intermediate,,BAO_0000218
12941,,0,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,,,,,,1,,A,CHEMBL630284,22224,,U,Autocuration,,BAO_0000019
12942,,0,Alkylating activity was determined,,,,,,,1,,A,CHEMBL630285,22224,,U,Autocuration,,BAO_0000019
12943,Microsomes,0,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,,,,,,1,,A,CHEMBL630286,22224,,U,Autocuration,,BAO_0000251
12944,,1,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630069,50592,,N,Intermediate,,BAO_0000218
12945,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630070,50592,,N,Intermediate,,BAO_0000218
12946,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630071,50592,,N,Intermediate,,BAO_0000218
12947,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL630072,50592,,N,Intermediate,,BAO_0000218
12948,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL875110,50592,,N,Intermediate,,BAO_0000218
12949,,1,Compound was tested for antidiuretic activity in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630073,50597,,N,Intermediate,,BAO_0000218
12950,,0,Compound was tested for inactivation kinetic values,,,,,,,1,,A,CHEMBL630074,22224,,U,Autocuration,,BAO_0000019
12951,,0,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,,,,,,1,,A,CHEMBL630075,22224,,U,Autocuration,,BAO_0000218
12952,,0,Dissociation rate calculated from the first-order equation using the t1/2 value,,,,,,,1,,A,CHEMBL630076,22224,,U,Autocuration,,BAO_0000019
12953,,0,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,,,,,,1,,P,CHEMBL630077,22229,,U,Autocuration,,BAO_0000100
12954,,0,Aqueous solubility was measured,,,,,,,1,,P,CHEMBL630078,22229,,U,Autocuration,,BAO_0000100
12955,,0,Aqueous solubility was measured at a pH 4,,,,,,,1,,P,CHEMBL630079,22229,,U,Autocuration,,BAO_0000100
12956,,0,Aqueous solubility (pH 7),,,,,,,1,,P,CHEMBL630080,22229,,U,Autocuration,,BAO_0000100
12957,,0,Aqueous solubility was measured at a pH 9,,,,,,,1,,P,CHEMBL630081,22229,,U,Autocuration,,BAO_0000100
12958,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,,,,,,1,,A,CHEMBL630082,22224,,U,Autocuration,,BAO_0000019
12959,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,1,,A,CHEMBL630083,22224,,U,Autocuration,,BAO_0000019
12960,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,,,,,,1,,A,CHEMBL630084,22224,,U,Autocuration,,BAO_0000019
12961,,0,Aqueous solubility of the compound,,,,,,,1,,P,CHEMBL629198,22229,,U,Autocuration,,BAO_0000100
12962,,0,Aqueous solubility at 37 degree Celsius at pH 7.38,,,,,,,1,,P,CHEMBL629199,22229,,U,Autocuration,,BAO_0000100
12963,,0,Aqueous solubility in pH 7.4 phosphate buffer,,,,,,,1,,P,CHEMBL629200,22229,,U,Autocuration,,BAO_0000100
12964,,1,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629201,50588,,N,Intermediate,,BAO_0000218
12965,,1,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629202,50588,,N,Intermediate,,BAO_0000218
12966,,1,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,Homo sapiens,,,,,,1,9606.0,A,CHEMBL875111,50587,,N,Intermediate,,BAO_0000218
12967,,1,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,Homo sapiens,,,,,,1,9606.0,A,CHEMBL629203,50587,,N,Intermediate,,BAO_0000218
12968,,1,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,Homo sapiens,,,,,,1,9606.0,A,CHEMBL629204,50587,,N,Intermediate,,BAO_0000218
12969,,1,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,Homo sapiens,,,,,,1,9606.0,A,CHEMBL629205,50587,,N,Intermediate,,BAO_0000218
12970,,1,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,Homo sapiens,,,,,,1,9606.0,A,CHEMBL629206,50587,,N,Intermediate,,BAO_0000218
12971,,0,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,,,,,,1,,A,CHEMBL631185,22224,,U,Autocuration,,BAO_0000019
12972,,1,Compound was evaluated for the average bile flow rat in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631186,50597,,N,Intermediate,,BAO_0000218
12973,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL631187,50592,,N,Intermediate,,BAO_0000218
12974,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL631188,50592,,N,Intermediate,,BAO_0000218
12975,,0,Average half life period was determined,,,,,,,1,,A,CHEMBL876419,22224,,U,Autocuration,,BAO_0000019
12976,,0,Average half life period was determined,,,,,,,1,,A,CHEMBL631189,22224,,U,Autocuration,,BAO_0000019
12977,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL631190,50602,,N,Intermediate,,BAO_0000218
12978,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL631191,50602,,N,Intermediate,,BAO_0000218
12979,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL631192,50602,,N,Intermediate,,BAO_0000218
12980,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632400,50602,,N,Intermediate,,BAO_0000218
12981,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL630564,50602,,N,Intermediate,,BAO_0000218
12982,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL630565,50602,,N,Intermediate,,BAO_0000218
12983,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL630566,50602,,N,Intermediate,,BAO_0000218
12984,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL631229,50602,,N,Intermediate,,BAO_0000218
12985,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL631230,50602,,N,Intermediate,,BAO_0000218
12986,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL876428,22229,,U,Autocuration,,BAO_0000100
12987,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631231,22229,,U,Autocuration,,BAO_0000100
12988,,0,Calculated partition coefficient (clogP) (MacLogP),,,,,,,1,,P,CHEMBL631232,22229,,U,Autocuration,,BAO_0000100
12989,,0,Hydrophilicity was determined,,,,,,,1,,A,CHEMBL631233,22224,,U,Autocuration,,BAO_0000019
12990,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631234,22229,,U,Autocuration,,BAO_0000100
12991,,0,Increased absorption was determined,,,,,,,1,,A,CHEMBL883126,22224,,U,Autocuration,,BAO_0000019
12992,,0,Lipophilicity value was evaluated,,,,,,,1,,P,CHEMBL631235,22224,,U,Autocuration,,BAO_0000100
12993,,0,Log P value of the compound.,,,,,,,1,,P,CHEMBL631236,22224,,U,Autocuration,,BAO_0000100
12994,,0,Partition coefficient of compound was determined,,,,,,,1,,A,CHEMBL631237,22224,,U,Autocuration,,BAO_0000019
12995,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631238,22229,,U,Autocuration,,BAO_0000100
12996,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL876429,22229,,U,Autocuration,,BAO_0000100
12997,,0,Partition coefficient was measured by medchem software; Not calculated,,,,,,,1,,A,CHEMBL631414,22224,,U,Autocuration,,BAO_0000019
12998,,0,Partition coefficient was measured by octanol-water using standard shake-flask method,,,,,,,1,,P,CHEMBL631415,22224,,U,Autocuration,,BAO_0000100
12999,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631416,22229,,U,Autocuration,,BAO_0000100
13000,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL631417,22224,,U,Autocuration,,BAO_0000019
13001,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631418,22229,,U,Autocuration,,BAO_0000100
13002,,0,The Octanol/Water partition coefficient CLogP,,,,,,,1,,P,CHEMBL631419,22229,,U,Autocuration,,BAO_0000100
13003,,0,The pharmacokinetic parameter C Log p was reported,,,,,,,1,,A,CHEMBL631420,22224,,U,Autocuration,,BAO_0000019
13004,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631421,22229,,U,Autocuration,,BAO_0000100
13005,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631422,22229,,U,Autocuration,,BAO_0000100
13006,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL631423,22229,,U,Autocuration,,BAO_0000100
13007,,1,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL876430,50597,,N,Intermediate,,BAO_0000218
13008,,1,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL631424,50597,,N,Intermediate,,BAO_0000218
13009,,1,Compound was administered intravenously in dog to evaluate plasma clearance values,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL631425,50588,,N,Intermediate,,BAO_0000218
13010,,0,Compound was administered intravenously in monkey to evaluate plasma clearance values,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL631426,22224,,U,Autocuration,,BAO_0000218
13011,,1,Compound was administered intravenously in mouse to evaluate plasma clearance values,Mus musculus,,,Plasma,1969.0,,1,10090.0,A,CHEMBL631427,50594,,N,Intermediate,,BAO_0000218
13012,,1,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL631428,50588,,N,Intermediate,,BAO_0000218
13013,Microsomes,1,Intrinsic clearance in Rhesus liver microsome,Macaca mulatta,,,Liver,2107.0,,1,9544.0,A,CHEMBL631429,50797,,N,Intermediate,,BAO_0000218
13014,Microsomes,1,Intrinsic clearance in dog liver microsome,Canis lupus familiaris,,,Liver,2107.0,,1,9615.0,A,CHEMBL631430,50588,,N,Intermediate,,BAO_0000218
13015,Microsomes,1,Intrinsic clearance in rat liver microsome,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631431,50597,,N,Intermediate,,BAO_0000218
13016,,1,Low plasma clearance was calculated in rhesus monkey,Macaca mulatta,,,Plasma,1969.0,,1,9544.0,A,CHEMBL631432,50797,,N,Intermediate,,BAO_0000218
13017,,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631433,50588,,N,Intermediate,,BAO_0000218
13018,,0,Plasma clearance after intravenous dose of 0.3 mg/kg,,,,,,,1,,A,CHEMBL631434,22224,,U,Autocuration,,BAO_0000218
13019,,0,Plasma clearance after intravenous dose of 1 mg/kg,,,,,,,1,,A,CHEMBL631435,22224,,U,Autocuration,,BAO_0000218
13020,,0,Plasma clearance after intravenous dose of 3 mg/kg,,,,,,,1,,A,CHEMBL631436,22224,,U,Autocuration,,BAO_0000218
13021,,0,Plasma clearance after intravenous dose of 3.87 mg/kg,,,,,,,1,,A,CHEMBL631437,22224,,U,Autocuration,,BAO_0000218
13022,,1,Plasma clearance after peroral administration at 10 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631438,50597,,N,Intermediate,,BAO_0000218
13023,,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL876431,50797,,N,Intermediate,,BAO_0000218
13024,,1,Plasma clearance after peroral administration at 10 mpk in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631439,50588,,N,Intermediate,,BAO_0000218
13025,,1,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631440,50597,,N,Intermediate,,BAO_0000218
13026,,0,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,,,,,,1,,A,CHEMBL631441,22224,,U,Autocuration,,BAO_0000019
13027,,0,Critical Micellar concentration was determined,,,,,,,1,,A,CHEMBL631442,22224,,U,Autocuration,,BAO_0000019
13028,,0,Critical Micellar concentration of the compound. was determined,,,,,,,1,,A,CHEMBL626525,22224,,U,Autocuration,,BAO_0000019
13029,,0,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,,,,,,1,,A,CHEMBL627168,22224,,U,Autocuration,,BAO_0000019
13030,,0,Critical micellar concentration was measured in water by the dye solubilization method,,,,,,,1,,A,CHEMBL875618,22224,,U,Autocuration,,BAO_0000019
13031,,0,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,,,,,,1,,B,CHEMBL626612,22224,,U,Autocuration,,BAO_0000019
13032,,0,CMR value (relative to BAY K 8644),,,,,,,1,,A,CHEMBL626613,22224,,U,Autocuration,,BAO_0000019
13033,,0,Carbamoylating activity was determined,,,,,,,1,,A,CHEMBL626614,22224,,U,Autocuration,,BAO_0000019
13034,,0,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,Simiiformes,,,,,,1,314293.0,A,CHEMBL626615,22224,,U,Autocuration,,BAO_0000218
13035,,0,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,,,,,,1,,A,CHEMBL626616,22224,,U,Autocuration,,BAO_0000019
13036,,0,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,,,,,,1,,A,CHEMBL626617,22224,,U,Autocuration,,BAO_0000019
13037,,1,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626618,50588,,N,Intermediate,,BAO_0000218
13038,,1,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626619,50597,,N,Intermediate,,BAO_0000218
13039,,1,"Clearance rate at 0.46 mg/kg, iv, in dogs",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626620,50588,,N,Intermediate,,BAO_0000218
13040,,1,"Clearance rate at 5.5 mg/kg, iv, in rat",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626621,50597,,N,Intermediate,,BAO_0000218
13041,,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL626622,100710,,N,Intermediate,,BAO_0000218
13042,,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL626623,100710,,N,Intermediate,,BAO_0000218
13043,,1,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626624,50588,,N,Intermediate,,BAO_0000218
13044,,1,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626625,50597,,N,Intermediate,,BAO_0000218
13045,,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL626626,50597,,N,Intermediate,,BAO_0000218
13046,,0,Tested for the total clearance of the compound,,,,,,,1,,A,CHEMBL626627,22224,,U,Autocuration,,BAO_0000218
13047,,1,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626628,50588,,N,Intermediate,,BAO_0000218
13048,,0,Total body clearance was determined,,,,,,,1,,A,CHEMBL626629,22224,,U,Autocuration,,BAO_0000218
13049,,1,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626630,50597,,N,Intermediate,,BAO_0000218
13050,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626631,50597,,N,Intermediate,,BAO_0000218
13051,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,1,,P,CHEMBL626632,22229,,U,Autocuration,,BAO_0000100
13052,,0,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,1,,P,CHEMBL626633,22229,,U,Autocuration,,BAO_0000100
13053,,0,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,,,,,,1,,P,CHEMBL626634,22229,,U,Autocuration,,BAO_0000100
13054,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,,,,,,1,,P,CHEMBL626635,22229,,U,Autocuration,,BAO_0000100
13055,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,,,,,,1,,P,CHEMBL626636,22229,,U,Autocuration,,BAO_0000100
13056,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,,,,,,1,,P,CHEMBL626637,22229,,U,Autocuration,,BAO_0000100
13057,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL626638,50339,,N,Intermediate,,BAO_0000218
13058,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL626639,50339,,N,Intermediate,,BAO_0000218
13059,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL626640,50339,,N,Intermediate,,BAO_0000218
13060,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL626641,50339,,N,Intermediate,,BAO_0000218
13061,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL627272,50339,,N,Intermediate,,BAO_0000218
13062,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL627273,50339,,N,Intermediate,,BAO_0000218
13063,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL627441,50339,,N,Intermediate,,BAO_0000218
13064,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL628355,50339,,N,Intermediate,,BAO_0000218
13065,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL628356,50339,,N,Intermediate,,BAO_0000218
13066,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL628357,50339,,N,Intermediate,,BAO_0000218
13067,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL628358,50339,,N,Intermediate,,BAO_0000218
13068,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),Pneumocystis carinii,,,,,,1,4754.0,A,CHEMBL622307,50339,,N,Intermediate,,BAO_0000218
13069,,0,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,,,,,,1,,A,CHEMBL622527,22224,,U,Autocuration,,BAO_0000019
13070,,0,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,,,,,,1,,A,CHEMBL622528,22224,,U,Autocuration,,BAO_0000019
13071,,0,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,,,,,,1,,A,CHEMBL622529,22224,,U,Autocuration,,BAO_0000019
13072,,0,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,,,,,,1,,A,CHEMBL622992,22224,,U,Autocuration,,BAO_0000019
13073,,0,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,,,,,,1,,A,CHEMBL622993,22224,,U,Autocuration,,BAO_0000019
13074,,0,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,,,,,,1,,A,CHEMBL622994,22224,,U,Autocuration,,BAO_0000019
13075,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622995,50597,,N,Intermediate,,BAO_0000218
13076,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622996,50597,,N,Intermediate,,BAO_0000218
13077,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622997,50597,,N,Intermediate,,BAO_0000218
13078,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622998,50597,,N,Intermediate,,BAO_0000218
13079,,0,Cp max following ip administration at 1 mg/kg,,,,,,,1,,A,CHEMBL622999,22224,,U,Autocuration,,BAO_0000218
13080,,0,Maximum concentration in plasma was reported at 0.5 hour,,,,Plasma,1969.0,,1,,A,CHEMBL623000,22224,,U,Autocuration,,BAO_0000218
13081,,0,Maximum concentration in plasma was reported at 2 hour,,,,Plasma,1969.0,,1,,A,CHEMBL623001,22224,,U,Autocuration,,BAO_0000218
13082,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,Mus musculus,,,,,,1,10090.0,A,CHEMBL623002,50594,,N,Intermediate,,BAO_0000218
13083,,0,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,,,,,,1,,P,CHEMBL623003,22229,,U,Autocuration,,BAO_0000100
13084,,0,Steady state concentration was evaluated,,,,,,,1,,A,CHEMBL623004,22224,,U,Autocuration,,BAO_0000019
13085,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL623005,22224,,U,Autocuration,,BAO_0000019
13086,,0,Partition coefficient (logD7.4),,,,,,,1,,A,CHEMBL623006,22224,,U,Autocuration,,BAO_0000019
13087,,1,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623007,50597,,N,Intermediate,,BAO_0000218
13088,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL623008,50597,,N,Intermediate,,BAO_0000218
13089,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL876654,50597,,N,Intermediate,,BAO_0000218
13090,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623009,50597,,N,Intermediate,,BAO_0000218
13091,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623010,50597,,N,Intermediate,,BAO_0000218
13092,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623011,50597,,N,Intermediate,,BAO_0000218
13093,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL623012,50597,,N,Intermediate,,BAO_0000218
13094,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,,,,,,1,,A,CHEMBL623013,22224,,U,Autocuration,,BAO_0000019
13095,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,,,,,,1,,A,CHEMBL623014,22224,,U,Autocuration,,BAO_0000019
13096,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,,,Urine,1088.0,,1,,A,CHEMBL623015,22224,,U,Autocuration,,BAO_0000019
13097,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,,,Urine,1088.0,,1,,A,CHEMBL623016,22224,,U,Autocuration,,BAO_0000019
13098,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,,,Urine,1088.0,,1,,A,CHEMBL624858,22224,,U,Autocuration,,BAO_0000019
13099,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624859,50597,,N,Intermediate,,BAO_0000218
13100,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624860,50597,,N,Intermediate,,BAO_0000218
13101,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624861,50597,,N,Intermediate,,BAO_0000218
13102,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624862,50597,,N,Intermediate,,BAO_0000218
13103,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624863,50597,,N,Intermediate,,BAO_0000218
13104,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876655,50597,,N,Intermediate,,BAO_0000218
13105,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624864,50588,,N,Intermediate,,BAO_0000218
13106,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624865,50588,,N,Intermediate,,BAO_0000218
13107,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624866,50588,,N,Intermediate,,BAO_0000218
13108,,1,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,F,CHEMBL624867,50588,,N,Expert,,BAO_0000218
13109,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL624868,50588,,N,Intermediate,,BAO_0000218
13110,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628450,50588,,N,Intermediate,,BAO_0000218
13111,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628451,50588,,N,Intermediate,,BAO_0000218
13112,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628452,50588,,N,Intermediate,,BAO_0000218
13113,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628453,50588,,N,Intermediate,,BAO_0000218
13114,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628454,50588,,N,Intermediate,,BAO_0000218
13115,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628455,50588,,N,Intermediate,,BAO_0000218
13116,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628456,50588,,N,Intermediate,,BAO_0000218
13117,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628457,50588,,N,Intermediate,,BAO_0000218
13118,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL877505,50588,,N,Intermediate,,BAO_0000218
13119,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628458,50588,,N,Intermediate,,BAO_0000218
13120,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628459,50588,,N,Intermediate,,BAO_0000218
13121,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628460,50588,,N,Intermediate,,BAO_0000218
13122,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628461,50588,,N,Intermediate,,BAO_0000218
13123,,0,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,,,,,,1,,B,CHEMBL628462,22224,,U,Autocuration,,BAO_0000218
13124,,1,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628463,50588,,N,Intermediate,,BAO_0000218
13125,,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL625666,50597,,N,Expert,,BAO_0000218
13126,,0,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,,,,,,1,,B,CHEMBL625667,22224,,U,Autocuration,,BAO_0000218
13127,,1,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625668,50597,,N,Expert,,BAO_0000218
13128,,1,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625669,50597,,N,Intermediate,,BAO_0000218
13129,,0,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,,,,,,1,,A,CHEMBL625670,22224,,U,Autocuration,,BAO_0000019
13130,,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625671,50597,,N,Intermediate,,BAO_0000218
13131,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL625672,50602,,N,Intermediate,,BAO_0000218
13132,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL625673,50602,,N,Intermediate,,BAO_0000218
13133,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL625674,50602,,N,Intermediate,,BAO_0000218
13134,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL625675,50602,,N,Intermediate,,BAO_0000218
13135,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627637,50602,,N,Intermediate,,BAO_0000218
13136,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627638,50602,,N,Intermediate,,BAO_0000218
13137,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627639,50602,,N,Intermediate,,BAO_0000218
13138,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627640,50602,,N,Intermediate,,BAO_0000218
13139,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627641,50602,,N,Intermediate,,BAO_0000218
13140,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL627642,50602,,N,Intermediate,,BAO_0000218
13141,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL877506,50602,,N,Intermediate,,BAO_0000218
13142,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,Mus musculus,,,,,,1,10090.0,A,CHEMBL627275,50594,,N,Intermediate,,BAO_0000218
13143,,1,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL627643,50506,,N,Intermediate,,BAO_0000218
13144,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL631246,50506,,N,Intermediate,,BAO_0000218
13145,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL631247,50506,,N,Intermediate,,BAO_0000218
13146,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL629532,50506,,N,Intermediate,,BAO_0000218
13147,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL629533,50506,,N,Intermediate,,BAO_0000218
13148,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL629534,50506,,N,Intermediate,,BAO_0000218
13149,,1,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL629535,50506,,N,Intermediate,,BAO_0000218
13150,,0,Pharmacokinetic parameter :drug bound to plasma was reported,,,,,,,1,,A,CHEMBL625932,22224,,U,Autocuration,,BAO_0000019
13151,,0,compound was evaluated for drug bound in plasma,,,,,,,1,,A,CHEMBL625933,22224,,U,Autocuration,,BAO_0000019
13152,,1,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625934,50597,,N,Intermediate,,BAO_0000218
13153,,0,Bioavailability,Eutheria,,,,,,1,9347.0,A,CHEMBL625935,22224,,U,Autocuration,,BAO_0000218
13154,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625936,50597,,N,Intermediate,,BAO_0000218
13155,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625937,50597,,N,Intermediate,,BAO_0000218
13156,,1,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625938,50588,,N,Intermediate,,BAO_0000218
13157,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL625939,50597,,N,Intermediate,,BAO_0000218
13158,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL625940,50597,,N,Intermediate,,BAO_0000218
13159,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL874464,50597,,N,Intermediate,,BAO_0000218
13160,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL625941,50597,,N,Intermediate,,BAO_0000218
13161,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL625942,50597,,N,Intermediate,,BAO_0000218
13162,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Rattus norvegicus,,,Bile,1970.0,,1,10116.0,A,CHEMBL625943,50597,,N,Intermediate,,BAO_0000218
13163,,1,In vitro protein binding in human serum at 5 ug/ml,Homo sapiens,,,Serum,1977.0,,1,9606.0,A,CHEMBL625944,50587,,N,Intermediate,,BAO_0000218
13164,,0,Serum protein binding ability was measured,,,,,,,1,,A,CHEMBL625945,22224,,U,Autocuration,,BAO_0000019
13165,,0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,,,,,,1,,A,CHEMBL625946,22224,,U,Autocuration,,BAO_0000019
13166,,0,Oral bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625947,22224,,U,Autocuration,,BAO_0000218
13167,,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625948,50597,,N,Intermediate,,BAO_0000218
13168,,0,Absolute oral bioavailability at an iv dose of 14 mg/kg,,,,,,,1,,A,CHEMBL625949,22224,,U,Autocuration,,BAO_0000218
13169,,0,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,,,,,,1,,A,CHEMBL625950,22224,,U,Autocuration,,BAO_0000218
13170,,0,Oral bioavailability (dose 15 mg/kg i.v.),Eutheria,,,,,,1,9347.0,A,CHEMBL625951,22224,,U,Autocuration,,BAO_0000218
13171,,0,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,,,,,,1,,A,CHEMBL625952,22224,,U,Autocuration,,BAO_0000218
13172,,0,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,,,,,,1,,A,CHEMBL625953,22224,,U,Autocuration,,BAO_0000218
13173,,0,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,,,,,,1,,A,CHEMBL625954,22224,,U,Autocuration,,BAO_0000218
13174,,0,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,,,,,,1,,A,CHEMBL882959,22224,,U,Autocuration,,BAO_0000218
13175,,1,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625955,50588,,N,Intermediate,,BAO_0000218
13176,,0,Bioavailability in ferret,Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL625956,22224,,U,Autocuration,,BAO_0000218
13177,,1,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL625957,100710,,N,Intermediate,,BAO_0000218
13178,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625958,50597,,N,Intermediate,,BAO_0000218
13179,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625959,50597,,N,Intermediate,,BAO_0000218
13180,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626642,50597,,N,Intermediate,,BAO_0000218
13181,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631330,50597,,N,Intermediate,,BAO_0000218
13182,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631331,50597,,N,Intermediate,,BAO_0000218
13183,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631332,50597,,N,Intermediate,,BAO_0000218
13184,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631333,50597,,N,Intermediate,,BAO_0000218
13185,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632018,50597,,N,Intermediate,,BAO_0000218
13186,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632019,50597,,N,Intermediate,,BAO_0000218
13187,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632020,50597,,N,Intermediate,,BAO_0000218
13188,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632021,50597,,N,Intermediate,,BAO_0000218
13189,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632022,50597,,N,Intermediate,,BAO_0000218
13190,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632023,50597,,N,Intermediate,,BAO_0000218
13191,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632024,50597,,N,Intermediate,,BAO_0000218
13192,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874472,50597,,N,Intermediate,,BAO_0000218
13193,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632025,50597,,N,Intermediate,,BAO_0000218
13194,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632026,50597,,N,Intermediate,,BAO_0000218
13195,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632027,50597,,N,Intermediate,,BAO_0000218
13196,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632028,50597,,N,Intermediate,,BAO_0000218
13197,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626430,50597,,N,Intermediate,,BAO_0000218
13198,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626431,50597,,N,Intermediate,,BAO_0000218
13199,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626432,50597,,N,Intermediate,,BAO_0000218
13200,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626433,50597,,N,Intermediate,,BAO_0000218
13201,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626434,50597,,N,Intermediate,,BAO_0000218
13202,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627280,50597,,N,Intermediate,,BAO_0000218
13203,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627281,50597,,N,Intermediate,,BAO_0000218
13204,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627282,50597,,N,Intermediate,,BAO_0000218
13205,,0,Total body clearance was measured at given dose,,,,,,,1,,A,CHEMBL627283,22224,,U,Autocuration,,BAO_0000019
13206,,0,Total body clearance was measured at given dose.,,,,,,,1,,A,CHEMBL627284,22224,,U,Autocuration,,BAO_0000218
13207,,1,Metabolic clearance from the body in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627285,50597,,N,Intermediate,,BAO_0000218
13208,,0,Renal clearance from the body,,,,,,,1,,A,CHEMBL627286,22224,,U,Autocuration,,BAO_0000218
13209,,1,Renal clearance from the body in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875477,50597,,N,Intermediate,,BAO_0000218
13210,,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627287,50597,,N,Intermediate,,BAO_0000218
13211,,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL627288,50588,,N,Intermediate,,BAO_0000218
13212,,1,Total clearance from the body in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627289,50597,,N,Intermediate,,BAO_0000218
13213,,1,Clearance into cortex from rat plasma or PBS,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627290,50597,,N,Intermediate,,BAO_0000218
13214,,0,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,,,,,,1,,A,CHEMBL627291,22224,,U,Autocuration,,BAO_0000218
13215,,0,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,,,,,,1,,A,CHEMBL627292,22224,,U,Autocuration,,BAO_0000218
13216,,0,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,,,,,,1,,A,CHEMBL627293,22224,,U,Autocuration,,BAO_0000218
13217,,0,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,,,,,,1,,A,CHEMBL627294,22224,,U,Autocuration,,BAO_0000218
13218,,0,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,,,,,,1,,A,CHEMBL875478,22224,,U,Autocuration,,BAO_0000218
13219,,0,Clearance was determined,,,,,,,1,,A,CHEMBL627295,22224,,U,Autocuration,,BAO_0000218
13220,,1,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,Mus musculus,,,,,,1,10090.0,A,CHEMBL627296,50594,,N,Intermediate,,BAO_0000218
13221,,1,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,Oryctolagus cuniculus,,,,,,1,9986.0,A,CHEMBL626119,50592,,N,Intermediate,,BAO_0000218
13222,,1,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626120,50597,,N,Intermediate,,BAO_0000218
13223,,1,Clearance in rat after iv dose (100 ug/kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626121,50597,,N,Intermediate,,BAO_0000218
13224,,0,Clearance in guinea pig,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL626122,22224,,U,Autocuration,,BAO_0000218
13225,,1,Compound was evaluated for clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626123,50597,,N,Intermediate,,BAO_0000218
13226,,1,Compound was evaluated for the clearance in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL623456,50588,,N,Intermediate,,BAO_0000218
13227,,1,Compound was evaluated for the clearance in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623457,50597,,N,Intermediate,,BAO_0000218
13228,,1,Compound was tested in vivo for clearance after iv administration in the rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623458,50597,,N,Intermediate,,BAO_0000218
13229,,0,IV clearance determined at an iv dose of 14 mg/kg,,,,,,,1,,A,CHEMBL623459,22224,,U,Autocuration,,BAO_0000218
13230,,0,IV clearance determined at an iv dose of 15.2 mg/kg,,,,,,,1,,A,CHEMBL875484,22224,,U,Autocuration,,BAO_0000218
13231,,0,IV clearance determined at an iv dose of 15 mg/kg,,,,,,,1,,A,CHEMBL623460,22224,,U,Autocuration,,BAO_0000218
13232,,0,IV clearance determined at an peroral dose of 30 mg/kg.,,,,,,,1,,A,CHEMBL623461,22224,,U,Autocuration,,BAO_0000218
13233,,0,IV clearance determined at an peroral dose of 30.2 mg/kg.,,,,,,,1,,A,CHEMBL623462,22224,,U,Autocuration,,BAO_0000218
13234,,0,IV clearance determined at an peroral dose of 30.3 mg/kg.,,,,,,,1,,A,CHEMBL627386,22224,,U,Autocuration,,BAO_0000218
13235,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627387,50597,,N,Intermediate,,BAO_0000218
13236,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627388,50597,,N,Intermediate,,BAO_0000218
13237,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627389,50597,,N,Intermediate,,BAO_0000218
13238,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627390,50597,,N,Intermediate,,BAO_0000218
13239,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627391,50597,,N,Intermediate,,BAO_0000218
13240,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627392,50597,,N,Intermediate,,BAO_0000218
13241,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL627393,50597,,N,Intermediate,,BAO_0000218
13242,,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Rattus norvegicus,,,Trachea,3126.0,,1,10116.0,A,CHEMBL627394,50597,,N,Intermediate,,BAO_0000218
13243,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627395,50597,,N,Intermediate,,BAO_0000218
13244,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL875485,50597,,N,Intermediate,,BAO_0000218
13245,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627396,50597,,N,Intermediate,,BAO_0000218
13246,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627397,50597,,N,Intermediate,,BAO_0000218
13247,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL627398,50597,,N,Intermediate,,BAO_0000218
13248,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL627399,50597,,N,Intermediate,,BAO_0000218
13249,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627400,50597,,N,Intermediate,,BAO_0000218
13250,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627401,50597,,N,Intermediate,,BAO_0000218
13251,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627402,50597,,N,Intermediate,,BAO_0000218
13252,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL627403,50597,,N,Intermediate,,BAO_0000218
13253,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL627404,50597,,N,Intermediate,,BAO_0000218
13254,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623101,50597,,N,Intermediate,,BAO_0000218
13255,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL877480,50597,,N,Intermediate,,BAO_0000218
13256,,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Rattus norvegicus,,,Trachea,3126.0,,1,10116.0,A,CHEMBL623102,50597,,N,Intermediate,,BAO_0000218
13257,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL623103,50597,,N,Intermediate,,BAO_0000218
13258,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL623104,50597,,N,Intermediate,,BAO_0000218
13259,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623105,50597,,N,Intermediate,,BAO_0000218
13260,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623106,50597,,N,Intermediate,,BAO_0000218
13261,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL623107,50597,,N,Intermediate,,BAO_0000218
13262,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL623108,50597,,N,Intermediate,,BAO_0000218
13263,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL623109,50597,,N,Intermediate,,BAO_0000218
13264,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL623110,50597,,N,Intermediate,,BAO_0000218
13265,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL623111,50597,,N,Intermediate,,BAO_0000218
13266,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625060,50597,,N,Intermediate,,BAO_0000218
13267,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625061,50597,,N,Intermediate,,BAO_0000218
13268,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625062,50597,,N,Intermediate,,BAO_0000218
13269,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625063,50597,,N,Intermediate,,BAO_0000218
13270,,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Rattus norvegicus,,,Trachea,3126.0,,1,10116.0,A,CHEMBL625064,50597,,N,Intermediate,,BAO_0000218
13271,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Rattus norvegicus,,,Bone,10000001.0,,1,10116.0,A,CHEMBL625065,50597,,N,Intermediate,,BAO_0000218
13272,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL625066,50597,,N,Intermediate,,BAO_0000218
13273,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625067,50597,,N,Intermediate,,BAO_0000218
13274,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625068,50597,,N,Intermediate,,BAO_0000218
13275,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL622159,50597,,N,Intermediate,,BAO_0000218
13276,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Rattus norvegicus,,,Intestine,160.0,,1,10116.0,A,CHEMBL622160,50597,,N,Intermediate,,BAO_0000218
13277,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL622161,50597,,N,Intermediate,,BAO_0000218
13278,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL622162,50597,,N,Intermediate,,BAO_0000218
13279,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL622163,50597,,N,Intermediate,,BAO_0000218
13280,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622313,50597,,N,Intermediate,,BAO_0000218
13281,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622314,50597,,N,Intermediate,,BAO_0000218
13282,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622315,50597,,N,Intermediate,,BAO_0000218
13283,,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Rattus norvegicus,,,Trachea,3126.0,,1,10116.0,A,CHEMBL622316,50597,,N,Intermediate,,BAO_0000218
13284,,1,Normal diffusion coefficient in water for Escherichia coli,Escherichia coli,,,,,,1,562.0,A,CHEMBL877486,50212,,N,Intermediate,,BAO_0000218
13285,,0,Average max percent decrease in RVR (renal vascular resistance) was determined,,,,,,,1,,A,CHEMBL622317,22224,,U,Autocuration,,BAO_0000019
13286,,0,Average max percent decrease in RVR (renal vascular resistance) was determined.,,,,,,,1,,A,CHEMBL622318,22224,,U,Autocuration,,BAO_0000019
13287,,0,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,,,,,,1,,A,CHEMBL622319,22224,,U,Autocuration,,BAO_0000019
13288,,0,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,,,,,,1,,A,CHEMBL622320,22224,,U,Autocuration,,BAO_0000019
13289,,0,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,,,,,,1,,A,CHEMBL622321,22224,,U,Autocuration,,BAO_0000019
13290,,0,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,,,,,,1,,A,CHEMBL622322,22224,,U,Autocuration,,BAO_0000019
13291,,0,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,,,,,,1,,A,CHEMBL622323,22224,,U,Autocuration,,BAO_0000019
13292,,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622324,50597,,N,Intermediate,,BAO_0000218
13293,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622325,50588,,N,Intermediate,,BAO_0000218
13294,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622326,50588,,N,Intermediate,,BAO_0000218
13295,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL877487,50588,,N,Intermediate,,BAO_0000218
13296,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622327,50588,,N,Intermediate,,BAO_0000218
13297,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622328,50588,,N,Intermediate,,BAO_0000218
13298,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622329,50588,,N,Intermediate,,BAO_0000218
13299,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622330,50588,,N,Intermediate,,BAO_0000218
13300,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622331,50588,,N,Intermediate,,BAO_0000218
13301,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622332,50588,,N,Intermediate,,BAO_0000218
13302,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622333,50588,,N,Intermediate,,BAO_0000218
13303,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL627658,22224,,U,Autocuration,,BAO_0000218
13304,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL630428,22224,,U,Autocuration,,BAO_0000218
13305,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL630429,22224,,U,Autocuration,,BAO_0000218
13306,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL630430,22224,,U,Autocuration,,BAO_0000218
13307,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL630431,22224,,U,Autocuration,,BAO_0000218
13308,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL630432,50597,,N,Intermediate,,BAO_0000218
13309,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL630433,50597,,N,Intermediate,,BAO_0000218
13310,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL630434,50597,,N,Intermediate,,BAO_0000218
13311,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629372,50597,,N,Intermediate,,BAO_0000218
13312,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629553,50597,,N,Intermediate,,BAO_0000218
13313,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629554,50597,,N,Intermediate,,BAO_0000218
13314,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL874447,50597,,N,Intermediate,,BAO_0000218
13315,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629555,50597,,N,Intermediate,,BAO_0000218
13316,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629556,50597,,N,Intermediate,,BAO_0000218
13317,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629557,50597,,N,Intermediate,,BAO_0000218
13318,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629558,50597,,N,Intermediate,,BAO_0000218
13319,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629559,50597,,N,Intermediate,,BAO_0000218
13320,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629560,50597,,N,Intermediate,,BAO_0000218
13321,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629561,50588,,N,Intermediate,,BAO_0000218
13322,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629562,50588,,N,Intermediate,,BAO_0000218
13323,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629563,50588,,N,Intermediate,,BAO_0000218
13324,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629564,50588,,N,Intermediate,,BAO_0000218
13325,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629565,50588,,N,Intermediate,,BAO_0000218
13326,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629566,50588,,N,Intermediate,,BAO_0000218
13327,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629567,50588,,N,Intermediate,,BAO_0000218
13328,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629568,50588,,N,Intermediate,,BAO_0000218
13329,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629569,50588,,N,Intermediate,,BAO_0000218
13330,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL629570,50588,,N,Intermediate,,BAO_0000218
13331,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL629571,22224,,U,Autocuration,,BAO_0000218
13332,,0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629572,22224,,U,Autocuration,,BAO_0000218
13333,,0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629573,22224,,U,Autocuration,,BAO_0000218
13334,,0,Bioavailability (dose 20 mg/kg),Eutheria,,,,,,1,9347.0,A,CHEMBL629574,22224,,U,Autocuration,,BAO_0000218
13335,,0,Bioavailability in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629575,22224,,U,Autocuration,,BAO_0000218
13336,,0,Bioavailability in rat (Sprague-Dawley) (male),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874448,22224,,U,Autocuration,,BAO_0000218
13337,,0,Bioavailability in monkey (dose 10 mg/kg i.d.),Primates,,,,,,1,9443.0,A,CHEMBL629576,22224,,U,Autocuration,,BAO_0000218
13338,,0,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629577,22224,,U,Autocuration,,BAO_0000218
13339,,0,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629578,22224,,U,Autocuration,,BAO_0000218
13340,,0,Bioavailability in dog (dose 3.0 mg/kg p.o.),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629579,22224,,U,Autocuration,,BAO_0000218
13341,,0,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL882958,22224,,U,Autocuration,,BAO_0000218
13342,,1,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,Pan troglodytes,,,,,,1,9598.0,A,CHEMBL629580,50505,,N,Intermediate,,BAO_0000218
13343,,0,Bioavailability,Eutheria,,,,,,1,9347.0,A,CHEMBL629581,22224,,U,Autocuration,,BAO_0000218
13344,,0,Bioavailability in squirrel monkey,Saimiri,,,,,,1,9520.0,A,CHEMBL629582,22224,,U,Autocuration,,BAO_0000218
13345,,1,Bioavailability was evaluated in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628522,50588,,N,Intermediate,,BAO_0000218
13346,,1,Bioavailability was evaluated in hamster,Cricetinae,,,,,,1,10026.0,A,CHEMBL625432,100712,,N,Intermediate,,BAO_0000218
13347,,0,Bioavailability in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625433,22224,,U,Autocuration,,BAO_0000218
13348,,1,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625434,50597,,N,Intermediate,,BAO_0000218
13349,,1,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL625435,50597,,N,Intermediate,,BAO_0000218
13350,,0,Bioavailability in rat (dose 10 mg/kg p.o.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625436,22224,,U,Autocuration,,BAO_0000218
13351,,1,Bioavailability was measured in cynomolgus monkeys.,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL874588,100710,,N,Intermediate,,BAO_0000218
13352,,1,Bioavailability was measured in nude mice.,Mus musculus,,,,,,1,10090.0,A,CHEMBL625437,50594,,N,Intermediate,,BAO_0000218
13353,,0,Bioavailability in ferret (dose 10 mg/kg i.d.),Mustela putorius furo,,,,,,1,9669.0,A,CHEMBL625438,22224,,U,Autocuration,,BAO_0000218
13354,,0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),Simiiformes,,,,,,1,314293.0,A,CHEMBL625439,22224,,U,Autocuration,,BAO_0000218
13355,,0,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",Simiiformes,,,,,,1,314293.0,A,CHEMBL625440,22224,,U,Autocuration,,BAO_0000218
13356,,0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),Simiiformes,,,,,,1,314293.0,A,CHEMBL625441,22224,,U,Autocuration,,BAO_0000218
13357,,0,Bioavailability in rat (dose 10 mg/kg i.d.),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625442,22224,,U,Autocuration,,BAO_0000218
13358,,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625443,50597,,N,Intermediate,,BAO_0000218
13359,,0,Bioavailability was determined; extremely poor,,,,,,,1,,A,CHEMBL625444,22224,,U,Autocuration,,BAO_0000218
13360,,1,% bioavailability in mice after oral administration of prodrug,Mus musculus,,,,,,1,10090.0,A,CHEMBL625445,50594,,N,Intermediate,,BAO_0000218
13361,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625446,50588,,N,Intermediate,,BAO_0000218
13362,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL882960,50588,,N,Intermediate,,BAO_0000218
13363,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625447,50588,,N,Intermediate,,BAO_0000218
13364,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625448,50588,,N,Intermediate,,BAO_0000218
13365,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625449,50588,,N,Intermediate,,BAO_0000218
13366,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL874589,50588,,N,Intermediate,,BAO_0000218
13367,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625450,50588,,N,Intermediate,,BAO_0000218
13368,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625451,50588,,N,Intermediate,,BAO_0000218
13369,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626584,50588,,N,Intermediate,,BAO_0000218
13370,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626585,50588,,N,Intermediate,,BAO_0000218
13371,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626586,50588,,N,Intermediate,,BAO_0000218
13372,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626587,50588,,N,Intermediate,,BAO_0000218
13373,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626588,50588,,N,Intermediate,,BAO_0000218
13374,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626589,50588,,N,Intermediate,,BAO_0000218
13375,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626590,50588,,N,Intermediate,,BAO_0000218
13376,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626591,50588,,N,Intermediate,,BAO_0000218
13377,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL627181,50588,,N,Intermediate,,BAO_0000218
13378,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628083,50588,,N,Intermediate,,BAO_0000218
13379,,0,IV clearance determined at an peroral dose of 15 mg/kg.,,,,,,,1,,A,CHEMBL628084,22224,,U,Autocuration,,BAO_0000218
13380,,1,Mouse oral clearance was measured against Hymenolepiasis nana.,Hymenolepis nana,,,,,,1,102285.0,F,CHEMBL628085,50064,,N,Expert,,BAO_0000218
13381,,1,Mouse oral clearance was measured against Nematospiroides dubius,Heligmosomoides polygyrus,,,,,,1,6339.0,F,CHEMBL628086,50545,,N,Expert,,BAO_0000218
13382,,0,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,,,,,,1,,F,CHEMBL628087,22224,,U,Autocuration,,BAO_0000218
13383,,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,Mus musculus,,,,,,1,10090.0,A,CHEMBL628088,50594,,N,Intermediate,,BAO_0000218
13384,,0,Mouse oral clearance was measured against N. nana; NT is Not Tested,,,,,,,1,,B,CHEMBL628089,22224,,U,Autocuration,,BAO_0000218
13385,,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL628090,22224,,U,Autocuration,,BAO_0000218
13386,,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL628091,22224,,U,Autocuration,,BAO_0000218
13387,,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL628092,22224,,U,Autocuration,,BAO_0000218
13388,,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL628093,22224,,U,Autocuration,,BAO_0000218
13389,,0,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL875607,22224,,U,Autocuration,,BAO_0000218
13390,,0,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL625710,22224,,U,Autocuration,,BAO_0000218
13391,,0,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL625711,22224,,U,Autocuration,,BAO_0000218
13392,,0,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL625712,22224,,U,Autocuration,,BAO_0000218
13393,,0,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,,,,,,1,,A,CHEMBL625713,22224,,U,Autocuration,,BAO_0000218
13394,,1,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625714,50588,,N,Intermediate,,BAO_0000218
13395,,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL625715,50797,,N,Intermediate,,BAO_0000218
13396,,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625716,50597,,N,Intermediate,,BAO_0000218
13397,,1,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625717,50597,,N,Intermediate,,BAO_0000218
13398,,1,Plasma clearance was determined for the compound in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625718,50597,,N,Intermediate,,BAO_0000218
13399,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625719,50597,,N,Intermediate,,BAO_0000218
13400,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625720,50597,,N,Intermediate,,BAO_0000218
13401,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625721,50597,,N,Intermediate,,BAO_0000218
13402,,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625722,50597,,N,Intermediate,,BAO_0000218
13403,,1,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625723,50597,,N,Intermediate,,BAO_0000218
13404,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,Heligmosomoides polygyrus,,,,,,1,6339.0,A,CHEMBL625724,50545,,N,Intermediate,,BAO_0000218
13405,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,Heligmosomoides polygyrus,,,,,,1,6339.0,A,CHEMBL625725,50545,,N,Intermediate,,BAO_0000218
13406,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,Heligmosomoides polygyrus,,,,,,1,6339.0,A,CHEMBL625726,50545,,N,Intermediate,,BAO_0000218
13407,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,Heligmosomoides polygyrus,,,,,,1,6339.0,A,CHEMBL875608,50545,,N,Intermediate,,BAO_0000218
13408,,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,Heligmosomoides polygyrus,,,,,,1,6339.0,A,CHEMBL625727,50545,,N,Intermediate,,BAO_0000218
13409,,0,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625728,22224,,U,Autocuration,,BAO_0000218
13410,,0,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625729,22224,,U,Autocuration,,BAO_0000218
13411,,0,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625730,22224,,U,Autocuration,,BAO_0000218
13412,,0,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625731,22224,,U,Autocuration,,BAO_0000218
13413,,0,Urinary clearance was determined in rat at 25 mg/kg os dosage,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626417,22224,,U,Autocuration,,BAO_0000218
13414,,1,Urinary clearance was determined at 100 mg/kg oral dosage in human,Homo sapiens,,,Urine,1088.0,,1,9606.0,A,CHEMBL626418,50587,,N,Intermediate,,BAO_0000218
13415,,1,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL626419,50588,,N,Intermediate,,BAO_0000218
13416,,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626592,50588,,N,Intermediate,,BAO_0000218
13417,,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626593,50597,,N,Intermediate,,BAO_0000218
13418,,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626594,50597,,N,Intermediate,,BAO_0000218
13419,,1,Clearance rate in dogs,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625035,50588,,N,Intermediate,,BAO_0000218
13420,,0,Compound was measured for intrinsic clearance,,,,,,,1,,A,CHEMBL625036,22224,,U,Autocuration,,BAO_0000019
13421,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625037,22229,,U,Autocuration,,BAO_0000100
13422,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625038,22229,,U,Autocuration,,BAO_0000100
13423,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625039,22229,,U,Autocuration,,BAO_0000100
13424,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625040,22229,,U,Autocuration,,BAO_0000100
13425,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625041,22229,,U,Autocuration,,BAO_0000100
13426,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625042,22229,,U,Autocuration,,BAO_0000100
13427,,0,Partition coefficient of the compound,,,,,,,1,,A,CHEMBL874411,22224,,U,Autocuration,,BAO_0000019
13428,,0,Permeability,,,,,,,1,,A,CHEMBL625043,22224,,U,Autocuration,,BAO_0000019
13429,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625044,22229,,U,Autocuration,,BAO_0000100
13430,,0,Partition coefficient (logD),,,,,,,1,,A,CHEMBL625045,22224,,U,Autocuration,,BAO_0000019
13431,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,1,,P,CHEMBL625046,22229,,U,Autocuration,,BAO_0000100
13432,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,,,,,,1,,P,CHEMBL625047,22229,,U,Autocuration,,BAO_0000100
13433,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625048,22229,,U,Autocuration,,BAO_0000100
13434,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625049,22229,,U,Autocuration,,BAO_0000100
13435,,0,Calculated logarithm of partition coefficient (P) was determined,,,,,,,1,,P,CHEMBL625050,22229,,U,Autocuration,,BAO_0000100
13436,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625051,22229,,U,Autocuration,,BAO_0000100
13437,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL874412,22229,,U,Autocuration,,BAO_0000100
13438,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625052,22229,,U,Autocuration,,BAO_0000100
13439,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL625053,22229,,U,Autocuration,,BAO_0000100
13440,,0,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,,,,,,1,,A,CHEMBL623250,22224,,U,Autocuration,,BAO_0000019
13441,,0,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,,,,,,1,,A,CHEMBL623251,22224,,U,Autocuration,,BAO_0000019
13442,,0,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,,,,,,1,,A,CHEMBL623252,22224,,U,Autocuration,,BAO_0000019
13443,,0,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,,,,,,1,,A,CHEMBL623253,22224,,U,Autocuration,,BAO_0000019
13444,,0,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,,,,,,1,,A,CHEMBL623254,22224,,U,Autocuration,,BAO_0000019
13445,,0,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,,,,,,1,,A,CHEMBL623255,22224,,U,Autocuration,,BAO_0000019
13446,,0,Percent degradation of compound at a pH of 1 over a 18 hr period,,,,,,,1,,A,CHEMBL626831,22224,,U,Autocuration,,BAO_0000019
13447,,0,Percent degradation of compound at pH of 1 over an 18 hr period,,,,,,,1,,A,CHEMBL877494,22224,,U,Autocuration,,BAO_0000019
13448,,0,Delta Logarithm of Partition Coefficient value was determined.,,,,,,,1,,A,CHEMBL626832,22224,,U,Autocuration,,BAO_0000019
13449,,0,Delta logPoct-cyc,,,,,,,1,,A,CHEMBL626833,22224,,U,Autocuration,,BAO_0000019
13450,,0,Lipophilicity estimated on reversed phase TLC,,,,,,,1,,P,CHEMBL626834,22224,,U,Autocuration,,BAO_0000100
13451,,0,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,,,,,,1,,A,CHEMBL626835,22224,,U,Autocuration,,BAO_0000019
13452,,0,Delta logPoct-cyc,,,,,,,1,,A,CHEMBL626836,22224,,U,Autocuration,,BAO_0000019
13453,,0,Change in logarithm of partition coefficient of the compound,,,,,,,1,,P,CHEMBL626837,22229,,U,Autocuration,,BAO_0000100
13454,,0,Delta logD (pH 6.5),,,,,,,1,,A,CHEMBL626838,22224,,U,Autocuration,,BAO_0000019
13455,,0,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,,,,,,1,,P,CHEMBL626839,22224,,U,Autocuration,,BAO_0000100
13456,,0,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,,,,,,1,,A,CHEMBL626840,22224,,U,Autocuration,,BAO_0000019
13457,,0,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,,,,,,1,,A,CHEMBL626841,22224,,U,Autocuration,,BAO_0000019
13458,,0,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,,,,,,1,,A,CHEMBL626842,22224,,U,Autocuration,,BAO_0000219
13459,,0,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,,,,,,1,,A,CHEMBL626843,22224,,U,Autocuration,,BAO_0000219
13460,,1,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626844,50597,,N,Intermediate,,BAO_0000218
13461,,1,Amount of deuterium retained was reported after normal workup in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL877495,50597,,N,Intermediate,,BAO_0000218
13462,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626845,50597,,N,Intermediate,,BAO_0000218
13463,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626846,50597,,N,Intermediate,,BAO_0000218
13464,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626847,50597,,N,Intermediate,,BAO_0000218
13465,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628677,50597,,N,Intermediate,,BAO_0000218
13466,,1,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628678,50597,,N,Intermediate,,BAO_0000218
13467,,0,Compound was subjected to electrochemical oxidation,,,,,,,1,,A,CHEMBL628679,22224,,U,Autocuration,,BAO_0000019
13468,,0,Compound was subjected to photochemical oxidation,,,,,,,1,,A,CHEMBL628680,22224,,U,Autocuration,,BAO_0000019
13469,,0,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,,,,,,1,,A,CHEMBL628681,22224,,U,Autocuration,,BAO_0000019
13470,,0,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,,,,,,1,,A,CHEMBL628682,22224,,U,Autocuration,,BAO_0000019
13471,,0,Oxidation of compound by methemoglobin in presence of hydroperoxide,,,,,,,1,,A,CHEMBL628683,22224,,U,Autocuration,,BAO_0000019
13472,,1,Percent diffusion through fuzzy rat skin after 48 h of incubation,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628684,50597,,N,Intermediate,,BAO_0000218
13473,,0,Dissociation constant (pKa),,,,,,,1,,P,CHEMBL877501,22229,,U,Autocuration,,BAO_0000100
13474,,0,Dissociation constant value of the compound; ND means not determined.,,,,,,,1,,P,CHEMBL628685,22224,,U,Autocuration,,BAO_0000100
13475,,1,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628686,50597,,N,Intermediate,,BAO_0000218
13476,,1,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL628687,50597,,N,Intermediate,,BAO_0000218
13477,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628688,50597,,N,Intermediate,,BAO_0000218
13478,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628689,50597,,N,Intermediate,,BAO_0000218
13479,,1,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628690,50597,,N,Intermediate,,BAO_0000218
13480,,1,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL629363,50597,,N,Intermediate,,BAO_0000218
13481,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL629364,50597,,N,Intermediate,,BAO_0000218
13482,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL629365,50597,,N,Intermediate,,BAO_0000218
13483,,1,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629366,50597,,N,Intermediate,,BAO_0000218
13484,,1,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629367,50597,,N,Intermediate,,BAO_0000218
13485,,1,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL629368,50597,,N,Intermediate,,BAO_0000218
13486,,1,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL877502,50597,,N,Intermediate,,BAO_0000218
13487,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Mus musculus,,,Cerebellum,2037.0,,1,10090.0,A,CHEMBL629369,50594,,N,Intermediate,,BAO_0000218
13488,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL629370,50594,,N,Intermediate,,BAO_0000218
13489,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL629371,22224,,U,Autocuration,,BAO_0000218
13490,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL626276,22224,,U,Autocuration,,BAO_0000218
13491,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL626277,22224,,U,Autocuration,,BAO_0000218
13492,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL631250,22224,,U,Autocuration,,BAO_0000218
13493,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631251,50597,,N,Intermediate,,BAO_0000218
13494,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631252,50597,,N,Intermediate,,BAO_0000218
13495,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631253,50597,,N,Intermediate,,BAO_0000218
13496,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631254,50597,,N,Intermediate,,BAO_0000218
13497,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631255,50597,,N,Intermediate,,BAO_0000218
13498,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631256,50597,,N,Intermediate,,BAO_0000218
13499,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631257,50597,,N,Intermediate,,BAO_0000218
13500,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628009,50597,,N,Intermediate,,BAO_0000218
13501,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628010,50597,,N,Intermediate,,BAO_0000218
13502,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628011,50597,,N,Intermediate,,BAO_0000218
13503,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628012,50597,,N,Intermediate,,BAO_0000218
13504,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628013,50597,,N,Intermediate,,BAO_0000218
13505,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628014,50597,,N,Intermediate,,BAO_0000218
13506,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628015,50588,,N,Intermediate,,BAO_0000218
13507,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628016,50588,,N,Intermediate,,BAO_0000218
13508,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL874461,50588,,N,Intermediate,,BAO_0000218
13509,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628017,50588,,N,Intermediate,,BAO_0000218
13510,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628018,50588,,N,Intermediate,,BAO_0000218
13511,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628019,50588,,N,Intermediate,,BAO_0000218
13512,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628020,50588,,N,Intermediate,,BAO_0000218
13513,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628021,50588,,N,Intermediate,,BAO_0000218
13514,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628022,50588,,N,Intermediate,,BAO_0000218
13515,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL628023,50588,,N,Intermediate,,BAO_0000218
13516,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL628024,22224,,U,Autocuration,,BAO_0000218
13517,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL628025,22224,,U,Autocuration,,BAO_0000218
13518,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL628026,22224,,U,Autocuration,,BAO_0000218
13519,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL628027,22224,,U,Autocuration,,BAO_0000218
13520,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Simiiformes,,,Urine,1088.0,,1,314293.0,A,CHEMBL628028,22224,,U,Autocuration,,BAO_0000218
13521,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628029,50597,,N,Intermediate,,BAO_0000218
13522,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628030,50597,,N,Intermediate,,BAO_0000218
13523,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628031,50597,,N,Intermediate,,BAO_0000218
13524,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628032,50597,,N,Intermediate,,BAO_0000218
13525,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628033,50597,,N,Intermediate,,BAO_0000218
13526,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628034,50597,,N,Intermediate,,BAO_0000218
13527,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628035,50597,,N,Intermediate,,BAO_0000218
13528,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628036,50597,,N,Intermediate,,BAO_0000218
13529,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL874462,50597,,N,Intermediate,,BAO_0000218
13530,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628037,50588,,N,Intermediate,,BAO_0000218
13531,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628123,50588,,N,Intermediate,,BAO_0000218
13532,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628124,50588,,N,Intermediate,,BAO_0000218
13533,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628125,50588,,N,Intermediate,,BAO_0000218
13534,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628126,50588,,N,Intermediate,,BAO_0000218
13535,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628127,50588,,N,Intermediate,,BAO_0000218
13536,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628128,50588,,N,Intermediate,,BAO_0000218
13537,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628129,50588,,N,Intermediate,,BAO_0000218
13538,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628130,50588,,N,Intermediate,,BAO_0000218
13539,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628131,50588,,N,Intermediate,,BAO_0000218
13540,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628132,50588,,N,Intermediate,,BAO_0000218
13541,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628133,50588,,N,Intermediate,,BAO_0000218
13542,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628134,50588,,N,Intermediate,,BAO_0000218
13543,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628135,50588,,N,Intermediate,,BAO_0000218
13544,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628136,50588,,N,Intermediate,,BAO_0000218
13545,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628137,50588,,N,Intermediate,,BAO_0000218
13546,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628138,50588,,N,Intermediate,,BAO_0000218
13547,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628139,50588,,N,Intermediate,,BAO_0000218
13548,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628140,50588,,N,Intermediate,,BAO_0000218
13549,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628141,50588,,N,Intermediate,,BAO_0000218
13550,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628142,50588,,N,Intermediate,,BAO_0000218
13551,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628143,50588,,N,Intermediate,,BAO_0000218
13552,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628144,50588,,N,Intermediate,,BAO_0000218
13553,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628145,50588,,N,Intermediate,,BAO_0000218
13554,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL628146,50588,,N,Intermediate,,BAO_0000218
13555,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625355,50588,,N,Intermediate,,BAO_0000218
13556,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625356,50588,,N,Intermediate,,BAO_0000218
13557,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625357,50588,,N,Intermediate,,BAO_0000218
13558,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625527,50588,,N,Intermediate,,BAO_0000218
13559,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL875473,50588,,N,Intermediate,,BAO_0000218
13560,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL625528,50588,,N,Intermediate,,BAO_0000218
13561,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626304,50597,,N,Intermediate,,BAO_0000218
13562,,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Canis lupus familiaris,,,Artery,1637.0,,1,9615.0,A,CHEMBL624138,50588,,N,Intermediate,,BAO_0000218
13563,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624139,22229,,U,Autocuration,,BAO_0000100
13564,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624140,22229,,U,Autocuration,,BAO_0000100
13565,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624141,22229,,U,Autocuration,,BAO_0000100
13566,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624142,22229,,U,Autocuration,,BAO_0000100
13567,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624143,22229,,U,Autocuration,,BAO_0000100
13568,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624144,22229,,U,Autocuration,,BAO_0000100
13569,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624145,22229,,U,Autocuration,,BAO_0000100
13570,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624146,22229,,U,Autocuration,,BAO_0000100
13571,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624147,22229,,U,Autocuration,,BAO_0000100
13572,,0,Calculated partition coefficient (clogP) (MacLogP),,,,,,,1,,P,CHEMBL883123,22229,,U,Autocuration,,BAO_0000100
13573,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL624148,22224,,U,Autocuration,,BAO_0000019
13574,,0,Kinetic parameter was determined,,,,,,,1,,A,CHEMBL874416,22224,,U,Autocuration,,BAO_0000019
13575,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624149,22229,,U,Autocuration,,BAO_0000100
13576,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL624150,22229,,U,Autocuration,,BAO_0000100
13577,,0,Lipophilicity was determined,,,,,,,1,,P,CHEMBL624151,22224,,U,Autocuration,,BAO_0000100
13578,,0,Lipophilicity was determined,,,,,,,1,,P,CHEMBL624152,22224,,U,Autocuration,,BAO_0000100
13579,,0,Lipophilicity was determined,,,,,,,1,,P,CHEMBL622139,22224,,U,Autocuration,,BAO_0000100
13580,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL622140,22229,,U,Autocuration,,BAO_0000100
13581,,0,Lipophilicity was determined,,,,,,,1,,P,CHEMBL622141,22224,,U,Autocuration,,BAO_0000100
13582,,0,Lipophilicity in octanol-water,,,,,,,1,,P,CHEMBL622142,22224,,U,Autocuration,,BAO_0000100
13583,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL622143,22229,,U,Autocuration,,BAO_0000100
13584,,0,Octanol-water partition coefficient was determined,,,,,,,1,,P,CHEMBL622144,22229,,U,Autocuration,,BAO_0000100
13585,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL877473,22224,,U,Autocuration,,BAO_0000019
13586,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL622145,22229,,U,Autocuration,,BAO_0000100
13587,,0,Partition coefficient was determined; ND means not determined,,,,,,,1,,A,CHEMBL622146,22224,,U,Autocuration,,BAO_0000019
13588,,0,Calculated partition coefficient (clogP),,,,,,,1,,P,CHEMBL622147,22229,,U,Autocuration,,BAO_0000100
13589,,0,Partition coefficient of the compound,,,,,,,1,,A,CHEMBL622148,22224,,U,Autocuration,,BAO_0000019
13590,,0,Permeability was determined,,,,,,,1,,A,CHEMBL883124,22224,,U,Autocuration,,BAO_0000019
13591,,0,The compound was evaluated for the partition coefficient,,,,,,,1,,P,CHEMBL622149,22229,,U,Autocuration,,BAO_0000100
13592,,0,Partition coefficient (logP),,,,,,,1,,A,CHEMBL622150,22224,,U,Autocuration,,BAO_0000019
13593,,0,The lipophilicity was reported,,,,,,,1,,P,CHEMBL622151,22224,,U,Autocuration,,BAO_0000100
13594,,0,logarithm of the octanol-water partition coefficient for the compound,,,,,,,1,,P,CHEMBL622152,22229,,U,Autocuration,,BAO_0000100
13595,,0,Clogp value was determined,,,,,,,1,,A,CHEMBL622153,22224,,U,Autocuration,,BAO_0000019
13596,,0,Clp at a dose of 1.5 mg/kg,,,,,,,1,,A,CHEMBL877474,22224,,U,Autocuration,,BAO_0000218
13597,,0,Clp at a dose of 2.0 mg/kg,,,,,,,1,,A,CHEMBL622154,22224,,U,Autocuration,,BAO_0000218
13598,,0,"Clp, plasma clearance at a dose of 10 mg/kg",,,,Plasma,1969.0,,1,,A,CHEMBL622155,22224,,U,Autocuration,,BAO_0000218
13599,,0,"Clp, plasma clearance at a dose of 50 mg/kg",,,,Plasma,1969.0,,1,,A,CHEMBL622156,22224,,U,Autocuration,,BAO_0000218
13600,,1,Compound was tested for plasma clearance in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622157,50597,,N,Intermediate,,BAO_0000218
13601,,1,Compound was tested for plasma clearance in rat; Not determined,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622158,50597,,N,Intermediate,,BAO_0000218
13602,,1,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622807,50597,,N,Intermediate,,BAO_0000218
13603,,1,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL622808,50797,,N,Intermediate,,BAO_0000218
13604,,0,Plasma clearance by iv administration at a dose 0.003 ug/mL,,,,,,,1,,A,CHEMBL622809,22224,,U,Autocuration,,BAO_0000218
13605,,0,Plasma clearance determined,,,,,,,1,,A,CHEMBL622810,22224,,U,Autocuration,,BAO_0000218
13606,,1,Plasma clearance after iv administration at 3 mg/kg in hamster,Cricetinae,,,,,,1,10026.0,A,CHEMBL876653,100712,,N,Intermediate,,BAO_0000218
13607,,1,Plasma clearance after iv administration at 4 mg/kg in hamster,Cricetinae,,,,,,1,10026.0,A,CHEMBL622811,100712,,N,Intermediate,,BAO_0000218
13608,,1,Rate of clearance in rat was determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622986,50597,,N,Intermediate,,BAO_0000218
13609,,1,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622987,50597,,N,Intermediate,,BAO_0000218
13610,,1,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622988,50597,,N,Intermediate,,BAO_0000218
13611,,1,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622989,50597,,N,Intermediate,,BAO_0000218
13612,,1,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622990,50597,,N,Intermediate,,BAO_0000218
13613,,0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Simiiformes,,,Plasma,1969.0,,1,314293.0,A,CHEMBL622991,22224,,U,Autocuration,,BAO_0000218
13614,,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL622227,50597,,N,Intermediate,,BAO_0000218
13615,,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL622228,50588,,N,Intermediate,,BAO_0000218
13616,,1,Clpl value in rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622229,50597,,N,Intermediate,,BAO_0000218
13617,,1,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,Cavia porcellus,,,,,,1,10141.0,A,CHEMBL622230,50512,,N,Intermediate,,BAO_0000218
13618,,1,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL622231,50597,,N,Intermediate,,BAO_0000218
13619,,1,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL622232,100710,,N,Intermediate,,BAO_0000218
13620,,0,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622233,22224,,U,Autocuration,,BAO_0000218
13621,,0,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622234,22224,,U,Autocuration,,BAO_0000218
13622,,0,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622235,22224,,U,Autocuration,,BAO_0000218
13623,,0,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622236,22224,,U,Autocuration,,BAO_0000218
13624,,0,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622237,22224,,U,Autocuration,,BAO_0000218
13625,,0,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,,,,,,1,,A,CHEMBL877482,22224,,U,Autocuration,,BAO_0000218
13626,,0,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622238,22224,,U,Autocuration,,BAO_0000218
13627,,0,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,,,,,,1,,A,CHEMBL622239,22224,,U,Autocuration,,BAO_0000218
13628,,0,Cmax was calculated as maximum concentration reached in the blood,,,,Blood,178.0,,1,,A,CHEMBL622240,22224,,U,Autocuration,,BAO_0000218
13629,,0,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,,,Blood,178.0,,1,,A,CHEMBL622241,22224,,U,Autocuration,,BAO_0000218
13630,,1,Cmax was determine after peroral administration at 10 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631013,50597,,N,Intermediate,,BAO_0000218
13631,,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,Macaca mulatta,,,,,,1,9544.0,A,CHEMBL631014,50797,,N,Intermediate,,BAO_0000218
13632,,1,Cmax was determine after peroral administration at 10 mpk in dog,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631015,50588,,N,Intermediate,,BAO_0000218
13633,,1,Cmax was determine after peroral administration at 160 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631016,50597,,N,Intermediate,,BAO_0000218
13634,,1,Cmax was determine after peroral administration at 20 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631017,50597,,N,Intermediate,,BAO_0000218
13635,,1,Cmax was determine after peroral administration at 50 mpk in Rat,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631018,50597,,N,Intermediate,,BAO_0000218
13636,,0,Cmax was determined,,,,,,,1,,A,CHEMBL631019,22224,,U,Autocuration,,BAO_0000218
13637,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL875761,50594,,N,Intermediate,,BAO_0000218
13638,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL631020,50594,,N,Intermediate,,BAO_0000218
13639,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL631669,50594,,N,Intermediate,,BAO_0000218
13640,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL631670,50594,,N,Intermediate,,BAO_0000218
13641,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Mus musculus,,,Striatum,2435.0,,1,10090.0,A,CHEMBL631671,50594,,N,Intermediate,,BAO_0000218
13642,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631672,50597,,N,Intermediate,,BAO_0000218
13643,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631673,50597,,N,Intermediate,,BAO_0000218
13644,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631856,50597,,N,Intermediate,,BAO_0000218
13645,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631857,50597,,N,Intermediate,,BAO_0000218
13646,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631858,50597,,N,Intermediate,,BAO_0000218
13647,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631859,50597,,N,Intermediate,,BAO_0000218
13648,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631860,50597,,N,Intermediate,,BAO_0000218
13649,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631861,50597,,N,Intermediate,,BAO_0000218
13650,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631862,50597,,N,Intermediate,,BAO_0000218
13651,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631863,50597,,N,Intermediate,,BAO_0000218
13652,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631864,50597,,N,Intermediate,,BAO_0000218
13653,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631865,50597,,N,Intermediate,,BAO_0000218
13654,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631866,50597,,N,Intermediate,,BAO_0000218
13655,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629360,50597,,N,Intermediate,,BAO_0000218
13656,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629361,50597,,N,Intermediate,,BAO_0000218
13657,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL629362,50597,,N,Intermediate,,BAO_0000218
13658,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630740,50597,,N,Intermediate,,BAO_0000218
13659,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630741,50597,,N,Intermediate,,BAO_0000218
13660,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630742,50597,,N,Intermediate,,BAO_0000218
13661,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630743,50597,,N,Intermediate,,BAO_0000218
13662,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630744,50597,,N,Intermediate,,BAO_0000218
13663,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630745,50597,,N,Intermediate,,BAO_0000218
13664,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630746,50597,,N,Intermediate,,BAO_0000218
13665,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630747,50597,,N,Intermediate,,BAO_0000218
13666,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630748,50597,,N,Intermediate,,BAO_0000218
13667,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632056,50597,,N,Intermediate,,BAO_0000218
13668,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632057,50597,,N,Intermediate,,BAO_0000218
13669,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632058,50597,,N,Intermediate,,BAO_0000218
13670,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632059,50597,,N,Intermediate,,BAO_0000218
13671,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632060,50597,,N,Intermediate,,BAO_0000218
13672,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632061,50597,,N,Intermediate,,BAO_0000218
13673,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629207,50597,,N,Intermediate,,BAO_0000218
13674,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629208,50597,,N,Intermediate,,BAO_0000218
13675,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629209,50597,,N,Intermediate,,BAO_0000218
13676,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629210,50597,,N,Intermediate,,BAO_0000218
13677,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629211,50597,,N,Intermediate,,BAO_0000218
13678,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629212,50597,,N,Intermediate,,BAO_0000218
13679,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629213,50597,,N,Intermediate,,BAO_0000218
13680,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629214,50597,,N,Intermediate,,BAO_0000218
13681,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629215,50597,,N,Intermediate,,BAO_0000218
13682,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL635154,50597,,N,Intermediate,,BAO_0000218
13683,,1,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629216,50597,,N,Intermediate,,BAO_0000218
13684,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629217,50597,,N,Intermediate,,BAO_0000218
13685,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629218,50597,,N,Intermediate,,BAO_0000218
13686,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629219,50597,,N,Intermediate,,BAO_0000218
13687,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629220,50597,,N,Intermediate,,BAO_0000218
13688,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629221,50597,,N,Intermediate,,BAO_0000218
13689,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631127,50597,,N,Intermediate,,BAO_0000218
13690,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631128,50597,,N,Intermediate,,BAO_0000218
13691,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631129,50597,,N,Intermediate,,BAO_0000218
13692,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631130,50597,,N,Intermediate,,BAO_0000218
13693,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631131,50597,,N,Intermediate,,BAO_0000218
13694,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631132,50597,,N,Intermediate,,BAO_0000218
13695,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631133,50597,,N,Intermediate,,BAO_0000218
13696,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631134,50597,,N,Intermediate,,BAO_0000218
13697,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875120,50597,,N,Intermediate,,BAO_0000218
13698,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631135,50597,,N,Intermediate,,BAO_0000218
13699,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631136,50597,,N,Intermediate,,BAO_0000218
13700,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631137,50597,,N,Intermediate,,BAO_0000218
13701,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631138,50597,,N,Intermediate,,BAO_0000218
13702,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631139,50597,,N,Intermediate,,BAO_0000218
13703,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631140,50597,,N,Intermediate,,BAO_0000218
13704,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631141,50597,,N,Intermediate,,BAO_0000218
13705,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631142,50597,,N,Intermediate,,BAO_0000218
13706,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631143,50597,,N,Intermediate,,BAO_0000218
13707,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631144,50597,,N,Intermediate,,BAO_0000218
13708,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631145,50588,,N,Intermediate,,BAO_0000218
13709,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631146,50588,,N,Intermediate,,BAO_0000218
13710,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631147,50588,,N,Intermediate,,BAO_0000218
13711,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631148,50588,,N,Intermediate,,BAO_0000218
13712,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631149,50588,,N,Intermediate,,BAO_0000218
13713,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631150,50588,,N,Intermediate,,BAO_0000218
13714,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631151,50588,,N,Intermediate,,BAO_0000218
13715,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631152,50588,,N,Intermediate,,BAO_0000218
13716,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631443,50588,,N,Intermediate,,BAO_0000218
13717,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631444,50588,,N,Intermediate,,BAO_0000218
13718,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631445,50588,,N,Intermediate,,BAO_0000218
13719,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631446,50588,,N,Intermediate,,BAO_0000218
13720,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631447,50588,,N,Intermediate,,BAO_0000218
13721,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631448,50588,,N,Intermediate,,BAO_0000218
13722,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631449,50588,,N,Intermediate,,BAO_0000218
13723,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL631450,50588,,N,Intermediate,,BAO_0000218
13724,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629724,50588,,N,Intermediate,,BAO_0000218
13725,,1,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL629725,50594,,N,Intermediate,,BAO_0000218
13726,,1,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Zone of skin,14.0,,1,10090.0,A,CHEMBL629726,50594,,N,Intermediate,,BAO_0000218
13727,,1,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL629727,50594,,N,Intermediate,,BAO_0000218
13728,,1,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL630404,50594,,N,Intermediate,,BAO_0000218
13729,,1,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL630405,50594,,N,Intermediate,,BAO_0000218
13730,,1,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL630406,50594,,N,Intermediate,,BAO_0000218
13731,,1,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Stomach,945.0,,1,10090.0,A,CHEMBL630407,50594,,N,Intermediate,,BAO_0000218
13732,,1,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Stomach,945.0,,1,10090.0,A,CHEMBL630573,50594,,N,Intermediate,,BAO_0000218
13733,,1,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Stomach,945.0,,1,10090.0,A,CHEMBL630574,50594,,N,Intermediate,,BAO_0000218
13734,,1,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,Stomach,945.0,,1,10090.0,A,CHEMBL630575,50594,,N,Intermediate,,BAO_0000218
13735,,1,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,,,,1,10090.0,A,CHEMBL630576,50594,,N,Intermediate,,BAO_0000218
13736,,1,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,,,,1,10090.0,A,CHEMBL630577,50594,,N,Intermediate,,BAO_0000218
13737,,1,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,,,,1,10090.0,A,CHEMBL630578,50594,,N,Intermediate,,BAO_0000218
13738,,1,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Mus musculus,,,,,,1,10090.0,A,CHEMBL630579,50594,,N,Intermediate,,BAO_0000218
13739,,1,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630580,50594,,N,Intermediate,,BAO_0000218
13740,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630581,50594,,N,Intermediate,,BAO_0000218
13741,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630582,50594,,N,Intermediate,,BAO_0000218
13742,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,Mus musculus,,,,,,1,10090.0,A,CHEMBL630583,50594,,N,Intermediate,,BAO_0000218
13743,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),Mus musculus,,,,,,1,10090.0,A,CHEMBL630584,50594,,N,Intermediate,,BAO_0000218
13744,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,Mus musculus,,,,,,1,10090.0,A,CHEMBL630585,50594,,N,Intermediate,,BAO_0000218
13745,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),Mus musculus,,,,,,1,10090.0,A,CHEMBL630586,50594,,N,Intermediate,,BAO_0000218
13746,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,Mus musculus,,,,,,1,10090.0,A,CHEMBL630587,50594,,N,Intermediate,,BAO_0000218
13747,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),Mus musculus,,,,,,1,10090.0,A,CHEMBL630588,50594,,N,Intermediate,,BAO_0000218
13748,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,Mus musculus,,,,,,1,10090.0,A,CHEMBL630589,50594,,N,Intermediate,,BAO_0000218
13749,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),Mus musculus,,,,,,1,10090.0,A,CHEMBL630590,50594,,N,Intermediate,,BAO_0000218
13750,,0,Removal of 238-Plutonium(IV) in feces at 24 h,,,,Feces,1988.0,,1,,A,CHEMBL630591,22224,,U,Autocuration,,BAO_0000019
13751,,0,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,,,Feces,1988.0,,1,,A,CHEMBL630592,22224,,U,Autocuration,,BAO_0000019
13752,,0,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,,,,,,1,,A,CHEMBL630593,22224,,U,Autocuration,,BAO_0000019
13753,,0,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,,,,,,1,,A,CHEMBL630594,22224,,U,Autocuration,,BAO_0000019
13754,,0,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630595,22224,,U,Autocuration,,BAO_0000019
13755,,0,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630596,22224,,U,Autocuration,,BAO_0000019
13756,,0,Removal of 238-Plutonium(IV) in urine after 0-24 h,,,,Urine,1088.0,,1,,A,CHEMBL630597,22224,,U,Autocuration,,BAO_0000019
13757,,0,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630598,22224,,U,Autocuration,,BAO_0000019
13758,,0,Removal of 238-Plutonium(IV) in urine after 0-4 h,,,,Urine,1088.0,,1,,A,CHEMBL630599,22224,,U,Autocuration,,BAO_0000019
13759,,0,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630600,22224,,U,Autocuration,,BAO_0000019
13760,,0,Removal of 238-Plutonium(IV) in urine after 4-24 h,,,,Urine,1088.0,,1,,A,CHEMBL630601,22224,,U,Autocuration,,BAO_0000019
13761,,0,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630602,22224,,U,Autocuration,,BAO_0000019
13762,,0,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630603,22224,,U,Autocuration,,BAO_0000019
13763,,0,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,,,Urine,1088.0,,1,,A,CHEMBL630604,22224,,U,Autocuration,,BAO_0000019
13764,,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624869,50597,,N,Intermediate,,BAO_0000218
13765,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL624870,50597,,N,Intermediate,,BAO_0000218
13766,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623189,50597,,N,Intermediate,,BAO_0000218
13767,,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623190,50597,,N,Intermediate,,BAO_0000218
13768,,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623191,50597,,N,Intermediate,,BAO_0000218
13769,,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623192,50597,,N,Intermediate,,BAO_0000218
13770,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623193,50597,,N,Intermediate,,BAO_0000218
13771,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623194,50597,,N,Intermediate,,BAO_0000218
13772,,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623195,50597,,N,Intermediate,,BAO_0000218
13773,,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623196,50597,,N,Intermediate,,BAO_0000218
13774,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623197,50597,,N,Intermediate,,BAO_0000218
13775,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623198,50597,,N,Intermediate,,BAO_0000218
13776,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623199,50597,,N,Intermediate,,BAO_0000218
13777,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623200,50597,,N,Intermediate,,BAO_0000218
13778,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623201,50597,,N,Intermediate,,BAO_0000218
13779,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623202,50597,,N,Intermediate,,BAO_0000218
13780,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623203,50597,,N,Intermediate,,BAO_0000218
13781,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623204,50597,,N,Intermediate,,BAO_0000218
13782,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623205,50597,,N,Intermediate,,BAO_0000218
13783,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623206,50597,,N,Intermediate,,BAO_0000218
13784,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623207,50597,,N,Intermediate,,BAO_0000218
13785,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623208,50597,,N,Intermediate,,BAO_0000218
13786,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623209,50597,,N,Intermediate,,BAO_0000218
13787,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL623210,50597,,N,Intermediate,,BAO_0000218
13788,,1,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623211,50597,,N,Intermediate,,BAO_0000218
13789,,1,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL623212,50597,,N,Intermediate,,BAO_0000218
13790,,0,Tested in vitro for intrinsic activity relative to quinpirole,,,,,,,1,,A,CHEMBL623213,22224,,U,Autocuration,,BAO_0000019
13791,,0,"Relative ion enhancement, determined in pulsed ultrafiltration",,,,,,,1,,A,CHEMBL623214,22224,,U,Autocuration,,BAO_0000019
13792,,0,% ionization at the pH 7.4 at 37 degree Centigrade,,,,,,,1,,A,CHEMBL623215,22224,,U,Autocuration,,BAO_0000019
13793,,0,Percentage ionization was measured,,,,,,,1,,A,CHEMBL623216,22224,,U,Autocuration,,BAO_0000019
13794,,1,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,Bos taurus,,,,,,1,9913.0,A,CHEMBL623217,50591,,N,Intermediate,,BAO_0000218
13795,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,,,,,,1,,A,CHEMBL623218,22224,,U,Autocuration,,BAO_0000019
13796,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,,,,,,1,,A,CHEMBL623913,22224,,U,Autocuration,,BAO_0000019
13797,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,,,,,,1,,A,CHEMBL623914,22224,,U,Autocuration,,BAO_0000019
13798,,0,Compound was evaluated for the partition coefficient in octanol/water,,,,,,,1,,P,CHEMBL623915,22229,,U,Autocuration,,BAO_0000100
13799,,0,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,,,,,,1,,P,CHEMBL624080,22229,,U,Autocuration,,BAO_0000100
13800,,0,Equilibrium constant measured by the pulse radiolysis at pH 7,,,,,,,1,,A,CHEMBL624081,22224,,U,Autocuration,,BAO_0000019
13801,,1,In vitro hydrolytic rate constant determined in human blood,Homo sapiens,,,,,,1,9606.0,A,CHEMBL624082,50587,,N,Intermediate,,BAO_0000218
13802,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,Homo sapiens,,,,,,1,9606.0,A,CHEMBL625054,50587,,N,Intermediate,,BAO_0000218
13803,,0,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,,,,,,1,,A,CHEMBL877485,22224,,U,Autocuration,,BAO_0000019
13804,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,Mus musculus,,,,,,1,10090.0,A,CHEMBL625055,50594,,N,Intermediate,,BAO_0000218
13805,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,Mus musculus,,,,,,1,10090.0,A,CHEMBL625056,50594,,N,Intermediate,,BAO_0000218
13806,,1,In vitro oxidation of compound in presence of human plasma,Homo sapiens,,,,,,1,9606.0,A,CHEMBL625057,50587,,N,Intermediate,,BAO_0000218
13807,,0,In vitro oxidation of compound in presence of hydrogen peroxide,,,,,,,1,,A,CHEMBL625058,22224,,U,Autocuration,,BAO_0000019
13808,,1,In vitro oxidation of compound in presence of mouse brain homogenate,Mus musculus,,,,,,1,10090.0,A,CHEMBL625059,50594,,N,Intermediate,,BAO_0000218
13809,,1,In vitro oxidation of compound in presence of mouse liver homogenate,Mus musculus,,,,,,1,10090.0,A,CHEMBL629536,50594,,N,Intermediate,,BAO_0000218
13810,,1,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629537,50597,,N,Intermediate,,BAO_0000218
13811,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629538,50597,,N,Intermediate,,BAO_0000218
13812,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629539,50597,,N,Intermediate,,BAO_0000218
13813,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL874445,50597,,N,Intermediate,,BAO_0000218
13814,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629540,50597,,N,Intermediate,,BAO_0000218
13815,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629541,50597,,N,Intermediate,,BAO_0000218
13816,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629542,50597,,N,Intermediate,,BAO_0000218
13817,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630243,50597,,N,Intermediate,,BAO_0000218
13818,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630244,50597,,N,Intermediate,,BAO_0000218
13819,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630245,50597,,N,Intermediate,,BAO_0000218
13820,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630246,50597,,N,Intermediate,,BAO_0000218
13821,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630247,50597,,N,Intermediate,,BAO_0000218
13822,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630248,50597,,N,Intermediate,,BAO_0000218
13823,,1,Biodistribution in rat blood at 240 minutes after dose administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630249,50597,,N,Intermediate,,BAO_0000218
13824,,1,Biodistribution in rat blood at 30 minutes after dose administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630250,50597,,N,Intermediate,,BAO_0000218
13825,,1,Biodistribution in rat blood at 360 minutes after dose administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630251,50597,,N,Intermediate,,BAO_0000218
13826,,1,Biodistribution in rat blood at 3 hr after dose administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630252,50597,,N,Intermediate,,BAO_0000218
13827,,1,Biodistribution in rat blood at 60 minutes after dose administration.,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL630408,50597,,N,Intermediate,,BAO_0000218
13828,,1,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630409,50597,,N,Intermediate,,BAO_0000218
13829,,1,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL874446,50597,,N,Intermediate,,BAO_0000218
13830,,1,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630410,50597,,N,Intermediate,,BAO_0000218
13831,,1,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630411,50597,,N,Intermediate,,BAO_0000218
13832,,1,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630412,50597,,N,Intermediate,,BAO_0000218
13833,,1,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630413,50597,,N,Intermediate,,BAO_0000218
13834,,1,Biodistribution in rat cerebellum at 3 hr after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630414,50597,,N,Intermediate,,BAO_0000218
13835,,1,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL630415,50597,,N,Intermediate,,BAO_0000218
13836,,1,Biodistribution in rat cortex at 120 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630416,50597,,N,Intermediate,,BAO_0000218
13837,,1,Biodistribution in rat cortex at 1440 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630417,50597,,N,Intermediate,,BAO_0000218
13838,,1,Biodistribution in rat cortex at 15 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630418,50597,,N,Intermediate,,BAO_0000218
13839,,1,Biodistribution in rat cortex at 240 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630419,50597,,N,Intermediate,,BAO_0000218
13840,,1,Biodistribution in rat cortex at 30 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630420,50597,,N,Intermediate,,BAO_0000218
13841,,1,Biodistribution in rat cortex at 360 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630421,50597,,N,Intermediate,,BAO_0000218
13842,,1,Biodistribution in rat cortex at 3 hr after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630422,50597,,N,Intermediate,,BAO_0000218
13843,,1,Biodistribution in rat cortex at 60 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630423,50597,,N,Intermediate,,BAO_0000218
13844,,1,Biodistribution in rat heart at 120 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630424,50597,,N,Intermediate,,BAO_0000218
13845,,1,Biodistribution in rat heart at 15 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630425,50597,,N,Intermediate,,BAO_0000218
13846,,1,Biodistribution in rat heart at 240 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL629462,50597,,N,Intermediate,,BAO_0000218
13847,,1,Biodistribution in rat heart at 30 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630426,50597,,N,Intermediate,,BAO_0000218
13848,,1,Biodistribution in rat heart at 360 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL630427,50597,,N,Intermediate,,BAO_0000218
13849,,1,Biodistribution in rat heart at 3 hr after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625877,50597,,N,Intermediate,,BAO_0000218
13850,,1,Biodistribution in rat heart at 60 minutes after dose administration.,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625878,50597,,N,Intermediate,,BAO_0000218
13851,,1,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625879,50597,,N,Intermediate,,BAO_0000218
13852,,1,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625880,50597,,N,Intermediate,,BAO_0000218
13853,,1,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625881,50597,,N,Intermediate,,BAO_0000218
13854,,1,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625882,50597,,N,Intermediate,,BAO_0000218
13855,,1,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625883,50597,,N,Intermediate,,BAO_0000218
13856,,1,Biodistribution in rat kidney at 120 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625884,50597,,N,Intermediate,,BAO_0000218
13857,,1,Biodistribution in rat kidney at 1440 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625885,50597,,N,Intermediate,,BAO_0000218
13858,,1,Biodistribution in rat kidney at 15 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628649,50597,,N,Intermediate,,BAO_0000218
13859,,1,Biodistribution in rat kidney at 240 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628650,50597,,N,Intermediate,,BAO_0000218
13860,,1,Biodistribution in rat kidney at 30 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628651,50597,,N,Intermediate,,BAO_0000218
13861,,1,Biodistribution in rat kidney at 360 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628652,50597,,N,Intermediate,,BAO_0000218
13862,,1,Biodistribution in rat kidney at 60 minutes after dose administration.,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL628653,50597,,N,Intermediate,,BAO_0000218
13863,,1,Biodistribution in rat liver at 120 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628654,50597,,N,Intermediate,,BAO_0000218
13864,,1,Biodistribution in rat liver at 1440 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL628655,50597,,N,Intermediate,,BAO_0000218
13865,,1,Biodistribution in rat liver at 15 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625238,50597,,N,Intermediate,,BAO_0000218
13866,,1,Biodistribution in rat liver at 240 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625239,50597,,N,Intermediate,,BAO_0000218
13867,,1,Biodistribution in rat liver at 30 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625240,50597,,N,Intermediate,,BAO_0000218
13868,,1,Biodistribution in rat liver at 360 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625241,50597,,N,Intermediate,,BAO_0000218
13869,,1,Biodistribution in rat liver at 60 minutes after dose administration.,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625242,50597,,N,Intermediate,,BAO_0000218
13870,,1,Biodistribution in rat lung at 120 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL874587,50597,,N,Intermediate,,BAO_0000218
13871,,1,Biodistribution in rat lung at 1440 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625405,50597,,N,Intermediate,,BAO_0000218
13872,,1,Biodistribution in rat lung at 15 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625406,50597,,N,Intermediate,,BAO_0000218
13873,,1,Biodistribution in rat lung at 240 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625407,50597,,N,Intermediate,,BAO_0000218
13874,,1,Biodistribution in rat lung at 30 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625408,50597,,N,Intermediate,,BAO_0000218
13875,,1,Biodistribution in rat lung at 360 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625409,50597,,N,Intermediate,,BAO_0000218
13876,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625410,50597,,N,Intermediate,,BAO_0000218
13877,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625411,50597,,N,Intermediate,,BAO_0000218
13878,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625412,50597,,N,Intermediate,,BAO_0000218
13879,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625413,50597,,N,Intermediate,,BAO_0000218
13880,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625414,50597,,N,Intermediate,,BAO_0000218
13881,,1,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625415,50597,,N,Intermediate,,BAO_0000218
13882,,1,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Rattus norvegicus,,,Thoracic aorta,1515.0,,1,10116.0,A,CHEMBL625416,50597,,N,Intermediate,,BAO_0000218
13883,,1,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625417,50597,,N,Intermediate,,BAO_0000218
13884,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL625418,50597,,N,Intermediate,,BAO_0000218
13885,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625419,50597,,N,Intermediate,,BAO_0000218
13886,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625420,50597,,N,Intermediate,,BAO_0000218
13887,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626996,50597,,N,Intermediate,,BAO_0000218
13888,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL626997,50597,,N,Intermediate,,BAO_0000218
13889,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626998,50597,,N,Intermediate,,BAO_0000218
13890,,1,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626999,50597,,N,Intermediate,,BAO_0000218
13891,,1,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,Mus musculus,,,,,,1,10090.0,A,CHEMBL627000,50594,,N,Intermediate,,BAO_0000218
13892,,1,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,Mus musculus,,,,,,1,10090.0,A,CHEMBL627001,50594,,N,Intermediate,,BAO_0000218
13893,,1,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,Mus musculus,,,,,,1,10090.0,A,CHEMBL627002,50594,,N,Intermediate,,BAO_0000218
13894,,1,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,Mus musculus,,,,,,1,10090.0,A,CHEMBL627003,50594,,N,Intermediate,,BAO_0000218
13895,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627004,50594,,N,Intermediate,,BAO_0000218
13896,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627005,50594,,N,Intermediate,,BAO_0000218
13897,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL874594,50594,,N,Intermediate,,BAO_0000218
13898,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627006,50594,,N,Intermediate,,BAO_0000218
13899,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627007,50594,,N,Intermediate,,BAO_0000218
13900,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627884,50594,,N,Intermediate,,BAO_0000218
13901,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627885,50594,,N,Intermediate,,BAO_0000218
13902,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627886,50594,,N,Intermediate,,BAO_0000218
13903,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627887,50594,,N,Intermediate,,BAO_0000218
13904,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627888,50594,,N,Intermediate,,BAO_0000218
13905,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL628057,50594,,N,Intermediate,,BAO_0000218
13906,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627405,50594,,N,Intermediate,,BAO_0000218
13907,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627406,50588,,N,Intermediate,,BAO_0000218
13908,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627407,50588,,N,Intermediate,,BAO_0000218
13909,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627408,50588,,N,Intermediate,,BAO_0000218
13910,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627409,50588,,N,Intermediate,,BAO_0000218
13911,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL875486,50588,,N,Intermediate,,BAO_0000218
13912,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627410,50588,,N,Intermediate,,BAO_0000218
13913,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627411,50588,,N,Intermediate,,BAO_0000218
13914,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627412,50588,,N,Intermediate,,BAO_0000218
13915,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627413,50588,,N,Intermediate,,BAO_0000218
13916,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627414,50588,,N,Intermediate,,BAO_0000218
13917,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627415,50588,,N,Intermediate,,BAO_0000218
13918,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627416,50588,,N,Intermediate,,BAO_0000218
13919,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627417,50588,,N,Intermediate,,BAO_0000218
13920,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627418,50588,,N,Intermediate,,BAO_0000218
13921,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627419,50588,,N,Intermediate,,BAO_0000218
13922,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627320,50588,,N,Intermediate,,BAO_0000218
13923,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627321,50588,,N,Intermediate,,BAO_0000218
13924,,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627322,50597,,N,Intermediate,,BAO_0000218
13925,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627323,50597,,N,Intermediate,,BAO_0000218
13926,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627491,50597,,N,Intermediate,,BAO_0000218
13927,,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627492,50597,,N,Intermediate,,BAO_0000218
13928,,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL627493,50597,,N,Intermediate,,BAO_0000218
13929,,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627494,50597,,N,Intermediate,,BAO_0000218
13930,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627495,50597,,N,Intermediate,,BAO_0000218
13931,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627496,50597,,N,Intermediate,,BAO_0000218
13932,,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627497,50597,,N,Intermediate,,BAO_0000218
13933,,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL627498,50597,,N,Intermediate,,BAO_0000218
13934,,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627499,50597,,N,Intermediate,,BAO_0000218
13935,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627500,50597,,N,Intermediate,,BAO_0000218
13936,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627501,50597,,N,Intermediate,,BAO_0000218
13937,,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625616,50597,,N,Intermediate,,BAO_0000218
13938,,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625617,50597,,N,Intermediate,,BAO_0000218
13939,,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625618,50597,,N,Intermediate,,BAO_0000218
13940,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625619,50597,,N,Intermediate,,BAO_0000218
13941,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625620,50597,,N,Intermediate,,BAO_0000218
13942,,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625621,50597,,N,Intermediate,,BAO_0000218
13943,,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625622,50597,,N,Intermediate,,BAO_0000218
13944,,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625788,50597,,N,Intermediate,,BAO_0000218
13945,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625789,50597,,N,Intermediate,,BAO_0000218
13946,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625790,50597,,N,Intermediate,,BAO_0000218
13947,,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625791,50597,,N,Intermediate,,BAO_0000218
13948,,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL622334,50597,,N,Intermediate,,BAO_0000218
13949,,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622335,50597,,N,Intermediate,,BAO_0000218
13950,,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622336,50597,,N,Intermediate,,BAO_0000218
13951,,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622337,50597,,N,Intermediate,,BAO_0000218
13952,,1,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622338,50597,,N,Intermediate,,BAO_0000218
13953,,1,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL622339,50597,,N,Intermediate,,BAO_0000218
13954,,1,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL624153,50597,,N,Intermediate,,BAO_0000218
13955,,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628430,50597,,N,Intermediate,,BAO_0000218
13956,,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628431,50597,,N,Intermediate,,BAO_0000218
13957,,1,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628432,50597,,N,Intermediate,,BAO_0000218
13958,,1,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628433,50597,,N,Intermediate,,BAO_0000218
13959,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL628434,50597,,N,Intermediate,,BAO_0000218
13960,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL626789,50597,,N,Intermediate,,BAO_0000218
13961,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL626790,50597,,N,Intermediate,,BAO_0000218
13962,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL626791,50597,,N,Intermediate,,BAO_0000218
13963,,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL626792,50597,,N,Intermediate,,BAO_0000218
13964,,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL626793,50597,,N,Intermediate,,BAO_0000218
13965,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627436,50597,,N,Intermediate,,BAO_0000218
13966,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627437,50597,,N,Intermediate,,BAO_0000218
13967,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627438,50597,,N,Intermediate,,BAO_0000218
13968,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627439,50597,,N,Intermediate,,BAO_0000218
13969,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627440,50597,,N,Intermediate,,BAO_0000218
13970,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627602,50597,,N,Intermediate,,BAO_0000218
13971,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627603,50597,,N,Intermediate,,BAO_0000218
13972,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627604,50597,,N,Intermediate,,BAO_0000218
13973,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627605,50597,,N,Intermediate,,BAO_0000218
13974,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627606,50597,,N,Intermediate,,BAO_0000218
13975,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627607,50597,,N,Intermediate,,BAO_0000218
13976,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627608,50597,,N,Intermediate,,BAO_0000218
13977,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627609,50597,,N,Intermediate,,BAO_0000218
13978,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627610,50597,,N,Intermediate,,BAO_0000218
13979,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627611,50597,,N,Intermediate,,BAO_0000218
13980,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627612,50597,,N,Intermediate,,BAO_0000218
13981,,0,Octanol:water partition coefficient is evaluated,,,,,,,1,,P,CHEMBL627613,22229,,U,Autocuration,,BAO_0000100
13982,,0,Partition coefficient in 1-octanol/water system,,,,,,,1,,P,CHEMBL627614,22224,,U,Autocuration,,BAO_0000100
13983,,0,Partition coefficient in 1-octanol/water system measured using radio active compounds,,,,,,,1,,P,CHEMBL627615,22224,,U,Autocuration,,BAO_0000100
13984,,0,Partition coefficient in octanol/water system was determined,,,,,,,1,,P,CHEMBL627616,22224,,U,Autocuration,,BAO_0000100
13985,,0,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,,,,,,1,,P,CHEMBL627617,22224,,U,Autocuration,,BAO_0000100
13986,,0,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,,,,,,1,,A,CHEMBL627618,22224,,U,Autocuration,,BAO_0000019
13987,,0,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,,,,,,1,,A,CHEMBL627619,22224,,U,Autocuration,,BAO_0000019
13988,,0,Pseudo-first-order rate constant of the compound,,,,,,,1,,A,CHEMBL627620,22224,,U,Autocuration,,BAO_0000019
13989,,0,Pseudo-first-order rate constant with 1-min time point,,,,,,,1,,A,CHEMBL627621,22224,,U,Autocuration,,BAO_0000019
13990,,0,Pseudo-first-order rate constant without 1-min time point,,,,,,,1,,A,CHEMBL627622,22224,,U,Autocuration,,BAO_0000019
13991,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,,,,,,1,,A,CHEMBL627623,22224,,U,Autocuration,,BAO_0000019
13992,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,,,,,,1,,A,CHEMBL627624,22224,,U,Autocuration,,BAO_0000019
13993,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,,,,,,1,,A,CHEMBL627625,22224,,U,Autocuration,,BAO_0000019
13994,,0,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,,,,,,1,,A,CHEMBL628523,22224,,U,Autocuration,,BAO_0000019
13995,,0,The alkaline hydrolysis second order rate constant(K OH) of the compound,,,,,,,1,,A,CHEMBL628524,22224,,U,Autocuration,,BAO_0000019
13996,,0,The efflux rate constant of the compound,,,,,,,1,,A,CHEMBL628525,22224,,U,Autocuration,,BAO_0000019
13997,,0,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,1,,A,CHEMBL625732,22224,,U,Autocuration,,BAO_0000019
13998,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,1,,A,CHEMBL625733,22224,,U,Autocuration,,BAO_0000019
13999,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,,,,,,1,,F,CHEMBL625734,22224,,U,Autocuration,,BAO_0000019
14000,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,,,,,,1,,A,CHEMBL625913,22224,,U,Autocuration,,BAO_0000019
14001,,0,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,,,,,,1,,A,CHEMBL625914,22224,,U,Autocuration,,BAO_0000019
14002,,0,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,,,,,,1,,A,CHEMBL625915,22224,,U,Autocuration,,BAO_0000019
14003,,0,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,,,,,,1,,A,CHEMBL625916,22224,,U,Autocuration,,BAO_0000019
14004,,0,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,,,,,,1,,A,CHEMBL625917,22224,,U,Autocuration,,BAO_0000019
14005,,0,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625918,22224,,U,Autocuration,,BAO_0000019
14006,,0,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625919,22224,,U,Autocuration,,BAO_0000019
14007,,0,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625920,22224,,U,Autocuration,,BAO_0000019
14008,,0,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL874453,22224,,U,Autocuration,,BAO_0000019
14009,,0,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625921,22224,,U,Autocuration,,BAO_0000019
14010,,0,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,,,,,,1,,A,CHEMBL625922,22224,,U,Autocuration,,BAO_0000019
14011,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625923,22224,,U,Autocuration,,BAO_0000019
14012,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625924,22224,,U,Autocuration,,BAO_0000019
14013,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625925,22224,,U,Autocuration,,BAO_0000019
14014,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL625926,22224,,U,Autocuration,,BAO_0000019
14015,,1,Biodistribution in rat lung at 60 minutes after dose administration.,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL627704,50597,,N,Intermediate,,BAO_0000218
14016,,1,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627705,50597,,N,Intermediate,,BAO_0000218
14017,,1,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627706,50597,,N,Intermediate,,BAO_0000218
14018,,1,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627707,50597,,N,Intermediate,,BAO_0000218
14019,,1,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627708,50597,,N,Intermediate,,BAO_0000218
14020,,1,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628361,50597,,N,Intermediate,,BAO_0000218
14021,,1,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628362,50597,,N,Intermediate,,BAO_0000218
14022,,1,Biodistribution in rat striatum at 120 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628363,50597,,N,Intermediate,,BAO_0000218
14023,,1,Biodistribution in rat striatum at 1440 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628364,50597,,N,Intermediate,,BAO_0000218
14024,,1,Biodistribution in rat striatum at 15 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628365,50597,,N,Intermediate,,BAO_0000218
14025,,1,Biodistribution in rat striatum at 240 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL874454,50597,,N,Intermediate,,BAO_0000218
14026,,1,Biodistribution in rat striatum at 30 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628531,50597,,N,Intermediate,,BAO_0000218
14027,,1,Biodistribution in rat striatum at 360 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628532,50597,,N,Intermediate,,BAO_0000218
14028,,1,Biodistribution in rat striatum at 3 hr after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628533,50597,,N,Intermediate,,BAO_0000218
14029,,1,Biodistribution in rat striatum at 60 minutes after dose administration.,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,A,CHEMBL628534,50597,,N,Intermediate,,BAO_0000218
14030,,1,Biodistribution in rat thyroid at 120 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628535,50597,,N,Intermediate,,BAO_0000218
14031,,1,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628536,50597,,N,Intermediate,,BAO_0000218
14032,,1,Biodistribution in rat thyroid at 15 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628537,50597,,N,Intermediate,,BAO_0000218
14033,,1,Biodistribution in rat thyroid at 240 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628538,50597,,N,Intermediate,,BAO_0000218
14034,,1,Biodistribution in rat thyroid at 30 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL628539,50597,,N,Intermediate,,BAO_0000218
14035,,1,Biodistribution in rat thyroid at 360 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630297,50597,,N,Intermediate,,BAO_0000218
14036,,1,Biodistribution in rat thyroid at 60 minutes after dose administration.,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL630298,50597,,N,Intermediate,,BAO_0000218
14037,,1,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL630299,50597,,N,Intermediate,,BAO_0000218
14038,,1,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL628094,50597,,N,Intermediate,,BAO_0000218
14039,,1,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL628095,50597,,N,Intermediate,,BAO_0000218
14040,,1,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL874648,50597,,N,Intermediate,,BAO_0000218
14041,,1,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL628096,50597,,N,Intermediate,,BAO_0000218
14042,,1,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL628097,50597,,N,Intermediate,,BAO_0000218
14043,,1,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL628098,50597,,N,Intermediate,,BAO_0000218
14044,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,,,,,,1,,A,CHEMBL628099,22224,,U,Autocuration,,BAO_0000019
14045,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,1,,A,CHEMBL628100,22224,,U,Autocuration,,BAO_0000019
14046,,0,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,,,,,,1,,A,CHEMBL628101,22224,,U,Autocuration,,BAO_0000019
14047,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,,,,,,1,,A,CHEMBL628102,22224,,U,Autocuration,,BAO_0000019
14048,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,,,,,,1,,A,CHEMBL628103,22224,,U,Autocuration,,BAO_0000019
14049,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,,,,,,1,,A,CHEMBL628104,22224,,U,Autocuration,,BAO_0000019
14050,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,,,,,,1,,A,CHEMBL628105,22224,,U,Autocuration,,BAO_0000019
14051,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,,,,,,1,,A,CHEMBL628106,22224,,U,Autocuration,,BAO_0000019
14052,,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628107,50597,,N,Intermediate,,BAO_0000218
14053,,0,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,,,Urine,1088.0,,1,,F,CHEMBL628108,22224,,U,Autocuration,,BAO_0000218
14054,,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628109,50597,,N,Intermediate,,BAO_0000218
14055,,0,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,,,Urine,1088.0,,1,,F,CHEMBL625299,22224,,U,Autocuration,,BAO_0000218
14056,,1,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625300,50597,,N,Intermediate,,BAO_0000218
14057,,1,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625301,50597,,N,Intermediate,,BAO_0000218
14058,,1,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625302,50597,,N,Intermediate,,BAO_0000218
14059,,1,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL874649,50597,,N,Intermediate,,BAO_0000218
14060,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625303,50597,,N,Intermediate,,BAO_0000218
14061,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625463,50597,,N,Intermediate,,BAO_0000218
14062,,1,In vitro metabolism in human liver microsomes,Homo sapiens,,,Liver,2107.0,,1,9606.0,A,CHEMBL625464,50587,,N,Intermediate,,BAO_0000218
14063,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,Homo sapiens,,,,,,1,9606.0,A,CHEMBL625465,50587,,N,Intermediate,,BAO_0000218
14064,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625466,50588,,N,Intermediate,,BAO_0000218
14065,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625467,50588,,N,Intermediate,,BAO_0000218
14066,,1,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625468,50597,,N,Intermediate,,BAO_0000218
14067,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625469,50597,,N,Intermediate,,BAO_0000218
14068,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625470,50597,,N,Intermediate,,BAO_0000218
14069,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL632418,50597,,N,Intermediate,,BAO_0000218
14070,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627250,50597,,N,Intermediate,,BAO_0000218
14071,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627251,50597,,N,Intermediate,,BAO_0000218
14072,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627252,50597,,N,Intermediate,,BAO_0000218
14073,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627253,50597,,N,Intermediate,,BAO_0000218
14074,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627254,50597,,N,Intermediate,,BAO_0000218
14075,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875471,50597,,N,Intermediate,,BAO_0000218
14076,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627255,50597,,N,Intermediate,,BAO_0000218
14077,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627256,50597,,N,Intermediate,,BAO_0000218
14078,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627257,50597,,N,Intermediate,,BAO_0000218
14079,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627258,50597,,N,Intermediate,,BAO_0000218
14080,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627259,50597,,N,Intermediate,,BAO_0000218
14081,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627260,50597,,N,Intermediate,,BAO_0000218
14082,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623256,50597,,N,Intermediate,,BAO_0000218
14083,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL874413,50597,,N,Intermediate,,BAO_0000218
14084,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623257,50597,,N,Intermediate,,BAO_0000218
14085,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623258,50597,,N,Intermediate,,BAO_0000218
14086,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623259,50597,,N,Intermediate,,BAO_0000218
14087,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623260,50597,,N,Intermediate,,BAO_0000218
14088,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623261,50597,,N,Intermediate,,BAO_0000218
14089,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623262,50597,,N,Intermediate,,BAO_0000218
14090,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623263,50597,,N,Intermediate,,BAO_0000218
14091,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623264,50597,,N,Intermediate,,BAO_0000218
14092,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623265,50597,,N,Intermediate,,BAO_0000218
14093,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623266,50597,,N,Intermediate,,BAO_0000218
14094,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623267,50597,,N,Intermediate,,BAO_0000218
14095,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623268,50597,,N,Intermediate,,BAO_0000218
14096,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623269,50597,,N,Intermediate,,BAO_0000218
14097,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623270,50597,,N,Intermediate,,BAO_0000218
14098,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623271,50597,,N,Intermediate,,BAO_0000218
14099,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623272,50597,,N,Intermediate,,BAO_0000218
14100,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623273,50597,,N,Intermediate,,BAO_0000218
14101,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623274,50597,,N,Intermediate,,BAO_0000218
14102,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL874414,50597,,N,Intermediate,,BAO_0000218
14103,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623275,50597,,N,Intermediate,,BAO_0000218
14104,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629150,50597,,N,Intermediate,,BAO_0000218
14105,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623276,50597,,N,Intermediate,,BAO_0000218
14106,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623277,50597,,N,Intermediate,,BAO_0000218
14107,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623112,50597,,N,Intermediate,,BAO_0000218
14108,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623113,50597,,N,Intermediate,,BAO_0000218
14109,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623800,50597,,N,Intermediate,,BAO_0000218
14110,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623801,50597,,N,Intermediate,,BAO_0000218
14111,,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL623802,50597,,N,Intermediate,,BAO_0000218
14112,,1,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL623803,50597,,N,Intermediate,,BAO_0000218
14113,,1,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL623970,50597,,N,Intermediate,,BAO_0000218
14114,,1,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Uterus,995.0,,1,10116.0,A,CHEMBL623971,50597,,N,Intermediate,,BAO_0000218
14115,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623972,50597,,N,Intermediate,,BAO_0000218
14116,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623973,50597,,N,Intermediate,,BAO_0000218
14117,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623974,50597,,N,Intermediate,,BAO_0000218
14118,,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL623975,50597,,N,Intermediate,,BAO_0000218
14119,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623976,50597,,N,Intermediate,,BAO_0000218
14120,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623977,50597,,N,Intermediate,,BAO_0000218
14121,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623978,50597,,N,Intermediate,,BAO_0000218
14122,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL623979,50597,,N,Intermediate,,BAO_0000218
14123,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623980,50597,,N,Intermediate,,BAO_0000218
14124,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL623981,50597,,N,Intermediate,,BAO_0000218
14125,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626278,50597,,N,Intermediate,,BAO_0000218
14126,,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626279,50597,,N,Intermediate,,BAO_0000218
14127,,1,Biodistribution in mice bladder plus excreted urine was determined,Mus musculus,,,,,,1,10090.0,A,CHEMBL626280,50594,,N,Intermediate,,BAO_0000218
14128,,1,"Percentage biodistribution in mouse blood, 10 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626281,50594,,N,Intermediate,,BAO_0000218
14129,,1,"Percentage biodistribution in mouse blood, 30 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626282,50594,,N,Intermediate,,BAO_0000218
14130,,1,"Percentage biodistribution in mouse blood, 5 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626283,50594,,N,Intermediate,,BAO_0000218
14131,,1,"Percentage biodistribution in mouse blood, 60 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626284,50594,,N,Intermediate,,BAO_0000218
14132,,1,"Percentage biodistribution in mouse brain, 10 minutes post injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL626285,50594,,N,Intermediate,,BAO_0000218
14133,,1,"Percentage biodistribution in mouse brain, 30 minutes post injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL626286,50594,,N,Intermediate,,BAO_0000218
14134,,1,"Percentage biodistribution in mouse brain, 5 minutes post injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL626287,50594,,N,Intermediate,,BAO_0000218
14135,,1,"Percentage biodistribution in mouse brain, 60 minutes post injection",Mus musculus,,,Brain,955.0,,1,10090.0,A,CHEMBL626288,50594,,N,Intermediate,,BAO_0000218
14136,,1,"Percentage biodistribution in mouse heart, 10 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626289,50594,,N,Intermediate,,BAO_0000218
14137,,1,"Percentage biodistribution in mouse heart, 30 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626290,50594,,N,Intermediate,,BAO_0000218
14138,,1,"Percentage biodistribution in mouse heart, 5 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL626291,50594,,N,Intermediate,,BAO_0000218
14139,,1,"Percentage biodistribution in mouse heart, 60 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL839888,50594,,N,Intermediate,,BAO_0000218
14140,,1,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Mus musculus,,,Intestine,160.0,,1,10090.0,A,CHEMBL626292,50594,,N,Intermediate,,BAO_0000218
14141,,1,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Mus musculus,,,Intestine,160.0,,1,10090.0,A,CHEMBL626293,50594,,N,Intermediate,,BAO_0000218
14142,,1,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Mus musculus,,,Intestine,160.0,,1,10090.0,A,CHEMBL626294,50594,,N,Intermediate,,BAO_0000218
14143,,1,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Mus musculus,,,Intestine,160.0,,1,10090.0,A,CHEMBL626295,50594,,N,Intermediate,,BAO_0000218
14144,,1,"Percentage biodistribution in mouse liver, 10 minutes post injection",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627659,50594,,N,Intermediate,,BAO_0000218
14145,,1,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627660,50594,,N,Intermediate,,BAO_0000218
14146,,1,"Percentage biodistribution in mouse liver, 5 minutes post injection",Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627661,50594,,N,Intermediate,,BAO_0000218
14147,,1,Biodistribution in mice liver at 60 minutes of post injection,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL627662,50594,,N,Intermediate,,BAO_0000218
14148,,1,Biodistribution in mice lungs at 10 min of post injection,Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL627663,50594,,N,Intermediate,,BAO_0000218
14149,,1,"Percentage biodistribution in mouse lung, 30 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL627664,50594,,N,Intermediate,,BAO_0000218
14150,,1,"Percentage biodistribution in mousee lung, 5 minutes post injection",Mus musculus,,,,,,1,10090.0,A,CHEMBL627665,50594,,N,Intermediate,,BAO_0000218
14151,,1,Biodistribution in mice lungs at 60 min of post injection,Mus musculus,,,Lung,2048.0,,1,10090.0,A,CHEMBL627666,50594,,N,Intermediate,,BAO_0000218
14152,,1,Percentage biodistribution in mouse spleen,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL627667,50594,,N,Intermediate,,BAO_0000218
14153,,1,Percentage biodistribution in mouse stomach,Mus musculus,,,Stomach,945.0,,1,10090.0,A,CHEMBL627668,50594,,N,Intermediate,,BAO_0000218
14154,,1,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Mus musculus,,,Urine,1088.0,,1,10090.0,A,CHEMBL627669,50594,,N,Intermediate,,BAO_0000218
14155,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,,,Urinary bladder,1255.0,,1,,A,CHEMBL627670,22224,,U,Autocuration,,BAO_0000218
14156,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,,,Blood,178.0,,1,,A,CHEMBL627671,22224,,U,Autocuration,,BAO_0000218
14157,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,,,Bone element,1474.0,,1,,A,CHEMBL627672,22224,,U,Autocuration,,BAO_0000218
14158,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,,,,,,1,,A,CHEMBL627673,22224,,U,Autocuration,,BAO_0000218
14159,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,,,Kidney,2113.0,,1,,A,CHEMBL627674,22224,,U,Autocuration,,BAO_0000218
14160,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,,,Liver,2107.0,,1,,A,CHEMBL627675,22224,,U,Autocuration,,BAO_0000218
14161,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,,,Lung,2048.0,,1,,A,CHEMBL627676,22224,,U,Autocuration,,BAO_0000218
14162,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627677,22224,,U,Autocuration,,BAO_0000218
14163,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL627678,22224,,U,Autocuration,,BAO_0000019
14164,,1,Affinity for protein binding expressed as association constant in fresh rat serum,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL627679,50597,,N,Intermediate,,BAO_0000218
14165,,0,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,1,,A,CHEMBL627680,22224,,U,Autocuration,,BAO_0000019
14166,,0,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,1,,A,CHEMBL627681,22224,,U,Autocuration,,BAO_0000019
14167,,0,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,,,,,,1,,A,CHEMBL627682,22224,,U,Autocuration,,BAO_0000019
14168,,0,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,,,,,,1,,A,CHEMBL627683,22224,,U,Autocuration,,BAO_0000019
14169,,0,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,,,,,,1,,A,CHEMBL627684,22224,,U,Autocuration,,BAO_0000019
14170,,0,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,1,,A,CHEMBL874441,22224,,U,Autocuration,,BAO_0000019
14171,,0,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,,,,,,1,,A,CHEMBL627685,22224,,U,Autocuration,,BAO_0000019
14172,,0,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,,,,,,1,,A,CHEMBL627686,22224,,U,Autocuration,,BAO_0000019
14173,,0,Apparent rate constant Koff for inactivation of dTMP synthase.,,,,,,,1,,A,CHEMBL627687,22224,,U,Autocuration,,BAO_0000019
14174,,0,The irreversible inhibitor activity by second order rate equation.,,,,,,,1,,A,CHEMBL627688,22224,,U,Autocuration,,BAO_0000019
14175,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628038,50597,,N,Intermediate,,BAO_0000218
14176,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628039,50597,,N,Intermediate,,BAO_0000218
14177,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628040,50597,,N,Intermediate,,BAO_0000218
14178,,0,Dissociation rate calculated from the first-order equation using t1/2 value,,,,,,,1,,A,CHEMBL628041,22224,,U,Autocuration,,BAO_0000019
14179,,0,The compound was tested for Binding constant against DNA,,,,,,,1,,A,CHEMBL630226,22224,,U,Autocuration,,BAO_0000019
14180,,0,First order rate constant for cyclization of the compound,,,,,,,1,,A,CHEMBL628042,22224,,U,Autocuration,,BAO_0000019
14181,,0,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,1,,A,CHEMBL625232,22224,,U,Autocuration,,BAO_0000019
14182,,0,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,1,,A,CHEMBL625233,22224,,U,Autocuration,,BAO_0000019
14183,,0,Hydrolysis rate constant was determined,,,,,,,1,,A,CHEMBL625979,22224,,U,Autocuration,,BAO_0000019
14184,,0,Observed first order rate constant,,,,,,,1,,A,CHEMBL625980,22224,,U,Autocuration,,BAO_0000019
14185,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,1,,A,CHEMBL625981,22224,,U,Autocuration,,BAO_0000019
14186,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,1,,A,CHEMBL625982,22224,,U,Autocuration,,BAO_0000019
14187,,0,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,,,,,,1,,A,CHEMBL625983,22224,,U,Autocuration,,BAO_0000019
14188,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625984,22224,,U,Autocuration,,BAO_0000019
14189,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625985,22224,,U,Autocuration,,BAO_0000019
14190,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625986,22224,,U,Autocuration,,BAO_0000019
14191,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625987,22224,,U,Autocuration,,BAO_0000019
14192,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625988,22224,,U,Autocuration,,BAO_0000019
14193,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625989,22224,,U,Autocuration,,BAO_0000019
14194,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625990,22224,,U,Autocuration,,BAO_0000019
14195,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625991,22224,,U,Autocuration,,BAO_0000019
14196,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625992,22224,,U,Autocuration,,BAO_0000019
14197,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL625993,22224,,U,Autocuration,,BAO_0000019
14198,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL631973,22224,,U,Autocuration,,BAO_0000019
14199,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632143,22224,,U,Autocuration,,BAO_0000019
14200,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632144,22224,,U,Autocuration,,BAO_0000019
14201,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632145,22224,,U,Autocuration,,BAO_0000019
14202,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632146,22224,,U,Autocuration,,BAO_0000019
14203,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632147,22224,,U,Autocuration,,BAO_0000019
14204,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632148,22224,,U,Autocuration,,BAO_0000019
14205,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632149,22224,,U,Autocuration,,BAO_0000019
14206,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632150,22224,,U,Autocuration,,BAO_0000019
14207,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL632151,22224,,U,Autocuration,,BAO_0000019
14208,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,Homo sapiens,,,,,,1,9606.0,A,CHEMBL632152,50587,,N,Intermediate,,BAO_0000218
14209,,1,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Homo sapiens,,,,,,1,9606.0,A,CHEMBL632153,50587,,N,Intermediate,,BAO_0000218
14210,,1,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,Homo sapiens,,,,,,1,9606.0,A,CHEMBL632154,50587,,N,Intermediate,,BAO_0000218
14211,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632155,50602,,N,Intermediate,,BAO_0000218
14212,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632156,50602,,N,Intermediate,,BAO_0000218
14213,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632157,50602,,N,Intermediate,,BAO_0000218
14214,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632158,50602,,N,Intermediate,,BAO_0000218
14215,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL632159,50602,,N,Intermediate,,BAO_0000218
14216,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626305,50602,,N,Intermediate,,BAO_0000218
14217,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626306,50602,,N,Intermediate,,BAO_0000218
14218,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626307,50602,,N,Intermediate,,BAO_0000218
14219,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626308,50602,,N,Intermediate,,BAO_0000218
14220,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626479,50602,,N,Intermediate,,BAO_0000218
14221,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,Human herpesvirus 1,,,,,,1,10298.0,A,CHEMBL626480,50602,,N,Intermediate,,BAO_0000218
14222,,0,Calculated partition coefficient (clogP) (MlogP),,,,,,,1,,P,CHEMBL626481,22229,,U,Autocuration,,BAO_0000100
14223,,0,Equipotent potent ratio relative to carbachol (nicotinic activity),,,,,,,1,,A,CHEMBL626482,22224,,U,Autocuration,,BAO_0000019
14224,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626483,50588,,N,Intermediate,,BAO_0000218
14225,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL626484,50588,,N,Intermediate,,BAO_0000218
14226,,0,Solubility at pH 7.4 in micro g/mL;NA denotes available,,,,,,,1,,P,CHEMBL626485,22229,,U,Autocuration,,BAO_0000100
14227,,0,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,,,,,,1,,P,CHEMBL626486,22229,,U,Autocuration,,BAO_0000100
14228,,0,Solubility at pH 7.4 in ug/mL;NA denotes not available,,,,,,,1,,P,CHEMBL626487,22229,,U,Autocuration,,BAO_0000100
14229,,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Canis lupus familiaris,,,Plasma,1969.0,,1,9615.0,A,CHEMBL626488,50588,,N,Intermediate,,BAO_0000218
14230,,1,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Rattus norvegicus,,,Serum,1977.0,,1,10116.0,A,CHEMBL626489,50597,,N,Intermediate,,BAO_0000218
14231,,0,Area under the MAP curve measured over 5 min; ND means Not determined,,,,,,,1,,A,CHEMBL626490,22224,,U,Autocuration,,BAO_0000019
14232,,0,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,,,,,,1,,P,CHEMBL626491,22224,,U,Autocuration,,BAO_0000100
14233,,0,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,,,,,,1,,P,CHEMBL626492,22229,,U,Autocuration,,BAO_0000100
14234,,0,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,,,,,,1,,A,CHEMBL626493,22224,,U,Autocuration,,BAO_0000019
14235,,1,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626494,50597,,N,Intermediate,,BAO_0000218
14236,,0,Half life after oral tested,,,,,,,1,,A,CHEMBL626495,22224,,U,Autocuration,,BAO_0000218
14237,,1,Half life was determined in plasma of rat; NT indicates not tested,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626496,50597,,N,Intermediate,,BAO_0000218
14238,,1,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626497,50597,,N,Intermediate,,BAO_0000218
14239,,0,Oral bioavailability after oral tested,,,,,,,1,,A,CHEMBL626498,22224,,U,Autocuration,,BAO_0000218
14240,,1,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626499,50597,,N,Intermediate,,BAO_0000218
14241,,1,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626500,50597,,N,Intermediate,,BAO_0000218
14242,,1,half life was determined in plasma of rat; NT indicates not tested,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626501,50597,,N,Intermediate,,BAO_0000218
14243,,1,half life was determined in plasma of rat; NT means not tested,Rattus norvegicus,,,Plasma,1969.0,,1,10116.0,A,CHEMBL626502,50597,,N,Intermediate,,BAO_0000218
14244,,1,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626503,50597,,N,Intermediate,,BAO_0000218
14245,,1,Mean sodium excretion in rats (Control/Drug treatment value); inactive,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626504,50597,,N,Intermediate,,BAO_0000218
14246,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626505,50597,,N,Intermediate,,BAO_0000218
14247,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626506,50597,,N,Intermediate,,BAO_0000218
14248,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626507,50597,,N,Intermediate,,BAO_0000218
14249,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626508,50597,,N,Intermediate,,BAO_0000218
14250,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626509,50597,,N,Intermediate,,BAO_0000218
14251,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875480,50597,,N,Intermediate,,BAO_0000218
14252,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626510,50597,,N,Intermediate,,BAO_0000218
14253,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626511,50597,,N,Intermediate,,BAO_0000218
14254,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL626512,50597,,N,Intermediate,,BAO_0000218
14255,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628208,50597,,N,Intermediate,,BAO_0000218
14256,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628209,50597,,N,Intermediate,,BAO_0000218
14257,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628210,50597,,N,Intermediate,,BAO_0000218
14258,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628211,50597,,N,Intermediate,,BAO_0000218
14259,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628212,50597,,N,Intermediate,,BAO_0000218
14260,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628213,50597,,N,Intermediate,,BAO_0000218
14261,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628214,50597,,N,Intermediate,,BAO_0000218
14262,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628215,50597,,N,Intermediate,,BAO_0000218
14263,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628216,50597,,N,Intermediate,,BAO_0000218
14264,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626595,50597,,N,Intermediate,,BAO_0000218
14265,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626596,50597,,N,Intermediate,,BAO_0000218
14266,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626597,50597,,N,Intermediate,,BAO_0000218
14267,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626598,50597,,N,Intermediate,,BAO_0000218
14268,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622242,50597,,N,Intermediate,,BAO_0000218
14269,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622243,50597,,N,Intermediate,,BAO_0000218
14270,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622244,50597,,N,Intermediate,,BAO_0000218
14271,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622245,50597,,N,Intermediate,,BAO_0000218
14272,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622246,50597,,N,Intermediate,,BAO_0000218
14273,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622247,50597,,N,Intermediate,,BAO_0000218
14274,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622248,50597,,N,Intermediate,,BAO_0000218
14275,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL877483,50597,,N,Intermediate,,BAO_0000218
14276,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL622249,50597,,N,Intermediate,,BAO_0000218
14277,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622250,50588,,N,Intermediate,,BAO_0000218
14278,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622251,50588,,N,Intermediate,,BAO_0000218
14279,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622252,50588,,N,Intermediate,,BAO_0000218
14280,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622253,50588,,N,Intermediate,,BAO_0000218
14281,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622254,50588,,N,Intermediate,,BAO_0000218
14282,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622255,50588,,N,Intermediate,,BAO_0000218
14283,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622256,50588,,N,Intermediate,,BAO_0000218
14284,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622257,50588,,N,Intermediate,,BAO_0000218
14285,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622258,50588,,N,Intermediate,,BAO_0000218
14286,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622259,50588,,N,Intermediate,,BAO_0000218
14287,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622927,50588,,N,Intermediate,,BAO_0000218
14288,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622928,50588,,N,Intermediate,,BAO_0000218
14289,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL622929,50588,,N,Intermediate,,BAO_0000218
14290,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL623182,50588,,N,Intermediate,,BAO_0000218
14291,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL623183,50588,,N,Intermediate,,BAO_0000218
14292,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623184,50597,,N,Intermediate,,BAO_0000218
14293,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623185,50597,,N,Intermediate,,BAO_0000218
14294,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL877484,50597,,N,Intermediate,,BAO_0000218
14295,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL627274,50597,,N,Intermediate,,BAO_0000218
14296,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623186,50597,,N,Intermediate,,BAO_0000218
14297,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623187,50597,,N,Intermediate,,BAO_0000218
14298,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL623188,50597,,N,Intermediate,,BAO_0000218
14299,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628055,50597,,N,Intermediate,,BAO_0000218
14300,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628056,50597,,N,Intermediate,,BAO_0000218
14301,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628200,50597,,N,Intermediate,,BAO_0000218
14302,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628201,50597,,N,Intermediate,,BAO_0000218
14303,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628202,50597,,N,Intermediate,,BAO_0000218
14304,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628203,50597,,N,Intermediate,,BAO_0000218
14305,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628204,50597,,N,Intermediate,,BAO_0000218
14306,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628205,50597,,N,Intermediate,,BAO_0000218
14307,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628206,50597,,N,Intermediate,,BAO_0000218
14308,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,,,Prostate gland,2367.0,,1,,A,CHEMBL628207,22224,,U,Autocuration,,BAO_0000218
14309,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,,,Prostate gland,2367.0,,1,,A,CHEMBL627220,22224,,U,Autocuration,,BAO_0000218
14310,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627221,22224,,U,Autocuration,,BAO_0000218
14311,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,,,Prostate gland,2367.0,,1,,A,CHEMBL627222,22224,,U,Autocuration,,BAO_0000218
14312,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,,,,,,1,,A,CHEMBL627223,22224,,U,Autocuration,,BAO_0000218
14313,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL632062,22224,,U,Autocuration,,BAO_0000218
14314,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,,,Spleen,2106.0,,1,,A,CHEMBL632063,22224,,U,Autocuration,,BAO_0000218
14315,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,,,Urinary bladder,1255.0,,1,,A,CHEMBL632064,22224,,U,Autocuration,,BAO_0000218
14316,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,,,Blood,178.0,,1,,A,CHEMBL632065,22224,,U,Autocuration,,BAO_0000218
14317,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,,,Bone element,1474.0,,1,,A,CHEMBL632066,22224,,U,Autocuration,,BAO_0000218
14318,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,,,,,,1,,A,CHEMBL632067,22224,,U,Autocuration,,BAO_0000218
14319,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,,,Kidney,2113.0,,1,,A,CHEMBL629188,22224,,U,Autocuration,,BAO_0000218
14320,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,,,Liver,2107.0,,1,,A,CHEMBL629189,22224,,U,Autocuration,,BAO_0000218
14321,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,,,Lung,2048.0,,1,,A,CHEMBL629190,22224,,U,Autocuration,,BAO_0000218
14322,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629191,22224,,U,Autocuration,,BAO_0000218
14323,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,,,Prostate gland,2367.0,,1,,A,CHEMBL629192,22224,,U,Autocuration,,BAO_0000218
14324,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629193,22224,,U,Autocuration,,BAO_0000218
14325,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,,,Prostate gland,2367.0,,1,,A,CHEMBL629194,22224,,U,Autocuration,,BAO_0000218
14326,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,,,,,,1,,A,CHEMBL629195,22224,,U,Autocuration,,BAO_0000218
14327,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629373,22224,,U,Autocuration,,BAO_0000218
14328,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,,,Spleen,2106.0,,1,,A,CHEMBL629374,22224,,U,Autocuration,,BAO_0000218
14329,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,,,Prostate gland,2367.0,,1,,A,CHEMBL629375,22224,,U,Autocuration,,BAO_0000218
14330,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,,,Urinary bladder,1255.0,,1,,A,CHEMBL629376,22224,,U,Autocuration,,BAO_0000218
14331,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,,,Blood,178.0,,1,,A,CHEMBL629377,22224,,U,Autocuration,,BAO_0000218
14332,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,,,Bone element,1474.0,,1,,A,CHEMBL629378,22224,,U,Autocuration,,BAO_0000218
14333,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,,,,,,1,,A,CHEMBL629379,22224,,U,Autocuration,,BAO_0000218
14334,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,,,Kidney,2113.0,,1,,A,CHEMBL629151,22224,,U,Autocuration,,BAO_0000218
14335,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,,,Liver,2107.0,,1,,A,CHEMBL629152,22224,,U,Autocuration,,BAO_0000218
14336,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,,,Lung,2048.0,,1,,A,CHEMBL629153,22224,,U,Autocuration,,BAO_0000218
14337,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629154,22224,,U,Autocuration,,BAO_0000218
14338,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,,,Prostate gland,2367.0,,1,,A,CHEMBL629155,22224,,U,Autocuration,,BAO_0000218
14339,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,,,Prostate gland,2367.0,,1,,A,CHEMBL629156,22224,,U,Autocuration,,BAO_0000218
14340,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629157,22224,,U,Autocuration,,BAO_0000218
14341,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,,,Prostate gland,2367.0,,1,,A,CHEMBL629158,22224,,U,Autocuration,,BAO_0000218
14342,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,,,,,,1,,A,CHEMBL629159,22224,,U,Autocuration,,BAO_0000218
14343,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629160,22224,,U,Autocuration,,BAO_0000218
14344,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,,,Spleen,2106.0,,1,,A,CHEMBL629161,22224,,U,Autocuration,,BAO_0000218
14345,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,,,Urinary bladder,1255.0,,1,,A,CHEMBL629162,22224,,U,Autocuration,,BAO_0000218
14346,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,,,Blood,178.0,,1,,A,CHEMBL629163,22224,,U,Autocuration,,BAO_0000218
14347,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,,,Bone element,1474.0,,1,,A,CHEMBL629164,22224,,U,Autocuration,,BAO_0000218
14348,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,,,,,,1,,A,CHEMBL629165,22224,,U,Autocuration,,BAO_0000218
14349,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,,,Liver,2107.0,,1,,A,CHEMBL629166,22224,,U,Autocuration,,BAO_0000218
14350,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,,,Lung,2048.0,,1,,A,CHEMBL629167,22224,,U,Autocuration,,BAO_0000218
14351,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL629168,22224,,U,Autocuration,,BAO_0000218
14352,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,,,,,,1,,A,CHEMBL629169,22224,,U,Autocuration,,BAO_0000019
14353,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,,,,,,1,,A,CHEMBL629170,22224,,U,Autocuration,,BAO_0000019
14354,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,,,,,,1,,A,CHEMBL631153,22224,,U,Autocuration,,BAO_0000019
14355,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,,,,,,1,,A,CHEMBL875121,22224,,U,Autocuration,,BAO_0000019
14356,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,,,,,,1,,A,CHEMBL631154,22224,,U,Autocuration,,BAO_0000019
14357,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,,,,,,1,,A,CHEMBL631155,22224,,U,Autocuration,,BAO_0000019
14358,,0,Hydrolysis rate constant was determined,,,,,,,1,,A,CHEMBL631156,22224,,U,Autocuration,,BAO_0000019
14359,,0,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,,,,,,1,,A,CHEMBL631157,22224,,U,Autocuration,,BAO_0000019
14360,,0,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,1,,A,CHEMBL631158,22224,,U,Autocuration,,BAO_0000019
14361,,0,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,1,,A,CHEMBL631159,22224,,U,Autocuration,,BAO_0000019
14362,,0,Observed second order rate constant,,,,,,,1,,A,CHEMBL631160,22224,,U,Autocuration,,BAO_0000019
14363,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,,,,,,1,,A,CHEMBL631161,22224,,U,Autocuration,,BAO_0000019
14364,,0,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,,,,,,1,,A,CHEMBL631162,22224,,U,Autocuration,,BAO_0000019
14365,,0,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,,,,,,1,,A,CHEMBL630313,22224,,U,Autocuration,,BAO_0000019
14366,,0,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,,,,,,1,,A,CHEMBL630314,22224,,U,Autocuration,,BAO_0000019
14367,,0,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,,,,,,1,,A,CHEMBL630315,22224,,U,Autocuration,,BAO_0000019
14368,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630316,22224,,U,Autocuration,,BAO_0000019
14369,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630986,22224,,U,Autocuration,,BAO_0000019
14370,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630987,22224,,U,Autocuration,,BAO_0000019
14371,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630988,22224,,U,Autocuration,,BAO_0000019
14372,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630989,22224,,U,Autocuration,,BAO_0000019
14373,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630990,22224,,U,Autocuration,,BAO_0000019
14374,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630991,22224,,U,Autocuration,,BAO_0000019
14375,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630992,22224,,U,Autocuration,,BAO_0000019
14376,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630993,22224,,U,Autocuration,,BAO_0000019
14377,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,,,,,,1,,A,CHEMBL630994,22224,,U,Autocuration,,BAO_0000019
14378,,1,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630995,50597,,N,Intermediate,,BAO_0000218
14379,,0,Association constant for compound at 31 degree C was determined,,,,,,,1,,A,CHEMBL629252,22224,,U,Autocuration,,BAO_0000019
14380,,0,Calculated antagonist equilibrium dissociation constant of the compound,,,,,,,1,,A,CHEMBL629253,22224,,U,Autocuration,,BAO_0000019
14381,,0,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,,,,,,1,,A,CHEMBL629944,22224,,U,Autocuration,,BAO_0000019
14382,,1,Dissociation constants vs LTE4 on guinea pig trachea,Cavia porcellus,,,Trachea,3126.0,,1,10141.0,A,CHEMBL629945,50512,,N,Intermediate,,BAO_0000218
14383,,0,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,,,,,,1,,A,CHEMBL629946,22224,,U,Autocuration,,BAO_0000019
14384,,0,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,,,,,,1,,A,CHEMBL629947,22224,,U,Autocuration,,BAO_0000019
14385,,0,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,,,,,,1,,A,CHEMBL629948,22224,,U,Autocuration,,BAO_0000019
14386,,0,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,,,,,,1,,A,CHEMBL856024,22224,,U,Autocuration,,BAO_0000019
14387,,0,Affinity constant KD value was derived from TMP,,,,,,,1,,A,CHEMBL629949,22224,,U,Autocuration,,BAO_0000019
14388,,0,Apparent dissociation (binding) rate constant was evaluated,,,,,,,1,,A,CHEMBL629950,22224,,U,Autocuration,,BAO_0000019
14389,,0,Dissociation constant (KD) of the compound,,,,,,,1,,P,CHEMBL630127,22224,,U,Autocuration,,BAO_0000100
14390,,0,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,,,,,,1,,P,CHEMBL630128,22224,,U,Autocuration,,BAO_0000100
14391,,0,Dissociation constant from ESR titration experiments,,,,,,,1,,P,CHEMBL630129,22224,,U,Autocuration,,BAO_0000100
14392,,0,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,,1,,,CHEMBL630130,22224,,U,Autocuration,,BAO_0000019
14393,,0,Dissociation constant was evaluated.,,,,,,,1,,P,CHEMBL875234,22224,,U,Autocuration,,BAO_0000100
14394,,0,Dissociation constant was reported,,,,,,,1,,P,CHEMBL630131,22224,,U,Autocuration,,BAO_0000100
14395,,1,Dissociation constant was determined in rat pituitary cells.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630132,50597,,N,Intermediate,,BAO_0000218
14396,,0,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,,,,,,1,,A,CHEMBL630133,22224,,U,Autocuration,,BAO_0000019
14397,,0,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,,,,,,1,,A,CHEMBL630134,22224,,U,Autocuration,,BAO_0000019
14398,,0,Equilibrium dissociation constant of the compound,,,,,,,1,,A,CHEMBL630135,22224,,U,Autocuration,,BAO_0000019
14399,,0,Equilibrium dissociation constant was determined,,,,,,,1,,A,CHEMBL630136,22224,,U,Autocuration,,BAO_0000019
14400,,0,Kinetic constant KD was evaluated,,,,,,,1,,A,CHEMBL630137,22224,,U,Autocuration,,BAO_0000019
14401,,0,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,,,,,,1,,A,CHEMBL630138,22224,,U,Autocuration,,BAO_0000019
14402,,0,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,,,,,,1,,A,CHEMBL630139,22224,,U,Autocuration,,BAO_0000019
14403,,0,Rate constant for hydrolysis in aqueous acetone.,,,,,,,1,,A,CHEMBL630140,22224,,U,Autocuration,,BAO_0000019
14404,,0,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,,,,,,1,,A,CHEMBL875235,22224,,U,Autocuration,,BAO_0000019
14405,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876439,50597,,N,Intermediate,,BAO_0000218
14406,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630605,50597,,N,Intermediate,,BAO_0000218
14407,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630606,50597,,N,Intermediate,,BAO_0000218
14408,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630607,50597,,N,Intermediate,,BAO_0000218
14409,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630608,50597,,N,Intermediate,,BAO_0000218
14410,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630609,50597,,N,Intermediate,,BAO_0000218
14411,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630610,50597,,N,Intermediate,,BAO_0000218
14412,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630611,50597,,N,Intermediate,,BAO_0000218
14413,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629552,50597,,N,Intermediate,,BAO_0000218
14414,,1,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629733,50597,,N,Intermediate,,BAO_0000218
14415,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629734,50597,,N,Intermediate,,BAO_0000218
14416,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629735,50597,,N,Intermediate,,BAO_0000218
14417,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629736,50597,,N,Intermediate,,BAO_0000218
14418,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629737,50597,,N,Intermediate,,BAO_0000218
14419,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629738,50597,,N,Intermediate,,BAO_0000218
14420,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629739,50597,,N,Intermediate,,BAO_0000218
14421,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629740,50597,,N,Intermediate,,BAO_0000218
14422,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629741,50597,,N,Intermediate,,BAO_0000218
14423,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629742,50597,,N,Intermediate,,BAO_0000218
14424,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629743,50597,,N,Intermediate,,BAO_0000218
14425,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629744,50597,,N,Intermediate,,BAO_0000218
14426,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629745,50597,,N,Intermediate,,BAO_0000218
14427,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629746,50597,,N,Intermediate,,BAO_0000218
14428,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629747,50597,,N,Intermediate,,BAO_0000218
14429,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629748,50597,,N,Intermediate,,BAO_0000218
14430,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629749,50597,,N,Intermediate,,BAO_0000218
14431,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629750,50597,,N,Intermediate,,BAO_0000218
14432,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629751,50597,,N,Intermediate,,BAO_0000218
14433,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629752,50597,,N,Intermediate,,BAO_0000218
14434,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629753,50597,,N,Intermediate,,BAO_0000218
14435,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629754,50597,,N,Intermediate,,BAO_0000218
14436,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629755,50597,,N,Intermediate,,BAO_0000218
14437,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629756,50597,,N,Intermediate,,BAO_0000218
14438,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629757,50597,,N,Intermediate,,BAO_0000218
14439,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629758,50597,,N,Intermediate,,BAO_0000218
14440,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629759,50597,,N,Intermediate,,BAO_0000218
14441,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629760,50597,,N,Intermediate,,BAO_0000218
14442,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876443,50597,,N,Intermediate,,BAO_0000218
14443,,1,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629761,50588,,N,Intermediate,,BAO_0000218
14444,,1,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629762,50588,,N,Intermediate,,BAO_0000218
14445,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629763,50594,,N,Intermediate,,BAO_0000218
14446,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629764,50594,,N,Intermediate,,BAO_0000218
14447,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629765,50594,,N,Intermediate,,BAO_0000218
14448,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629766,50594,,N,Intermediate,,BAO_0000218
14449,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629767,50594,,N,Intermediate,,BAO_0000218
14450,,1,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629768,50588,,N,Intermediate,,BAO_0000218
14451,,1,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629769,50594,,N,Intermediate,,BAO_0000218
14452,,1,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629770,50588,,N,Intermediate,,BAO_0000218
14453,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL629771,50588,,N,Intermediate,,BAO_0000218
14454,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629772,50594,,N,Intermediate,,BAO_0000218
14455,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL629773,50594,,N,Intermediate,,BAO_0000218
14456,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL625455,50594,,N,Intermediate,,BAO_0000218
14457,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL625456,50594,,N,Intermediate,,BAO_0000218
14458,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,Mus musculus,,,,,,1,10090.0,A,CHEMBL625457,50594,,N,Intermediate,,BAO_0000218
14459,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625458,50597,,N,Intermediate,,BAO_0000218
14460,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625459,50597,,N,Intermediate,,BAO_0000218
14461,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875483,50597,,N,Intermediate,,BAO_0000218
14462,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL634779,50597,,N,Intermediate,,BAO_0000218
14463,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625460,50597,,N,Intermediate,,BAO_0000218
14464,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626117,50597,,N,Intermediate,,BAO_0000218
14465,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626118,50597,,N,Intermediate,,BAO_0000218
14466,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628342,50597,,N,Intermediate,,BAO_0000218
14467,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628343,50597,,N,Intermediate,,BAO_0000218
14468,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628344,50597,,N,Intermediate,,BAO_0000218
14469,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628345,50597,,N,Intermediate,,BAO_0000218
14470,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628346,50597,,N,Intermediate,,BAO_0000218
14471,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628347,50597,,N,Intermediate,,BAO_0000218
14472,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628348,50597,,N,Intermediate,,BAO_0000218
14473,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628349,50597,,N,Intermediate,,BAO_0000218
14474,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875611,50597,,N,Intermediate,,BAO_0000218
14475,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628350,50597,,N,Intermediate,,BAO_0000218
14476,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628351,50597,,N,Intermediate,,BAO_0000218
14477,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628352,50597,,N,Intermediate,,BAO_0000218
14478,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628353,50597,,N,Intermediate,,BAO_0000218
14479,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628354,50597,,N,Intermediate,,BAO_0000218
14480,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626667,50597,,N,Intermediate,,BAO_0000218
14481,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626668,50597,,N,Intermediate,,BAO_0000218
14482,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626669,50597,,N,Intermediate,,BAO_0000218
14483,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626670,50597,,N,Intermediate,,BAO_0000218
14484,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626671,50597,,N,Intermediate,,BAO_0000218
14485,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626672,50597,,N,Intermediate,,BAO_0000218
14486,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626673,50597,,N,Intermediate,,BAO_0000218
14487,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626674,50597,,N,Intermediate,,BAO_0000218
14488,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626675,50597,,N,Intermediate,,BAO_0000218
14489,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626676,50597,,N,Intermediate,,BAO_0000218
14490,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626677,50597,,N,Intermediate,,BAO_0000218
14491,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626678,50597,,N,Intermediate,,BAO_0000218
14492,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626679,50597,,N,Intermediate,,BAO_0000218
14493,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875612,50597,,N,Intermediate,,BAO_0000218
14494,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626680,50597,,N,Intermediate,,BAO_0000218
14495,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626681,50597,,N,Intermediate,,BAO_0000218
14496,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626682,50597,,N,Intermediate,,BAO_0000218
14497,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626683,50597,,N,Intermediate,,BAO_0000218
14498,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626684,50597,,N,Intermediate,,BAO_0000218
14499,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626685,50597,,N,Intermediate,,BAO_0000218
14500,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626686,50597,,N,Intermediate,,BAO_0000218
14501,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626687,50597,,N,Intermediate,,BAO_0000218
14502,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624978,50597,,N,Intermediate,,BAO_0000218
14503,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624979,50597,,N,Intermediate,,BAO_0000218
14504,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624980,50597,,N,Intermediate,,BAO_0000218
14505,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL624981,50597,,N,Intermediate,,BAO_0000218
14506,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL624982,50588,,N,Intermediate,,BAO_0000218
14507,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,,,Prostate gland,2367.0,,1,,A,CHEMBL627564,22224,,U,Autocuration,,BAO_0000218
14508,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,,,Prostate gland,2367.0,,1,,A,CHEMBL627565,22224,,U,Autocuration,,BAO_0000218
14509,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,,,,,,1,,A,CHEMBL627566,22224,,U,Autocuration,,BAO_0000218
14510,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627567,22224,,U,Autocuration,,BAO_0000218
14511,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,,,Spleen,2106.0,,1,,A,CHEMBL627568,22224,,U,Autocuration,,BAO_0000218
14512,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,,,Kidney,2113.0,,1,,A,CHEMBL627569,22224,,U,Autocuration,,BAO_0000218
14513,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,,,Urinary bladder,1255.0,,1,,A,CHEMBL627570,22224,,U,Autocuration,,BAO_0000218
14514,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,,,Blood,178.0,,1,,A,CHEMBL627571,22224,,U,Autocuration,,BAO_0000218
14515,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,,,Bone element,1474.0,,1,,A,CHEMBL627572,22224,,U,Autocuration,,BAO_0000218
14516,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,,,,,,1,,A,CHEMBL627573,22224,,U,Autocuration,,BAO_0000218
14517,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,,,Kidney,2113.0,,1,,A,CHEMBL627574,22224,,U,Autocuration,,BAO_0000218
14518,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,,,Liver,2107.0,,1,,A,CHEMBL627575,22224,,U,Autocuration,,BAO_0000218
14519,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,,,Lung,2048.0,,1,,A,CHEMBL627576,22224,,U,Autocuration,,BAO_0000218
14520,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627577,22224,,U,Autocuration,,BAO_0000218
14521,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,,,Prostate gland,2367.0,,1,,A,CHEMBL627578,22224,,U,Autocuration,,BAO_0000218
14522,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,,,Prostate gland,2367.0,,1,,A,CHEMBL627579,22224,,U,Autocuration,,BAO_0000218
14523,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627580,22224,,U,Autocuration,,BAO_0000218
14524,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,,,Prostate gland,2367.0,,1,,A,CHEMBL627581,22224,,U,Autocuration,,BAO_0000218
14525,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,,,,,,1,,A,CHEMBL627582,22224,,U,Autocuration,,BAO_0000218
14526,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627583,22224,,U,Autocuration,,BAO_0000218
14527,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,,,Spleen,2106.0,,1,,A,CHEMBL627584,22224,,U,Autocuration,,BAO_0000218
14528,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,,,Prostate gland,2367.0,,1,,A,CHEMBL627585,22224,,U,Autocuration,,BAO_0000218
14529,,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,,,Muscle tissue,2385.0,,1,,A,CHEMBL627586,22224,,U,Autocuration,,BAO_0000218
14530,,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627587,50597,,N,Intermediate,,BAO_0000218
14531,,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL627588,50597,,N,Intermediate,,BAO_0000218
14532,,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628250,50597,,N,Intermediate,,BAO_0000218
14533,,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628251,50597,,N,Intermediate,,BAO_0000218
14534,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628252,50597,,N,Intermediate,,BAO_0000218
14535,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628253,50597,,N,Intermediate,,BAO_0000218
14536,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL628254,50597,,N,Intermediate,,BAO_0000218
14537,,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL877493,50597,,N,Intermediate,,BAO_0000218
14538,,1,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628255,50597,,N,Intermediate,,BAO_0000218
14539,,1,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628256,50597,,N,Intermediate,,BAO_0000218
14540,,1,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL628257,50597,,N,Intermediate,,BAO_0000218
14541,,1,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL628258,50597,,N,Intermediate,,BAO_0000218
14542,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628259,50597,,N,Intermediate,,BAO_0000218
14543,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628429,50597,,N,Intermediate,,BAO_0000218
14544,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL626862,50597,,N,Intermediate,,BAO_0000218
14545,,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL626863,50597,,N,Intermediate,,BAO_0000218
14546,,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL625886,50597,,N,Intermediate,,BAO_0000218
14547,,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL625887,50597,,N,Intermediate,,BAO_0000218
14548,,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625888,50597,,N,Intermediate,,BAO_0000218
14549,,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625889,50597,,N,Intermediate,,BAO_0000218
14550,,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625890,50597,,N,Intermediate,,BAO_0000218
14551,,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL625891,50597,,N,Intermediate,,BAO_0000218
14552,,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL625892,50597,,N,Intermediate,,BAO_0000218
14553,,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL625893,50597,,N,Intermediate,,BAO_0000218
14554,,1,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,A,CHEMBL625894,50597,,N,Intermediate,,BAO_0000218
14555,,1,Biodistribution of the [18F]-radiolabeled compound in rat cortex,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625895,50597,,N,Intermediate,,BAO_0000218
14556,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,1,,A,CHEMBL625896,22224,,U,Autocuration,,BAO_0000019
14557,,0,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,,,,,,1,,A,CHEMBL625897,22224,,U,Autocuration,,BAO_0000019
14558,,0,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,1,,A,CHEMBL625898,22224,,U,Autocuration,,BAO_0000019
14559,,0,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,,,,,,1,,A,CHEMBL625899,22224,,U,Autocuration,,BAO_0000019
14560,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,1,,A,CHEMBL626124,22224,,U,Autocuration,,BAO_0000019
14561,,1,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,Escherichia coli,,,,,,1,562.0,A,CHEMBL628500,50212,,N,Intermediate,,BAO_0000218
14562,,1,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL857856,50597,,N,Intermediate,,BAO_0000218
14563,,1,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628501,50597,,N,Intermediate,,BAO_0000218
14564,,0,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,,,,,,1,,A,CHEMBL628502,22224,,U,Autocuration,,BAO_0000019
14565,,0,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,,,,,,1,,A,CHEMBL628503,22224,,U,Autocuration,,BAO_0000019
14566,,0,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,,,,,,1,,A,CHEMBL628504,22224,,U,Autocuration,,BAO_0000019
14567,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,1,,A,CHEMBL628505,22224,,U,Autocuration,,BAO_0000019
14568,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,1,,A,CHEMBL874452,22224,,U,Autocuration,,BAO_0000019
14569,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,,,,,,1,,A,CHEMBL628506,22224,,U,Autocuration,,BAO_0000019
14570,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,,,,,,1,,A,CHEMBL628507,22224,,U,Autocuration,,BAO_0000019
14571,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,,,,,,1,,A,CHEMBL628508,22224,,U,Autocuration,,BAO_0000019
14572,,0,Michaelis constant (KM) was evaluated,,,,,,,1,,A,CHEMBL628509,22224,,U,Autocuration,,BAO_0000019
14573,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,,,,,,,1,,A,CHEMBL628510,22224,,U,Autocuration,,BAO_0000019
14574,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,,,,,,1,,B,CHEMBL628511,22224,,U,Autocuration,,BAO_0000019
14575,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,,,,,,1,,B,CHEMBL628512,22224,,U,Autocuration,,BAO_0000019
14576,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,,,,,,1,,B,CHEMBL628513,22224,,U,Autocuration,,BAO_0000019
14577,,0,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,,,,,,1,,B,CHEMBL628514,22224,,U,Autocuration,,BAO_0000019
14578,,0,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,,,,,,1,,A,CHEMBL628515,22224,,U,Autocuration,,BAO_0000019
14579,,0,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,,,,,,1,,A,CHEMBL628516,22224,,U,Autocuration,,BAO_0000019
14580,,0,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,1,,A,CHEMBL628517,22224,,U,Autocuration,,BAO_0000019
14581,,0,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,,,,,,1,,A,CHEMBL628518,22224,,U,Autocuration,,BAO_0000019
14582,,0,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,,,,,,1,,A,CHEMBL628519,22224,,U,Autocuration,,BAO_0000019
14583,,0,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,,,,,,1,,A,CHEMBL628520,22224,,U,Autocuration,,BAO_0000019
14584,,0,Binding constant was determined,,,,,,,1,,A,CHEMBL628521,22224,,U,Autocuration,,BAO_0000019
14585,,0,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,,,,,,1,,A,CHEMBL630443,22224,,U,Autocuration,,BAO_0000019
14586,,0,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,,,,,,1,,A,CHEMBL630444,22224,,U,Autocuration,,BAO_0000019
14587,,0,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,,,,,,1,,A,CHEMBL857732,22224,,U,Autocuration,,BAO_0000019
14588,,0,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,,,,,,1,,P,CHEMBL630445,22224,,U,Autocuration,,BAO_0000100
14589,,0,Catalytic rate constant of the compound,,,,,,,1,,A,CHEMBL630446,22224,,U,Autocuration,,BAO_0000019
14590,,0,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,,,,,,1,,B,CHEMBL630447,22224,,U,Autocuration,,BAO_0000019
14591,,0,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,,,,,,1,,A,CHEMBL630448,22224,,U,Autocuration,,BAO_0000019
14592,,0,Catalytic rate constant against phospholipase A2 was determined,,,,,,,1,,A,CHEMBL630449,22224,,U,Autocuration,,BAO_0000019
14593,,0,"Compound was evaluated for catalytic constant, Kcat",,,,,,,1,,A,CHEMBL630450,22224,,U,Autocuration,,BAO_0000019
14594,,0,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,,,,,,1,,A,CHEMBL630451,22224,,U,Autocuration,,BAO_0000019
14595,,0,Kcat calculated from 0.693/T1/2,,,,,,,1,,A,CHEMBL630452,22224,,U,Autocuration,,BAO_0000019
14596,,0,Kcat was determined,,,,,,,1,,A,CHEMBL630453,22224,,U,Autocuration,,BAO_0000019
14597,,0,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,,,,,,1,,A,CHEMBL630454,22224,,U,Autocuration,,BAO_0000019
14598,,0,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,,,,,,1,,A,CHEMBL630455,22224,,U,Autocuration,,BAO_0000019
14599,,0,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,,,,,,1,,A,CHEMBL631487,22224,,U,Autocuration,,BAO_0000019
14600,,0,Kcat value was determined,,,,,,,1,,A,CHEMBL631488,22224,,U,Autocuration,,BAO_0000019
14601,,0,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,,,,,,1,,A,CHEMBL876440,22224,,U,Autocuration,,BAO_0000019
14602,,0,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,,,,,,1,,A,CHEMBL631489,22224,,U,Autocuration,,BAO_0000019
14603,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,1,,A,CHEMBL857742,22224,,U,Autocuration,,BAO_0000019
14604,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,1,,A,CHEMBL631490,22224,,U,Autocuration,,BAO_0000019
14605,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,,,,,,1,,A,CHEMBL631491,22224,,U,Autocuration,,BAO_0000019
14606,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,,,,,,1,,A,CHEMBL631492,22224,,U,Autocuration,,BAO_0000019
14607,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,,,,,,1,,A,CHEMBL631493,22224,,U,Autocuration,,BAO_0000019
14608,,0,Kinetic parameter for rate of conversion to PABA was determined,,,,,,,1,,A,CHEMBL631494,22224,,U,Autocuration,,BAO_0000019
14609,,0,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,1,,A,CHEMBL631495,22224,,U,Autocuration,,BAO_0000019
14610,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Rattus norvegicus,,,Feces,1988.0,,1,10116.0,A,CHEMBL631496,50597,,N,Intermediate,,BAO_0000218
14611,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631497,50597,,N,Intermediate,,BAO_0000218
14612,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631498,50597,,N,Intermediate,,BAO_0000218
14613,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629776,50597,,N,Intermediate,,BAO_0000218
14614,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629777,50597,,N,Intermediate,,BAO_0000218
14615,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL629778,50597,,N,Intermediate,,BAO_0000218
14616,,1,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630456,50597,,N,Intermediate,,BAO_0000218
14617,,1,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630457,50597,,N,Intermediate,,BAO_0000218
14618,,1,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630458,50597,,N,Intermediate,,BAO_0000218
14619,,1,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630459,50597,,N,Intermediate,,BAO_0000218
14620,,1,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630460,50597,,N,Intermediate,,BAO_0000218
14621,,1,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL876550,50597,,N,Intermediate,,BAO_0000218
14622,,1,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630461,50597,,N,Intermediate,,BAO_0000218
14623,,1,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630462,50597,,N,Intermediate,,BAO_0000218
14624,,1,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630463,50597,,N,Intermediate,,BAO_0000218
14625,,1,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630464,50597,,N,Intermediate,,BAO_0000218
14626,,1,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630465,50597,,N,Intermediate,,BAO_0000218
14627,,1,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630466,50597,,N,Intermediate,,BAO_0000218
14628,,1,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630467,50597,,N,Intermediate,,BAO_0000218
14629,,1,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630633,50597,,N,Intermediate,,BAO_0000218
14630,,1,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630634,50597,,N,Intermediate,,BAO_0000218
14631,,1,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630635,50597,,N,Intermediate,,BAO_0000218
14632,,1,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630636,50597,,N,Intermediate,,BAO_0000218
14633,,1,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630637,50597,,N,Intermediate,,BAO_0000218
14634,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL630638,50592,,N,Intermediate,,BAO_0000218
14635,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL630639,50592,,N,Intermediate,,BAO_0000218
14636,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL630640,50592,,N,Intermediate,,BAO_0000218
14637,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL876551,50592,,N,Intermediate,,BAO_0000218
14638,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL630641,50592,,N,Intermediate,,BAO_0000218
14639,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL630642,50592,,N,Intermediate,,BAO_0000218
14640,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL630643,50592,,N,Intermediate,,BAO_0000218
14641,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL630644,50592,,N,Intermediate,,BAO_0000218
14642,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL630645,50592,,N,Intermediate,,BAO_0000218
14643,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL625599,50592,,N,Intermediate,,BAO_0000218
14644,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL625600,50592,,N,Intermediate,,BAO_0000218
14645,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL625601,50592,,N,Intermediate,,BAO_0000218
14646,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Oryctolagus cuniculus,,,Feces,1988.0,,1,9986.0,A,CHEMBL625602,50592,,N,Intermediate,,BAO_0000218
14647,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL627470,50592,,N,Intermediate,,BAO_0000218
14648,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL627471,50592,,N,Intermediate,,BAO_0000218
14649,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL627472,50592,,N,Intermediate,,BAO_0000218
14650,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL627473,50592,,N,Intermediate,,BAO_0000218
14651,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Oryctolagus cuniculus,,,Urine,1088.0,,1,9986.0,A,CHEMBL627474,50592,,N,Intermediate,,BAO_0000218
14652,,1,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627475,50597,,N,Intermediate,,BAO_0000218
14653,,1,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL627476,50597,,N,Intermediate,,BAO_0000218
14654,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627477,50588,,N,Intermediate,,BAO_0000218
14655,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627478,50588,,N,Intermediate,,BAO_0000218
14656,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627479,50588,,N,Intermediate,,BAO_0000218
14657,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627480,50588,,N,Intermediate,,BAO_0000218
14658,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627481,50588,,N,Intermediate,,BAO_0000218
14659,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627482,50588,,N,Intermediate,,BAO_0000218
14660,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL627483,50588,,N,Intermediate,,BAO_0000218
14661,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL875636,50588,,N,Intermediate,,BAO_0000218
14662,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625764,50588,,N,Intermediate,,BAO_0000218
14663,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625765,50588,,N,Intermediate,,BAO_0000218
14664,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625766,50588,,N,Intermediate,,BAO_0000218
14665,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625767,50588,,N,Intermediate,,BAO_0000218
14666,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625768,50588,,N,Intermediate,,BAO_0000218
14667,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625769,50588,,N,Intermediate,,BAO_0000218
14668,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625770,50588,,N,Intermediate,,BAO_0000218
14669,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625771,50588,,N,Intermediate,,BAO_0000218
14670,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625772,50588,,N,Intermediate,,BAO_0000218
14671,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Canis lupus familiaris,,,Urine,1088.0,,1,9615.0,A,CHEMBL625773,50588,,N,Intermediate,,BAO_0000218
14672,,1,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625774,50597,,N,Intermediate,,BAO_0000218
14673,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625775,50597,,N,Intermediate,,BAO_0000218
14674,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625776,50597,,N,Intermediate,,BAO_0000218
14675,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625777,50597,,N,Intermediate,,BAO_0000218
14676,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625778,50597,,N,Intermediate,,BAO_0000218
14677,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625779,50597,,N,Intermediate,,BAO_0000218
14678,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625780,50597,,N,Intermediate,,BAO_0000218
14679,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL625781,50597,,N,Intermediate,,BAO_0000218
14680,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875637,50597,,N,Intermediate,,BAO_0000218
14681,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626473,50597,,N,Intermediate,,BAO_0000218
14682,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626474,50597,,N,Intermediate,,BAO_0000218
14683,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626475,50597,,N,Intermediate,,BAO_0000218
14684,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626476,50597,,N,Intermediate,,BAO_0000218
14685,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL634397,50597,,N,Intermediate,,BAO_0000218
14686,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL626477,50597,,N,Intermediate,,BAO_0000218
14687,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631069,50597,,N,Intermediate,,BAO_0000218
14688,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631070,50597,,N,Intermediate,,BAO_0000218
14689,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631071,50597,,N,Intermediate,,BAO_0000218
14690,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631072,50597,,N,Intermediate,,BAO_0000218
14691,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631073,50597,,N,Intermediate,,BAO_0000218
14692,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631074,50597,,N,Intermediate,,BAO_0000218
14693,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631075,50597,,N,Intermediate,,BAO_0000218
14694,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631725,50597,,N,Intermediate,,BAO_0000218
14695,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631726,50597,,N,Intermediate,,BAO_0000218
14696,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631727,50597,,N,Intermediate,,BAO_0000218
14697,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631728,50597,,N,Intermediate,,BAO_0000218
14698,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631729,50597,,N,Intermediate,,BAO_0000218
14699,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631730,50597,,N,Intermediate,,BAO_0000218
14700,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631731,50597,,N,Intermediate,,BAO_0000218
14701,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631910,50597,,N,Intermediate,,BAO_0000218
14702,,1,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,A,CHEMBL631911,50597,,N,Intermediate,,BAO_0000218
14703,,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL631912,50597,,N,Intermediate,,BAO_0000218
14704,,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Rattus norvegicus,,,Hypothalamus,1898.0,,1,10116.0,A,CHEMBL631913,50597,,N,Intermediate,,BAO_0000218
14705,,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631914,50597,,N,Intermediate,,BAO_0000218
14706,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631915,50597,,N,Intermediate,,BAO_0000218
14707,,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL875778,50597,,N,Intermediate,,BAO_0000218
14708,,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631916,50597,,N,Intermediate,,BAO_0000218
14709,,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631917,50597,,N,Intermediate,,BAO_0000218
14710,,1,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631918,50597,,N,Intermediate,,BAO_0000218
14711,,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631919,50597,,N,Intermediate,,BAO_0000218
14712,,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631920,50597,,N,Intermediate,,BAO_0000218
14713,,1,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631921,50597,,N,Intermediate,,BAO_0000218
14714,,1,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631922,50597,,N,Intermediate,,BAO_0000218
14715,,1,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL631923,50597,,N,Intermediate,,BAO_0000218
14716,,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631924,50597,,N,Intermediate,,BAO_0000218
14717,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630234,50597,,N,Intermediate,,BAO_0000218
14718,,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630235,50597,,N,Intermediate,,BAO_0000218
14719,,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630236,50597,,N,Intermediate,,BAO_0000218
14720,,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630237,50597,,N,Intermediate,,BAO_0000218
14721,,1,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630238,50597,,N,Intermediate,,BAO_0000218
14722,,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630239,50597,,N,Intermediate,,BAO_0000218
14723,,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630303,50597,,N,Intermediate,,BAO_0000218
14724,,1,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630304,50597,,N,Intermediate,,BAO_0000218
14725,,1,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630305,50597,,N,Intermediate,,BAO_0000218
14726,,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630306,50597,,N,Intermediate,,BAO_0000218
14727,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630307,50597,,N,Intermediate,,BAO_0000218
14728,,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630308,50597,,N,Intermediate,,BAO_0000218
14729,,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL630309,50597,,N,Intermediate,,BAO_0000218
14730,,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL629309,50597,,N,Intermediate,,BAO_0000218
14731,,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL629993,50597,,N,Intermediate,,BAO_0000218
14732,,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL629994,50597,,N,Intermediate,,BAO_0000218
14733,,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL629995,50597,,N,Intermediate,,BAO_0000218
14734,,1,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631993,50597,,N,Intermediate,,BAO_0000218
14735,,1,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631994,50597,,N,Intermediate,,BAO_0000218
14736,,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL631995,50597,,N,Intermediate,,BAO_0000218
14737,,1,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631996,50597,,N,Intermediate,,BAO_0000218
14738,,1,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631997,50597,,N,Intermediate,,BAO_0000218
14739,,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631998,50597,,N,Intermediate,,BAO_0000218
14740,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631999,50597,,N,Intermediate,,BAO_0000218
14741,,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL632000,50597,,N,Intermediate,,BAO_0000218
14742,,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL632001,50597,,N,Intermediate,,BAO_0000218
14743,,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL874424,50597,,N,Intermediate,,BAO_0000218
14744,,1,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL632002,50597,,N,Intermediate,,BAO_0000218
14745,,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL632003,50597,,N,Intermediate,,BAO_0000218
14746,,0,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,,,,,,1,,A,CHEMBL632004,22224,,U,Autocuration,,BAO_0000019
14747,,0,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,,,,,,1,,A,CHEMBL632005,22224,,U,Autocuration,,BAO_0000019
14748,,0,Compound was tested for amidase rate in the presence of N62C screen enzyme,,,,,,,1,,A,CHEMBL632006,22224,,U,Autocuration,,BAO_0000019
14749,,0,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,,,,,,1,,A,CHEMBL632007,22224,,U,Autocuration,,BAO_0000019
14750,,0,Compound was tested for amidase rate in the presence of S166C screen enzyme,,,,,,,1,,A,CHEMBL632008,22224,,U,Autocuration,,BAO_0000019
14751,,0,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,,,,,,1,,A,CHEMBL632009,22224,,U,Autocuration,,BAO_0000019
14752,,0,Compound was tested for esterase rate in the presence of N62C screen enzyme,,,,,,,1,,A,CHEMBL632010,22224,,U,Autocuration,,BAO_0000019
14753,,0,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,,,,,,1,,A,CHEMBL857750,22224,,U,Autocuration,,BAO_0000019
14754,,0,Compound was tested for esterase rate in the presence of S166C screen enzyme,,,,,,,1,,A,CHEMBL632011,22224,,U,Autocuration,,BAO_0000019
14755,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL632012,22224,,U,Autocuration,,BAO_0000019
14756,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL632013,22224,,U,Autocuration,,BAO_0000019
14757,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL632014,22224,,U,Autocuration,,BAO_0000019
14758,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL629622,22224,,U,Autocuration,,BAO_0000019
14759,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL629623,22224,,U,Autocuration,,BAO_0000019
14760,,0,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,,,,,,1,,A,CHEMBL629624,22224,,U,Autocuration,,BAO_0000019
14761,,0,Ratio of Kcat to that of Km was determined,,,,,,,1,,A,CHEMBL629625,22224,,U,Autocuration,,BAO_0000019
14762,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,1,,A,CHEMBL629626,22224,,U,Autocuration,,BAO_0000019
14763,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,,,,,,1,,A,CHEMBL629627,22224,,U,Autocuration,,BAO_0000019
14764,,0,"Compound was evaluated for constant, Kd",,,,,,,1,,A,CHEMBL629628,22224,,U,Autocuration,,BAO_0000019
14765,,0,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,,,,,,1,,A,CHEMBL629629,22224,,U,Autocuration,,BAO_0000019
14766,,0,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,,,,,,1,,A,CHEMBL629630,22224,,U,Autocuration,,BAO_0000019
14767,,0,Dissociation Constant of compound determined,,,,,,,1,,A,CHEMBL856030,22224,,U,Autocuration,,BAO_0000019
14768,,0,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,,,,,,1,,B,CHEMBL629631,22224,,U,Autocuration,,BAO_0000019
14769,,0,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,,,,,,1,,B,CHEMBL629632,22224,,U,Autocuration,,BAO_0000019
14770,,0,Dissociation constant of compound with Fructose was determined,,,,,,,1,,P,CHEMBL629633,22224,,U,Autocuration,,BAO_0000100
14771,,0,Dissociation constant of compound with Fructose was determined; Not determined,,,,,,,1,,P,CHEMBL629634,22224,,U,Autocuration,,BAO_0000100
14772,,0,Dissociation constant of compound with Lactulose was determined,,,,,,,1,,P,CHEMBL629635,22224,,U,Autocuration,,BAO_0000100
14773,,0,Dissociation constant of compound with Lactulose was determined; Not determined,,,,,,,1,,P,CHEMBL629636,22224,,U,Autocuration,,BAO_0000100
14774,,0,Dissociation constant of the Compound,,,,,,,1,,P,CHEMBL629637,22224,,U,Autocuration,,BAO_0000100
14775,,0,Dissociation constant by non-linear regression analysis,,,,,,,1,,P,CHEMBL629638,22224,,U,Autocuration,,BAO_0000100
14776,,0,Dissociation constant was determined,,,,,,,1,,P,CHEMBL629639,22224,,U,Autocuration,,BAO_0000100
14777,,0,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,,,,,,1,,P,CHEMBL629640,22224,,U,Autocuration,,BAO_0000100
14778,,0,Dissociation constant was determined,,,,,,,1,,P,CHEMBL629641,22224,,U,Autocuration,,BAO_0000100
14779,,0,Dissociation constant was determined,,,,,,,1,,P,CHEMBL631344,22224,,U,Autocuration,,BAO_0000100
14780,,1,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631345,50597,,N,Intermediate,,BAO_0000218
14781,,0,The dissociation constant determined by fluorescence displacement assay,,,,,,,1,,A,CHEMBL631346,22224,,U,Autocuration,,BAO_0000019
14782,,0,kd value surface plasmon resonance (SPR) method,,,,,,,1,,A,CHEMBL631524,22224,,U,Autocuration,,BAO_0000019
14783,,1,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631525,50597,,N,Intermediate,,BAO_0000218
14784,,0,First dissociation constant of the binding of compound to V30M TTR,,,,,,,1,,F,CHEMBL631526,22224,,U,Autocuration,,BAO_0000019
14785,,0,Second dissociation constant of the binding of compound to V30M TTR,,,,,,,1,,F,CHEMBL631527,22224,,U,Autocuration,,BAO_0000019
14786,,0,"Compound was evaluated for equilibrium constant, Ke",,,,,,,1,,A,CHEMBL631528,22224,,U,Autocuration,,BAO_0000019
14787,,0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,,,Hypothalamus,1898.0,,1,,A,CHEMBL631529,22224,,U,Autocuration,,BAO_0000019
14788,,0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,,,Hypothalamus,1898.0,,1,,A,CHEMBL631530,22224,,U,Autocuration,,BAO_0000019
14789,,0,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,1,,A,CHEMBL631531,22224,,U,Autocuration,,BAO_0000019
14790,,0,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,1,,A,CHEMBL631532,22224,,U,Autocuration,,BAO_0000019
14791,,0,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,,,,,,1,,A,CHEMBL631533,22224,,U,Autocuration,,BAO_0000019
14792,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL876552,50594,,N,Intermediate,,BAO_0000218
14793,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631534,50594,,N,Intermediate,,BAO_0000218
14794,,1,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631535,50594,,N,Intermediate,,BAO_0000218
14795,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631536,50594,,N,Intermediate,,BAO_0000218
14796,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631537,50594,,N,Intermediate,,BAO_0000218
14797,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631538,50594,,N,Intermediate,,BAO_0000218
14798,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631539,50594,,N,Intermediate,,BAO_0000218
14799,,1,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,Mus musculus,,,,,,1,10090.0,A,CHEMBL631540,50594,,N,Intermediate,,BAO_0000218
14800,,1,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625637,50597,,N,Intermediate,,BAO_0000218
14801,,1,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625638,50597,,N,Intermediate,,BAO_0000218
14802,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL625639,50597,,N,Intermediate,,BAO_0000218
14803,,1,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625640,50597,,N,Intermediate,,BAO_0000218
14804,,1,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625641,50597,,N,Intermediate,,BAO_0000218
14805,,1,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625642,50597,,N,Intermediate,,BAO_0000218
14806,,1,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625643,50597,,N,Intermediate,,BAO_0000218
14807,,1,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625644,50597,,N,Intermediate,,BAO_0000218
14808,,1,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Kidney,2113.0,,1,10116.0,A,CHEMBL625645,50597,,N,Intermediate,,BAO_0000218
14809,,1,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625646,50597,,N,Intermediate,,BAO_0000218
14810,,1,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625647,50597,,N,Intermediate,,BAO_0000218
14811,,1,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625648,50597,,N,Intermediate,,BAO_0000218
14812,,1,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL625649,50597,,N,Intermediate,,BAO_0000218
14813,,1,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625650,50597,,N,Intermediate,,BAO_0000218
14814,,1,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL625651,50597,,N,Intermediate,,BAO_0000218
14815,,1,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL625652,50597,,N,Intermediate,,BAO_0000218
14816,,1,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Zone of skin,14.0,,1,10116.0,A,CHEMBL625653,50597,,N,Intermediate,,BAO_0000218
14817,,1,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625654,50597,,N,Intermediate,,BAO_0000218
14818,,1,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL625655,50597,,N,Intermediate,,BAO_0000218
14819,,1,Biodistribution of Compound in rat blood after 15 minutes of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625656,50597,,N,Intermediate,,BAO_0000218
14820,,1,Biodistribution of Compound in rat blood after 2 minutes of administration,Rattus norvegicus,,,Blood,178.0,,1,10116.0,A,CHEMBL625657,50597,,N,Intermediate,,BAO_0000218
14821,,1,Biodistribution of Compound in rat brain after 15 minutes of administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625658,50597,,N,Intermediate,,BAO_0000218
14822,,1,Biodistribution of Compound in rat brain after 2 minutes of administration,Rattus norvegicus,,,Brain,955.0,,1,10116.0,A,CHEMBL625659,50597,,N,Intermediate,,BAO_0000218
14823,,1,Biodistribution of Compound in rat heart after 15 minutes of administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625660,50597,,N,Intermediate,,BAO_0000218
14824,,1,Biodistribution of Compound in rat heart after 2 minutes of administration,Rattus norvegicus,,,Heart,948.0,,1,10116.0,A,CHEMBL625661,50597,,N,Intermediate,,BAO_0000218
14825,,1,Biodistribution of Compound in rat liver after 15 minutes of administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625662,50597,,N,Intermediate,,BAO_0000218
14826,,1,Biodistribution of Compound in rat liver after 2 minutes of administration,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL625663,50597,,N,Intermediate,,BAO_0000218
14827,,1,Biodistribution of Compound in rat lung after 15 minutes of administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL875621,50597,,N,Intermediate,,BAO_0000218
14828,,1,Biodistribution of Compound in rat lung after 2 minutes of administration,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL628382,50597,,N,Intermediate,,BAO_0000218
14829,,1,Biodistribution of Compound in rat muscle after 15 minutes of administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL628383,50597,,N,Intermediate,,BAO_0000218
14830,,1,Biodistribution of Compound in rat muscle after 2 minutes of administration,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL628384,50597,,N,Intermediate,,BAO_0000218
14831,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628385,50597,,N,Intermediate,,BAO_0000218
14832,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875753,50597,,N,Intermediate,,BAO_0000218
14833,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628386,50597,,N,Intermediate,,BAO_0000218
14834,,1,Organ distribution in rat blood 2 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628387,50597,,N,Intermediate,,BAO_0000218
14835,,1,Organ distribution in rat blood 2 hr after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628388,50597,,N,Intermediate,,BAO_0000218
14836,,1,Organ distribution in rat blood 30 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628389,50597,,N,Intermediate,,BAO_0000218
14837,,1,Organ distribution in rat blood 30 min after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL632756,50597,,N,Intermediate,,BAO_0000218
14838,,1,Organ distribution in rat brain 2 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628390,50597,,N,Intermediate,,BAO_0000218
14839,,1,Organ distribution in rat brain 2 hr after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631811,50597,,N,Intermediate,,BAO_0000218
14840,,1,Organ distribution in rat brain 30 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631812,50597,,N,Intermediate,,BAO_0000218
14841,,1,Organ distribution in rat heart 2 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631813,50597,,N,Intermediate,,BAO_0000218
14842,,1,Organ distribution in rat heart 2 hr after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631814,50597,,N,Intermediate,,BAO_0000218
14843,,1,Organ distribution in rat heart 30 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631815,50597,,N,Intermediate,,BAO_0000218
14844,,1,Organ distribution in rat kidney 2 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631816,50597,,N,Intermediate,,BAO_0000218
14845,,1,Organ distribution in rat kidney 2 hr after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL875758,50597,,N,Intermediate,,BAO_0000218
14846,,1,Organ distribution in rat kidney 30 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631817,50597,,N,Intermediate,,BAO_0000218
14847,,1,Organ distribution in rat liver 2 minutes after intravenous injection,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631818,50597,,N,Intermediate,,BAO_0000218
14848,,1,Organ distribution in rat liver 2 hr after intravenous injection,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631819,50597,,N,Intermediate,,BAO_0000218
14849,,1,Organ distribution in rat liver 30 minutes after intravenous injection,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL631820,50597,,N,Intermediate,,BAO_0000218
14850,,1,Organ distribution in rat lung 2 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631821,50597,,N,Intermediate,,BAO_0000218
14851,,1,Organ distribution in rat lung 2 hr after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631822,50597,,N,Intermediate,,BAO_0000218
14852,,1,Organ distribution in rat lung 30 minutes after intravenous injection,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL631823,50597,,N,Intermediate,,BAO_0000218
14853,,1,Organ distribution in rat muscle 2 minutes after intravenous injection,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631824,50597,,N,Intermediate,,BAO_0000218
14854,,1,Organ distribution in rat muscle 2 hr after intravenous injection,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631825,50597,,N,Intermediate,,BAO_0000218
14855,,1,Organ distribution in rat muscle 30 minutes after intravenous injection,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631826,50597,,N,Intermediate,,BAO_0000218
14856,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL631827,50594,,N,Intermediate,,BAO_0000218
14857,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),Mus musculus,,,,,,1,10090.0,A,CHEMBL631828,50594,,N,Intermediate,,BAO_0000218
14858,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL631829,50594,,N,Intermediate,,BAO_0000218
14859,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875759,50597,,N,Intermediate,,BAO_0000218
14860,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631830,50597,,N,Intermediate,,BAO_0000218
14861,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631831,50597,,N,Intermediate,,BAO_0000218
14862,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631832,50597,,N,Intermediate,,BAO_0000218
14863,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631833,50597,,N,Intermediate,,BAO_0000218
14864,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631834,50597,,N,Intermediate,,BAO_0000218
14865,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631835,50597,,N,Intermediate,,BAO_0000218
14866,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631836,50597,,N,Intermediate,,BAO_0000218
14867,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631837,50597,,N,Intermediate,,BAO_0000218
14868,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631838,50597,,N,Intermediate,,BAO_0000218
14869,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631839,50597,,N,Intermediate,,BAO_0000218
14870,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631840,50597,,N,Intermediate,,BAO_0000218
14871,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631841,50597,,N,Intermediate,,BAO_0000218
14872,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631842,50597,,N,Intermediate,,BAO_0000218
14873,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631843,50597,,N,Intermediate,,BAO_0000218
14874,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631844,50597,,N,Intermediate,,BAO_0000218
14875,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631845,50597,,N,Intermediate,,BAO_0000218
14876,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631846,50597,,N,Intermediate,,BAO_0000218
14877,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL875760,50597,,N,Intermediate,,BAO_0000218
14878,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL632199,50597,,N,Intermediate,,BAO_0000218
14879,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631847,50597,,N,Intermediate,,BAO_0000218
14880,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL631848,50597,,N,Intermediate,,BAO_0000218
14881,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628707,50597,,N,Intermediate,,BAO_0000218
14882,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628708,50597,,N,Intermediate,,BAO_0000218
14883,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628709,50597,,N,Intermediate,,BAO_0000218
14884,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628710,50597,,N,Intermediate,,BAO_0000218
14885,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628711,50597,,N,Intermediate,,BAO_0000218
14886,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628712,50597,,N,Intermediate,,BAO_0000218
14887,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628713,50597,,N,Intermediate,,BAO_0000218
14888,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Rattus norvegicus,,,Urine,1088.0,,1,10116.0,A,CHEMBL628714,50597,,N,Intermediate,,BAO_0000218
14889,,1,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL628715,50597,,N,Intermediate,,BAO_0000218
14890,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,,,,,,1,,A,CHEMBL629179,22224,,U,Autocuration,,BAO_0000019
14891,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,,,,,,1,,A,CHEMBL629180,22224,,U,Autocuration,,BAO_0000019
14892,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,,,,,,1,,A,CHEMBL875108,22224,,U,Autocuration,,BAO_0000019
14893,,0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629181,22224,,U,Autocuration,,BAO_0000019
14894,,0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629182,22224,,U,Autocuration,,BAO_0000019
14895,,0,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629183,22224,,U,Autocuration,,BAO_0000019
14896,,0,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629184,22224,,U,Autocuration,,BAO_0000019
14897,,0,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629185,22224,,U,Autocuration,,BAO_0000019
14898,,0,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629186,22224,,U,Autocuration,,BAO_0000019
14899,,0,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629187,22224,,U,Autocuration,,BAO_0000019
14900,,0,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629887,22224,,U,Autocuration,,BAO_0000019
14901,,0,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629888,22224,,U,Autocuration,,BAO_0000019
14902,,0,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629889,22224,,U,Autocuration,,BAO_0000019
14903,,0,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629890,22224,,U,Autocuration,,BAO_0000019
14904,,0,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629891,22224,,U,Autocuration,,BAO_0000019
14905,,0,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629892,22224,,U,Autocuration,,BAO_0000019
14906,,0,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,,,Adrenal cortex,1235.0,,1,,A,CHEMBL629893,22224,,U,Autocuration,,BAO_0000019
14907,,0,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629894,22224,,U,Autocuration,,BAO_0000019
14908,,0,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,,,,,,1,,A,CHEMBL629895,22224,,U,Autocuration,,BAO_0000019
14909,,0,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",Canis lupus familiaris,,,,,,1,9615.0,A,CHEMBL875109,22224,,U,Autocuration,,BAO_0000218
14910,,0,Absolute bioavailability in male cynomolgus monkeys,Macaca fascicularis,,,,,,1,9541.0,A,CHEMBL629896,22224,,U,Autocuration,,BAO_0000218
14911,,0,Absolute bioavailability in maleSprague-Dawley rats,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL629897,22224,,U,Autocuration,,BAO_0000218
14912,,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL629898,50597,,N,Intermediate,,BAO_0000218
14913,,1,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL630057,50597,,N,Intermediate,,BAO_0000218
14914,,1,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,A,CHEMBL630058,50597,,N,Intermediate,,BAO_0000218
14915,,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630059,50597,,N,Intermediate,,BAO_0000218
14916,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630060,50597,,N,Intermediate,,BAO_0000218
14917,,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630061,50597,,N,Intermediate,,BAO_0000218
14918,,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630062,50597,,N,Intermediate,,BAO_0000218
14919,,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630063,50597,,N,Intermediate,,BAO_0000218
14920,,1,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630064,50597,,N,Intermediate,,BAO_0000218
14921,,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630065,50597,,N,Intermediate,,BAO_0000218
14922,,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630066,50597,,N,Intermediate,,BAO_0000218
14923,,1,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630067,50597,,N,Intermediate,,BAO_0000218
14924,,1,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Lung,2048.0,,1,10116.0,A,CHEMBL630068,50597,,N,Intermediate,,BAO_0000218
14925,,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631113,50597,,N,Intermediate,,BAO_0000218
14926,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631114,50597,,N,Intermediate,,BAO_0000218
14927,,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631115,50597,,N,Intermediate,,BAO_0000218
14928,,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL631116,50597,,N,Intermediate,,BAO_0000218
14929,,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630528,50597,,N,Intermediate,,BAO_0000218
14930,,1,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630529,50597,,N,Intermediate,,BAO_0000218
14931,,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630530,50597,,N,Intermediate,,BAO_0000218
14932,,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630531,50597,,N,Intermediate,,BAO_0000218
14933,,1,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630532,50597,,N,Intermediate,,BAO_0000218
14934,,1,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Muscle tissue,2385.0,,1,10116.0,A,CHEMBL630533,50597,,N,Intermediate,,BAO_0000218
14935,,1,Biodistribution in normal mice blood after 120 hr,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL630534,50594,,N,Intermediate,,BAO_0000218
14936,,1,Biodistribution in normal mice blood after 24 hr,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL630535,50594,,N,Intermediate,,BAO_0000218
14937,,1,Biodistribution in normal mice blood after 4 hr,Mus musculus,,,Blood,178.0,,1,10090.0,A,CHEMBL630536,50594,,N,Intermediate,,BAO_0000218
14938,,1,Biodistribution in normal mice bone after 120 hr,Mus musculus,,,Bone,10000001.0,,1,10090.0,A,CHEMBL630537,50594,,N,Intermediate,,BAO_0000218
14939,,1,Biodistribution in normal mice bone after 24 hr,Mus musculus,,,Bone,10000001.0,,1,10090.0,A,CHEMBL630538,50594,,N,Intermediate,,BAO_0000218
14940,,1,Biodistribution in normal mice bone after 4 hr,Mus musculus,,,Bone,10000001.0,,1,10090.0,A,CHEMBL630539,50594,,N,Intermediate,,BAO_0000218
14941,,1,Biodistribution in normal mice heart after 120 hr,Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL630540,50594,,N,Intermediate,,BAO_0000218
14942,,1,Biodistribution in normal mice heart after 24 hr,Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL630541,50594,,N,Intermediate,,BAO_0000218
14943,,1,Biodistribution in normal mice heart after 4 hr,Mus musculus,,,Heart,948.0,,1,10090.0,A,CHEMBL630542,50594,,N,Intermediate,,BAO_0000218
14944,,1,Biodistribution in normal mice kidney after 120 hr,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630543,50594,,N,Intermediate,,BAO_0000218
14945,,1,Biodistribution in normal mice kidney after 24 hr,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630544,50594,,N,Intermediate,,BAO_0000218
14946,,1,Biodistribution in normal mice kidney after 4 hr,Mus musculus,,,Kidney,2113.0,,1,10090.0,A,CHEMBL630545,50594,,N,Intermediate,,BAO_0000218
14947,,1,Biodistribution in normal mice liver after 120 hr,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL630546,50594,,N,Intermediate,,BAO_0000218
14948,,1,Biodistribution in normal mice liver after 24 hr,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL630547,50594,,N,Intermediate,,BAO_0000218
14949,,1,Biodistribution in normal mice liver after 4 hr,Mus musculus,,,Liver,2107.0,,1,10090.0,A,CHEMBL630548,50594,,N,Intermediate,,BAO_0000218
14950,,1,Biodistribution in normal mice spleen after 120 hr,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL630549,50594,,N,Intermediate,,BAO_0000218
14951,,1,Biodistribution in normal mice spleen after 24 hr,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL630550,50594,,N,Intermediate,,BAO_0000218
14952,,1,Biodistribution in normal mice spleen after 4 hr,Mus musculus,,,Spleen,2106.0,,1,10090.0,A,CHEMBL876426,50594,,N,Intermediate,,BAO_0000218
14953,,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630551,50597,,N,Intermediate,,BAO_0000218
14954,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630552,50597,,N,Intermediate,,BAO_0000218
14955,,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630553,50597,,N,Intermediate,,BAO_0000218
14956,,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630554,50597,,N,Intermediate,,BAO_0000218
14957,,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630555,50597,,N,Intermediate,,BAO_0000218
14958,,1,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630556,50597,,N,Intermediate,,BAO_0000218
14959,,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630557,50597,,N,Intermediate,,BAO_0000218
14960,,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630558,50597,,N,Intermediate,,BAO_0000218
14961,,1,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630559,50597,,N,Intermediate,,BAO_0000218
14962,,1,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Spleen,2106.0,,1,10116.0,A,CHEMBL630560,50597,,N,Intermediate,,BAO_0000218
14963,,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Rattus norvegicus,,,Thyroid gland,2046.0,,1,10116.0,A,CHEMBL876427,50597,,N,Intermediate,,BAO_0000218
14964,,1,The Kel values in female wistar rats.,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL630561,50597,,N,Intermediate,,BAO_0000218
14965,,0,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,,,,,,1,,A,CHEMBL630562,22224,,U,Autocuration,,BAO_0000019
14966,,0,Hydrolysis rate constant of the compound,,,,,,,1,,A,CHEMBL630563,22224,,U,Autocuration,,BAO_0000019
14967,,0,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,,,,,,1,,P,CHEMBL629673,22229,,U,Autocuration,,BAO_0000100
14968,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,,,,,,1,,A,CHEMBL629674,22224,,U,Autocuration,,BAO_0000019
14969,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,,,,,,1,,A,CHEMBL629675,22224,,U,Autocuration,,BAO_0000019
14970,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,,,,,,1,,A,CHEMBL629676,22224,,U,Autocuration,,BAO_0000019
14971,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,,,,,,1,,A,CHEMBL629677,22224,,U,Autocuration,,BAO_0000019
14972,,0,Apparent inactivation rate constant was evaluated,,,,,,,1,,A,CHEMBL629678,22224,,U,Autocuration,,BAO_0000019
14973,,0,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,,,,,,1,,A,CHEMBL629679,22224,,U,Autocuration,,BAO_0000019
14974,,0,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,,,,,,1,,A,CHEMBL629680,22224,,U,Autocuration,,BAO_0000019
14975,,0,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,,,,,,1,,A,CHEMBL629681,22224,,U,Autocuration,,BAO_0000019
14976,,0,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,,,,,,1,,A,CHEMBL629682,22224,,U,Autocuration,,BAO_0000019
14977,,0,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,,,,,,1,,A,CHEMBL629683,22224,,U,Autocuration,,BAO_0000019
14978,,0,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,,,,,,1,,F,CHEMBL629684,22224,,U,Autocuration,,BAO_0000019
14979,,0,Dissociation constant was determined,,,,,,,1,,P,CHEMBL629685,22224,,U,Autocuration,,BAO_0000100
14980,,0,Dissociation constant was determined,,,,,,,1,,P,CHEMBL629686,22224,,U,Autocuration,,BAO_0000100
14981,,0,Dissociation constant at pH 7.4,,,,,,,1,,P,CHEMBL872932,22224,,U,Autocuration,,BAO_0000100
14982,,0,Dissociation constant in presence of 1 mM dithiothreitol,,,,,,,1,,P,CHEMBL629687,22224,,U,Autocuration,,BAO_0000100
14983,,0,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,1,,A,CHEMBL872931,22224,,U,Autocuration,,BAO_0000019
14984,,0,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,,,,,,1,,A,CHEMBL628151,22224,,U,Autocuration,,BAO_0000019
14985,,0,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,1,,A,CHEMBL628152,22224,,U,Autocuration,,BAO_0000019
14986,,0,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,,,,,,1,,A,CHEMBL628153,22224,,U,Autocuration,,BAO_0000019
14987,,0,Kinetic constant for aromatization of androstenedione,,,,,,,1,,A,CHEMBL628154,22224,,U,Autocuration,,BAO_0000019
14988,,0,Kinetic constant for aromatization of testosterone,,,,,,,1,,A,CHEMBL628155,22224,,U,Autocuration,,BAO_0000019
14989,,0,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,,,,,,1,,A,CHEMBL628156,22224,,U,Autocuration,,BAO_0000019
14990,,0,Local inhibition constant was determined,,,,,,,1,,A,CHEMBL628157,22224,,U,Autocuration,,BAO_0000019
14991,,1,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,Saccharomyces cerevisiae,,,,,,1,4932.0,A,CHEMBL857533,50347,,N,Intermediate,,BAO_0000218
14992,,0,Dissociation constant value of the compound,,,,,,,1,,P,CHEMBL628158,22224,,U,Autocuration,,BAO_0000100
14993,,0,In vitro permeability through cornea without epithelium,,,,Cornea,964.0,,1,,A,CHEMBL628159,22224,,U,Autocuration,,BAO_0000019
14994,,0,In vitro permeability through intact cornea,,,,Cornea,964.0,,1,,A,CHEMBL875616,22224,,U,Autocuration,,BAO_0000019
14995,,1,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Oryctolagus cuniculus,,,Cornea,964.0,,1,9986.0,A,CHEMBL628160,50592,,N,Intermediate,,BAO_0000218
14996,,0,Rate of enzyme inactivation for the compound was determined,,,,,,,1,,A,CHEMBL628161,22224,,U,Autocuration,,BAO_0000019
14997,,0,In vitro permeability through cornea without epithelium,,,,Cornea,964.0,,1,,A,CHEMBL628162,22224,,U,Autocuration,,BAO_0000019
14998,,0,In vitro permeability through intact cornea,,,,Cornea,964.0,,1,,A,CHEMBL628163,22224,,U,Autocuration,,BAO_0000019
14999,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628164,22224,,U,Autocuration,,BAO_0000019
15000,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628165,22224,,U,Autocuration,,BAO_0000019
15001,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628166,22224,,U,Autocuration,,BAO_0000019
15002,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628167,22224,,U,Autocuration,,BAO_0000019
15003,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628168,22224,,U,Autocuration,,BAO_0000019
15004,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628169,22224,,U,Autocuration,,BAO_0000019
15005,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628170,22224,,U,Autocuration,,BAO_0000019
15006,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628171,22224,,U,Autocuration,,BAO_0000019
15007,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL627434,22224,,U,Autocuration,,BAO_0000019
15008,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL627435,22224,,U,Autocuration,,BAO_0000019
15009,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628110,22224,,U,Autocuration,,BAO_0000019
15010,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628111,22224,,U,Autocuration,,BAO_0000019
15011,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628112,22224,,U,Autocuration,,BAO_0000019
15012,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628260,22224,,U,Autocuration,,BAO_0000019
15013,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,,,,,,1,,A,CHEMBL628261,22224,,U,Autocuration,,BAO_0000019
15014,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL628262,50594,,N,Intermediate,,BAO_0000218
15015,,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,Homo sapiens,,,,,,1,9606.0,A,CHEMBL628263,50587,,N,Intermediate,,BAO_0000218
15016,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL628264,50594,,N,Intermediate,,BAO_0000218
15017,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),Mus musculus,,,,,,1,10090.0,A,CHEMBL628265,50594,,N,Intermediate,,BAO_0000218
15018,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL628266,50594,,N,Intermediate,,BAO_0000218
15019,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL628267,50594,,N,Intermediate,,BAO_0000218
15020,,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,Mus musculus,,,,,,1,10090.0,A,CHEMBL628268,50594,,N,Intermediate,,BAO_0000218
15021,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),Mus musculus,,,,,,1,10090.0,A,CHEMBL628269,50594,,N,Intermediate,,BAO_0000218
15022,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),Mus musculus,,,,,,1,10090.0,A,CHEMBL628270,50594,,N,Intermediate,,BAO_0000218
15023,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),Mus musculus,,,,,,1,10090.0,A,CHEMBL628271,50594,,N,Intermediate,,BAO_0000218
15024,,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),Mus musculus,,,,,,1,10090.0,A,CHEMBL628272,50594,,N,Intermediate,,BAO_0000218
1,,8,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,,,,,,1,,B,CHEMBL615117,12052,,H,Autocuration,,BAO_0000019
2,,0,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,,,,,,1,,F,CHEMBL615118,22226,,U,Autocuration,,BAO_0000219
3,,0,,,,,,,,1,,B,CHEMBL615119,22226,,U,Autocuration,,BAO_0000019
4,,4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Bos taurus,,,,,,1,9913.0,B,CHEMBL615120,104729,,H,Autocuration,,BAO_0000249
5,,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615121,80001,,N,Intermediate,,BAO_0000219
6,,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615122,80001,,N,Intermediate,,BAO_0000219
7,,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Mus musculus,,,,,163.0,1,10090.0,F,CHEMBL615123,80001,,N,Intermediate,,BAO_0000219
8,,1,In vitro cell cytotoxicity was determined against 143B cell line,Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615124,80001,,N,Expert,,BAO_0000219
9,,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615125,80001,,N,Intermediate,,BAO_0000219
10,,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615126,80001,,N,Intermediate,,BAO_0000219
11,,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615127,80001,,N,Intermediate,,BAO_0000219
12,,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Homo sapiens,,,,,163.0,1,9606.0,F,CHEMBL615128,80001,,N,Expert,,BAO_0000219
13,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,,,,,,1,1280.0,F,CHEMBL857900,50185,,N,Intermediate,,BAO_0000218
14,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,,,,,,1,1280.0,F,CHEMBL615129,50185,,N,Intermediate,,BAO_0000218
15,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,,,,,,1,1280.0,F,CHEMBL615130,50185,,N,Intermediate,,BAO_0000218
16,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Staphylococcus aureus,,,,,,1,1280.0,F,CHEMBL615131,50185,,N,Intermediate,,BAO_0000218
17,,9,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL884521,100122,,D,Expert,,BAO_0000357
18,,8,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,1,,B,CHEMBL615132,12054,,H,Autocuration,,BAO_0000357
19,,8,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,,,,,,1,,B,CHEMBL615133,12054,,H,Autocuration,,BAO_0000019
20,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,1,,B,CHEMBL615134,12054,,H,Autocuration,,BAO_0000357
21,,8,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,1,,B,CHEMBL615135,12054,,H,Autocuration,,BAO_0000357
22,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,,,,,,1,,B,CHEMBL615136,12054,,H,Autocuration,,BAO_0000357
23,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,1,,B,CHEMBL615137,12054,,H,Autocuration,,BAO_0000357
24,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,,,,,,1,,B,CHEMBL615138,12054,,H,Autocuration,,BAO_0000357
25,,0,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,,,,,,1,,B,CHEMBL836324,22226,,U,Autocuration,,BAO_0000219
26,,8,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615139,12054,,H,Autocuration,,BAO_0000357
27,,8,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615140,12054,,H,Autocuration,,BAO_0000357
28,,8,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,,,,,,1,,B,CHEMBL615141,12426,,H,Autocuration,,BAO_0000219
29,,8,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,soya bean,,,,,,1,3847.0,B,CHEMBL615142,12054,,H,Autocuration,,BAO_0000357
30,,8,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Glycine max,,,,,,1,3847.0,B,CHEMBL615143,12054,,H,Autocuration,,BAO_0000357
31,,8,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Glycine max,,,,,,1,3847.0,B,CHEMBL615144,12054,,H,Autocuration,,BAO_0000357
32,,8,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Glycine max,,,,,,1,3847.0,B,CHEMBL872867,12054,,H,Autocuration,,BAO_0000357
33,,8,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Glycine max,,,,,,1,3847.0,B,CHEMBL615145,12054,,H,Autocuration,,BAO_0000357
34,,8,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,,,,,,1,3847.0,B,CHEMBL615146,12054,,H,Autocuration,,BAO_0000357
35,,8,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Glycine max,,,,,,1,3847.0,B,CHEMBL615147,12054,,H,Autocuration,,BAO_0000357
36,,0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL615148,22226,,U,Autocuration,,BAO_0000019
37,,0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Escherichia coli,,,,,,1,562.0,B,CHEMBL615149,22226,,U,Autocuration,,BAO_0000019
38,,0,Dissociation constant with dimeric 16S rRNA RNA construct B,,,,,,,1,,B,CHEMBL615150,22226,,U,Autocuration,,BAO_0000019
39,,3,Dissociation constant towards 16S rRNA construct A,,,,,,,1,,B,CHEMBL615151,22222,,M,Intermediate,,BAO_0000225
40,,3,Dissociation constant towards 16S rRNA construct B,,,,,,,1,,B,CHEMBL615152,22222,,M,Intermediate,,BAO_0000225
41,,3,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL615153,100263,,M,Expert,,BAO_0000225
42,,3,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL615154,100263,,M,Expert,,BAO_0000225
43,,8,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,1,,B,CHEMBL615155,13053,,H,Autocuration,,BAO_0000019
44,,8,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,1,,B,CHEMBL615156,13053,,H,Autocuration,,BAO_0000019
45,,8,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615157,20001,,H,Autocuration,,BAO_0000019
46,,8,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615158,20001,,H,Autocuration,,BAO_0000019
47,,9,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615159,12971,,D,Expert,,BAO_0000019
48,,9,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615172,12971,,D,Expert,,BAO_0000019
49,,9,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615173,12971,,D,Expert,,BAO_0000019
50,,9,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615174,12971,,D,Expert,,BAO_0000019
51,,8,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,,,,,,1,,B,CHEMBL884518,13053,,H,Autocuration,,BAO_0000019
52,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,,,,,,1,,B,CHEMBL615175,11512,,H,Autocuration,,BAO_0000357
53,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,,,,,,1,,B,CHEMBL615176,11512,,H,Autocuration,,BAO_0000357
54,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,,,,,,1,,B,CHEMBL615177,11512,,H,Autocuration,,BAO_0000357
55,Membranes,5,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615178,104740,,D,Autocuration,,BAO_0000249
56,,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615179,80002,,N,Intermediate,,BAO_0000219
57,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615180,104835,,D,Autocuration,,BAO_0000219
58,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615181,104821,,D,Autocuration,,BAO_0000219
59,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615182,104848,,D,Autocuration,,BAO_0000219
60,,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615183,80002,,N,Expert,,BAO_0000219
61,,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615184,80002,,N,Intermediate,,BAO_0000219
62,,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615185,80002,,N,Intermediate,,BAO_0000219
63,,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615186,80002,,N,Intermediate,,BAO_0000219
64,,1,Effective dose of compound against replication of 1A9 cell line was evaluated,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615187,80002,,N,Intermediate,,BAO_0000219
65,,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL885343,80002,,N,Expert,,BAO_0000219
66,,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615188,80002,,N,Intermediate,,BAO_0000219
67,,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615189,80002,,N,Intermediate,,BAO_0000219
68,,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615190,80002,,N,Intermediate,,BAO_0000219
69,,1,Inhibitory activity against Taxol resistant 1A9 cell lines,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615191,80002,,N,Intermediate,,BAO_0000219
70,,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615192,80002,,N,Expert,,BAO_0000219
71,,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL827083,80002,,N,Expert,,BAO_0000219
72,,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615193,80002,,N,Expert,,BAO_0000219
73,,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615194,80002,,N,Intermediate,,BAO_0000219
74,,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615195,80002,,N,Intermediate,,BAO_0000219
75,,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Homo sapiens,,,,,506.0,1,9606.0,F,CHEMBL615196,80002,,N,Intermediate,,BAO_0000219
76,,1,Inhibitory concentration against Jurkat cells,Homo sapiens,,,,,503.0,1,9606.0,F,CHEMBL615197,81072,,N,Intermediate,,BAO_0000219
77,,0,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,,,,,,1,,F,CHEMBL615198,22226,,U,Intermediate,,BAO_0000019
78,,9,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Rattus norvegicus,,,,,,1,10116.0,A,CHEMBL615199,100121,,D,Expert,,BAO_0000357
79,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,1,,B,CHEMBL615200,11231,,H,Expert,,BAO_0000357
80,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,,,,,,1,,B,CHEMBL615201,11231,,H,Expert,,BAO_0000357
81,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,,,,,,1,,B,CHEMBL615202,11231,,H,Expert,,BAO_0000357
82,Microsomes,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Candida albicans,,,,,,1,5476.0,B,CHEMBL615203,11231,,H,Autocuration,,BAO_0000251
83,Microsomes,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Candida albicans,,,,,,1,5476.0,B,CHEMBL615204,11231,,H,Autocuration,,BAO_0000251
84,Microsomes,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,,,,,,1,4932.0,B,CHEMBL615205,11231,,H,Autocuration,,BAO_0000251
85,Microsomes,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Saccharomyces cerevisiae,,,,,,1,4932.0,B,CHEMBL615206,11231,,H,Autocuration,,BAO_0000251
86,Microsomes,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Sus scrofa,,,Liver,2107.0,,1,9823.0,B,CHEMBL615207,12083,,H,Autocuration,,BAO_0000251
87,,8,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL827084,11231,,H,Autocuration,,BAO_0000019
88,,8,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615208,11231,,H,Autocuration,,BAO_0000019
89,,8,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615209,11231,,H,Autocuration,,BAO_0000019
90,Microsomes,9,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615210,12083,,D,Autocuration,,BAO_0000251
91,Microsomes,9,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615211,12083,,D,Autocuration,,BAO_0000251
92,Microsomes,9,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615212,12083,,D,Autocuration,,BAO_0000251
93,,8,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,,,,,,1,,B,CHEMBL615213,11377,,H,Expert,,BAO_0000357
94,,8,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,,,,,,1,,B,CHEMBL615273,11377,,H,Expert,,BAO_0000357
95,,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615274,81020,,N,Expert,,BAO_0000219
96,,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615275,81020,,N,Intermediate,,BAO_0000219
97,,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615276,81020,,N,Intermediate,,BAO_0000219
98,,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615277,81020,,N,Intermediate,,BAO_0000219
99,,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615326,81020,,N,Intermediate,,BAO_0000219
100,,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Hepatitis B virus,,,,,,1,10407.0,F,CHEMBL883130,50606,,N,Expert,,BAO_0000218
101,,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL884519,81020,,N,Intermediate,,BAO_0000219
102,,1,Concentration required to inhibit 50% of 2.2.15 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615327,81020,,N,Intermediate,,BAO_0000219
103,,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Homo sapiens,,,,,726.0,1,9606.0,A,CHEMBL615328,81020,,N,Intermediate,,BAO_0000219
104,,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615329,50587,,N,Intermediate,,BAO_0000218
105,,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615330,50587,,N,Intermediate,,BAO_0000218
106,,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Hepatitis B virus,,,,,,1,10407.0,F,CHEMBL615331,50606,,N,Expert,,BAO_0000218
107,,1,In vitro anti-HBV activity in 2.2.15 cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615332,50587,,N,Intermediate,,BAO_0000218
108,,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615333,50587,,N,Intermediate,,BAO_0000218
109,,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615334,50587,,N,Intermediate,,BAO_0000218
110,,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615335,50587,,N,Intermediate,,BAO_0000218
111,,1,Cytotoxicity in 2.2.15 cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615336,50587,,N,Intermediate,,BAO_0000218
112,,1,Cytotoxicity in 2.2.15 cells; Not determined,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615337,50587,,N,Intermediate,,BAO_0000218
113,,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615338,50587,,N,Intermediate,,BAO_0000218
114,,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615339,50587,,N,Intermediate,,BAO_0000218
115,,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615340,50587,,N,Intermediate,,BAO_0000218
116,,1,Antiviral activity against HBV was determined in 2.215 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615341,81020,,N,Intermediate,,BAO_0000219
117,Microsomes,0,Inhibition of 20-HETE synthesis in human renal microsomes,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615342,22226,,U,Autocuration,,BAO_0000251
118,,0,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,,,,,,1,,B,CHEMBL615343,22226,,U,Autocuration,,BAO_0000019
119,,1,Inhibitory concentration against 2008 (ovarian) cells,Homo sapiens,,,,,388.0,1,9606.0,F,CHEMBL615344,80612,,N,Intermediate,,BAO_0000219
120,,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Homo sapiens,,,,,388.0,1,9606.0,F,CHEMBL615345,80612,,N,Intermediate,,BAO_0000219
121,,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Homo sapiens,,,,,388.0,1,9606.0,F,CHEMBL615346,80612,,N,Intermediate,,BAO_0000219
122,,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Homo sapiens,,,,,388.0,1,9606.0,F,CHEMBL615347,80612,,N,Intermediate,,BAO_0000219
123,,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Homo sapiens,,,,,388.0,1,9606.0,F,CHEMBL615348,80612,,N,Intermediate,,BAO_0000219
124,,1,In vitro inhibition of 2008/R ovarian cancer cell line,Homo sapiens,,,,,561.0,1,9606.0,F,CHEMBL827085,80613,,N,Intermediate,,BAO_0000219
125,,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Homo sapiens,,,,,561.0,1,9606.0,F,CHEMBL615349,80613,,N,Intermediate,,BAO_0000219
126,,1,In vitro inhibition of 2008/S ovarian cancer cell line,Homo sapiens,,,,,389.0,1,9606.0,F,CHEMBL615350,80614,,N,Intermediate,,BAO_0000219
127,,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Homo sapiens,,,,,389.0,1,9606.0,F,CHEMBL615351,80614,,N,Intermediate,,BAO_0000219
128,,2,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615352,100256,,S,Expert,,BAO_0000220
129,,2,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615353,100256,,S,Intermediate,,BAO_0000220
130,,2,Inhibition of chymotrypsin-like activity of 20S proteasome,,,,,,,1,,B,CHEMBL615354,100256,,S,Expert,,BAO_0000220
131,,2,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,,,,,,1,,B,CHEMBL615355,100256,,S,Expert,,BAO_0000220
132,,2,Inhibitory activity against 20S proteosome,,,,,,,1,,B,CHEMBL615356,100256,,S,Intermediate,,BAO_0000220
133,,0,Compound was tested for inhibitory activity against tryptase,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615357,22226,,U,Autocuration,,BAO_0000019
134,,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL615358,81020,,N,Intermediate,,BAO_0000219
135,,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Homo sapiens,,,,,726.0,1,9606.0,F,CHEMBL827086,81020,,N,Intermediate,,BAO_0000219
136,,0,Compound was tested for the inhibition of Alpha-glucosidase,,,,,,,1,,B,CHEMBL615359,22226,,U,Autocuration,,BAO_0000019
137,,8,Inhibitory concentration against human neutrophil elastase (HNE),,,,,,,1,,B,CHEMBL615360,235,,H,Autocuration,,BAO_0000357
138,,0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Rattus norvegicus,,,Heart,948.0,,1,10116.0,F,CHEMBL615361,22226,,U,Autocuration,,BAO_0000218
139,,8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,1,,F,CHEMBL615362,19640,,H,Autocuration,,BAO_0000019
140,,8,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,1,,F,CHEMBL615363,19640,,H,Expert,,BAO_0000019
141,,8,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,1,,B,CHEMBL615364,19640,,H,Autocuration,,BAO_0000357
142,,8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,,,,,,1,,F,CHEMBL615365,19640,,H,Expert,,BAO_0000019
143,,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Mus musculus,,,,,524.0,1,10090.0,F,CHEMBL615366,80360,,N,Intermediate,,BAO_0000219
144,,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Mus musculus,,,,,524.0,1,10090.0,F,CHEMBL615367,80360,,N,Intermediate,,BAO_0000219
145,,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Homo sapiens,,,,,554.0,1,9606.0,F,CHEMBL615368,80384,,N,Intermediate,,BAO_0000219
146,,0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Ovis aries,,,,,,1,9940.0,F,CHEMBL615369,22226,,U,Autocuration,,BAO_0000019
147,,0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Ovis aries,,,,,,1,9940.0,F,CHEMBL615370,22226,,U,Autocuration,,BAO_0000019
148,,8,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,,,,,,1,,B,CHEMBL615673,191,,H,Autocuration,,BAO_0000357
149,,0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615674,22226,,U,Autocuration,,BAO_0000019
150,,0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615675,22226,,U,Autocuration,,BAO_0000019
151,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Homo sapiens,,,,,635.0,1,9606.0,F,CHEMBL615676,22226,,U,Autocuration,,BAO_0000219
152,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Homo sapiens,,,,,635.0,1,9606.0,F,CHEMBL615677,22226,,U,Autocuration,,BAO_0000219
153,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Homo sapiens,,,,,635.0,1,9606.0,F,CHEMBL615678,22226,,U,Autocuration,,BAO_0000219
154,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Homo sapiens,,,,,635.0,1,9606.0,F,CHEMBL615679,22226,,U,Autocuration,,BAO_0000219
155,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615680,22226,,U,Autocuration,,BAO_0000019
156,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615681,22226,,U,Autocuration,,BAO_0000019
157,,6,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,,,,,,1,,B,CHEMBL857972,104290,,H,Autocuration,,BAO_0000249
158,,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Streptococcus pyogenes,,,,,,1,1314.0,F,CHEMBL857899,50264,,N,Intermediate,,BAO_0000218
159,,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Human herpesvirus 3,,,,,,1,10335.0,F,CHEMBL615371,50527,,N,Intermediate,,BAO_0000218
160,,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,vericilla zoster virus,,,,,468.0,1,10335.0,F,CHEMBL615372,50527,,N,Expert,,BAO_0000218
161,,1,Antiviral activity against 07/1 strain of VZV; ND: No data,vericilla zoster virus,,,,,,1,10335.0,F,CHEMBL615373,50527,,N,Intermediate,,BAO_0000218
162,,1,Antiviral activity against 07/1 strain of VZV; ND=No data,vericilla zoster virus,,,,,,1,10335.0,F,CHEMBL615374,50527,,N,Intermediate,,BAO_0000218
163,,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",escherichia cloac,,,,,,1,561.0,F,CHEMBL615375,50145,,N,Intermediate,,BAO_0000218
164,,0,Ratio of Ki at A2 to Ki at A1 receptors,,,,,,,1,,B,CHEMBL615376,22226,,U,Autocuration,,BAO_0000019
165,,8,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Candida albicans,,,,,,1,5476.0,B,CHEMBL615377,11143,,H,Expert,,BAO_0000249
166,,8,"Inhibition of 1,3-beta-glucan synthase",Candida glabrata CBS 138,,,,,,1,284593.0,B,CHEMBL615378,18077,,H,Expert,,BAO_0000357
167,,1,Inhibition of growth of 1-87 human tumor cell line,Homo sapiens,,,,,832.0,1,9606.0,F,CHEMBL615379,80609,,N,Intermediate,,BAO_0000219
168,,9,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615380,12166,,D,Expert,,BAO_0000219
169,,9,Inhibitory activity against soybean 1-lipoxygenase (SLO),Glycine max,,,,,,1,3847.0,B,CHEMBL615381,100171,,D,Autocuration,,BAO_0000357
170,,9,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Glycine max,,,,,,1,3847.0,B,CHEMBL615382,100171,,D,Autocuration,,BAO_0000357
171,,9,% inhibition against soybean 1-lipoxygenase (SLO),Glycine max,,,,,,1,3847.0,B,CHEMBL615383,100171,,D,Autocuration,,BAO_0000357
172,,9,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Glycine max,,,,,,1,3847.0,B,CHEMBL615384,100171,,D,Autocuration,,BAO_0000357
173,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Glycine max,,,,,,1,3847.0,B,CHEMBL615385,100171,,D,Autocuration,,BAO_0000357
174,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Glycine max,,,,,,1,3847.0,B,CHEMBL615386,100171,,D,Autocuration,,BAO_0000357
175,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Glycine max,,,,,,1,3847.0,B,CHEMBL615387,100171,,D,Autocuration,,BAO_0000357
176,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Glycine max,,,,,,1,3847.0,B,CHEMBL615388,100171,,D,Autocuration,,BAO_0000357
177,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Glycine max,,,,,,1,3847.0,B,CHEMBL615214,100171,,D,Autocuration,,BAO_0000357
178,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Glycine max,,,,,,1,3847.0,B,CHEMBL827087,100171,,D,Autocuration,,BAO_0000357
179,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Glycine max,,,,,,1,3847.0,B,CHEMBL615215,100171,,D,Autocuration,,BAO_0000357
180,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Glycine max,,,,,,1,3847.0,B,CHEMBL615216,100171,,D,Autocuration,,BAO_0000357
181,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Glycine max,,,,,,1,3847.0,B,CHEMBL615217,100171,,D,Autocuration,,BAO_0000357
182,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Glycine max,,,,,,1,3847.0,B,CHEMBL615218,100171,,D,Autocuration,,BAO_0000357
183,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Glycine max,,,,,,1,3847.0,B,CHEMBL615219,100171,,D,Autocuration,,BAO_0000357
184,,0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Mus musculus,,,,,,1,10090.0,B,CHEMBL615220,22226,,U,Autocuration,,BAO_0000019
185,,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Mus musculus,,,,,294.0,1,10090.0,F,CHEMBL615221,80049,,N,Intermediate,,BAO_0000219
186,,0,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,,,,,,1,,F,CHEMBL615222,22226,,U,Intermediate,,BAO_0000019
187,,8,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,1,,B,CHEMBL615223,11489,,H,Autocuration,,BAO_0000357
188,,8,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,,,,,,1,,B,CHEMBL615224,11862,,H,Autocuration,,BAO_0000357
189,,8,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,,,,,,1,,B,CHEMBL615225,11862,,H,Autocuration,,BAO_0000357
190,,8,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,,,,,,1,,B,CHEMBL615226,11489,,H,Autocuration,,BAO_0000357
191,,8,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,,,,,,1,,B,CHEMBL615227,11862,,H,Autocuration,,BAO_0000357
192,,9,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Bos taurus,,,,,,1,9913.0,F,CHEMBL615228,12347,,D,Expert,,BAO_0000019
193,,9,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615229,100120,,D,Expert,,BAO_0000357
194,,9,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Rattus norvegicus,,,Adrenal gland,2369.0,,1,10116.0,B,CHEMBL615230,100120,,D,Expert,,BAO_0000357
195,,9,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615231,100120,,D,Expert,,BAO_0000357
196,,9,Inhibition of rat adrenal 11-beta-hydroxylase,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL884520,100120,,D,Expert,,BAO_0000357
197,,9,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615232,100120,,D,Expert,,BAO_0000357
198,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,,,,,,1,,B,CHEMBL615233,10328,,H,Autocuration,,BAO_0000019
199,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,1,,B,CHEMBL827088,11490,,H,Autocuration,,BAO_0000357
200,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,,,,,,1,,B,CHEMBL615234,11490,,H,Autocuration,,BAO_0000357
201,,8,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,,,,,,1,,F,CHEMBL615235,11134,,H,Autocuration,,BAO_0000019
202,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,1,,B,CHEMBL615236,12052,,H,Autocuration,,BAO_0000019
203,,8,Compound was tested in vitro for inhibition of 12-LO human platelet,,,,,,,1,,B,CHEMBL615237,11134,,H,Autocuration,,BAO_0000019
204,,8,Inhibitory concentration against human platelet 12-lipoxygenase,,,,,,,1,,F,CHEMBL615238,11134,,H,Autocuration,,BAO_0000019
205,,8,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,,,,,,1,,B,CHEMBL615239,11134,,H,Autocuration,,BAO_0000019
206,,9,Inhibitory concentration against human platelet 12-lipoxygenase,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615240,11134,,D,Autocuration,,BAO_0000019
207,,8,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,,,,,,1,,B,CHEMBL615241,11835,,H,Expert,,BAO_0000019
208,,8,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,,,,,,1,,B,CHEMBL615242,11601,,H,Expert,,BAO_0000357
209,,8,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,,,,,,1,,B,CHEMBL615243,11134,,H,Autocuration,,BAO_0000019
210,,8,Inhibitory activity against human platelet 12-lipoxygenase,,,,,,,1,,B,CHEMBL615244,11134,,H,Autocuration,,BAO_0000019
211,,8,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,,,,,,1,,B,CHEMBL615245,11134,,H,Autocuration,,BAO_0000019
212,,8,% inhibition against human platelet 12-lipoxygenase (12-HLO),,,,,,,1,,B,CHEMBL615246,11134,,H,Autocuration,,BAO_0000019
213,,8,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,,,,,,1,,B,CHEMBL615247,11134,,H,Autocuration,,BAO_0000019
214,,8,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,,,,,,1,,B,CHEMBL615248,11134,,H,Autocuration,,BAO_0000019
215,,8,Inhibitory activity towards porcine 12-lipoxygenase,,,,,,,1,,B,CHEMBL615249,11601,,H,Autocuration,,BAO_0000357
216,,8,Tested for inhibition against porcine 12-LO,,,,,,,1,,B,CHEMBL615250,11601,,H,Autocuration,,BAO_0000357
217,,8,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,,,,,,1,,B,CHEMBL615251,12052,,H,Autocuration,,BAO_0000019
218,,8,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,,,,,,1,,B,CHEMBL615252,12052,,H,Autocuration,,BAO_0000019
219,,8,In vitro inhibition of rat platelet 12-lipoxygenase,,,,,,,1,,B,CHEMBL828340,12052,,H,Expert,,BAO_0000019
220,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,1,,B,CHEMBL615253,12052,,H,Autocuration,,BAO_0000019
221,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,,,,,,1,,B,CHEMBL615254,12052,,H,Autocuration,,BAO_0000019
222,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,,,,,,1,,B,CHEMBL615255,12052,,H,Autocuration,,BAO_0000019
223,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,,,,,,1,,B,CHEMBL615256,12052,,H,Autocuration,,BAO_0000019
224,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,,,,,,1,,B,CHEMBL615257,12052,,H,Autocuration,,BAO_0000019
225,,8,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,,,,,,1,,B,CHEMBL615258,12052,,H,Autocuration,,BAO_0000019
226,,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615259,80007,,N,Intermediate,,BAO_0000219
227,,1,In vitro antitumor activity against 41M cell line.,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615260,80007,,N,Expert,,BAO_0000219
228,,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615261,80007,,N,Intermediate,,BAO_0000219
229,,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615262,80007,,N,Intermediate,,BAO_0000219
230,,1,In vitro antitumor activity against 41McisR cell line.,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615263,80007,,N,Expert,,BAO_0000219
231,,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL838393,80007,,N,Expert,,BAO_0000219
232,,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Homo sapiens,,,,,621.0,1,9606.0,F,CHEMBL615264,80007,,N,Intermediate,,BAO_0000219
233,,9,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Homo sapiens,,,,,,1,9606.0,B,CHEMBL615265,84,,D,Expert,,BAO_0000357
234,,9,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Homo sapiens,,,,,,1,9606.0,B,CHEMBL615266,68,,D,Expert,,BAO_0000357
235,,8,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,,,,,,1,,B,CHEMBL615267,68,,H,Expert,,BAO_0000357
236,,8,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,1,,B,CHEMBL615268,10201,,H,Expert,,BAO_0000357
237,,8,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,,,,,,1,,B,CHEMBL615269,10201,,H,Expert,,BAO_0000357
238,,8,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,,,,,,1,,B,CHEMBL615270,10201,,H,Expert,,BAO_0000357
239,,8,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,1,,B,CHEMBL615271,12220,,H,Autocuration,,BAO_0000357
240,,8,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,,,,,,1,562.0,B,CHEMBL615272,11303,,H,Autocuration,,BAO_0000357
241,,8,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Escherichia coli,,,,,,1,562.0,B,CHEMBL615103,11303,,H,Autocuration,,BAO_0000357
242,,8,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Escherichia coli,,,,,,1,562.0,B,CHEMBL615104,11303,,H,Autocuration,,BAO_0000357
243,,8,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,,,,,,1,,B,CHEMBL615105,12220,,H,Autocuration,,BAO_0000357
244,,8,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,,,,,,1,,B,CHEMBL872866,12220,,H,Autocuration,,BAO_0000357
245,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615106,11303,,H,Autocuration,,BAO_0000357
246,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615107,11303,,H,Autocuration,,BAO_0000019
247,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615108,11303,,H,Autocuration,,BAO_0000357
248,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615109,11303,,H,Autocuration,,BAO_0000357
249,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615110,11303,,H,Autocuration,,BAO_0000357
250,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL840105,11303,,H,Autocuration,,BAO_0000019
251,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615111,11303,,H,Autocuration,,BAO_0000019
252,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615112,11303,,H,Autocuration,,BAO_0000019
253,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615113,11303,,H,Autocuration,,BAO_0000019
254,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615114,11303,,H,Autocuration,,BAO_0000019
255,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615115,11303,,H,Autocuration,,BAO_0000357
256,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615116,11303,,H,Autocuration,,BAO_0000019
257,,8,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,,,,,,1,,B,CHEMBL615698,11303,,H,Autocuration,,BAO_0000357
258,,0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615699,22226,,U,Autocuration,,BAO_0000019
259,,0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Sus scrofa,,,,,,1,9823.0,B,CHEMBL615700,22226,,U,Autocuration,,BAO_0000019
260,,8,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Saccharomyces cerevisiae,,,,,,1,4932.0,B,CHEMBL615701,100249,,H,Expert,,BAO_0000357
261,,0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615702,22226,,U,Autocuration,,BAO_0000019
262,,0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615703,22226,,U,Autocuration,,BAO_0000019
263,,0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615704,22226,,U,Autocuration,,BAO_0000019
264,,6,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,1,,F,CHEMBL615705,104698,,H,Autocuration,,BAO_0000019
265,,6,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,,,,,,1,,F,CHEMBL615706,104698,,H,Autocuration,,BAO_0000019
266,,9,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL615707,20033,,D,Intermediate,,BAO_0000221
267,,8,Stimulatory activity of intragastric pressure was tested in the rat,,,,,,,1,,F,CHEMBL615708,10623,,H,Expert,,BAO_0000019
268,,8,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,,,,,,1,,B,CHEMBL615709,121,,H,Autocuration,,BAO_0000357
269,,0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615710,22226,,U,Autocuration,,BAO_0000218
270,,8,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,1,,F,CHEMBL615711,12688,,H,Autocuration,,BAO_0000019
271,,9,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615712,121,,D,Expert,,BAO_0000357
272,,9,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Homo sapiens,,,,,,1,9606.0,B,CHEMBL836325,121,,D,Expert,,BAO_0000357
273,,8,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,,,,,,1,,F,CHEMBL615713,12198,,H,Autocuration,,BAO_0000019
274,,8,Inhibition constant of high-affinity 5-HT uptake,,,,,,,1,,B,CHEMBL615714,12198,,H,Autocuration,,BAO_0000357
275,,8,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,,,,,,1,,F,CHEMBL615715,12198,,H,Autocuration,,BAO_0000019
276,,8,Maximum rate was determined for high affinity transport of 5-HT,,,,,,,1,,F,CHEMBL615716,12198,,H,Autocuration,,BAO_0000019
277,,4,Compound was tested for agonistic activity against 5-HT uptake,,,,,,,1,,F,CHEMBL615717,104714,,H,Autocuration,,BAO_0000019
278,,8,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,,,,,,1,,B,CHEMBL881818,10577,,H,Expert,,BAO_0000019
279,,8,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Bos taurus,,,,,,1,9913.0,B,CHEMBL884540,105,,H,Expert,,BAO_0000357
280,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615718,104744,,D,Autocuration,,BAO_0000224
281,,4,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL615719,104744,,H,Autocuration,,BAO_0000224
282,Membranes,4,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,,,,,,1,,B,CHEMBL615720,104744,,H,Autocuration,,BAO_0000249
283,Membranes,4,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,,,,,,1,,B,CHEMBL615721,104744,,H,Autocuration,,BAO_0000249
284,,4,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL615722,104744,,H,Autocuration,,BAO_0000019
285,,8,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,,,,,,1,,F,CHEMBL615723,51,,H,Autocuration,,BAO_0000019
286,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615724,51,,H,Autocuration,,BAO_0000221
287,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615725,51,,H,Autocuration,,BAO_0000221
288,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615726,51,,H,Autocuration,,BAO_0000221
289,,8,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,,,,,,1,,F,CHEMBL615727,10576,,H,Autocuration,,BAO_0000218
290,,9,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL615728,105570,,D,Intermediate,,BAO_0000019
291,,8,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL857971,279,,H,Autocuration,,BAO_0000219
292,,8,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL615729,107,,H,Autocuration,,BAO_0000357
293,,9,Efficacy against 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615730,12687,,D,Expert,,BAO_0000019
294,,8,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,,,,,,1,,F,CHEMBL615731,12687,,H,Expert,,BAO_0000019
295,,8,Relative potency towards 5-HT2A receptor of rat tail artery,,,,,,,1,,F,CHEMBL615732,12687,,H,Expert,,BAO_0000019
296,,8,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,1,,F,CHEMBL615733,12687,,H,Expert,,BAO_0000019
297,,8,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,,,,,,1,,F,CHEMBL615734,12687,,H,Expert,,BAO_0000019
298,,8,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,,,,,,1,,F,CHEMBL615735,12687,,H,Autocuration,,BAO_0000019
299,,8,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,,,,,,1,,F,CHEMBL615736,12687,,H,Expert,,BAO_0000019
300,,9,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL615737,20033,,D,Intermediate,,BAO_0000221
301,,9,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL615738,20033,,D,Intermediate,,BAO_0000221
302,,9,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL615739,20033,,D,Intermediate,,BAO_0000221
303,,8,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,,,,,,1,,B,CHEMBL615278,10623,,H,Autocuration,,BAO_0000357
304,,9,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615279,10623,,D,Expert,,BAO_0000019
305,,8,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL615280,168,,H,Expert,,BAO_0000357
306,,0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Gallus gallus,,,,,,1,9031.0,B,CHEMBL615281,22226,,U,Autocuration,,BAO_0000019
307,,0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615282,22226,,U,Autocuration,,BAO_0000019
308,,0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615283,22226,,U,Autocuration,,BAO_0000019
309,,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Homo sapiens,,,,,649.0,1,9606.0,B,CHEMBL615284,80156,,N,Autocuration,,BAO_0000219
310,,0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615285,22226,,U,Autocuration,,BAO_0000019
311,,0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615286,22226,,U,Autocuration,,BAO_0000019
312,,7,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615287,104703,,D,Autocuration,,BAO_0000219
313,,2,Chymotryptic inhibitory activity against 26S proteasome,,,,,,,1,,F,CHEMBL615288,100256,,S,Intermediate,,BAO_0000220
314,,2,Inhibitory activity against 26S proteasome degradation of IkB,,,,,,,1,,B,CHEMBL615289,100256,,S,Intermediate,,BAO_0000220
315,,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,Homo sapiens,,,,,478.0,1,9606.0,F,CHEMBL615290,81034,,N,Intermediate,,BAO_0000219
316,,1,In vitro inhibition of 2780/S ovarian cancer cell line,Homo sapiens,,,,,478.0,1,9606.0,F,CHEMBL884522,81034,,N,Intermediate,,BAO_0000219
317,,0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615291,22226,,U,Autocuration,,BAO_0000019
318,,3,Association constant for binding to AATT 28-mer AATT hairpin,,,,,,,1,,B,CHEMBL615292,22222,,M,Intermediate,,BAO_0000225
319,,3,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,,,,,,1,,B,CHEMBL615293,22222,,M,Intermediate,,BAO_0000225
320,,3,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,1,,B,CHEMBL615294,22222,,M,Intermediate,,BAO_0000225
321,,3,Reaction Rate Parameter for 28-mer AATT hairpin,,,,,,,1,,B,CHEMBL615295,22222,,M,Intermediate,,BAO_0000225
322,,0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Homo sapiens,,,,,,1,9606.0,F,CHEMBL825021,22226,,U,Autocuration,,BAO_0000019
323,,0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Homo sapiens,,,,,,1,9606.0,F,CHEMBL615296,22226,,U,Autocuration,,BAO_0000019
324,,0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615297,22226,,U,Autocuration,,BAO_0000019
325,,0,Cytotoxicity against cell line 2SC/20 determined by MTT test,Cricetulus griseus,,,,,,1,10029.0,F,CHEMBL615298,22226,,U,Autocuration,,BAO_0000019
326,,0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Cricetulus griseus,,,,,,1,10029.0,F,CHEMBL615299,22226,,U,Autocuration,,BAO_0000019
327,,0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Cricetulus griseus,,,,,,1,10029.0,F,CHEMBL615300,22226,,U,Autocuration,,BAO_0000019
328,,8,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,,,,,,1,,B,CHEMBL615301,241,,H,Autocuration,,BAO_0000357
329,,9,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615302,241,,D,Expert,,BAO_0000357
330,,0,Selectivity ratio of ID50 in liver and heart,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615303,22226,,U,Autocuration,,BAO_0000019
331,,8,"Selectivity, ratio of relative ID50 in liver and heart",,,,,,,1,,B,CHEMBL615304,12132,,H,Autocuration,,BAO_0000019
332,,8,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,,,,,,1,,B,CHEMBL615305,12132,,H,Autocuration,,BAO_0000019
333,,8,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615306,12132,,H,Autocuration,,BAO_0000218
334,,8,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615307,12132,,H,Autocuration,,BAO_0000218
335,,8,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615308,12132,,H,Autocuration,,BAO_0000218
336,,8,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,F,CHEMBL615309,12132,,H,Autocuration,,BAO_0000218
337,,0,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,,,,,,1,,B,CHEMBL615310,22226,,U,Autocuration,,BAO_0000019
338,,8,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,,,,,,1,,B,CHEMBL615311,12132,,H,Autocuration,,BAO_0000019
339,,0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Homo sapiens,,,,,,1,9606.0,B,CHEMBL615312,22226,,U,Autocuration,,BAO_0000019
340,,8,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,1,,B,CHEMBL615313,12132,,H,Autocuration,,BAO_0000019
341,,8,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,,,,,,1,,F,CHEMBL615314,12132,,H,Autocuration,,BAO_0000019
342,,8,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615315,12132,,H,Autocuration,,BAO_0000019
343,,0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615316,22226,,U,Autocuration,,BAO_0000218
344,,8,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,,,,,,1,,B,CHEMBL615317,12132,,H,Autocuration,,BAO_0000218
345,,8,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615318,12132,,H,Autocuration,,BAO_0000218
346,,0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615319,22226,,U,Autocuration,,BAO_0000218
347,,8,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,B,CHEMBL615320,12132,,H,Autocuration,,BAO_0000019
348,,8,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,,,,,,1,,F,CHEMBL615321,12132,,H,Autocuration,,BAO_0000019
349,,0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615322,22226,,U,Autocuration,,BAO_0000019
350,,8,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL615323,19690,,H,Autocuration,,BAO_0000357
351,,8,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL615407,19690,,H,Autocuration,,BAO_0000357
352,,8,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL857267,19690,,H,Autocuration,,BAO_0000357
353,,8,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Escherichia coli,,,,,,1,562.0,B,CHEMBL615408,19690,,H,Autocuration,,BAO_0000357
354,,8,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,,,,,,1,,B,CHEMBL615409,19690,,H,Autocuration,,BAO_0000357
355,,8,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,,,,,,1,,B,CHEMBL615410,19690,,H,Autocuration,,BAO_0000357
356,,8,Inhibition constant against 3-dehydroquinate synthase,,,,,,,1,,B,CHEMBL615411,19690,,H,Autocuration,,BAO_0000357
357,,8,Association rate constant against 3-dehydroquinate synthase,,,,,,,1,,B,CHEMBL615412,19690,,H,Autocuration,,BAO_0000357
358,,8,Rate constant against 3-dehydroquinate synthase,,,,,,,1,,B,CHEMBL615413,19690,,H,Autocuration,,BAO_0000357
359,,0,Inhibitory activity against fuc-TVII,,,,,,,1,,B,CHEMBL615414,22226,,U,Autocuration,,BAO_0000019
360,Microsomes,9,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615415,12236,,D,Autocuration,,BAO_0000251
361,Microsomes,9,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615416,12236,,D,Autocuration,,BAO_0000251
362,Microsomes,9,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615417,12236,,D,Autocuration,,BAO_0000251
363,Microsomes,9,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615418,12236,,D,Autocuration,,BAO_0000251
364,Microsomes,9,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615419,12236,,D,Autocuration,,BAO_0000251
365,Microsomes,9,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615420,12236,,D,Autocuration,,BAO_0000251
366,Microsomes,9,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615421,12236,,D,Autocuration,,BAO_0000251
367,Microsomes,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615422,12236,,D,Autocuration,,BAO_0000251
368,Microsomes,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615423,12236,,D,Autocuration,,BAO_0000251
369,Microsomes,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL872868,12236,,D,Autocuration,,BAO_0000251
370,Microsomes,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Rattus norvegicus,,,Liver,2107.0,,1,10116.0,B,CHEMBL615424,12236,,D,Autocuration,,BAO_0000251
371,,4,Inhibitory activity against 3-phosphoglycerate kinase.,,,,,,,1,,B,CHEMBL825022,104832,,H,Autocuration,,BAO_0000224
372,,4,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,,,,,,1,,B,CHEMBL615425,104832,,H,Autocuration,,BAO_0000224
373,,4,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,,,,,,1,,B,CHEMBL615426,104832,,H,Autocuration,,BAO_0000224
374,,9,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615427,10612,,D,Expert,,BAO_0000357
375,,1,Cytotoxicity on 3677 melanoma cells,Homo sapiens,,,,,844.0,1,9606.0,F,CHEMBL615428,80616,,N,Intermediate,,BAO_0000219
376,,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Homo sapiens,,,,,844.0,1,9606.0,F,CHEMBL615429,80616,,N,Intermediate,,BAO_0000219
377,,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Mus musculus,,,,,700.0,1,10090.0,F,CHEMBL615430,80617,,N,Intermediate,,BAO_0000219
378,,0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615431,22226,,U,Intermediate,,BAO_0000019
379,,0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,,,,,798.0,1,,F,CHEMBL615432,22226,,U,Autocuration,,BAO_0000218
380,,0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,,,,,798.0,1,,F,CHEMBL615433,22226,,U,Autocuration,,BAO_0000218
381,,9,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Human rhinovirus 14,,,,,,1,12131.0,F,CHEMBL615434,12464,,D,Expert,,BAO_0000019
382,,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Human rhinovirus sp.,,,,,,1,169066.0,F,CHEMBL615435,50085,,N,Intermediate,,BAO_0000218
383,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,human rhinovirus type 14,,,,,,1,169066.0,F,CHEMBL615436,50679,,N,Intermediate,,BAO_0000218
384,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,human rhinovirus type 14,,,,,,1,169066.0,F,CHEMBL615437,50679,,N,Intermediate,,BAO_0000218
385,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,,,,,,1,12131.0,F,CHEMBL615438,12464,,D,Expert,,BAO_0000019
386,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,,,,,,1,12131.0,F,CHEMBL615439,12464,,D,Expert,,BAO_0000019
387,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Human rhinovirus 14,,,,,,1,12131.0,F,CHEMBL615440,12464,,D,Expert,,BAO_0000019
388,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Human rhinovirus 14,,,,,,1,12131.0,F,CHEMBL615441,12464,,D,Expert,,BAO_0000019
389,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Enterovirus,,,,,,1,12059.0,F,CHEMBL615641,50665,,N,Intermediate,,BAO_0000218
390,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Enterovirus,,,,,,1,12059.0,F,CHEMBL872065,50665,,N,Intermediate,,BAO_0000218
391,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Enterovirus,,,,,,1,12059.0,F,CHEMBL825023,50665,,N,Intermediate,,BAO_0000218
392,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Enterovirus,,,,,,1,12059.0,F,CHEMBL615642,50665,,N,Intermediate,,BAO_0000218
393,,8,Inhibition of human rhinovirus 3C protease,Human rhinovirus B,,,,,,1,147712.0,B,CHEMBL615643,12464,,H,Expert,,BAO_0000357
394,,0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615644,22226,,U,Autocuration,,BAO_0000019
395,,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615645,80619,,N,Intermediate,,BAO_0000218
396,,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615646,80619,,N,Intermediate,,BAO_0000218
397,,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615647,80619,,N,Intermediate,,BAO_0000218
398,,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615648,80619,,N,Intermediate,,BAO_0000218
399,,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615649,80619,,N,Intermediate,,BAO_0000218
400,,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Mus musculus,,,,,833.0,1,10090.0,F,CHEMBL615650,80619,,N,Intermediate,,BAO_0000218
401,,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615651,80620,,N,Intermediate,,BAO_0000218
402,,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615652,80620,,N,Intermediate,,BAO_0000218
403,,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615653,80620,,N,Expert,,BAO_0000218
404,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615654,80620,,N,Intermediate,,BAO_0000219
405,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615655,80620,,N,Intermediate,,BAO_0000219
406,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL825024,80620,,N,Intermediate,,BAO_0000219
407,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615656,80620,,N,Intermediate,,BAO_0000219
408,,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615657,80620,,N,Intermediate,,BAO_0000219
409,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615658,80620,,N,Intermediate,,BAO_0000219
410,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615659,80620,,N,Intermediate,,BAO_0000219
411,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615660,80620,,N,Intermediate,,BAO_0000219
412,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615661,80620,,N,Intermediate,,BAO_0000219
413,,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615662,80620,,N,Intermediate,,BAO_0000219
414,,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615663,80620,,N,Intermediate,,BAO_0000219
415,,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615664,80620,,N,Intermediate,,BAO_0000219
416,,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615665,80620,,N,Intermediate,,BAO_0000219
417,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615666,80620,,N,Intermediate,,BAO_0000219
418,,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615667,80620,,N,Intermediate,,BAO_0000219
419,,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615668,80620,,N,Intermediate,,BAO_0000219
420,,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615669,80620,,N,Intermediate,,BAO_0000219
421,,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615670,80620,,N,Intermediate,,BAO_0000219
422,,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL836739,80620,,N,Intermediate,,BAO_0000219
423,,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615671,80620,,N,Intermediate,,BAO_0000219
424,,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615672,80620,,N,Intermediate,,BAO_0000219
425,,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615791,80620,,N,Intermediate,,BAO_0000219
426,,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615792,80620,,N,Intermediate,,BAO_0000219
427,,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615793,80620,,N,Intermediate,,BAO_0000219
428,,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615794,80620,,N,Intermediate,,BAO_0000219
429,,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Mus musculus,,,,,847.0,1,10090.0,F,CHEMBL615795,80620,,N,Intermediate,,BAO_0000219
430,,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Homo sapiens,,,,,971.0,1,9606.0,F,CHEMBL615590,80621,,N,Intermediate,,BAO_0000219
431,,0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,,,,,,1,,F,CHEMBL615591,22226,,U,Autocuration,,BAO_0000218
432,,0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,,,,,,1,,F,CHEMBL615592,22226,,U,Autocuration,,BAO_0000218
433,,0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,,,,,,1,,F,CHEMBL615593,22226,,U,Autocuration,,BAO_0000218
434,,0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,,,,,,1,,F,CHEMBL615594,22226,,U,Autocuration,,BAO_0000218
435,,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615595,80951,,N,Intermediate,,BAO_0000219
436,,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615596,80951,,N,Intermediate,,BAO_0000219
437,,8,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,,,,,723.0,1,,F,CHEMBL615597,11169,,H,Expert,,BAO_0000219
438,,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615598,80951,,N,Intermediate,,BAO_0000219
439,,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615599,80951,,N,Intermediate,,BAO_0000219
440,,1,Effective dose against murine 3T3 fibroblasts cells,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615600,80951,,N,Expert,,BAO_0000219
441,,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615601,80951,,N,Expert,,BAO_0000219
442,,1,Cytotoxic effect on 3T3 cells,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615602,80951,,N,Expert,,BAO_0000219
443,,1,Cytotoxic effect on 3T3 cells,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615603,80951,,N,Expert,,BAO_0000219
444,,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615604,80951,,N,Intermediate,,BAO_0000219
445,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615605,80951,,N,Intermediate,,BAO_0000219
446,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615606,80951,,N,Intermediate,,BAO_0000219
447,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL884526,80951,,N,Expert,,BAO_0000219
448,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615607,80951,,N,Expert,,BAO_0000219
449,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615608,80951,,N,Intermediate,,BAO_0000219
450,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615609,80951,,N,Expert,,BAO_0000219
451,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615682,80951,,N,Expert,,BAO_0000219
452,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615683,80951,,N,Intermediate,,BAO_0000219
453,,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615684,80951,,N,Expert,,BAO_0000218
454,,7,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Mus musculus,,,,,,1,10090.0,F,CHEMBL615685,104860,,D,Autocuration,,BAO_0000219
455,,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615686,80951,,N,Expert,,BAO_0000219
456,,1,Inhibitory activity against 3T3 cell line,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615687,80951,,N,Intermediate,,BAO_0000219
457,,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL884523,80951,,N,Intermediate,,BAO_0000219
458,,8,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,,,,,,1,,F,CHEMBL615688,11169,,H,Expert,,BAO_0000019
459,,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615689,80951,,N,Intermediate,,BAO_0000219
460,,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615690,80951,,N,Intermediate,,BAO_0000219
461,,8,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,,,,,,1,,F,CHEMBL615691,11169,,H,Expert,,BAO_0000019
462,,8,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,,,,,,1,,F,CHEMBL615692,11169,,H,Expert,,BAO_0000019
463,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615693,80951,,N,Intermediate,,BAO_0000219
464,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615324,80951,,N,Expert,,BAO_0000219
465,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Homo sapiens,,,,,723.0,1,9606.0,F,CHEMBL615325,9,,D,Expert,,BAO_0000219
466,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Homo sapiens,,,,,723.0,1,9606.0,F,CHEMBL615490,9,,D,Expert,,BAO_0000219
467,,9,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Homo sapiens,,,,,723.0,1,9606.0,F,CHEMBL615491,188,,D,Expert,,BAO_0000219
468,,9,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Homo sapiens,,,,,723.0,1,9606.0,F,CHEMBL615492,188,,D,Expert,,BAO_0000219
469,,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615493,80951,,N,Intermediate,,BAO_0000219
470,,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615494,80951,,N,Intermediate,,BAO_0000219
471,,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615495,80951,,N,Intermediate,,BAO_0000219
472,,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615496,80951,,N,Intermediate,,BAO_0000219
473,,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615497,80951,,N,Intermediate,,BAO_0000219
474,,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615498,80951,,N,Expert,,BAO_0000219
475,,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Mus musculus,,,,,723.0,1,10090.0,A,CHEMBL615499,80951,,N,Intermediate,,BAO_0000219
476,,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL835522,80951,,N,Expert,,BAO_0000219
477,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615500,80951,,N,Intermediate,,BAO_0000219
478,,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615501,80951,,N,Intermediate,,BAO_0000219
479,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615502,80951,,N,Intermediate,,BAO_0000219
480,,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615503,80951,,N,Intermediate,,BAO_0000219
481,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615504,80951,,N,Intermediate,,BAO_0000219
482,,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615505,80951,,N,Intermediate,,BAO_0000219
483,,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615506,80951,,N,Expert,,BAO_0000219
484,,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Mus musculus,,,,,723.0,1,10090.0,F,CHEMBL615507,80951,,N,Intermediate,,BAO_0000219
485,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,620.0,1,,F,CHEMBL615508,80006,,N,Intermediate,,BAO_0000218
486,,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615509,80006,,N,Intermediate,,BAO_0000219
487,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615510,80006,,N,Intermediate,,BAO_0000219
488,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615511,80006,,N,Intermediate,,BAO_0000219
489,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615512,80006,,N,Intermediate,,BAO_0000219
490,,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615513,80006,,N,Intermediate,,BAO_0000218
491,,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615514,80006,,N,Intermediate,,BAO_0000218
492,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,,,,,620.0,1,,F,CHEMBL615515,80006,,N,Intermediate,,BAO_0000219
493,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,,620.0,1,,F,CHEMBL615516,80006,,N,Intermediate,,BAO_0000219
494,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,620.0,1,,F,CHEMBL615517,80006,,N,Intermediate,,BAO_0000219
495,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,,620.0,1,,F,CHEMBL615518,80006,,N,Intermediate,,BAO_0000219
496,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,620.0,1,,F,CHEMBL615519,80006,,N,Intermediate,,BAO_0000219
497,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,,,,,620.0,1,,F,CHEMBL615520,80006,,N,Intermediate,,BAO_0000218
498,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,,,,,620.0,1,,F,CHEMBL615521,80006,,N,Intermediate,,BAO_0000218
499,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,,620.0,1,,F,CHEMBL615522,80006,,N,Intermediate,,BAO_0000218
500,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,620.0,1,,F,CHEMBL615523,80006,,N,Intermediate,,BAO_0000218
501,,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,,620.0,1,,F,CHEMBL615524,80006,,N,Expert,,BAO_0000218
502,,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,620.0,1,,F,CHEMBL615525,80006,,N,Expert,,BAO_0000218
503,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,,,,,620.0,1,,F,CHEMBL615526,80006,,N,Intermediate,,BAO_0000218
504,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,620.0,1,,F,CHEMBL615527,80006,,N,Intermediate,,BAO_0000218
505,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,,,,,620.0,1,,F,CHEMBL615528,80006,,N,Intermediate,,BAO_0000218
506,,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,620.0,1,,F,CHEMBL615529,80006,,N,Expert,,BAO_0000218
507,,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,620.0,1,,F,CHEMBL615530,80006,,N,Expert,,BAO_0000218
508,,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,,620.0,1,,F,CHEMBL615531,80006,,N,Expert,,BAO_0000218
509,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,,,,,620.0,1,,F,CHEMBL615532,80006,,N,Intermediate,,BAO_0000219
510,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,,,,,620.0,1,,F,CHEMBL615533,80006,,N,Intermediate,,BAO_0000219
511,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,,,,,620.0,1,,F,CHEMBL615534,80006,,N,Intermediate,,BAO_0000219
512,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,,,,,620.0,1,,F,CHEMBL615535,80006,,N,Intermediate,,BAO_0000218
513,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,,,,,620.0,1,,F,CHEMBL615536,80006,,N,Intermediate,,BAO_0000218
514,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,,,,,620.0,1,,F,CHEMBL615537,80006,,N,Intermediate,,BAO_0000218
515,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,,,,,620.0,1,,F,CHEMBL615538,80006,,N,Intermediate,,BAO_0000218
516,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,,,,,620.0,1,,F,CHEMBL836166,80006,,N,Intermediate,,BAO_0000218
517,,8,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,,,,,620.0,1,,F,CHEMBL615539,11214,,H,Expert,,BAO_0000219
518,,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615540,80006,,N,Intermediate,,BAO_0000219
519,,8,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,,,,,620.0,1,,F,CHEMBL615541,11214,,H,Expert,,BAO_0000219
520,,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615542,80006,,N,Expert,,BAO_0000219
521,,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615543,80006,,N,Intermediate,,BAO_0000219
522,,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615544,80006,,N,Expert,,BAO_0000219
523,,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615545,80006,,N,Expert,,BAO_0000219
524,,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615546,80006,,N,Expert,,BAO_0000219
525,,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615547,80006,,N,Expert,,BAO_0000219
526,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615548,80006,,N,Expert,,BAO_0000219
527,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615549,80006,,N,Expert,,BAO_0000219
528,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Mus musculus,,,,,620.0,1,10090.0,F,CHEMBL615550,80006,,N,Expert,,BAO_0000219
529,,1,Inhibitory activity against rat fibroblast (3Y1) cell line,Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615551,80622,,N,Intermediate,,BAO_0000219
530,,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615552,80622,,N,Expert,,BAO_0000219
531,,1,Cytotoxicity in 3Y1 cells.,Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615553,80622,,N,Expert,,BAO_0000219
532,,1,Cytostatic effect in 3Y1 cells.,Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615554,80622,,N,Expert,,BAO_0000219
533,,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615555,80622,,N,Intermediate,,BAO_0000219
534,,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Rattus norvegicus,,,,,1118.0,1,10116.0,F,CHEMBL615556,80622,,N,Expert,,BAO_0000219
535,,0,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,,,,,,1,,B,CHEMBL615557,22226,,U,Autocuration,,BAO_0000019
536,,0,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,1,,B,CHEMBL615558,22226,,U,Autocuration,,BAO_0000019
537,,0,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,,,,,,1,,B,CHEMBL872066,22226,,U,Autocuration,,BAO_0000019
538,,9,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Sus scrofa,,,,,,1,9823.0,B,CHEMBL615559,11607,,D,Expert,,BAO_0000019
539,,8,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,,,,,,1,,B,CHEMBL615560,11607,,H,Autocuration,,BAO_0000019
540,,8,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,,,,,,1,,B,CHEMBL615561,11607,,H,Autocuration,,BAO_0000019
541,,8,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,,,,,,1,,B,CHEMBL857062,11607,,H,Expert,,BAO_0000019
542,,8,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,,,,,,1,,B,CHEMBL615562,11607,,H,Expert,,BAO_0000019
543,,8,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,,,,,,1,,B,CHEMBL615563,11607,,H,Autocuration,,BAO_0000019
544,,8,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,,,,,,1,,B,CHEMBL615564,11607,,H,Autocuration,,BAO_0000357
545,,8,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,,,,,,1,,B,CHEMBL615565,11607,,H,Autocuration,,BAO_0000019
546,,8,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,,,,,,1,,B,CHEMBL615566,11607,,H,Autocuration,,BAO_0000019
547,,9,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Sus scrofa,,,,,,1,9823.0,B,CHEMBL615567,11607,,D,Expert,,BAO_0000019
548,,8,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,,,,,,1,,B,CHEMBL615568,11607,,H,Autocuration,,BAO_0000019
549,,8,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,,,,,,1,,B,CHEMBL615569,11607,,H,Autocuration,,BAO_0000357
550,,8,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,,,,,,1,,B,CHEMBL615570,11607,,H,Autocuration,,BAO_0000019
551,,8,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,,,,,,1,,B,CHEMBL615571,11607,,H,Autocuration,,BAO_0000019
552,,4,Binding affinity against melatonin (MT1) receptor (pC1),,,,,,,1,,B,CHEMBL615572,104733,,H,Autocuration,,BAO_0000224
553,,0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615573,22226,,U,Autocuration,,BAO_0000019
554,,0,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,,,,,,1,,B,CHEMBL615574,22226,,U,Autocuration,,BAO_0000019
555,,0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,,,,,,1,,B,CHEMBL615575,22226,,U,Autocuration,,BAO_0000019
556,,8,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,,,,,,1,,B,CHEMBL615576,10619,,H,Autocuration,,BAO_0000357
557,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL615577,10619,,H,Autocuration,,BAO_0000357
558,,8,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615578,51,,H,Autocuration,,BAO_0000221
559,,8,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615579,51,,H,Expert,,BAO_0000357
560,,8,Binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615580,51,,H,Expert,,BAO_0000357
561,,8,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,,,,,,1,,B,CHEMBL615581,51,,H,Expert,,BAO_0000019
562,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615582,51,,H,Autocuration,,BAO_0000221
563,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615583,51,,H,Autocuration,,BAO_0000221
564,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615584,51,,H,Autocuration,,BAO_0000221
565,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL833691,51,,H,Autocuration,,BAO_0000221
566,,8,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615585,51,,H,Autocuration,,BAO_0000221
567,,8,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615586,51,,H,Autocuration,,BAO_0000221
568,,8,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL884524,51,,H,Autocuration,,BAO_0000221
569,,8,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615587,51,,H,Autocuration,,BAO_0000221
570,,8,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,Hippocampus,10000000.0,,1,,B,CHEMBL615588,51,,H,Autocuration,,BAO_0000221
571,Membranes,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615589,10576,,D,Expert,,BAO_0000249
572,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Bos taurus,,,Hippocampus,10000000.0,,1,9913.0,B,CHEMBL615442,51,,H,Expert,,BAO_0000221
573,,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615443,51,,H,Autocuration,,BAO_0000221
574,,8,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615444,51,,H,Autocuration,,BAO_0000221
575,,8,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615445,51,,H,Expert,,BAO_0000221
576,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615446,51,,H,Autocuration,,BAO_0000221
577,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,,,,,449.0,1,,B,CHEMBL615447,51,,H,Autocuration,,BAO_0000219
578,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615448,51,,H,Expert,,BAO_0000221
579,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615449,51,,H,Expert,,BAO_0000221
580,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL615450,51,,H,Autocuration,,BAO_0000219
581,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,,,Hippocampus,10000000.0,,1,,B,CHEMBL615451,51,,H,Expert,,BAO_0000221
582,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,1,,B,CHEMBL615452,51,,H,Autocuration,,BAO_0000357
583,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615453,51,,H,Autocuration,,BAO_0000221
584,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615454,51,,H,Autocuration,,BAO_0000221
585,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615455,51,,H,Autocuration,,BAO_0000221
586,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615456,51,,H,Autocuration,,BAO_0000221
587,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615457,51,,H,Autocuration,,BAO_0000221
588,,8,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615458,51,,H,Expert,,BAO_0000218
589,,8,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615459,51,,H,Expert,,BAO_0000221
590,,9,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL615460,51,,D,Expert,,BAO_0000219
591,,8,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL615461,51,,H,Autocuration,,BAO_0000019
592,,8,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL615462,51,,H,Autocuration,,BAO_0000019
593,,8,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Cavia porcellus,,,Hippocampus,10000000.0,,1,10141.0,F,CHEMBL615463,51,,H,Autocuration,,BAO_0000221
594,,8,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615464,51,,H,Autocuration,,BAO_0000221
595,,8,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615465,51,,H,Autocuration,,BAO_0000221
596,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615466,51,,H,Autocuration,,BAO_0000221
597,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615467,51,,H,Autocuration,,BAO_0000221
598,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615468,51,,H,Autocuration,,BAO_0000221
599,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL615469,51,,H,Autocuration,,BAO_0000221
600,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL615470,51,,H,Autocuration,,BAO_0000357
601,,8,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL615471,51,,H,Autocuration,,BAO_0000357
602,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL615472,51,,H,Autocuration,,BAO_0000357
603,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,,,Hippocampus,10000000.0,,1,10141.0,B,CHEMBL883242,106,,H,Autocuration,,BAO_0000221
604,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Cavia porcellus,,,Hippocampus,10000000.0,,1,10141.0,F,CHEMBL615473,106,,H,Autocuration,,BAO_0000221
605,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Cricetulus griseus,,,,,449.0,1,10029.0,B,CHEMBL615474,11863,,H,Autocuration,,BAO_0000218
606,,8,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615475,51,,H,Autocuration,,BAO_0000357
607,,8,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,,,,,308.0,1,,F,CHEMBL615476,51,,H,Autocuration,,BAO_0000219
608,,8,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,,,,,308.0,1,,F,CHEMBL615477,51,,H,Autocuration,,BAO_0000219
609,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL615478,51,,H,Autocuration,,BAO_0000019
610,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,F,CHEMBL615160,51,,H,Autocuration,,BAO_0000219
611,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,F,CHEMBL615161,51,,H,Expert,,BAO_0000219
612,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,,,,,449.0,1,,F,CHEMBL615162,51,,H,Autocuration,,BAO_0000219
613,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,,,,,449.0,1,,F,CHEMBL615163,51,,H,Autocuration,,BAO_0000219
614,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL615164,51,,H,Expert,,BAO_0000219
615,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL615165,51,,H,Expert,,BAO_0000219
616,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,,,,,449.0,1,,B,CHEMBL615166,51,,H,Autocuration,,BAO_0000219
617,,8,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,,,,,,1,,F,CHEMBL615167,51,,H,Autocuration,,BAO_0000219
618,,9,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL615168,51,,D,Expert,,BAO_0000219
619,,9,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL615169,51,,D,Expert,,BAO_0000219
620,,9,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL615170,51,,D,Expert,,BAO_0000219
621,,9,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL615171,51,,D,Expert,,BAO_0000219
622,,8,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL615694,51,,H,Autocuration,,BAO_0000019
623,,8,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL615695,51,,H,Autocuration,,BAO_0000019
624,,8,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL615696,51,,H,Autocuration,,BAO_0000019
625,,8,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,449.0,1,,F,CHEMBL615697,51,,H,Autocuration,,BAO_0000219
626,,9,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL859410,51,,D,Expert,,BAO_0000219
627,,8,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,,449.0,1,,F,CHEMBL615841,51,,H,Autocuration,,BAO_0000219
628,,9,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL615842,51,,D,Expert,,BAO_0000219
629,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,449.0,1,,F,CHEMBL835003,51,,H,Autocuration,,BAO_0000219
630,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,,,,,449.0,1,,F,CHEMBL615843,51,,H,Autocuration,,BAO_0000219
631,,9,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL615979,51,,D,Expert,,BAO_0000219
632,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,,,,,449.0,1,,F,CHEMBL615980,51,,H,Autocuration,,BAO_0000219
633,,9,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL615981,51,,D,Expert,,BAO_0000219
634,,9,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Homo sapiens,,,,,,1,9606.0,F,CHEMBL615982,51,,D,Expert,,BAO_0000019
635,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,,,,,,1,9606.0,F,CHEMBL615983,51,,D,Expert,,BAO_0000019
636,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,,,,,,1,9606.0,F,CHEMBL615984,51,,D,Expert,,BAO_0000019
637,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,,,,,,1,9606.0,F,CHEMBL615985,51,,D,Expert,,BAO_0000019
638,,8,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,449.0,1,,F,CHEMBL615986,51,,H,Autocuration,,BAO_0000219
639,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,449.0,1,,F,CHEMBL615987,51,,H,Autocuration,,BAO_0000219
640,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,,449.0,1,,F,CHEMBL615988,51,,H,Autocuration,,BAO_0000219
641,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,,,,,449.0,1,,F,CHEMBL615989,51,,H,Expert,,BAO_0000219
642,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,,,,,449.0,1,,F,CHEMBL615990,51,,H,Autocuration,,BAO_0000219
643,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,,,,,449.0,1,,F,CHEMBL615991,51,,H,Autocuration,,BAO_0000219
644,,8,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,449.0,1,,F,CHEMBL615992,51,,H,Autocuration,,BAO_0000219
645,,8,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,,449.0,1,,F,CHEMBL615993,51,,H,Autocuration,,BAO_0000219
646,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,449.0,1,,F,CHEMBL615994,51,,H,Expert,,BAO_0000219
647,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,,,,,449.0,1,,F,CHEMBL615995,51,,H,Autocuration,,BAO_0000219
648,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,,,,,449.0,1,,F,CHEMBL615996,51,,H,Autocuration,,BAO_0000219
649,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,,,,,449.0,1,,F,CHEMBL615997,51,,H,Autocuration,,BAO_0000219
650,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,1,,F,CHEMBL615998,51,,H,Autocuration,,BAO_0000019
651,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,1,,F,CHEMBL615999,51,,H,Autocuration,,BAO_0000019
652,,8,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,1,,F,CHEMBL616000,51,,H,Autocuration,,BAO_0000019
653,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,722.0,1,,F,CHEMBL616001,51,,H,Autocuration,,BAO_0000219
654,,9,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616002,51,,D,Expert,,BAO_0000019
655,,8,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,,,,,,1,,F,CHEMBL616003,51,,H,Expert,,BAO_0000019
656,,9,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616004,51,,D,Expert,,BAO_0000019
657,,9,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616005,51,,D,Expert,,BAO_0000019
658,,8,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,1,,F,CHEMBL616006,51,,H,Autocuration,,BAO_0000019
659,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,,,,,,1,,F,CHEMBL616007,51,,H,Expert,,BAO_0000019
660,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,1,,F,CHEMBL616008,51,,H,Autocuration,,BAO_0000019
661,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,,,,,,1,,F,CHEMBL616009,51,,H,Autocuration,,BAO_0000019
662,,8,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,,,,,,1,,F,CHEMBL616010,51,,H,Expert,,BAO_0000019
663,,9,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616011,51,,D,Expert,,BAO_0000019
664,,9,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Homo sapiens,,,,,,1,9606.0,F,CHEMBL615740,51,,D,Expert,,BAO_0000019
665,,8,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL615741,51,,H,Autocuration,,BAO_0000019
666,,8,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,1,,F,CHEMBL615742,51,,H,Expert,,BAO_0000019
667,,8,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,,,,,,1,,F,CHEMBL615743,51,,H,Autocuration,,BAO_0000019
668,,8,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,,,,,449.0,1,,F,CHEMBL615744,51,,H,Autocuration,,BAO_0000219
669,,8,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,,,,,449.0,1,,F,CHEMBL615745,51,,H,Expert,,BAO_0000219
670,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL615746,51,,H,Autocuration,,BAO_0000357
671,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL615747,51,,H,Autocuration,,BAO_0000357
672,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,1,,F,CHEMBL615748,51,,H,Autocuration,,BAO_0000019
673,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,,,,,,1,,F,CHEMBL615749,51,,H,Autocuration,,BAO_0000019
674,,8,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,,,,,,1,,F,CHEMBL615750,51,,H,Autocuration,,BAO_0000019
675,,9,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616259,51,,D,Expert,,BAO_0000019
676,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,1,,F,CHEMBL616260,51,,H,Autocuration,,BAO_0000019
677,,9,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616261,51,,D,Expert,,BAO_0000019
678,,9,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616262,51,,D,Expert,,BAO_0000019
679,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616263,51,,D,Expert,,BAO_0000019
680,,9,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616264,51,,D,Expert,,BAO_0000019
681,,9,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616265,51,,D,Expert,,BAO_0000019
682,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616266,51,,D,Expert,,BAO_0000019
683,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616267,51,,D,Expert,,BAO_0000019
684,,9,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616268,51,,D,Expert,,BAO_0000019
685,,9,Inhibition of human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616269,51,,D,Expert,,BAO_0000357
686,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL884528,51,,H,Autocuration,,BAO_0000219
687,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,,,,,722.0,1,,B,CHEMBL616270,105,,D,Expert,,BAO_0000219
688,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616271,51,,H,Autocuration,,BAO_0000219
689,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,F,CHEMBL616272,51,,H,Autocuration,,BAO_0000219
690,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,,,,,,1,,B,CHEMBL616273,51,,H,Expert,,BAO_0000357
691,,9,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616274,51,,D,Expert,,BAO_0000357
692,,8,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL616275,51,,H,Autocuration,,BAO_0000219
693,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL616276,51,,H,Autocuration,,BAO_0000219
694,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616277,22226,,U,Autocuration,,BAO_0000218
695,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616278,22226,,U,Autocuration,,BAO_0000218
696,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616279,22226,,U,Autocuration,,BAO_0000218
697,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616280,22226,,U,Autocuration,,BAO_0000218
698,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616281,22226,,U,Autocuration,,BAO_0000218
699,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616282,22226,,U,Autocuration,,BAO_0000218
700,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616283,22226,,U,Autocuration,,BAO_0000218
701,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616284,22226,,U,Autocuration,,BAO_0000218
702,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616285,22226,,U,Autocuration,,BAO_0000218
703,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616286,22226,,U,Autocuration,,BAO_0000218
704,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616287,22226,,U,Autocuration,,BAO_0000218
705,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616288,22226,,U,Autocuration,,BAO_0000218
706,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616289,22226,,U,Autocuration,,BAO_0000218
707,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615610,22226,,U,Autocuration,,BAO_0000218
708,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615611,22226,,U,Autocuration,,BAO_0000218
709,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615612,22226,,U,Autocuration,,BAO_0000218
710,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615613,22226,,U,Autocuration,,BAO_0000218
711,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615614,22226,,U,Autocuration,,BAO_0000218
712,,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615615,22226,,U,Autocuration,,BAO_0000218
713,,4,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,,,,,,1,,B,CHEMBL615616,105093,,H,Autocuration,,BAO_0000019
714,,8,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,,,Hypothalamus,1898.0,,1,,B,CHEMBL615617,11923,,H,Autocuration,,BAO_0000249
715,,8,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,,,,,,1,,B,CHEMBL615618,10577,,H,Autocuration,,BAO_0000019
716,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,,,,,,1,,B,CHEMBL615619,10577,,H,Autocuration,,BAO_0000019
717,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,,,,,,1,,B,CHEMBL615620,10577,,H,Expert,,BAO_0000019
718,,8,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,,,,,,1,,B,CHEMBL615621,55,,H,Autocuration,,BAO_0000357
719,,8,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,,,,,,1,,B,CHEMBL615622,55,,H,Autocuration,,BAO_0000357
720,,8,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,,,,,,1,,F,CHEMBL615623,12166,,H,Autocuration,,BAO_0000019
721,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,1,,F,CHEMBL615624,12166,,H,Autocuration,,BAO_0000019
722,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,1,,F,CHEMBL615625,12166,,H,Autocuration,,BAO_0000019
723,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,,,,,,1,,F,CHEMBL767045,12166,,H,Autocuration,,BAO_0000019
724,,8,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL615626,55,,H,Autocuration,,BAO_0000019
725,,8,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL615627,55,,H,Autocuration,,BAO_0000019
726,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL615628,55,,H,Autocuration,,BAO_0000019
727,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL615629,55,,H,Autocuration,,BAO_0000357
728,,9,Inhibitory concentration against 5-lipoxygenase from human whole blood,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615630,55,,D,Expert,,BAO_0000357
729,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,,,,,,1,,B,CHEMBL615631,55,,H,Autocuration,,BAO_0000219
730,,8,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,1,,F,CHEMBL615632,17087,,H,Autocuration,,BAO_0000218
731,,8,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,,,,,,1,,B,CHEMBL615633,17087,,H,Autocuration,,BAO_0000357
732,,8,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,,,,,,1,,F,CHEMBL615634,17087,,H,Autocuration,,BAO_0000218
733,,8,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL615635,55,,H,Expert,,BAO_0000019
734,,8,In vitro inhibition of rat 5-Lipoxygenase,,,,,,,1,,B,CHEMBL615636,12166,,H,Expert,,BAO_0000357
735,,9,Inhibitory activity against 5-Lipoxygenase,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615637,12166,,D,Expert,,BAO_0000357
736,,8,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,,,,,702.0,1,,B,CHEMBL615638,12166,,H,Expert,,BAO_0000219
737,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,,,,,702.0,1,,B,CHEMBL615639,12166,,H,Autocuration,,BAO_0000219
738,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,,,,,702.0,1,,B,CHEMBL615640,12166,,H,Autocuration,,BAO_0000219
739,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,,,,,,1,,B,CHEMBL615796,12166,,H,Autocuration,,BAO_0000019
740,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,,,,,,1,,B,CHEMBL615845,12166,,H,Autocuration,,BAO_0000219
741,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,1,,B,CHEMBL615846,12166,,H,Autocuration,,BAO_0000357
742,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,,,,,702.0,1,,B,CHEMBL615847,12166,,H,Autocuration,,BAO_0000219
743,,8,The compound was tested for inhibition of isolated 5-Lipoxygenase,,,,,,,1,,B,CHEMBL615848,12166,,H,Autocuration,,BAO_0000357
744,,0,Ratio of IC50 against 5-LO and COX,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615849,22226,,U,Autocuration,,BAO_0000019
745,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,,,,,,1,,B,CHEMBL615850,12166,,H,Autocuration,,BAO_0000357
746,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,,,,,,1,,B,CHEMBL615851,12166,,H,Autocuration,,BAO_0000357
747,,8,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,,,,,,1,,B,CHEMBL615852,12166,,H,Autocuration,,BAO_0000219
748,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,,,,,,1,,F,CHEMBL615853,12166,,H,Autocuration,,BAO_0000019
749,,8,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,,,Prostate gland,2367.0,,1,,B,CHEMBL884527,120,,H,Autocuration,,BAO_0000357
750,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Columba livia,,,,,,1,8932.0,B,CHEMBL872871,22226,,U,Autocuration,,BAO_0000019
751,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Columba livia,,,,,,1,8932.0,B,CHEMBL615854,22226,,U,Autocuration,,BAO_0000019
752,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Columba livia,,,,,,1,8932.0,B,CHEMBL767046,22226,,U,Autocuration,,BAO_0000019
753,,8,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,,,,,,1,,B,CHEMBL615855,10732,,H,Autocuration,,BAO_0000357
754,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615856,12198,,D,Expert,,BAO_0000019
755,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615857,12198,,D,Expert,,BAO_0000019
756,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615858,12198,,D,Expert,,BAO_0000019
757,,8,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615859,10576,,H,Expert,,BAO_0000221
758,,8,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615860,51,,H,Autocuration,,BAO_0000357
759,,0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615861,22226,,U,Autocuration,,BAO_0000019
760,,0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615862,22226,,U,Autocuration,,BAO_0000019
761,,0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615863,22226,,U,Autocuration,,BAO_0000019
762,,0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL615864,22226,,U,Autocuration,,BAO_0000019
763,,4,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615865,104744,,H,Autocuration,,BAO_0000221
764,,4,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615866,104744,,H,Autocuration,,BAO_0000221
765,,4,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615867,104744,,H,Autocuration,,BAO_0000221
766,Membranes,4,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,,,,,,1,,B,CHEMBL615868,104744,,H,Autocuration,,BAO_0000249
767,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615869,104744,,D,Autocuration,,BAO_0000249
768,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615870,104744,,D,Autocuration,,BAO_0000019
769,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615871,104744,,D,Autocuration,,BAO_0000019
770,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,,,,,,1,,B,CHEMBL615872,104744,,H,Autocuration,,BAO_0000224
771,,4,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL833492,104744,,H,Autocuration,,BAO_0000221
772,,4,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615873,104744,,H,Autocuration,,BAO_0000221
773,,4,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,,,,,,1,,B,CHEMBL615479,104744,,H,Autocuration,,BAO_0000224
774,,4,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,,,,,,1,,B,CHEMBL615480,104744,,H,Autocuration,,BAO_0000019
775,,5,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615481,104744,,D,Autocuration,,BAO_0000249
776,,4,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL872869,104744,,H,Autocuration,,BAO_0000019
777,,4,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL615482,104744,,H,Autocuration,,BAO_0000019
778,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain,955.0,,1,,B,CHEMBL615483,104744,,H,Autocuration,,BAO_0000221
779,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain,955.0,,1,,B,CHEMBL615484,104744,,H,Autocuration,,BAO_0000221
780,,4,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,,,,,,1,,B,CHEMBL615485,104744,,H,Autocuration,,BAO_0000019
781,,5,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615486,104744,,D,Autocuration,,BAO_0000224
782,,4,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615487,104744,,H,Autocuration,,BAO_0000224
783,,4,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615488,104744,,H,Autocuration,,BAO_0000224
784,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615489,104744,,H,Autocuration,,BAO_0000224
785,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615389,104744,,H,Autocuration,,BAO_0000224
786,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL615390,104744,,H,Autocuration,,BAO_0000019
787,,4,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL615391,104744,,H,Autocuration,,BAO_0000019
788,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,,,,,,1,,B,CHEMBL615392,104744,,H,Autocuration,,BAO_0000224
789,,0,Affinity for 5-hydroxytryptamine 1 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615393,22226,,U,Autocuration,,BAO_0000019
790,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,,,Brain,955.0,,1,,B,CHEMBL615394,104744,,H,Autocuration,,BAO_0000221
791,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,,,Brain,955.0,,1,,B,CHEMBL615395,104744,,H,Autocuration,,BAO_0000221
792,,4,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,,,,,,1,,B,CHEMBL615396,104744,,H,Autocuration,,BAO_0000224
793,,4,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,,,Brain,955.0,,1,,B,CHEMBL615397,104744,,H,Autocuration,,BAO_0000221
794,,4,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL615398,104744,,H,Autocuration,,BAO_0000019
795,,0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615399,22226,,U,Autocuration,,BAO_0000019
796,,4,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,,,,,,1,,B,CHEMBL615400,104744,,H,Autocuration,,BAO_0000019
797,,5,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615401,104744,,D,Autocuration,,BAO_0000019
798,,0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615402,22226,,U,Autocuration,,BAO_0000019
799,,4,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,,,,,,1,,B,CHEMBL615403,104744,,H,Autocuration,,BAO_0000019
800,,4,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,,,Brain,955.0,,1,,B,CHEMBL615404,104744,,H,Autocuration,,BAO_0000221
801,,4,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,,,,,,1,,B,CHEMBL615781,104744,,H,Autocuration,,BAO_0000019
802,,4,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,,,Brain,955.0,,1,,B,CHEMBL615782,104744,,H,Autocuration,,BAO_0000220
803,,4,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,,,Brain,955.0,,1,,B,CHEMBL615783,104744,,H,Autocuration,,BAO_0000221
804,,0,Compound was tested for binding affinity against 5-HT1 receptor,,,,,,,1,,B,CHEMBL873481,22226,,U,Autocuration,,BAO_0000019
805,,0,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,,,,,,1,,B,CHEMBL615784,22226,,U,Autocuration,,BAO_0000019
806,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,1,,B,CHEMBL615785,10576,,H,Expert,,BAO_0000357
807,,8,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL615786,10576,,H,Autocuration,,BAO_0000249
808,,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,,,1,,F,CHEMBL615787,10576,,H,Autocuration,,BAO_0000218
809,,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,,,1,,F,CHEMBL615788,10576,,H,Autocuration,,BAO_0000218
810,,8,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL767044,10576,,H,Autocuration,,BAO_0000019
811,,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,,,,,,1,,F,CHEMBL615789,10576,,H,Autocuration,,BAO_0000218
812,,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,,,,,,1,,F,CHEMBL615790,10576,,H,Autocuration,,BAO_0000218
813,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,,,,,,1,,F,CHEMBL615813,10576,,H,Autocuration,,BAO_0000019
814,,8,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,,,,,,1,,F,CHEMBL615814,10576,,H,Autocuration,,BAO_0000219
815,,8,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,,,,,,1,,F,CHEMBL615815,51,,H,Expert,,BAO_0000219
816,,8,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,,,,,,1,,F,CHEMBL615816,10576,,H,Autocuration,,BAO_0000219
817,,8,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,,,,,,1,,B,CHEMBL615817,10576,,H,Expert,,BAO_0000249
818,,8,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615818,10576,,H,Autocuration,,BAO_0000221
819,,8,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615819,10576,,H,Autocuration,,BAO_0000221
820,Membranes,8,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,,,,,,1,,B,CHEMBL615820,10576,,H,Expert,,BAO_0000249
821,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615821,10576,,D,Expert,,BAO_0000221
822,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615822,10576,,D,Expert,,BAO_0000221
823,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615823,10576,,H,Expert,,BAO_0000221
824,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615824,10576,,D,Expert,,BAO_0000221
825,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615825,10576,,D,Expert,,BAO_0000221
826,,8,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615826,10576,,H,Expert,,BAO_0000357
827,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615827,10576,,H,Expert,,BAO_0000249
828,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615828,10576,,H,Expert,,BAO_0000249
829,,8,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615829,10576,,H,Expert,,BAO_0000221
830,,8,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615830,10576,,H,Autocuration,,BAO_0000221
831,,8,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615831,10576,,H,Expert,,BAO_0000221
832,,8,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615832,10576,,H,Autocuration,,BAO_0000357
833,,8,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,,,,,,1,,B,CHEMBL615833,10576,,H,Autocuration,,BAO_0000019
834,,8,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615834,10576,,H,Autocuration,,BAO_0000221
835,,8,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,,,,,,1,,B,CHEMBL615835,10576,,H,Intermediate,,BAO_0000249
836,,8,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615836,10576,,H,Autocuration,,BAO_0000249
837,,9,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615837,10576,,D,Expert,,BAO_0000019
838,,9,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615838,10576,,D,Expert,,BAO_0000019
839,,8,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,,,,,,1,,B,CHEMBL615839,10576,,H,Expert,,BAO_0000249
840,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL884525,10576,,H,Autocuration,,BAO_0000019
841,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,1,,B,CHEMBL615840,10576,,H,Autocuration,,BAO_0000249
842,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615405,10576,,H,Expert,,BAO_0000221
843,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,1,,B,CHEMBL615406,10576,,H,Expert,,BAO_0000019
844,,8,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615900,10576,,H,Expert,,BAO_0000221
845,,8,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615901,10576,,H,Expert,,BAO_0000221
846,,8,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,,,,,,1,,B,CHEMBL615902,10576,,H,Expert,,BAO_0000357
847,,8,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615903,10576,,H,Autocuration,,BAO_0000221
848,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,,,,,,1,,B,CHEMBL615904,10576,,H,Autocuration,,BAO_0000357
849,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,,,,,,1,,B,CHEMBL615905,10576,,H,Expert,,BAO_0000357
850,,8,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,1,,B,CHEMBL615906,10576,,H,Autocuration,,BAO_0000019
851,,8,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,1,,F,CHEMBL615907,10576,,H,Autocuration,,BAO_0000019
852,,8,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL615908,10576,,H,Expert,,BAO_0000019
853,,8,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615909,10576,,H,Autocuration,,BAO_0000221
854,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,,,,,,1,,B,CHEMBL615910,10576,,H,Autocuration,,BAO_0000019
855,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,,,,,,1,,B,CHEMBL615911,10576,,H,Autocuration,,BAO_0000019
856,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,,,,,,1,,B,CHEMBL615912,10576,,H,Autocuration,,BAO_0000019
857,,8,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615913,10576,,H,Expert,,BAO_0000019
858,,8,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL615914,10576,,H,Expert,,BAO_0000357
859,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615915,10576,,H,Autocuration,,BAO_0000221
860,,8,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,,,,,,1,,B,CHEMBL615916,10576,,H,Autocuration,,BAO_0000357
861,,8,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,,,,,,1,,B,CHEMBL615917,10576,,H,Expert,,BAO_0000357
862,,8,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615918,10576,,H,Expert,,BAO_0000357
863,,8,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615919,10576,,H,Expert,,BAO_0000249
864,,9,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615920,10576,,D,Expert,,BAO_0000221
865,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615921,10576,,H,Autocuration,,BAO_0000357
866,,8,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,,,,,,1,,B,CHEMBL615922,10576,,H,Expert,,BAO_0000357
867,,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL881290,10576,,D,Expert,,BAO_0000249
868,,8,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,,,Hippocampus,10000000.0,,1,,B,CHEMBL615923,10576,,H,Autocuration,,BAO_0000221
869,,8,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,F,CHEMBL615924,10576,,H,Autocuration,,BAO_0000221
870,,8,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,F,CHEMBL615925,10576,,H,Autocuration,,BAO_0000221
871,,9,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615926,10576,,D,Expert,,BAO_0000357
872,,9,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615927,10576,,D,Expert,,BAO_0000019
873,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615928,10576,,H,Autocuration,,BAO_0000221
874,,9,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615929,10576,,D,Expert,,BAO_0000357
875,,8,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615930,10576,,H,Autocuration,,BAO_0000221
876,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,,,,,449.0,1,,B,CHEMBL615931,51,,H,Autocuration,,BAO_0000219
877,,8,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,F,CHEMBL615932,51,,H,Autocuration,,BAO_0000219
878,,8,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,F,CHEMBL615933,51,,H,Autocuration,,BAO_0000219
879,,8,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615934,51,,H,Autocuration,,BAO_0000357
880,,8,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,,,,,,1,,B,CHEMBL615935,51,,H,Autocuration,,BAO_0000357
881,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,,,,,,1,,F,CHEMBL615936,51,,H,Autocuration,,BAO_0000019
882,,8,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,,,,,449.0,1,,B,CHEMBL615937,51,,H,Autocuration,,BAO_0000219
883,,8,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615938,51,,H,Autocuration,,BAO_0000357
884,,8,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL615797,51,,H,Autocuration,,BAO_0000357
885,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615798,51,,H,Autocuration,,BAO_0000357
886,,8,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,,,,,,1,,B,CHEMBL872870,51,,H,Autocuration,,BAO_0000357
887,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,,,,,,1,,B,CHEMBL615799,51,,H,Autocuration,,BAO_0000357
888,,8,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615800,51,,H,Autocuration,,BAO_0000357
889,,8,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,722.0,1,,F,CHEMBL615801,51,,H,Autocuration,,BAO_0000219
890,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,,,,,,1,,B,CHEMBL615802,51,,H,Autocuration,,BAO_0000019
891,,8,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,,,,,,1,,B,CHEMBL615803,51,,H,Autocuration,,BAO_0000357
892,,8,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,,,,,,1,,F,CHEMBL835002,51,,H,Expert,,BAO_0000019
893,,8,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,,,,,,1,,F,CHEMBL615804,51,,H,Autocuration,,BAO_0000019
894,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,,,,,308.0,1,,B,CHEMBL615805,51,,H,Expert,,BAO_0000219
895,,8,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,,,,,449.0,1,,B,CHEMBL615806,51,,H,Autocuration,,BAO_0000219
896,,9,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615807,51,,D,Expert,,BAO_0000357
897,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,,,,,,1,,B,CHEMBL615808,51,,H,Autocuration,,BAO_0000357
898,,9,Binding affinity against 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615809,51,,D,Expert,,BAO_0000357
899,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,,,,,308.0,1,,B,CHEMBL615810,51,,H,Autocuration,,BAO_0000219
900,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615811,51,,H,Autocuration,,BAO_0000357
901,,8,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL615812,51,,H,Autocuration,,BAO_0000219
902,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL615751,51,,H,Autocuration,,BAO_0000219
903,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615752,51,,H,Autocuration,,BAO_0000357
904,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,,,,,449.0,1,,B,CHEMBL615753,51,,H,Expert,,BAO_0000219
905,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,,,,,449.0,1,,B,CHEMBL615754,51,,H,Autocuration,,BAO_0000219
906,,8,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615755,51,,H,Autocuration,,BAO_0000357
907,,9,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL615756,51,,D,Expert,,BAO_0000219
908,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615757,51,,H,Autocuration,,BAO_0000019
909,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL615758,51,,H,Autocuration,,BAO_0000357
910,,8,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,1,,B,CHEMBL615759,51,,H,Expert,,BAO_0000357
911,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615760,51,,H,Autocuration,,BAO_0000357
912,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,,,,,308.0,1,,B,CHEMBL615761,51,,H,Expert,,BAO_0000219
913,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,,,,,,1,,B,CHEMBL872104,51,,H,Autocuration,,BAO_0000357
914,,8,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615762,51,,H,Autocuration,,BAO_0000357
915,,8,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615763,51,,H,Autocuration,,BAO_0000357
916,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL615764,51,,H,Autocuration,,BAO_0000357
917,,8,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,,,,,1167.0,1,,B,CHEMBL615765,51,,H,Autocuration,,BAO_0000219
918,,8,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,,,,,,1,,B,CHEMBL615766,51,,H,Autocuration,,BAO_0000019
919,,8,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615767,51,,H,Autocuration,,BAO_0000357
920,,8,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615768,51,,H,Expert,,BAO_0000357
921,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615769,51,,H,Autocuration,,BAO_0000357
922,,8,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,,,,,,1,,B,CHEMBL615770,51,,H,Expert,,BAO_0000357
923,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615771,51,,H,Autocuration,,BAO_0000357
924,,8,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,,,,,,1,,B,CHEMBL615772,51,,H,Expert,,BAO_0000357
925,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL615773,51,,H,Autocuration,,BAO_0000357
926,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615774,51,,H,Expert,,BAO_0000357
927,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615775,51,,H,Autocuration,,BAO_0000357
928,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL615776,51,,H,Autocuration,,BAO_0000357
929,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615777,51,,H,Expert,,BAO_0000357
930,,8,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,,,,,,1,,B,CHEMBL615778,51,,H,Autocuration,,BAO_0000219
931,,9,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Homo sapiens,,,,,,1,9606.0,B,CHEMBL615779,51,,D,Expert,,BAO_0000357
932,,8,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,1,,B,CHEMBL615780,51,,H,Autocuration,,BAO_0000357
933,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616298,51,,H,Autocuration,,BAO_0000357
934,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616299,51,,H,Autocuration,,BAO_0000357
935,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL616300,51,,H,Autocuration,,BAO_0000219
936,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,,,,,485.0,1,,F,CHEMBL616301,51,,H,Expert,,BAO_0000219
937,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616302,51,,H,Autocuration,,BAO_0000019
938,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,,,,,,1,,B,CHEMBL616117,51,,H,Autocuration,,BAO_0000019
939,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,,,,,,1,,B,CHEMBL616118,51,,H,Autocuration,,BAO_0000019
940,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,,,,,,1,,B,CHEMBL616119,51,,H,Autocuration,,BAO_0000019
941,,9,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL616120,51,,D,Expert,,BAO_0000219
942,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616121,51,,H,Autocuration,,BAO_0000357
943,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,,,,,,1,,B,CHEMBL616122,51,,H,Autocuration,,BAO_0000357
944,,8,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616123,51,,H,Autocuration,,BAO_0000357
945,,9,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616124,51,,D,Expert,,BAO_0000357
946,,8,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,,,,,,1,,B,CHEMBL616125,51,,H,Expert,,BAO_0000357
947,,8,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616126,51,,H,Expert,,BAO_0000357
948,,8,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,,,,,449.0,1,,B,CHEMBL616127,51,,H,Autocuration,,BAO_0000219
949,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616128,51,,H,Expert,,BAO_0000019
950,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,,,,,,1,,B,CHEMBL616129,51,,H,Autocuration,,BAO_0000357
951,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616130,51,,H,Expert,,BAO_0000357
952,,8,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,,,,,,1,,B,CHEMBL616131,51,,H,Autocuration,,BAO_0000357
953,,8,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,,,,,308.0,1,,B,CHEMBL616132,51,,H,Autocuration,,BAO_0000219
954,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL616133,51,,D,Expert,,BAO_0000219
955,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616134,51,,H,Autocuration,,BAO_0000357
956,,8,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,,,,,,1,,B,CHEMBL616135,51,,H,Autocuration,,BAO_0000357
957,,9,Affinity for 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616136,51,,D,Expert,,BAO_0000357
958,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,,,,,,1,,B,CHEMBL616137,51,,H,Autocuration,,BAO_0000019
959,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,,,,,,1,,B,CHEMBL872105,51,,H,Autocuration,,BAO_0000019
960,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,,,,,,1,,B,CHEMBL616138,51,,H,Autocuration,,BAO_0000357
961,,9,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616139,51,,D,Expert,,BAO_0000357
962,,8,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,,,,,,1,,F,CHEMBL616140,51,,H,Autocuration,,BAO_0000019
963,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,,,,,,1,,B,CHEMBL616141,51,,H,Expert,,BAO_0000019
964,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616142,51,,H,Autocuration,,BAO_0000357
965,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,,,,,,1,,B,CHEMBL616143,51,,H,Autocuration,,BAO_0000357
966,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,308.0,1,,B,CHEMBL616144,51,,H,Autocuration,,BAO_0000219
967,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,,,,,308.0,1,,B,CHEMBL616145,51,,H,Autocuration,,BAO_0000219
968,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,308.0,1,,B,CHEMBL616012,51,,H,Autocuration,,BAO_0000219
969,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,,,,,308.0,1,,B,CHEMBL616013,51,,H,Autocuration,,BAO_0000219
970,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,1,,F,CHEMBL616014,51,,H,Autocuration,,BAO_0000019
971,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,1,,F,CHEMBL616015,51,,H,Autocuration,,BAO_0000019
972,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,,,,,,1,,F,CHEMBL616016,51,,H,Autocuration,,BAO_0000019
973,,8,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,,,,,,1,,F,CHEMBL616017,51,,H,Autocuration,,BAO_0000218
974,,8,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,,,,,,1,,B,CHEMBL616018,51,,H,Autocuration,,BAO_0000019
975,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,,,,,,1,,F,CHEMBL616019,51,,H,Autocuration,,BAO_0000019
976,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,,,,,,1,,F,CHEMBL616020,51,,H,Autocuration,,BAO_0000019
977,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL858018,51,,H,Autocuration,,BAO_0000357
978,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,722.0,1,,F,CHEMBL616021,51,,H,Autocuration,,BAO_0000219
979,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,,,,,,1,,F,CHEMBL616022,51,,H,Expert,,BAO_0000019
980,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,,,,,,1,,F,CHEMBL616023,51,,H,Autocuration,,BAO_0000019
981,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,,,,,,1,,F,CHEMBL616024,51,,H,Autocuration,,BAO_0000019
982,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,,,,,,1,,F,CHEMBL616025,51,,H,Autocuration,,BAO_0000019
983,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,,,,,449.0,1,,F,CHEMBL616026,51,,H,Autocuration,,BAO_0000219
984,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,,,,,,1,,F,CHEMBL616027,51,,H,Autocuration,,BAO_0000019
985,,9,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616028,51,,D,Expert,,BAO_0000019
986,,9,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616029,51,,D,Expert,,BAO_0000019
987,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,,,,,449.0,1,,B,CHEMBL616030,51,,H,Expert,,BAO_0000219
988,,8,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,,,,,,1,,B,CHEMBL616031,51,,H,Expert,,BAO_0000019
989,,9,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616032,51,,D,Expert,,BAO_0000019
990,,9,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Homo sapiens,,,,,,1,9606.0,F,CHEMBL616033,51,,D,Expert,,BAO_0000019
991,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,1,,F,CHEMBL616034,51,,H,Autocuration,,BAO_0000019
992,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,1,,F,CHEMBL616035,51,,H,Autocuration,,BAO_0000019
993,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL616036,51,,H,Autocuration,,BAO_0000019
994,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,1,,F,CHEMBL616037,51,,H,Autocuration,,BAO_0000019
995,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,1,,F,CHEMBL616038,51,,H,Autocuration,,BAO_0000019
996,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,,,,,,1,,F,CHEMBL616039,51,,H,Autocuration,,BAO_0000019
997,,8,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL616040,51,,H,Autocuration,,BAO_0000019
998,,9,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,F,CHEMBL616041,51,,D,Expert,,BAO_0000219
999,,9,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,F,CHEMBL616042,51,,D,Expert,,BAO_0000219
1000,,9,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,F,CHEMBL616043,51,,D,Expert,,BAO_0000219
1001,,8,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL616044,51,,H,Autocuration,,BAO_0000019
1002,,8,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL616045,51,,H,Autocuration,,BAO_0000019
1003,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,,,,,722.0,1,,F,CHEMBL616046,51,,H,Autocuration,,BAO_0000219
1004,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,,449.0,1,,F,CHEMBL616047,51,,H,Autocuration,,BAO_0000219
1005,,8,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,,,,,449.0,1,,F,CHEMBL616048,51,,H,Autocuration,,BAO_0000219
1006,,9,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL616049,51,,D,Expert,,BAO_0000219
1007,,8,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,,,,,449.0,1,,F,CHEMBL616050,51,,H,Autocuration,,BAO_0000219
1008,,8,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,,,,,,1,,F,CHEMBL616051,51,,H,Expert,,BAO_0000219
1009,,8,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,,,,,,1,,F,CHEMBL616212,51,,H,Autocuration,,BAO_0000219
1010,,8,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL616213,51,,H,Autocuration,,BAO_0000019
1011,,8,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,,,,,,1,,B,CHEMBL616214,51,,H,Expert,,BAO_0000219
1012,,8,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,,,,,,1,,B,CHEMBL616215,51,,H,Expert,,BAO_0000219
1013,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL616216,51,,H,Autocuration,,BAO_0000357
1014,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,1,,B,CHEMBL616217,51,,H,Autocuration,,BAO_0000019
1015,,8,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616218,51,,H,Autocuration,,BAO_0000357
1016,,8,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616219,51,,H,Autocuration,,BAO_0000357
1017,,8,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616220,51,,H,Autocuration,,BAO_0000357
1018,,9,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL833493,51,,D,Expert,,BAO_0000357
1019,,8,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616221,51,,H,Autocuration,,BAO_0000357
1020,,9,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616222,51,,D,Expert,,BAO_0000219
1021,,8,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL616223,51,,H,Autocuration,,BAO_0000019
1022,,8,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,,,,,,1,,F,CHEMBL616224,51,,H,Autocuration,,BAO_0000019
1023,,8,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,,,,,,1,,B,CHEMBL616225,51,,H,Expert,,BAO_0000019
1024,,9,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL616226,51,,D,Expert,,BAO_0000219
1025,,8,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,,,,,722.0,1,,B,CHEMBL616227,51,,H,Autocuration,,BAO_0000219
1026,,8,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,,,,,722.0,1,,B,CHEMBL616228,51,,H,Autocuration,,BAO_0000219
1027,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,,722.0,1,,B,CHEMBL616229,51,,H,Autocuration,,BAO_0000219
1028,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,,,,,722.0,1,,B,CHEMBL616230,51,,H,Autocuration,,BAO_0000219
1029,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,,,,,722.0,1,,B,CHEMBL616231,51,,H,Autocuration,,BAO_0000219
1030,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616232,51,,H,Autocuration,,BAO_0000357
1031,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,,,,,722.0,1,,B,CHEMBL616233,51,,H,Autocuration,,BAO_0000219
1032,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,,,,,722.0,1,,B,CHEMBL857973,51,,H,Autocuration,,BAO_0000219
1033,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,,,,,,1,,B,CHEMBL616234,51,,H,Autocuration,,BAO_0000219
1034,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616235,51,,H,Autocuration,,BAO_0000357
1035,,8,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,308.0,1,,B,CHEMBL616236,51,,H,Expert,,BAO_0000219
1036,,8,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,,,,,,1,,B,CHEMBL616237,51,,H,Expert,,BAO_0000019
1037,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,,,,,722.0,1,,B,CHEMBL616238,51,,H,Autocuration,,BAO_0000219
1038,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,,722.0,1,,B,CHEMBL616239,51,,H,Autocuration,,BAO_0000219
1039,,8,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,,,,,,1,,B,CHEMBL616240,51,,H,Autocuration,,BAO_0000219
1040,,9,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL616241,51,,D,Expert,,BAO_0000219
1041,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,,,,,722.0,1,,B,CHEMBL616242,51,,H,Autocuration,,BAO_0000219
1042,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,,,,,722.0,1,,B,CHEMBL616243,51,,H,Autocuration,,BAO_0000219
1043,,9,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616244,51,,D,Expert,,BAO_0000357
1044,,9,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616245,51,,D,Autocuration,,BAO_0000357
1045,,8,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,1,,B,CHEMBL616246,106,,H,Autocuration,,BAO_0000357
1046,,8,Binding affinity against 5-HT1D receptor,,,,,,,1,,B,CHEMBL616247,105,,H,Autocuration,,BAO_0000357
1047,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616248,105,,H,Autocuration,,BAO_0000357
1048,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL616249,107,,H,Autocuration,,BAO_0000357
1049,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616250,10576,,H,Autocuration,,BAO_0000357
1050,,8,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616251,51,,H,Autocuration,,BAO_0000357
1051,,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,,,,,,1,,F,CHEMBL616252,11863,,H,Autocuration,,BAO_0000218
1052,,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,,,,,,1,,F,CHEMBL616253,11863,,H,Autocuration,,BAO_0000218
1053,,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,,,,,,1,,F,CHEMBL616254,11863,,H,Autocuration,,BAO_0000218
1054,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL616255,11863,,D,Expert,,BAO_0000218
1055,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL832872,11863,,D,Expert,,BAO_0000218
1056,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL616256,11863,,D,Expert,,BAO_0000218
1057,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL616257,11863,,D,Expert,,BAO_0000218
1058,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL616258,11863,,D,Expert,,BAO_0000218
1059,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Mus musculus,,,,,,1,10090.0,F,CHEMBL616384,11863,,D,Expert,,BAO_0000218
1060,,8,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616385,11863,,H,Autocuration,,BAO_0000221
1061,,8,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,,,,,,1,,B,CHEMBL616386,11863,,H,Expert,,BAO_0000357
1062,,9,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,,,Hippocampus,10000000.0,,1,10090.0,B,CHEMBL616387,11863,,D,Expert,,BAO_0000221
1063,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616388,11863,,H,Autocuration,,BAO_0000221
1064,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Mus musculus,,,Hippocampus,10000000.0,,1,10090.0,B,CHEMBL616389,11863,,D,Expert,,BAO_0000221
1065,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616390,11863,,H,Autocuration,,BAO_0000221
1066,,8,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,,,,,,1,,B,CHEMBL616391,11863,,H,Autocuration,,BAO_0000357
1067,,9,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Mus musculus,,,Hippocampus,10000000.0,,1,10090.0,B,CHEMBL616392,11863,,D,Expert,,BAO_0000221
1068,,8,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616393,51,,H,Autocuration,,BAO_0000357
1069,,8,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616394,51,,H,Autocuration,,BAO_0000357
1070,,8,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616395,51,,H,Autocuration,,BAO_0000019
1071,,8,Compound was evaluated for the binding affinity at 5- HT1A receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616396,51,,H,Autocuration,,BAO_0000357
1072,,8,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,,,,,,1,9823.0,B,CHEMBL872907,51,,H,Autocuration,,BAO_0000019
1073,,8,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616397,51,,H,Autocuration,,BAO_0000019
1074,,8,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616398,51,,H,Autocuration,,BAO_0000019
1075,,8,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616399,51,,H,Expert,,BAO_0000357
1076,,8,Binding activity radioligand.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL857065,51,,H,Autocuration,,BAO_0000357
1077,,8,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616400,51,,H,Expert,,BAO_0000019
1078,,8,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616401,51,,H,Autocuration,,BAO_0000019
1079,,8,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,,,,,,1,,B,CHEMBL616402,10624,,H,Expert,,BAO_0000019
1080,,8,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616403,51,,H,Expert,,BAO_0000019
1081,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Sus scrofa,,,Hippocampus,10000000.0,,1,9823.0,B,CHEMBL616404,51,,H,Autocuration,,BAO_0000221
1082,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616405,51,,H,Autocuration,,BAO_0000249
1083,,8,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616406,51,,H,Autocuration,,BAO_0000019
1084,,8,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Sus scrofa,,,,,,1,9823.0,F,CHEMBL616407,51,,H,Expert,,BAO_0000019
1085,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616408,51,,H,Autocuration,,BAO_0000019
1086,,9,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616409,10576,,D,Expert,,BAO_0000249
1087,,9,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616410,10576,,D,Expert,,BAO_0000221
1088,,8,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,,,,,,1,,B,CHEMBL616411,10576,,H,Autocuration,,BAO_0000357
1089,Membranes,9,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616412,10576,,D,Expert,,BAO_0000249
1090,Membranes,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,F,CHEMBL616413,10576,,D,Expert,,BAO_0000249
1091,,8,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616414,10576,,H,Autocuration,,BAO_0000221
1092,,9,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616415,10576,,D,Expert,,BAO_0000221
1093,,8,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,,,,,,1,,B,CHEMBL616416,10576,,H,Autocuration,,BAO_0000019
1094,,8,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL616417,10576,,H,Expert,,BAO_0000357
1095,,8,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL616418,10576,,H,Autocuration,,BAO_0000357
1096,,8,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,1,,B,CHEMBL616419,10576,,H,Autocuration,,BAO_0000219
1097,,8,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,,,,,,1,,B,CHEMBL616420,10576,,H,Autocuration,,BAO_0000357
1098,Membranes,8,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,1,,B,CHEMBL616421,10576,,H,Autocuration,,BAO_0000249
1099,Membranes,8,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,,,,,,1,,B,CHEMBL616422,10576,,H,Autocuration,,BAO_0000249
1100,Membranes,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,,,,,,1,,B,CHEMBL616423,10576,,H,Expert,,BAO_0000249
1101,,9,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616424,10576,,D,Expert,,BAO_0000357
1102,,8,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616425,10576,,H,Expert,,BAO_0000357
1103,,8,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,,,,,,1,,B,CHEMBL616426,10576,,H,Expert,,BAO_0000357
1104,,8,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616427,10576,,H,Autocuration,,BAO_0000221
1105,,8,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616428,10576,,H,Autocuration,,BAO_0000221
1106,,8,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616290,10576,,H,Autocuration,,BAO_0000221
1107,,9,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616052,10576,,D,Expert,,BAO_0000357
1108,,8,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616053,10576,,H,Autocuration,,BAO_0000357
1109,,8,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616054,10576,,H,Autocuration,,BAO_0000249
1110,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616055,10576,,H,Autocuration,,BAO_0000357
1111,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,,,,,,1,,B,CHEMBL616056,10576,,H,Autocuration,,BAO_0000357
1112,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,1,,B,CHEMBL616057,10576,,H,Expert,,BAO_0000019
1113,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Rattus norvegicus,,,Brain,955.0,,1,10116.0,B,CHEMBL616058,10576,,D,Expert,,BAO_0000221
1114,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,Brain,955.0,,1,,B,CHEMBL616059,10576,,H,Autocuration,,BAO_0000221
1115,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616060,10576,,H,Autocuration,,BAO_0000249
1116,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616061,10576,,D,Expert,,BAO_0000221
1117,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616062,10576,,H,Expert,,BAO_0000221
1118,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616063,10576,,H,Autocuration,,BAO_0000249
1119,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,Striatum,2435.0,,1,,B,CHEMBL616064,10576,,H,Autocuration,,BAO_0000249
1120,Membranes,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616065,10576,,D,Expert,,BAO_0000249
1121,Membranes,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616066,10576,,D,Expert,,BAO_0000249
1122,,8,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616067,10576,,H,Autocuration,,BAO_0000221
1123,,8,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616068,10576,,H,Autocuration,,BAO_0000221
1124,,8,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616069,10576,,H,Intermediate,,BAO_0000221
1125,,8,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,1,,B,CHEMBL616070,10576,,H,Expert,,BAO_0000249
1126,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616071,10576,,H,Autocuration,,BAO_0000221
1127,,8,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616072,10576,,H,Expert,,BAO_0000221
1128,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616073,10576,,H,Autocuration,,BAO_0000221
1129,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616074,10576,,H,Autocuration,,BAO_0000221
1130,,8,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,,,,,,1,,B,CHEMBL616075,10576,,H,Expert,,BAO_0000019
1131,,8,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616076,10576,,H,Autocuration,,BAO_0000357
1132,,9,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616077,10576,,D,Expert,,BAO_0000019
1133,,9,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616078,10576,,D,Expert,,BAO_0000019
1134,,9,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616079,10576,,D,Expert,,BAO_0000019
1135,,9,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,,,,,485.0,1,10116.0,B,CHEMBL616080,10576,,D,Expert,,BAO_0000219
1136,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616081,10576,,H,Autocuration,,BAO_0000357
1137,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616082,10576,,D,Expert,,BAO_0000221
1138,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616083,10576,,H,Autocuration,,BAO_0000221
1139,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL616084,10576,,H,Autocuration,,BAO_0000019
1140,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,,,,,,1,,B,CHEMBL616085,10576,,H,Expert,,BAO_0000019
1141,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,,,,,,1,,B,CHEMBL616086,10576,,H,Autocuration,,BAO_0000019
1142,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,,,Hippocampus,10000000.0,,1,,B,CHEMBL616087,10576,,H,Autocuration,,BAO_0000221
1143,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,,,,,,1,,B,CHEMBL616088,10576,,H,Expert,,BAO_0000357
1144,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,,,,,,1,,B,CHEMBL616089,10576,,H,Autocuration,,BAO_0000019
1145,,9,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616090,10576,,D,Expert,,BAO_0000357
1146,,8,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,,,,,,1,,B,CHEMBL616091,10576,,H,Autocuration,,BAO_0000357
1147,Membranes,8,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,,,Striatum,2435.0,,1,,B,CHEMBL616092,10576,,H,Autocuration,,BAO_0000249
1148,,8,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,,,,,,1,,B,CHEMBL616093,10576,,H,Autocuration,,BAO_0000357
1149,,8,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,,,,,,1,,B,CHEMBL616094,10576,,H,Autocuration,,BAO_0000218
1150,,8,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,,,Brain,955.0,,1,,B,CHEMBL616095,10576,,H,Autocuration,,BAO_0000221
1151,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616096,10576,,D,Expert,,BAO_0000357
1152,,8,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,,,,,,1,,B,CHEMBL616097,10576,,H,Expert,,BAO_0000249
1153,Membranes,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616098,10576,,D,Expert,,BAO_0000249
1154,,8,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616099,10576,,H,Autocuration,,BAO_0000221
1155,,8,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616100,10576,,H,Autocuration,,BAO_0000221
1156,,8,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616101,10576,,H,Expert,,BAO_0000357
1157,,8,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,,,,,,1,,B,CHEMBL616102,10576,,H,Expert,,BAO_0000249
1158,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616103,10576,,H,Autocuration,,BAO_0000357
1159,,8,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,,,,,,1,,B,CHEMBL616104,10576,,H,Expert,,BAO_0000019
1160,,8,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,,,,,,1,,B,CHEMBL616105,10576,,H,Expert,,BAO_0000019
1161,,9,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616106,10576,,D,Expert,,BAO_0000019
1162,,8,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,,,,,,1,,B,CHEMBL616107,10576,,H,Autocuration,,BAO_0000019
1163,,8,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,,,,,,1,,B,CHEMBL616108,10576,,H,Expert,,BAO_0000357
1164,,8,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616109,10576,,H,Expert,,BAO_0000221
1165,,8,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,,,,,,1,,B,CHEMBL616110,10576,,H,Autocuration,,BAO_0000357
1166,,8,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,,,,,449.0,1,,B,CHEMBL616111,10576,,H,Expert,,BAO_0000219
1167,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616112,10576,,H,Expert,,BAO_0000019
1168,,8,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616113,10576,,H,Autocuration,,BAO_0000221
1169,,8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616114,10576,,H,Autocuration,,BAO_0000019
1170,,8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616115,10576,,H,Autocuration,,BAO_0000019
1171,,8,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616116,10576,,H,Autocuration,,BAO_0000357
1172,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,,,Brain,955.0,,1,,B,CHEMBL615844,10576,,H,Expert,,BAO_0000221
1173,,8,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615939,10576,,H,Expert,,BAO_0000221
1174,,8,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,,,,,,1,,B,CHEMBL615940,10576,,H,Expert,,BAO_0000019
1175,,8,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615941,10576,,H,Expert,,BAO_0000221
1176,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615942,10576,,H,Autocuration,,BAO_0000221
1177,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615943,10576,,H,Autocuration,,BAO_0000221
1178,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615944,10576,,H,Autocuration,,BAO_0000221
1179,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615945,10576,,H,Autocuration,,BAO_0000221
1180,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615946,10576,,H,Autocuration,,BAO_0000221
1181,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615947,10576,,H,Autocuration,,BAO_0000221
1182,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615948,10576,,H,Autocuration,,BAO_0000221
1183,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615949,10576,,H,Autocuration,,BAO_0000221
1184,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615950,10576,,H,Autocuration,,BAO_0000221
1185,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615951,10576,,H,Autocuration,,BAO_0000221
1186,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615952,10576,,H,Autocuration,,BAO_0000221
1187,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615953,10576,,H,Autocuration,,BAO_0000221
1188,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615954,10576,,H,Autocuration,,BAO_0000221
1189,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL615955,10576,,D,Expert,,BAO_0000221
1190,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615956,10576,,H,Autocuration,,BAO_0000221
1191,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,,,Hippocampus,10000000.0,,1,,B,CHEMBL615957,10576,,H,Autocuration,,BAO_0000221
1192,,8,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,,,,,,1,,B,CHEMBL615958,10576,,H,Expert,,BAO_0000019
1193,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,,,,,,1,,B,CHEMBL615959,10576,,H,Expert,,BAO_0000019
1194,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,,,,,,1,,B,CHEMBL615960,10576,,H,Autocuration,,BAO_0000019
1195,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,,,,,,1,,B,CHEMBL615961,10576,,H,Autocuration,,BAO_0000019
1196,,8,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,,,Brain,955.0,,1,,B,CHEMBL615962,10576,,H,Expert,,BAO_0000221
1197,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,,,,,,1,,B,CHEMBL615963,10576,,H,Expert,,BAO_0000019
1198,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,,,,,,1,,B,CHEMBL615964,10576,,H,Autocuration,,BAO_0000019
1199,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,,,,,,1,,B,CHEMBL615965,10576,,H,Autocuration,,BAO_0000019
1200,,8,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,,,,,449.0,1,,B,CHEMBL615966,10576,,H,Expert,,BAO_0000219
1201,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,,,,,,1,,B,CHEMBL615967,10576,,H,Expert,,BAO_0000249
1202,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL615968,10576,,H,Expert,,BAO_0000019
1203,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,,,,,449.0,1,,B,CHEMBL615969,10576,,H,Autocuration,,BAO_0000218
1204,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,,,,,,1,,B,CHEMBL615970,10576,,H,Autocuration,,BAO_0000218
1205,,9,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615971,10576,,D,Expert,,BAO_0000357
1206,Membranes,8,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,1,,B,CHEMBL615972,10576,,H,Expert,,BAO_0000249
1207,,8,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,,,,,,1,,B,CHEMBL615973,10576,,H,Autocuration,,BAO_0000249
1208,,8,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,,,,,,1,,B,CHEMBL615974,10576,,H,Autocuration,,BAO_0000249
1209,,9,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL615975,51,,D,Expert,,BAO_0000219
1210,,8,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,,,,,,1,,B,CHEMBL615976,10576,,H,Expert,,BAO_0000249
1211,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL872106,10576,,D,Expert,,BAO_0000221
1212,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL615977,10576,,H,Autocuration,,BAO_0000357
1213,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,,,,,,1,,B,CHEMBL615978,10576,,H,Autocuration,,BAO_0000357
1214,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,,,,,,1,,B,CHEMBL616166,10576,,H,Autocuration,,BAO_0000357
1215,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,,,,,,1,,B,CHEMBL616167,10576,,H,Autocuration,,BAO_0000357
1216,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,,,,,,1,,B,CHEMBL616168,10576,,H,Autocuration,,BAO_0000357
1217,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,,,,,,1,,B,CHEMBL616169,10576,,H,Autocuration,,BAO_0000357
1218,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,,,,,,1,,B,CHEMBL616170,10576,,H,Autocuration,,BAO_0000357
1219,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,,,,,,1,,B,CHEMBL616171,10576,,H,Autocuration,,BAO_0000357
1220,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,,,,,,1,,B,CHEMBL616172,10576,,H,Autocuration,,BAO_0000357
1221,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,,,,,,1,,B,CHEMBL616173,10576,,H,Autocuration,,BAO_0000357
1222,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,,,,,,1,,B,CHEMBL616174,10576,,H,Autocuration,,BAO_0000357
1223,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,,,,,,1,,B,CHEMBL616175,10576,,H,Autocuration,,BAO_0000357
1224,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,,,,,,1,,B,CHEMBL616176,10576,,H,Autocuration,,BAO_0000357
1225,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,,,,,,1,,B,CHEMBL616177,10576,,H,Autocuration,,BAO_0000357
1226,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,,,,,,1,,B,CHEMBL616178,10576,,H,Autocuration,,BAO_0000357
1227,,8,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,,,,,,1,,B,CHEMBL616179,10576,,H,Autocuration,,BAO_0000019
1228,,8,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616180,10576,,H,Autocuration,,BAO_0000357
1229,,8,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,,,,,,1,,B,CHEMBL616181,10576,,H,Autocuration,,BAO_0000357
1230,,8,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,,,,,,1,,B,CHEMBL616182,10576,,H,Autocuration,,BAO_0000019
1231,,8,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616183,10576,,H,Autocuration,,BAO_0000221
1232,,8,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,,,,,,1,,B,CHEMBL615874,10576,,H,Expert,,BAO_0000019
1233,,9,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Rattus norvegicus,,,,,485.0,1,10116.0,B,CHEMBL615875,10576,,D,Expert,,BAO_0000219
1234,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,,,,,,1,,B,CHEMBL615876,10576,,H,Autocuration,,BAO_0000019
1235,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,,,,,,1,,B,CHEMBL615877,10576,,H,Autocuration,,BAO_0000019
1236,,8,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,,,,,,1,,B,CHEMBL615878,10576,,H,Autocuration,,BAO_0000357
1237,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,,,,,,1,,B,CHEMBL615879,10576,,H,Expert,,BAO_0000357
1238,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,,,,,,1,,B,CHEMBL615880,10576,,H,Expert,,BAO_0000357
1239,,8,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,,,,,,1,,B,CHEMBL615881,10576,,H,Autocuration,,BAO_0000019
1240,,9,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL615882,10576,,D,Expert,,BAO_0000019
1241,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,,,,,,1,,F,CHEMBL615883,10576,,H,Autocuration,,BAO_0000218
1242,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,,,,,,1,,F,CHEMBL615884,10576,,H,Autocuration,,BAO_0000218
1243,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,,,,,,1,,F,CHEMBL615885,10576,,H,Autocuration,,BAO_0000218
1244,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,,,,,,1,,F,CHEMBL615886,10576,,H,Autocuration,,BAO_0000218
1245,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,,,,,,1,,F,CHEMBL615887,10576,,H,Autocuration,,BAO_0000218
1246,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,,,,,,1,,F,CHEMBL615888,10576,,H,Autocuration,,BAO_0000218
1247,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,,,,,,1,,F,CHEMBL615889,10576,,H,Autocuration,,BAO_0000218
1248,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,,,,,,1,,F,CHEMBL615890,10576,,H,Autocuration,,BAO_0000218
1249,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,,,,,,1,,F,CHEMBL615891,10576,,H,Autocuration,,BAO_0000218
1250,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,,,,,,1,,F,CHEMBL615892,10576,,H,Autocuration,,BAO_0000218
1251,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,,,,,,1,,F,CHEMBL615893,10576,,H,Autocuration,,BAO_0000218
1252,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,,,,,,1,,F,CHEMBL615894,10576,,H,Autocuration,,BAO_0000218
1253,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,,,,,,1,,F,CHEMBL615895,10576,,H,Autocuration,,BAO_0000218
1254,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,,,,,,1,,F,CHEMBL615896,10576,,H,Autocuration,,BAO_0000218
1255,,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,,,,,,1,,F,CHEMBL615897,10576,,H,Autocuration,,BAO_0000218
1256,Membranes,9,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL615898,10576,,D,Expert,,BAO_0000249
1257,,8,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,,,,,,1,,B,CHEMBL615899,10576,,H,Autocuration,,BAO_0000019
1258,,8,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,,,,,,1,,B,CHEMBL616291,10576,,H,Autocuration,,BAO_0000019
1259,,8,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,,,,,,1,,B,CHEMBL616292,10576,,H,Autocuration,,BAO_0000357
1260,,8,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,,,,,,1,,F,CHEMBL616293,10576,,H,Autocuration,,BAO_0000249
1261,,8,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616294,10576,,H,Expert,,BAO_0000221
1262,,8,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616295,10576,,H,Autocuration,,BAO_0000249
1263,,8,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,,,Brain,955.0,,1,,B,CHEMBL616296,10576,,H,Autocuration,,BAO_0000221
1264,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,1,,F,CHEMBL616297,10576,,H,Autocuration,,BAO_0000019
1265,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,,,,,,1,,F,CHEMBL616605,10576,,H,Autocuration,,BAO_0000019
1266,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,,,,,,1,,F,CHEMBL616606,10576,,H,Autocuration,,BAO_0000019
1267,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,1,,F,CHEMBL616607,10576,,H,Autocuration,,BAO_0000019
1268,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,,,,,,1,,F,CHEMBL616608,10576,,H,Expert,,BAO_0000019
1269,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,,,,,,1,,F,CHEMBL616609,10576,,H,Autocuration,,BAO_0000019
1270,,9,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616610,10576,,D,Expert,,BAO_0000019
1271,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,,,,,,1,,F,CHEMBL616611,10576,,H,Autocuration,,BAO_0000019
1272,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,,,,,,1,,F,CHEMBL616612,10576,,H,Expert,,BAO_0000019
1273,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,,,,,,1,,F,CHEMBL616613,10576,,H,Autocuration,,BAO_0000019
1274,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,,,,,,1,,F,CHEMBL616614,10576,,H,Expert,,BAO_0000019
1275,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,,,,,,1,,F,CHEMBL616615,10576,,H,Autocuration,,BAO_0000019
1276,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,1,,F,CHEMBL616616,10576,,H,Expert,,BAO_0000019
1277,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,,,,,,1,,F,CHEMBL616617,10576,,H,Autocuration,,BAO_0000019
1278,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,1,,F,CHEMBL616618,10576,,H,Autocuration,,BAO_0000019
1279,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,,,,,,1,,F,CHEMBL616619,10576,,H,Autocuration,,BAO_0000019
1280,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,,,,,,1,,F,CHEMBL616620,10576,,H,Expert,,BAO_0000019
1281,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,1,,F,CHEMBL616621,10576,,H,Expert,,BAO_0000019
1282,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,,,,,,1,,F,CHEMBL616622,10576,,H,Autocuration,,BAO_0000019
1283,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,,,,,,1,,F,CHEMBL616146,10576,,H,Expert,,BAO_0000019
1284,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,,,,,,1,,F,CHEMBL832873,10576,,H,Autocuration,,BAO_0000019
1285,,8,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,,,,,,1,,F,CHEMBL616147,10576,,H,Autocuration,,BAO_0000019
1286,,8,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,,,,,,1,,F,CHEMBL872872,10576,,H,Autocuration,,BAO_0000019
1287,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,,,,,,1,,F,CHEMBL616148,10576,,H,Autocuration,,BAO_0000019
1288,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616149,10576,,H,Autocuration,,BAO_0000221
1289,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616150,10576,,H,Expert,,BAO_0000221
1290,Membranes,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616151,10576,,D,Expert,,BAO_0000249
1291,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,,,Hippocampus,10000000.0,,1,,B,CHEMBL872873,10576,,H,Expert,,BAO_0000221
1292,,8,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616670,10576,,H,Autocuration,,BAO_0000221
1293,,8,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616671,10576,,H,Autocuration,,BAO_0000221
1294,,9,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL884861,10576,,D,Expert,,BAO_0000249
1295,,8,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,,,,,,1,,B,CHEMBL616672,10576,,H,Autocuration,,BAO_0000357
1296,,8,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,1,,B,CHEMBL616673,10576,,H,Autocuration,,BAO_0000019
1297,,8,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,,,,,,1,,F,CHEMBL616674,10576,,H,Expert,,BAO_0000019
1298,,8,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,1,,B,CHEMBL616675,10576,,H,Autocuration,,BAO_0000357
1299,,8,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616676,10576,,H,Autocuration,,BAO_0000221
1300,,8,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616677,10576,,H,Autocuration,,BAO_0000221
1301,,8,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616678,10576,,H,Autocuration,,BAO_0000221
1302,,9,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616679,10576,,D,Expert,,BAO_0000357
1303,,8,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616680,10576,,H,Expert,,BAO_0000221
1304,,8,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616681,10576,,H,Autocuration,,BAO_0000221
1305,,8,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616682,10576,,H,Autocuration,,BAO_0000221
1306,,8,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616683,10576,,H,Autocuration,,BAO_0000221
1307,,8,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616684,10576,,H,Autocuration,,BAO_0000221
1308,,8,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616685,10576,,H,Autocuration,,BAO_0000221
1309,,8,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,,,Brain,955.0,,1,,B,CHEMBL616686,10576,,H,Autocuration,,BAO_0000221
1310,,8,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,1,,B,CHEMBL616687,10576,,H,Autocuration,,BAO_0000357
1311,,8,Affinity for 5-hydroxytryptamine 1A receptor site,,,,,,,1,,B,CHEMBL616688,10576,,H,Autocuration,,BAO_0000357
1312,,8,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616689,10576,,H,Autocuration,,BAO_0000221
1313,,8,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,,,,,,1,,B,CHEMBL616690,10576,,H,Autocuration,,BAO_0000357
1314,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616691,10576,,H,Expert,,BAO_0000357
1315,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616692,10576,,D,Expert,,BAO_0000221
1316,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,,,,,,1,,B,CHEMBL616693,10576,,H,Expert,,BAO_0000249
1317,,9,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616694,10576,,D,Expert,,BAO_0000019
1318,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616695,10576,,H,Autocuration,,BAO_0000221
1319,,8,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,,,,,,1,,B,CHEMBL616696,10576,,H,Autocuration,,BAO_0000357
1320,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL616697,10576,,H,Autocuration,,BAO_0000357
1321,,8,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616698,10576,,H,Autocuration,,BAO_0000357
1322,,9,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616949,10576,,D,Expert,,BAO_0000019
1323,,8,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616950,10576,,H,Autocuration,,BAO_0000221
1324,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,,,,,,1,,B,CHEMBL832875,10576,,H,Autocuration,,BAO_0000357
1325,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain,955.0,,1,,B,CHEMBL616951,10576,,H,Expert,,BAO_0000221
1326,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain,955.0,,1,,B,CHEMBL616952,10576,,H,Expert,,BAO_0000221
1327,,8,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,,,,,,1,,B,CHEMBL616953,10576,,H,Expert,,BAO_0000357
1328,,8,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,,,,,,1,,B,CHEMBL616954,10576,,H,Autocuration,,BAO_0000357
1329,,8,GTPgammaS radioligand binding assay,,,,,,,1,,B,CHEMBL616955,106,,H,Autocuration,,BAO_0000357
1330,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,1,,B,CHEMBL616956,106,,H,Autocuration,,BAO_0000357
1331,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,,,,,,1,,F,CHEMBL616957,106,,H,Autocuration,,BAO_0000019
1332,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,,,,,,1,,F,CHEMBL616958,106,,H,Autocuration,,BAO_0000019
1333,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616959,106,,H,Autocuration,,BAO_0000357
1334,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,,,,,,1,,B,CHEMBL616960,106,,H,Autocuration,,BAO_0000357
1335,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,,,,,,1,,F,CHEMBL616961,106,,H,Autocuration,,BAO_0000019
1336,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,,,,,308.0,1,,B,CHEMBL616962,106,,H,Expert,,BAO_0000219
1337,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,,,,,308.0,1,,B,CHEMBL616963,106,,H,Autocuration,,BAO_0000219
1338,,9,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616524,106,,D,Expert,,BAO_0000357
1339,,8,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,,,,,449.0,1,,B,CHEMBL616525,106,,H,Autocuration,,BAO_0000219
1340,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL872908,106,,H,Autocuration,,BAO_0000019
1341,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,,,,,,1,,B,CHEMBL616526,106,,H,Autocuration,,BAO_0000019
1342,,9,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616527,106,,D,Expert,,BAO_0000357
1343,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,1,,B,CHEMBL616528,106,,H,Expert,,BAO_0000219
1344,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL616529,106,,H,Autocuration,,BAO_0000357
1345,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL616530,106,,H,Autocuration,,BAO_0000357
1346,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616531,106,,H,Expert,,BAO_0000357
1347,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616532,106,,H,Autocuration,,BAO_0000357
1348,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616533,106,,H,Autocuration,,BAO_0000357
1349,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616534,106,,H,Expert,,BAO_0000357
1350,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,1,,B,CHEMBL616535,106,,H,Expert,,BAO_0000357
1351,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,,,,,,1,,B,CHEMBL616536,106,,H,Autocuration,,BAO_0000357
1352,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616537,106,,H,Autocuration,,BAO_0000357
1353,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,,,,,485.0,1,,F,CHEMBL616538,106,,H,Expert,,BAO_0000219
1354,,8,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,,,,,,1,,F,CHEMBL616539,106,,H,Expert,,BAO_0000019
1355,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616540,106,,H,Expert,,BAO_0000019
1356,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,1,,B,CHEMBL616429,106,,H,Autocuration,,BAO_0000357
1357,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616430,106,,H,Expert,,BAO_0000357
1358,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616431,106,,D,Expert,,BAO_0000219
1359,,9,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616432,106,,D,Expert,,BAO_0000357
1360,,9,Affinity for 5-hydroxytryptamine 1B receptor subtype,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616433,106,,D,Expert,,BAO_0000357
1361,,9,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616434,106,,D,Expert,,BAO_0000357
1362,,8,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,,,,,449.0,1,,B,CHEMBL616435,106,,H,Autocuration,,BAO_0000219
1363,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,,,,,,1,,B,CHEMBL616436,106,,H,Expert,,BAO_0000019
1364,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,,308.0,1,,B,CHEMBL616437,106,,H,Autocuration,,BAO_0000219
1365,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,,,,,308.0,1,,B,CHEMBL616438,106,,H,Autocuration,,BAO_0000219
1366,,8,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,,,,,308.0,1,,B,CHEMBL616439,106,,H,Autocuration,,BAO_0000219
1367,,9,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616440,106,,D,Expert,,BAO_0000357
1368,,8,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,,,,,485.0,1,,B,CHEMBL616441,106,,H,Autocuration,,BAO_0000219
1369,,8,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,,,,,,1,,B,CHEMBL616442,106,,H,Expert,,BAO_0000357
1370,,8,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616443,106,,H,Autocuration,,BAO_0000357
1371,,8,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,,,,,485.0,1,,B,CHEMBL616444,106,,H,Expert,,BAO_0000219
1372,,9,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616445,106,,D,Expert,,BAO_0000357
1373,,9,Binding activity against human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616446,106,,D,Expert,,BAO_0000357
1374,,9,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616447,106,,D,Expert,,BAO_0000219
1375,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,,,,,,1,,B,CHEMBL616448,106,,H,Autocuration,,BAO_0000357
1376,,8,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,,,,,449.0,1,,B,CHEMBL616449,106,,H,Autocuration,,BAO_0000219
1377,,8,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,,,,,449.0,1,,B,CHEMBL616450,106,,H,Autocuration,,BAO_0000219
1378,,8,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,,,,,449.0,1,,B,CHEMBL857974,106,,H,Autocuration,,BAO_0000219
1379,,8,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,449.0,1,,B,CHEMBL616451,106,,H,Autocuration,,BAO_0000219
1380,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,449.0,1,,B,CHEMBL616452,106,,H,Autocuration,,BAO_0000219
1381,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,,449.0,1,,B,CHEMBL616453,106,,H,Autocuration,,BAO_0000219
1382,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,449.0,1,,B,CHEMBL616454,106,,H,Autocuration,,BAO_0000219
1383,,9,Binding affinity for human 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616455,106,,D,Expert,,BAO_0000357
1384,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,,449.0,1,,B,CHEMBL616456,106,,H,Autocuration,,BAO_0000219
1385,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL616457,106,,H,Autocuration,,BAO_0000357
1386,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,,,,,449.0,1,,B,CHEMBL616458,106,,H,Autocuration,,BAO_0000219
1387,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL616459,106,,H,Autocuration,,BAO_0000219
1388,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,,,,,,1,,F,CHEMBL616460,106,,H,Expert,,BAO_0000019
1389,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,,,,,,1,,F,CHEMBL616461,106,,H,Expert,,BAO_0000019
1390,,8,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,,449.0,1,,F,CHEMBL616462,106,,H,Autocuration,,BAO_0000219
1391,,8,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,,,,,449.0,1,,F,CHEMBL616463,106,,H,Autocuration,,BAO_0000219
1392,,8,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,,,,,,1,,F,CHEMBL616464,105,,H,Autocuration,,BAO_0000019
1393,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,,,,,449.0,1,,B,CHEMBL616465,105,,H,Autocuration,,BAO_0000219
1394,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL832874,17105,,H,Autocuration,,BAO_0000357
1395,,8,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL616184,106,,H,Autocuration,,BAO_0000019
1396,,8,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616185,106,,H,Autocuration,,BAO_0000019
1397,,8,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616186,106,,H,Intermediate,,BAO_0000019
1398,,8,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616187,106,,H,Autocuration,,BAO_0000019
1399,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616188,10577,,H,Expert,,BAO_0000357
1400,,9,Binding affinity for 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL873475,10577,,D,Intermediate,,BAO_0000357
1401,,9,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,B,CHEMBL616189,10577,,D,Expert,,BAO_0000019
1402,,8,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,1,,B,CHEMBL616190,10577,,H,Expert,,BAO_0000357
1403,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,,,,,,1,,B,CHEMBL616191,10576,,H,Autocuration,,BAO_0000357
1404,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,,,,,,1,,B,CHEMBL616192,10576,,H,Autocuration,,BAO_0000357
1405,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,,,,,,1,,B,CHEMBL616193,10576,,H,Autocuration,,BAO_0000357
1406,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,,,,,,1,,B,CHEMBL616194,10576,,H,Autocuration,,BAO_0000357
1407,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,,,,,,1,,B,CHEMBL616195,10576,,H,Autocuration,,BAO_0000357
1408,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,,,,,,1,,B,CHEMBL616196,10576,,H,Autocuration,,BAO_0000357
1409,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616197,10576,,H,Autocuration,,BAO_0000249
1410,,8,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616198,10576,,H,Intermediate,,BAO_0000019
1411,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616199,10576,,H,Autocuration,,BAO_0000221
1412,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616200,10576,,H,Expert,,BAO_0000221
1413,,8,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616201,10576,,H,Expert,,BAO_0000221
1414,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616202,10576,,H,Expert,,BAO_0000221
1415,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616203,10576,,H,Expert,,BAO_0000221
1416,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616204,10576,,H,Expert,,BAO_0000221
1417,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616205,10576,,H,Expert,,BAO_0000221
1418,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616206,10576,,H,Expert,,BAO_0000221
1419,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,,,,,,1,,B,CHEMBL616207,10576,,H,Expert,,BAO_0000249
1420,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,,,,,,1,,B,CHEMBL616208,10576,,H,Autocuration,,BAO_0000249
1421,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,,,,,,1,,B,CHEMBL616209,10576,,H,Autocuration,,BAO_0000249
1422,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,,,,,,1,,B,CHEMBL616210,10576,,H,Expert,,BAO_0000357
1423,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616211,10576,,H,Expert,,BAO_0000221
1424,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616504,10576,,H,Autocuration,,BAO_0000221
1425,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616505,10576,,D,Expert,,BAO_0000221
1426,,8,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,,,,,,1,,F,CHEMBL616506,10576,,H,Autocuration,,BAO_0000019
1427,,8,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,,,Hippocampus,10000000.0,,1,,B,CHEMBL872107,10576,,H,Autocuration,,BAO_0000221
1428,,9,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616507,10576,,D,Expert,,BAO_0000221
1429,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,,,,,,1,,B,CHEMBL616303,10576,,H,Autocuration,,BAO_0000249
1430,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616304,10576,,H,Autocuration,,BAO_0000221
1431,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616305,10576,,H,Expert,,BAO_0000221
1432,,8,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,,,Hippocampus,10000000.0,,1,,F,CHEMBL616306,10576,,H,Intermediate,,BAO_0000221
1433,,8,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616307,10576,,H,Autocuration,,BAO_0000357
1434,,9,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL881829,10576,,D,Expert,,BAO_0000221
1435,,8,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,,,,,,1,,B,CHEMBL616308,10576,,H,Expert,,BAO_0000357
1436,,8,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,,,,,,1,,B,CHEMBL616309,10576,,H,Autocuration,,BAO_0000019
1437,,8,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,,,,,,1,,B,CHEMBL616310,10576,,H,Expert,,BAO_0000019
1438,,8,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,,,,,449.0,1,,B,CHEMBL616311,10576,,H,Autocuration,,BAO_0000219
1439,,8,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616312,10576,,H,Expert,,BAO_0000357
1440,,8,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,,,,,,1,,B,CHEMBL616313,10576,,H,Autocuration,,BAO_0000357
1441,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616314,10576,,D,Expert,,BAO_0000221
1442,,8,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616315,10576,,H,Autocuration,,BAO_0000221
1443,,8,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616567,10576,,H,Autocuration,,BAO_0000221
1444,,8,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616568,10576,,H,Autocuration,,BAO_0000221
1445,,8,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,,,,,,1,,B,CHEMBL616569,10576,,H,Intermediate,,BAO_0000019
1446,,8,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,,,,,,1,,B,CHEMBL616570,10576,,H,Expert,,BAO_0000357
1447,,8,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,,,,,,1,,B,CHEMBL616571,10576,,H,Autocuration,,BAO_0000357
1448,,8,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616572,10576,,H,Autocuration,,BAO_0000221
1449,,8,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,,,,,,1,,B,CHEMBL616573,10576,,H,Expert,,BAO_0000249
1450,,9,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616574,10576,,D,Expert,,BAO_0000357
1451,,8,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616575,10576,,H,Expert,,BAO_0000221
1452,,8,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,,,Hippocampus,10000000.0,,1,,B,CHEMBL872108,10576,,H,Autocuration,,BAO_0000221
1453,,8,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL616576,10576,,H,Autocuration,,BAO_0000357
1454,,8,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,,,,,,1,,B,CHEMBL616577,10576,,H,Autocuration,,BAO_0000249
1455,,8,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,,,,,,1,,B,CHEMBL616578,10576,,H,Autocuration,,BAO_0000249
1456,,8,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,,,,,,1,,B,CHEMBL616579,10576,,H,Expert,,BAO_0000357
1457,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616580,10576,,D,Expert,,BAO_0000019
1458,,8,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,,,,,,1,,B,CHEMBL616581,10576,,H,Autocuration,,BAO_0000019
1459,,8,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616582,10576,,H,Autocuration,,BAO_0000221
1460,,8,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616583,10576,,H,Expert,,BAO_0000221
1461,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616584,10576,,D,Expert,,BAO_0000221
1462,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616585,10576,,H,Expert,,BAO_0000357
1463,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616586,10576,,D,Expert,,BAO_0000221
1464,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616587,10576,,H,Autocuration,,BAO_0000221
1465,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616588,10576,,H,Autocuration,,BAO_0000221
1466,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616589,10576,,H,Autocuration,,BAO_0000221
1467,,8,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616590,10576,,H,Expert,,BAO_0000221
1468,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,,,,,449.0,1,,B,CHEMBL616591,10576,,H,Expert,,BAO_0000219
1469,,8,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616592,10576,,H,Expert,,BAO_0000357
1470,,8,The inhibition activity of 5-HT1A at 1 uM,,,,,,,1,,B,CHEMBL616593,10576,,H,Autocuration,,BAO_0000357
1471,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,,,,,485.0,1,,B,CHEMBL616594,10576,,H,Expert,,BAO_0000219
1472,,8,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,,,,,,1,,B,CHEMBL616595,10576,,H,Expert,,BAO_0000249
1473,,8,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,,,,,,1,,B,CHEMBL616596,10576,,H,Autocuration,,BAO_0000357
1474,,8,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616597,10576,,H,Autocuration,,BAO_0000221
1475,,8,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616598,10576,,H,Expert,,BAO_0000221
1476,Membranes,9,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL616599,10576,,D,Expert,,BAO_0000249
1477,Membranes,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,F,CHEMBL616600,10576,,D,Expert,,BAO_0000249
1478,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,,,,,,1,,B,CHEMBL616601,10576,,H,Autocuration,,BAO_0000019
1479,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,,,,,,1,,B,CHEMBL616602,10576,,H,Autocuration,,BAO_0000019
1480,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,,,,,,1,,B,CHEMBL616603,10576,,H,Autocuration,,BAO_0000019
1481,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,,,,,,1,,B,CHEMBL616604,10576,,H,Autocuration,,BAO_0000019
1482,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,,,,,,1,,B,CHEMBL616316,10576,,H,Autocuration,,BAO_0000249
1483,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,,,,,,1,,B,CHEMBL616317,10576,,H,Autocuration,,BAO_0000249
1484,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616318,10576,,D,Expert,,BAO_0000019
1485,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616319,10576,,H,Autocuration,,BAO_0000221
1486,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616320,10576,,H,Autocuration,,BAO_0000221
1487,,9,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616321,10576,,D,Expert,,BAO_0000221
1488,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,1,,F,CHEMBL616322,10576,,H,Autocuration,,BAO_0000019
1489,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,,,,,,1,,F,CHEMBL616323,10576,,H,Autocuration,,BAO_0000019
1490,,8,Ratio of binding affinity to 5-HT 1A and D2 receptor,,,,,,,1,,B,CHEMBL616324,10576,,H,Autocuration,,BAO_0000357
1491,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616325,10576,,H,Autocuration,,BAO_0000221
1492,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616326,10576,,H,Autocuration,,BAO_0000221
1493,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616327,10576,,H,Autocuration,,BAO_0000221
1494,,8,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616328,10576,,H,Autocuration,,BAO_0000357
1495,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,1,,B,CHEMBL858110,10576,,H,Autocuration,,BAO_0000249
1496,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,,,,,,1,,F,CHEMBL616329,10576,,H,Autocuration,,BAO_0000249
1497,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,1,,B,CHEMBL616330,10576,,H,Autocuration,,BAO_0000249
1498,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,,,,,,1,,F,CHEMBL616331,10576,,H,Autocuration,,BAO_0000249
1499,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,1,,F,CHEMBL616332,10576,,H,Autocuration,,BAO_0000249
1500,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain,955.0,,1,,B,CHEMBL857063,10576,,H,Autocuration,,BAO_0000249
1501,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,1,,B,CHEMBL616333,10576,,H,Autocuration,,BAO_0000019
1502,,8,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,,,,,,1,,F,CHEMBL616334,10576,,H,Expert,,BAO_0000019
1503,,8,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616335,10576,,H,Autocuration,,BAO_0000221
1504,,8,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,,,,,,1,,B,CHEMBL616336,10576,,H,Autocuration,,BAO_0000019
1505,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL616337,10576,,H,Expert,,BAO_0000249
1506,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,,,,,,1,,B,CHEMBL616338,10576,,H,Autocuration,,BAO_0000019
1507,,8,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616339,10576,,H,Autocuration,,BAO_0000221
1508,,8,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616340,10576,,H,Autocuration,,BAO_0000221
1509,,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL616341,10576,,H,Autocuration,,BAO_0000357
1510,,9,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616342,10576,,D,Expert,,BAO_0000357
1511,,9,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616343,10576,,D,Expert,,BAO_0000019
1512,,8,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,,,,,,1,,B,CHEMBL616344,10576,,H,Expert,,BAO_0000019
1513,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL616345,10576,,H,Expert,,BAO_0000357
1514,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,,,,,,1,,B,CHEMBL616346,10576,,H,Expert,,BAO_0000019
1515,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616347,10576,,H,Autocuration,,BAO_0000221
1516,,8,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,,,,,,1,,B,CHEMBL616348,10576,,H,Expert,,BAO_0000019
1517,,8,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616349,10576,,H,Expert,,BAO_0000357
1518,Membranes,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616152,10576,,D,Expert,,BAO_0000249
1519,,8,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,,,,,,1,,B,CHEMBL616153,10576,,H,Autocuration,,BAO_0000249
1520,,8,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,,,,,,1,,B,CHEMBL616154,10576,,H,Expert,,BAO_0000019
1521,,8,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL616155,10576,,H,Autocuration,,BAO_0000019
1522,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616156,10576,,D,Expert,,BAO_0000221
1523,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL616157,10576,,D,Expert,,BAO_0000221
1524,,8,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616158,10576,,H,Autocuration,,BAO_0000221
1525,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,,,,,,1,,B,CHEMBL616159,10576,,H,Autocuration,,BAO_0000357
1526,,8,pKi value against rat 5-hydroxytryptamine 1A receptor.,,,,,,,1,,B,CHEMBL616160,10576,,H,Expert,,BAO_0000357
1527,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,,,,,,1,,B,CHEMBL616161,10576,,H,Autocuration,,BAO_0000019
1528,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,,,,,,1,,F,CHEMBL616162,10576,,H,Autocuration,,BAO_0000019
1529,,9,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616163,12687,,D,Expert,,BAO_0000357
1530,Membranes,8,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,,,,,,1,,B,CHEMBL616164,10626,,H,Expert,,BAO_0000249
1531,,8,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,,,Brain,955.0,,1,,B,CHEMBL616165,10576,,H,Autocuration,,BAO_0000221
1532,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616355,51,,H,Autocuration,,BAO_0000019
1533,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,,,,,,1,,F,CHEMBL616356,10576,,H,Autocuration,,BAO_0000019
1534,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,,,Brain,955.0,,1,,B,CHEMBL616357,10576,,H,Autocuration,,BAO_0000221
1535,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,,,,,,1,,B,CHEMBL616358,10576,,H,Autocuration,,BAO_0000019
1536,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616359,51,,H,Autocuration,,BAO_0000357
1537,,8,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,,,,,,1,,B,CHEMBL616360,51,,H,Expert,,BAO_0000357
1538,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616361,51,,H,Expert,,BAO_0000357
1539,,8,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616362,51,,H,Autocuration,,BAO_0000357
1540,Brain membranes,8,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,,,,,,1,,B,CHEMBL616363,51,,H,Autocuration,,BAO_0000249
1541,,8,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL616364,51,,H,Autocuration,,BAO_0000357
1542,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616365,51,,H,Autocuration,,BAO_0000357
1543,,8,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616366,51,,H,Expert,,BAO_0000357
1544,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL872906,51,,H,Expert,,BAO_0000357
1545,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,,,,,,1,,B,CHEMBL616367,51,,H,Autocuration,,BAO_0000357
1546,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616368,51,,H,Autocuration,,BAO_0000357
1547,,8,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL616369,51,,H,Autocuration,,BAO_0000357
1548,,9,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616370,51,,D,Expert,,BAO_0000357
1549,,9,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616371,51,,D,Expert,,BAO_0000357
1550,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL616372,51,,H,Autocuration,,BAO_0000219
1551,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,,,,,,1,,B,CHEMBL616373,51,,H,Expert,,BAO_0000219
1552,,8,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616374,51,,H,Autocuration,,BAO_0000218
1553,,8,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL616375,51,,H,Autocuration,,BAO_0000221
1554,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL616376,51,,H,Autocuration,,BAO_0000357
1555,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,,,,,,1,,B,CHEMBL857064,51,,H,Expert,,BAO_0000357
1556,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL616377,51,,H,Autocuration,,BAO_0000357
1557,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,,,,,,1,,B,CHEMBL616378,51,,H,Autocuration,,BAO_0000357
1558,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616379,51,,H,Autocuration,,BAO_0000357
1559,,8,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616380,11863,,H,Autocuration,,BAO_0000357
1560,,8,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,,,,,,1,,B,CHEMBL616381,11863,,H,Autocuration,,BAO_0000357
1561,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616382,11863,,H,Autocuration,,BAO_0000357
1562,,8,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,,,,,,1,,B,CHEMBL616383,11863,,H,Autocuration,,BAO_0000357
1563,,9,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Mus musculus,,,,,449.0,1,10090.0,B,CHEMBL616350,11863,,D,Expert,,BAO_0000219
1564,,8,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616351,11863,,H,Autocuration,,BAO_0000357
1565,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,,,,,,1,,B,CHEMBL616352,11863,,H,Autocuration,,BAO_0000357
1566,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616353,11863,,H,Autocuration,,BAO_0000357
1567,,8,Binding affinity against serotonergic 5-HT1a receptor,,,,,,,1,,B,CHEMBL616354,11863,,H,Autocuration,,BAO_0000357
1568,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616508,11863,,H,Autocuration,,BAO_0000357
1569,,9,Binding affinity for 5-hydroxytryptamine 1A receptor,Mus musculus,,,,,,1,10090.0,B,CHEMBL616559,11863,,D,Expert,,BAO_0000357
1570,,8,Binding affinity at 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616560,11863,,H,Autocuration,,BAO_0000357
1571,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,,,,,,1,,B,CHEMBL616561,11863,,H,Autocuration,,BAO_0000357
1572,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL616562,11863,,H,Autocuration,,BAO_0000219
1573,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,,,,,449.0,1,,B,CHEMBL616563,11863,,H,Autocuration,,BAO_0000219
1574,,8,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616564,11863,,H,Autocuration,,BAO_0000357
1575,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616565,11863,,H,Autocuration,,BAO_0000357
1576,,8,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616566,11863,,H,Autocuration,,BAO_0000218
1577,,8,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,,,,,,1,,B,CHEMBL616989,11863,,H,Autocuration,,BAO_0000357
1578,,8,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL857975,11863,,H,Autocuration,,BAO_0000357
1579,,9,Binding affinity against 5-hydroxytryptamine 1A receptor,Mus musculus,,,,,,1,10090.0,B,CHEMBL616990,11863,,D,Expert,,BAO_0000357
1580,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL616991,11863,,H,Autocuration,,BAO_0000357
1581,,8,Tested against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616992,11863,,H,Autocuration,,BAO_0000357
1582,,8,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL616993,11863,,H,Autocuration,,BAO_0000357
1583,,8,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616994,106,,H,Expert,,BAO_0000019
1584,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616995,106,,H,Autocuration,,BAO_0000019
1585,,9,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,,,,,722.0,1,9593.0,B,CHEMBL616996,105571,,D,Intermediate,,BAO_0000219
1586,,8,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616997,106,,H,Autocuration,,BAO_0000218
1587,,8,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616998,106,,H,Autocuration,,BAO_0000218
1588,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616999,106,,H,Autocuration,,BAO_0000019
1589,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617000,106,,H,Autocuration,,BAO_0000019
1590,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617001,106,,H,Autocuration,,BAO_0000019
1591,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL858111,106,,H,Autocuration,,BAO_0000019
1592,,8,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,,,,,,1,,F,CHEMBL617002,106,,H,Autocuration,,BAO_0000019
1593,,8,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,,,,,,1,,F,CHEMBL617003,106,,H,Autocuration,,BAO_0000019
1594,,8,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,,,,,,1,,F,CHEMBL617004,106,,H,Autocuration,,BAO_0000019
1595,,9,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Homo sapiens,,,,,,1,9606.0,F,CHEMBL617005,106,,D,Expert,,BAO_0000019
1596,,9,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Homo sapiens,,,,,485.0,1,9606.0,F,CHEMBL616623,106,,D,Expert,,BAO_0000219
1597,,8,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,,,,,449.0,1,,F,CHEMBL616624,106,,H,Autocuration,,BAO_0000219
1598,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL883243,106,,H,Autocuration,,BAO_0000357
1599,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,,,,,,1,,F,CHEMBL616625,106,,H,Autocuration,,BAO_0000019
1600,,8,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,,,,,449.0,1,,F,CHEMBL616626,106,,H,Expert,,BAO_0000219
1601,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,,,,,449.0,1,,F,CHEMBL616627,106,,H,Autocuration,,BAO_0000219
1602,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,,,,,449.0,1,,F,CHEMBL616628,106,,H,Autocuration,,BAO_0000219
1603,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,,,,,449.0,1,,F,CHEMBL616629,106,,H,Autocuration,,BAO_0000219
1604,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,,,,,449.0,1,,F,CHEMBL616630,106,,H,Autocuration,,BAO_0000219
1605,,8,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,1,,F,CHEMBL616631,106,,H,Expert,,BAO_0000019
1606,,8,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,1,,F,CHEMBL616632,106,,H,Autocuration,,BAO_0000019
1607,,9,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616633,106,,D,Expert,,BAO_0000357
1608,,8,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,,,,,449.0,1,,B,CHEMBL616634,106,,H,Expert,,BAO_0000219
1609,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL616635,106,,H,Autocuration,,BAO_0000357
1610,,9,Binding affinity against 5-hydroxytryptamine 1B receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL885358,106,,D,Expert,,BAO_0000357
1611,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616636,106,,D,Expert,,BAO_0000219
1612,,8,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,,,,,449.0,1,,B,CHEMBL616637,106,,H,Expert,,BAO_0000219
1613,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616638,106,,H,Autocuration,,BAO_0000357
1614,,8,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616639,106,,H,Expert,,BAO_0000219
1615,,8,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,,449.0,1,,B,CHEMBL616640,106,,H,Expert,,BAO_0000219
1616,,8,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616641,106,,H,Expert,,BAO_0000219
1617,,8,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,,,,,449.0,1,,B,CHEMBL616642,106,,H,Expert,,BAO_0000219
1618,,8,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616643,106,,H,Expert,,BAO_0000219
1619,,8,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL616644,106,,H,Autocuration,,BAO_0000357
1620,,8,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,,,,,,1,,B,CHEMBL616645,106,,H,Autocuration,,BAO_0000357
1621,,8,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL616646,105,,H,Autocuration,,BAO_0000019
1622,,8,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL616647,105,,H,Expert,,BAO_0000019
1623,,8,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,,,,,,1,,B,CHEMBL616509,105,,H,Autocuration,,BAO_0000357
1624,,8,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,,,,,,1,,B,CHEMBL616510,105,,H,Autocuration,,BAO_0000357
1625,,8,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616511,105,,H,Autocuration,,BAO_0000357
1626,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Bos taurus,,,,,,1,9913.0,B,CHEMBL616512,105,,H,Expert,,BAO_0000357
1627,,8,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Bos taurus,,,,,,1,9913.0,B,CHEMBL616513,105,,H,Autocuration,,BAO_0000357
1628,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,,,Striatum,2435.0,,1,9913.0,B,CHEMBL616514,105,,H,Autocuration,,BAO_0000019
1629,,8,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Bos taurus,,,,,,1,9913.0,B,CHEMBL616515,105,,H,Expert,,BAO_0000357
1630,,8,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Bos taurus,,,,,,1,9913.0,B,CHEMBL616516,105,,H,Autocuration,,BAO_0000019
1631,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616517,105,,H,Autocuration,,BAO_0000357
1632,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616518,105,,H,Autocuration,,BAO_0000357
1633,,8,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616519,105,,H,Autocuration,,BAO_0000357
1634,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616520,105,,H,Autocuration,,BAO_0000357
1635,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616521,105,,H,Autocuration,,BAO_0000357
1636,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Bos taurus,,,,,,1,9913.0,B,CHEMBL616522,105,,H,Autocuration,,BAO_0000357
1637,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,,,,,,1,9913.0,B,CHEMBL884531,105,,H,Autocuration,,BAO_0000357
1638,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL616523,105,,H,Autocuration,,BAO_0000357
1639,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Bos taurus,,,Striatum,2435.0,,1,9913.0,B,CHEMBL616731,105,,H,Autocuration,,BAO_0000019
1640,,8,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Bos taurus,,,,,,1,9913.0,B,CHEMBL616732,105,,H,Autocuration,,BAO_0000019
1641,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Bos taurus,,,,,,1,9913.0,B,CHEMBL616733,105,,H,Autocuration,,BAO_0000357
1642,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Bos taurus,,,,,,1,9913.0,B,CHEMBL616734,105,,H,Autocuration,,BAO_0000357
1643,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Bos taurus,,,,,,1,9913.0,B,CHEMBL616735,105,,H,Autocuration,,BAO_0000249
1644,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Bos taurus,,,,,,1,9913.0,B,CHEMBL616736,105,,H,Autocuration,,BAO_0000249
1645,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,,,,,,1,9913.0,F,CHEMBL616737,105,,H,Expert,,BAO_0000019
1646,,8,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Bos taurus,,,,,,1,9913.0,B,CHEMBL616738,105,,H,Autocuration,,BAO_0000019
1647,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,,,,,,1,9913.0,F,CHEMBL616739,105,,H,Expert,,BAO_0000019
1648,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,,,,,,1,9913.0,F,CHEMBL616740,105,,H,Expert,,BAO_0000019
1649,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Bos taurus,,,,,,1,9913.0,F,CHEMBL616741,105,,H,Expert,,BAO_0000019
1650,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Gorilla gorilla,,,,,722.0,1,9593.0,B,CHEMBL616742,105,,H,Autocuration,,BAO_0000219
1651,,9,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616743,105570,,D,Intermediate,,BAO_0000019
1652,,9,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616744,105570,,D,Intermediate,,BAO_0000019
1653,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616745,105570,,D,Intermediate,,BAO_0000019
1654,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616746,105570,,D,Intermediate,,BAO_0000019
1655,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616747,105570,,D,Intermediate,,BAO_0000019
1656,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616748,105570,,D,Intermediate,,BAO_0000019
1657,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616648,105570,,D,Intermediate,,BAO_0000019
1658,,9,Binding affinity against 5-hydroxytryptamine 1D receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616649,105570,,D,Intermediate,,BAO_0000357
1659,,9,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616650,105570,,D,Intermediate,,BAO_0000357
1660,,9,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616651,105570,,D,Intermediate,,BAO_0000218
1661,,9,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616652,105570,,D,Intermediate,,BAO_0000218
1662,,9,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616653,105570,,D,Intermediate,,BAO_0000218
1663,,9,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL616654,105570,,D,Intermediate,,BAO_0000218
1664,,9,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616655,105570,,D,Intermediate,,BAO_0000019
1665,,9,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616656,105570,,D,Intermediate,,BAO_0000357
1666,,8,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616657,105,,H,Autocuration,,BAO_0000019
1667,,9,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL616658,105570,,D,Intermediate,,BAO_0000357
1668,,9,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL616659,105570,,D,Intermediate,,BAO_0000357
1669,,8,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616660,51,,H,Autocuration,,BAO_0000357
1670,,8,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL616661,106,,H,Autocuration,,BAO_0000357
1671,,8,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL616662,105,,H,Expert,,BAO_0000019
1672,,8,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL616663,105,,H,Autocuration,,BAO_0000019
1673,,8,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL616664,105,,H,Autocuration,,BAO_0000019
1674,,9,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL881820,105,,D,Expert,,BAO_0000219
1675,,8,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,,,,,449.0,1,,F,CHEMBL616665,105,,H,Autocuration,,BAO_0000219
1676,,8,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,,449.0,1,,B,CHEMBL616666,105,,H,Expert,,BAO_0000219
1677,,8,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,,,,,449.0,1,,B,CHEMBL616667,105,,H,Autocuration,,BAO_0000219
1678,,8,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,,,,,449.0,1,,F,CHEMBL616668,105,,H,Expert,,BAO_0000219
1679,,9,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL616669,105,,D,Expert,,BAO_0000219
1680,,8,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,,,,,449.0,1,,F,CHEMBL617040,105,,H,Expert,,BAO_0000219
1681,,8,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,,,,,449.0,1,,F,CHEMBL617041,105,,H,Autocuration,,BAO_0000219
1682,,8,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,,,,,449.0,1,,F,CHEMBL617042,105,,H,Expert,,BAO_0000219
1683,,8,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,,,,,449.0,1,,F,CHEMBL617043,105,,H,Expert,,BAO_0000219
1684,,8,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL617044,105,,H,Autocuration,,BAO_0000019
1685,,8,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,,,,,449.0,1,,F,CHEMBL617045,105,,H,Expert,,BAO_0000219
1686,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617046,105,,D,Expert,,BAO_0000219
1687,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617047,105,,D,Expert,,BAO_0000219
1688,,8,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,,,,,,1,,F,CHEMBL617048,105,,H,Expert,,BAO_0000019
1689,,8,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,,,,,,1,,F,CHEMBL616897,105,,H,Autocuration,,BAO_0000019
1690,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Homo sapiens,,,,,,1,9606.0,F,CHEMBL616898,105,,D,Expert,,BAO_0000019
1691,,9,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL858201,105,,D,Expert,,BAO_0000219
1692,,8,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL616899,105,,H,Autocuration,,BAO_0000019
1693,,8,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,,,,,,1,,B,CHEMBL616900,105,,H,Autocuration,,BAO_0000219
1694,,8,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,,,,,449.0,1,,B,CHEMBL616901,105,,H,Expert,,BAO_0000219
1695,,8,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL616902,105,,H,Autocuration,,BAO_0000357
1696,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616903,105,,D,Expert,,BAO_0000219
1697,,8,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,,,,,449.0,1,,B,CHEMBL616904,105,,H,Expert,,BAO_0000219
1698,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616905,105,,H,Autocuration,,BAO_0000357
1699,,8,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,,,,,449.0,1,,B,CHEMBL616906,105,,H,Expert,,BAO_0000219
1700,,8,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616907,105,,H,Expert,,BAO_0000219
1701,,8,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616908,105,,H,Expert,,BAO_0000219
1702,,9,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616909,105,,D,Expert,,BAO_0000219
1703,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616910,105,,D,Expert,,BAO_0000219
1704,,8,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616911,105,,H,Expert,,BAO_0000219
1705,,8,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616912,105,,H,Expert,,BAO_0000219
1706,,8,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL616913,105,,H,Autocuration,,BAO_0000357
1707,,9,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616914,105,,D,Expert,,BAO_0000219
1708,,8,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,,,,,449.0,1,,B,CHEMBL616915,105,,H,Autocuration,,BAO_0000219
1709,,8,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL616916,105,,H,Autocuration,,BAO_0000019
1710,,9,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616917,105,,D,Expert,,BAO_0000357
1711,,8,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,,,,,,1,,B,CHEMBL616918,105,,H,Autocuration,,BAO_0000357
1712,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,,,,,,1,,B,CHEMBL616919,105,,H,Expert,,BAO_0000219
1713,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616920,105,,H,Autocuration,,BAO_0000357
1714,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL872914,105,,H,Autocuration,,BAO_0000357
1715,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,,,,,,1,,B,CHEMBL616921,105,,H,Autocuration,,BAO_0000357
1716,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616922,105,,H,Expert,,BAO_0000357
1717,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616923,105,,H,Autocuration,,BAO_0000357
1718,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616924,105,,H,Expert,,BAO_0000357
1719,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,,,,,,1,,B,CHEMBL875909,105,,H,Expert,,BAO_0000357
1720,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,,,,,,1,,B,CHEMBL616925,105,,H,Autocuration,,BAO_0000357
1721,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,,,,,,1,,B,CHEMBL616926,105,,H,Autocuration,,BAO_0000357
1722,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616927,105,,H,Autocuration,,BAO_0000357
1723,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,,,,,485.0,1,,F,CHEMBL616928,105,,H,Expert,,BAO_0000219
1724,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Homo sapiens,,,,,,1,9606.0,B,CHEMBL616929,105,,D,Expert,,BAO_0000219
1725,,9,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616930,105,,D,Expert,,BAO_0000357
1726,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616931,105,,H,Expert,,BAO_0000019
1727,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,1,,B,CHEMBL616932,105,,H,Autocuration,,BAO_0000357
1728,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616933,105,,H,Expert,,BAO_0000357
1729,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616934,105,,D,Expert,,BAO_0000219
1730,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616935,105,,D,Expert,,BAO_0000357
1731,,8,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,,,,,,1,,B,CHEMBL616936,105,,H,Autocuration,,BAO_0000357
1732,,9,Affinity for 5-hydroxytryptamine 1D receptor subtype,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616937,105,,D,Expert,,BAO_0000357
1733,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616938,105,,D,Expert,,BAO_0000357
1734,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616939,105,,H,Autocuration,,BAO_0000019
1735,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,,,,,,1,,B,CHEMBL616940,105,,H,Expert,,BAO_0000019
1736,,9,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616941,105,,D,Expert,,BAO_0000357
1737,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,,,,,485.0,1,,B,CHEMBL616942,105,,H,Autocuration,,BAO_0000219
1738,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,,,,,485.0,1,,B,CHEMBL616943,105,,H,Autocuration,,BAO_0000219
1739,,4,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,,,,,449.0,1,,B,CHEMBL616944,104802,,H,Autocuration,,BAO_0000219
1740,,8,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,,,,,,1,,F,CHEMBL616945,105,,H,Autocuration,,BAO_0000019
1741,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL616946,105,,H,Autocuration,,BAO_0000357
1742,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,1,,B,CHEMBL616947,105,,H,Autocuration,,BAO_0000019
1743,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,,,,,485.0,1,,B,CHEMBL616948,105,,H,Expert,,BAO_0000219
1744,,8,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616851,105,,H,Autocuration,,BAO_0000357
1745,,8,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616852,105,,H,Autocuration,,BAO_0000357
1746,,8,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616853,105,,H,Autocuration,,BAO_0000357
1747,,9,Binding activity against human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616854,105,,D,Expert,,BAO_0000357
1748,,9,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616855,105,,D,Expert,,BAO_0000219
1749,,8,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL616856,105,,H,Autocuration,,BAO_0000219
1750,,8,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL616857,105,,H,Autocuration,,BAO_0000219
1751,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616858,105,,H,Autocuration,,BAO_0000357
1752,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL616859,105,,H,Autocuration,,BAO_0000219
1753,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,,,,,449.0,1,,B,CHEMBL616860,105,,H,Autocuration,,BAO_0000219
1754,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,,722.0,1,,B,CHEMBL616861,105,,H,Autocuration,,BAO_0000219
1755,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,,,,,722.0,1,,B,CHEMBL616541,105,,H,Autocuration,,BAO_0000219
1756,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,,,,,722.0,1,,B,CHEMBL616542,105,,H,Autocuration,,BAO_0000219
1757,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,449.0,1,,B,CHEMBL616543,105,,H,Autocuration,,BAO_0000219
1758,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616544,105,,D,Expert,,BAO_0000357
1759,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,,,,,449.0,1,,B,CHEMBL616545,105,,H,Autocuration,,BAO_0000219
1760,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL616546,105,,H,Autocuration,,BAO_0000357
1761,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,,,,,449.0,1,,B,CHEMBL616547,105,,H,Autocuration,,BAO_0000219
1762,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL616548,105,,H,Autocuration,,BAO_0000219
1763,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,,,,,,1,,F,CHEMBL616549,105,,H,Expert,,BAO_0000019
1764,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,,,,,,1,,F,CHEMBL616550,105,,H,Expert,,BAO_0000019
1765,,8,Binding affinity against 5-HT2C receptor,,,,,,,1,,B,CHEMBL857066,108,,H,Autocuration,,BAO_0000357
1766,,8,Binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616551,108,,H,Autocuration,,BAO_0000357
1767,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,1,,B,CHEMBL616552,10577,,H,Autocuration,,BAO_0000357
1768,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,,,,,,1,,F,CHEMBL832876,10577,,H,Autocuration,,BAO_0000019
1769,,8,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,,,,,,1,,B,CHEMBL616553,10577,,H,Expert,,BAO_0000019
1770,,8,Binding affinity towards 5-HT1B was determined,,,,,,,1,,B,CHEMBL616554,10577,,H,Autocuration,,BAO_0000357
1771,,8,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,,,,,,1,,B,CHEMBL616555,10577,,H,Expert,,BAO_0000019
1772,,8,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,,,,,,1,,B,CHEMBL616556,10577,,H,Expert,,BAO_0000019
1773,,8,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,,,,,,1,,B,CHEMBL616557,10577,,H,Autocuration,,BAO_0000019
1774,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,1,,B,CHEMBL616558,10577,,H,Expert,,BAO_0000019
1775,,9,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616749,10577,,D,Expert,,BAO_0000019
1776,,8,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,,,,,,1,,B,CHEMBL616750,10577,,H,Autocuration,,BAO_0000357
1777,,8,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,,,,,,1,,B,CHEMBL616751,10577,,H,Autocuration,,BAO_0000357
1778,,8,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,1,,B,CHEMBL616752,10577,,H,Autocuration,,BAO_0000249
1779,,8,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,,,Striatum,2435.0,,1,,B,CHEMBL616753,10577,,H,Autocuration,,BAO_0000019
1780,,9,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616754,10577,,D,Expert,,BAO_0000357
1781,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,,,,,,1,,B,CHEMBL616755,10577,,H,Autocuration,,BAO_0000019
1782,,8,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,,,Striatum,2435.0,,1,,B,CHEMBL616756,10577,,H,Autocuration,,BAO_0000019
1783,,8,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,,,Striatum,2435.0,,1,,B,CHEMBL616757,10577,,H,Autocuration,,BAO_0000019
1784,,8,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,,,Striatum,2435.0,,1,,B,CHEMBL616758,10577,,H,Autocuration,,BAO_0000357
1785,,8,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,,,,,,1,,B,CHEMBL616759,10577,,H,Autocuration,,BAO_0000249
1786,,8,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,,,,,,1,,B,CHEMBL616760,10577,,H,Autocuration,,BAO_0000357
1787,,8,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,,,Striatum,2435.0,,1,,B,CHEMBL616761,10577,,H,Autocuration,,BAO_0000019
1788,,8,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,,,Striatum,2435.0,,1,,B,CHEMBL616762,10577,,H,Autocuration,,BAO_0000019
1789,,8,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,,,,,,1,,B,CHEMBL616763,10577,,H,Autocuration,,BAO_0000019
1790,,8,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,,,,,,1,,B,CHEMBL872909,10577,,H,Expert,,BAO_0000357
1791,,8,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616764,10577,,H,Autocuration,,BAO_0000357
1792,,9,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616765,10577,,D,Expert,,BAO_0000357
1793,,8,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,,,Striatum,2435.0,,1,,B,CHEMBL616766,10577,,H,Autocuration,,BAO_0000357
1794,,8,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,,,Striatum,2435.0,,1,,B,CHEMBL616767,10577,,H,Autocuration,,BAO_0000357
1795,,8,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616768,10577,,H,Autocuration,,BAO_0000357
1796,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616769,10577,,H,Autocuration,,BAO_0000357
1797,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,,,,,,1,,B,CHEMBL616770,10577,,H,Autocuration,,BAO_0000019
1798,,8,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,,,,,,1,,B,CHEMBL616771,10577,,H,Autocuration,,BAO_0000019
1799,,8,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,,,Striatum,2435.0,,1,,B,CHEMBL616772,10577,,H,Autocuration,,BAO_0000019
1800,,8,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,,,,,,1,,B,CHEMBL616773,10577,,H,Expert,,BAO_0000019
1801,,8,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,,,,,,1,,B,CHEMBL616774,10577,,H,Autocuration,,BAO_0000019
1802,,8,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616775,10577,,H,Autocuration,,BAO_0000357
1803,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL616776,10577,,H,Autocuration,,BAO_0000249
1804,,8,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,,,,,,1,,B,CHEMBL616777,10577,,H,Autocuration,,BAO_0000357
1805,,8,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,,,,,,1,,B,CHEMBL616778,10577,,H,Autocuration,,BAO_0000357
1806,,9,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616779,10577,,D,Expert,,BAO_0000249
1807,,9,Binding affinity towards 5-hydroxytryptamine 1B receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616780,10577,,D,Expert,,BAO_0000357
1808,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,,,,,,1,,B,CHEMBL616781,10577,,H,Autocuration,,BAO_0000019
1809,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616782,10577,,H,Autocuration,,BAO_0000357
1810,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL616783,10577,,H,Autocuration,,BAO_0000357
1811,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,,,Striatum,2435.0,,1,,B,CHEMBL616784,10577,,H,Expert,,BAO_0000019
1812,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL616785,10577,,H,Autocuration,,BAO_0000357
1813,,8,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain,955.0,,1,,B,CHEMBL857067,10577,,H,Autocuration,,BAO_0000249
1814,,8,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,,,,,,1,,B,CHEMBL616786,10577,,H,Autocuration,,BAO_0000019
1815,,8,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain,955.0,,1,,B,CHEMBL616787,10577,,H,Autocuration,,BAO_0000249
1816,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,,,,,,1,,B,CHEMBL616788,10577,,H,Autocuration,,BAO_0000357
1817,,8,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616789,10577,,H,Autocuration,,BAO_0000357
1818,,9,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616790,10577,,D,Expert,,BAO_0000019
1819,,8,Binding affinity at 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616791,10577,,H,Expert,,BAO_0000357
1820,,8,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,,,,,,1,,B,CHEMBL616792,10577,,H,Autocuration,,BAO_0000019
1821,,9,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616793,10577,,D,Expert,,BAO_0000249
1822,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616794,10577,,H,Autocuration,,BAO_0000357
1823,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL616795,10577,,H,Autocuration,,BAO_0000357
1824,,4,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,,,,,,1,,B,CHEMBL616796,104686,,H,Autocuration,,BAO_0000019
1825,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616797,106,,H,Autocuration,,BAO_0000357
1826,Brain membranes,8,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,,,,,,1,,B,CHEMBL616798,106,,H,Autocuration,,BAO_0000249
1827,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,,,,,,1,,B,CHEMBL616799,106,,H,Autocuration,,BAO_0000357
1828,,8,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL616800,106,,H,Autocuration,,BAO_0000357
1829,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616801,106,,H,Autocuration,,BAO_0000357
1830,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,,,,,,1,,B,CHEMBL616802,106,,H,Autocuration,,BAO_0000357
1831,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,,,,,,1,,B,CHEMBL616803,106,,H,Autocuration,,BAO_0000357
1832,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,,,,,,1,,B,CHEMBL857068,106,,H,Expert,,BAO_0000357
1833,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,,,,,,1,,B,CHEMBL616804,106,,H,Autocuration,,BAO_0000357
1834,,8,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,,,,,,1,,B,CHEMBL616805,106,,H,Autocuration,,BAO_0000357
1835,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616806,106,,H,Autocuration,,BAO_0000357
1836,,8,Binding affinity against 5-hydroxytryptamine 1B receptor,,,,,,,1,,B,CHEMBL616807,106,,H,Autocuration,,BAO_0000357
1837,,8,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616808,106,,H,Autocuration,,BAO_0000357
1838,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL616809,106,,H,Autocuration,,BAO_0000357
1839,,8,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,,,,,,1,,B,CHEMBL616810,106,,H,Autocuration,,BAO_0000357
1840,,4,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,,,,,,1,,B,CHEMBL616811,104802,,H,Autocuration,,BAO_0000224
1841,,8,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Bos taurus,,,,,,1,9913.0,B,CHEMBL616812,108,,H,Autocuration,,BAO_0000357
1842,,8,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616813,108,,H,Autocuration,,BAO_0000357
1843,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616814,108,,H,Autocuration,,BAO_0000357
1844,,8,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616815,108,,H,Autocuration,,BAO_0000357
1845,,8,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616816,108,,H,Autocuration,,BAO_0000357
1846,,8,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616817,108,,H,Autocuration,,BAO_0000357
1847,,8,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616818,108,,H,Autocuration,,BAO_0000357
1848,,8,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616819,108,,H,Expert,,BAO_0000357
1849,,8,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616820,108,,H,Expert,,BAO_0000357
1850,,8,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616821,108,,H,Expert,,BAO_0000019
1851,,8,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Sus scrofa,,,,,,1,9823.0,B,CHEMBL616822,108,,H,Autocuration,,BAO_0000357
1852,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616823,108,,H,Autocuration,,BAO_0000019
1853,,9,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616824,12689,,D,Autocuration,,BAO_0000357
1854,,9,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616825,12689,,D,Autocuration,,BAO_0000357
1855,,9,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616826,12689,,D,Autocuration,,BAO_0000357
1856,,9,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616827,12689,,D,Expert,,BAO_0000019
1857,,9,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616828,12689,,D,Autocuration,,BAO_0000357
1858,,9,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616829,12689,,D,Autocuration,,BAO_0000357
1859,,9,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616830,12689,,D,Autocuration,,BAO_0000019
1860,,9,Binding affinity against 5-hydroxytryptamine 1C receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616831,12689,,D,Expert,,BAO_0000357
1861,,9,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616832,12689,,D,Autocuration,,BAO_0000019
1862,,9,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616833,12689,,D,Autocuration,,BAO_0000019
1863,,9,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616834,12689,,D,Expert,,BAO_0000019
1864,,9,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL829595,12689,,D,Autocuration,,BAO_0000019
1865,,9,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616835,12689,,D,Autocuration,,BAO_0000357
1866,,9,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL872910,12689,,D,Autocuration,,BAO_0000249
1867,,8,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL616836,12689,,H,Expert,,BAO_0000357
1868,,9,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616837,12689,,D,Autocuration,,BAO_0000357
1869,,9,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616466,12689,,D,Autocuration,,BAO_0000019
1870,,9,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Rattus norvegicus,,,,,722.0,1,10116.0,B,CHEMBL616467,12689,,D,Autocuration,,BAO_0000219
1871,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,1,,B,CHEMBL616468,108,,H,Autocuration,,BAO_0000357
1872,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL616469,108,,H,Autocuration,,BAO_0000357
1873,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL616470,108,,H,Autocuration,,BAO_0000357
1874,,8,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,1,,B,CHEMBL616471,12689,,H,Autocuration,,BAO_0000357
1875,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,,,,,,1,,B,CHEMBL616472,12689,,H,Autocuration,,BAO_0000357
1876,,8,Binding affinity against 5-hydroxytryptamine 1C receptor,,,,,,,1,,B,CHEMBL616473,12689,,H,Autocuration,,BAO_0000357
1877,,8,Binding affinity against serotonergic 5-HT1c receptor,,,,,,,1,,B,CHEMBL616474,12689,,H,Autocuration,,BAO_0000357
1878,,8,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,,,,,,1,,B,CHEMBL616475,12689,,H,Autocuration,,BAO_0000357
1879,,8,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,,,,,,1,,B,CHEMBL616476,12689,,H,Autocuration,,BAO_0000357
1880,,8,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616477,105,,H,Autocuration,,BAO_0000019
1881,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,,,,,,1,,B,CHEMBL616478,104686,,H,Autocuration,,BAO_0000224
1882,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,,,,,,1,,B,CHEMBL616479,104686,,H,Autocuration,,BAO_0000224
1883,,4,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,,,,,,1,,B,CHEMBL616480,104686,,H,Autocuration,,BAO_0000019
1884,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616481,104686,,D,Autocuration,,BAO_0000019
1885,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616482,104686,,D,Autocuration,,BAO_0000249
1886,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,,,Brain,955.0,,1,10116.0,B,CHEMBL884713,104686,,D,Autocuration,,BAO_0000221
1887,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,,,,,,1,,B,CHEMBL616483,104686,,H,Autocuration,,BAO_0000224
1888,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,,,,,,1,,B,CHEMBL616484,104686,,H,Autocuration,,BAO_0000224
1889,,4,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,,,,,,1,,B,CHEMBL616485,104686,,H,Autocuration,,BAO_0000019
1890,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,1,,B,CHEMBL616486,104686,,H,Autocuration,,BAO_0000224
1891,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,,,,,,1,,B,CHEMBL616487,104686,,H,Autocuration,,BAO_0000224
1892,,4,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,1,,B,CHEMBL616488,104686,,H,Autocuration,,BAO_0000224
1893,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616489,104686,,H,Autocuration,,BAO_0000019
1894,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616490,104686,,H,Autocuration,,BAO_0000019
1895,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,,,,,,1,,B,CHEMBL616491,104686,,H,Autocuration,,BAO_0000019
1896,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,,,,,,1,,B,CHEMBL616492,104686,,H,Autocuration,,BAO_0000019
1897,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616493,104686,,H,Autocuration,,BAO_0000019
1898,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL616494,104686,,H,Autocuration,,BAO_0000019
1899,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL616495,104686,,H,Autocuration,,BAO_0000019
1900,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,,,,,,1,,B,CHEMBL616496,104686,,H,Autocuration,,BAO_0000019
1901,,4,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616497,104686,,H,Autocuration,,BAO_0000019
1902,,4,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616498,104686,,H,Autocuration,,BAO_0000019
1903,,4,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,,,,,,1,,B,CHEMBL616499,104686,,H,Autocuration,,BAO_0000019
1904,,4,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,,,,,,1,,B,CHEMBL616500,104686,,H,Autocuration,,BAO_0000019
1905,,5,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,,,Brain,955.0,,1,10116.0,B,CHEMBL616501,104686,,D,Autocuration,,BAO_0000221
1906,,4,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,,,Brain,955.0,,1,,B,CHEMBL616502,104686,,H,Autocuration,,BAO_0000221
1907,Membranes,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,1,,B,CHEMBL884529,104686,,H,Autocuration,,BAO_0000249
1908,Membranes,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,1,,B,CHEMBL616503,104686,,H,Autocuration,,BAO_0000249
1909,,4,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL616964,104686,,H,Autocuration,,BAO_0000224
1910,Membranes,4,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,,,,,,1,,B,CHEMBL616965,104686,,H,Autocuration,,BAO_0000249
1911,,4,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,,,,,,1,,B,CHEMBL616966,104686,,H,Autocuration,,BAO_0000224
1912,,4,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,1,,B,CHEMBL616967,104686,,H,Autocuration,,BAO_0000224
1913,,5,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616968,104686,,D,Autocuration,,BAO_0000224
1914,,4,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,1,,B,CHEMBL616969,104686,,H,Autocuration,,BAO_0000224
1915,,4,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,,,,,,1,,B,CHEMBL884530,104686,,H,Autocuration,,BAO_0000019
1916,,4,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL616970,104686,,H,Autocuration,,BAO_0000224
1917,,4,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,1,,B,CHEMBL616971,104686,,H,Autocuration,,BAO_0000224
1918,,4,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,1,,B,CHEMBL616972,104686,,H,Autocuration,,BAO_0000224
1919,,4,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,,,,,,1,,B,CHEMBL616973,104686,,H,Autocuration,,BAO_0000224
1920,,4,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,,,,,,1,,B,CHEMBL616974,104686,,H,Autocuration,,BAO_0000224
1921,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,,,,,,1,,B,CHEMBL616975,104686,,H,Autocuration,,BAO_0000019
1922,,4,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL616976,104686,,H,Autocuration,,BAO_0000019
1923,,4,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL616977,104686,,H,Autocuration,,BAO_0000224
1924,,4,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,1,,B,CHEMBL616978,104686,,H,Autocuration,,BAO_0000224
1925,,4,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,,,,,,1,,B,CHEMBL616979,104686,,H,Autocuration,,BAO_0000224
1926,,4,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL616980,104686,,H,Autocuration,,BAO_0000224
1927,Membranes,4,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,,,,,,1,,B,CHEMBL616981,104686,,H,Autocuration,,BAO_0000249
1928,Membranes,4,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,,,,,,1,,B,CHEMBL616982,104686,,H,Autocuration,,BAO_0000249
1929,,4,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,,,,,,1,,B,CHEMBL616983,104686,,H,Autocuration,,BAO_0000224
1930,,4,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,,,,,,1,,B,CHEMBL616984,104686,,H,Autocuration,,BAO_0000019
1931,,5,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL616985,104686,,D,Autocuration,,BAO_0000224
1932,,4,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,1,,B,CHEMBL616986,104686,,H,Autocuration,,BAO_0000224
1933,,4,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,,,,,,1,,B,CHEMBL616987,104686,,H,Autocuration,,BAO_0000224
1934,,4,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,,,,,,1,,B,CHEMBL616988,104686,,H,Autocuration,,BAO_0000019
1935,,4,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,1,,B,CHEMBL617243,104686,,H,Autocuration,,BAO_0000019
1936,,4,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,,,,,,1,,B,CHEMBL617244,104686,,H,Autocuration,,BAO_0000019
1937,,5,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,,,,,485.0,1,10116.0,B,CHEMBL617245,104686,,D,Autocuration,,BAO_0000219
1938,Membranes,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,,,,,,1,,B,CHEMBL617246,104686,,H,Autocuration,,BAO_0000249
1939,,4,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,,,,,,1,,B,CHEMBL617546,104686,,H,Autocuration,,BAO_0000224
1940,Brain membranes,4,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,,,,,,1,,B,CHEMBL617547,104686,,H,Autocuration,,BAO_0000249
1941,,4,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,1,,B,CHEMBL617548,104686,,H,Autocuration,,BAO_0000219
1942,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617549,104686,,H,Autocuration,,BAO_0000224
1943,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,1,,B,CHEMBL617550,104686,,H,Autocuration,,BAO_0000224
1944,,4,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,,,,,,1,,B,CHEMBL617551,104686,,H,Autocuration,,BAO_0000224
1945,Membranes,4,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,,,,,,1,,B,CHEMBL617552,104686,,H,Autocuration,,BAO_0000249
1946,Membranes,4,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,,,,,,1,,B,CHEMBL617553,104686,,H,Autocuration,,BAO_0000249
1947,,4,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,,,Thoracic aorta,1515.0,,1,,F,CHEMBL617554,104686,,H,Autocuration,,BAO_0000019
1948,,4,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617555,104686,,H,Autocuration,,BAO_0000019
1949,,4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,1,,B,CHEMBL617556,104686,,H,Autocuration,,BAO_0000224
1950,,8,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,,,,,,1,,B,CHEMBL617557,10624,,H,Autocuration,,BAO_0000357
1951,,8,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,,,,,,1,,B,CHEMBL617558,10624,,H,Autocuration,,BAO_0000357
1952,,8,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617559,17106,,H,Expert,,BAO_0000357
1953,,9,Binding affinity for 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL617560,17106,,D,Expert,,BAO_0000357
1954,,8,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,1,,B,CHEMBL617561,17106,,H,Autocuration,,BAO_0000249
1955,,8,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,1,,B,CHEMBL617562,17106,,H,Autocuration,,BAO_0000249
1956,,8,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,,,Striatum,2435.0,,1,,B,CHEMBL617563,17106,,H,Autocuration,,BAO_0000357
1957,,8,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL617564,17106,,H,Autocuration,,BAO_0000019
1958,,8,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617565,17106,,H,Expert,,BAO_0000019
1959,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL856076,17106,,H,Autocuration,,BAO_0000357
1960,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617566,17106,,H,Autocuration,,BAO_0000019
1961,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,1,,B,CHEMBL875911,17106,,H,Expert,,BAO_0000019
1962,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,1,,B,CHEMBL617567,17106,,H,Autocuration,,BAO_0000019
1963,,8,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,,,,,,1,,B,CHEMBL617568,17106,,H,Autocuration,,BAO_0000249
1964,,8,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,,,,,,1,,B,CHEMBL617569,17106,,H,Expert,,BAO_0000019
1965,,8,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,,,,,,1,,B,CHEMBL617570,17106,,H,Expert,,BAO_0000249
1966,,8,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,,,,,,1,,B,CHEMBL617571,17106,,H,Autocuration,,BAO_0000357
1967,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617572,105,,H,Autocuration,,BAO_0000357
1968,,8,The compound was tested for intrinsic activity against 5-HT1D receptor,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617573,105,,H,Expert,,BAO_0000357
1969,,8,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617574,105,,H,Autocuration,,BAO_0000019
1970,,8,The compound was tested for binding affinity against 5-HT1D receptor,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617575,105,,H,Expert,,BAO_0000357
1971,,8,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,,,,,,1,,B,CHEMBL617576,10578,,H,Autocuration,,BAO_0000357
1972,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,,,,,,1,,F,CHEMBL617577,10578,,H,Autocuration,,BAO_0000019
1973,,8,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,,,,,,1,,F,CHEMBL617578,10578,,H,Autocuration,,BAO_0000019
1974,,8,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL617579,10578,,H,Autocuration,,BAO_0000357
1975,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,,,,,,1,,B,CHEMBL617580,10578,,H,Expert,,BAO_0000019
1976,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL617581,10578,,H,Autocuration,,BAO_0000249
1977,,8,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,,,,,,1,,B,CHEMBL617582,10578,,H,Autocuration,,BAO_0000357
1978,,8,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,,,,,,1,,B,CHEMBL617583,10578,,H,Expert,,BAO_0000019
1979,,8,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL617584,105,,H,Autocuration,,BAO_0000357
1980,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL617585,105,,H,Autocuration,,BAO_0000357
1981,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL875912,105,,H,Autocuration,,BAO_0000357
1982,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL617586,105,,H,Autocuration,,BAO_0000357
1983,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,,,,,,1,,B,CHEMBL617587,105,,H,Autocuration,,BAO_0000357
1984,,8,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,,,,,,1,,B,CHEMBL617588,105,,H,Autocuration,,BAO_0000357
1985,,8,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL857980,105,,H,Autocuration,,BAO_0000357
1986,,8,Tested against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL617589,105,,H,Autocuration,,BAO_0000357
1987,,8,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617590,105,,H,Autocuration,,BAO_0000357
1988,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL617591,105,,H,Autocuration,,BAO_0000219
1989,,9,Binding affinity against 5-Hydroxytryptamine 1D receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617592,105,,D,Expert,,BAO_0000357
1990,,8,,,,,,,,1,,B,CHEMBL617593,105,,H,Autocuration,,BAO_0000357
1991,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL617594,106,,H,Autocuration,,BAO_0000219
1992,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL617595,105,,H,Autocuration,,BAO_0000219
1993,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,,722.0,1,,B,CHEMBL617596,105,,H,Autocuration,,BAO_0000219
1994,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,,722.0,1,,B,CHEMBL617597,105,,H,Autocuration,,BAO_0000219
1995,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,1,,B,CHEMBL617598,105,,H,Autocuration,,BAO_0000019
1996,,8,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,,,,,,1,,B,CHEMBL872916,105,,H,Autocuration,,BAO_0000357
1997,,8,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,,,,,,1,,B,CHEMBL617599,105,,H,Expert,,BAO_0000357
1998,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,,,,,,1,,B,CHEMBL617091,105,,H,Autocuration,,BAO_0000357
1999,,8,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,,,,,485.0,1,,B,CHEMBL617092,105,,H,Expert,,BAO_0000219
2000,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL617093,105,,H,Autocuration,,BAO_0000219
2001,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,,,,,,1,,F,CHEMBL617094,105,,H,Autocuration,,BAO_0000019
2002,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,1,,F,CHEMBL617095,105,,H,Autocuration,,BAO_0000019
2003,,8,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,1,,F,CHEMBL617096,105,,H,Autocuration,,BAO_0000019
2004,,8,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,1,,F,CHEMBL617097,105,,H,Autocuration,,BAO_0000019
2005,,8,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,,,,,,1,,F,CHEMBL617098,105,,H,Autocuration,,BAO_0000019
2006,,8,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617301,105,,H,Autocuration,,BAO_0000357
2007,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617302,105,,H,Autocuration,,BAO_0000357
2008,,8,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617303,105,,H,Autocuration,,BAO_0000357
2009,,8,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617304,105,,H,Expert,,BAO_0000357
2010,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL617305,105,,H,Expert,,BAO_0000219
2011,,9,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617306,105,,D,Autocuration,,BAO_0000219
2012,,8,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,,,,,,1,,B,CHEMBL617307,17106,,H,Autocuration,,BAO_0000357
2013,,8,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617308,105,,H,Autocuration,,BAO_0000019
2014,,8,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617309,105,,H,Autocuration,,BAO_0000357
2015,,8,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617310,105,,H,Autocuration,,BAO_0000357
2016,,8,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617311,105,,H,Autocuration,,BAO_0000357
2017,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL617312,105,,H,Autocuration,,BAO_0000357
2018,,8,Affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617313,105,,H,Autocuration,,BAO_0000357
2019,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,,,,,,1,,B,CHEMBL617314,105,,H,Expert,,BAO_0000357
2020,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,1,,F,CHEMBL617315,106,,H,Autocuration,,BAO_0000019
2021,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,,,,,722.0,1,,B,CHEMBL617316,106,,H,Autocuration,,BAO_0000219
2022,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,,,,,722.0,1,,B,CHEMBL617317,106,,H,Autocuration,,BAO_0000219
2023,,8,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL617318,106,,H,Autocuration,,BAO_0000219
2024,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,,,,,,1,,B,CHEMBL617319,106,,H,Autocuration,,BAO_0000019
2025,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL617320,106,,D,Expert,,BAO_0000357
2026,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL617321,106,,D,Expert,,BAO_0000357
2027,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL617322,106,,D,Expert,,BAO_0000357
2028,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616862,106,,H,Autocuration,,BAO_0000357
2029,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL616863,106,,H,Autocuration,,BAO_0000357
2030,,8,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,,,,,449.0,1,,B,CHEMBL616864,106,,H,Autocuration,,BAO_0000219
2031,,8,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL616865,106,,H,Autocuration,,BAO_0000219
2032,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL616866,106,,H,Autocuration,,BAO_0000219
2033,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,,,,,,1,,F,CHEMBL616867,106,,H,Autocuration,,BAO_0000019
2034,,8,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,,,,,485.0,1,,B,CHEMBL616868,106,,H,Expert,,BAO_0000219
2035,,8,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL616869,105,,H,Expert,,BAO_0000357
2036,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL616870,106,,H,Expert,,BAO_0000219
2037,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,,,,,485.0,1,,F,CHEMBL616871,105,,H,Autocuration,,BAO_0000219
2038,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,,,,,485.0,1,,F,CHEMBL616872,105,,H,Autocuration,,BAO_0000219
2039,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,,,,,485.0,1,,F,CHEMBL616873,105,,H,Autocuration,,BAO_0000219
2040,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,,,,,485.0,1,,F,CHEMBL616838,105,,H,Autocuration,,BAO_0000219
2041,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,,,,,,1,,B,CHEMBL616839,105,,H,Autocuration,,BAO_0000357
2042,,8,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL616840,106,,H,Autocuration,,BAO_0000019
2043,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,,,,,,1,,B,CHEMBL616841,105,,H,Autocuration,,BAO_0000357
2044,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616842,105,,H,Autocuration,,BAO_0000357
2045,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,,,,,,1,,B,CHEMBL857976,105,,H,Expert,,BAO_0000357
2046,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616843,10618,,H,Autocuration,,BAO_0000219
2047,,9,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616844,10618,,D,Expert,,BAO_0000357
2048,,8,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,,,,,,1,,B,CHEMBL616845,10618,,H,Autocuration,,BAO_0000357
2049,,9,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616846,10618,,D,Expert,,BAO_0000357
2050,,8,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616847,10618,,H,Autocuration,,BAO_0000357
2051,,8,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,,,,,,1,,B,CHEMBL616848,10618,,H,Autocuration,,BAO_0000019
2052,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL616849,10618,,H,Autocuration,,BAO_0000357
2053,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL872911,10618,,H,Autocuration,,BAO_0000357
2054,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL616850,10618,,H,Autocuration,,BAO_0000019
2055,,9,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616699,10618,,D,Expert,,BAO_0000219
2056,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,,,,,,1,,B,CHEMBL616700,10618,,H,Autocuration,,BAO_0000357
2057,,8,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL616701,10618,,H,Autocuration,,BAO_0000219
2058,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL616702,10618,,H,Autocuration,,BAO_0000219
2059,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,,,,,449.0,1,,B,CHEMBL616703,10618,,H,Autocuration,,BAO_0000219
2060,,8,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,,,,,,1,,B,CHEMBL616704,10618,,H,Autocuration,,BAO_0000357
2061,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,,,,,449.0,1,,B,CHEMBL616705,10618,,H,Autocuration,,BAO_0000219
2062,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL616706,10618,,H,Autocuration,,BAO_0000357
2063,,8,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,,,,,449.0,1,,B,CHEMBL616707,10618,,H,Autocuration,,BAO_0000219
2064,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL616708,10618,,H,Autocuration,,BAO_0000357
2065,,8,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL616709,10618,,H,Autocuration,,BAO_0000357
2066,,8,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,,,,,449.0,1,,B,CHEMBL616710,10618,,H,Autocuration,,BAO_0000219
2067,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,,,,,449.0,1,,B,CHEMBL616711,10618,,H,Autocuration,,BAO_0000219
2068,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL616712,10618,,H,Autocuration,,BAO_0000219
2069,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,,,,,,1,,B,CHEMBL616713,10618,,H,Autocuration,,BAO_0000357
2070,,8,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,,,,,,1,,B,CHEMBL616714,10618,,H,Autocuration,,BAO_0000357
2071,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL616715,10618,,H,Autocuration,,BAO_0000357
2072,,8,Binding affinity towards 5-hydroxytryptamine 1E receptor,,,,,,,1,,B,CHEMBL616716,10618,,H,Autocuration,,BAO_0000357
2073,,8,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,,,,,,1,,F,CHEMBL616717,279,,H,Autocuration,,BAO_0000019
2074,,8,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,,,,,,1,,F,CHEMBL616718,279,,H,Expert,,BAO_0000019
2075,,8,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,1,,F,CHEMBL875905,279,,H,Autocuration,,BAO_0000019
2076,,8,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,,,,,,1,,F,CHEMBL616719,279,,H,Autocuration,,BAO_0000019
2077,,8,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,,,,,,1,,F,CHEMBL616720,279,,H,Expert,,BAO_0000019
2078,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL616721,279,,H,Autocuration,,BAO_0000357
2079,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL616722,279,,H,Autocuration,,BAO_0000219
2080,,8,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL616723,279,,H,Autocuration,,BAO_0000357
2081,,8,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,,,,,449.0,1,,B,CHEMBL616724,279,,H,Autocuration,,BAO_0000219
2082,,8,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,,,,,,1,,B,CHEMBL616725,279,,H,Autocuration,,BAO_0000357
2083,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL616726,279,,H,Autocuration,,BAO_0000357
2084,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,,,,,,1,,B,CHEMBL616727,279,,H,Autocuration,,BAO_0000357
2085,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,,,,,,1,,B,CHEMBL616728,279,,H,Autocuration,,BAO_0000357
2086,,8,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL616729,279,,H,Autocuration,,BAO_0000357
2087,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL616730,279,,H,Expert,,BAO_0000019
2088,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL617125,279,,H,Autocuration,,BAO_0000357
2089,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,,,,,,1,,B,CHEMBL857977,279,,H,Autocuration,,BAO_0000357
2090,,8,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,,,,,449.0,1,,B,CHEMBL617126,279,,H,Autocuration,,BAO_0000219
2091,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,,,,,449.0,1,,B,CHEMBL617127,279,,H,Autocuration,,BAO_0000219
2092,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL617128,279,,H,Autocuration,,BAO_0000357
2093,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,,,,,449.0,1,,B,CHEMBL617129,279,,H,Autocuration,,BAO_0000219
2094,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,,,,,,1,,B,CHEMBL617130,279,,H,Autocuration,,BAO_0000357
2095,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,,,,,449.0,1,,B,CHEMBL617131,279,,H,Autocuration,,BAO_0000219
2096,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL617132,279,,H,Autocuration,,BAO_0000219
2097,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,,,,,449.0,1,,B,CHEMBL617133,279,,H,Autocuration,,BAO_0000219
2098,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,,,,,,1,,B,CHEMBL617134,279,,H,Autocuration,,BAO_0000357
2099,,8,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,,,,,,1,,B,CHEMBL617135,279,,H,Autocuration,,BAO_0000357
2100,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,,,,,,1,,B,CHEMBL617136,279,,H,Autocuration,,BAO_0000357
2101,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,,,,,,1,,B,CHEMBL617137,104686,,H,Autocuration,,BAO_0000019
2102,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,1,,B,CHEMBL617138,104686,,H,Autocuration,,BAO_0000019
2103,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,1,,B,CHEMBL617139,104686,,H,Autocuration,,BAO_0000019
2104,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617140,12687,,H,Autocuration,,BAO_0000019
2105,,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,,,,,,1,,F,CHEMBL617141,104686,,H,Autocuration,,BAO_0000218
2106,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL858112,104686,,H,Autocuration,,BAO_0000019
2107,,8,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,,,,,,1,,B,CHEMBL617142,17005,,H,Intermediate,,BAO_0000019
2108,,0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Bos taurus,,,,,,1,9913.0,B,CHEMBL617143,22226,,U,Autocuration,,BAO_0000019
2109,,0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Bos taurus,,,,,,1,9913.0,B,CHEMBL617144,22226,,U,Autocuration,,BAO_0000019
2110,,0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Bos taurus,,,,,,1,9913.0,B,CHEMBL617145,22226,,U,Autocuration,,BAO_0000019
2111,,0,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,,,,,,1,,B,CHEMBL617146,22226,,U,Autocuration,,BAO_0000019
2112,,4,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617147,104784,,H,Autocuration,,BAO_0000019
2113,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617148,104784,,H,Autocuration,,BAO_0000019
2114,,4,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617149,104784,,H,Autocuration,,BAO_0000019
2115,,4,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,,,,,,1,,B,CHEMBL617150,104784,,H,Autocuration,,BAO_0000224
2116,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,1,,B,CHEMBL617151,104784,,H,Autocuration,,BAO_0000224
2117,,4,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617201,104784,,H,Autocuration,,BAO_0000224
2118,,8,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,,,,,,1,,B,CHEMBL617202,10209,,H,Autocuration,,BAO_0000357
2119,,4,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,,,1,,B,CHEMBL617203,104826,,H,Autocuration,,BAO_0000218
2120,,4,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,,,,,,1,,B,CHEMBL617204,104826,,H,Autocuration,,BAO_0000019
2121,,4,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,,,,,,1,,B,CHEMBL617205,104826,,H,Autocuration,,BAO_0000224
2122,,5,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Mus musculus,,,,,,1,10090.0,B,CHEMBL617206,104826,,D,Autocuration,,BAO_0000019
2123,,4,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,,,,,,1,,B,CHEMBL617207,104826,,H,Autocuration,,BAO_0000218
2124,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Mus musculus,,,,,,1,10090.0,B,CHEMBL617208,104826,,D,Autocuration,,BAO_0000019
2125,,4,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617209,104826,,H,Autocuration,,BAO_0000224
2126,,4,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,,,,,,1,,B,CHEMBL617210,104826,,H,Autocuration,,BAO_0000224
2127,,4,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,,,,,,1,,B,CHEMBL617211,104826,,H,Autocuration,,BAO_0000224
2128,,5,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Mus musculus,,,,,,1,10090.0,B,CHEMBL617212,104826,,D,Autocuration,,BAO_0000019
2129,,4,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617213,104784,,H,Autocuration,,BAO_0000224
2130,,4,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617214,104784,,H,Autocuration,,BAO_0000224
2131,,0,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,1,,B,CHEMBL617215,22226,,U,Autocuration,,BAO_0000221
2132,,0,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,,,,,,1,,B,CHEMBL617216,22226,,U,Autocuration,,BAO_0000221
2133,,8,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617217,17005,,H,Autocuration,,BAO_0000357
2134,,4,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617218,104686,,H,Autocuration,,BAO_0000019
2135,,4,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL872913,104686,,H,Autocuration,,BAO_0000019
2136,,4,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,,,,,,1,,B,CHEMBL617219,104826,,H,Autocuration,,BAO_0000019
2137,,4,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL873482,104686,,H,Autocuration,,BAO_0000224
2138,,5,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617220,104686,,D,Autocuration,,BAO_0000019
2139,,4,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,,,,,,1,,B,CHEMBL617221,104686,,H,Autocuration,,BAO_0000019
2140,,4,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,,,,,,1,,B,CHEMBL617222,104686,,H,Autocuration,,BAO_0000019
2141,,4,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,,,,,,1,,F,CHEMBL875906,104686,,H,Autocuration,,BAO_0000019
2142,,4,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,,,,,,1,,B,CHEMBL617223,104686,,H,Autocuration,,BAO_0000019
2143,,4,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617224,104686,,H,Autocuration,,BAO_0000224
2144,,5,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617225,104686,,D,Autocuration,,BAO_0000224
2145,,4,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,,,,,,1,,B,CHEMBL617226,104686,,H,Autocuration,,BAO_0000224
2146,,4,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,,,,,,1,,B,CHEMBL617227,104686,,H,Autocuration,,BAO_0000224
2147,,4,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,,,,,,1,,B,CHEMBL617228,104686,,H,Autocuration,,BAO_0000224
2148,,4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,,,,,,1,,B,CHEMBL617229,104686,,H,Autocuration,,BAO_0000224
2149,,4,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,,,,,,1,,B,CHEMBL617230,104686,,H,Autocuration,,BAO_0000224
2150,,4,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,,,,,,1,,B,CHEMBL617231,104686,,H,Autocuration,,BAO_0000224
2151,,4,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,,,,,,1,,B,CHEMBL617232,104686,,H,Autocuration,,BAO_0000224
2152,,4,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617233,104686,,H,Autocuration,,BAO_0000224
2153,,4,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,,,,,,1,,B,CHEMBL617234,104686,,H,Autocuration,,BAO_0000224
2154,,4,Compound was tested for the inhibition of quipazine induced head twitches in rats,,,,,,,1,,F,CHEMBL617235,104686,,H,Autocuration,,BAO_0000019
2155,,4,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,,,,,,1,,F,CHEMBL617236,104686,,H,Autocuration,,BAO_0000019
2156,,4,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,,,Hippocampus,10000000.0,,1,,B,CHEMBL617237,104686,,H,Autocuration,,BAO_0000221
2157,,4,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,,,Hippocampus,10000000.0,,1,,B,CHEMBL617238,104686,,H,Autocuration,,BAO_0000221
2158,,5,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Rattus norvegicus,,,Brain,955.0,,1,10116.0,B,CHEMBL617239,104686,,D,Autocuration,,BAO_0000221
2159,,4,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,1,,B,CHEMBL617240,104686,,H,Autocuration,,BAO_0000019
2160,Membranes,4,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,1,,B,CHEMBL617241,104686,,H,Autocuration,,BAO_0000249
2161,Membranes,4,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,,,,,,1,,B,CHEMBL875907,104686,,H,Autocuration,,BAO_0000249
2162,,4,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,,,,,,1,,B,CHEMBL617242,104686,,H,Autocuration,,BAO_0000019
2163,,4,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,,,,,,1,,F,CHEMBL617152,104686,,H,Autocuration,,BAO_0000019
2164,,5,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Rattus norvegicus,,,Brain,955.0,,1,10116.0,B,CHEMBL617153,104686,,D,Autocuration,,BAO_0000221
2165,Membranes,5,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617154,104686,,D,Autocuration,,BAO_0000249
2166,,4,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,,,Brain,955.0,,1,,B,CHEMBL617155,104686,,H,Autocuration,,BAO_0000221
2167,,4,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,1,,F,CHEMBL617156,104686,,H,Autocuration,,BAO_0000019
2168,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL617157,104686,,H,Autocuration,,BAO_0000019
2169,,4,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL617158,104686,,H,Autocuration,,BAO_0000019
2170,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,1,,F,CHEMBL617159,104686,,H,Autocuration,,BAO_0000019
2171,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,,,,,,1,,F,CHEMBL617160,104686,,H,Autocuration,,BAO_0000019
2172,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL858113,104686,,H,Autocuration,,BAO_0000019
2173,,4,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,,,Brain,955.0,,1,,B,CHEMBL617247,104686,,H,Autocuration,,BAO_0000220
2174,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617248,104686,,H,Autocuration,,BAO_0000019
2175,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,,,Brain,955.0,,1,,B,CHEMBL617249,104686,,H,Autocuration,,BAO_0000249
2176,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,,,,,,1,,B,CHEMBL617250,104686,,H,Autocuration,,BAO_0000019
2177,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617251,104686,,H,Autocuration,,BAO_0000019
2178,,5,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617252,104686,,D,Autocuration,,BAO_0000019
2179,,4,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,,,,,,1,,B,CHEMBL617006,104686,,H,Autocuration,,BAO_0000019
2180,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,,,,,,1,,B,CHEMBL617007,104686,,H,Autocuration,,BAO_0000019
2181,,4,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,,,,,,1,,F,CHEMBL617008,104686,,H,Autocuration,,BAO_0000019
2182,,4,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,,,,,,1,,B,CHEMBL617009,104686,,H,Autocuration,,BAO_0000019
2183,,5,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617010,104686,,D,Autocuration,,BAO_0000224
2184,,5,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL857978,104686,,D,Autocuration,,BAO_0000019
2185,,5,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617011,104686,,D,Autocuration,,BAO_0000019
2186,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617012,104686,,D,Autocuration,,BAO_0000019
2187,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,,,,,,1,,B,CHEMBL617013,104686,,H,Autocuration,,BAO_0000224
2188,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,,,,,,1,,B,CHEMBL617014,104686,,H,Autocuration,,BAO_0000249
2189,,4,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617015,104686,,H,Autocuration,,BAO_0000019
2190,,4,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,,,,,,1,,B,CHEMBL617016,104686,,H,Autocuration,,BAO_0000019
2191,,4,pKi value for 5-hydroxytryptamine 2 receptor binding site,,,,,,,1,,B,CHEMBL617017,104686,,H,Autocuration,,BAO_0000224
2192,,4,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,,,Brain,955.0,,1,,B,CHEMBL617018,104686,,H,Autocuration,,BAO_0000221
2193,,4,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,,,,,,1,,F,CHEMBL617019,104686,,H,Autocuration,,BAO_0000019
2194,,4,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617020,105075,,H,Autocuration,,BAO_0000019
2195,,4,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617021,105075,,H,Autocuration,,BAO_0000019
2196,,4,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617022,105075,,H,Autocuration,,BAO_0000019
2197,,4,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617023,105075,,H,Autocuration,,BAO_0000019
2198,,4,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617024,105075,,H,Autocuration,,BAO_0000019
2199,,4,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617025,105075,,H,Autocuration,,BAO_0000019
2200,,4,Hill coefficient of compound was determined,,,,,,,1,,B,CHEMBL617026,105075,,H,Autocuration,,BAO_0000224
2201,,0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617027,22226,,U,Autocuration,,BAO_0000019
2202,,5,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617028,104686,,D,Autocuration,,BAO_0000019
2203,,8,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,,,,,,1,,B,CHEMBL617029,12687,,H,Expert,,BAO_0000019
2204,,8,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,,,,,,1,,B,CHEMBL875908,12687,,H,Expert,,BAO_0000019
2205,,8,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,,,,,,1,,B,CHEMBL617030,12687,,H,Autocuration,,BAO_0000357
2206,,8,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,,,,,,1,,B,CHEMBL617031,12687,,H,Autocuration,,BAO_0000019
2207,,8,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,,,,,,1,,B,CHEMBL617032,12687,,H,Autocuration,,BAO_0000019
2208,,5,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617033,104686,,D,Autocuration,,BAO_0000224
2209,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,,,,,,1,,B,CHEMBL617034,104686,,H,Autocuration,,BAO_0000224
2210,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,,,,,,1,,B,CHEMBL617035,104686,,H,Autocuration,,BAO_0000224
2211,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,1,,B,CHEMBL617036,104686,,H,Autocuration,,BAO_0000019
2212,,4,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617037,104784,,H,Autocuration,,BAO_0000224
2213,,0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,,,,,,1,,B,CHEMBL617038,22226,,U,Autocuration,,BAO_0000219
2214,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,,,,,,1,,B,CHEMBL617039,104784,,H,Autocuration,,BAO_0000219
2215,,4,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617161,104784,,H,Autocuration,,BAO_0000224
2216,,4,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617162,104784,,H,Autocuration,,BAO_0000224
2217,,4,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617163,104784,,H,Autocuration,,BAO_0000224
2218,,4,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617164,104784,,H,Autocuration,,BAO_0000224
2219,Brain membranes,4,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,,,,,,1,,B,CHEMBL617165,104784,,H,Autocuration,,BAO_0000249
2220,,4,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617166,104784,,H,Autocuration,,BAO_0000224
2221,,4,Binding affinity towards 5-HT2 receptor,,,,,,,1,,B,CHEMBL617167,104784,,H,Autocuration,,BAO_0000224
2222,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL872912,104784,,H,Autocuration,,BAO_0000224
2223,,4,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,,,,,,1,,B,CHEMBL617168,104784,,H,Autocuration,,BAO_0000224
2224,,4,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,,,,,,1,,B,CHEMBL617169,104686,,H,Autocuration,,BAO_0000224
2225,,4,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617170,104784,,H,Autocuration,,BAO_0000224
2226,,4,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,,,,,,1,,B,CHEMBL617171,104784,,H,Autocuration,,BAO_0000224
2227,,4,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,,,,,,1,,B,CHEMBL617172,104784,,H,Autocuration,,BAO_0000224
2228,,4,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617173,104784,,H,Autocuration,,BAO_0000224
2229,,0,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617174,22226,,U,Autocuration,,BAO_0000019
2230,,4,5-hydroxytryptamine 2 receptor binding affinity,,,,,,,1,,B,CHEMBL617175,104784,,H,Autocuration,,BAO_0000224
2231,,8,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,,,,,,1,,B,CHEMBL617176,17005,,H,Autocuration,,BAO_0000357
2232,,8,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617177,17005,,H,Autocuration,,BAO_0000357
2233,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,1,,B,CHEMBL617178,104784,,H,Autocuration,,BAO_0000224
2234,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,,,,,,1,,B,CHEMBL617179,104784,,H,Autocuration,,BAO_0000224
2235,,4,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,,,,,,1,,B,CHEMBL617180,104784,,H,Autocuration,,BAO_0000224
2236,,8,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,,,,,,1,,B,CHEMBL617181,17005,,H,Autocuration,,BAO_0000357
2237,,8,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617182,17005,,H,Autocuration,,BAO_0000357
2238,,8,Binding affinity against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617183,17005,,H,Autocuration,,BAO_0000357
2239,,8,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617184,17005,,H,Autocuration,,BAO_0000357
2240,,8,Binding affinity against serotonergic 5-HT2 receptor,,,,,,,1,,B,CHEMBL617185,17005,,H,Autocuration,,BAO_0000357
2241,,8,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617186,17005,,H,Autocuration,,BAO_0000357
2242,,8,Compound was evaluated for the binding affinity at 5- HT2 receptor,,,,,,,1,,B,CHEMBL617187,17005,,H,Autocuration,,BAO_0000357
2243,,8,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617188,17005,,H,Autocuration,,BAO_0000357
2244,,8,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617189,17005,,H,Autocuration,,BAO_0000218
2245,,5,Inhibitory activity against cloned human 5-HT2 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617190,104784,,D,Autocuration,,BAO_0000224
2246,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL617191,104784,,D,Autocuration,,BAO_0000219
2247,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL617192,104784,,D,Autocuration,,BAO_0000219
2248,,5,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL617193,104784,,D,Autocuration,,BAO_0000219
2249,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL617194,104784,,D,Autocuration,,BAO_0000219
2250,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617195,104784,,H,Autocuration,,BAO_0000224
2251,,4,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,,,,,,1,,B,CHEMBL881830,104784,,H,Autocuration,,BAO_0000224
2252,,8,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617196,17005,,H,Autocuration,,BAO_0000357
2253,,4,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,,,,,,1,,B,CHEMBL617197,104686,,H,Autocuration,,BAO_0000224
2254,,8,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617198,17005,,H,Expert,,BAO_0000357
2255,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL873476,17005,,H,Expert,,BAO_0000357
2256,,8,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,,,,,,1,,B,CHEMBL617199,17005,,H,Expert,,BAO_0000019
2257,,8,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617200,107,,H,Autocuration,,BAO_0000357
2258,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,1,,B,CHEMBL617484,51,,H,Autocuration,,BAO_0000357
2259,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,1,,B,CHEMBL617485,107,,H,Autocuration,,BAO_0000357
2260,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,1,,B,CHEMBL617486,51,,H,Autocuration,,BAO_0000357
2261,,8,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL858022,107,,H,Autocuration,,BAO_0000357
2262,,8,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,,449.0,1,,B,CHEMBL617049,107,,H,Autocuration,,BAO_0000219
2263,,9,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617050,107,,D,Expert,,BAO_0000219
2264,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,1,,F,CHEMBL617051,107,,H,Autocuration,,BAO_0000219
2265,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,,,,,,1,,F,CHEMBL617052,107,,H,Autocuration,,BAO_0000219
2266,,8,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,,,,,,1,,F,CHEMBL617053,107,,H,Autocuration,,BAO_0000219
2267,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,,,,,449.0,1,,B,CHEMBL617054,107,,H,Autocuration,,BAO_0000219
2268,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,,,,,449.0,1,,B,CHEMBL617055,107,,H,Autocuration,,BAO_0000219
2269,,8,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,,,,,,1,,B,CHEMBL882924,107,,H,Autocuration,,BAO_0000357
2270,,9,Inhibition of human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617056,107,,D,Expert,,BAO_0000357
2271,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617057,107,,H,Autocuration,,BAO_0000219
2272,,8,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,,,,,,1,,B,CHEMBL617058,107,,H,Expert,,BAO_0000219
2273,,8,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL617059,107,,H,Autocuration,,BAO_0000357
2274,,8,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,,,,,449.0,1,,B,CHEMBL617060,107,,H,Autocuration,,BAO_0000219
2275,,8,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,,,,,449.0,1,,B,CHEMBL617061,107,,H,Expert,,BAO_0000219
2276,,8,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,,,,,307.0,1,,B,CHEMBL617062,107,,H,Expert,,BAO_0000219
2277,,8,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617063,107,,H,Expert,,BAO_0000219
2278,,8,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,,,,,,1,,F,CHEMBL617064,107,,H,Autocuration,,BAO_0000019
2279,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,1,,F,CHEMBL617065,107,,H,Autocuration,,BAO_0000019
2280,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,,,,,449.0,1,,B,CHEMBL617066,107,,H,Autocuration,,BAO_0000219
2281,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,,,,,449.0,1,,B,CHEMBL617067,107,,H,Autocuration,,BAO_0000219
2282,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,,,,,,1,,F,CHEMBL617068,107,,H,Autocuration,,BAO_0000019
2283,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,,,,,,1,,F,CHEMBL617069,107,,H,Autocuration,,BAO_0000019
2284,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,F,CHEMBL617070,107,,H,Autocuration,,BAO_0000019
2285,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,,,,,,1,,B,CHEMBL617071,107,,H,Autocuration,,BAO_0000357
2286,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL872915,107,,H,Autocuration,,BAO_0000357
2287,,8,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,,,,,,1,,B,CHEMBL617072,107,,H,Autocuration,,BAO_0000357
2288,,8,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,,,,,,1,,B,CHEMBL617073,107,,H,Autocuration,,BAO_0000357
2289,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,,,,,,1,,B,CHEMBL617074,107,,H,Autocuration,,BAO_0000357
2290,,8,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617075,107,,H,Expert,,BAO_0000219
2291,,8,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617076,107,,H,Autocuration,,BAO_0000357
2292,,9,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617077,107,,D,Expert,,BAO_0000019
2293,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,,,,,,1,,B,CHEMBL617078,107,,H,Expert,,BAO_0000357
2294,,9,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617079,107,,D,Expert,,BAO_0000357
2295,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL617080,107,,H,Autocuration,,BAO_0000357
2296,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617081,107,,H,Expert,,BAO_0000219
2297,,8,Binding affinity towards human 5-HT2A receptor in BEK cells,,,,,,,1,,B,CHEMBL617082,107,,H,Expert,,BAO_0000219
2298,,8,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617083,107,,H,Autocuration,,BAO_0000357
2299,,8,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,,,,,,1,,B,CHEMBL617084,107,,H,Autocuration,,BAO_0000357
2300,,9,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617085,107,,D,Expert,,BAO_0000357
2301,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL617086,107,,H,Autocuration,,BAO_0000357
2302,,8,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,,,,,,1,,B,CHEMBL617087,107,,H,Autocuration,,BAO_0000219
2303,,8,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617088,107,,H,Autocuration,,BAO_0000357
2304,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617089,107,,H,Autocuration,,BAO_0000357
2305,,8,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,,,,,,1,,B,CHEMBL617090,107,,H,Expert,,BAO_0000019
2306,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617513,107,,H,Autocuration,,BAO_0000357
2307,,8,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL617514,107,,H,Autocuration,,BAO_0000219
2308,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617515,107,,H,Autocuration,,BAO_0000019
2309,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,,,,,,1,,B,CHEMBL617516,107,,H,Autocuration,,BAO_0000357
2310,,9,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617517,107,,D,Expert,,BAO_0000357
2311,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL617518,107,,D,Expert,,BAO_0000219
2312,,8,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617519,107,,H,Autocuration,,BAO_0000357
2313,,9,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617520,107,,D,Expert,,BAO_0000357
2314,,8,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,,,,,,1,,B,CHEMBL617521,107,,H,Autocuration,,BAO_0000357
2315,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617522,107,,D,Expert,,BAO_0000357
2316,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617523,107,,H,Autocuration,,BAO_0000357
2317,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL617524,107,,H,Autocuration,,BAO_0000357
2318,,4,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,,,,,,1,,B,CHEMBL617525,104686,,H,Autocuration,,BAO_0000019
2319,,5,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617526,104686,,D,Autocuration,,BAO_0000019
2320,,4,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,,,,,,1,,B,CHEMBL617527,104686,,H,Autocuration,,BAO_0000224
2321,,4,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,1,,B,CHEMBL617528,104686,,H,Autocuration,,BAO_0000019
2322,,4,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,,,,,,1,,B,CHEMBL617529,104686,,H,Autocuration,,BAO_0000019
2323,,4,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,,,,,,1,,B,CHEMBL617530,104686,,H,Autocuration,,BAO_0000224
2324,,4,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,1,,B,CHEMBL617531,104686,,H,Autocuration,,BAO_0000019
2325,,4,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,,,,,,1,,B,CHEMBL617532,104686,,H,Autocuration,,BAO_0000019
2326,,4,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617533,104686,,H,Autocuration,,BAO_0000019
2327,,4,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,,,,,,1,,B,CHEMBL617534,104686,,H,Autocuration,,BAO_0000019
2328,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617535,104686,,H,Autocuration,,BAO_0000224
2329,,4,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,,,,,,1,,B,CHEMBL617536,104686,,H,Autocuration,,BAO_0000224
2330,,4,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617537,104686,,H,Autocuration,,BAO_0000224
2331,,4,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617538,104686,,H,Autocuration,,BAO_0000224
2332,,4,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,,,,,,1,,B,CHEMBL617539,104686,,H,Autocuration,,BAO_0000219
2333,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617540,104686,,D,Autocuration,,BAO_0000224
2334,,5,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617541,104686,,D,Autocuration,,BAO_0000224
2335,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617542,104686,,H,Autocuration,,BAO_0000224
2336,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,,,,,,1,,B,CHEMBL617543,104686,,H,Autocuration,,BAO_0000224
2337,,5,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,,,,,485.0,1,10116.0,B,CHEMBL617544,104686,,D,Autocuration,,BAO_0000219
2338,,5,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Rattus norvegicus,,,,,485.0,1,10116.0,B,CHEMBL617545,104686,,D,Autocuration,,BAO_0000219
2339,,5,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617413,104686,,D,Autocuration,,BAO_0000019
2340,,4,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,,,,,,1,,B,CHEMBL617414,104686,,H,Autocuration,,BAO_0000019
2341,,5,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617415,104686,,D,Autocuration,,BAO_0000019
2342,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617416,104686,,H,Autocuration,,BAO_0000224
2343,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,,,,,,1,,B,CHEMBL617417,104686,,H,Autocuration,,BAO_0000224
2344,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,,,,,,1,,B,CHEMBL617418,104686,,H,Autocuration,,BAO_0000019
2345,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,,,,,,1,,B,CHEMBL617419,104686,,H,Autocuration,,BAO_0000019
2346,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,,,,,,1,,B,CHEMBL617420,104686,,H,Autocuration,,BAO_0000224
2347,,5,Affinity for 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617421,104686,,D,Autocuration,,BAO_0000224
2348,,4,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,,,,,,1,,B,CHEMBL617422,104686,,H,Autocuration,,BAO_0000224
2349,,4,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,,,,,,1,,B,CHEMBL617423,104686,,H,Autocuration,,BAO_0000019
2350,,4,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,,,,,,1,,B,CHEMBL617424,104686,,H,Autocuration,,BAO_0000019
2351,,4,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,,,,,,1,,B,CHEMBL617425,104686,,H,Autocuration,,BAO_0000019
2352,,4,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,,,,,,1,,B,CHEMBL617426,104686,,H,Autocuration,,BAO_0000224
2353,,4,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,,,,,,1,,B,CHEMBL617427,104686,,H,Autocuration,,BAO_0000218
2354,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,,,Brain,955.0,,1,,B,CHEMBL617428,104686,,H,Autocuration,,BAO_0000221
2355,,4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,,,,,,1,,B,CHEMBL617429,104686,,H,Autocuration,,BAO_0000224
2356,,4,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,1,,B,CHEMBL617430,104686,,H,Autocuration,,BAO_0000019
2357,,4,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,,,,,,1,,B,CHEMBL617431,104686,,H,Autocuration,,BAO_0000019
2358,,4,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,,,Frontal cortex,1870.0,,1,,B,CHEMBL617432,104686,,H,Autocuration,,BAO_0000019
2359,,4,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617433,104686,,H,Autocuration,,BAO_0000224
2360,,4,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617434,104686,,H,Autocuration,,BAO_0000224
2361,,5,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617435,104686,,D,Autocuration,,BAO_0000224
2362,,4,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,,,,,,1,,B,CHEMBL617436,104686,,H,Autocuration,,BAO_0000019
2363,,5,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,B,CHEMBL617437,104686,,D,Autocuration,,BAO_0000019
2364,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,,,,,,1,,B,CHEMBL617438,104686,,H,Autocuration,,BAO_0000019
2365,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,,,,,,1,,B,CHEMBL617439,104686,,H,Autocuration,,BAO_0000019
2366,,4,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617440,104686,,H,Autocuration,,BAO_0000224
2367,,4,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617441,104686,,H,Autocuration,,BAO_0000224
2368,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL872918,104686,,D,Autocuration,,BAO_0000019
2369,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617442,104686,,D,Autocuration,,BAO_0000019
2370,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,1,,B,CHEMBL617443,104686,,H,Autocuration,,BAO_0000019
2371,,4,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,,,,,,1,,B,CHEMBL617444,104686,,H,Autocuration,,BAO_0000019
2372,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,,,,,,1,,B,CHEMBL617445,104686,,H,Autocuration,,BAO_0000019
2373,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,,,,,,1,,B,CHEMBL617446,104686,,H,Autocuration,,BAO_0000019
2374,,4,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,,,,,,1,,B,CHEMBL617447,104686,,H,Autocuration,,BAO_0000249
2375,,4,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,,,,,,1,,B,CHEMBL617448,104686,,H,Autocuration,,BAO_0000019
2376,,4,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,,,,,,1,,B,CHEMBL617449,104686,,H,Autocuration,,BAO_0000019
2377,,4,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,,,,,,1,,B,CHEMBL617450,104686,,H,Autocuration,,BAO_0000019
2378,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,,,,,,1,,B,CHEMBL617451,104686,,H,Autocuration,,BAO_0000019
2379,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,,,,,,1,,B,CHEMBL617452,104686,,H,Autocuration,,BAO_0000019
2380,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,,,,,,1,,B,CHEMBL617453,104686,,H,Autocuration,,BAO_0000019
2381,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,,,,,,1,,B,CHEMBL617660,104686,,H,Autocuration,,BAO_0000019
2382,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,,,,,,1,,B,CHEMBL617661,104686,,H,Autocuration,,BAO_0000019
2383,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,,,,,,1,,B,CHEMBL617662,104686,,H,Autocuration,,BAO_0000019
2384,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,,,,,,1,,B,CHEMBL872919,104686,,H,Autocuration,,BAO_0000019
2385,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,,,,,,1,,B,CHEMBL617663,104686,,H,Autocuration,,BAO_0000019
2386,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,,,,,,1,,B,CHEMBL617664,104686,,H,Autocuration,,BAO_0000019
2387,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,,,,,,1,,B,CHEMBL617665,104686,,H,Autocuration,,BAO_0000019
2388,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,,,,,,1,,B,CHEMBL617666,104686,,H,Autocuration,,BAO_0000019
2389,,4,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,,,,,,1,,B,CHEMBL617667,104686,,H,Autocuration,,BAO_0000019
2390,,4,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,,,,,,1,,B,CHEMBL617668,104686,,H,Autocuration,,BAO_0000249
2391,,4,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,,,,,,1,,B,CHEMBL617669,104686,,H,Autocuration,,BAO_0000249
2392,,4,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617670,104686,,H,Autocuration,,BAO_0000224
2393,,5,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617671,104686,,D,Autocuration,,BAO_0000224
2394,,4,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617672,104686,,H,Autocuration,,BAO_0000224
2395,,4,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,,,,,,1,,B,CHEMBL617673,104686,,H,Autocuration,,BAO_0000019
2396,,4,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617674,104686,,H,Autocuration,,BAO_0000224
2397,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,,,,,,1,,B,CHEMBL617675,104686,,H,Autocuration,,BAO_0000019
2398,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,,,,,,1,,B,CHEMBL617676,104686,,H,Autocuration,,BAO_0000019
2399,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,,,,,,1,,B,CHEMBL617677,104686,,H,Autocuration,,BAO_0000019
2400,,5,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617678,104686,,D,Autocuration,,BAO_0000019
2401,,4,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,,,,,,1,,B,CHEMBL617679,104686,,H,Autocuration,,BAO_0000224
2402,,4,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,,,,,,1,,B,CHEMBL617680,104686,,H,Autocuration,,BAO_0000224
2403,,4,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,,,,,,1,,B,CHEMBL617681,104686,,H,Autocuration,,BAO_0000019
2404,,4,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,,,Brain,955.0,,1,,B,CHEMBL617682,104686,,H,Autocuration,,BAO_0000221
2405,,4,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,,,,,,1,,B,CHEMBL617683,104686,,H,Autocuration,,BAO_0000224
2406,,4,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,,,,,,1,,B,CHEMBL617684,104686,,H,Autocuration,,BAO_0000224
2407,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617685,104686,,D,Autocuration,,BAO_0000224
2408,,4,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,,,,,,1,,B,CHEMBL617686,104686,,H,Autocuration,,BAO_0000019
2409,,4,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,,,,,,1,,B,CHEMBL617687,104686,,H,Autocuration,,BAO_0000224
2410,,4,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,,,,,,1,,B,CHEMBL617688,104686,,H,Autocuration,,BAO_0000224
2411,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL617689,104686,,H,Autocuration,,BAO_0000019
2412,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,,,,,,1,,F,CHEMBL617690,104686,,H,Autocuration,,BAO_0000019
2413,,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,,,1,,F,CHEMBL617691,104686,,H,Autocuration,,BAO_0000218
2414,,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,,,1,,F,CHEMBL617692,104686,,H,Autocuration,,BAO_0000218
2415,,4,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,,,,,,1,,F,CHEMBL617693,104686,,H,Autocuration,,BAO_0000218
2416,,4,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,,,,,,1,,F,CHEMBL617694,104686,,H,Autocuration,,BAO_0000218
2417,,8,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,,,Brain,955.0,,1,,B,CHEMBL857985,12687,,H,Expert,,BAO_0000221
2418,,9,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617695,12687,,D,Expert,,BAO_0000019
2419,,8,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,,,,,,1,,B,CHEMBL617696,12687,,H,Autocuration,,BAO_0000019
2420,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,,,,,,1,,B,CHEMBL617697,12687,,H,Autocuration,,BAO_0000357
2421,,9,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617257,12687,,D,Expert,,BAO_0000019
2422,,9,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617258,12687,,D,Expert,,BAO_0000357
2423,,8,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,,,,,,1,,B,CHEMBL617259,12687,,H,Expert,,BAO_0000019
2424,,8,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,,,,,,1,,B,CHEMBL617260,12687,,H,Autocuration,,BAO_0000357
2425,,9,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617261,12687,,D,Expert,,BAO_0000357
2426,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,,,,,,1,,B,CHEMBL617262,12687,,H,Autocuration,,BAO_0000019
2427,,8,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,1,,B,CHEMBL617263,12687,,H,Expert,,BAO_0000019
2428,,8,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,,,,,,1,,B,CHEMBL617264,12687,,H,Autocuration,,BAO_0000019
2429,,9,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617265,12687,,D,Expert,,BAO_0000019
2430,Membranes,8,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617266,12687,,H,Autocuration,,BAO_0000249
2431,,8,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,,,,,,1,,B,CHEMBL617267,12687,,H,Autocuration,,BAO_0000019
2432,,8,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,,,,,,1,,B,CHEMBL617268,12687,,H,Expert,,BAO_0000019
2433,,8,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,,,,,449.0,1,,B,CHEMBL617269,12687,,H,Autocuration,,BAO_0000219
2434,,8,Kinetic inhibition constant evaluated by measuring serotonergic activity,,,,,,,1,,B,CHEMBL617323,12687,,H,Expert,,BAO_0000357
2435,,8,Serotonergic activity of the compound.,,,,,,,1,,B,CHEMBL617324,12687,,H,Autocuration,,BAO_0000357
2436,,8,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,,,,,,1,,B,CHEMBL617325,12687,,H,Autocuration,,BAO_0000249
2437,,9,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617326,12687,,D,Expert,,BAO_0000019
2438,,8,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,,,,,,1,,B,CHEMBL617327,12687,,H,Expert,,BAO_0000249
2439,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617328,12687,,D,Expert,,BAO_0000019
2440,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617329,12687,,D,Expert,,BAO_0000019
2441,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617330,12687,,D,Expert,,BAO_0000019
2442,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617331,12687,,H,Autocuration,,BAO_0000357
2443,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL617332,12687,,H,Autocuration,,BAO_0000357
2444,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617333,107,,H,Expert,,BAO_0000357
2445,,8,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,,,,,,1,,B,CHEMBL617334,107,,H,Autocuration,,BAO_0000357
2446,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,,,,,,1,,B,CHEMBL617335,107,,H,Autocuration,,BAO_0000357
2447,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,,,,,,1,,B,CHEMBL617336,107,,H,Autocuration,,BAO_0000357
2448,,8,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL617337,107,,H,Autocuration,,BAO_0000357
2449,,9,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617338,107,,D,Expert,,BAO_0000357
2450,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617339,107,,H,Autocuration,,BAO_0000357
2451,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617340,107,,H,Expert,,BAO_0000357
2452,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,,,,,,1,,B,CHEMBL617341,107,,H,Autocuration,,BAO_0000357
2453,,8,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617342,107,,H,Expert,,BAO_0000357
2454,,8,Affinity for 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617343,107,,H,Expert,,BAO_0000357
2455,,8,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,,,,,723.0,1,,B,CHEMBL617344,107,,H,Expert,,BAO_0000219
2456,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,,,,,,1,,B,CHEMBL617345,107,,H,Expert,,BAO_0000357
2457,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,,,,,,1,,B,CHEMBL617346,107,,H,Expert,,BAO_0000357
2458,,8,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617347,107,,H,Autocuration,,BAO_0000357
2459,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,,,,,,1,,B,CHEMBL617348,107,,H,Autocuration,,BAO_0000357
2460,,8,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,,,,,,1,,B,CHEMBL617349,107,,H,Autocuration,,BAO_0000357
2461,,8,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,F,CHEMBL617350,107,,H,Autocuration,,BAO_0000019
2462,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,,,,,,1,,B,CHEMBL872339,107,,H,Expert,,BAO_0000357
2463,,8,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,,,,,,1,,B,CHEMBL617351,107,,H,Autocuration,,BAO_0000357
2464,,8,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617352,107,,H,Expert,,BAO_0000357
2465,,8,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617353,107,,H,Autocuration,,BAO_0000357
2466,,8,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617354,107,,H,Autocuration,,BAO_0000357
2467,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617355,107,,H,Autocuration,,BAO_0000357
2468,,8,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Mus musculus,,,,,449.0,1,10090.0,B,CHEMBL617356,107,,H,Expert,,BAO_0000219
2469,,8,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617357,107,,H,Autocuration,,BAO_0000357
2470,,8,Binding affinity at 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617358,107,,H,Autocuration,,BAO_0000357
2471,,8,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617359,107,,H,Expert,,BAO_0000357
2472,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,,,,,,1,,B,CHEMBL617360,107,,H,Autocuration,,BAO_0000357
2473,,8,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,,,,,,1,,B,CHEMBL875913,107,,H,Autocuration,,BAO_0000357
2474,,8,Affinity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617361,107,,H,Autocuration,,BAO_0000357
2475,,9,Binding affinity against 5-Hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617362,107,,D,Expert,,BAO_0000357
2476,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL617363,107,,H,Autocuration,,BAO_0000357
2477,,8,Tested against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617364,107,,H,Autocuration,,BAO_0000357
2478,,4,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,1,,B,CHEMBL617365,105075,,H,Autocuration,,BAO_0000224
2479,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,,,,,,1,,B,CHEMBL617366,105075,,H,Autocuration,,BAO_0000224
2480,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,,,,,,1,,B,CHEMBL617367,105075,,H,Autocuration,,BAO_0000224
2481,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,,,,,,1,,B,CHEMBL617368,105075,,H,Autocuration,,BAO_0000224
2482,,8,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,,,,,,1,,B,CHEMBL617369,107,,H,Autocuration,,BAO_0000357
2483,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617370,227,,D,Expert,,BAO_0000219
2484,,9,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617371,227,,D,Expert,,BAO_0000219
2485,,8,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL617372,227,,H,Autocuration,,BAO_0000357
2486,,9,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617373,227,,D,Expert,,BAO_0000357
2487,,8,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,,,,,,1,,F,CHEMBL617374,227,,H,Autocuration,,BAO_0000019
2488,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,,,,,,1,,F,CHEMBL617375,227,,H,Autocuration,,BAO_0000019
2489,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,,,,,,1,,F,CHEMBL617376,227,,H,Autocuration,,BAO_0000019
2490,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,,,,,,1,,F,CHEMBL617377,227,,H,Autocuration,,BAO_0000019
2491,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,,,,,,1,,F,CHEMBL617378,227,,H,Autocuration,,BAO_0000019
2492,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,1,,F,CHEMBL617379,227,,H,Autocuration,,BAO_0000019
2493,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,,,,,,1,,B,CHEMBL617380,227,,H,Autocuration,,BAO_0000357
2494,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,,,,,,1,,B,CHEMBL617381,227,,H,Autocuration,,BAO_0000357
2495,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,,,,,,1,,B,CHEMBL617382,227,,H,Autocuration,,BAO_0000357
2496,,8,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617383,107,,H,Autocuration,,BAO_0000357
2497,,8,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,,,,,,1,,B,CHEMBL617384,107,,H,Expert,,BAO_0000357
2498,,8,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,,,,,,1,,B,CHEMBL617385,107,,H,Expert,,BAO_0000357
2499,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,,,,,,1,,B,CHEMBL617386,107,,H,Autocuration,,BAO_0000019
2500,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,,,,,,1,,B,CHEMBL617387,107,,H,Autocuration,,BAO_0000019
2501,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,723.0,1,,B,CHEMBL617388,107,,H,Autocuration,,BAO_0000219
2502,,8,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,,,,,449.0,1,,F,CHEMBL617389,107,,H,Autocuration,,BAO_0000219
2503,,9,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617390,107,,D,Expert,,BAO_0000219
2504,,4,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,,,,,,1,,B,CHEMBL617391,104817,,H,Autocuration,,BAO_0000224
2505,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL617392,107,,H,Autocuration,,BAO_0000357
2506,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617393,107,,H,Autocuration,,BAO_0000019
2507,,8,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,,307.0,1,,B,CHEMBL617394,107,,H,Autocuration,,BAO_0000219
2508,,8,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,,,,,307.0,1,,B,CHEMBL617395,107,,H,Expert,,BAO_0000219
2509,,8,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,,,,,307.0,1,,B,CHEMBL617396,107,,H,Expert,,BAO_0000219
2510,,8,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,,,,,307.0,1,,B,CHEMBL617397,107,,H,Autocuration,,BAO_0000219
2511,,8,Binding affinity against 5-HT2A receptor,,,,,,,1,,B,CHEMBL617398,107,,H,Autocuration,,BAO_0000357
2512,,8,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617399,107,,H,Autocuration,,BAO_0000357
2513,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL617400,107,,H,Autocuration,,BAO_0000219
2514,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617401,107,,H,Autocuration,,BAO_0000219
2515,,9,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617402,107,,D,Expert,,BAO_0000219
2516,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617403,107,,D,Expert,,BAO_0000219
2517,,8,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,,,,,,1,,B,CHEMBL617404,107,,H,Expert,,BAO_0000357
2518,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL857981,107,,D,Expert,,BAO_0000219
2519,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617405,107,,D,Expert,,BAO_0000219
2520,,9,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617253,107,,D,Expert,,BAO_0000219
2521,,8,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,,,,,,1,,B,CHEMBL617254,107,,H,Expert,,BAO_0000357
2522,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL617255,107,,H,Autocuration,,BAO_0000219
2523,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL617256,107,,H,Autocuration,,BAO_0000219
2524,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL616874,107,,H,Autocuration,,BAO_0000219
2525,,9,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL616875,107,,D,Expert,,BAO_0000219
2526,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,,,,,722.0,1,,B,CHEMBL616876,107,,H,Expert,,BAO_0000219
2527,,8,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,,,,,722.0,1,,B,CHEMBL616877,107,,H,Expert,,BAO_0000219
2528,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL616878,107,,D,Expert,,BAO_0000219
2529,,8,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,,,,,722.0,1,,B,CHEMBL616879,107,,H,Expert,,BAO_0000219
2530,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,,,,,722.0,1,,B,CHEMBL616880,107,,H,Expert,,BAO_0000219
2531,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL616881,107,,D,Expert,,BAO_0000219
2532,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,,723.0,1,,B,CHEMBL616882,107,,H,Autocuration,,BAO_0000219
2533,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,723.0,1,,B,CHEMBL616883,107,,H,Autocuration,,BAO_0000219
2534,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,723.0,1,,B,CHEMBL616884,107,,H,Autocuration,,BAO_0000219
2535,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,,,,,722.0,1,,B,CHEMBL616885,107,,H,Autocuration,,BAO_0000219
2536,,8,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,,,,,485.0,1,,B,CHEMBL616886,107,,H,Autocuration,,BAO_0000219
2537,,8,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL616887,107,,H,Expert,,BAO_0000219
2538,,9,Binding affinity for human 5-hydroxytryptamine 2A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL616888,107,,D,Expert,,BAO_0000357
2539,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,,,,,722.0,1,,B,CHEMBL616889,107,,H,Autocuration,,BAO_0000219
2540,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,,722.0,1,,B,CHEMBL616890,107,,H,Autocuration,,BAO_0000219
2541,,9,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL616891,107,,D,Expert,,BAO_0000219
2542,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,,,,,722.0,1,,B,CHEMBL616892,107,,H,Autocuration,,BAO_0000219
2543,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,,,,,722.0,1,,B,CHEMBL616893,107,,H,Autocuration,,BAO_0000219
2544,,8,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,,,,,723.0,1,,F,CHEMBL616894,10620,,H,Autocuration,,BAO_0000219
2545,,8,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,,,,,723.0,1,,B,CHEMBL616895,107,,H,Expert,,BAO_0000219
2546,,8,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,,1,,F,CHEMBL616896,10620,,H,Autocuration,,BAO_0000019
2547,,8,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617099,10621,,H,Autocuration,,BAO_0000357
2548,,8,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,,,,,,1,,B,CHEMBL617100,10621,,H,Autocuration,,BAO_0000357
2549,,8,Binding affinity against rabbit aorta 5-HT2A receptor,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL884532,107,,H,Autocuration,,BAO_0000357
2550,,8,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617101,107,,H,Expert,,BAO_0000357
2551,,8,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617102,107,,H,Expert,,BAO_0000357
2552,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617103,107,,H,Autocuration,,BAO_0000019
2553,,8,The compound was tested for binding affinity against 5-HT2A receptor,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617104,107,,H,Expert,,BAO_0000357
2554,,8,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL857979,10576,,H,Autocuration,,BAO_0000219
2555,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,,,,,,1,,B,CHEMBL857502,12687,,H,Autocuration,,BAO_0000019
2556,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,1,,B,CHEMBL617105,12687,,H,Autocuration,,BAO_0000019
2557,,8,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,,,Stomach,945.0,,1,,B,CHEMBL858021,12687,,H,Autocuration,,BAO_0000019
2558,,9,Binding affinity for 5-HT 2A in rat stomach fundus,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL875910,12687,,D,Expert,,BAO_0000019
2559,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,,,,,,1,,B,CHEMBL617106,12687,,H,Autocuration,,BAO_0000019
2560,,8,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,,,,,723.0,1,,B,CHEMBL617107,12687,,H,Expert,,BAO_0000219
2561,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,,,,,,1,,F,CHEMBL617108,12687,,H,Autocuration,,BAO_0000019
2562,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,,,,,,1,,F,CHEMBL617109,12687,,H,Autocuration,,BAO_0000019
2563,,8,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617110,12687,,H,Autocuration,,BAO_0000357
2564,,8,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,,,,,,1,,B,CHEMBL617111,12687,,H,Autocuration,,BAO_0000357
2565,,9,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617112,12687,,D,Expert,,BAO_0000019
2566,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617113,12687,,H,Autocuration,,BAO_0000357
2567,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617114,12687,,H,Autocuration,,BAO_0000357
2568,,8,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617115,12687,,H,Autocuration,,BAO_0000357
2569,,8,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,1,,F,CHEMBL617116,12687,,H,Autocuration,,BAO_0000219
2570,,8,Efficacy at 5-hydroxytryptamine 2A receptor,,,,,,,1,,F,CHEMBL617117,12687,,H,Autocuration,,BAO_0000019
2571,,8,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,,,,,,1,,B,CHEMBL617118,12687,,H,Autocuration,,BAO_0000357
2572,,9,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617119,12687,,D,Expert,,BAO_0000357
2573,,9,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617120,12687,,D,Expert,,BAO_0000357
2574,,9,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617121,12687,,D,Expert,,BAO_0000219
2575,,8,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,,,,,,1,,F,CHEMBL617122,12687,,H,Autocuration,,BAO_0000219
2576,,8,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617123,12687,,H,Autocuration,,BAO_0000019
2577,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,1,,B,CHEMBL617124,12687,,H,Expert,,BAO_0000019
2578,,8,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,,,,,,1,,B,CHEMBL617600,12687,,H,Expert,,BAO_0000249
2579,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,,,,,,1,,B,CHEMBL617601,12687,,H,Expert,,BAO_0000357
2580,,8,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,,,,,,1,,B,CHEMBL882923,12687,,H,Expert,,BAO_0000019
2581,,8,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617602,12687,,H,Autocuration,,BAO_0000357
2582,,8,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,,,,,,1,,B,CHEMBL617603,12687,,H,Autocuration,,BAO_0000019
2583,,8,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617604,12687,,H,Autocuration,,BAO_0000357
2584,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617605,12687,,H,Expert,,BAO_0000019
2585,,8,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617606,12687,,H,Expert,,BAO_0000019
2586,,9,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617607,12687,,D,Expert,,BAO_0000019
2587,,8,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617455,12687,,H,Autocuration,,BAO_0000249
2588,,9,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617456,12687,,D,Expert,,BAO_0000019
2589,,8,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,,,,,,1,,B,CHEMBL617457,12687,,H,Expert,,BAO_0000357
2590,,9,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617458,12687,,D,Expert,,BAO_0000357
2591,,9,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617459,12687,,D,Expert,,BAO_0000019
2592,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,,,,,,1,,B,CHEMBL617460,12687,,H,Expert,,BAO_0000357
2593,,8,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,,,,,,1,,B,CHEMBL617461,12687,,H,Expert,,BAO_0000357
2594,,9,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617462,12687,,D,Expert,,BAO_0000019
2595,,8,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,,,,,,1,,B,CHEMBL617463,12687,,H,Autocuration,,BAO_0000357
2596,,8,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,,,,,,1,,B,CHEMBL617464,12687,,H,Autocuration,,BAO_0000019
2597,,8,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,,,,,,1,,B,CHEMBL617465,12687,,H,Autocuration,,BAO_0000019
2598,,8,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,,,,,,1,,B,CHEMBL617466,12687,,H,Expert,,BAO_0000019
2599,,8,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,1,,B,CHEMBL617467,12687,,H,Autocuration,,BAO_0000019
2600,,8,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,,,,,,1,,B,CHEMBL617468,12687,,H,Expert,,BAO_0000019
2601,,8,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,,,,,,1,,B,CHEMBL617469,12687,,H,Autocuration,,BAO_0000019
2602,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617470,12687,,H,Autocuration,,BAO_0000019
2603,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,,,,,,1,,B,CHEMBL617471,12687,,H,Autocuration,,BAO_0000019
2604,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,,,,,723.0,1,,B,CHEMBL617472,12687,,H,Expert,,BAO_0000219
2605,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,,,,,,1,,B,CHEMBL617473,12687,,H,Expert,,BAO_0000357
2606,,9,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617474,12687,,D,Expert,,BAO_0000019
2607,,9,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617475,12687,,D,Expert,,BAO_0000019
2608,,8,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,,,Brain,955.0,,1,,B,CHEMBL617476,12687,,H,Autocuration,,BAO_0000221
2609,,8,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617477,12687,,H,Expert,,BAO_0000357
2610,,8,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,,,,,723.0,1,,B,CHEMBL617478,12687,,H,Expert,,BAO_0000219
2611,,8,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,,,,,,1,,F,CHEMBL617479,12687,,H,Autocuration,,BAO_0000221
2612,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,,,,,,1,,B,CHEMBL617480,12687,,H,Autocuration,,BAO_0000357
2613,,8,Binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617481,12687,,H,Expert,,BAO_0000357
2614,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,,,,,,1,,B,CHEMBL617482,12687,,H,Expert,,BAO_0000019
2615,,8,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617483,12687,,H,Autocuration,,BAO_0000019
2616,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL621528,12687,,H,Autocuration,,BAO_0000357
2617,,9,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Rattus norvegicus,,,,,723.0,1,10116.0,B,CHEMBL621529,12687,,D,Expert,,BAO_0000219
2618,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL621530,12687,,H,Expert,,BAO_0000357
2619,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL621531,12687,,H,Expert,,BAO_0000357
2620,,9,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL621532,12687,,D,Expert,,BAO_0000019
2621,,8,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL621533,12687,,H,Expert,,BAO_0000357
2622,,8,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL621534,12687,,H,Expert,,BAO_0000219
2623,,8,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,,,,,,1,,B,CHEMBL621535,12687,,H,Autocuration,,BAO_0000019
2624,,8,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL621536,12687,,H,Autocuration,,BAO_0000357
2625,,8,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL621537,12687,,H,Autocuration,,BAO_0000357
2626,,9,Binding affinity for 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL621538,12687,,D,Expert,,BAO_0000357
2627,,8,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,,,,,,1,,B,CHEMBL621539,12687,,H,Autocuration,,BAO_0000019
2628,,8,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,,,,,,1,,B,CHEMBL621540,12687,,H,Autocuration,,BAO_0000019
2629,,8,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,,,,,,1,,B,CHEMBL621541,12687,,H,Autocuration,,BAO_0000019
2630,,8,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL621542,12687,,H,Autocuration,,BAO_0000019
2631,,8,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,,,,,,1,,B,CHEMBL621543,12687,,H,Expert,,BAO_0000357
2632,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL621544,12687,,H,Expert,,BAO_0000357
2633,,9,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL621545,12687,,D,Expert,,BAO_0000357
2634,,8,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL621546,12687,,H,Autocuration,,BAO_0000357
2635,,8,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,,,,,,1,,B,CHEMBL621547,12687,,H,Autocuration,,BAO_0000357
2636,,8,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,,,,,723.0,1,,B,CHEMBL618692,12687,,H,Expert,,BAO_0000219
2637,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL618693,12687,,H,Autocuration,,BAO_0000357
2638,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL872922,12687,,H,Autocuration,,BAO_0000357
2639,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL618694,12687,,H,Autocuration,,BAO_0000357
2640,,9,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL618695,12687,,D,Expert,,BAO_0000357
2641,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,,,,,,1,,B,CHEMBL618696,12687,,H,Autocuration,,BAO_0000357
2642,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,,,,,,1,,B,CHEMBL618697,12687,,H,Expert,,BAO_0000357
2643,,8,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL618892,12687,,H,Autocuration,,BAO_0000357
2644,,8,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL618893,12687,,H,Autocuration,,BAO_0000357
2645,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL618894,12687,,H,Autocuration,,BAO_0000357
2646,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,,,,,723.0,1,,B,CHEMBL618895,12687,,H,Expert,,BAO_0000219
2647,,9,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL618896,12687,,D,Expert,,BAO_0000357
2648,,8,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,,,Caudate-putamen,5383.0,,1,,B,CHEMBL618897,12687,,H,Autocuration,,BAO_0000019
2649,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,,,,,,1,,B,CHEMBL618898,12687,,H,Autocuration,,BAO_0000357
2650,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,,,,,,1,,B,CHEMBL618899,12687,,H,Autocuration,,BAO_0000357
2651,,8,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,,,,,,1,,B,CHEMBL618900,12687,,H,Autocuration,,BAO_0000357
2652,,8,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,,,,,,1,,B,CHEMBL618901,12687,,H,Autocuration,,BAO_0000019
2653,,8,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL618902,12687,,H,Autocuration,,BAO_0000357
2654,,9,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,Hippocampus,10000000.0,,1,10116.0,B,CHEMBL618903,12687,,D,Expert,,BAO_0000221
2655,,8,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL618904,12687,,H,Autocuration,,BAO_0000357
2656,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,,,,,,1,,B,CHEMBL618905,12687,,H,Autocuration,,BAO_0000357
2657,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,,,,,,1,,B,CHEMBL618906,12687,,H,Autocuration,,BAO_0000357
2658,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,,,,,723.0,1,,B,CHEMBL618907,12687,,H,Expert,,BAO_0000219
2659,,8,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,,,,,,1,,B,CHEMBL618908,12687,,H,Autocuration,,BAO_0000019
2660,,8,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617909,12687,,H,Autocuration,,BAO_0000357
2661,,8,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,,,,,,1,,B,CHEMBL617910,12687,,H,Expert,,BAO_0000019
2662,,8,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,,,Brain,955.0,,1,,B,CHEMBL617911,12687,,H,Autocuration,,BAO_0000221
2663,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL872923,12687,,H,Autocuration,,BAO_0000249
2664,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617912,12687,,H,Autocuration,,BAO_0000249
2665,,9,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617913,12687,,D,Expert,,BAO_0000019
2666,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617914,12687,,H,Expert,,BAO_0000249
2667,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617915,12687,,H,Autocuration,,BAO_0000249
2668,,8,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617916,12687,,H,Autocuration,,BAO_0000249
2669,,9,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617917,12687,,D,Expert,,BAO_0000019
2670,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617918,12687,,H,Expert,,BAO_0000019
2671,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,,,,,,1,,B,CHEMBL617919,12687,,H,Autocuration,,BAO_0000019
2672,,9,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617920,12687,,D,Expert,,BAO_0000019
2673,,9,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617921,12687,,D,Expert,,BAO_0000019
2674,,5,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617922,105102,,D,Expert,,BAO_0000224
2675,,8,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL617923,12687,,H,Autocuration,,BAO_0000357
2676,,8,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,,,,,,1,,B,CHEMBL617924,12687,,H,Autocuration,,BAO_0000357
2677,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,,,,,,1,,B,CHEMBL617925,12687,,H,Autocuration,,BAO_0000357
2678,,9,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617926,12687,,D,Expert,,BAO_0000357
2679,,8,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,,,,,,1,,B,CHEMBL617927,12687,,H,Autocuration,,BAO_0000357
2680,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,,,,,,1,,B,CHEMBL617928,12687,,H,Autocuration,,BAO_0000357
2681,,9,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617929,12687,,D,Expert,,BAO_0000019
2682,,8,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,,,,,,1,,B,CHEMBL617930,12687,,H,Expert,,BAO_0000019
2683,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL617931,12687,,H,Autocuration,,BAO_0000019
2684,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL617932,12687,,H,Autocuration,,BAO_0000019
2685,,8,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,,,,,449.0,1,,B,CHEMBL617933,12687,,H,Autocuration,,BAO_0000219
2686,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,1,,B,CHEMBL617934,12687,,H,Autocuration,,BAO_0000019
2687,,8,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,,,,,,1,,B,CHEMBL617935,12687,,H,Autocuration,,BAO_0000019
2688,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,,,,,,1,,B,CHEMBL617936,12687,,H,Autocuration,,BAO_0000357
2689,,8,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,,,,,,1,,B,CHEMBL617937,12687,,H,Autocuration,,BAO_0000019
2690,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,,,,,,1,,B,CHEMBL617938,12687,,H,Autocuration,,BAO_0000019
2691,,8,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,,,,,,1,,B,CHEMBL617939,12687,,H,Autocuration,,BAO_0000218
2692,,8,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,,,,,,1,,B,CHEMBL617940,12687,,H,Autocuration,,BAO_0000218
2693,,8,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,,,,,,1,,B,CHEMBL617941,12687,,H,Autocuration,,BAO_0000218
2694,,8,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,,,,,,1,,B,CHEMBL617942,12687,,H,Expert,,BAO_0000357
2695,,8,Ratio of pKi of 5-HT2A to that of D2 receptor,,,,,,,1,,B,CHEMBL617943,12687,,H,Expert,,BAO_0000357
2696,,4,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617944,105093,,H,Expert,,BAO_0000224
2697,,4,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617945,105093,,H,Expert,,BAO_0000224
2698,,4,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617946,105075,,H,Expert,,BAO_0000224
2699,,8,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,,,,,,1,,B,CHEMBL617947,12687,,H,Autocuration,,BAO_0000357
2700,,8,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,,,,,,1,,B,CHEMBL617948,12687,,H,Expert,,BAO_0000357
2701,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,,,,,,1,,F,CHEMBL858116,12687,,H,Autocuration,,BAO_0000019
2702,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,,,,,,1,,F,CHEMBL617949,12687,,H,Autocuration,,BAO_0000019
2703,,8,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,,,,,,1,,F,CHEMBL617950,12687,,H,Autocuration,,BAO_0000019
2704,,8,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,,,Thoracic aorta,1515.0,,1,,F,CHEMBL617951,12687,,H,Expert,,BAO_0000019
2705,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,,,Thoracic aorta,1515.0,,1,,F,CHEMBL617952,12687,,H,Expert,,BAO_0000019
2706,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,,,Thoracic aorta,1515.0,,1,,F,CHEMBL617953,12687,,H,Autocuration,,BAO_0000019
2707,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL617954,12687,,H,Autocuration,,BAO_0000357
2708,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617955,12687,,H,Expert,,BAO_0000019
2709,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,1,,B,CHEMBL857071,12687,,H,Autocuration,,BAO_0000019
2710,,8,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,,,,,,1,,B,CHEMBL617270,12687,,H,Expert,,BAO_0000019
2711,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,,,,,339.0,1,,B,CHEMBL617271,12687,,H,Autocuration,,BAO_0000219
2712,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,,,,,339.0,1,,B,CHEMBL617272,12687,,H,Autocuration,,BAO_0000219
2713,,8,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,,,,,,1,,B,CHEMBL617273,12687,,H,Autocuration,,BAO_0000019
2714,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617274,12687,,D,Expert,,BAO_0000019
2715,,8,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617275,108,,H,Autocuration,,BAO_0000357
2716,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617276,108,,H,Autocuration,,BAO_0000357
2717,,8,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617277,108,,H,Autocuration,,BAO_0000357
2718,,8,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617278,108,,H,Expert,,BAO_0000019
2719,,8,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,,,,,,1,,B,CHEMBL617279,108,,H,Expert,,BAO_0000019
2720,,8,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617280,108,,H,Expert,,BAO_0000019
2721,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617281,108,,H,Autocuration,,BAO_0000357
2722,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617282,108,,H,Autocuration,,BAO_0000357
2723,,8,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,,,,,,1,,B,CHEMBL617283,108,,H,Expert,,BAO_0000019
2724,,8,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,,,,,,1,,B,CHEMBL617284,108,,H,Expert,,BAO_0000019
2725,,8,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617285,108,,H,Autocuration,,BAO_0000219
2726,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617286,108,,H,Autocuration,,BAO_0000019
2727,,9,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617287,108,,D,Expert,,BAO_0000357
2728,,8,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,,,,,,1,,B,CHEMBL617288,108,,H,Expert,,BAO_0000357
2729,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,,,,,,1,,B,CHEMBL617289,108,,H,Autocuration,,BAO_0000357
2730,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL872917,108,,H,Autocuration,,BAO_0000357
2731,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617290,108,,H,Autocuration,,BAO_0000357
2732,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617291,108,,H,Autocuration,,BAO_0000219
2733,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,,,,,449.0,1,,B,CHEMBL617292,108,,H,Autocuration,,BAO_0000219
2734,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,,,,,723.0,1,,B,CHEMBL617293,108,,H,Autocuration,,BAO_0000219
2735,,9,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617294,108,,D,Expert,,BAO_0000219
2736,,8,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,1,,B,CHEMBL617295,108,,H,Expert,,BAO_0000019
2737,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL617296,108,,H,Autocuration,,BAO_0000357
2738,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617297,108,,H,Autocuration,,BAO_0000019
2739,,8,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,,,,,449.0,1,,B,CHEMBL617298,108,,H,Expert,,BAO_0000219
2740,,8,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,,,,,449.0,1,,B,CHEMBL617299,108,,H,Expert,,BAO_0000219
2741,,8,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,,,,,449.0,1,,B,CHEMBL617300,108,,H,Autocuration,,BAO_0000219
2742,,8,Binding affinity against 5-HT2C receptor,,,,,,,1,,B,CHEMBL617454,108,,H,Autocuration,,BAO_0000357
2743,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617505,108,,H,Autocuration,,BAO_0000219
2744,,9,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617506,108,,D,Expert,,BAO_0000219
2745,,9,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617507,108,,D,Expert,,BAO_0000219
2746,,8,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,,,,,,1,,B,CHEMBL617508,108,,H,Expert,,BAO_0000357
2747,,9,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL857982,108,,D,Expert,,BAO_0000219
2748,,9,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617509,108,,D,Expert,,BAO_0000219
2749,,9,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617510,108,,D,Expert,,BAO_0000219
2750,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,,,,,,1,,B,CHEMBL617511,108,,H,Autocuration,,BAO_0000357
2751,,8,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617512,108,,H,Autocuration,,BAO_0000219
2752,,8,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617749,108,,H,Autocuration,,BAO_0000219
2753,,8,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,722.0,1,,B,CHEMBL617750,108,,H,Autocuration,,BAO_0000219
2754,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,722.0,1,,B,CHEMBL617751,108,,H,Autocuration,,BAO_0000219
2755,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,,,,,722.0,1,,B,CHEMBL617752,108,,H,Expert,,BAO_0000219
2756,,8,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,,,,,722.0,1,,B,CHEMBL617753,108,,H,Autocuration,,BAO_0000219
2757,,8,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,,,,,722.0,1,,B,CHEMBL617754,108,,H,Expert,,BAO_0000219
2758,,9,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617755,108,,D,Expert,,BAO_0000219
2759,,8,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,,,,,722.0,1,,B,CHEMBL617756,108,,H,Autocuration,,BAO_0000219
2760,,8,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,,,,,722.0,1,,B,CHEMBL617757,108,,H,Expert,,BAO_0000219
2761,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,,,,,722.0,1,,B,CHEMBL617758,108,,H,Expert,,BAO_0000219
2762,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,,,,,723.0,1,,B,CHEMBL617759,108,,H,Autocuration,,BAO_0000219
2763,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,,,,,722.0,1,,B,CHEMBL617760,108,,H,Autocuration,,BAO_0000219
2764,,8,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,,,,,485.0,1,,B,CHEMBL617761,108,,H,Expert,,BAO_0000219
2765,,9,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617762,108,,D,Expert,,BAO_0000357
2766,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617763,108,,H,Autocuration,,BAO_0000357
2767,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,,,,,722.0,1,,B,CHEMBL857983,108,,H,Autocuration,,BAO_0000219
2768,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,,,,,722.0,1,,B,CHEMBL617764,108,,H,Autocuration,,BAO_0000219
2769,,8,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,,,,,308.0,1,,B,CHEMBL617765,108,,H,Autocuration,,BAO_0000219
2770,,8,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,,,,,,1,,F,CHEMBL617766,108,,H,Autocuration,,BAO_0000019
2771,,8,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,,,Hippocampus,10000000.0,,1,,F,CHEMBL617767,108,,H,Autocuration,,BAO_0000221
2772,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,,,,,722.0,1,,B,CHEMBL617768,108,,H,Autocuration,,BAO_0000219
2773,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,,,,,722.0,1,,B,CHEMBL617769,108,,H,Autocuration,,BAO_0000219
2774,,8,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL858023,11864,,H,Autocuration,,BAO_0000357
2775,,8,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,,,Stomach,945.0,,1,,B,CHEMBL617770,11864,,H,Autocuration,,BAO_0000019
2776,,8,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,,,Stomach,945.0,,1,,B,CHEMBL617771,11864,,H,Autocuration,,BAO_0000019
2777,,8,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,,,,,625.0,1,,F,CHEMBL617772,11864,,H,Autocuration,,BAO_0000219
2778,,8,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,,723.0,1,,B,CHEMBL617773,11864,,H,Autocuration,,BAO_0000219
2779,,8,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,,,,,723.0,1,,B,CHEMBL617850,11864,,H,Autocuration,,BAO_0000219
2780,,8,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,,,,,723.0,1,,B,CHEMBL617851,11864,,H,Autocuration,,BAO_0000219
2781,,8,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,,,,,,1,,F,CHEMBL617852,11864,,H,Autocuration,,BAO_0000019
2782,,8,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Mus musculus,,,Stomach,945.0,,1,10090.0,B,CHEMBL858024,12689,,H,Autocuration,,BAO_0000019
2783,,9,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617853,12689,,D,Expert,,BAO_0000019
2784,,8,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,,,,,,1,,B,CHEMBL617854,108,,H,Expert,,BAO_0000357
2785,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL873477,108,,H,Expert,,BAO_0000357
2786,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617855,108,,H,Expert,,BAO_0000357
2787,,8,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,,,,,,1,,B,CHEMBL617856,108,,H,Expert,,BAO_0000019
2788,,8,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,,,,,,1,,B,CHEMBL617857,108,,H,Autocuration,,BAO_0000019
2789,,8,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,,,,,,1,,B,CHEMBL617858,108,,H,Autocuration,,BAO_0000249
2790,,8,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617859,108,,H,Autocuration,,BAO_0000357
2791,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617860,108,,H,Autocuration,,BAO_0000357
2792,,8,Binding activity radioligand.,,,,,,,1,,B,CHEMBL617861,108,,H,Autocuration,,BAO_0000357
2793,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617862,108,,H,Expert,,BAO_0000019
2794,,8,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,,,,,,1,,B,CHEMBL617863,108,,H,Autocuration,,BAO_0000019
2795,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,,,,,,1,,B,CHEMBL617864,108,,H,Autocuration,,BAO_0000249
2796,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,,,,,,1,,B,CHEMBL617649,108,,H,Autocuration,,BAO_0000249
2797,,8,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,,,,,,1,9823.0,F,CHEMBL617650,108,,H,Expert,,BAO_0000019
2798,,8,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Sus scrofa,,,,,,1,9823.0,F,CHEMBL617651,108,,H,Expert,,BAO_0000019
2799,,8,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617652,108,,H,Autocuration,,BAO_0000357
2800,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Sus scrofa,,,,,,1,9823.0,B,CHEMBL857072,108,,H,Autocuration,,BAO_0000019
2801,,8,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617653,108,,H,Autocuration,,BAO_0000357
2802,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617654,12687,,H,Autocuration,,BAO_0000019
2803,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,,,,,,1,,F,CHEMBL617655,12689,,H,Autocuration,,BAO_0000019
2804,,8,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL617656,12689,,H,Expert,,BAO_0000357
2805,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL617657,12689,,H,Autocuration,,BAO_0000357
2806,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,,,,,,1,,B,CHEMBL617658,12689,,H,Autocuration,,BAO_0000357
2807,,9,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617659,12689,,D,Expert,,BAO_0000357
2808,,9,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617838,12689,,D,Expert,,BAO_0000357
2809,Brain membranes,9,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617839,12689,,D,Expert,,BAO_0000249
2810,,8,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,,,,,,1,,B,CHEMBL617840,12689,,H,Autocuration,,BAO_0000357
2811,,8,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,,,,,,1,,B,CHEMBL617841,12689,,H,Autocuration,,BAO_0000019
2812,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,,,,,,1,,B,CHEMBL875915,12689,,H,Autocuration,,BAO_0000019
2813,,8,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,,,,,,1,,B,CHEMBL617842,12689,,H,Expert,,BAO_0000219
2814,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,,,,,723.0,1,,B,CHEMBL617843,12689,,H,Expert,,BAO_0000219
2815,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,,,,,,1,,B,CHEMBL617844,12689,,H,Expert,,BAO_0000357
2816,,8,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617845,12689,,H,Expert,,BAO_0000357
2817,,8,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,,,,,723.0,1,,B,CHEMBL617846,12689,,H,Expert,,BAO_0000219
2818,,8,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,,,,,,1,,B,CHEMBL617847,12689,,H,Autocuration,,BAO_0000357
2819,,8,Binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617848,12689,,H,Expert,,BAO_0000357
2820,,8,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL617849,12689,,H,Autocuration,,BAO_0000357
2821,,8,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL621507,12689,,H,Expert,,BAO_0000357
2822,,8,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,,,,,,1,,B,CHEMBL621508,12689,,H,Expert,,BAO_0000357
2823,,8,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,,,,,,1,,B,CHEMBL621509,12689,,H,Autocuration,,BAO_0000019
2824,,8,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,,,,,,1,,B,CHEMBL621510,12689,,H,Autocuration,,BAO_0000019
2825,,8,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,,,,,,1,,B,CHEMBL621511,12689,,H,Autocuration,,BAO_0000019
2826,,8,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,,,,,625.0,1,,B,CHEMBL621512,12689,,H,Expert,,BAO_0000219
2827,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL621513,12689,,H,Autocuration,,BAO_0000357
2828,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,,,,,,1,,B,CHEMBL621514,12689,,H,Expert,,BAO_0000357
2829,,8,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL621515,12689,,H,Expert,,BAO_0000219
2830,,8,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,,,,,,1,,B,CHEMBL621516,12689,,H,Autocuration,,BAO_0000219
2831,,8,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,,,Caudate-putamen,5383.0,,1,,B,CHEMBL621517,12689,,H,Autocuration,,BAO_0000019
2832,,8,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,,,,,,1,,B,CHEMBL621518,12689,,H,Autocuration,,BAO_0000357
2833,,8,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,,,,,,1,,B,CHEMBL621519,12689,,H,Autocuration,,BAO_0000019
2834,,8,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621520,12689,,H,Autocuration,,BAO_0000357
2835,,8,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621521,12689,,H,Autocuration,,BAO_0000357
2836,,8,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621522,12689,,H,Autocuration,,BAO_0000357
2837,,8,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,,,,,,1,,B,CHEMBL621523,12689,,H,Expert,,BAO_0000219
2838,,8,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621524,12689,,H,Autocuration,,BAO_0000357
2839,,9,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL621525,12689,,D,Expert,,BAO_0000357
2840,,8,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,,,,,,1,,B,CHEMBL872921,12689,,H,Autocuration,,BAO_0000357
2841,,8,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621526,12689,,H,Autocuration,,BAO_0000357
2842,,8,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,,,,,,1,,B,CHEMBL621527,12689,,H,Expert,,BAO_0000219
2843,,9,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617865,12689,,D,Expert,,BAO_0000019
2844,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617866,12689,,H,Autocuration,,BAO_0000357
2845,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL617867,12689,,H,Autocuration,,BAO_0000019
2846,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL617487,12689,,H,Autocuration,,BAO_0000357
2847,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617488,12689,,H,Expert,,BAO_0000357
2848,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,,,,,,1,,B,CHEMBL617489,12689,,H,Autocuration,,BAO_0000357
2849,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,,,,,,1,,B,CHEMBL617490,12689,,H,Autocuration,,BAO_0000019
2850,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,,,,,,1,,B,CHEMBL617491,12689,,H,Autocuration,,BAO_0000019
2851,,8,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,,,,,,1,,B,CHEMBL617492,12689,,H,Autocuration,,BAO_0000019
2852,,8,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,,,,,,1,,B,CHEMBL617493,12689,,H,Autocuration,,BAO_0000019
2853,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,,,,,,1,,B,CHEMBL617494,12689,,H,Autocuration,,BAO_0000357
2854,,9,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617495,12689,,D,Expert,,BAO_0000019
2855,,8,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617496,12689,,H,Autocuration,,BAO_0000357
2856,,8,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,,,,,485.0,1,,B,CHEMBL617497,12689,,H,Autocuration,,BAO_0000219
2857,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL617498,12689,,H,Autocuration,,BAO_0000357
2858,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,,,,,,1,,B,CHEMBL617499,12689,,H,Autocuration,,BAO_0000357
2859,,8,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,,,,,,1,,F,CHEMBL617500,12689,,H,Autocuration,,BAO_0000019
2860,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617501,108,,H,Autocuration,,BAO_0000357
2861,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617502,108,,H,Expert,,BAO_0000357
2862,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,,,,,,1,,B,CHEMBL617503,227,,H,Autocuration,,BAO_0000357
2863,,8,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,,,,,,1,,B,CHEMBL617504,227,,H,Autocuration,,BAO_0000357
2864,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,,,,,,1,,B,CHEMBL617406,227,,H,Autocuration,,BAO_0000357
2865,,9,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617407,227,,D,Expert,,BAO_0000019
2866,,8,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL617408,227,,H,Autocuration,,BAO_0000357
2867,,8,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617409,227,,H,Autocuration,,BAO_0000357
2868,,8,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617410,227,,H,Autocuration,,BAO_0000357
2869,,8,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617411,227,,H,Autocuration,,BAO_0000357
2870,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617412,227,,H,Autocuration,,BAO_0000019
2871,,9,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617774,227,,D,Expert,,BAO_0000357
2872,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617775,227,,D,Expert,,BAO_0000219
2873,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617776,227,,D,Expert,,BAO_0000219
2874,,9,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617777,227,,D,Expert,,BAO_0000219
2875,,9,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617778,227,,D,Expert,,BAO_0000219
2876,,8,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,722.0,1,,B,CHEMBL617779,227,,H,Autocuration,,BAO_0000219
2877,,8,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,,,,,722.0,1,,B,CHEMBL617780,227,,H,Expert,,BAO_0000219
2878,,8,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,,,,,722.0,1,,B,CHEMBL617781,227,,H,Autocuration,,BAO_0000219
2879,,9,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617782,227,,D,Expert,,BAO_0000219
2880,,9,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617783,227,,D,Expert,,BAO_0000219
2881,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,,,,,,1,,B,CHEMBL617784,227,,H,Autocuration,,BAO_0000357
2882,,8,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,,,,,722.0,1,,B,CHEMBL617785,227,,H,Autocuration,,BAO_0000219
2883,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,,,,,722.0,1,,B,CHEMBL857984,227,,H,Expert,,BAO_0000219
2884,,8,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,,,,,722.0,1,,B,CHEMBL617786,227,,H,Expert,,BAO_0000219
2885,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,,,,,722.0,1,,B,CHEMBL617787,227,,H,Expert,,BAO_0000219
2886,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617788,227,,D,Expert,,BAO_0000219
2887,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL617789,227,,D,Expert,,BAO_0000219
2888,,8,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,,,,,722.0,1,,B,CHEMBL617790,227,,H,Autocuration,,BAO_0000219
2889,,8,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,,,,,485.0,1,,B,CHEMBL617791,227,,H,Expert,,BAO_0000219
2890,,8,Binding affinity against 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617608,227,,H,Expert,,BAO_0000357
2891,,8,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,,,,,722.0,1,,B,CHEMBL617609,227,,H,Autocuration,,BAO_0000219
2892,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,,,,,722.0,1,,B,CHEMBL617610,227,,H,Autocuration,,BAO_0000219
2893,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,,,,,722.0,1,,B,CHEMBL617611,227,,H,Autocuration,,BAO_0000219
2894,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,722.0,1,,B,CHEMBL617612,227,,H,Autocuration,,BAO_0000219
2895,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,,,,,722.0,1,,B,CHEMBL617613,227,,H,Autocuration,,BAO_0000219
2896,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617614,227,,H,Autocuration,,BAO_0000019
2897,,8,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,,,Stomach,945.0,,1,,B,CHEMBL617615,12688,,H,Expert,,BAO_0000019
2898,,8,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,,,Stomach,945.0,,1,,B,CHEMBL858114,12688,,H,Expert,,BAO_0000357
2899,,8,Affinity against serotonergic receptor in the isolated rat stomach fundus,,,,Stomach,945.0,,1,,B,CHEMBL617616,12688,,H,Autocuration,,BAO_0000357
2900,,9,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,F,CHEMBL617617,12688,,D,Expert,,BAO_0000019
2901,,9,Antagonistic against 5-hydroxytryptamine 2B receptor,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL875914,12688,,D,Expert,,BAO_0000019
2902,,8,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,,,Stomach,945.0,,1,,F,CHEMBL617618,12688,,H,Autocuration,,BAO_0000019
2903,,9,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617619,12688,,D,Expert,,BAO_0000357
2904,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,,,,,,1,,F,CHEMBL617620,12688,,H,Autocuration,,BAO_0000019
2905,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,,,,,,1,,F,CHEMBL617621,12688,,H,Autocuration,,BAO_0000019
2906,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,,,,,,1,,F,CHEMBL617622,12688,,H,Autocuration,,BAO_0000019
2907,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617623,12688,,D,Expert,,BAO_0000357
2908,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617624,12688,,D,Expert,,BAO_0000357
2909,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617625,12688,,D,Expert,,BAO_0000357
2910,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL617626,12688,,D,Expert,,BAO_0000357
2911,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,Stomach,945.0,,1,,F,CHEMBL617627,12688,,H,Autocuration,,BAO_0000019
2912,,8,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,,,Stomach,945.0,,1,,F,CHEMBL617628,12688,,H,Expert,,BAO_0000019
2913,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,,,Stomach,945.0,,1,,F,CHEMBL617629,12688,,H,Autocuration,,BAO_0000019
2914,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,,,Stomach,945.0,,1,,F,CHEMBL858115,12688,,H,Autocuration,,BAO_0000019
2915,,9,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,F,CHEMBL617630,12688,,D,Expert,,BAO_0000019
2916,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,,,Thoracic aorta,1515.0,,1,,F,CHEMBL617631,12688,,H,Autocuration,,BAO_0000019
2917,,8,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,1,,B,CHEMBL617632,12688,,H,Autocuration,,BAO_0000357
2918,,8,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,,,,,,1,,B,CHEMBL617633,12688,,H,Expert,,BAO_0000357
2919,,8,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,1,,B,CHEMBL617634,12688,,H,Autocuration,,BAO_0000357
2920,,8,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,,,,,,1,,B,CHEMBL617635,12688,,H,Autocuration,,BAO_0000357
2922,,9,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,F,CHEMBL617637,12688,,D,Autocuration,,BAO_0000019
2923,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,,,,,,,1,,B,CHEMBL617638,227,,H,Autocuration,,BAO_0000357
2924,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,,,,,,1,,B,CHEMBL617639,227,,H,Autocuration,,BAO_0000357
2925,,8,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,,,,,,1,,B,CHEMBL617640,227,,H,Autocuration,,BAO_0000357
2926,,8,Evaluated for the binding affinity to 5-HT 2B receptor,,,,,,,1,,B,CHEMBL617641,227,,H,Autocuration,,BAO_0000357
2927,,8,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617642,227,,H,Autocuration,,BAO_0000357
2928,,8,Binding affinities against 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617643,227,,H,Autocuration,,BAO_0000357
2929,,8,Binding affinities towards 5-hydroxytryptamine 2B receptor,,,,,,,1,,B,CHEMBL617644,227,,H,Autocuration,,BAO_0000357
2930,,8,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,,,,,,1,,B,CHEMBL617645,227,,H,Autocuration,,BAO_0000357
2931,,8,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,,,,,,1,,B,CHEMBL617646,108,,H,Expert,,BAO_0000357
2932,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,,,,,,1,9913.0,B,CHEMBL617647,108,,H,Autocuration,,BAO_0000357
2933,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Bos taurus,,,,,,1,9913.0,B,CHEMBL617648,108,,H,Autocuration,,BAO_0000357
2934,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Bos taurus,,,,,,1,9913.0,B,CHEMBL617875,108,,H,Autocuration,,BAO_0000357
2935,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Bos taurus,,,,,,1,9913.0,B,CHEMBL617876,108,,H,Autocuration,,BAO_0000357
2936,,8,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Bos taurus,,,,,,1,9913.0,B,CHEMBL617877,108,,H,Expert,,BAO_0000357
2937,,8,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Bos taurus,,,,,,1,9913.0,B,CHEMBL617878,108,,H,Expert,,BAO_0000357
2938,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Bos taurus,,,,,,1,9913.0,B,CHEMBL617879,108,,H,Autocuration,,BAO_0000357
2939,,8,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617880,108,,H,Autocuration,,BAO_0000019
2940,,9,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617881,20033,,D,Intermediate,,BAO_0000357
2941,,8,Binding affinity against 5-HT1A receptor,,,,,,,1,,B,CHEMBL857073,51,,H,Autocuration,,BAO_0000357
2942,,8,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,,,,,449.0,1,,F,CHEMBL617882,108,,H,Expert,,BAO_0000219
2943,,9,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Homo sapiens,,,,,449.0,1,9606.0,F,CHEMBL617883,108,,D,Expert,,BAO_0000219
2944,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,,,,,,1,,F,CHEMBL617884,108,,H,Autocuration,,BAO_0000219
2945,,8,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,,,,,449.0,1,,B,CHEMBL617885,108,,H,Autocuration,,BAO_0000219
2946,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,,,,,449.0,1,,B,CHEMBL617886,108,,H,Autocuration,,BAO_0000219
2947,,9,Inhibition of human 5-hydroxytryptamine 2C receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617887,108,,D,Expert,,BAO_0000357
2948,,8,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL617888,108,,H,Autocuration,,BAO_0000357
2949,,8,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,,,,,,1,,B,CHEMBL617889,108,,H,Autocuration,,BAO_0000019
2950,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL617890,108,,H,Autocuration,,BAO_0000357
2951,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,1,,B,CHEMBL617891,108,,H,Autocuration,,BAO_0000357
2952,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,,,,,,1,,B,CHEMBL617892,108,,H,Autocuration,,BAO_0000357
2953,,8,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,,,,,449.0,1,,B,CHEMBL617893,108,,H,Expert,,BAO_0000219
2954,,8,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617894,108,,H,Expert,,BAO_0000219
2955,,8,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL617895,108,,H,Expert,,BAO_0000219
2956,,8,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,,,,,449.0,1,,B,CHEMBL617896,108,,H,Autocuration,,BAO_0000219
2957,,9,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617897,108,,D,Expert,,BAO_0000357
2958,,8,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,,,,,,1,,F,CHEMBL617898,108,,H,Autocuration,,BAO_0000019
2959,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,,,,,,1,,F,CHEMBL617899,108,,H,Autocuration,,BAO_0000019
2960,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Rattus norvegicus,,,,,449.0,1,10116.0,B,CHEMBL617900,108,,H,Expert,,BAO_0000219
2961,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,,,,,,1,,F,CHEMBL617901,108,,H,Autocuration,,BAO_0000019
2962,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,,,,,,1,,F,CHEMBL617902,108,,H,Autocuration,,BAO_0000019
2963,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,1,,F,CHEMBL617903,108,,H,Autocuration,,BAO_0000019
2964,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,,,,,,1,,B,CHEMBL617904,108,,H,Autocuration,,BAO_0000357
2965,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,,,,,,1,,B,CHEMBL617905,108,,H,Autocuration,,BAO_0000357
2966,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,,,,,,1,,B,CHEMBL617906,108,,H,Autocuration,,BAO_0000357
2967,,8,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,,,,,,1,,B,CHEMBL617907,108,,H,Autocuration,,BAO_0000357
2968,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,,,,,,1,,B,CHEMBL617908,108,,H,Autocuration,,BAO_0000357
2969,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL620617,108,,H,Expert,,BAO_0000219
2970,,9,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620618,108,,D,Expert,,BAO_0000019
2971,,8,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,,,,,,1,,B,CHEMBL620619,108,,H,Expert,,BAO_0000357
2972,,9,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620620,108,,D,Expert,,BAO_0000357
2973,,8,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,,,,,,1,,B,CHEMBL620621,108,,H,Autocuration,,BAO_0000357
2974,Membranes,7,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL872920,104698,,D,Autocuration,,BAO_0000249
2975,,6,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,,,,,,1,,B,CHEMBL620622,104698,,H,Autocuration,,BAO_0000223
2976,,7,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL620623,104698,,D,Autocuration,,BAO_0000019
2977,,6,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,,,,,,1,,B,CHEMBL620624,104698,,H,Autocuration,,BAO_0000019
2978,,6,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,,,,,,1,,B,CHEMBL620625,104698,,H,Autocuration,,BAO_0000019
2979,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,,,,,,1,,B,CHEMBL620626,104698,,H,Autocuration,,BAO_0000219
2980,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,,,,,,1,,B,CHEMBL621307,104698,,H,Autocuration,,BAO_0000019
2981,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,,,,,,1,,B,CHEMBL621308,104698,,H,Autocuration,,BAO_0000019
2982,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,,,,,,1,,B,CHEMBL621309,104698,,H,Autocuration,,BAO_0000223
2983,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,,,,,,1,,B,CHEMBL621310,104698,,H,Autocuration,,BAO_0000223
2984,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,,,,,,1,,B,CHEMBL621311,104698,,H,Autocuration,,BAO_0000223
2985,,6,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,1,,B,CHEMBL621502,104698,,H,Autocuration,,BAO_0000249
2986,,6,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,,,,,,1,,B,CHEMBL621503,104698,,H,Autocuration,,BAO_0000249
2987,Membranes,6,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,,,,,,1,,B,CHEMBL621504,104698,,H,Autocuration,,BAO_0000249
2988,,6,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL621505,104698,,H,Autocuration,,BAO_0000223
2989,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,1,,B,CHEMBL621506,104698,,H,Autocuration,,BAO_0000019
2990,,6,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,,,,,,1,,B,CHEMBL619781,104698,,H,Autocuration,,BAO_0000223
2991,,6,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,,,,,,1,,B,CHEMBL619782,104698,,H,Autocuration,,BAO_0000223
2992,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,,,,,,1,,B,CHEMBL619783,104698,,H,Autocuration,,BAO_0000019
2993,,7,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619784,104698,,D,Autocuration,,BAO_0000019
2994,,6,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL619785,104698,,H,Autocuration,,BAO_0000249
2995,,6,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL619786,104698,,H,Autocuration,,BAO_0000223
2996,,6,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,,,,,,1,,B,CHEMBL619787,104698,,H,Autocuration,,BAO_0000019
2997,,6,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,,,,,,1,,B,CHEMBL872925,104698,,H,Autocuration,,BAO_0000019
2998,,6,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,,,,,,1,,B,CHEMBL619788,104698,,H,Autocuration,,BAO_0000019
2999,,6,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,1,,B,CHEMBL619789,104698,,H,Autocuration,,BAO_0000249
3000,,6,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,,,,,,1,,B,CHEMBL619790,104698,,H,Autocuration,,BAO_0000249
3001,,6,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,1,,B,CHEMBL619791,104698,,H,Autocuration,,BAO_0000019
3002,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,,,,,,1,,B,CHEMBL619792,104698,,H,Autocuration,,BAO_0000019
3003,Membranes,6,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,,,,,,1,,B,CHEMBL619793,104698,,H,Autocuration,,BAO_0000249
3004,,7,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619794,104698,,D,Autocuration,,BAO_0000223
3005,,6,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,,,Brain,955.0,,1,,B,CHEMBL619795,104698,,H,Autocuration,,BAO_0000221
3006,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,,,,,,1,,B,CHEMBL619796,104698,,H,Autocuration,,BAO_0000019
3007,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,,,,,,1,,B,CHEMBL620448,104698,,H,Autocuration,,BAO_0000223
3008,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,1,,B,CHEMBL620449,104698,,H,Autocuration,,BAO_0000223
3009,,6,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,,,,,,1,,B,CHEMBL620450,104698,,H,Autocuration,,BAO_0000223
3010,,6,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,,,,,,1,,B,CHEMBL620451,104698,,H,Autocuration,,BAO_0000223
3011,,6,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,,,,,,1,,B,CHEMBL620631,104698,,H,Autocuration,,BAO_0000223
3012,,6,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,,,,,,1,,B,CHEMBL620632,104698,,H,Autocuration,,BAO_0000019
3013,,6,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,,,,,,1,,B,CHEMBL620633,104698,,H,Autocuration,,BAO_0000019
3014,,6,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,,,,,,1,,B,CHEMBL620634,104698,,H,Autocuration,,BAO_0000223
3015,,6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,,,,,,1,,B,CHEMBL620635,104698,,H,Autocuration,,BAO_0000019
3016,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620636,104698,,H,Autocuration,,BAO_0000218
3017,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620637,104698,,H,Autocuration,,BAO_0000218
3018,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620638,104698,,H,Autocuration,,BAO_0000218
3019,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620639,104698,,H,Autocuration,,BAO_0000218
3020,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620640,104698,,H,Autocuration,,BAO_0000218
3021,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620641,104698,,H,Autocuration,,BAO_0000218
3022,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620642,104698,,H,Autocuration,,BAO_0000218
3023,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620643,104698,,H,Autocuration,,BAO_0000218
3024,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620644,104698,,H,Autocuration,,BAO_0000218
3025,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620645,104698,,H,Autocuration,,BAO_0000218
3026,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620646,104698,,H,Autocuration,,BAO_0000218
3027,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620647,104698,,H,Autocuration,,BAO_0000218
3028,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620648,104698,,H,Autocuration,,BAO_0000218
3029,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620649,104698,,H,Autocuration,,BAO_0000218
3030,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620650,104698,,H,Autocuration,,BAO_0000218
3031,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620651,104698,,H,Autocuration,,BAO_0000218
3032,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL872875,104698,,H,Autocuration,,BAO_0000218
3033,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL620652,104698,,H,Autocuration,,BAO_0000218
3034,,6,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,,,,,,1,,F,CHEMBL620653,104698,,H,Autocuration,,BAO_0000019
3035,,6,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,,,,,,1,,B,CHEMBL857076,104698,,H,Autocuration,,BAO_0000019
3036,,7,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL620654,104698,,D,Autocuration,,BAO_0000019
3037,,6,Binding activity radioligand.,,,,,,,1,,B,CHEMBL620655,104698,,H,Autocuration,,BAO_0000223
3038,Brain membranes,6,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,,,,,,1,,B,CHEMBL620656,104698,,H,Autocuration,,BAO_0000249
3039,Brain membranes,6,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,,,,,,1,,B,CHEMBL620657,104698,,H,Autocuration,,BAO_0000249
3040,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,,,,,,1,,B,CHEMBL620658,108,,H,Autocuration,,BAO_0000357
3041,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,,,,,,1,,B,CHEMBL620659,108,,H,Autocuration,,BAO_0000357
3042,,8,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL620660,108,,H,Autocuration,,BAO_0000357
3043,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620661,108,,H,Autocuration,,BAO_0000357
3044,,8,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620662,108,,H,Autocuration,,BAO_0000357
3045,,8,Affinity for 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620663,108,,H,Expert,,BAO_0000357
3046,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,,,,,,1,,B,CHEMBL620664,108,,H,Autocuration,,BAO_0000357
3047,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,,,,,,1,,B,CHEMBL620665,108,,H,Expert,,BAO_0000357
3048,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,,,,,,1,,B,CHEMBL620666,108,,H,Autocuration,,BAO_0000357
3049,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,,,,,,1,,B,CHEMBL620667,108,,H,Autocuration,,BAO_0000357
3050,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,,,,,,1,,B,CHEMBL620668,108,,H,Expert,,BAO_0000357
3051,,8,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,,,,,,1,,B,CHEMBL620669,108,,H,Autocuration,,BAO_0000357
3052,,8,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620670,108,,H,Expert,,BAO_0000357
3053,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620671,108,,H,Autocuration,,BAO_0000357
3054,,8,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,,,,,,1,,B,CHEMBL620672,108,,H,Autocuration,,BAO_0000357
3055,,8,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,,,,,,1,,B,CHEMBL620673,108,,H,Autocuration,,BAO_0000357
3056,,8,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620674,108,,H,Autocuration,,BAO_0000357
3057,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL620675,108,,H,Autocuration,,BAO_0000357
3058,,8,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,,,,,,1,,B,CHEMBL620676,108,,H,Autocuration,,BAO_0000357
3059,,8,Affinity against 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL621382,108,,H,Autocuration,,BAO_0000357
3060,,9,Binding affinity against 5-hydroxytryptamine 2C receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL621383,108,,D,Expert,,BAO_0000357
3061,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL621384,108,,H,Autocuration,,BAO_0000357
3062,,8,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Bos taurus,,,,,,1,9913.0,B,CHEMBL621385,144,,H,Autocuration,,BAO_0000357
3063,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Bos taurus,,,,,,1,9913.0,B,CHEMBL617989,144,,H,Autocuration,,BAO_0000357
3064,,4,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617990,104714,,H,Expert,,BAO_0000019
3065,,4,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL875085,104714,,H,Autocuration,,BAO_0000221
3066,,4,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617991,104714,,H,Autocuration,,BAO_0000019
3067,,4,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617992,104714,,H,Autocuration,,BAO_0000019
3068,,4,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617993,104714,,H,Autocuration,,BAO_0000221
3069,,4,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617994,104714,,H,Autocuration,,BAO_0000221
3070,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617995,104714,,H,Autocuration,,BAO_0000019
3071,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617996,104714,,H,Autocuration,,BAO_0000019
3072,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617997,104714,,H,Autocuration,,BAO_0000019
3073,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617998,104714,,H,Autocuration,,BAO_0000019
3074,,4,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL617999,104714,,H,Autocuration,,BAO_0000019
3075,,4,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618000,104714,,H,Autocuration,,BAO_0000019
3076,,4,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617815,104714,,H,Autocuration,,BAO_0000221
3077,,4,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617816,104714,,H,Autocuration,,BAO_0000221
3078,,4,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617817,104714,,H,Autocuration,,BAO_0000221
3079,,4,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617818,104714,,H,Autocuration,,BAO_0000221
3080,,4,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617819,104714,,H,Autocuration,,BAO_0000221
3081,,4,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617820,104714,,H,Autocuration,,BAO_0000223
3082,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617821,104714,,H,Autocuration,,BAO_0000221
3083,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617822,104714,,H,Autocuration,,BAO_0000221
3084,,4,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617823,104714,,H,Autocuration,,BAO_0000221
3085,,4,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617824,104714,,H,Autocuration,,BAO_0000221
3086,,4,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617825,104714,,H,Autocuration,,BAO_0000221
3087,,4,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617826,104714,,H,Autocuration,,BAO_0000221
3088,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617827,104714,,H,Autocuration,,BAO_0000221
3089,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617828,104714,,H,Autocuration,,BAO_0000221
3090,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617829,104714,,H,Autocuration,,BAO_0000221
3091,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617830,104714,,H,Autocuration,,BAO_0000221
3092,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617831,104714,,H,Autocuration,,BAO_0000221
3093,,4,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL617832,104714,,H,Autocuration,,BAO_0000221
3094,,0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617833,22226,,U,Autocuration,,BAO_0000019
3095,,8,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,,,,,,1,,B,CHEMBL617834,51,,H,Autocuration,,BAO_0000357
3096,,5,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL617835,104714,,D,Expert,,BAO_0000223
3097,,4,Binding affinity towards 5-HT3 receptor,,,,,,,1,,B,CHEMBL617836,104714,,H,Autocuration,,BAO_0000223
3098,,4,Binding activity radioligand.,,,,,,,1,,B,CHEMBL617837,104714,,H,Autocuration,,BAO_0000223
3099,,4,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,,,,,,1,,B,CHEMBL620392,104714,,H,Autocuration,,BAO_0000019
3100,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620393,104714,,H,Autocuration,,BAO_0000223
3101,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620394,104714,,H,Autocuration,,BAO_0000223
3102,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,,,,,,1,,B,CHEMBL620395,104714,,H,Autocuration,,BAO_0000223
3103,,0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620396,22226,,U,Autocuration,,BAO_0000019
3104,,4,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,,,,,433.0,1,,B,CHEMBL620582,105030,,H,Expert,,BAO_0000219
3105,,4,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,,,,,,1,,B,CHEMBL620583,105030,,H,Autocuration,,BAO_0000218
3106,,4,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,1,,B,CHEMBL620584,105030,,H,Autocuration,,BAO_0000019
3107,,4,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,,,,,,1,,B,CHEMBL620585,105030,,H,Autocuration,,BAO_0000224
3108,,4,Compound was evaluated for the binding affinity at 5- HT3 receptor,,,,,,,1,,B,CHEMBL620586,105030,,H,Autocuration,,BAO_0000224
3109,,4,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,,,,,,1,,B,CHEMBL620587,105030,,H,Autocuration,,BAO_0000019
3110,,4,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,1,,B,CHEMBL620588,105030,,H,Autocuration,,BAO_0000019
3111,,4,5-hydroxytryptamine 3 receptor agonism in mouse,,,,,,,1,,F,CHEMBL620589,105030,,H,Autocuration,,BAO_0000218
3112,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,,,,,,1,,B,CHEMBL620590,105030,,H,Autocuration,,BAO_0000219
3113,,4,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,1,,B,CHEMBL617956,105030,,H,Autocuration,,BAO_0000019
3114,,4,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,,,,,,1,,B,CHEMBL617957,105030,,H,Autocuration,,BAO_0000019
3115,,4,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,,,,,,1,,B,CHEMBL617958,105030,,H,Autocuration,,BAO_0000224
3116,,4,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,1,,B,CHEMBL617959,105030,,H,Autocuration,,BAO_0000219
3117,,4,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,,,,,,1,,B,CHEMBL617960,105030,,H,Autocuration,,BAO_0000219
3118,,4,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,,,,,,1,,B,CHEMBL617961,105030,,H,Autocuration,,BAO_0000224
3119,,4,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,,,,,,1,,B,CHEMBL617962,105030,,H,Autocuration,,BAO_0000219
3120,,4,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,,,,,339.0,1,,B,CHEMBL617963,105030,,H,Autocuration,,BAO_0000219
3121,,8,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,1,,B,CHEMBL617964,11765,,H,Autocuration,,BAO_0000019
3122,,8,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,,,,,,1,,B,CHEMBL617965,11765,,H,Autocuration,,BAO_0000219
3123,,9,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Mus musculus,,,,,,1,10090.0,B,CHEMBL617966,10630,,D,Autocuration,,BAO_0000357
3124,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,,,,,,1,,B,CHEMBL857074,17106,,H,Autocuration,,BAO_0000019
3125,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617967,144,,H,Autocuration,,BAO_0000357
3126,,8,Binding activity radioligand.,Sus scrofa,,,,,,1,9823.0,B,CHEMBL617968,144,,H,Autocuration,,BAO_0000357
3127,,4,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617969,104714,,H,Autocuration,,BAO_0000223
3128,,4,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617970,104714,,H,Autocuration,,BAO_0000223
3129,,4,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617971,104714,,H,Autocuration,,BAO_0000223
3130,,4,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL617972,104714,,H,Autocuration,,BAO_0000019
3131,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617973,104714,,H,Autocuration,,BAO_0000019
3132,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617974,104714,,H,Autocuration,,BAO_0000019
3133,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Oryctolagus cuniculus,,,Ileum,2116.0,,1,9986.0,F,CHEMBL617975,104714,,H,Autocuration,,BAO_0000221
3134,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617976,104714,,H,Autocuration,,BAO_0000019
3135,,4,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617977,104714,,H,Autocuration,,BAO_0000019
3136,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617978,104714,,H,Autocuration,,BAO_0000019
3137,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Oryctolagus cuniculus,,,,,,1,9986.0,F,CHEMBL617979,104714,,H,Autocuration,,BAO_0000019
3138,,4,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Oryctolagus cuniculus,,,,,449.0,1,9986.0,B,CHEMBL617980,104714,,H,Autocuration,,BAO_0000219
3139,,7,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617981,104698,,D,Autocuration,,BAO_0000019
3140,,8,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,,,,,,1,,B,CHEMBL617982,12020,,H,Autocuration,,BAO_0000019
3141,,8,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,,,,,,1,,B,CHEMBL617983,12020,,H,Autocuration,,BAO_0000357
3142,,7,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617984,104698,,D,Autocuration,,BAO_0000019
3143,,6,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,,,,,,1,,B,CHEMBL617985,104698,,H,Autocuration,,BAO_0000019
3144,,6,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,Heart,948.0,,1,,F,CHEMBL617986,104698,,H,Autocuration,,BAO_0000218
3145,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,Heart,948.0,,1,,F,CHEMBL617987,104698,,H,Autocuration,,BAO_0000019
3146,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,,,Heart,948.0,,1,,F,CHEMBL617988,104698,,H,Autocuration,,BAO_0000019
3147,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,,,Heart,948.0,,1,,F,CHEMBL617792,104698,,H,Autocuration,,BAO_0000019
3148,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,,,Heart,948.0,,1,,F,CHEMBL617793,104698,,H,Autocuration,,BAO_0000019
3149,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,1,,F,CHEMBL617794,104698,,H,Autocuration,,BAO_0000019
3150,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,1,,F,CHEMBL617795,104698,,H,Autocuration,,BAO_0000019
3151,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,1,,F,CHEMBL617796,104698,,H,Autocuration,,BAO_0000019
3152,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,,,,,,1,,F,CHEMBL617797,104698,,H,Autocuration,,BAO_0000019
3153,,7,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617798,104698,,D,Autocuration,,BAO_0000218
3154,,6,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,,,,,,1,,F,CHEMBL617799,104698,,H,Autocuration,,BAO_0000218
3155,,7,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617800,104698,,D,Autocuration,,BAO_0000218
3156,,7,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617801,104698,,D,Autocuration,,BAO_0000019
3157,,7,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617802,104698,,D,Autocuration,,BAO_0000218
3158,,7,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617803,104698,,D,Autocuration,,BAO_0000019
3159,,6,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,1,,B,CHEMBL617804,104698,,H,Autocuration,,BAO_0000019
3160,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617805,104698,,D,Autocuration,,BAO_0000019
3161,,6,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL617806,104698,,H,Autocuration,,BAO_0000223
3162,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,,,,,,1,,B,CHEMBL617807,104698,,H,Autocuration,,BAO_0000019
3163,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,,,,,,1,,B,CHEMBL617808,104698,,H,Autocuration,,BAO_0000019
3164,,6,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,,,,,,1,,B,CHEMBL617809,104698,,H,Autocuration,,BAO_0000249
3165,,6,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,,,,,,1,,B,CHEMBL617810,104698,,H,Autocuration,,BAO_0000019
3166,,6,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,,,Brain,955.0,,1,,B,CHEMBL617811,104698,,H,Autocuration,,BAO_0000249
3167,,6,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,,,Brain,955.0,,1,,B,CHEMBL617812,104698,,H,Autocuration,,BAO_0000221
3168,,6,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617813,104698,,H,Autocuration,,BAO_0000249
3169,,6,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,,,,,,1,,B,CHEMBL617814,104698,,H,Autocuration,,BAO_0000249
3170,,6,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,,,,,,1,,B,CHEMBL617698,104698,,H,Autocuration,,BAO_0000019
3171,,7,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617699,104698,,D,Autocuration,,BAO_0000019
3172,,7,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617700,104698,,D,Autocuration,,BAO_0000019
3173,,7,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617701,104698,,D,Autocuration,,BAO_0000223
3174,,6,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,,,,,,1,,B,CHEMBL617702,104698,,H,Autocuration,,BAO_0000019
3175,Membranes,6,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,,,,,,1,,B,CHEMBL617703,104698,,H,Autocuration,,BAO_0000249
3176,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617704,104698,,D,Autocuration,,BAO_0000019
3177,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,,,,,,1,,B,CHEMBL617705,104698,,H,Autocuration,,BAO_0000223
3178,,7,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL617706,104698,,D,Autocuration,,BAO_0000223
3179,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,,,,,433.0,1,,B,CHEMBL617707,104698,,H,Autocuration,,BAO_0000219
3180,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,,,,,433.0,1,,B,CHEMBL617708,104698,,H,Autocuration,,BAO_0000219
3181,,6,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,,,,,,1,,B,CHEMBL617709,104698,,H,Autocuration,,BAO_0000019
3182,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,,,,,,1,,B,CHEMBL617710,104698,,H,Autocuration,,BAO_0000019
3183,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,,,,,,1,,B,CHEMBL882925,104698,,H,Autocuration,,BAO_0000019
3184,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,,,,,,1,,B,CHEMBL617711,104698,,H,Autocuration,,BAO_0000019
3185,,6,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,,,,,,1,,F,CHEMBL617712,104698,,H,Autocuration,,BAO_0000019
3186,,7,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617713,104698,,D,Autocuration,,BAO_0000019
3187,,6,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,,,,,,1,,F,CHEMBL617714,104698,,H,Autocuration,,BAO_0000019
3188,,6,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,,,,,,1,,F,CHEMBL617715,104698,,H,Autocuration,,BAO_0000218
3189,,6,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,,,,,,1,,F,CHEMBL617716,104698,,H,Autocuration,,BAO_0000218
3190,,6,Inhibition of 5-HT evoked reflex bradycardia in rat.,,,,,,,1,,F,CHEMBL617717,104698,,H,Autocuration,,BAO_0000218
3191,,6,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617718,104698,,H,Autocuration,,BAO_0000218
3192,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617719,104698,,H,Autocuration,,BAO_0000218
3193,,6,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,,,,,,1,,F,CHEMBL617720,104698,,H,Autocuration,,BAO_0000218
3194,,7,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL617721,104698,,D,Autocuration,,BAO_0000218
3195,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617722,104698,,H,Autocuration,,BAO_0000218
3196,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,,,,,,1,,F,CHEMBL617723,104698,,H,Autocuration,,BAO_0000218
3197,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617724,104698,,H,Autocuration,,BAO_0000218
3198,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617725,104698,,H,Autocuration,,BAO_0000218
3199,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617726,104698,,H,Autocuration,,BAO_0000218
3200,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617727,104698,,H,Autocuration,,BAO_0000218
3201,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617728,104698,,H,Autocuration,,BAO_0000218
3202,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617729,104698,,H,Autocuration,,BAO_0000218
3203,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617730,104698,,H,Autocuration,,BAO_0000218
3204,,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617731,104698,,H,Autocuration,,BAO_0000218
3205,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617732,104698,,H,Autocuration,,BAO_0000218
3206,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617733,104698,,H,Autocuration,,BAO_0000218
3207,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617734,104698,,H,Autocuration,,BAO_0000218
3208,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,,,,,,1,,F,CHEMBL872874,104698,,H,Autocuration,,BAO_0000218
3209,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,,,,,,1,,F,CHEMBL617735,104698,,H,Autocuration,,BAO_0000218
3210,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,,,,,,1,,F,CHEMBL617736,104698,,H,Autocuration,,BAO_0000218
3211,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,,,,,,1,,F,CHEMBL617737,104698,,H,Autocuration,,BAO_0000218
3212,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,,,,,,1,,F,CHEMBL617738,104698,,H,Autocuration,,BAO_0000218
3213,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617739,104698,,H,Autocuration,,BAO_0000218
3214,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617740,104698,,H,Autocuration,,BAO_0000218
3215,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617741,104698,,H,Autocuration,,BAO_0000218
3216,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617742,104698,,H,Autocuration,,BAO_0000218
3217,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617743,104698,,H,Autocuration,,BAO_0000218
3218,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617744,104698,,H,Autocuration,,BAO_0000218
3219,,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,,,,,,1,,F,CHEMBL617745,104698,,H,Autocuration,,BAO_0000218
3220,,6,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,,,,,,1,,F,CHEMBL617746,104698,,H,Autocuration,,BAO_0000218
3221,,6,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,,,,,,1,,F,CHEMBL617747,104698,,H,Autocuration,,BAO_0000218
3222,,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,,,,,,1,,F,CHEMBL617748,104698,,H,Autocuration,,BAO_0000218
3223,,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,,,,,,1,,F,CHEMBL618909,104698,,H,Autocuration,,BAO_0000218
3224,,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,,,,,,1,,F,CHEMBL618910,104698,,H,Autocuration,,BAO_0000218
3225,,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,,,,,,1,,F,CHEMBL618911,104698,,H,Autocuration,,BAO_0000218
3226,,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,,,,,,1,,F,CHEMBL618912,104698,,H,Autocuration,,BAO_0000218
3227,,6,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,,,,,,1,,F,CHEMBL618913,104698,,H,Autocuration,,BAO_0000218
3228,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,1,,F,CHEMBL618914,104698,,H,Autocuration,,BAO_0000019
3229,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,,,,,,1,,F,CHEMBL618915,104698,,H,Autocuration,,BAO_0000019
3230,,7,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL618916,104698,,D,Autocuration,,BAO_0000223
3231,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,,,,,,1,,F,CHEMBL618917,104698,,H,Autocuration,,BAO_0000019
3232,,7,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,,,Hippocampus,10000000.0,,1,,B,CHEMBL618918,104698,,D,Intermediate,,BAO_0000221
3233,,7,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL618919,104698,,D,Autocuration,,BAO_0000019
3234,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL618920,104698,,D,Autocuration,,BAO_0000019
3235,,6,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618921,104698,,H,Autocuration,,BAO_0000223
3236,,6,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618922,104698,,H,Autocuration,,BAO_0000019
3237,,6,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,,,,,,1,,B,CHEMBL618923,104698,,H,Autocuration,,BAO_0000019
3238,,6,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,,,,,,1,,B,CHEMBL618924,104698,,H,Autocuration,,BAO_0000019
3239,,6,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,,,,,,1,,B,CHEMBL618925,104698,,H,Autocuration,,BAO_0000019
3240,,6,Binding affinity towards 5-HT3 receptor in rat was evaluated,,,,,,,1,,B,CHEMBL618926,104698,,H,Autocuration,,BAO_0000019
3241,,9,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL618927,20033,,D,Intermediate,,BAO_0000221
3242,,9,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL618928,20033,,D,Intermediate,,BAO_0000221
3243,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL618929,20033,,D,Intermediate,,BAO_0000221
3244,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL618930,20033,,D,Intermediate,,BAO_0000221
3245,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL618931,20033,,D,Intermediate,,BAO_0000221
3246,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619594,20033,,D,Intermediate,,BAO_0000221
3247,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619595,20033,,D,Intermediate,,BAO_0000221
3248,,9,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619596,20033,,D,Intermediate,,BAO_0000221
3249,,9,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619755,20033,,D,Intermediate,,BAO_0000221
3250,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619756,20033,,D,Intermediate,,BAO_0000221
3251,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619757,20033,,D,Intermediate,,BAO_0000221
3252,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619758,20033,,D,Intermediate,,BAO_0000221
3253,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619759,20033,,D,Intermediate,,BAO_0000221
3254,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619760,20033,,D,Intermediate,,BAO_0000221
3255,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619761,20033,,D,Intermediate,,BAO_0000221
3256,,9,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619762,20033,,D,Intermediate,,BAO_0000221
3257,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619763,20033,,D,Intermediate,,BAO_0000221
3258,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL617868,20033,,D,Intermediate,,BAO_0000221
3259,,9,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL617869,20033,,D,Intermediate,,BAO_0000357
3260,,9,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL882926,20033,,D,Intermediate,,BAO_0000249
3261,,9,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617870,20033,,D,Intermediate,,BAO_0000249
3262,,9,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617871,20033,,D,Intermediate,,BAO_0000357
3263,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617872,20033,,D,Intermediate,,BAO_0000357
3264,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617873,20033,,D,Intermediate,,BAO_0000357
3265,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL617874,20033,,D,Intermediate,,BAO_0000357
3266,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619067,20033,,D,Intermediate,,BAO_0000221
3267,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619068,20033,,D,Intermediate,,BAO_0000221
3268,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619069,20033,,D,Intermediate,,BAO_0000221
3269,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619070,20033,,D,Intermediate,,BAO_0000357
3270,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619071,20033,,D,Intermediate,,BAO_0000357
3271,,9,Agonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619072,20033,,D,Intermediate,,BAO_0000019
3272,,9,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619073,20033,,D,Intermediate,,BAO_0000019
3273,,9,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619074,20033,,D,Intermediate,,BAO_0000019
3274,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619075,20033,,D,Intermediate,,BAO_0000357
3275,,9,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL619076,20033,,D,Intermediate,,BAO_0000357
3276,,9,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL619077,20033,,D,Intermediate,,BAO_0000357
3277,,9,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL619078,20033,,D,Intermediate,,BAO_0000249
3278,,9,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL619079,20033,,D,Intermediate,,BAO_0000249
3279,,9,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL619080,20033,,D,Intermediate,,BAO_0000221
3280,,9,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619081,20033,,D,Expert,,BAO_0000357
3281,,9,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619082,20033,,D,Intermediate,,BAO_0000357
3282,,9,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619083,20033,,D,Intermediate,,BAO_0000357
3283,,9,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619084,20033,,D,Intermediate,,BAO_0000357
3284,,9,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL859397,20033,,D,Intermediate,,BAO_0000221
3285,,9,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619085,20033,,D,Intermediate,,BAO_0000221
3286,,9,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619086,20033,,D,Intermediate,,BAO_0000221
3287,,9,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619087,20033,,D,Intermediate,,BAO_0000221
3288,,9,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619088,20033,,D,Intermediate,,BAO_0000221
3289,,9,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619089,20033,,D,Intermediate,,BAO_0000357
3290,,8,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619090,168,,H,Autocuration,,BAO_0000357
3291,,9,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619091,20033,,D,Intermediate,,BAO_0000019
3292,,9,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619092,20033,,D,Intermediate,,BAO_0000357
3293,,9,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619093,20033,,D,Intermediate,,BAO_0000019
3294,,8,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Cavia porcellus,,,,,722.0,1,10141.0,B,CHEMBL619094,168,,H,Autocuration,,BAO_0000219
3295,,9,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619095,20033,,D,Intermediate,,BAO_0000019
3296,,9,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL857988,20033,,D,Intermediate,,BAO_0000357
3297,,9,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619096,20033,,D,Intermediate,,BAO_0000357
3298,,9,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Cavia porcellus,,,Striatum,2435.0,,1,10141.0,B,CHEMBL619097,20033,,D,Intermediate,,BAO_0000357
3299,,9,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Cavia porcellus,,,Hippocampus,10000000.0,,1,10141.0,B,CHEMBL619098,20033,,D,Intermediate,,BAO_0000221
3300,,9,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619751,20033,,D,Intermediate,,BAO_0000357
3301,,9,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619752,20033,,D,Intermediate,,BAO_0000357
3302,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL875096,20033,,D,Intermediate,,BAO_0000221
3303,,8,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,,,,,,1,,B,CHEMBL619004,108,,H,Autocuration,,BAO_0000357
3304,,8,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL619005,168,,H,Autocuration,,BAO_0000357
3305,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL619006,168,,H,Autocuration,,BAO_0000019
3306,,8,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,,,,,308.0,1,,B,CHEMBL619007,168,,H,Autocuration,,BAO_0000219
3307,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL619008,168,,H,Autocuration,,BAO_0000357
3308,,8,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL619009,168,,H,Autocuration,,BAO_0000357
3309,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,,,,,308.0,1,,B,CHEMBL619010,168,,H,Autocuration,,BAO_0000219
3310,,8,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,,,,,,1,,B,CHEMBL619011,10622,,H,Autocuration,,BAO_0000357
3311,,8,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,,,,,,1,,B,CHEMBL619012,10622,,H,Autocuration,,BAO_0000357
3312,,8,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,,,,,,1,,B,CHEMBL619013,10622,,H,Autocuration,,BAO_0000219
3313,,8,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,,,,,,1,,B,CHEMBL619014,10622,,H,Autocuration,,BAO_0000357
3314,,8,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,,,Cardiac atrium,2081.0,,1,,F,CHEMBL857503,11249,,H,Autocuration,,BAO_0000019
3315,,8,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,,,Cardiac atrium,2081.0,,1,,F,CHEMBL619015,11249,,H,Autocuration,,BAO_0000019
3316,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL619016,11249,,H,Autocuration,,BAO_0000357
3317,,8,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,,,Hippocampus,10000000.0,,1,,B,CHEMBL619017,11249,,H,Autocuration,,BAO_0000221
3318,,8,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Sus scrofa,,,Hippocampus,10000000.0,,1,9823.0,B,CHEMBL619018,168,,H,Autocuration,,BAO_0000221
3319,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL619019,168,,H,Autocuration,,BAO_0000019
3320,,9,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619020,10623,,D,Expert,,BAO_0000357
3321,,8,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,1,,F,CHEMBL619021,10623,,H,Autocuration,,BAO_0000019
3322,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,,,,,,1,,B,CHEMBL619022,10623,,H,Autocuration,,BAO_0000357
3323,,8,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,,,,,,1,,B,CHEMBL619023,10623,,H,Autocuration,,BAO_0000357
3324,,8,lntrinsic activity relative to 5-HT receptor,,,,,,,1,,F,CHEMBL619024,10623,,H,Autocuration,,BAO_0000019
3325,,8,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,,,,,,1,,F,CHEMBL619025,10623,,H,Autocuration,,BAO_0000019
3326,,8,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,,,,,,1,,F,CHEMBL619026,10623,,H,Expert,,BAO_0000019
3327,,8,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,,,,,,1,,F,CHEMBL619027,10623,,H,Autocuration,,BAO_0000019
3328,,8,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,,,,,,1,,F,CHEMBL619028,10623,,H,Autocuration,,BAO_0000019
3329,,8,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,,,,,,1,,F,CHEMBL619029,10623,,H,Autocuration,,BAO_0000019
3330,,8,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,,,,,,1,,F,CHEMBL619030,10623,,H,Autocuration,,BAO_0000019
3331,,8,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,,,,,,1,,B,CHEMBL619031,10623,,H,Expert,,BAO_0000357
3332,,8,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,,,,,,1,,F,CHEMBL619032,10623,,H,Autocuration,,BAO_0000019
3333,,9,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619033,10623,,D,Expert,,BAO_0000357
3334,,8,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,,,,,,1,,B,CHEMBL619034,10623,,H,Autocuration,,BAO_0000357
3335,,8,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,,,,,,1,,B,CHEMBL619035,10623,,H,Autocuration,,BAO_0000357
3336,,8,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,,,,,,1,,B,CHEMBL619036,10623,,H,Autocuration,,BAO_0000357
3337,,9,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619037,10623,,D,Expert,,BAO_0000019
3338,,8,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,,,Striatum,2435.0,,1,,B,CHEMBL619038,10623,,H,Autocuration,,BAO_0000249
3339,,8,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,,,,,,1,,B,CHEMBL619039,10623,,H,Autocuration,,BAO_0000249
3340,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,,,,,,1,,B,CHEMBL619040,10623,,H,Expert,,BAO_0000249
3341,,9,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Rattus norvegicus,,,Striatum,2435.0,,1,10116.0,B,CHEMBL619041,10623,,D,Expert,,BAO_0000019
3342,,8,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,,,Striatum,2435.0,,1,,B,CHEMBL619042,10623,,H,Autocuration,,BAO_0000019
3343,,8,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,,,Striatum,2435.0,,1,,B,CHEMBL619043,10623,,H,Expert,,BAO_0000249
3344,,8,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,,,Striatum,2435.0,,1,,B,CHEMBL619044,10623,,H,Expert,,BAO_0000019
3345,,8,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,,,Striatum,2435.0,,1,,B,CHEMBL619045,10623,,H,Expert,,BAO_0000249
3346,,8,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,Striatum,2435.0,,1,,B,CHEMBL619046,10623,,H,Expert,,BAO_0000249
3347,,8,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,,,,,,1,,B,CHEMBL619047,10623,,H,Expert,,BAO_0000249
3348,,8,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,,,Brain,955.0,,1,,F,CHEMBL619048,10623,,H,Autocuration,,BAO_0000221
3349,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,,,,,,1,,F,CHEMBL859398,10623,,H,Autocuration,,BAO_0000019
3350,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,,,,,,1,,F,CHEMBL619049,10623,,H,Autocuration,,BAO_0000019
3351,,8,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,,,,,,1,,F,CHEMBL857886,10623,,H,Autocuration,,BAO_0000019
3352,,8,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,,,,,,1,,F,CHEMBL619050,10623,,H,Autocuration,,BAO_0000019
3353,,8,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,,,,,,1,,F,CHEMBL620591,10623,,H,Autocuration,,BAO_0000019
3354,,9,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL620592,10623,,D,Expert,,BAO_0000357
3355,,8,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,,,Striatum,2435.0,,1,,B,CHEMBL620593,10623,,H,Expert,,BAO_0000249
3356,,9,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL620594,10623,,D,Expert,,BAO_0000019
3357,,8,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,,,,,,1,,F,CHEMBL875079,10623,,H,Expert,,BAO_0000019
3358,,8,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,1,,F,CHEMBL620595,10623,,H,Expert,,BAO_0000019
3359,,9,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL620596,10623,,D,Expert,,BAO_0000019
3360,,8,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,,,,,,1,,F,CHEMBL620597,10623,,H,Autocuration,,BAO_0000019
3361,,8,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,,,,,,1,,F,CHEMBL620598,10623,,H,Expert,,BAO_0000019
3362,,8,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,,,,,,1,,F,CHEMBL620599,10623,,H,Expert,,BAO_0000218
3363,,8,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,,,,,,1,,F,CHEMBL620600,10623,,H,Autocuration,,BAO_0000019
3364,,8,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL620601,168,,H,Autocuration,,BAO_0000019
3365,,8,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,,,,,,1,,F,CHEMBL620602,168,,H,Autocuration,,BAO_0000019
3366,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620603,168,,H,Autocuration,,BAO_0000357
3367,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,,,,,,1,,B,CHEMBL620604,168,,H,Autocuration,,BAO_0000357
3368,,8,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,,,,,,1,,B,CHEMBL620605,168,,H,Autocuration,,BAO_0000357
3369,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620606,168,,H,Autocuration,,BAO_0000357
3370,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,1,,F,CHEMBL620607,168,,H,Autocuration,,BAO_0000019
3371,,8,In vitro binding affinity towards 5-HT4 receptor was determined,,,,,,,1,,B,CHEMBL620608,168,,H,Autocuration,,BAO_0000357
3372,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,1,,F,CHEMBL620609,168,,H,Autocuration,,BAO_0000019
3373,,8,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,,,,,,1,,F,CHEMBL620610,168,,H,Autocuration,,BAO_0000019
3374,,8,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620611,168,,H,Autocuration,,BAO_0000357
3375,,8,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,,,,,,1,,B,CHEMBL620612,168,,H,Autocuration,,BAO_0000357
3376,,8,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,,,,,,1,,B,CHEMBL620613,168,,H,Autocuration,,BAO_0000357
3377,,8,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,,,,,,1,,B,CHEMBL620614,168,,H,Autocuration,,BAO_0000357
3378,,8,Binding affinity against 5-Hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620615,168,,H,Expert,,BAO_0000357
3379,Brain membranes,6,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,,,,,,1,,B,CHEMBL857075,104698,,H,Autocuration,,BAO_0000249
3380,Brain membranes,6,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,,,,,,1,,B,CHEMBL620616,104698,,H,Autocuration,,BAO_0000249
3381,Brain membranes,6,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,,,,,,1,,B,CHEMBL619411,104698,,H,Autocuration,,BAO_0000249
3382,,6,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,,,,,,1,,B,CHEMBL619412,104698,,H,Autocuration,,BAO_0000019
3383,,7,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619413,104698,,D,Autocuration,,BAO_0000019
3384,,6,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,,,Hippocampus,10000000.0,,1,,B,CHEMBL619414,104698,,H,Autocuration,,BAO_0000221
3385,,6,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,,,,,,1,,B,CHEMBL619415,104698,,H,Autocuration,,BAO_0000019
3386,,6,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,,,,,,1,,B,CHEMBL619416,104698,,H,Autocuration,,BAO_0000019
3387,,6,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,,,,,,1,,F,CHEMBL619417,104698,,H,Autocuration,,BAO_0000019
3388,,7,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619418,104698,,D,Autocuration,,BAO_0000223
3389,,7,Binding affinity against 5-Hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619419,104698,,D,Autocuration,,BAO_0000223
3390,,6,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,,,,,,1,,B,CHEMBL619420,104698,,H,Autocuration,,BAO_0000019
3391,,6,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,,,,,,1,,B,CHEMBL619421,104698,,H,Autocuration,,BAO_0000249
3392,,7,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619422,104698,,D,Autocuration,,BAO_0000019
3393,,6,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,,,,,,1,,B,CHEMBL619423,104698,,H,Autocuration,,BAO_0000019
3394,,6,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,,,,,,1,,B,CHEMBL875080,104698,,H,Autocuration,,BAO_0000019
3395,,6,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,,,,,,1,,B,CHEMBL619424,104698,,H,Autocuration,,BAO_0000019
3396,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,,,,,,1,,B,CHEMBL619425,104698,,H,Autocuration,,BAO_0000249
3397,,6,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,,,,,,1,,B,CHEMBL619426,104698,,H,Autocuration,,BAO_0000223
3398,,6,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,,,,,,1,,B,CHEMBL619427,104698,,H,Autocuration,,BAO_0000223
3399,,7,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619645,104698,,D,Autocuration,,BAO_0000223
3400,,9,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,,,,,,1,,B,CHEMBL619646,10576,,D,Expert,,BAO_0000249
3401,,8,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,,,Brain,955.0,,1,,F,CHEMBL619647,12020,,H,Autocuration,,BAO_0000221
3402,,8,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,,,,,,1,,F,CHEMBL619648,12020,,H,Autocuration,,BAO_0000019
3403,,8,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,,,,,,1,,F,CHEMBL619165,12020,,H,Autocuration,,BAO_0000019
3404,,8,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,F,CHEMBL620719,12020,,H,Autocuration,,BAO_0000218
3405,,8,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,1,,B,CHEMBL872924,12020,,H,Autocuration,,BAO_0000019
3406,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620720,12020,,H,Autocuration,,BAO_0000357
3407,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,,,,,,1,,B,CHEMBL620721,12020,,H,Autocuration,,BAO_0000019
3408,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,,,,,,1,,B,CHEMBL620722,12020,,H,Autocuration,,BAO_0000019
3409,,6,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,,,,,,1,,B,CHEMBL620723,104698,,H,Autocuration,,BAO_0000019
3410,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,,,,,,1,,B,CHEMBL620724,12020,,H,Autocuration,,BAO_0000019
3411,,6,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,,,,,,1,,B,CHEMBL620725,104698,,H,Autocuration,,BAO_0000249
3412,,9,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL620726,12020,,D,Autocuration,,BAO_0000019
3413,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620727,144,,H,Expert,,BAO_0000357
3414,,4,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,,,,,,1,,B,CHEMBL620728,104714,,H,Autocuration,,BAO_0000223
3415,,0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,1,,B,CHEMBL620729,22226,,U,Autocuration,,BAO_0000019
3416,,4,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,,,,,,1,,F,CHEMBL858288,104714,,H,Autocuration,,BAO_0000019
3417,,4,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620730,104714,,H,Autocuration,,BAO_0000223
3418,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL620731,104714,,H,Autocuration,,BAO_0000223
3419,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL620732,104714,,H,Autocuration,,BAO_0000019
3420,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618042,104714,,H,Autocuration,,BAO_0000019
3421,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618043,104714,,H,Autocuration,,BAO_0000019
3422,,4,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618044,104714,,H,Autocuration,,BAO_0000223
3423,,4,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,,,,,,1,,F,CHEMBL618045,104714,,H,Autocuration,,BAO_0000019
3424,,4,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,,,,,,1,,B,CHEMBL618046,104714,,H,Autocuration,,BAO_0000223
3425,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,,,,,,1,,F,CHEMBL618047,104714,,H,Autocuration,,BAO_0000019
3426,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,,,,,,1,,F,CHEMBL875084,104714,,H,Autocuration,,BAO_0000019
3427,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,,,,,,1,,F,CHEMBL618048,104714,,H,Autocuration,,BAO_0000019
3428,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,,,,,,1,,B,CHEMBL618049,104714,,H,Autocuration,,BAO_0000223
3429,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,,,,,,1,,F,CHEMBL619764,104714,,H,Autocuration,,BAO_0000019
3430,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,,,,,,1,,F,CHEMBL619765,104714,,H,Autocuration,,BAO_0000019
3431,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,,,,,,1,,F,CHEMBL619766,104714,,H,Autocuration,,BAO_0000019
3432,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,,,,,,1,,B,CHEMBL619767,104714,,H,Autocuration,,BAO_0000223
3433,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,,,,,,1,,B,CHEMBL619768,104714,,H,Autocuration,,BAO_0000223
3434,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,,,,,,1,,F,CHEMBL619769,104714,,H,Autocuration,,BAO_0000019
3435,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,,,,,,1,,B,CHEMBL619770,104714,,H,Autocuration,,BAO_0000223
3436,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL619771,104714,,H,Autocuration,,BAO_0000223
3437,,4,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,,,,,,1,,B,CHEMBL619772,104714,,H,Autocuration,,BAO_0000219
3438,,4,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,,,,,,1,,B,CHEMBL619773,104714,,H,Autocuration,,BAO_0000223
3439,,4,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,,,,,433.0,1,,B,CHEMBL619774,104714,,H,Autocuration,,BAO_0000219
3440,,4,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,,,,,,1,,B,CHEMBL875083,104714,,H,Autocuration,,BAO_0000019
3441,,4,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,,,,,433.0,1,,B,CHEMBL620718,104714,,H,Autocuration,,BAO_0000219
3442,,4,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,1,,B,CHEMBL618127,104714,,H,Autocuration,,BAO_0000223
3443,,4,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,1,,B,CHEMBL618128,104714,,H,Autocuration,,BAO_0000223
3444,,4,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,,,,,,1,,B,CHEMBL618129,104714,,H,Autocuration,,BAO_0000219
3445,,4,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,1,,B,CHEMBL618130,104714,,H,Autocuration,,BAO_0000223
3446,,4,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,,,,,,1,,F,CHEMBL618131,104714,,H,Autocuration,,BAO_0000019
3447,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618132,104714,,H,Autocuration,,BAO_0000019
3448,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618133,104714,,H,Autocuration,,BAO_0000019
3449,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618134,104714,,H,Autocuration,,BAO_0000019
3450,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618135,104714,,H,Autocuration,,BAO_0000019
3451,,4,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,,,,,,1,,B,CHEMBL618136,104714,,H,Autocuration,,BAO_0000223
3452,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618137,104714,,H,Autocuration,,BAO_0000223
3453,,4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,,,,,,1,,B,CHEMBL618138,104714,,H,Autocuration,,BAO_0000223
3454,,4,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,,,,,,1,,B,CHEMBL618139,104714,,H,Autocuration,,BAO_0000223
3455,,4,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,,,,,,1,,B,CHEMBL618140,104714,,H,Autocuration,,BAO_0000223
3456,,4,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,,,,,,1,,B,CHEMBL618141,104714,,H,Autocuration,,BAO_0000223
3457,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,,,,,,,1,,B,CHEMBL873478,108,,H,Expert,,BAO_0000357
3458,,6,Binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618142,104698,,H,Autocuration,,BAO_0000223
3459,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618143,144,,H,Autocuration,,BAO_0000357
3460,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618144,144,,H,Autocuration,,BAO_0000357
3461,,8,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618145,144,,H,Autocuration,,BAO_0000357
3462,,4,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,1,,B,CHEMBL618146,104714,,H,Autocuration,,BAO_0000223
3463,,4,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,,,,,,1,,B,CHEMBL618147,104714,,H,Autocuration,,BAO_0000223
3464,,4,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,,,,,,1,,B,CHEMBL618148,104714,,H,Autocuration,,BAO_0000223
3465,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,,,,,,1,,B,CHEMBL618149,144,,H,Autocuration,,BAO_0000019
3466,,8,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL872927,144,,H,Autocuration,,BAO_0000357
3467,,8,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL618150,144,,H,Autocuration,,BAO_0000357
3468,,8,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,,,,,,1,,B,CHEMBL618151,144,,H,Autocuration,,BAO_0000357
3469,,8,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL875094,144,,H,Autocuration,,BAO_0000357
3470,,8,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,,,,,,1,,B,CHEMBL618152,144,,H,Autocuration,,BAO_0000019
3471,,8,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,,,,,,1,,B,CHEMBL618153,144,,H,Autocuration,,BAO_0000357
3472,,8,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,,,,,,1,,B,CHEMBL618888,144,,H,Autocuration,,BAO_0000357
3473,,8,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,,,,,,1,,F,CHEMBL618889,144,,H,Autocuration,,BAO_0000019
3474,,8,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,,,,,,1,,B,CHEMBL618890,144,,H,Autocuration,,BAO_0000357
3475,,8,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,,,,,,1,,B,CHEMBL618891,144,,H,Autocuration,,BAO_0000019
3476,,8,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,,,,,,1,,B,CHEMBL619054,144,,H,Autocuration,,BAO_0000019
3477,,4,Binding affinity against the 5-hydroxytryptamine 3 receptor,,,,,,,1,,B,CHEMBL619055,104714,,H,Autocuration,,BAO_0000223
3478,,8,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,1,,B,CHEMBL619056,144,,H,Autocuration,,BAO_0000357
3479,,8,Percent efficacy against 5-hydroxytryptamine 3A receptor,,,,,,,1,,F,CHEMBL619057,144,,H,Autocuration,,BAO_0000019
3480,,8,Binding affinity against human 5-hydroxytryptamine 3A receptor,,,,,,,1,,B,CHEMBL619058,144,,H,Autocuration,,BAO_0000357
3481,,9,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL619059,12020,,D,Expert,,BAO_0000219
3482,,9,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL619060,12020,,D,Expert,,BAO_0000219
3483,,9,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Rattus norvegicus,,,,,,1,10116.0,F,CHEMBL875095,12020,,D,Expert,,BAO_0000219
3484,,9,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619061,20033,,D,Intermediate,,BAO_0000221
3485,,9,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,F,CHEMBL619062,20033,,D,Intermediate,,BAO_0000221
3486,,9,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619063,20033,,D,Intermediate,,BAO_0000019
3487,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL619064,20033,,D,Intermediate,,BAO_0000221
3488,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619065,20033,,D,Intermediate,,BAO_0000357
3489,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL619066,20033,,D,Intermediate,,BAO_0000221
3490,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,,,Ileum,2116.0,,1,,B,CHEMBL619775,10209,,H,Autocuration,,BAO_0000221
3491,,8,Affinity against 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL619776,10209,,H,Autocuration,,BAO_0000357
3492,,4,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619777,104841,,H,Autocuration,,BAO_0000224
3493,,4,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619778,104841,,H,Autocuration,,BAO_0000224
3494,,4,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Cavia porcellus,,,Ileum,2116.0,,1,10141.0,B,CHEMBL619779,104841,,H,Autocuration,,BAO_0000221
3495,,4,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619780,104841,,H,Autocuration,,BAO_0000224
3496,,4,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Cavia porcellus,,,,,,1,10141.0,B,CHEMBL619166,104841,,H,Autocuration,,BAO_0000224
3497,,4,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619167,104841,,H,Autocuration,,BAO_0000019
3498,,4,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL619168,104841,,H,Autocuration,,BAO_0000019
3499,,9,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Homo sapiens,,,Cardiac atrium,2081.0,,1,9606.0,B,CHEMBL619169,168,,D,Expert,,BAO_0000219
3500,,9,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Homo sapiens,,,Cardiac atrium,2081.0,,1,9606.0,B,CHEMBL619170,168,,D,Expert,,BAO_0000219
3501,,5,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Homo sapiens,,,,,,1,9606.0,F,CHEMBL619171,104841,,D,Autocuration,,BAO_0000019
3502,,9,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Homo sapiens,,,Cardiac atrium,2081.0,,1,9606.0,F,CHEMBL619172,168,,D,Expert,,BAO_0000219
3503,,0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Mus musculus,,,,,,1,10090.0,B,CHEMBL619173,22226,,U,Autocuration,,BAO_0000019
3504,,0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Mus musculus,,,,,,1,10090.0,B,CHEMBL619174,22226,,U,Autocuration,,BAO_0000019
3505,,4,5-hydroxytryptamine receptor binding affinity was determined in rats,,,,,,,1,,B,CHEMBL619175,104705,,H,Autocuration,,BAO_0000019
3506,,4,Binding affinity at rat 5-hydroxytryptamine receptor.,,,,,,,1,,B,CHEMBL619176,104705,,H,Autocuration,,BAO_0000224
3507,,4,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,,,,,,1,,B,CHEMBL619177,104705,,H,Autocuration,,BAO_0000019
3508,,4,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,,,,,,1,,B,CHEMBL619178,104705,,H,Autocuration,,BAO_0000224
3509,,4,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,,,,,,1,,B,CHEMBL619179,104705,,H,Autocuration,,BAO_0000224
3510,,4,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,,,Stomach,945.0,,1,,F,CHEMBL619180,104705,,H,Autocuration,,BAO_0000019
3511,,4,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,,,Stomach,945.0,,1,,F,CHEMBL619181,104705,,H,Autocuration,,BAO_0000019
3512,,4,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,,,,,,1,,F,CHEMBL619182,104705,,H,Autocuration,,BAO_0000019
3513,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,,,,,,1,,B,CHEMBL619183,104705,,H,Autocuration,,BAO_0000224
3514,,4,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,,,,,,1,,B,CHEMBL619184,104705,,H,Autocuration,,BAO_0000224
3515,,8,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,,,Hippocampus,10000000.0,,1,,B,CHEMBL619185,10576,,H,Autocuration,,BAO_0000221
3516,,8,Binding affinity for rat 5-hydroxytryptamine transporter.,,,,,,,1,,B,CHEMBL619186,12198,,H,Expert,,BAO_0000357
3517,,4,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,,,,,,1,,B,CHEMBL619187,104705,,H,Autocuration,,BAO_0000019
3518,,5,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619188,104705,,D,Autocuration,,BAO_0000019
3519,,5,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619189,104705,,D,Autocuration,,BAO_0000224
3520,,9,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Rattus norvegicus,,,Brain,955.0,,1,10116.0,F,CHEMBL619190,12198,,D,Expert,,BAO_0000019
3521,,9,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Rattus norvegicus,,,Cerebellum,2037.0,,1,10116.0,F,CHEMBL619191,12198,,D,Expert,,BAO_0000221
3522,,5,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619192,104705,,D,Autocuration,,BAO_0000019
3523,,5,Percent binding affinity against 5-hydroxytryptamine receptor,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619193,104705,,D,Autocuration,,BAO_0000224
3524,,0,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,,,,,,1,,B,CHEMBL619194,22226,,U,Autocuration,,BAO_0000019
3525,,5,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619195,104705,,D,Autocuration,,BAO_0000224
3526,,5,Affinity against 5-hydroxytryptamine receptor was determined,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL619196,104705,,D,Autocuration,,BAO_0000224
3527,,5,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Rattus norvegicus,,,Stomach,945.0,,1,10116.0,B,CHEMBL619197,104705,,D,Autocuration,,BAO_0000019
3528,,9,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,,,,,,1,9606.0,B,CHEMBL619198,121,,D,Expert,,BAO_0000219
3529,,9,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Homo sapiens,,,,,,1,9606.0,B,CHEMBL875081,121,,D,Expert,,BAO_0000219
3530,,8,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,,,,,,1,,B,CHEMBL884712,18065,,H,Autocuration,,BAO_0000357
3531,,8,Inhibition of 5-hydroxytryptamine reuptake,,,,,,,1,,B,CHEMBL884710,121,,H,Expert,,BAO_0000357
3532,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,,,,,,1,,F,CHEMBL619199,18065,,H,Autocuration,,BAO_0000019
3533,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,,,,,,1,,F,CHEMBL619200,18065,,H,Autocuration,,BAO_0000019
3534,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,,,,,,1,,F,CHEMBL619201,18065,,H,Autocuration,,BAO_0000019
3535,,8,Tested for 5-hydroxytryptamine receptor uptake,,,,,,,1,,F,CHEMBL619202,18065,,H,Autocuration,,BAO_0000019
3536,,9,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Homo sapiens,,,,,449.0,1,9606.0,B,CHEMBL619203,51,,D,Expert,,BAO_0000219
3537,,9,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Homo sapiens,,,,,,1,9606.0,F,CHEMBL619204,51,,D,Expert,,BAO_0000019
3538,,8,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Homo sapiens,,,,,,1,9606.0,B,CHEMBL619205,10576,,H,Autocuration,,BAO_0000249
3539,,8,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,,,,,,1,,B,CHEMBL619206,10576,,H,Autocuration,,BAO_0000357
3540,,8,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,,,,,,1,,B,CHEMBL619207,10576,,H,Expert,,BAO_0000249
3541,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL619208,10825,,H,Autocuration,,BAO_0000019
3542,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL619209,10825,,H,Autocuration,,BAO_0000019
3543,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL619210,10825,,H,Autocuration,,BAO_0000019
3544,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL619211,10825,,H,Autocuration,,BAO_0000019
3545,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL619212,10825,,H,Autocuration,,BAO_0000019
3546,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620681,10825,,H,Autocuration,,BAO_0000019
3547,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620682,10825,,H,Autocuration,,BAO_0000019
3548,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620683,10825,,H,Autocuration,,BAO_0000019
3549,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620684,10825,,H,Autocuration,,BAO_0000019
3550,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620685,10825,,H,Autocuration,,BAO_0000019
3551,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,,,Striatum,2435.0,,1,,F,CHEMBL620686,10825,,H,Autocuration,,BAO_0000019
3552,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620687,10825,,H,Autocuration,,BAO_0000019
3553,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620688,10825,,H,Autocuration,,BAO_0000019
3554,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620689,10825,,H,Autocuration,,BAO_0000019
3555,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620690,10825,,H,Autocuration,,BAO_0000019
3556,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620691,10825,,H,Autocuration,,BAO_0000019
3557,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620692,10825,,H,Autocuration,,BAO_0000019
3558,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,,,Limbic system,349.0,,1,,F,CHEMBL620693,10825,,H,Autocuration,,BAO_0000019
3559,,8,Binding affinity against 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620694,168,,H,Expert,,BAO_0000357
3560,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,,,,,,1,,F,CHEMBL857986,168,,H,Autocuration,,BAO_0000019
3561,,8,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,,,,,,1,,B,CHEMBL620695,168,,H,Autocuration,,BAO_0000357
3562,,8,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620696,168,,H,Expert,,BAO_0000357
3563,,8,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,,,,,,1,,B,CHEMBL620697,168,,H,Autocuration,,BAO_0000357
3564,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor,,,,,,,1,,B,CHEMBL620698,168,,H,Autocuration,,BAO_0000357
3565,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,1,,B,CHEMBL620699,168,,H,Autocuration,,BAO_0000357
3566,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,,,,,,1,,B,CHEMBL620700,168,,H,Autocuration,,BAO_0000357
3567,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL620701,168,,H,Autocuration,,BAO_0000219
3568,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL875082,168,,H,Autocuration,,BAO_0000219
3569,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL620702,168,,H,Autocuration,,BAO_0000219
3570,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL620703,168,,H,Autocuration,,BAO_0000219
3571,,8,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,,673.0,1,,B,CHEMBL620704,168,,H,Autocuration,,BAO_0000219
3572,,8,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,,,,,673.0,1,,B,CHEMBL620705,168,,H,Expert,,BAO_0000219
3573,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,,,,,673.0,1,,B,CHEMBL620706,168,,H,Expert,,BAO_0000219
3574,,8,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,,,,,673.0,1,,B,CHEMBL620707,168,,H,Expert,,BAO_0000219
3575,,8,Binding affinity towards 5-hydroxytryptamine 5 receptor,,,,,,,1,,B,CHEMBL620708,10624,,H,Expert,,BAO_0000357
3576,,8,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,,,,,,1,,B,CHEMBL620709,105,,H,Autocuration,,BAO_0000357
3577,,9,Binding affinity against 5-hydroxytryptamine 5A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620710,10624,,D,Expert,,BAO_0000357
3578,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL620711,10624,,H,Autocuration,,BAO_0000219
3579,,9,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620712,10624,,D,Expert,,BAO_0000357
3580,,9,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620713,10624,,D,Expert,,BAO_0000357
3581,,9,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620714,10624,,D,Expert,,BAO_0000357
3582,,9,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620715,10624,,D,Expert,,BAO_0000357
3583,,8,Binding affinity towards 5-HT5A receptor,,,,,,,1,,B,CHEMBL620716,10624,,H,Autocuration,,BAO_0000357
3584,,8,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,1,,B,CHEMBL620717,10624,,H,Expert,,BAO_0000357
3585,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,,,,,,1,,B,CHEMBL618072,10624,,H,Autocuration,,BAO_0000357
3586,,8,Binding affinity towards cloned human 5-HT5A receptor was determined,,,,,,,1,,B,CHEMBL857987,10624,,H,Autocuration,,BAO_0000357
3587,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,722.0,1,,B,CHEMBL618073,10624,,H,Autocuration,,BAO_0000219
3588,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,,722.0,1,,B,CHEMBL618074,10624,,H,Autocuration,,BAO_0000219
3589,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,,,,,722.0,1,,B,CHEMBL618075,10624,,H,Autocuration,,BAO_0000219
3590,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Mus musculus,,,,,,1,10090.0,B,CHEMBL618076,10625,,D,Expert,,BAO_0000357
3591,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Mus musculus,,,,,,1,10090.0,B,CHEMBL618077,10625,,D,Expert,,BAO_0000357
3592,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Mus musculus,,,,,,1,10090.0,B,CHEMBL618078,10625,,D,Expert,,BAO_0000357
3593,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Mus musculus,,,,,,1,10090.0,B,CHEMBL881821,10625,,D,Expert,,BAO_0000357
3594,,9,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Mus musculus,,,,,,1,10090.0,B,CHEMBL618079,10625,,D,Expert,,BAO_0000357
3595,,8,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,,,,,,1,,B,CHEMBL618080,10625,,H,Expert,,BAO_0000357
3596,,8,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,,722.0,1,,B,CHEMBL618081,10576,,H,Autocuration,,BAO_0000219
3597,,8,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,,,,,722.0,1,,B,CHEMBL618082,10626,,H,Autocuration,,BAO_0000219
3598,,8,Binding affinity towards 5-HT5a receptor,,,,,,,1,,B,CHEMBL618083,10624,,H,Expert,,BAO_0000357
3599,,9,Binding affinity towards 5-hydroxytryptamine 5A receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618084,10624,,D,Expert,,BAO_0000357
3600,,8,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,,,,,,1,,B,CHEMBL618085,10624,,H,Expert,,BAO_0000357
3601,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,,,,,,1,,B,CHEMBL618086,10624,,H,Expert,,BAO_0000357
3602,,8,Binding affinities against 5-hydroxytryptamine 5A receptor,,,,,,,1,,B,CHEMBL875092,10624,,H,Autocuration,,BAO_0000357
3603,,8,Binding affinities towards 5-hydroxytryptamine 5A receptor,,,,,,,1,,B,CHEMBL618087,10624,,H,Autocuration,,BAO_0000357
3604,,8,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,,,,,,1,,B,CHEMBL872926,10624,,H,Autocuration,,BAO_0000357
3605,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Cavia porcellus,,,,,,1,10141.0,F,CHEMBL618088,104714,,H,Autocuration,,BAO_0000019
3606,,4,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,,,,,,1,,B,CHEMBL618089,104714,,H,Autocuration,,BAO_0000223
3607,,9,Inhibition of human 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618090,10627,,D,Expert,,BAO_0000357
3608,,9,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618091,10627,,D,Expert,,BAO_0000357
3609,,8,Inhibition against human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL618092,10627,,H,Autocuration,,BAO_0000357
3610,,9,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618093,10627,,D,Expert,,BAO_0000357
3611,,8,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,,,,,308.0,1,,B,CHEMBL618094,10627,,H,Expert,,BAO_0000219
3612,,9,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618095,10627,,D,Expert,,BAO_0000357
3613,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL875093,10627,,D,Expert,,BAO_0000357
3614,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618096,10627,,D,Expert,,BAO_0000357
3615,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618118,10627,,D,Expert,,BAO_0000357
3616,,9,Binding affinity against 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618119,10627,,D,Expert,,BAO_0000357
3617,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL618120,10627,,H,Expert,,BAO_0000357
3618,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL618121,10627,,H,Autocuration,,BAO_0000357
3619,,8,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,,,,,722.0,1,,B,CHEMBL618122,10627,,H,Expert,,BAO_0000219
3620,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,,,,,,1,,B,CHEMBL618123,10627,,H,Autocuration,,BAO_0000357
3621,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,,,,,722.0,1,,B,CHEMBL618124,10627,,H,Expert,,BAO_0000219
3622,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL618125,10627,,H,Autocuration,,BAO_0000357
3623,,9,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL618126,10627,,D,Expert,,BAO_0000219
3624,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,,,,,,1,,B,CHEMBL618236,10627,,H,Expert,,BAO_0000019
3625,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,1,,B,CHEMBL618237,10627,,H,Expert,,BAO_0000019
3626,,8,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL618238,10627,,H,Expert,,BAO_0000219
3627,,9,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL618239,10627,,D,Expert,,BAO_0000357
3628,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL618240,10627,,H,Autocuration,,BAO_0000019
3629,,8,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,,,,,,1,,B,CHEMBL618241,10627,,H,Autocuration,,BAO_0000357
3630,,8,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,,,,,722.0,1,,B,CHEMBL859399,10627,,H,Autocuration,,BAO_0000219
3631,,8,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,,,,,,1,,F,CHEMBL618242,10627,,H,Autocuration,,BAO_0000019
3632,,8,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL857991,10627,,H,Autocuration,,BAO_0000357
3633,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL619951,10627,,H,Expert,,BAO_0000357
3634,,9,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL619952,10627,,D,Expert,,BAO_0000219
3635,,9,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL619953,10627,,D,Expert,,BAO_0000219
3636,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,,,,,308.0,1,,B,CHEMBL619954,10627,,H,Autocuration,,BAO_0000219
3637,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,,308.0,1,,B,CHEMBL619955,10627,,H,Autocuration,,BAO_0000219
3638,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,,,,,308.0,1,,B,CHEMBL619956,10627,,H,Autocuration,,BAO_0000219
3639,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,,,,,449.0,1,,B,CHEMBL619957,10627,,H,Autocuration,,BAO_0000219
3640,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,,,,,722.0,1,,B,CHEMBL619958,10627,,H,Autocuration,,BAO_0000219
3641,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,,,,,722.0,1,,B,CHEMBL620627,10627,,H,Autocuration,,BAO_0000219
3642,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,,,,,722.0,1,,B,CHEMBL620628,10627,,H,Autocuration,,BAO_0000219
3643,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,,,,,308.0,1,,B,CHEMBL620629,10627,,H,Autocuration,,BAO_0000219
3644,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620630,10627,,H,Autocuration,,BAO_0000357
3645,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,,,,,308.0,1,,B,CHEMBL620782,10627,,H,Autocuration,,BAO_0000219
3646,,8,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620783,10627,,H,Autocuration,,BAO_0000357
3647,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620784,10627,,H,Expert,,BAO_0000357
3648,,8,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,,,,,308.0,1,,B,CHEMBL620785,10627,,H,Expert,,BAO_0000219
3649,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,,,,,,1,,B,CHEMBL857992,10627,,H,Autocuration,,BAO_0000357
3650,,8,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,,,,,,1,,B,CHEMBL620786,10627,,H,Autocuration,,BAO_0000219
3651,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,,,,,308.0,1,,B,CHEMBL620787,10627,,H,Autocuration,,BAO_0000219
3652,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,,,,,308.0,1,,B,CHEMBL620788,10627,,H,Autocuration,,BAO_0000219
3653,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,,,,,308.0,1,,B,CHEMBL620789,10627,,H,Autocuration,,BAO_0000219
3654,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,,,,,308.0,1,,B,CHEMBL620790,10627,,H,Autocuration,,BAO_0000219
3655,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL620791,10628,,H,Autocuration,,BAO_0000219
3656,,8,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,,,,,,1,,B,CHEMBL620792,10628,,H,Autocuration,,BAO_0000019
3657,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620793,10628,,H,Autocuration,,BAO_0000357
3658,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,,,,,,1,,B,CHEMBL620794,10628,,H,Autocuration,,BAO_0000357
3659,,9,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Homo sapiens,,,,,308.0,1,9606.0,B,CHEMBL620795,10627,,D,Autocuration,,BAO_0000219
3660,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620796,10627,,H,Expert,,BAO_0000357
3661,,8,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,,,,,,1,,B,CHEMBL620797,10627,,H,Autocuration,,BAO_0000357
3662,,9,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Homo sapiens,,,,,,1,9606.0,F,CHEMBL620798,10627,,D,Expert,,BAO_0000019
3663,,8,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,,,,,,1,,B,CHEMBL620799,10627,,H,Autocuration,,BAO_0000357
3664,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620800,10627,,H,Expert,,BAO_0000357
3665,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,,,,,,1,,B,CHEMBL620801,10627,,H,Autocuration,,BAO_0000357
3666,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL875100,10627,,H,Autocuration,,BAO_0000357
3667,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,,,,,,1,,B,CHEMBL620802,10627,,H,Autocuration,,BAO_0000357
3668,,8,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,,,,,,1,,F,CHEMBL620803,10627,,H,Expert,,BAO_0000019
3669,,8,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,,,,,,1,,F,CHEMBL620804,10627,,H,Expert,,BAO_0000019
3670,,8,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,,,,,,1,,B,CHEMBL620805,10627,,H,Autocuration,,BAO_0000357
3671,,8,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620806,10627,,H,Autocuration,,BAO_0000357
3672,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,,,,,,1,,B,CHEMBL620807,10627,,H,Autocuration,,BAO_0000357
3673,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,,,,,,1,,B,CHEMBL620808,10627,,H,Autocuration,,BAO_0000357
3674,,8,Binding affinities against 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620809,10627,,H,Autocuration,,BAO_0000357
3675,,8,Binding affinities towards 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620810,10627,,H,Autocuration,,BAO_0000357
3676,,9,Binding affinity towards 5-hydroxytryptamine 6 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620811,10627,,D,Expert,,BAO_0000357
3677,,8,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,,,,,,1,,B,CHEMBL620812,10627,,H,Autocuration,,BAO_0000357
3678,,8,Affinity against 5-hydroxytryptamine 6 receptor,,,,,,,1,,B,CHEMBL620813,10627,,H,Autocuration,,BAO_0000357
3679,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,,,,,,1,,B,CHEMBL620814,10627,,H,Autocuration,,BAO_0000357
3680,,9,Inhibition of human 5-hydroxytryptamine 7 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620815,10209,,D,Expert,,BAO_0000357
3681,,8,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,,,,,722.0,1,,B,CHEMBL620816,10209,,H,Autocuration,,BAO_0000219
3682,,8,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620817,10209,,H,Autocuration,,BAO_0000357
3683,,8,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,,,,,,1,,B,CHEMBL620818,10209,,H,Autocuration,,BAO_0000357
3684,,8,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,,,,,722.0,1,,B,CHEMBL620819,10209,,H,Expert,,BAO_0000219
3685,,9,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620820,10209,,D,Expert,,BAO_0000357
3686,,8,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,,,,,449.0,1,,B,CHEMBL620821,10209,,H,Autocuration,,BAO_0000219
3687,,9,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620822,10209,,D,Expert,,BAO_0000357
3688,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620823,10209,,D,Expert,,BAO_0000357
3689,,9,Binding affinity against 5-hydroxytryptamine 7 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620824,10209,,D,Expert,,BAO_0000357
3690,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL620825,10209,,H,Expert,,BAO_0000219
3691,,8,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,,,,,,1,,B,CHEMBL872930,10209,,H,Autocuration,,BAO_0000357
3692,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620826,10209,,H,Autocuration,,BAO_0000357
3693,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,,,,,,1,,B,CHEMBL620827,10209,,H,Autocuration,,BAO_0000357
3694,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620828,10209,,H,Autocuration,,BAO_0000357
3695,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620829,10209,,H,Autocuration,,BAO_0000357
3696,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,,,,,722.0,1,,B,CHEMBL620830,10209,,H,Expert,,BAO_0000219
3697,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,,,,,,1,,B,CHEMBL620831,10209,,H,Expert,,BAO_0000019
3698,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,,,,,,1,,B,CHEMBL620832,10209,,H,Expert,,BAO_0000019
3699,,9,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Homo sapiens,,,,,,1,9606.0,B,CHEMBL621548,10209,,D,Expert,,BAO_0000357
3700,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL621549,10209,,H,Autocuration,,BAO_0000019
3701,,8,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,,,,,,1,,B,CHEMBL621550,10209,,H,Autocuration,,BAO_0000357
3702,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,,,,,449.0,1,,B,CHEMBL621551,10209,,H,Autocuration,,BAO_0000219
3703,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,,,,,,1,,B,CHEMBL621552,10209,,H,Autocuration,,BAO_0000019
3704,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL857077,10209,,H,Autocuration,,BAO_0000357
3705,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,,,,,,1,,B,CHEMBL618158,10209,,H,Autocuration,,BAO_0000357
3706,,9,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Homo sapiens,,,,,643.0,1,9606.0,B,CHEMBL618159,10209,,D,Expert,,BAO_0000219
3707,,8,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,,,,,643.0,1,,B,CHEMBL875101,10209,,H,Autocuration,,BAO_0000219
3708,,9,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL618160,10209,,D,Expert,,BAO_0000219
3709,,8,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,,,,,,1,,B,CHEMBL618161,10209,,H,Expert,,BAO_0000357
3710,,8,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,,,,,722.0,1,,B,CHEMBL618162,10209,,H,Expert,,BAO_0000219
3711,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL618163,10209,,H,Expert,,BAO_0000357
3712,,8,Binding affinity against 5-hydroxytryptamine 7 human receptors,,,,,,,1,,B,CHEMBL618164,10209,,H,Autocuration,,BAO_0000357
3713,,8,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL618165,10209,,H,Expert,,BAO_0000219
3714,,8,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,,,,,722.0,1,,B,CHEMBL618166,10209,,H,Autocuration,,BAO_0000219
3715,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,722.0,1,,B,CHEMBL857989,10209,,H,Autocuration,,BAO_0000219
3716,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,722.0,1,,B,CHEMBL619888,10209,,H,Autocuration,,BAO_0000219
3717,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,722.0,1,,B,CHEMBL619889,10209,,H,Autocuration,,BAO_0000219
3718,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,,,,,722.0,1,,B,CHEMBL619890,10209,,H,Autocuration,,BAO_0000219
3719,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,,,,,449.0,1,,B,CHEMBL619891,10209,,H,Autocuration,,BAO_0000219
3720,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,,,,,722.0,1,,B,CHEMBL619892,10209,,H,Autocuration,,BAO_0000219
3721,,9,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,,,,,722.0,1,,B,CHEMBL619893,10209,,D,Expert,,BAO_0000219
3722,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,,,,,722.0,1,,B,CHEMBL619894,10209,,H,Autocuration,,BAO_0000219
3723,,9,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,,,,,722.0,1,,B,CHEMBL619895,10209,,D,Intermediate,,BAO_0000219
3724,,9,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,,,,,,1,,B,CHEMBL619896,10209,,D,Intermediate,,BAO_0000357
3725,,8,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,,,,,643.0,1,,B,CHEMBL619897,10209,,H,Autocuration,,BAO_0000219
3726,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,,,,,722.0,1,,B,CHEMBL619898,10209,,H,Autocuration,,BAO_0000219
3727,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,,,,,722.0,1,,B,CHEMBL619899,10209,,H,Expert,,BAO_0000219
3728,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,,,,,722.0,1,,B,CHEMBL619900,10209,,H,Autocuration,,BAO_0000219
3729,,9,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Homo sapiens,,,,,722.0,1,9606.0,B,CHEMBL619901,10209,,D,Expert,,BAO_0000219
3730,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,,,,,722.0,1,,B,CHEMBL620580,10209,,H,Autocuration,,BAO_0000219
3731,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,,,,,722.0,1,,B,CHEMBL620581,10209,,H,Autocuration,,BAO_0000219
3732,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,,,,,722.0,1,,B,CHEMBL620733,10209,,H,Autocuration,,BAO_0000219
3733,,9,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Homo sapiens,,,,,,1,9606.0,B,CHEMBL620734,10209,,D,Autocuration,,BAO_0000357
3734,,9,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Mus musculus,,,,,,1,10090.0,B,CHEMBL620735,10022,,D,Expert,,BAO_0000357
3735,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Oryctolagus cuniculus,,,,,,1,9986.0,B,CHEMBL620736,10209,,H,Autocuration,,BAO_0000019
3736,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,,,,,449.0,1,,B,CHEMBL620737,11923,,H,Autocuration,,BAO_0000219
3737,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,,,,,449.0,1,,B,CHEMBL620738,11923,,H,Autocuration,,BAO_0000219
3738,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,,,,,449.0,1,,B,CHEMBL620739,11923,,H,Autocuration,,BAO_0000219
3739,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,,,,,449.0,1,,B,CHEMBL620740,11923,,H,Autocuration,,BAO_0000219
3740,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,,,,,449.0,1,,B,CHEMBL620741,11923,,H,Autocuration,,BAO_0000219
3741,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,,,,,449.0,1,,B,CHEMBL620742,11923,,H,Autocuration,,BAO_0000219
3742,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,,,,,449.0,1,,B,CHEMBL620743,11923,,H,Autocuration,,BAO_0000219
3743,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,,,,,449.0,1,,B,CHEMBL620744,11923,,H,Autocuration,,BAO_0000219
3744,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,,,,,449.0,1,,B,CHEMBL620745,11923,,H,Autocuration,,BAO_0000219
3745,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,,,,,449.0,1,,B,CHEMBL620746,11923,,H,Autocuration,,BAO_0000219
3746,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,,,,,449.0,1,,B,CHEMBL620747,11923,,H,Autocuration,,BAO_0000219
3747,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,,,,,449.0,1,,B,CHEMBL620748,11923,,H,Autocuration,,BAO_0000219
3748,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,,,,,449.0,1,,B,CHEMBL620749,11923,,H,Autocuration,,BAO_0000219
3749,,8,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620750,11923,,H,Expert,,BAO_0000357
3750,,9,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Rattus norvegicus,,,,,,1,10116.0,B,CHEMBL620751,11923,,D,Expert,,BAO_0000357
3751,,8,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,,,,,,1,,B,CHEMBL620752,11923,,H,Expert,,BAO_0000357
